Official Title:         
NCT Number: 
Document Dates:  ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 
304801) An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients With Familial Chylomicronemia Syndrome 
(FCS)
 [STUDY_ID_REMOVED]
Protocol Amendment 10 - [LOCATION_009]: 01 May 2019 
Protocol Amendment 9: 25 May 2018 
Amendment 8: 10 April 2017 
Amendment 7: 3 February 2017  Protocol 
Amendment 6: 16 September 2016  Protocol 
Protocol Amendment 5: [ADDRESS_37678] 2016  Protocol 
Protocol Amendment 4: 6 June 2016 
Protocol Amendment 3: 9 May 2016 
Amendment 2: 22 April 2016  
Protocol Amendment 1: 2 February 2016  Protocol  
Ori
ginal Protocol
: [ADDRESS_37679] 2015
 
 
Sponsor:  
Akcea Therapeutics  
[ADDRESS_37680], 9th Floor 
[LOCATION_011], MA  [ZIP_CODE]   Collaborator: 
  Ionis Pharmaceuticals, Inc.  
  [ADDRESS_37681]  
  Carlsbad, CA  [ZIP_CODE] 
ISIS 304801-CS7 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)
An Open-Label Study of Volaneso r sen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
Protocol Amendment 10 - [LOCATION_009] – [ADDRESS_37682] No:  2015-003755-
21 

ISIS 304801-CS7 
Protocol -[LOCATION_009] CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment I 0 
01 May2019 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 10 -[LOCATION_009] -01 May 2019 
Protocol History: 
Original Protocol: [ADDRESS_37683] 2015 
Protocol Amendment 1: 2 February 2016 
Protocol Amendment 2: 22 April 2016 
Protocol Amendment 3: 9 May 2016 
Protocol Amendment 4: 6 June 2016 
Protocol Amendment 5: [ADDRESS_37684] 2016 
Protocol Amendment 6: 16 September 2016 
Protocol Amendment 7: 3 February 2017 
Protocol Amendment 8: 10 April 2017 
Protocol Amendment 9: 25 May 20 I 8 
Approved by: 
[CONTACT_37673], Inc. 
[ADDRESS_37685], 9th Floor 
Bosto n, MA [ZIP_CODE] 
Telephone:  
 MD 
Akcea Therapeutics, Inc. 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019 
 
3  Protocol Number:  ISIS 304801- CS7 
Protocol Amendment [ADDRESS_37686] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Akcea Therapeutics , Inc.  
[ADDRESS_37687], 9th Floor 
[LOCATION_011], MA [ZIP_CODE] 
Telephone:  
Key Sponsor Contact:  
[CONTACT_37673], Inc.  
[ADDRESS_37688], 9th Floor  
[LOCATION_011], MA [ZIP_CODE] 
Phone:  
Email:  
Collaborator:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_37689]  
Carlsbad, CA [ZIP_CODE]  
Date:  [ADDRESS_37690] of the clinical investigation without the prior written consent of Akcea Therapeutics,  Inc. and Ionis Pharmaceuticals, 
Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019 
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to Patients 
with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 10 - [LOCATION_009] 
Date:    [ADDRESS_37691] read and understand the attached clinical protocol, entitled “A n Open-
Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) ”, Amendment 10 – [LOCATION_009], dated  [ADDRESS_37692] the stu dy as 
described herein. 
I agree to comply with the International Conference on Harmonization Tripartite Guideline on Good 
Clinical Practice E6 (R2). 
I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month  YYY Y) 
  
ISIS [ADDRESS_37693] ............................................................................................ 40 
4. PATIENT ENROLLMENT ........................................................................................................ 40 
4.1 Qualification  .............................................................................................................................. 40 
4.2 Enrollment  ................................................................................................................................. 40 
5. PATIENT ELIGIBILITY ........................................................................................................... 40 
5.1 Inclusion Criteria  ....................................................................................................................... 40 
5.2 Exclusion Criteria  ...................................................................................................................... 41 
6. STUDY PROCEDURES  ............................................................................................................. 44 
6.1 Study Schedule  .......................................................................................................................... 44 
6.1.1  Qualification  ...................................................................................................................... 44 
6.1.2  Treatment Period  ............................................................................................................... 44 
6.1.3  Extended Treatment Period  ............................................................................................... 44 
6.1.4  Pharmacokinetic (PK) Subgroup ....................................................................................... [ADDRESS_37694]-Treatment Follow -up ................................................................................................. 45 
6.2 Additional Study Assessments  .................................................................................................. 45 
6.2.1  Laboratory Assessments  .................................................................................................... 45 
6.2.2  Physical Exams and Vital Signs  ........................................................................................ 46 
[IP_ADDRESS]  Eruptive Xanthoma ..................................................................................................... 46 
[IP_ADDRESS]  Lipemia Retinalis  ....................................................................................................... 46 
6.2.3  Echocardiography  .............................................................................................................. 46 
6.2.4  ECG   ............................................................................................................................ 46 
6.2.5  MRI   ............................................................................................................................ 47 
6.2.6  Quality of Life Assessments .............................................................................................. 47 
6.2.7  Disease Symptom Diary  .................................................................................................... 47 
6.2.8  Diet Monitoring  ................................................................................................................. 47 
6.2.9  Family History  ................................................................................................................... 47 
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2)  ............. [ADDRESS_37695]-Treatment Follow-up Period  ............. 60 
8.9 Withdrawal of Patients from the Study  ..................................................................................... 60 
8.10  Concomitant Therapy and Procedures  ....................................................................................... 61 
8.10.1  Concomitant Therapy  ........................................................................................................ 61 
8.10.2  Concomitant Procedures  .................................................................................................... 61 
8.11  Treatment Compliance  .............................................................................................................. 62 
9. SERIOUS AND NON- SERI OUS ADVERSE EVENT REPORTING  .................................... 62 
9.1 Sponsor Review of Safety Information  ..................................................................................... 62 
9.2 Regulatory Requirements  .......................................................................................................... 62 
9.3 Definitions  ................................................................................................................................. 63 
9.3.1  Adverse Event  ................................................................................................................... 63 
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ......................................................... 63 
9.3.3  Serious Adverse Event (SAE)  ........................................................................................... 63 
9.4 Monitoring and Recording Adverse Events  .............................................................................. 64 
9.4.1  Serious Adverse Events  ..................................................................................................... 64 
9.4.2  Non-Serious Adverse Events  ............................................................................................. 64 
9.4.3  Evaluation of Adverse Events (Serious and Non- Serious)  ................................................ 64 
[IP_ADDRESS]  Relationship to the Study Drug  .................................................................................. 64 
[IP_ADDRESS]  Severity ....................................................................................................................... 65 
[IP_ADDRESS]  Action Taken with Volanesorsen  ............................................................................... 65 
[IP_ADDRESS]  Treatment Given for Adverse Event ........................................................................... 65 
[IP_ADDRESS]  Outcome of the Adverse Event  .................................................................................. 65 
9.4.4  Adjudication Committees  .................................................................................................. 66 
9.5 Procedures for Handling Special Situations  .............................................................................. 66 
9.5.1  Abnormalities of Laboratory Tests  .................................................................................... 66 
9.5.2  Prescheduled or Elective Procedures or Routinely S ch
eduled Treatments  ....................... 66 
9.5.3  Treatment Errors ................................................................................................................ 67 
9.5.4  Contraception and Pregnancy ............................................................................................ 67 
10. STATISTICAL CONSIDERATIONS  ....................................................................................... 68 
10.1  Study Endpoints  ........................................................................................................................ 68 
10.1.1  Efficacy Endpoints  ............................................................................................................ 68 
10.1.2  Safety Endpoints ................................................................................................................ 68 
10.2  Sample Size  ............................................................................................................................... 68 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019 
 
8  10.3  Populations  ................................................................................................................................ 69 
10.4  Definition of Baseline ................................................................................................................ 69 
10.5  Interim Analysis  ........................................................................................................................ 69 
10.6  Planned Methods of Analysis  .................................................................................................... 69 
10.6.1  Demographic and Baseline Characteristics  ....................................................................... 70 
10.6.2  Safety Analysis  .................................................................................................................. 70 
10.6.3  Efficacy Analysis  .............................................................................................................. 70 
10.6.4  Pharmacokinetic and Immunogenicity Analysis  ............................................................... 71 
[IP_ADDRESS]  Pharmacokinetic Analysis  .......................................................................................... 71 
[IP_ADDRESS]  Immunogenicity Analysis ........................................................................................... 71 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .......................................................... [ADDRESS_37696] of the Study  ..................................................................................................... 72 
11.3  Independent Ethics Committee/Institutional Review Board  ..................................................... [ADDRESS_37697] of Laboratory Analytes  ....................................................................................... 90 
Appendix C  Pharmacokinetic Sampling Schedule  ......................................................................... 92 
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities  ................ 95 
 
TABLE OF TABLES 
Page  
Table  1 Volanesorsen (ISIS 304801) Characteristics  .................................................................... 49 
Table  2 Labs to Be Performed in the Event of a Platelet Count Less than the Lower 
Limit of Normal (×2) or < 100,000/ mm3 (×1)*  ................................................................ 52 
Table  3 Actions in Patients with Low Platelet Count  .................................................................... 58 
Table  4 Expected Event for the Protocol Defined Population by [CONTACT_37674] ........................................................................................................... 62 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019 
 
9  TABLE OF FIGURES 
Page  
Figure 1 ApoC-III Regulates Lipoprotein Metabolism by [CONTACT_37675] .......................... 33 
Figure 2 Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown  ............................................... 35 
Figure 3 Fasting Triglycerides in Patients with FCS Treated with Volanesorsen ........................... 37 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
10  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open -Label Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment Number:   10 - [LOCATION_009]  
Amendment Date:  01 May 2019 
 
The purpose of this protocol amendment is to implement the following modifications to Protocol ISIS 
304801- CS7 Amendment 9 - [LOCATION_009] dated 25 May 2018:   
• To add an up to 52 weeks of additional treatment to the Extended Treatment Period, to clarify the 
option for patients to receive a volanesorsen dose reduction of 300 mg every two weeks, to clarify discontinuation of patients from the treatment period who are on a dose pause for ≥ 3 months, and 
to remove the references to landmark visits (if patient stops treatment  then they enter the follow-
up period). 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of the original protocol but these chan ges do not 
impact subject safety, exposure, or the overall study design. 
The following table provides a summary list of major changes to the protocol, additions are indicated as 
underline and deletions are indicated as strikethrough: 
Protocol Section  Descr iption of Change  Rationale  
Section 2.3.4  
Clinical 
Experience  Volanesorsen has been evaluated in one Phase 1 study 
and two Phase 2 studies, all double blinded and 
placebo controlled.  The total exposures comprise 99 
patients and healthy volunteers administered 
volanesorsen from 50 to 400 mg subcutaneously up to 
3 mon ths (compared to 37  administered placebo). The 
clinical experience with volanesorsen includes clinical 
trials in healthy subjects, patients with 
hypertriglyceridemia, FCS, or familial partial 
lipodystrophy. Overall, [ADDRESS_37698] 1 dose of 
volanesorsen. Ninety -five (95) patients with FCS have 
been enrolled in studies, all showing clinically 
meaningful reductions in plasma triglyceride. Patients 
with FCS continue on treatment in the open- label 
extension (OLE) and triglyceride reductions persist at 
similar levels as reported in earlier studies.  
In the completed Phase [ADDRESS_37699] on the renal (serum creatinine, proteinuria) or 
hepatic systems (alanine aminotransferase [ALT], 
aspartate aminotransferase [AST], bilirubin). There was 
a reduction (mean reduction < 30%) in platelets in 
volanesorsen vs. placebo with mean nadirs for all doses 
remaining above the lower limit of normal (LLN). The 
most frequently reported adverse events (AEs) were 
mild, non -progressive events at the injection s ite. In 
Phase 2, a single serious adverse event (SAE) of 
secondary serum sickness -like reaction was reported 
as related to Study Drug.  
… 
In the completed pooled Phase 3 studies (ISIS 304801-
CS6 (hereafter referred to as CS6) and ISIS 304801-CS16 (hereafter referred to as CS16), the most 
common AEs associated with volanesorsen administration were tolerability at the injection site and platelet reductions. The majority of the injection site 
AEs were mild, none were severe, and the incidence 
appeared to decrease over time. No deaths have been 
associated with volanesorsen treatment to date. No cardiac toxicity was associated with volanesorsen treatment. There were no abnormal QTc findings and no study -drug related adjudicated major adverse 
cardiac events (MACE). There is no evident association between volanesorsen treatment and changes in renal or liver functions.In clinical studies conducted to date 
volanesorsen has been well -tolerated and has shown a 
favorable safety profile.  There has been no clinic al or 
laboratory evidence of drug-drug interactions.  
The safety profile of volanesorsen has been well-
described in this development program, which has 
identified 3 safety risks: thrombocytopenia (an identified 
risk), constitutional symptoms (flu -like react ions and 
influenza-like illness), and injection site reactions (a 
tolerability signal). Spontaneous, mild to severe 
thrombocytopenia has been described in the FCS 
patient population (Gaudet et al. 2017) but is increased 
by [CONTACT_37676]. Less  frequent and less 
pronounced platelet declines were also observed with 
volanesorsen treatment in the hypertriglyceridemic 
(HTG) population of CS16. When fully complied with, 
frequent monitoring for this effect and appropriate dose 
adjustments have been successful both in preventing 
and promptly detecting the occurrence of severe 
platelet declines and often in retaining patients on 
treatment .In the completed studies there have been no 
volanesorsen associated laboratory abnormalities 
suggestive of an effect on the renal (serum creatinine, 
proteinuria) or hepatic systems (alanine 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
12  aminotransferase [ALT], aspartate aminotransferase 
[AST], bilirubin).  In Phase [ADDRESS_37700] -treatment 
period and was not associated with platelet -related 
adverse events (AEs).  In the blinded ongoing clinical 
trials of ISIS 304801, 2 patients of 142 dosed (as of 
February 29, 2016) had a decrease in platelet count to 
less than 50,000/mm3 in the absence of major bleeding 
or clinically -relevant non- major bleeding and had Study 
Drug paused as per the monitoring and stoppi[INVESTIGATOR_37442] (Section 8.6.3).   Platelet counts 
recovered following suspension of dosing.  
The most frequently observed AEs with volanesorsen 
were local reactions at the injection site.  Local 
cutaneous reactions at the injection site defined as 
those events presenting as either pain, tenderness, 
erythema, pruritus or swelling occurring on the day of 
injection and persisting for at least 2 days were 
infrequent (~15% of injections), were almost always 
mild, resolved spontaneously, were non-progressive, 
and were not associated with systemic sequelae.  
Section 2.4 
Rationale for 
Dose and Schedule of Administration  The dose and sche dule selected for this study is 300 
mg per week for 52 weeks, with the option of continuing dosingtreatment for up to an additional [ZIP_CODE] weeks.  
The dose of 300 mg per week and dose reduction of 
300 mg every 2 weeks (delivered as a single 300 mg 
dose)  are is supported by [CONTACT_37677] 2 clinical data.  
… 
No nonNon clinical findings were not considered to be 
related to the pharmacologic inhibition of apoC -III. 
… 
In addition to the nonclinical and clinical experience of volanesorsen, the dose and schedule of administration is supported by [CONTACT_37678] 2′ MOE -modified ASOs that 
have been safely  administered intravenously and 
subcutaneously in multiple clinical studies at doses up to 10001200 mg and for treatment durations that 
exceed 24 months (Santos et al. 2015).  Language added to clarify  dose 
reductions as 300 mg every 2 weeks according to pat ient’s 
tolerability on the 300 mg weekly dose, given similar extents of triglyceride lowering anticipated based on population pharmacokinetic/  
pharmacodynamic model -based 
simulations.  
 
  
Updated to reflect data presented 
in source listed.
 
 
Synopsis : Study 
Design, Study 
Visit Schedule and Procedures  
 
  Synopsis  
All patients will receive volanesorsen [ADDRESS_37701] -treatment follow -up period 
visits will be conducted on Weeks 53, 54, 55, 56, 57, 
58, 65, 71, and 78 (Weeks 53, 54, 55, 56, 57, 58, and 
71 may be conducted by a home healthcare nurse).  
For patients who have entered the first 52-week 
extended treatment period, but will not continue into the 
second 52-weeks of the extended treatment period, the 
post-treatment follow -up period visits will be conducted 
on Weeks 105, 106, 107, 108, 109, 110, 117, 123 and 
130 (Weeks 105, 106, 107, 108, 109, 110 and 123 may 
be conducted by a home healthcare nurse).  
For patients who have entered the second 52-week 
extended treatment period, the post -treatment follow -up 
period visits will be on Weeks 157, 158, 159, 160, 161, 
162, 169, 175 and 182 (Weeks 157, 158, 159, 160, 161, 
162 and 175 may be conducted by a home healthcare 
nurse).  
Section 6.1.[ADDRESS_37702] 9  Study 
Center visits on Weeks 53, 54, 55, 56, 57, 58, 65, 71, and 78 (Weeks 53, 54, 55, 56, 57, 58, and 71 may be conducted by a home healthcare nurse). An additional 
[ADDRESS_37703] -
treatment follow -up period visits will be conducted on 
Weeks 105, 106, 107, 108, 109, 110, 117, 118,123 and 
125130  (Weeks 105, 106, 107, 108, 109, 110 and 
118123  may be conducted by a home healthcare 
nurse).  
For patients who enter the second 52-week extended 
treatment period, the post -treatment follow -up period 
visits will be on Weeks 157, 158, 159, 160, 161, 162, 
169, 175 and 182 (Weeks 157, 158, 159, 160, 161, 162 
and 175 may be conducted by a home healthcare 
nurse).  
Section 5.2 
Exclusion Criteria   
Synopsis , Study 
Population  14. Use of any of the following:  
… 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification unless approved by [CONTACT_37679]  
… 
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37443] (ISIS  304801 or placebo) Exceptions to inclusion or 
exclusion criteria will not be granted
. 
Section 6.1.3  
Extended 
Treatment Period  Blood sampling will be conducted weekly  at Weeks 53, 
54, 55, 56, 57, 58, 59, 60, 61, 62,63, 65, 66, 67, 68, 69, 
70, 71, 72, 73, 74, 75, 77, 78, 79, 80, 81, 82, 83, 84, 85, 
86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 
101, 102, and 103 may be conducted by a home 
healthcare nurse  Modif ied to indicate that blood 
sampling will occur weekly for 
increased clarity and to include an 
up to 104 additional weeks of 
extended treatment . 
Section 6.2.1  
Laboratory 
Assessments  
Section 8.5.4  
Safety Monitoring 
for Constitutional 
Symptoms  Should a patient experience constitutional or flu -like 
symptoms after Study Drug administration, investigators 
may consider additional laboratory assessments.  For 
example, plasma and serum samples may be drawn for 
complement (Total C3, C4, C5a and Bb), high-
sensitivity C -reactive protein (hsCRP ) and for cytokine 
analysis.  To add additional laboratory 
assessments permitted for safety 
purposes.  
ISIS [ADDRESS_37704] -
treatment follow -up period.  
Section 8.1 
Volanesorsen Administration  For each individual patient, volanesorsen will be 
administered subcutaneously as a single 1.5 mL 300 mg injection once weekl y for Weeks 1 -52.  Patients 
entering this ISIS 304801-CS7 study on a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will continue to 
receive study drug as a single 300 mg/1.5 mL injection 
once-weekly for Weeks 53- 156104 receive a reduced 
dose or dose frequency of volanesorsen for continued 
safety or tolerability  as outlined in Sections 8.5 and 8.6.  
Patients  on dose reduction will receive 300 mg/1.5 mL 
injections every 2 weeks  entering this CS7 study having 
dose or dose frequency reduced in the CS16 index 
study after 13 weeks of treatment, as outlined in CS16 
Amendment 4 Section 8.7, can receive the 300 mg 
once weekly dose of volanesorsen.  
Patients should receive 1 dose per week, unless on a 
dose reduction of 300 mg every 2 weeks, with weeks 
always defined relative to Study Day 1. Added language clarifying details 
of dose reduction option  as 
300 mg every 2 weeks . 
Section 8.5.2  
Safety Monitoring for Platelet Count 
Results  Monitor every 1 week unless otherwise specified. In 
addition, platelet function may be evaluated at any time 
during the study by [CONTACT_37680], using an approved 
point -of-care diagnostic device, in some patients.  This 
additional functional testing may be performed at 
selected study centers.  
… 
Due to the [ADDRESS_37705] with the study patients.  However, if the above options are not possible, a temporary interruption of study treatment will be planned with a platelet count drawn within 3-5 days 
prior to departure and with a prompt blood draw upon 
the patient’s return which must be reported and reviewed by [CONTACT_37681] t. Additional point -of-care platelet 
function testing may be conducted 
on patients at participating study 
centers.    
 
 
 Included an additional blood draw 
to assess platelet count prior to any travel that would result in missing a weekly monitoring visit.   
ISIS [ADDRESS_37706] 
be 
documented in the patient’s  
medical records. Monitor every 1 
week unless otherwise specified  
In addition, platelet 
function may be 
evaluated during 
the study by 
[CONTACT_37680], 
using an approved 
point - of-care 
diagnostic device, 
in some patients.  
This additional 
functional testing 
may be performed 
at selected study 
centers.  
Patients on dose 
pause should be 
monitored as per 
the platelet 
monitoring rules 
outlined in Section 
8.8.1  until Study 
Drug 
administration is 
resumed.  
Obtain additional 
lab tests (Table 2) 
if 2 occurrences 
(consecutive or 
non-c onsec
utive) 
of platelet c ount  
140K - 
> 100K/mm3 or 1 
occurrence of 
platelet count ≤  
100K/mm3.  Labs 
only nee d to be 
performed once.  
Labs m ay be 
collected over 
multiple
 visits, if 
blood r equirements 
are a concern, as To provide clarification to the 
platelet safety monitoring rules, 
including dose reduction options.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
17  per Investigator 
discretion.  
> 100K/mm3 Once  Wweekly 
300 mg Study 
Drug 
administration   
100K/mm3 - 
> 75K/mm3 Permanently 
reduce dose frequency to 300 mg every 
2 weeks .   
75K/mm3 
- > 50K/mm3 If occurs while on dose of 300 
mg every 2 
weeks , then 
permanently discontinue Study Drug, otherwise dose pause. If dose 
pause is 
≥ [ADDRESS_37707] 
discontinue 
treatment and 
enter the follow 
up period.  
When platelet count returns to > 100K/mm
3 
restart dosing  
treatment  at 
dose frequency of 300 mg every 
2 weeks only if 
approved by  [CONTACT_37682] 2-3 
days until 
2 successive 
values are > 
75K/mm3 then 
monitor every 1 week  
Consider discontinuation of antiplatelet agents/NSAIDS/ 
anticoagulant 
medication  
≤ 50K/mm3 
or a rate of decline ≥ 50% between two consecutive assessments, irrespective of the platelet level  Permanently 
discontinue Study Drug and the patient 
will enter the 
follow up 
period . • Monitor daily until 2 successive values show improvement then monitor every  
2-3 days until 
2 successive 
values are 
> 75K/mm3 then 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
18  monitor every 
1 week  
• Patient should be 
evaluated by a hematologist to 
provide 
diagnostic and therapeutic 
management  
• Steroids 
recommended*.  
It is strongly recommended that, unless the patient has a medical contraindication to receiving glucocorticoids, the patient receives glucocorticoid therapy to 
reverse the platelet decline.   
• Monitor 
triglyceride levels 
weekly and 
continue A E 
monitoring during 
steroid therapy  
• Discontinue antiplatelet 
agents/ NSAIDS/ anticoagulant medication while platelet count is < 50K/mm
3 if 
possible  
 
Section 8.7 
Adjustment of 
Dose Frequency  Other dose adjustments, including dose interruptions, 
and/or decreasing the dose or dose  frequency to 
[ADDRESS_37708] be discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to 2 
adjustments in the treatment schedule may be allowed.  
Patients may  be dose paused in response to AEs after 
consultation with, and the Study Medical Monitor  is 
informed.  If a patient is dose paused for ≥ [ADDRESS_37709] been on dose pause and off study drug for >[ADDRESS_37710] permanently discontinue study treatment for any of the following:  
… 
•The patient is dose-paused for ≥ [ADDRESS_37711] 6 
weeks after discontinuing Study Drug.  Following this period, if the platelet count is stable (at least 3 consecutive values that are stable as determined by 
[CONTACT_37683] >  100,000/mm
3), the 
next platelet count should be taken within at least [ADDRESS_37712] 12 weeks after discontinuing Study Drug.  Patients should 
also be strongly encouraged to attend applicable 
landmark visits  at Weeks 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to 
collect fasting lipid panels and conduct safety 
assessments in accordance with the Schedule of 
Procedures in Appendix A.  Any  patient who 
disc
ontinues t reatment af ter Week 44 should also be 
strongly en coura ged to atten d a final f ollow -up visit 
(Week 78 v
isit assessments) a pproximately [ADDRESS_37713] -treatment 
follow -up period . 
Section 8.9 
Withdrawal of Patient from the 
Study  Other reasons for withdrawal of patients from the study 
might include:  
•At the discretion of the Investigator for medical
reasons
•At the discretion of the 
Investigator or Sponsor for
noncompliance
•Significant protocol deviation
•Commercialization of productAdded commercialization of 
product as an additional reason 
for withdrawal from study.  
Section 8.10.2  
Concomitant Procedures  Section 8.10.2  
A concomitant procedure is any therapeutic intervention 
(e.g., surgery/biopsy, physical therapy) or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between signing of informed consent and Week 78 (or Week [ADDRESS_37714] or second extended treatment period, 
respectively)  visit. Updated to include  follow -up 
period for the first and second Extended Treatment Periods.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
20  Section 9.4.1  
Serious Adverse 
Events  
 
  
Section 9.4.2  
Non-Serious 
Adverse Events  Section 9.4.1  
The collection of SAEs will begin after the patient signs 
the informed consent form and stop at the end of the 
patient’s follow -up period which is defined as the 
Week  78 (or Week [ADDRESS_37715] or second extended treatment period, respectively) 
visit. 
 
Section 9.4.2  
The recording of non-serious AEs will begin after the 
patient signs the informed consent form and will stop at 
the end of the patient’s follow -up period, which is 
defined as the Week 78 (or Week [ADDRESS_37716] or second extended treatment 
period, respectively)  visit. 
Section 13 
REFERENCES  Gaudet D, Baass A, Tremblay K, et al. Natural History 
(up to 15 years) of Platelet Count in 84 Patients with 
Familial Hyperchylomicronemia Due to Lipoprotein 
Lipase Deficiency. Journal of Clinical Lipi[INVESTIGATOR_37444] 2017; 
11(3): 797-798.  Addition of reference  
Section  14. 
APPENDICES  Appendix A Schedule of Procedures  
The following footnotes have been added to the tables for
 both the qualification through treatment period and 
the post -treatment follow -up period.  
g Genetic testing can be conducted for study Qualification (Group 2 ISIS 304801-CS16 roll over patients); genetic testing will only be conducted if allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing. A blood sample for potential 
gene sequencing may be collected at timepoints 
other than Screening or Qualification Visits.  
 
The table for the first 52-week extended treatment 
period and post -treatment follow -up period have been 
defined and additional tables added for the second 
52-week extended treatment period and post -treatment 
follow -up period.   
 
Also added platelet function analysis to the first 
extended treatment period.  With Footnote g May be 
done  Clarification that blood sampling 
for gene sequencing may occur 
during  the study.  
 
  
 
   
 
 
Added an additional year of 
extended treatment  
 
 
 
Indication that platelet function 
may be assessed.  
Section  14. 
APPENDICES  Appendix B List of Laboratory Analytes  
Platelet Function  
Platelet aggregation3 
Platelet function5 
Footnote 5: May be done using a point -of-care device 
on site. Addition of laboratory analyte to 
measure platelet function.  
ISIS [ADDRESS_37717] and Second 52-Week Extended Treatment 
Period s. Addition of  PK sampling 
timepoints  for additional year of  
extended treatment.  
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
22  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study  Objectives To evaluate the safety and efficacy of treatment  and extended treatment with 
volanesorsen  in patients with FCS  
Study Design  This is a multi-center open-label study  of: 
Group 1:  ISIS 304801 -CS6 (index study) roll  over FCS patients  
Group 2:  ISIS 304801 -CS16 (index study) roll  over FCS patients  
All patients will receive volanesorsen [ADDRESS_37718] -treatment 
follow -up period.  
Number of  Patient s Up to a pproximately 70 patients dosed 
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed and 
dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS  304801 -
CS16 (index studies) with an acceptable safety profile, per Sponsor and Investigator judgement.  
 Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the following criteria in order to enter into the open-label study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of the following:  
• Confirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-causing 
genes (such as lipoprotein lipase [LPL] , apoC -II, GPI[INVESTIGATOR_37445]1, or lipase 
maturation factor [LMF1 ]) 
• Post heparin plasma LPL activity of ≤ 2 0% of normal in medical 
history.  Note:  testing of LPL activity should not be performed to confirm eligibility for the study  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS  304801 -
CS16 index study  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
23  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria: Continued 
4. Able and willing to participate in a 78 -week study 5. Satisfy 1 of the 
following:  
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal 
occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of spontaneous 
amenorrhea in females > 55 years of age or, in females  ≤ 55 years, 12 
months of spontaneous amenorrhea without an alternative medical cause and follicle stimulating hormone ( FSH) levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in sexual relations of child -bearing pot ential, patient is using an acceptable 
contraceptive method (refer to 
Section  6.3.1) from tim
e of signing the 
informed consent form until
 [ADDRESS_37719] dose of Study Drug 
administration  
b. Males:  Surgically sterile, abstinent* or if engaged in s exual relations 
with a female of child -bearing potential, patient is utilizing an acceptable 
contraceptive method (refer to Section  6.3.1 ) from the time of signing the 
informed consent form until [ADDRESS_37720] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line 
with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial and withdrawal are not acceptable 
methods of contraception  
Exclusion Criteria: 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of Qualification 
b. HbA1c ≥ 9.0% at Qualification  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or 
addition of new medication within 12 weeks of Qualification [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the treatment 
period of the Study (with the exception of ± 10 units of insulin)  
e. Current use of  glucagon -like peptide -1 (GLP -1) agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia 
syndrome  
3. Active pancreatitis within 4 weeks prior to Qualification  
4. History w ithin 6 months of Qualification of acute or unstable cardiac ischemia 
(myocardial infarction, acute coronary syndrome, new onset angina), stroke, 
transient ischemic attack or unstable congestive cardiac failure requiring a change in medication or major surgery within 3 months of Qualification  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
24  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued 
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which case 
total bilirubin must be ≤ 3 mg/dL 
• ALT > 2.[ADDRESS_37721]  
• AST > 2.[ADDRESS_37722]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for protein 
on urine dipstick.  In the event of a positive test eligibility may be 
confirmed by a quantitative total urine protein measurement of < 500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace positive) 
for blood on urine dipstick.  In the event of a positive test eligibility may be confirmed with urine microscopy showing ≤  5 
red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault for 
estimation of glomerular filtration rate (GFR ) in patients with low 
body weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL-C >  130 mg/dL at Qualification  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding 
diathesis or coagulopathy or c linically -significant abnormality in coagulation 
parameters at Qualification  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day  [ADDRESS_37723] for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1  
month of Qualification , or 5 half -lives of investigational agent, whichever is 
longer  
13. Unwilling to comply with lifestyle requirements (Section  6.3) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
25  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued 
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and over-the-counter [ OTC ]), or 
fibrates unless on a stable dose for at least 3 months prior to Qualification  
and dose and regimen expected to remain constant during the treatment 
period.  Patients taking OTC omega -3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on 
a stable dose for at least [ADDRESS_37724] 4  weeks 
prior to Qualification  and dose and regimen expected to remain constant 
during the treatment period  
f. Glybera gene therapy within 2 years prior to Qualification  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) 
unless on a stable dose for at least [ADDRESS_37725] 4 weeks prior to Qualification  
(Occasio nal or intermittent use of over-the -counter medications will be 
allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of >  499 mL 
within 60 days of Qualification  
16. Known hypersensitivity to any of the  excipi[INVESTIGATOR_37449] (ISIS  304801)  
17. Have any other conditions, including new or worsening of existing condition, which, in the opi[INVESTIGATOR_37450], or could interfere with t he patient participating in or 
completing the study  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the Sponsor Medical Monitor.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
26  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The d ose of 300 mg once weekly was chosen  for the double -blinded 
placebo -controlled Phase 3 index studies ( ISIS 304801 -CS6  and ISIS  304801 -CS16 ) 
based on the pharmacodynamic and safety analysis of the Phase 2 studies  
(Section  2.4) which included a subset of patients with FCS .  The same dose of 
[ADDRESS_37726] of the following periods:  
• A qualification period of up to 2  weeks (unless appr oved by [CONTACT_1034]) .  
Please refer to Section  4.1 and Appendix  A 
o A 52 -week treatment period during wh
ich volanesorsen  will be 
administered as a once weekly SC injection  
o Option to participate in an extended treatment period (up to an additional 104 weeks)  
o A [ADDRESS_37727] patient’s Week [ADDRESS_37728] . 
Collection and measurement of vital signs, clinical laboratory parameters (including 
hematology, serum chemistry, and urinalysis), adverse events  (AE) , concomitant 
medication/procedure information, lipid panel, blood viscosity, volanesorsen  plasma 
concentrations, immunog enicity (IM) testing, platelet aggregation, liver/spleen 
magnetic resonance imaging ( MRI ), electrocardiograms ( ECGs ), echocardiograms 
and quality of life assessments will be performed according to the schedule of procedures in Appendix  A.  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food/drink  diary will be 
completed  for the week prior to each quarterly visit by [CONTACT_6904] .  Following the 
Week  [ADDRESS_37729] -
treatment follow -up period.  
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by [CONTACT_37686] (including 
independe ntly adjudicated events of acute pancreatitis and MACE), withdrawals due 
to adverse events, and changes in laboratory and other safety parameters.  
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
27  PROTOCOL SYNOPSIS Continued  
Planned Analyses  Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis and 
MACE  
• Vital signs and weight 
• Physical examination s 
• Clinical laboratory tests (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• ECGs  
• Use of concomitant medications  
• MRIs 
• Platelet aggregation (may be evaluated)  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the 
treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non -high-density 
lipoprotein -cholesterol  (non-HDL -C), apolipoprotein B [apoB] , high -
density lipoprotein -cholester ol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low-density lipoprotein-cholesterol (VLDL -C), and LDL -C 
• Percent change from baseline in fasting total apolipoprotein C -III (apoC-
III) 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate 
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of volanesorsen  
as follows : trough leve
ls (pre-dose)  throughout treatment and post-treatment levels 
during the post -treatment follow -up period .  In a subset of patients, more frequent 
assessment of plasma concentrations of volanesorsen will be performed to determine 
volanesorsen pharmacokinetic parameters .  Plasma sample collection time points are 
detailed in Appendix  A and Appendix  C. 
Statistical Considerations  No sample size calculations were performed as this is an open- label study . 
Sponsor  Akcea Therapeutics , Inc. 
Collaborator  Ionis Pharmaceuticals, Inc.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
28  STUDY DESIGN AND TREATMENT SCHEMA  
 
QUALIFICATION PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET) 
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety 
assessments.  PK and PD/efficacy 
assessments at specified time points  
FIRST EXTENDED TREATMENT PERIOD  
Weeks [ADDRESS_37730]- TREATMENT FOLLOW -UP 
Weeks 53 to 78*  
(Treatment Period Post Treatment Follow -
Up) 
 
And Weeks 105 to 130  
(FIRST Extended Treatment Period Post 
Treatment Follow -Up) 
 
And Weeks 157 to 182  
(SECOND Extended Treatment Period 
Post Treatment Follow -Up) 
 
Safety, efficacy, PK and PD assessments  
* If needed, the post -treatment follow -up 
period will be extended (with patients 
monitored every 6 weeks) until apoC -III 
levels return to baseline values  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
29  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_37731]  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
ET early termination  
FAS full analysis set 
FCS Familial Chylomicronemia Syndrome  
FSH follicle stimulating hormone  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
GLP -1 glucagon -like peptide -1 
GPI[INVESTIGATOR_37445]1  Glycosylphosphatidylinositol -anchored HDL -binding Protein 1  
HAPI  [INVESTIGATOR_37451]1c  Glycated Hemoglobin  
HDL  High -Density Lipoprotein  
HDL -C High -Density Lipoprotein -Cholesterol  
hsCRP  High -sensitivity C -reactive protein  
ICH International Conference on Harmonization  
IDL Intermediate density lipoprotein  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
30  Abbreviation/Acronym  Definition  
IEC Independent Ethics Committee  
IM immunogenicity  
Index  Studies  ISIS [ADDRESS_37732]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LLN  Lower Limit of Normal  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_37733] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MedDRA  Medical Dictionary for Regulatory Activities  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
SMPG  self-monitor ed plasma glucose  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_37734]  upper limit of normal  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
31  Abbreviation/Acronym  Definition  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
32  1. OBJECTIVES
The objective of the study is to evaluate the safety and efficacy of treatment  and extended treatment  with 
volanesorsen  in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIONALE
2.1 Overview of D isease
Famil ial C hylomicronemi a Syndrome (FCS) i s an i nherited d isease characterized by [CONTACT_37687] i
glyceridemia and chylomicronemia, a nd risk o r history of  pancreatitis.  I t is a rar e autosom al 
recessive dise ase that c an be diagnosed e ither in childhood or adulthood. 
Fasting  plasma triglyceride  (TG) l evels in FCS pa tients ar e typi[INVESTIGATOR_897] 10 -fold to 100-fold a bove normal 
(1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily 
calori e intake) (Brunzell 1999-2011).  Patients with FCS often present in infancy or childhood with 
frequent and severe abdominal pain, repetitive colicky pain,  repeated  epi[INVESTIGATOR_37453], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011
).  Physical examination 
frequently  reveals eruptiv e xanthomas, lipemia retinalis and hepatosplenomegaly, and plasma from 
patients appears lactescent, interfering with  determination of other laboratory parameters (Tremblay et 
al. 2011). 
Patients 
with fasting  triglyce ride levels >  10 mmol/L probably have a component of chylomicronemia.  
Clinical d iagnosis would include  evidence of cl inical f eatures of  chylomicronemia sy ndrome and  
secondary cau ses such
 as uncontrolled t ype 1 o r type 2 diabetes mellitus (T2DM) , hypothyroidism, poor 
diet, alcohol use, nephrotic syndrome or use of associated medications should be ruled out.  The diagnosis 
of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37454] (LPL) enzyme activity in post heparin plasma (Brunzell 1999-2011). 
Patients wit
h FCS ca rry a heavy bur den of  medical compl ications, the m ost ser ious, as described abov e, 
being  an ex treme ri
sk of  recurrent  and potentially f atal pa ncreatitis.  Due to the recurrent epi[INVESTIGATOR_37455], these patients may al so de velop  chronic pancreatitis and  signs of exoc rine or  endocrine 
pancreatic insufficiency, in cluding  diabetes m ellitus  (Gaudet et al. 2013) .  Whi le the pathophysiology 
underlying chylom
icron- related pa ncreatiti s has not b een com pletely el ucidated, 1 hypothesis is that lar ge 
chylomicrons lodged in pa ncreati c capi[INVESTIGATOR_37456], with the subsequent 
release of  free fatty aci ds through t he hydrolysi s of chylomicron -associat ed TGs.  High concentrations of 
free fatty 
acids are thought  to da mage pancreati c cells leading  to emer gent pancreatitis ( Yang e t al. 2009 ; 
Berglund e t 
al. 2012 ). 
The etiology of  extreme hypertriglyceridemi a in FCS is considered to be ineffective triglyceride 
clearance,  due to an extremel y low level of  LPL activit y.  LPL normally functions to hydrolyze 
triglycerides (TG) in chylomicrons along  the luminal surface of ca pi[INVESTIGATOR_11037], m ainly i n heart, sk eletal 
m
uscle, and adipos
e tissue, promoting  triglycerid e clearan ce from  the circulation .  LPL i s regulated by  a 
number of key genes, and loss-of- function  mutations  in one  of these genes, or  the LPL g ene itself, r esults 
in FC S (Surendran e t al. 2012).  In additi on to loss of functi on mutations, null mutations, and nonsen se 
m
utations i n the LPL gene, other genes currently ide ntified in FCS patients , and known to directly 
influence LPL acti
vity include: apolipoprotein C- II (A POC2) a c ofactor for LPL ( Schuster et al. 2011); 
apolipoprotein A
-V (APOA5)  an enhancer of LPL activity  (Schaap e t al. 2004 ); lipase maturation  factor 1 
(LMF1), a transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphospha t
idylinositol-anchored h igh-density lipoprotein ( HDL )-binding protein 1 ( GPI[INVESTIGATOR_37445]1), a 
ISIS [ADDRESS_37735] -mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale  
Apolipoprotein C- III (ApoC -III), a key regulator of plasma triglycerid e levels, is a  79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major regulator 
of lipoprotein metab
olism and plays a pi[INVESTIGATOR_37457] ( Chan  et al. 2008 ).  It is 
a component of triglyceride- rich lipoproteins (TRLs) and
 a potent inhibitor of LPL ( Lemieux et al. 2003 ).  
At higher concentrations apoC- III also inhibits hepatic lipase activity ( Kinnunen and Ehnolm 1976), an 
enzyme which plays an important role in the conversion of dense very-low- density lipoprotein ( VLDL ) to 
intermediate density lipoprotein ( IDL) and to LDL ( Mendivil et al. 2010 ), as well as in the remodeling of 
HDL ( Brown et al. 2010 ).  In addition, increased apoC -III content adversely affects apolipoprotein E 
(apoE)- mediated hepatic uptake of TG -rich remnants ( Mann et al. 1997) .  Thus, elevated plasma apoC -III 
levels are associated with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein -triglyceride ( VLDL -TG) and chylomicrons in plasma and the development of 
hypertriglyceridemia ( Ito et al. 1990).  
 
Figure [ADDRESS_37736]
e Mechanisms  
From Ooi et al. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  
Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in inhibiting LPL, 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
34  apoC-I II inhibits TRL remnant (TG-depleted remnant lipoprotein) uptake by [CONTACT_37689]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or nonsense 
mutations) and negative effects with 
gain of function mutations (Atzmon e t al. 2006; Pollin et al. 2008; 
Petersen et al.  2010).  A novel nonsense mutation in the apoC-III gene was identified in the heritability 
and phenotype intervention (HAPI) heart study in Old Order Amish that results 
in lower plasma apoC-I II 
and TG levels and lower lo w-de nsity lipoprotein-cholesterol (L DL-C), increased HDL-C and reduced 
atherosclerosis (Pollin et al. 2008).  In another study involving a group 
of 214 A shkenazi Jews of 
advanced ag e (had passed or
 nearly reached 100 years of age), genotype analysis revealed a 
polymorphism in the apoC-I II gene (APOC3-641CC genotype) with a clear pattern of age-dependent 
frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein 
profile and increased longevity (Atzmon e t al. 2006).  In contrast to the Amish and Ashkenazi apoC-I II 
polymorphisms 
associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma 
TG have also been recently described (Petersen et al.  2010).  In a cohort of lean (mean body mass index 
[BMI] = 24.7 ± 3.6 kg/m2) Asian Indians, carriers of apoC-I II variant alleles 
(C-482T, T-455C, or both) 
were noted to have significantly higher plasma apoC-III and TG levels, an d decreased ability to clear 
postprandial 
plasma TG from the circulation
.  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC-I II levels in order to r educe the very high circulating 
triglyceride and chylomicron levels that a
re accompanied by [CONTACT_37690]. 
Given the profound reductions in TGs observed with v olanesorsen treatment in FCS patients who have no 
detectable LPL 
activity (See Section 2.3.4), and the mechanistic data available to date on apoC-I II 
function, potential mechanisms that explain how apoC-I II inhibition results in triglyceride r
eduction in 
FCS patients include:  (1) enhancing the very small residual amounts of LPL activity that th ese patients 
may have, below the limit
 of detection of the assay in many cases (2) potentially enhanced activity of 
other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or
 endothelial 
lipase (Kinnunen and Ehnolm 1976), and (3) apoC-I II interaction w ith Apolipoprotein E (apoE), an 
important factor in liver reuptake
 of lipid particles by [CONTACT_37691]-m ediated uptake of lipid particles in 
the
 liver (Breyer et al.
 1999 ), and therefore, reducing apoC-I II might enhance apoE-m ediated  uptake of 
lipid particles.  Volanesorsen-mediated reduction of apoC-III could be contributing to one or all of these 
mechan
isms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC-III lowering mechanism of action, 
volanesorsen may provide the potential to 
manage triglyceride levels in FCS patients. 
2.3 Volanesorsen  
2.3.1 Mechani
sm of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO)  drug target ed to human ap oC-III.  It 
is complementary to a region within the 3 ʹ untranslated region of the apoC-III messenger ribonucleic acid 
(mRNA ) and binds to the mRNA by [CONTACT_37692].  The hybridization (binding) of 
volanesorsen to the cognate mRNA , results in the RNase H1-mediated degradation of the ap oC-III 
mRNA, thus preventing production of the ap oC-III protein.  Maximal antisense- mediated reduction of 
targe t mRNA levels is typi[INVESTIGATOR_37458] 9 0% of control levels in sensitive tissues (Crooke and 
Bennett 1996; Zhang et al. 2010).  Furthermore, reduction in t
arget mRNA levels using th is approach 
correlates directly  with a subsequent reduction in target protein levels.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
35  2.3.2 Chemistry  
Chemically, volanesorsen i s a synthetic oligomer of 20 nucleotides (i.e., a 20-m er) that are connected 
sequentially by [CONTACT_37693].  The nucleotide sequence of volanesorsen (Figure 2)
 is 
complementary
 to a 20- nucleotide s t retc h within the 3ʹ untranslate d region o f the apoC-III mRNA 
transcript at base po sition 4 89-508.  Structurally, t he oligonucleoti de has 3 regions.  T wo (2) of them, the 
5 nucleotide s at the 5′ end and the 5 nucleotide s at the 3′ end, ar e composed of 2ʹ- O-(2-methoxyethyl) 
(MOE) -modified ribonucleotides.  These MOE -modifie d nuc leotide s confe r (1) increased affinity to the 
target m RNA ( Altmann et al. 1996 ; McKay et al.  1999), (2) increased r esistance to exonuc lease s and 
endonucleases (the
reby i ncreasing st ability i n tissue) (Geary et a l. 2003), and ( 3) ameliorati on of some of 
the h igh dos e toxiciti es thereby r esulting i n an improved safet y profile compare d to firs t generation 
antisense drugs containing phosphorothioat e modified oli godeoxynucleotide s (DNA ) (Henry e t al. 2000 ).  
The third region, the ce
ntral portion o f the oligonucl eotide, i s composed o f 10 oligodeoxynucleotides.  
This chimeric de sign i s called a MOE -Gapmer, and volanesorsen employ s this chimeric structure to 
enable use of the R Nase H 1-mechanism for ant isense activity .  This is because whi le the 2 ʹ-MOE 
modification con fers increased stability and a ffinity, it does not support R Nase H1 c atalysis of RNA 
hybridized to 2 ʹ-MOE-m odified nucleotides (McKay e t al.  1999).  This is caused by [CONTACT_37694] 2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H1 
enzymes (Inoue e t al.
 1987; Monia e t
 al. 1993).  B y limiting  the 2ʹ-MOE modification to nucleotides 
f
lanki ng the phos phorothioat e oligodeoxynucleoti de core, the beneficia l attribute s of the 2ʹ-MOE 
chemistry ar e preserved w hile also r etaining R Nase H 1 recognition. 
Figure 2 Design of Chimeric 2ʹ-M OE Phosphorothioate Oligonucleotides 
(MOE-G apmer).  T he sequence of volanesorsen i s shown.  
2.3.3 Preclinical Experience  
Inhibition of apoC -III using volanesorsen  has b
een shown to potently reduce hepatic apoC -III mR NA as 
well as plasma apoC -III protein and TG in a dose - and time- dependent fashion in several species, 
including human apoC-III transgenic mice, and other rodent and monkey models.  Treatment with 
volanesorsen  also resulted in reduced VLDL and chylomicron TG and reduced postprandial TG in 
hype rtriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volan
esorsen  have been assessed in mice, rats, and 
cynomolgus monkeys .  General toxicity studies with volanesorsen  for up to 39 weeks of treatment 
followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology program for 
volanesorsen  consists of single dose safety pharmacology studies in the monkey (cardiovascular) and 
2ʹ-MOE  
 2ʹ-Deoxy  
 2ʹ-MOE  
(RNase H 1 
 Sensitive)  
A  G  C  
 T 
T 
 C  T  
 T 
G  
T 
C  
C 
A 
G  
C 
 T 
T  
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
36  mouse (neurobehavioral and pulmonary assessment studies), in vitro  and in vivo genetic toxicity 
assessment, repeat dose fertility and/or developmental reproductive toxicology studies in the mouse and 
rabbit and evaluation in the in vitro  human Ether -á-go-go-related gene (hERG) assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with those 
expected for the 2′- MOE -class of ASOs.  Treatment -related findings included effects consistent with drug 
accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents 
and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC- III mRNA (>  75%) was not associated 
with any findings that could be considered related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_37737] effects in safety pharmacology studies ( in vitro  and in vivo ) and was 
non-genotoxic ( in vitro  and in vivo ).  Volanesorsen had no effects on fertility or embryo/fetal 
development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was 
detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the 
placenta to reach the fetus.  Reduction of apoC -III mRNA (64% in males and 47% in females) also did 
not affect fertility or cause untoward effects on embryo/fetal development in mice. 
Detailed information concerning the precli nical studies conducted with volan esorsen  can be found in the 
volanesorsen  Investigator’s Brochure.  
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen  can be found in the 
volanesorsen  Investigator’s Brochure .  A summary is included below. 
The clinical experience with volanesorsen includes clinical trials in healthy subjects, patients with 
hypertriglyceridemia, FCS, or familial partial lipodystrophy. Overall, [ADDRESS_37738] 1 dose of volanesorsen. Ninety -five (95) patients with FCS have been enrolled in studies, all showing clinically 
meaningful reductions in plasma triglyceride. Patients with FCS continue on treatment in the open- label 
extension (OLE) and triglyceride reductions persist at similar levels as reported in earlier studies.  
In the completed Phase [ADDRESS_37739] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin). There 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
37  was a reducti
on (mean reduction < 30%) in platelets i n volanesorsen vs. placebo with mean nadirs for all 
doses remaining above the lower limit of normal (LLN). The most frequently reported adverse events 
(AEs) were mild, non- progressive events at t he injection si te. In Phase 2,  a single serious adverse event 
(SAE) of  secondar
y ser um sickness- like reaction  was r eported as related t o Study Drug. 
All c
linica l trials 
of 
volanesorsen ha ve shown large and clini cally meaningful reducti ons in fasting plasma 
apoC- III and  TG (~80% a nd 70%, respecti vely, m ean r educti on from bas eline with 300 mg dose) with a 
very hi
gh de gree of  consistency of  response betw een t he di fferent p atient g roups .  This inc ludes healthy 
volunteers, p atients with m oderat e to severe hypertriglyceridemia no t on backgr ound TG-lowe ring 
therapy, pa tients w ith moderat e to sev ere hypertriglyceridemi a on a background s table fibrate therapy 
(Gaudet et al. 2015 ), patients wit h FC S, and patients with T2DM. I n a Phase 2 study , 3 pa tients w ith FCS  
were treated with 300 mg/wk volanesorsen in an open- label f ashion .  These patients had a mean ba seline 
fasting TG level of 1,844 mg/dL and all 3 patients achieved  TG levels below o
r close to 500 mg/dL 
during the treatment period out to Da y 92 (Figure 3).  Two (2) o f the FCS patients had an absolute 
reduction in fasting TG in excess of 1,500 m g/dL (Gaudet et al. 20 14). 
Figure 3 Fasting
 Triglycerides 
in Patients with FCS Treated with Volanesorsen  
In the completed pooled Phase 3 studies (ISIS 304801-CS6 (hereafter referred to as CS6) and ISIS 
304801- CS16 (hereafter referred to as CS16), the most common AEs associated with volanesorsen 
administration were tolerability at the injection site and platelet reductions. The majority of the injection site AEs were mild, none were severe, and the incidence appeared to decrease over time. No deaths have been associated with volanesorsen treatment to date. No cardiac toxicity was associated with volanesorsen treatment. There were no abnormal QTc findings and no study- drug related adjudicated major adverse 
cardiac events (MACE). There is no evident association between volanesorsen treatment and  changes in 
renal or liver functions. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
38  The safety profile of volanesorsen has been well-described in this development program, which has 
identified 3 safety risks: thrombocytopenia (an identified risk), constitutional symptoms (flu- like 
reactions and influe nza-like illness), and injection site reactions (a tolerability signal). Spontaneous, 
mild-to-severe thrombocytopenia has been described in the FCS patient population ( Gaudet et al. 2017) 
but is increased by [CONTACT_37676]. Less frequent and l ess pronounced platelet de clines were 
also observed with volanesorsen treatment in the hypertriglyceridemic (HTG) population of CS16. When 
fully complied with, frequent monitoring for this effect and appropriate dose adjustments have been 
successful both i n preventing and promptly detecting the occurrence of severe platelet declines and often 
in retaining patients on treatment.  
2.4 Rationale for Dose an
d Schedule of Administration  
The dose and schedule selected for this study is 300 mg per week for 52 weeks, with the option of continuing treatment  for up to an additional 104 weeks.  The dose of 300 mg per week and dose reduction 
of 300 mg every 2 weeks (delivered as a single 300 mg dose) are supported by [CONTACT_37677] [ADDRESS_37740] Level (NOAEL ) was defined by [CONTACT_37696].  No n clinical fin dings were not considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well-tolerated  at dose levels up to 300 mg  in 
patients with high triglycerides (including type 2 diabetes patients and administration in combination with 
fibrates and statins) with the most common AEs being local to the injection site and predominantly mild .  
A pooled analysis of safety for the Phase 2 studies did not demonstrate any clear dif ference in safety or 
tolerability between the different doses tested (100  mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen  was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmacodynamic (PD) effect on the target, apoC- III, with 
a clear difference in the TG -lowering effect between the different doses in the 100  mg to 300 mg dose 
range as compared to placebo . 
In addition to the nonclini cal and clinical experience 
 of volanesor sen, the dose  and schedule of 
administration  is supported by [CONTACT_37697] 2′- MOE -
modified ASOs that have been administered intravenously and subcutaneously in multiple clinical studies at doses up to 1200 mg and for treatment durations that exceed 24 months ( Santos et al. 2015). 
3. EXPERIM
ENTAL PLAN  
3.1 Study Design  
This is a n open- label study of: 
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801- CS16 (index study) roll over FCS patients 
Up to a pproximately [ADDRESS_37741] of the following periods: 3.4.1 Qualification 
A qualification period of up to 2 weeks  (unless approved by [CONTACT_1034]) is given to complete 
qualification assessments outlined in the Schedule of Procedures .  Please refer to Section  4.1 and 
Appendix A . 
3.4.2 Treatment  
The treatment period is 52 weeks.  E ligible patients will report to the Study Center for assessments at 
specified  intervals throughout the 52-w eek treatment period as detailed  in t he Schedule of Procedures 
(Appendix A ).  During the treatment period, v olanesorsen is administered by [CONTACT_37698] (SC) injection 
once weekly. 
3.4.[ADDRESS_37742]-treatment follow-up period 
visits will be  conducted on Weeks 53, 54, 55, 56, 57, 58 , 65, 71, and 78 (Weeks 53,  54, 55, 56, 57, 58 , 
and 71 may be conducted by a home healthcare nurse). 
For patients who have entered the first 52-week extended treatment period, but will not continue into the 
second 52-weeks of the extended treatment period, the post- treatment follow -up period visits will be 
conducted on Weeks 105, 106, 107, 108, 109, 110, 117, 123 and 130 (Weeks 105, 106, 107, 108, 109, 110 and 123 may be conducted by a home healthcare nurse). 
For patients who have entered the second 52-week extended treatment period, the post- treatment follow -
up period visits will be on Weeks 157, 158, 159, 160, 161, 162, 169, 175 and 182 (Weeks 157, 158, 159, 
160, 161, 162 and 175 may be conducted by a home healthcare nurse). 
ISIS [ADDRESS_37743] (DSMB) will review (as needed) safety, tolerability 
and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing assessment of the 
safety and tolerability of volanesorsen , the DSMB will p rovide recommendations to the Sponsor for 
modifying, stoppi[INVESTIGATOR_10483].  Details on the safety assessments, frequency of 
review and meeting schedules are outlined in the DSMB Charter and/or  the statistical analysis plan 
(SAP). 
4. PATIENT  ENROL LMENT
4.1 Qualification
Before patients may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s written 
independent ethics committee/institutional review board (IEC/IRB) approval of the protocol, informed 
consent form, and all other patient  information. 
Patients or their legally acceptable representatives must sign the consent form  before any study- specific 
procedures or evaluations related to this open- label study are performed .   
During the qualification period, the eligibility of the patient to enroll in the open- label study will be 
determined.  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 stud ies may be used for 
qualification.  A period  of up  to 2 weeks after completion of the ISIS 304801- CS6 or  ISIS 304801- CS16  
index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will 
retain the unique patient  identification number that was assigned to them during the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies.  The patient identification number will be used to identify the patient  
throughout the extension trial and must be used on all study documentation related to that patient .  The 
patient  identification number must remain constant throughout the extension trial. 
4.[ADDRESS_37744] been 
completed
 and after the Investigator has verified that they are eligible per criteria in Sections 5.1  and 5.2.  
No patient may begin treatment prior to enrollment. 
Eligible  
patients will be enrolled u
sing an Interactive Voice/Web-Response System (IXRS). 
5. PATIENT ELIGIBILITY
To be eligible to participate in this study candidates must meet the following eligibilit y criteria w ithin [ADDRESS_37745] give written informed consent to participate in the study (signed and dated) and any
authorizations required by [CONTACT_2371]
2. Age ≥ 18 years at time of informed consent
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
41  3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 (index  
studies) with an acceptable safety profile, per Sponsor and Investigator 
judgement.
Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the f ollowing criteria in 
order to enter into the open-l abel Study:
a. History of
 chylomicronemia as evidenced by [CONTACT_37684] (a creamy  
top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG  
measurement ≥ 880 mg/dL (10 m mol/L)
b.A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) 
supported by [CONTACT_37685] 1  of
 the following:
•Confirmed homozygote, compound heterozygote or double heterozygote for known loss-
of-function mutations in Type 1-causing genes (such as LPL, 
apoC-II, GPI[INVESTIGATOR_37445]1, or  
LMF1)
•Post heparin plasma LPL activity of ≤ 20% of normal in medical history.  Note: testing of  
LPL activity should not be performed to confirm eligibility for the study.
c.Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the ISIS 304801-CS16 index study
4.Able and willing  to participate in 
a 78-w eek study
5.Satisfy 1 of the following:
a. Females:  Non-pregnant and non-l actating; surgically s
terile (e.
g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post-menopausal (defined as  
12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤  55
 years, 
12 months of spontaneous amenorrhea without an alternative medical cause and f ollicle
 
stimulating hormone (F SH) l evels in the postmenopausal range for the laborato
ry involved), 
abstinent*, or if engaged in sexual relations of chil d-bearing potential, patient is using
 an 
acceptable contraceptive method  (refer to
 Section 6.3.1 ) from time of signing the informed 
consent form until [ADDRESS_37746] dose of Study Drug administration.
b. Males:  Surgically sterile,  abstinent* o r if en
gaged in sexual r elations with a female of child-
bearing potential, patient is utilizing an acceptable contraceptive method (refer to
Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_37747] 
dose of Study Drug administration. 
* Abstinence is onl
y acceptable as true abstinence, i.e., when this is in line with the preferred and
usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are notacceptable methods of contraception
5.2 Exclusion Criteria  
1.Diabetes mellitus with any of the following:
a.Newly diagnosed within 12 weeks of Qualification
b. HbA1c ≥ 9.0% at Qualificatio n
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
42  c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of Qualification  [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the  treatmen t period of the 
Study ( with the exception of ± 10 units of insulin ) 
e. Current use of glucagon -like peptide -1 (GLP -1) agonists 
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome 
3. Active pancreatitis within 4 weeks prior to  Qualification  
4. History within 6 months of Qualification  of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or 
unstable congestive cardiac failure requiring a change in medication or major surgery within 3 
months of Qualification  
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation 
of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL 
• ALT > 2.[ADDRESS_37748] 
• AST > 2.[ADDRESS_37749] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine dipstick.  In 
the event of a positive test eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥ trace positive) for blood on urine dipstick.  In the event of a positive test eligibility may be confirmed with urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37446]-
Gault for estimation of glomerular filtration rate (GFR ) in patients  with low body weight 
after discussion with Sponsor Medical Monitor) 
c. Cardiac Troponin I > ULN at Qualification  
d. LDL -C > 130 mg/dL at Qualification  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], 
would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP >  160/100 mm Hg) 
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding diathesis or 
coagulopathy or clinically- significant abnormality in coagulation param eters at Qualification  
8. History of heart failure with NYHA greater than Class II  
ISIS [ADDRESS_37750] for human immunodeficiency virus (HIV), hepatitis C or 
chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1 month of Qualification , or 5 half- lives of investigational agent, whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section  6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and over-the-counter [ OTC ]), or fibrates unless on a 
stable dose for at least 3 months prior to Qualification  and dose and regimen expected to 
remain constant during the treatment period.  Patients taking OTC omega- 3 fatty acids sho uld 
make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable dose for at least [ADDRESS_37751] 4  weeks prior to 
Qualification  and dose and regimen expected to remain constant during the treatment period 
f. Glybera gene therapy within 2 years prio r to Qualification  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable 
dose for at least [ADDRESS_37752] 4 weeks prior to Qualification  (Occasional or 
intermittent use of over -the-counter medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of >  499 mL within 60  days 
of Qualification  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801) 
17. Have any other conditions, including new or worsening of existing condition, which, in the 
opi[INVESTIGATOR_37450], or 
could interfere with the patient participating in or completing the study 
ISIS [ADDRESS_37753] 
patient’s Week [ADDRESS_37754]. 
During the treatment period, 
patients
 will report to the study center for clinic v isits a minimum of 5 times 
during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug 
will be administered once 
weekly (Section 8.1).  C ollection a
nd measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, 
and urinalysis), A Es, concomitant medication/procedu re 
information, lipid panel, blood viscosity, v olanesorsen pl asma concentrations, immunogenicity (IM) 
testing, p latelet ag
gregation, liver/spleen magnetic resonance imaging (MRI), e lectrocardiograms 
(ECGs), e chocardiograms and quality of l
ife assessments will be performed according to the schedule of 
procedures in Appendix A.  A dverse events at the injection site should  be collected
 as adverse events.  
Dietary counseling will be reinforced at intervals throughout the treatment and follow-up period and all 
patients will complete a 
daily food diary for o ne week prior to their quarterly visit.  All blood and urine 
samples should be c ollected prior to volanesorsen administration.  Blood sampling
 at Weeks 3, 4, 5, 6, 7, 
8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, [ADDRESS_37755] assessments and procedures done during Weeks 
54-156 a s per the Schedule of Procedures i n
 Appendix A.  Assessments and procedures may be conducted 
by [CONTACT_5640] a home healthcare service or the Study Center, however the patient will be required to visit the 
study center approximately every  3 months.  Study Drug will be administered once weekly unless the 
patient
 i
s on a biweekly treatment
 schedule for safety reasons (Section 8.1).  Collection and measurement 
of vital signs, clinical laboratory parameters (including hematology, ser um chemistry, and urinalysis), 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
45  AEs, concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, IM 
testing, ECGs, and physical examinations will be performed according to the Schedule of Procedures in 
Appendix A.  Advers e events at the injection site should be collected as adverse events.  Dietary 
counseling will be reinforced at intervals throughout the extended treatment period.  All blood and urine 
samples should be collected prior to volanesorsen administration.  Blood sampling will be conducted 
weekly and may be conducted by a home healthcare nurse.  Approval for study procedures to be 
conducted by a home healthcare nurse on other outpatient visit days will require prior approval by [CONTACT_1034].  Patients must be fasted prior to drawing all blood samples and samples drawn locally should also be sent to the central laboratory for analysis whenever possible.  Treatment  instructions and training 
will be provided to the patient where applicable.  
6.1.4 Pharmacokinetic (PK) Subgroup  
A subgroup of patients will participate in an e xtended P K collection .  Patients in this subgr oup w ill have 
more freque nt PK
 sampling over a 24-hour period following the first dose on Study Day [ADDRESS_37756] aw after 
treatment  on Day 1.  The detailed P K sam pling  schedules are outlined in Appendix C . 
Participation  in the PK sub
group i s optiona l fo r sites and pa tients, and conse nt may be withdrawn f or the 
s
ubgroup- specific procedures (e.g. , multipl e blood draw s for PK) withou t being w ithdraw n from the 
study.  If a patient withdraws consent from the subgroup procedures, he/she should remain on study and 
continue to follow all the non-subgroup assessments and procedures as 
outlined in Appendix A. 
6.1.[ADDRESS_37757] 9 Study Center visits on 
Weeks 53, 54 , 55, 56, 57, 58, 65, 71, and 78 ( Week s 53, 54, 55, 5 6, 57, 5 8, and 71 may be conducte d by a 
home health
care nurse).  
For patients who enter the first 52-week extended treatment period, but will not continue into the second 
52-weeks of the extended treatment period, the post- treatment follow -up period visits will be conducted 
on Weeks 105, 106, 107, 108, 109, 110, 117, 123 and 130 (Weeks 105, 106, 107, 108, 109, 110 and 123 
may be conducted by a home healthcare nurse).  
For patients who enter the second 52-week extended treatment period, the post-treatment follow -up 
period visits will be on Weeks 157, 158, 159, 160, 161, 162, 169, 175 and 182 (Weeks 157, 158, 159, 
160, 161, 162 and 175 may be conducted by a home healthcare nurse). 
These visits are outlined in the Schedule of Procedures in Appendix A. 
6.[ADDRESS_37758] of these analytes  is  contained in 
Appendix B . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
46  Each time a hemato logy lab is drawn and sent to the central laboratory for analysis , an additional sample 
should be collected in parallel and analyzed locally.  In the event that both the central and local sample 
are unreportable (e.g., due to hemolyzed or clumped blood samples), another sample must be repeated 
within [ADDRESS_37759] be reviewed by [CONTACT_37699].  All platelet count results will be promptly reviewed by [CONTACT_37700] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm
3, or the dose 
pause rule of 75,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor. 
Should a patient experience constitutional or flu- like symptoms after Study Drug administration, 
investigators may consider additional laboratory assessments.  For example, plasma and serum samples may be drawn for complement (Total C3, C4, C5a and Bb), hi gh-sensitivity C -reactive protein (hsCRP ) 
and for cytokine analysis.  
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A) .  Vital signs should include weight, blood pr essure, pulse rate, respi[INVESTIGATOR_37459].  Blood pressure and pulse rate will be recorded after the patient has been in a sitting position 
for at least 5 minutes .  Semi -supi[INVESTIGATOR_37460] (preferentially on the left arm) .  Height will be measured at  the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37461] n umber/duration of the events will be recorded.  Physical exams should also include skin 
examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37701] (for ISIS 304801-CS16 roll over patients) and repeated at Week 52.  Images will be 
evalu ated by [CONTACT_37702], blinded to the patient’s treatment assignment. 
6.2.[ADDRESS_37760]- treatment follow -up period. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
47  6.2.5 MRI  
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having meta l implants . 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37703].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, Week  13, 
Week  26, and Week 52. During the post -treatment follow -up, patients will complete an EQ-5D and SF-[ADDRESS_37761]- treatment follow -up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows: 
1. All patients will be required to maintain a [ADDRESS_37762]- treatment follow -up, patients will complete a 7-day food diary prior to 
Week s 65 and 78. 
2. Patients will receive diet/alcohol counseli ng by [CONTACT_37704].  Qualified study personnel will telephone the patient to 
provide diet/alcohol counseling for visits that are conducted by a clinical service.  
3. In addition to the 7- day f ood diary and the diet /alcohol counseling during clinic visits, telephone 
calls from a dietitian or qualified study personnel to assess as to how each patient is maintaining 
their diet will be conducted randomly during the treatment and post treatment follow-up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis will be collected for each patient.  
6.2.10 Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2)  
Patient records will be reviewed for incidents of acute pancreatitis occurring up to [ADDRESS_37763] refrain from sperm/egg donation and either 
be abstinent or, if engaged in sexual relations of child-bearing potential, practice effective contraception 
from the time of signing the informed consent form until at least [ADDRESS_37764]’s last dose of study trea tment.  
For the purposes of this Study, women of childbearing potential are defined as any female who has 
experienced menarche, and who does not  meet 1 of the following conditions:  
• Postmenopausal:  12 months of spontaneous amenorrhea in females >  55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative medical 
cause  and FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy  
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at follow -up, or 
the use of condoms together with spermicidal foam/gel/film/ cream/suppository.  Male patien ts 
must also encourage their female partner to use effective contraception from the time of signing 
the informed consent until 3 months after the patien t’s last dose of study treatment .  Effective 
contraceptive for the female partner includes: surgical sterilization (e.g., bilateral tubal ligation), 
hormonal contraception, intrauterine contraception/device, or barrier methods (female condom *, 
diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  
Male patien ts with partners that are pregnant must use condoms to ensure that  the fetus is not 
exposed to the Study Drug. 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical sterilization 
(e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 2 
barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical 
cap) together with spermicidal foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used togethe r as friction between the two can 
result in either product failing. 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
6.3.[ADDRESS_37765] 10 hours and preferably not more than 12 hours before visits requiring  fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_37766] will explain that the patient is in a clinical trial and that 
serum lipase and/or amylase measures should be done in order to adjudicate the event, based on Atlanta 
Classification ( Banks et al. 2013).  I f serum or amylase activity is less than 3  x upper limit of normal 
(ULN), imag
ing, preferably contrast- enhanced computed tomography, should be considered to confirm 
the diagnosis of acute pancreatitis per the Atlanta Criteria. 
7. STUDY DRUG
7.[ADDRESS_37767] (ISIS 304801) characteristics are listed in Table 1. 
Volanesorsen (ISIS 304801) is contained in glass prefilled sy ringes (PFS) .  Volanesorsen a nd its storage 
and preparati on instructions will be provided by [CONTACT_16015] .  Volanesorsen must be stored 
securely a t 2 °C to 8 °C and be protected from lig ht. 
Table 1  Volanesorsen ( ISIS 3048 01) Characteristics 
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
7.2 Packaging and La
beling  
The Sponsor will provide the Investigator with packaged volanesorsen labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of volanesorsen  
provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to the Sponsor or 
designee.  All used syringes must be disposed of as per the site’s hazardous waste destruction policy.  
8. T REATMENT OF PATIENT S
8.1 Volanesorsen  Administration
For each individual patient, volanesorsen  will be administered subcutaneously  as a single 1.5 mL 300 mg 
injection once weekly for Weeks 1 -52.  Patients entering this ISIS 304801-CS7 study on a reduced dose 
or dose frequency of Study Drug ( volanesorsen ), for safety or tolerability reasons in their index study 
(ISIS 304801-CS6 or ISIS 304801-CS16), will continue to receive Study D rug as a single 300 mg/1.5 mL 
injection once- weekly for Weeks 53 -156 as outlined in Sections 8.5 and 8.6.  Patients on dose reduc
tion 
will receive 300 mg/1.[ADDRESS_37768] 2  days apart.  
Please refer to the Study Drug Manual provided by [CONTACT_37705]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol-required drugs. 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treat ment procedures for this study. 
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study.  
8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_37769] measurement prior to Day 1  (e.g., qualification assessments or assessments from  the final visit s of 
ISIS 304801- CS6 and ISIS 304801- CS16  index studies if used for qualification) . 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are provided 
for the monitoring of selected parameters chosen based on preclinical and clinical observations.  
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), the initial 
clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37463] (ideally in the same laboratory that performed the initial 
measurement) on new specimens.  All new specimen collections should take place as soon as possible 
(ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], i f the initial laboratory result is 
observed during the Treatment Period , the results from the retest must be available prior to administering 
the next dose of volanesorsen . 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirmation of 
additional lab values.  
Re-treatment  Guidance :  Patien ts with initial laboratory test values that reach a stoppi[INVESTIGATOR_37464]-dosed until the re- test results are available.  In general, patien ts who do not meet the stoppi[INVESTIGATOR_37465] .  However, the Investigator and the Sponsor Medical Monitor 
(or appropriately qualified designe e) should confer as to whether additional close monitoring of the 
patien t is appropriate .  Reduction in dose or dose frequency may also be initiated as noted in Section  8.7.  
If any of the stoppi[INVESTIGATOR_37466] (refer to Sections 8.6.1 to 8.6.3) are met, the pa
tient will be 
dose paused or permanently
 discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further 
treatment with volanesorsen  and evaluated fully as outlined below and in consultation with the Sponsor 
Medical Monit or or appropriately qualified designee and will be followed up in accordance with 
Section  8.8 of the protocol.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
51  8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug-Induced Liver Injur y:  
Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human Services, Food 
and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in  Section  8.[ADDRESS_37770] measurement that is >  [ADDRESS_37771] (or the greater of [ADDRESS_37772] if the baseline value was > ULN)  at any time during the study ( Treatment or Post -Treatment 
Period ), the initial measurement(s) should be confirmed as described above.  Additiona l confirmatory 
measurements should also be performed if ALT or AST levels increase to [ADDRESS_37773] . 
Frequency of Repeat Measurements:  Patien ts with confirmed ALT or AST levels >  [ADDRESS_37774] (or the 
greater of [ADDRESS_37775] if the baseline value  was > ULN)  should have their liver 
chemistry tests (ALT, AST, alkaline phosphatase ( ALP), international normalized ratio ( INR) and total 
bilirubin) retested at least once- weekly until ALT and AST levels become ≤ 1.[ADDRESS_37776] or 1.2 x baseline 
value  if the baseline value was > ULN. 
Further Investigation into Liver Chemistry Elevations :  For patients wit h confirmed ALT or AST levels >  
[ADDRESS_37777] (or the greater of [ADDRESS_37778] if the baseline value was >  ULN) , the following 
evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, herbal 
and dietary supplement preparations), alcohol use, recreational drug use, and special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV antibody 
panel) 
5. Serology for autoimmune hepatit is (e.g., antinuclear antibody [ANA] ) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or MRI 
scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical 
Monitor.  Repet ition of the above evaluations should be considered if a patient ’s ALT and/o r AST levels 
reach [ADDRESS_37779] be documented in the patient’s 
medical records.  
ISIS [ADDRESS_37780] with the study patients.  However , if the above options are not possible, a temporary interruption 
of study treatment will be planned w ith a platelet count drawn within 3-5 days prior to departure and w ith 
a prompt blood draw upon the patient’s return which must be reporte d and reviewed by [CONTACT_37706]. 
Patients on dose pause should be monitored as per the platelet monitoring rules outlined in Section  8.8.1 
until Study Drug administration 
is resumed. 
The tests outlined in Table 2 should also be performed as soon  as possible.  Additional lab  tests will be 
determined by [CONTACT_13099]
r Medical Monitor or designee in consultation with the Investigator.  
Any case of  a platelet co unt < 50,000 /mm3 should be reported in a n expedited fashion t o the Sponsor (See 
al
so Stoppi[INVESTIGATOR_37468] 8.6.3). 
Table  2 Labs to 
Be Performed in the Event of a Platelet Count Less than the Lower Limit of 
Normal ( ×2) or < 100,000/mm3 (×1)* 
*In patients who have any 2 occurrences (consecutive or non- consecutive) of platelet count less than the
lower limit of normal or who have any 1 occurrence of platelets <  100,000/mm3.  Labs only need to be
performed once.  Labs may be collected over multiple visits, if blood requirements are a concern, as per
investigator discretion.
Note:  The following labs may change as additional data is assessed, and sites will be updated regardingany changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV  
Parvo B19  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
53  Auto -antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
 
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -relevant , 
non-major bleeding events (which are defined in Section  8.6.3 ), for example excess bruising, petechiae, 
gingival bleeding on brushing teeth.  If a m inor bleeding event occurs, the Investigator must notify the 
Sponsor Medical Monitor and additional testing of coagulation parameters activated partial 
thromboplastin time (aPTT ), prothrombin time ( PT), INR  and platelet count should be performed. 
8.5.4 Safety Monitoring for Constitutional Symptoms  
Patients will be instructed to promptly report any signs of symptoms of fever or constitutional  symptoms 
that may arise during the study and the Investigator should closely evaluate all potential causes, including concomitant illness.  Patients that experience persistent constitutional symptoms should be discussed with 
the Sponsor Medical Monitor or designee to determine whether additional monitoring or laboratory t ests 
are required.  
Should a patient experience constitutional or flu- like symptoms after Study Drug administration, 
investigators may consider additional laboratory assessments.  For example, plasma and serum samples may be drawn for complement (Total C3, C4, C5a and Bb), hsCRP and for cytokine analysis. 
8.5.[ADDRESS_37781] to notify the Investigator if a patient has a  low-
density lipoprotein -cholesterol ( LDL -C) > 160 mg/dL (> 130 mg/dL for patients with T2DM) on 
2 consecutive visits.  If this occurs, LDL -C values for this patient will be unblinded for the remainder of 
the study and the Investigator will be encouraged to initiate/adjust treatment to lower LDL -C according to 
country- specific guidelines (e.g., initiate statin therapy or increase the statin dose for patients who are 
already on treatment).  
8.5.[ADDRESS_37782] practice 
guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In addition, patients 
who are not on insulin but use a glucometer should also bring their glucometer and/or glucometer log 
printout to every clinic visit.  
• The Investigator  or delegate will review the glucometer reading or printout at every clinic visit to 
evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed threshold values as 
per the Safety Monitoring Rules for Hyperglycemia below. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
54  All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, as well 
as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator  or delegate will ask patients at every clinic visit if they made changes in their 
insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic epi[INVESTIGATOR_1865].  
o Patients will be instructed on the monitoring and management of hypoglycemic epi[INVESTIGATOR_37470].  
o Documente d symptomatic hypoglycemic epi[INVESTIGATOR_37471] ( CRF ). Documented symptomatic hypoglycemia is defined as 
typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as one in which the patient requires assistance of 
another person to obtain treatment for the event and has a plasma glucose level ≤ 70 mg/dL (≤ 3.9 
mmol/L).   The rescue treatment of hypoglycemia may include IV glucose or buccal or intramuscular 
glucagon. 
The definition of sev ere symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473] -treatment and which were thus thought to place patients at 
risk for injury to themselves or others.  Note that “requires assistance” means that the patient could not 
help himself or herself.  Someone being kind that assists spontaneously the patient when not necessary 
does not qualify as “requires assistance.”  
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take immediate action 
to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  Howe ver, there are certain 
classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be 
low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could occur if blood sugar correction is not 
performed.  
If patients suspect they might be having a hypoglycemia reaction, they sho uld check their blood glucose 
using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.   
If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for 
example, the n obtain and record a blood glucose value as soon as possible thereafter.  The time and nature 
of treatment should be noted, and especially if any blood glucose result was before or after treatment.  It 
would be helpful for the patient to note if a contrib utory factor (e.g., missed or reduced meals, 
unaccustomed physical activity) occurred earlier in the day of the event.  
ISIS [ADDRESS_37783] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be allo wed during 
the course of the study, unless specific threshold values are met at Week 13 or later and confirmed on 
subsequent testing (ideally within [ADDRESS_37784]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  If a fasting  
pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should check it again on the 
following [ADDRESS_37785] the Investigator and an unscheduled central laboratory fasting plasma glucose (FPG) measurement and HbA1c should be performed. 
The threshold values are defined as: 
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 1% from 
baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_37786])  
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency (e.g., surgery, infection), the Investigator can take appropriate measures for glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate  
If any of the above can reasonably explain the insufficient glycemic control, the Investigator should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event 
(AE)/concomitant medication parts of the e- CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional 
and stress on the absolute need to be compliant to diet and lifestyle recommendations 
A FPG/HbA1c follow- up assessment should be arranged after appropriate action has been taken.  If none 
from the above-mentioned reasons can be found, or if appropriate action fails to decr ease FPG/HbA1c 
under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37474], treatment  with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued treatment  and 
the need for any modification to treatment schedule (refer to Section  8.7) will be determined by [CONTACT_37707].  
ISIS [ADDRESS_37787] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an alternative 
explanation as discussed with the Sponsor Medical Monitor,  treatment  of a patient  with volanesorsen  
will be stopped permanently ; values that are not confirmed due to failure to retest or missing lab values 
will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_37788] >  [ADDRESS_37789], which is confirmed and persists for ≥ [ADDRESS_37790] >  [ADDRESS_37791] (or the greater of [ADDRESS_37792] if the baseline value was 
> ULN) , which is confirmed and total bilirubin >  [ADDRESS_37793]  or INR  > 1.[ADDRESS_37794] >  [ADDRESS_37795] (or the greater of [ADDRESS_37796] if the baseline value was 
> ULN), which is confirmed, and the new appearance (i.e., onset coincides with the changes in 
hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, 
rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37708]  
8.6.[ADDRESS_37797] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 3 criteria 
below, treatment  of a patient with volanesorsen  may be stopped  temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL (26.5 μmol/L) and 
≥ 40% above baseline creatinine values and > ULN 
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative tot al urine protein measurement of >  1.0 g/24 hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault ≤ 40 
mL/min that is confirmed by a 24- hour urine collection  
The possible treatment  re-initiation or follow -up schedule for any events meeting either of these criteria 
will be determined by [CONTACT_37710]. 
8.6.3 Stoppi[INVESTIGATOR_10020] s for Platelet Count Results  
Actions to be taken in  the event of a low platelet count are summarized in  Table  3 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or clinically -
relevant  non-major bleeding (defined below; Schulman et al. 2005), treatment  of a patien t with 
volanesor
sen will be stopped permanently.  The follow -up schedule for any events meeting this stoppi[INVESTIGATOR_37475].  
In the event of any platelet
 count less than 5 0,000/mm3, or a rate of decline ≥ 50% between two  
consecutive assessments, irrespective of the platelet level,  or a platelet count less than 75,000/mm3 that 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
57  occurs whil e the patient i s on treatment  at 300  mg every 2 w eeks, then treatment  of a pat ient w ith 
volanesorsen w ill be stopped permanently.  P latelet count  will be  monitored as outlined in Table 3. 
Administration  of
 steroids is recommended f or patients whose platelet count i s less than 50,000/mm3.  
Recov
ery in platelet count may be accelerated by [CONTACT_37711].  Treatment 
guidelines for immune thrombocytope nia (Provan et al . 2010) recomme nd Dexamethasone 40 mg daily 
for 4 days ever
y 2-4 weeks for 1- 4 cycle s; Prednis(ol) one 0.5-2 mg/kg/ d for 2-4 weeks then  taper; o r 
Methylprednisolone 30 mg/kg/day for 7 days ( note:  may require continuation w ith or al steroids a fter 
methyl pre
dnisolone).  In order to reduce the unlikely but pote ntial increase d risk of pancreatitis during the 
per
iod of corticosteroid t herapy, t riglyceride levels will be  monitored weekly , and AE monitoring will 
continue , during corticosteroid treatment and the laborator y alert w ill be changed fr om an increase of 
2,000 to 500 mg/dL during tha
t period. 
In the event of a platelet count less than 75,000/ mm3, and i n the absence of major ble eding or clinically -
relevant  non- major bleeding (defined below; Schulman e t al. 2005), treatment  of a patient with 
volanesorsen should be suspende d temporarily until the plate let count has recovered to> 100,0 00/mm3.  If 
treatment  is continue d it should be at a reduced dose frequency of 300 mg every 2 w eeks ( refer to 
Section  8.7).  The s ui
tability of  the patient f or continued  treatment  will be  det ermined by  [CONTACT_37712] r ate of 
decline  in the patient’s platelet cou nt, w hether a ny bleedi ng events wer e experienced  by [CONTACT_102], a nd 
the speed of recovery of platel et count upon holding of treatment. 
If after the  first treatment  recha llenge the platelet count ag ain  falls below  75,000/mm3, then t re atment  of 
the patient with Study Drug will be stopped permanently. 
Definition of Major Bleeding Events (Schulman et al. 2005): 
•Fatal bleeding, and/or
•Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], intraocular,
retroperitoneal, intraarterial or pericardial, or intramuscular with compartment syndrome, and/or
•Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, orleading  to transfusion of 2 or more units of whole or red cells
Definition of Clinically-Relevant, Non-Major Bleeding Events (Schulman et al. 2005): 
1.Multiple -source bleeding
2. Spontaneous hematoma > 25 cm2
3. Excessive wound h
ematoma (not injection site related)
4.Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an intervention)
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis
6. Bleeding after venipuncture for > [ADDRESS_37798] be documented in 
the patient’s medical records.  Monitor every 1 week unless 
otherwise specified  
In addition, platelet function may be evaluated during the study by 
[CONTACT_37680], using an approved point - of-care diagnostic device, in 
some patients.  This additional functional testing may be performed at 
selected study centers.  
Patients on dose pause should be 
monitored as per the platelet monitoring rules outlined in Section  8.8.1  until Study Drug 
administration is resumed.  
Obtain additional lab  tests  
(Table  2) if 2 occurrences  consecutive 
or non-consecutive of platelet count 
140K - > 100K/mm
3 or 1 occurrence 
of platelet count ≤  100K/mm3.  Labs 
only need to be performed once.   Labs 
may be collected over multiple visits, if blood requirements are a concern, as 
per Investigator discretion.  
> 100K/mm3 Once w eekly 300 mg Study Drug 
administration  
100K/mm3 - >75K/mm3 Permanently reduce dose frequency to 300 mg 
every 2 weeks . 
75K/mm3 - >50K/mm3 • If occurs while on dose of 300 mg every2 weeks , then permanently discontinue
Study Drug, otherwise dose pause.  If
dose pause is ≥  [ADDRESS_37799] discontinue treatment and enter the
follow up period.
• When platelet count returns to
> 100K/mm
3 restart treatment  at dose
frequency of 300 mg every 2 weeks  in
consultation with the  Sponsor Medical
Monitor• Monitor every 2-3 days until
2 successive values are
> 75K/mm3 then monitor every 1
week
• Consider discontinuation of
antiplatelet agents/NSAIDS/anticoagulant medication
< 50K/mm3 or a rate of decline ≥ 
50% between two consecutive 
assessments, irrespective of the platelet level  Permanently discontinue Study Drug  and the 
patient will enter the follow up period . •Monitor daily until 2 successive
values show improvement then
monitor every 2-3 days until2 successive values are > 75K/mm
3 
then monitor every 1 week
•Patient should be evaluated by a
hematologist to provide diagnosticand therapeutic management
•Steroids recommended *.  It is
strongly recommended that, unless
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
59  Platelet Count on Rx  Drug Dose Monitoring  
the patient has a medical 
contraindication to receiving 
glucocorticoids, the patient receives glucocorticoid therapy to reverse the 
platelet decline.   
•Monitor triglyceride levels weekly 
and continue AE monitoring during 
steroid therapy  
•Discontinue antiplatelet agents/NSAIDS/ anticoagulant medication while platelet count is<  50K/mm
3 if 
possible . 
Legend:  
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immunethrombocytopenia ( Provan et al. 2010 ) recomm 
end Dexamethason
e 40 mg daily for 4 days every 2 -4 weeks for 1 -4 cycles; 
Prednis(ol)one
 0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30  mg/kg/day for 7 days ( note:  may require 
continuation with oral steroids after Methylprednisolone).  I n order to reduce the unlikely but potential increased risk of  
pancreatitis during the period of corticosteroid therapy, triglyceride levels will be monitored weekly, and AE monitoring will continue, during corticosteroid treatment  and the laboratory alert will be changed from an increase of 2,000 to 500 
mg/dL during that period. 
8.[ADDRESS_37800] be made in accordance with Section  8.6.3 and Table  3 
(above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose frequency to [ADDRESS_37801] be discussed with, and approved by, the Study Medic al Monitor prior to initiation .  Up to 
2 adjustments in the treatment schedule may be allowed . 
Patients may be dose paused in response to AEs, and the Study Medical Monitor  is informed.  If a patient 
is dose paused for ≥ [ADDRESS_37802] permanently discontinue study treatment for any of the following: 
•The patien t becomes pregnant .  Report the pregnancy according to instructions in Section  9.5.4
•The patien t withdraws consent
•The patien t experiences an AE that necessitates permanent discontinuation of study treatment
•The patien t develops laboratory test abnorm alities that meet any of the stoppi[INVESTIGATOR_37477]  8.6
•The patient is dose paused for ≥ [ADDRESS_37803] 6 weeks after discontinuing Study Drug.  
Following this period, if the platelet count is stable (a t least 3  consecutive values that are stable as 
determined by [CONTACT_1034] M edical Monitor and >  100,000/mm3), the next platelet count should be taken 
within at least [ADDRESS_37804] 12 weeks after discontinuing Study 
Drug .  Any patient who discontinues treatment after  Week 44 should also be strongly encouraged to 
attend  a final follow -up visit ( Week 78 visit assessments) approximately [ADDRESS_37805] 12 weeks after discontinuing Study 
Drug.  
If the patient declines or is unable to participate in the above , an early termination (ET) visit 
(Week 52 visit assessments ) should be performed at the time of withdrawal, at a minimum, and ideally 
within [ADDRESS_37806] 6 
weeks after disc
ontinuing Study Drug.  Following this period, if the platelet count is stable ( at least 3 
consecutive 
value s that
 are stabl e as determined by  [CONTACT_37683] > 100,000/mm3), 
the next platelet count s hould be  taken w ithin a t least [ADDRESS_37807] 12 
weeks after discontinuing Study Drug.  Patients should al so be encouraged t o undergo a  final follow -up 
visit ( Week 78, s ee Appendix A ) prior to leaving the  study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange for the 
patient to have appropriate follow -up until the AE has resolved or stabilized.  
8.[ADDRESS_37808] be withdrawn from the study for any of the following: 
•Withdrawal of c
onsent
•The patient  is unwilling or unable to comply with the protocol
Other reasons for withdrawal of patient s from the study might include: 
•At the discretion of the Investigator for medical reasons
•At the discretion of the Investigator or Sponsor for noncompliance
•Significant protocol deviation
•Commercialization of product
ISIS [ADDRESS_37809].  T hese patients should be encouraged to 
complete the ET study procedures and observations at the time of withdrawal (see Section 8.8 and 
Appendix A
). 
For patients withdrawn for reasons other than withdrawal of consent every effort should be made to 
complete the early termination study procedures and observation s at the
 time of withdrawal (s ee 
Section 8.8 and A ppendix A). 
8.[ADDRESS_37810] be recorded on the patient ’s CRF .  
AEs related to administration of these therapi[INVESTIGATOR_37478]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-counter 
medications, herbal medications and vitamin supplements) administered between signing informed 
consent and completion of the post -treatment follow -up period.  All concomitant medications/treatments 
and significant non-drug therapi[INVESTIGATOR_014] (including supplements and assistive device s) received by a patient, 
including changes in the patient’s current medications, must be recorded in the patient’s source 
documents and CRF.  Patients taking over the counter ( OTC ) omega -3 fatty acids should make every 
effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_37713]. 
Disallowed Concomitant Therapy  
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega- 3 fatty acids  
[including OTC preparations] ), GLP -1 agonists, Glybera, or systemic corticosteroids may be started or 
adjusted after  basel ine Qualification .  Doses of existing oral anti -diabetic medication, oral contraceptives, 
hormone replacement therapy, anticoagulants, or drugs or dietary supplements with potential lipid-
altering effects should not be adjusted .  Study patients are prohibited from receiving other experimental 
agents during the study.  This includes marketed agents at experimental dosages that are being tested for 
the treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee pri or to initiating any new medication, 
including non-prescription or herbal compounds or any other non-drug therapy. 
8.10.2 Concomitant Procedures  
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) or 
diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between signing of 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
62  informed consent and Week 78 (or Week [ADDRESS_37811] or second extended 
treatment period, respectively ) visit. 
Disallowed Concomitant Procedure  
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment is to b e monitored and recorded by [CONTACT_37714].  The Study Center staff 
is required to document the receipt, dispensing, and return /destruction  of volanesorsen .  Patients that are 
self-administering volanesorsen  at home must  record treatment in a treatment diary that wi ll be reviewed 
periodically by [CONTACT_37715].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_37812] of the clinical trial.  
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the I nvestigators of serious 
adverse events (SAEs) including suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) per the 
International Conference on Harmoniz ation ( ICH) guidelines E2A and ICH E6 (R2) .  Country- specific 
regulatory requirements will be followed in accordance with local country regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any SAE 
according to applicable regulations.  The Independent DSMB  will be notified of any SAE as specified in 
the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor  or designee  will evaluate the 
available information and perform an independent assessment of relatedness.  While  the Sponsor may 
upgrade an Investigator ’s decision it is not permissible to downgrade the Investigator ’s opi[INVESTIGATOR_37479] a S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee  will not  report on an individual basis 
in an expedited manner because they are anticipated to occur in the study population independent of 
volanesorsen  exposure.  The I nvestigator still has the responsibility to report all SAEs to the Sponsor as 
described in Sections  9.4.1 to [IP_ADDRESS]. 
Table  4 Expected Ev
ent for the Protocol Defined Population by [CONTACT_37716]  (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis acute, pancreatitis chronic, pancreatitis necrotizing, pancreatitis 
relapsing  0.2-0.35 events  per patient -year   
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
63  Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The Sponsor and 
DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate of the event compared 
to the rate expected in a non -volanesorsen  exposed population.  If the aggregate analysis indicates that an 
event is occurring significantly more frequently or at a greater severity  than expected , then the event will 
be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37717] a 
reasonable possibility that the drug caused the event .  If the event is considered by [CONTACT_37718] a S[LOCATION_003]R  the event will be reported.  
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the study or use of 
investigational drug product, whether or not the AE is considered related to the investigational drug 
product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction 
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is a reasonable possibility that 
volanesorsen  drug caused the adverse event.  A suspected adverse reaction  implies a lesser degree of 
certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event that in the view of either the Investigator or Sponsor, meets 
any of the following criteria: 
• Resu lts in death  
• Is life threatening:  that is, poses an immediate risk of death at the time of the event 
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not include 
an AE  or suspected adverse reaction that , had it occur red in a more severe form, might have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081] 
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility and does 
not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
• Results in congenital anomaly or birth defect in the offspring of the patient (whether the patient is male or female)  
• Important m edical events that may not result in death, are not life- threatening, or do not require 
hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
64  they may jeopardize the patient  and may require medical or surgical interv ention to prevent one 
of the outcomes listed in this definition .  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events 
Any pre-existing conditions or signs and/or symptoms present in a patient  prior to the start of the study 
(i.e., before informed consent) should be recorded as Medical History and not recorded as AEs  unless the 
pre-existing condition worsened.  The Investigator should always group signs and symptoms into a single 
term that const itutes a  single unifying diagnosis  if possible.  
9.4.[ADDRESS_37813] of patient safety, and in order to fulfill regulatory requirements , all SAEs (regardless of 
their relationship to volanesorsen ) should be reported to the Sponsor  or designee within 24 hours of the 
Study Center’s first knowledge of the  event .  The collection of SAEs will begin after the patient signs the 
informed consent form and stop at the  end of the patient ’s follow -up period which is defined as the 
Week  78 (or Week [ADDRESS_37814] or second extended treatment period, 
respectively) visit.  When  the Investigator is reporting by [CONTACT_756], it is important to speak to someone in 
person versus leaving a message.  An  Initial Serious Adve rse Event Form should be completed and a copy 
should be faxed to the Sponsor or  designee. 
Detailed information should be actively sought and included on Follow- Up Serious Adverse Event Forms 
as soon as additional information becomes available.  All SAEs wi ll be followed until resolution.  SAEs 
that remain ongoing past the patient ’s last protocol- specified follow -up visit will be evaluated by [CONTACT_35299] .  If the Investigator and Sponsor agree the patient ’s condition is unlikely to 
resolve, the Investigator and Sponsor will deter mine the follow -up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form and will 
stop at the end of the patient ’s follow -up period, which is defined as the Week 78 (or Week [ADDRESS_37815] or second extended treatment period, respectively) visit.  The Investigator will 
monitor each patient  closely and record all observed or volunteered AEs on the Adverse Event Case 
Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_37481] : 
[IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen  is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen , e.g., 
confirmation by [CONTACT_37720] 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]  01 May 2 019 
65  •Possible:   The event cannot be explained by [CONTACT_102]’s medical condition, concomitant
therapy, or other causes, and there is a plausible temporal relationship between the event and
volanesorsen  administration
•Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g.,
concomitant medications or ongoing medical conditions) or the temporal relationship tovolanesorsen  administration and/or exposure suggests that a causal relationship is unlikely (For
reporting purposes, Unlikely/Remote will be grouped together with Not Related)
•Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical condition,
concomitant therapy, or other causes, and therefore, the Investigator believes no relationship
exists between the event and volanesorsen
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D).  A ny AE not listed in 
Appendix D will be graded as follows: 
•Mild:   The event is 
easily tolerated by [CONTACT_37721]’s usual daily
activities
•Moderate:   The event causes the patient more discomfort and interrupts the patient ’s usual daily
activities
•Severe:   The event is incapacitating and causes considerable interference with the patient’s usual
daily activities
If the event is an SAE, then all applicable seriousness criteria must be  indicated (criteria listed in 
Section  9.3.3). 
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen  due to the event is characterized by 1 of the following:  
•None:  No changes were made to volanesorsen  administration and dose
•Permanently Discontinued:   Volanesorsen  was discontinued and not restarted
•Temporarily Interrupted, restarted – same dose:   Treatment  was temporarily interrupted or
delayed due to the AE and restarted at the same dose
•Reduced schedule:   Treatment  frequency was reduced
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE should be recorded  on the A dverse 
Event Case Report Form (treatment  should also be recorded on the concomitant treatment or ancillary 
procedures CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the ev ent is a non- serious AE then the event’s outcome is characterized by 1 of the following:  
•AE Persists:   Patient terminates from  the trial and the AE continues
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
66  • Recovered:  Patient r ecovered completely from the AE 
• Became Serious:   The event became serious (the date that the event became serious should be 
recorded as the Resolution Date of that AE and the Onset Date of the corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following:  
• Ongoing:   SAE continuing  
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer meets 
serious criteria and should be captured as an AE on the non -serious AE electronic Case Report 
Form (eCRF ) (the SAE resolution date should be entered as the date of onset of that AE)  
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be entered 
as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be ente red as the SAE resolution date)  
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event (MA CE) 
will be adjudicated by a blinded, independent committee as outlined in the MACE Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute pancreatitis will 
be adjudicated by 
a blinded, independent committee according to the Atlanta classification of acute 
pancreatitis ( Banks et al. 2013) and 
as outlined in the Pancreatitis Adjudication Charter .  In addition, data 
for p
rior epi[INVESTIGATOR_37482]’s medical chart and these events w ill also be adjudicated. 
9.[ADDRESS_37816] results may, in the opi[INVESTIGATOR_689], constitute or 
be associated with an AE.  Examples of these include abnormal laboratory results that are associ ated with 
symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, tetany due to hypocalcemia, or 
cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed 
in preference to  abnormal laboratory values as AEs.  Clinically -significant abnormalities will be 
monitored by [CONTACT_37722] .  Laboratory abnormalities deemed not 
clinically -significant (NCS) by [CONTACT_37723].  Similarly, laboratory 
abnormalities reported as AEs by [CONTACT_37724]. 
The Investigator is respon sible for reviewing and signing all laboratory reports.  The signed clinical 
laboratory reports will serve as source documents and should include the Investigator’s assessment of 
clinical significance of out of range/abnormal laboratory values.  
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, 
even if the patient  is hospi[INVESTIGATOR_057]; the Study Center must document all of the following : 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
67  • The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was 
on a waiting list to be scheduled) prior to obtaining the patient ’s cons ent to participate in the 
study 
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the procedure or 
treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the 
intervention or hospi[INVESTIGATOR_063] 
9.5.3 Treatment  Errors  
Volanesorsen treatment  errors should be documented as Protocol Deviations.  A brief description should 
be provided in the deviation, including whether the patient  was symptomatic (list symptoms) or 
asymptomatic, and the ev ent accidental or intentional.  
Treatment  details should be capture
 d on the Treatment  Case Report Form .  If the  patient  takes a dose of 
volanesorsen  that exceeds protocol specifications and the  patient  is symptomatic, then the symptom(s) 
should be documented as an AE  and be reported per Section  9.4. 
Should an overdose 
occur , the Investigator or designee should refer to the Guidance to Investigator’s 
section of the Investigator’s Brochure and contact [CONTACT_37725] [ADDRESS_37817] 
learning of the occurrence of pregnancy.  Follow- up information including delivery or termin ation is 
reported on Follow-up Pregnancy Forms and reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s responsibility.  
Female patien ts:  If a suspected pregnancy occurs while on the study (incl uding follow -up), a pregnancy 
test will be performed .  The patient  with a confirmed pregnancy will be immediately withdrawn from 
treatment with volanesorsen .  However, the patient will be encouraged to complete the post- treatment 
follow-up portion of the study to the extent that study procedures do not interfere with the pregnancy.  
Regardless of continued study participation, the study physician will assist the patient  in getting 
obstetrical care and the progress of the pregnancy will be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results i n the birth 
of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed until the 
outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may request access to the 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
68  mother and infant’s medical records for an additional 8 weeks after birth .  Follow-up will be 
performed to the extent permitted by [CONTACT_37726].  
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurement s, the values at Month 3 analysis time point are defined as the average of 
Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 analysis time point 
is at the end of Month 6 are defined as the average of Week 25 (Day  169) and Week 26 (Day 176) fasting 
assessments, and the values at the Mo nth 12 analysis time point are defined as the average of Week 50 
(Day 344) and Week  52 (Day 358) fasting assessments.  
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including total 
cholesterol, non- HDL -C, apoB, HDL- C, apolipoprotein A-1 (apoA-1) , VLDL -C, and LDL-C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Change in blood viscosity (may be evaluated) 
• Quality of Life questionnaires (EQ -5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis 
10.1.2 Safety Endpoints  
• Adverse events including adjudicated events of pancreatitis and MACE  
• Vital signs and weight 
• Physical examin ations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis)  
• Echocardiography 
• Electrocardiograms (ECGs)  
• Use of concomitant medications 
• MRIs  
• Platelet aggregation (may be evaluated)  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
69  10.3 Populations 
Full Analysis Set (FAS) :  All patients who are enrolled and received at least [ADDRESS_37818] a baseline TG assessment .  The FAS represents the practically -feasible intent -to-treat (ITT) 
population as delineated in ICH Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_37819] efficacy and PD assessments.  
The detailed criteria will be specified and finalized prior to the final database lock. 
Safety Set :  All patients who are enrolled and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_37820] dose PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements, 2 baselines are defined for each patient in Groups 1 and 2:  Group 1 ( ISIS 
304801- CS6) or Group 2 ( ISIS 304801- CS16 ) index study baseline and the baseline in this open -label 
study, which is defined as the average of Day [ADDRESS_37821] measurement prior to 
Day 1  (e.g., qualification assessments or assessments from final visit of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies if used for qualification). 
For other measurements, basel ine for patients on active treatment in the ISIS 304801-CS6 or ISIS 
304801-CS16 index stud y will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study baseline.  For 
patients on placebo in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, baseline will be the last 
non-missing assessment prior to the first dose of Study Drug .  Details will be provided in the SAP.  
10.[ADDRESS_37822] patient’s Week [ADDRESS_37823] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and 
counts and percentages for categorical variables will be used to summarize most data by [CONTACT_37727] 304801-CS6 or ISIS 304801-CS16 
index studies, and pooled treatment naïve group which includes  patients on placebo in index studies .  
Where appropriate, p -values will be reported .  All statistical tests will be conducted using 2 -sided tests 
with 5% Type I error rates unless otherwise stated.  
TG related endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will be 
assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK endpoints will be 
assessed in the PK Set as applicable.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
70  10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by [CONTACT_17674] .  The patient disposition will be summarized by [CONTACT_14454] .  All 
patients enrolled will be included in a summary of patient disposition. 
10.6.2 Safety Analysis  
Treatment duration and amount of Study Drug received will be summarized by [CONTACT_14459] . 
Patient incidence rates of AEs will be tabulated by [CONTACT_10607] 
(MedDRA ) system organ class, MedDRA preferred term, and treatment group  of the index studies.   
Narratives of treatment -emergent  deaths, serious and significant AEs, including early withdrawals due to 
AEs, will also be provided. 
All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all treatment -
emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to Study Drug will be 
summarized.  
Injection Site Reactions (ISRs) will be summarized by [CONTACT_1570], MedDRA preferred term and 
severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_1570]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) with 
differential, coagulation panel, IM , complement etc., will be summarized by [CONTACT_37728]. 
These safety variables will also be presented as change and percent change from baseline over time after 
Study Drug administration, as appropriate.  
Vital sign s, weight, ECG measures, echocardiography assessments, and MRI assessments will be 
tabulated by [CONTACT_1570]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will be 
summarized by [CONTACT_1570].  Response rate of patients with fasting plasma TG <  750 mg/dL or 
achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and Month 12 will be 
summarized .  Response analysis will also be conducted using a range of fasting plasma TG thresholds for 
determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be summarized 
by [CONTACT_37729] f asting  lipid  measures including non- HDL -C, apoB, HDL-C, apoA-1, 
VLDL -C, and LDL- C, total cholesterol , and fasting total  apoC -III. 
The incremental effects of volanesorsen on lipid measures will be explored and the association between 
changes in lipid parameters and total amount of drug received will be examined, as appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event rate, 
quality of life assessments, and comparison of other symptoms including eruptive xanthomas and lipemia 
retinalis will be summarized by [CONTACT_1570]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
71  Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis  
For all patients, pre -dose and post- treatment volanesorsen plasma concentrations will be summarized 
using descriptive statistics by [CONTACT_37730].  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be carried o ut 
on each individual patient data set using data collected  in the open- label study from the intensive PK 
subgroup, following a single- dose (i.e., single -dose PK) or multiple doses (i.e., steady- state PK), 
depending on their earlier treatment in the index studies  (Group 1 and 2 patients) .  On Week [ADDRESS_37824] treatment of 
volanesorsen (single- dose PK), while patients who received volanesorsen in the index studies ha d been on 
volanesorsen treatment for 12 months (ISIS  304801-CS6) or 6 months (ISIS 304801-CS16), thus the PK 
data collected from these patients reflect steady -state PK .  The maximum observed drug concentration 
(Cmax) and the time taken to reach C max (T max) will be obtained directly from the concentration -time data .  
Area under the plasma concentration -time curve from time zero to 24  hours (AUC 0-24h) will be calculated 
using the linear trapezoidal rule.  Apparent systemic (plasma) clearance after SC administration (CL 0-
24h/F) will be calculated from CL 0-24h/F = Actual Dose/AUC 0-24h.  Mean residence time (MRT) from time 
zero to 24 hours after the SC administration will be calculated from the equation, MRT 0-24h = AUMC 0-24h 
/AUC 0-24h, where AUMC 0-24h is the area under the moment plasma concentration -time curve from time 
zero to [ADDRESS_37825] . 
Plasma PK parameters will be summarized using descriptive statistics by [CONTACT_37730] .  
Additional details regarding the PK  analysis will be described in the SAP.  
Population PK, PK/ PD, and covariate analysis may be performed if deemed appropriate, and results will 
be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not evaluable, and 
when applicable, titer of anti -volanesorsen  antibodies) before, during, and after treatment with Study 
Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be listed by [CONTACT_37731] 304801- CS6 or ISIS 304801- CS16  (Groups 1 and 2) and study day.  Subject ADA status 
(positive/negative or not evaluable) for all evaluable patients, along with the study day associated with the 
first positive IM status emerged (T first, i.e., onset of ADA development), the last positive IM status 
observed (T last), the last ADA sample collection day, and subject - peak titer if applicable, will be listed by 
[CONTACT_37732]  304801-CS6 and ISIS 304801- CS16  (Groups 1 and 2) and study day.  
Subjects with positive anti- volanesorsen  antibody status may be further classified (when applicable) as 
being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total numb er and percent of evaluated subjects with antibody negative, positive, and 
unknown status by [CONTACT_1570].  Furthermore, onset and titer of the ADA response, if applicable, will 
be summarized as median, quartiles (25% and 75%), and range. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
72  Additional det ails regarding the IM data analysis will be described in the SAP.  
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., 
% change in fasting TG from baseline at 3 -, 6-, and 12- month endpoints), safety, and PK  (e.g., C trough) 
measures will be evaluated using graphical analysis and statistical analysis.  These analyses will be either 
conducted and included in the study report, or data pooled and analyzed from all available Phase 2 and 3 studies  and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the Investigator is responsible for obtaining written informed 
consent from the patient  after adequate explanation of the aims, methods, anticipated benefits, and 
potential hazards of the study and before any protocol- specific qualification procedures or any Study 
Drug  are administered .  The patient  must be given sufficient time to consider whethe r to participate in the 
study. 
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her primary care 
physician should be documented in the patient’s medical records and the informed consent form should 
be signed an d personally dated by [CONTACT_37733] (not necessarily an I nvestigator) .  The original signed informed consent form should be 
retained in  the Study Master File and in any other locations required by [CONTACT_10569], and a copy of 
the signed consent form should be provided to the patient. 
11.[ADDRESS_37826] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October 200 2 
the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands 
of national drug and data protection laws and other applicable regulatory requirements will be strictly followed. 
11.3 Independent Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent form, other written patient  information, and any 
proposed advertising material must be submitted to the IEC/IRB for written approval.  A copy of the 
written approval of the protocol and informed consent form must be received by [CONTACT_37734] s into the study and shipment of volanesorsen .  A copy of the written approval of 
any other items/materials that must be approved by [CONTACT_10571]/IRB must also be received b y 
the Sponsor before recruitment of patients into the study and shipment of Study Drug.  The Investigator’s 
Brochure must be submitted to the IEC/IRB for acknowledgement. 
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB, for all 
subsequent protocol amendments and changes to the informed consent document.  The Investigator 
should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  E6 (R2) Section  4.5.2.  
The Investigator should also notify the IEC/IRB  of serious adverse events occurring at the Study Center  
and other adverse event reports received from the Sponsor, in accordance with local procedures. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
73  The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout the 
duration of the study .  Copi[INVESTIGATOR_1093] I nvestigator’s reports , all IEC/IRB  submissions and the IEC/IRB 
continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_37827] ensure that the patient ’s confidentiality is maintained .  On the case report forms  
(CRF)  or other documents submitted to the Sponsor , patient s should be identified by [CONTACT_37735] a 
patient  study number only.  Documents that are not for submission to the Sponsor  (e.g., signed informed 
consent forms) should be kept in strict confidence by [CONTACT_941] I nvestigator. 
In compliance with Federal and local r egulations/ICH E6 (R2) Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory agency(s), 
and the IEC/IRB  direct access to review the patient ’s original medical records for verification of study-
related procedures and data.  Direct access includes examining, analyzing, verifying, and reproducing any 
record s and reports that are important to the evaluation of the study.  The Investigator is obligated to 
inform and obtain the consent of the patient  to permit named representatives to have access to his/her 
study- related records without violating the confidenti ality of the patient . 
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS  
12.[ADDRESS_37828] be obtained for all protocol amendments and amendments to the informed consent document.  The regulatory authority and IEC/IRB must be informed of all amendments and give approval 
for any amendments likely to affect the safety of the patient s or the conduct of the trial .  The Investigator  
must  send a copy of the approval letter from the IEC/IRB  to the Sponsor . 
12.[ADDRESS_37829] .  The Investigator/Sponsor should notify the IEC/IRB in writing of the trial’s completion or 
early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentat ion and Storage 
An eCRF utilizing an Electronic Data Capture (EDC) application will be used for this study. 
The Investigator  should ensure that all  appropriately qualified persons to whom he/she has del egated trial 
duties are recorded on a Sponsor-approved Delegation of Site Responsibilities Form . 
Source documents are original documents, data, and records from which the patient’s CRF  data are 
obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and 
pharmacy records, d iaries, imaging , and correspondence .  In this study, CRFs may not be used as source 
documents. 
The Investigator and S tudy Center staffs are responsible for maintaining a comprehensive and centralized 
filing system of all study -related (essential) documentation in accordance with Section  8 of the ICH 
Guidelines E6 (R2), suitable for inspection at any time by [CONTACT_37736]/or 
applicable r egulatory authorities .  Elements should include:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
74  • Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_31653] 
• Study files containing the protocol with all amendments, Investigator’s Brochure, copi[INVESTIGATOR_10468]-
study documentation and all correspondence to and from the IEC /IRB  and the Sponsor 
• If volanesorsen supplies are  maintained at the Study Center, proof of receipt, volanesorsen  
Accountability Record, Return of volanesorsen  for Destruction, final study volanesorsen 
reconciliation, and all volanesorsen -related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and be 
readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  and the 
Investigator .  Should the I nvestigator wish to assign the study records to another party or move them to 
another location, he/she must notify the Sponsor . 
12.[ADDRESS_37830], inspecting the various records of the trial (e.g., CRFs and other pertinent data) provided that patient confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the study to 
verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to 
local regulations on the conduct of clinical research .  The monitor should have ac cess to patient medical 
records and other study- related records needed to verify the entries on the CRFs.  
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH E6 (R2) and the Sponsor’s audit plans, this study may be selected for audit by 
[CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of Study Center 
facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study- related records will occur 
to evaluate the  trial conduct and compliance with the protocol, ICH E6 (R2) , and applicable regulatory 
requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data 
received by [CONTACT_1034] .  During this review, patient  data will be checked for consistency, omissions, and 
any apparent discrepancies .  In addition, the data will be reviewed for adherence to the protocol and GCP .  
To resolve any questions arising from the clinical data management review process, data queries and/or 
Study Center notifications will be sent to the Study Center for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures will 
indicate that the principal Investigator [INVESTIGATOR_37485] , the data queries, and 
the Study Center notifications, and agrees with the content.  
12.[ADDRESS_37831] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow applicable local 
compensation laws.  Patient s will be treated a nd/or compensated for any study- related illness/injury in 
accordance with the information provided in the Compensation for Injury section of the Informed Consent document.
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
76  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of ac ute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons . Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically use ful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturat ion factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec 2014; 2200- 2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Gaudet D, Baass A, Tremblay K, et al. Natural History (up to 15 years) of Platelet Count in 84 Patients with 
Familial Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency. Journal of Clinical Lipi[INVESTIGATOR_37444] 2017; 11(3): 
797-798. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
77  Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oli gonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790-793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the gre ater effect of 12 -week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486]. Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C -III isofo rms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N E ngl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open- label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PC, Voshol  PJ, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyce ride (VLDL- TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2 019 
 
78  Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL , APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37-44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.
ISIS [ADDRESS_37832]-Treatment Follow -up 
(For patients not opting to participate in the Extended Treatment Period)  
 
First [ADDRESS_37833]- Treatmen t Follow -Up 
(For patients not opting to participate in the second 52- Week Extended Treatment Period)  
 
Second 52- Week Extended Treatment Period  
Second 52- Week Extended Treatment Period Post-Treatment Follow- Up 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019 
 
80  Appendix A Schedule of Procedure s – Qualification through Treatment Period 
Study Period  Quala Treatment Period  
Study Week  -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -14 to -7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 
Visit Window+/ - Days  0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Informed Consent  X                       
Outpatient Visit  X X Xj Xj X
j Xj Xj Xj X Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X 
Inclusion/Exclusion Criteria  X                       
Medical Historyq X                       
Vital Signs + body weight (+ height on Day 1 only)  X X  X  X   X     X    X     X 
Physical Examination  X X       X     X    X     X 
12- lead ECG (triplicate)  X        X     X    X     X 
MRI (liver/spleen)  X                      Xk 
Echocardiography  X             Xk         Xk Blood Draw (Fasting)c Chemistry Panel  X X  X  X   X  X   X  X  X  X   X 
CBC with Differentialb X  X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  
Serum Lipid Panel  X X  X  X  X X    X X    X    X X 
Blood viscosityr  X       X     X         X 
Platelet aggregationr X X       X     X         X 
Coagulation (aPTT, PT, INR)  X     X   X     X    X     X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37488] X       X     X         X 
Sedimentation Rate   X       X     X         X 
Complement (C5a, Bb)   X       X     X         X 
Plasma PK - Volanesorsen   Xl X X  X   X     X    X     X 
Anti-Volanesorsen Antibodies   X  X  X   X     X    X     X 
FSH (women only, if applicable)  X                       
Serum Pregnancy Testd X   X  X   X  X   X  X  X  X   X 
Archived Serum & Plasma Samplese  X    X   X     X         X 
Troponin Io X                       
Platelet Bound Autoantibodiesr  X                      
Archive blood sample for potential gene sequencing 
related to hypertriglyceridemia (Group 2 if not available 
from index study)g X                       
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019 
 
81  Appendix A Schedule of Procedures  - Qualification through Treatment Period Continued  
Study Period  Quala Treatment Period  
Study Week  -2 to -1 Wk 
1 W
k 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day -14 to  
 -7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 
Visit Window+/ - Days  0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Urinalysisc X Xm  X  X   Xm  Xm   Xm  Xm  Xm  Xm   Xm 
Fundus Photographyf X                      Xk 
Genetic testing for FCS diagnosis (if not 
available in medical history)g X                       
Weekly Study Drug:  SC Injection   X  X X X X X X X X X X X X X X X X X X X X 
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X       X     X         X 
Food/Drink Diary (quarterly)h  X       X     X         X 
Diet/Alcohol Counselingi X X  X  X   X     X    X     X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
82  Appendix A Schedule of Procedures – Post -Treatment Follow -up (for patients not opting to participate 
in the Extended Treatment Period)  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Outpatient Visit  Xj Xj X Xj X 
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X Blood Draw (Fasting)c Chemistry Panel   X X X X 
CBC with Differentialb Xs X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testd  X X X X 
Archived Serum & Plasma Samplese   X  X 
Urinalysisc  Xm Xm Xm Xm 
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Food/Drink Diary (quarterly)h   X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication  X X X X X 
Legend : 
a Qualification procedures performed (Please refer to Sections 3.4 , 4.1, and 6.1.2 ) 
b Each time a hematology lab is
 drawn a
nd sent to the central laboratory for analysis an additional sample should be collected in 
parallel and analyzed locally.  In the event  that both the central and local sample are unreportable (e.g., due to hemolyzed or 
clumped blood samples) another sample must be repeated within [ADDRESS_37834] be reviewed by [CONTACT_37740].  All platelet count results will be promptly reviewed by [CONTACT_37741] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, or the dose pause rule 
of 75,000/mm3.  Any case of a platelet count < 50,000/ mm3 should be reported in an expedited fashion to the Sponsor  
c Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During 
treatment period urine and blood samples will be collected prior to Study Drug administration.  Does not apply to 24- hour PK 
blood draw . 
d Females of childbearing potential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events 
(e.g., measurement of  cytokine and/or chemokine levels, measurement of additional markers of kidney function, measurement of 
antibodies, etc.) in this or subsequent clinical studies of volanesorsen 
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug (Group 2 ISIS 
304801-CS16 roll over patients
) and repeated at Week 52 (Please refer to Section  [IP_ADDRESS] ) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
83  g Genetic testing can be conducted for study Qualification (Group 2 ISIS 304801-CS16 roll over patients); genetic testing  will only 
be conducted if allowed in the geographic region and only after the patient has given specific written informed consent for 
genetic testing . A blood sample for potential gene sequencing may be collected at timepoints other than Screening or 
Qualification Visits.  
h In addition to diary, patients will be contact[CONTACT_37742]  
i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol a ssessments (phone visits) will also be 
performed by [CONTACT_37743]  
j Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37744]  
k A ± 7 -day window is allowed for MRI, echocardiography procedures and fundus photography  
l Full or abbreviated PK profile (see Appendix  C) 
m Expanded urinalysis (see Appendix  B) 
n HbA1c only  
o All abnormal troponin samples will be rerun at the central laboratory and also analyzed for CK -MB  
p If needed, the post -treatment follow -up period will be extended (with patients monitored every 6 weeks) until apoC -III levels 
return to baseline values  
q Patient charts will be reviewed in order to collect data for events of acute pancreati tis or suspected pancreatitis in the patient’s 
medical history.  Chart review may be conducted at any time during the study.  These events will be adjudicated in the same manner as for events of pancreatitis during the study  
r May be done.  Blood viscosity  and platelet aggregation in volanesorsen -treatment naïve patients only  
s Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of schedulin g
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
84  Appendix A Schedule of Procedures – First 52 -Week Extended Treatment Period  
Study Period  Extended Treatment Period  
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62  Mo 15 
Wk 64  Wk 66 
& 68  Wk 
70 Wk 72 
& 74  Mo 18 
Wk 76  Wk 78 
& 80  Wk 
82 Wk 84, 86, 
& 88  Mo 21 
Wk 90  Wk 92 
& 94  Wk 
96 Wk 98, 
100 & 
102 Mo 24 
Wk 104  
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 568  582, 596 & 
610 624 638 & 
652 666 680, 694 
& 708  722 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X 
Vital Signs (+ body weight)     X    X    X    X 
Physical Examination         X        X 
12- lead ECG (triplicate)         X        X 
Urinalysis (including P/C ratio)   X  X  X  X  X  X  X  X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X 
CBC with Differentiala X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  
Serum Lipid Panel    X    X    X    X 
Coagulation (aPTT, PT, INR)     X    X    X    X 
Troponin I     X    X    X    X 
Plasma PK - ISIS 304801c        X        X 
Anti-ISIS [ADDRESS_37835] specified windows to allow flexibility of scheduling.  
Weekly Study Drug: SC Injection  X X X X X X X X X X X X X X X X 
Diet/Alcohol Counselinge    X    X    X    X 
Adverse Events  X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X 
Legend : 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
85  a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. In the event that 
both the central and local sample are unreport able (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_37836] be 
reviewed by [CONTACT_37745].  All platelet count results will be promptly reviewed by [CONTACT_37746] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, or the dose pause rule of 75,000/mm3.  Any case of a platelet count < 50,000/mm3 
should be reported in an expedited fashion to the Sponsor  
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatment period urine and blood samples will be 
collected prior to Study  Drug administration  
c Abbreviated PK collection (see Appendix  C) 
d Females of childbearing potential only  
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the  Study Center as arranged by [CONTACT_37747]   
g May be done  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
86  Appendix A Schedule of Procedures – First [ADDRESS_37837] -Treatment 
Follow -Up (For patients not opting to participate in the second 52 Week Extended 
Treatment Period)  
Study Period  Post Treatment Follow -upa 
Study Week  Wk 106  
& 
108 Wk 
110 Wk 
117 Wk 
123 Wk 
130 
Study Day  736 
& 
750 764 813 855 904 
Visit Window+/ - Days  2 7 7 7 7 
Outpatient Visit  Xb Xb X Xb X 
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X Blood Draw (Fasting)e Chemistry Panel   X X X X 
CBC with Differentialc Xd X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testf  X X X X 
Archived Serum & Plasma Samplesg   X  X 
Urinalysis   Xh Xh Xh Xh 
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events  X X X X X 
Concomitant Medication  X X X X X 
Legend : 
a If needed, the post -treatment follow -up period will be extended (with patients monitored every 6 weeks) until apoC -III 
levels return to baseline values   
b Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37748]  
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected 
in parallel and analyzed locally.  In the event that both the central and local sample are unreportable (e.g., due to hemolyzed 
or clumped blood samples) another sample must be repeated within [ADDRESS_37838] be reviewed by [CONTACT_37749].  All platelet count results will be promptly 
reviewed by [CONTACT_37700] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, or 
the dose pause rule of 75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
d Platelets are assessed each calendar week, visits do not have specified windows to allow  flexibility of scheduling  
e Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.   
f Females of childbearing potential only  
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse 
events (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of kidney function, 
measurement of antibodies, etc.) in this or subsequent clinical studies of volanesorsen  
h Expanded urinalysis (see Appendix  B) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
87  i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be 
performed by [CONTACT_37750] 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
88  Appendix A Schedule of Procedures – Second 52 -Week Extended Treatment Period  
Study Period  Extended Treatment Period  
Study Week  Wk 116  Mo 30  
Wk 128  Mo 33  
Wk 142  Wk 156  
Study Day  806 [PHONE_608] 
Visit Window+/ - Days  2 2 2 2 
Outpatient Visit  X X X X 
Vital Signs (+ body weight)  X X X X 
Physical Examination   X  X 
Urinalysis (including P/C ratio)  X X X X Blood Draw (Fasting) b Chemistry Panel  X X X X 
CBC with Differentiala Xe 
Platelets are assessed each calendar week , visits do not have 
specified windows to allow flexibility of scheduling.  
Serum Lipid Panel  X X X X 
Serum Pregnancy Testc X X X X 
Anti-ISIS 304801 Antibodies     X 
Weekly Study Drug: SC Injection  X  
Diet/Alcohol Counselingd X X X X 
Adverse Events  X X X X 
Concomitant Medication  X X X X 
Legend:  
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected 
in parallel and analyzed locally. In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_37839] be reviewed by [CONTACT_37751].  All platelet count results will be promptly 
reviewed by [CONTACT_37700] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm
3, or 
the dose pause rule of 75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During 
treatment period urine and blood samples will be collected prior to Study Drug administration  
c Females of childbearing potential only  
d To reinforce compliance to the diet and alcohol restrictions  
e Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37752] 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
89  Appendix  A Schedule of Procedures – Second 52-Week Extended Treatment Period Post -
Treatment Follow -Up  
Study Period  Post Treatment Follow -upa 
Study Week  Wk 158 & 
160 Wk 162  Wk 169  Wk 175  Wk 182  
Study Day  1100 & 
1114  1128 1177 1219 1268 
Visit Window+/ - Days  2 7 7 7 7 
Outpatient Visit  Xb Xb X Xb X 
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X Blood Draw (Fasting)e Chemistry Panel   X X X X 
CBC with Differentialc Xd X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testf  X X X X 
Archived Serum & Plasma Samplesg   X  X 
Urinalysis   Xh Xh Xh Xh 
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events  X X X X X 
Concomitant Medication  X X X X X 
Legend:  
a If needed, the post -treatment follow -up period will be extended (with patients monitored every 6 weeks) until apoC -III 
levels return to baseline values   
b Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37748]  
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected 
in parallel and analyzed locally.  In the event that both the central and local sample are unreportable (e.g., due to hemolyzed 
or clumped blood samples) another sample must be repeated within [ADDRESS_37840] be reviewed by [CONTACT_37751].  All platelet count results will be promptly 
reviewed by [CONTACT_37753] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, or 
the dose pause rule of 75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
d Platelets are assess ed each calendar week, visits do not have specified windows to allow flexibility of scheduling  
e Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours   
f Females of childbearing potential only  
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse 
events (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of kidney function, 
measurement of antibodies, etc.) in this or subsequent clinical studies of volanesorsen  
h Expanded urinalysis (see Appendix  B) 
i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37750] [ADDRESS_37841] of Laboratory Analytes  
Based on emerging  data from this or future studies, additional tests not listed below may be performed on 
stored samples t o better characterize the  profile of volanesorsen or other similar oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium 
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) 
bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential 
(% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• Troponin I2 
• CK-MB2 
• Platelet Bound 
Autoantibodies3 
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  
• Blood viscosity3 Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic 
examination4 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
Platelet Function  
• Platelet aggregation3 
• Platelet function5 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, 
stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay development and/or 
validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_37842] -treatment follow -up period as noted in 
the tables below . 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 7 
Time Point  Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Anytime  Anytime  
 
PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  D540  
Visit Window 
+/- Days  [ADDRESS_37843]-dose  Pre-dose Pre-dose Pre-dose Pre-
dose Pre-
dose Pre-
dose Anytime  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24 -hour PK profile beginning on Study  Day 1.  
Participation is optional 
 
PK Sampling Schedule – First 52 -Week Extended Treatment Period 
Week  Wk 
76 Wk 
104 Wk 
117 Wk 
130 
Study Day  D526  D722  D813  D904  
Visit Window 
+/- Days  2 2 7 7 
Time Point  Pre-dose  Pre-dose Anytime  Anytime  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
94  PK Sampling Schedule – Second 52 -Week Extended Treatment Period 
Week  Wk 
169 Wk 
182 
Study Day  D1177  D1268  
Visit Window +/- 
Days  [ADDRESS_37844] abnormalities are based 
upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
97  Appendix D Grading Scale for Adverse Events Relating to Laboratory Abnormalities Continued 
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 10 
Protocol - [LOCATION_009]   01 May 2019  
 
98  Appendix D Grading Scale for Adverse Events Relating to Laboratory Abnormalities Continued 
 
 
 

Sponsor:  
Akcea Therapeutics 
[ADDRESS_37845]  
Cambridge, MA   [ZIP_CODE]        Collaborator:  
      Ionis Pharmaceuticals, Inc.  
      [ADDRESS_37846]  
      Carlsbad, CA  [ZIP_CODE]  
ISIS 304801 -CS7 
The APPROACH Open- Label Study  
Volanesorsen  (ISIS 304801)
An Open-Label Study of Volanesor s en Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
Protocol Amendment 9 - [LOCATION_009] – [ADDRESS_37847] No:  2015-0
[ZIP_CODE]-21 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
3   
Protocol Number:  ISIS 304801-CS7  
Protocol Amendment [ADDRESS_37848] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH Open- Label Study  
Volanesorsen  (ISIS 304801)  
An Open-Label Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Akcea Therapeutics , Inc.  
[ADDRESS_37849]:   
 
Akcea Therapeutics, Inc.  
[ADDRESS_37850]  
Cambridge, MA [ZIP_CODE]  
Phone:  
Email: 
Collaborator:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_37851]   
Carlsbad, CA [ZIP_CODE]  
Date:  [ADDRESS_37852] of the clinical investigation without the prior written consent 
of Akcea Therapeutics,  Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801-CS7 
Protocol Title:  An Open-Label Study of Volanesorsen  Administered Subcutaneously to Patients 
with Familial Chylomicronemia Syndrome (FCS)  
Amendment: Amendment 9 - [LOCATION_009] 
Date:    [ADDRESS_37853]  read and understand the attached clinical protocol , entitled “A n Open -
Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) ”, dated  [ADDRESS_37854] the study as described herein.  
I agree to comply with the International Conferenc e on Harmonization  Tripartite Guideline on Good 
Clinical Practice E6 (R2). 
I agree to ensure that the confidential information contained in this document will not be used for any 
purpose other than the evaluation or conduct of the clinical investigation wi thout the prior written consent 
of Akcea Therapeutics, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)  Date ( DD Month  YYY Y) 
  
ISIS [ADDRESS_37855] ............................................................................................ 30 
4. PATIENT ENROLLMENT  ........................................................................................................ 30 
4.1 Qualification .............................................................................................................................. 30 
4.2 Enrollment  ................................................................................................................................. 31 
5. PATIENT ELIGIBILITY ........................................................................................................... 31 
5.1 Inclusion Criteria  ....................................................................................................................... 31 
5.2 Exclusion Criteria  ...................................................................................................................... 32 
6. STUDY PROCEDURES  ............................................................................................................. 34 
6.1 Study Schedule  .......................................................................................................................... 34 
6.1.1  Qual ification ...................................................................................................................... 34 
6.1.2  Treatment Period  ............................................................................................................... 34 
6.1.3  Extended Treatment Period ............................................................................................... 35 
6.1.4  Pharmacokinetic (PK) Subgroup  ....................................................................................... [ADDRESS_37856]-Treatment Follow -up ................................................................................................. 35 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]  25 May 2018  
6  6.2 Additional Study Assessments .................................................................................................. 36 
6.2.1  Laboratory Assessments  .................................................................................................... 36 
6.2.2  Physical Exams and Vital Signs  ........................................................................................ 36 
[IP_ADDRESS]  Eruptive Xanthoma .................................................................................................... 36 
[IP_ADDRESS]  Lipemia Retinalis  ....................................................................................................... 36 
6.2.3 Echocardiography .............................................................................................................. 36 
6.2.4  ECG.....................................................................................................................................36 
6.2.5  MRI.....................................................................................................................................37 
6.2.6  Quality of Life Assessments .............................................................................................. 37 
6.2.7  Disease Symptom Diary  .................................................................................................... 37 
6.2.8  Diet Monitoring  ................................................................................................................. 37 
6.2.9  Family History ................................................................................................................... 37 
6.2.10  Chart Review for Incidents of Acute Pancreatitis in 
Medical History (Group 2) ............. [ADDRESS_37857]-Treatment Follow -up Period  ............. 49 
8.9 Withdrawal of Patients from the Study  ..................................................................................... 49 
8.10 Concomitant Therapy and Procedures  ....................................................................................... 50 
8.10.1  Concomitant Therapy ........................................................................................................ 50 
8.10.2  Concomitant Procedures  .................................................................................................... 51 
8.11 Treatment Compliance  .............................................................................................................. 51 
9. SERIOUS AND NON-SERIOUS ADVERSE EVENT RE PORTING  .................................... 51 
9.1 Sponsor Review of Safety Information  ..................................................................................... 51 
9.2 Regulatory Requirements .......................................................................................................... 51 
9.3 Definitions  ................................................................................................................................. 52 
9.3.1  Adverse Event  ................................................................................................................... 52 
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ......................................................... 52 
9.3.3  Serious Adverse Event (SAE)  ........................................................................................... 52 
9.4 Monitoring and Recording Adverse Events  .............................................................................. 53 
9.4.1  Serious Adverse Events  ..................................................................................................... 53 
9.4.2  Non-Serious Adverse Events ............................................................................................. 53 
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious)  ................................................ 53 
[IP_ADDRESS]  Relationship to the Study Drug  .................................................................................. 53 
[IP_ADDRESS]  Severity  ....................................................................................................................... 54 
[IP_ADDRESS]  Action Taken with Volanesorsen  ............................................................................... 54 
[IP_ADDRESS]  Treatment Given for Adverse Event ........................................................................... 54 
[IP_ADDRESS]  Outcome of the Adverse Event  .................................................................................. 54 
9.4.4  Adjudication Committees .................................................................................................. 55 
9.5 Procedures for Handling Special Situations  .............................................................................. 55 
9.5.1  Abnormalities of Laboratory Tests .................................................................................... 55 
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Tre atments ....................... 55 
9.5.3  Dosing Errors  .................................................................................................................... 56 
9.5.4  Contraception and Pregnancy ............................................................................................ 56 
10. STATISTICAL CONSIDERATIONS  ....................................................................................... 57 
10.1 Study Endpoints  ........................................................................................................................ 57 
10.1.1  Efficacy Endpoints  ............................................................................................................ 57 
10.1.2  Safety Endpoints ................................................................................................................ 57 
10.2 Sample Size  ............................................................................................................................... 57 
10.3 Populations  ................................................................................................................................ 58 
10.4 Definit ion of Baseline ................................................................................................................ 58 
10.5 Interim Analysis  ........................................................................................................................ 58 
10.6 Planned Methods of Analysis  .................................................................................................... 58 
10.6.1  Demographic and Baseline Characteristics  ....................................................................... 59 
10.6.2  Safety Analysis  .................................................................................................................. 59 
10.6.3  Efficacy Analysis  .............................................................................................................. 59 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]  25 May 2018  
8  10.6.4  Pharmacokinetic and Immunogenicity Analysis  ............................................................... 60 
[IP_ADDRESS]  Pharmacokinetic Analysis .......................................................................................... 60 
[IP_ADDRESS]  Immunogenicity Analysis  ........................................................................................... 60 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .......................................................... [ADDRESS_37858] of the Study ..................................................................................................... 61 
11.3 Independent Ethics Committee/Institutional Review Board  ..................................................... [ADDRESS_37859] of Laboratory Analytes ....................................................................................... 77 
Appendix C Pharmacokinetic Sampling Schedule  ......................................................................... 78 
Appendix
 D Grading Scale for Adverse Events Relating to Laboratory Abnor malities  ................ 79 
TABLE OF TABLES  
Page  
Table  1 Volanesorsen (ISIS 304801) Characteristics ................................................................. 39 
Table  2 Labs to Be Performed in the Event of a Platelet Count Less than the Lower 
Limit of Normal (x2) or < 100,000/mm3 (x1)* ................................................................. 42 
Table  3 Actions in Patients with Low Platelet Count  .................................................................... 47 
Table  4 Expected Event for the Protocol Defined Population by [CONTACT_37674] ........................................................................................................... 51 
TABLE OF FIGURES  
Page  
Figure 1  ApoC -III Regulates Lipoprotein Metabolism by [CONTACT_37675] .......................... 24 
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  (MOE -Gapmer).  The sequence of volanesorsen is shown  ............................................... 26 
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ........................... 28 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
9   
PROTOCOL AMENDMENT 
 
Protocol Number:  ISIS 304801-CS7 
Protocol Title:  An Open -Label Study of Volanesorsen  Administered Subcutaneously to Patient s with Familial Chylomicronemia 
Syndrome (FCS)  
Amendment Number:  9 - [LOCATION_009] 
Amendment Date:  25 May 2018  
 
The purpose of this protocol amendment is to implement the following modifications to Protocol ISIS 304801 -CS7 Amendment 8 dated 
10 April  2017 :  
1. To prolong the extended treatment period an additional 52 weeks.  
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall  
clarity of the original protocol but these changes do not impact subject safety, exposure, or the overall study design.  
The follow ing table provides a summary list of major changes to the protocol, additions are indicated as underline and deletions are indicated as 
strikethrough : 
Protocol Section Description of Change Rationale 
Protocol Synopsis : 
Study Design and 
Study Visit 
Schedule and Procedures 
 
3.[ADDRESS_37860]- treatment evaluation period or will 
participate in an expanded access program pending approval by [CONTACT_1026]/IEC, and the appropriate regulatory 
authorities. have the option to continue dosing for up to an additional [ADDRESS_37861]- treatment follow- up period.   To allow patients the option of 
continuing treatment with 
volanesorsen after completion of 
the 52 -week open -label treatment 
period.  
Protocol Synopsis: Study Visit Schedule and 
Procedures o An at least [ADDRESS_37862] -treatment evaluation period  Option to participate in an extended 
treatment period (up to an additional 52 weeks)  
o A [ADDRESS_37863] assessments and procedures done during Weeks 54- 104 
as per the Schedule of Procedures in Appendix A.  Assessments and procedures may be conducted by [CONTACT_5640] a 
home healthcare service or the Study Center, however the patient will be required to visit the study center 
approximately every 3  months.   Study Drug will be administered once weekly unless the patient is on a biweekly 
dosing schedule for safety reasons  (Section 8.1).  Collection and measurement of vital signs, clinical laboratory 
parameters (including hematology, serum chemistry, and urinalysis), AEs, concomitant medication/procedure 
information, lipid panel, volanesorsen plasma concentrations, IM testing, ECGs, and  physical examinations will 
be performed according to the Schedule of Procedures in Appendix A.  Adverse events at the injection site 
should be collected as adverse events.  Dietary counseling will be reinforced at intervals throughout the extended 
treatment period.  All blood and urine samples should be collected prior to volanesorsen administration.  Blood 
sampling at Weeks 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 79, 
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, and [ADDRESS_37864]- treatment evaluation period or will participate in an expanded access program pending approval by 
[CONTACT_1026]/IEC, and the appropriate regulatory authorities.  The 26-week period post-treatment follow- up consists 
of at least 9 Study Center visits on Weeks 53, 54, 55, 56, 57, 58, 65, 71, and 78 (Weeks  53, 54, 55, 56, 57, 58, 
and 71 may be conducted by a home healthcare nurse). An additional [ADDRESS_37865] 9 Study Center visits on Weeks 105, 106, 107, 108, 109, 110, 
117, 118, and 125 (Weeks 105, 106, 107, 108, 109, 110, and [ADDRESS_37866] 
follow up treatment period . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
11  Appendix A 
Schedule of Procedures—Post-
Treatment Follow-Up Study Period  Post Treatment  Follow -upp 
Study Week Wk 
54 
& 
56 Wk 
58 Wk 
65 W
k 
71 Wk 
78 
Study Day  372 
& 
386 400 449 49
1 540 
Visit Window+/ - Days  2 7 7 7 7 
Informed Consent       
Outpatient Visit X
j X
j X Xj X 
Inclusion/Exclusion Criteria       
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X 
MRI (liver/spleen)       
Echocardiography       Blood Draw (Fasting)c Chemistry Panel   X X X X 
CBC with Differentialb X
s X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testd  X X X X 
Archived Serum & Plasma Samplese   X  X 
Urinalysisc  X
m X
m Xm Xm 
Fundus Photographyf      
Genetic testing for FCS diagnosis (if not available in medical history)g      
Weekly Study Drug:  SC Injection       
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Food/Drink Diary (quarterly)h   X  X Removed assessments that were not 
conducted during the post -
treatment follow- up. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
12  Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication  X X X X X 
 
Appendix A: 
Schedule of 
Procedures—
Extended 
Treatment Period  A Schedule of Procedures table was added for the 52 week extended treatment period.   Schedule of procedures table added 
for the 52- week extended treatment 
period.  
Appendix A: Schedule of 
Procedures—
Extended Treatment Period Post-Treatment 
Follow-Up Study Period  Post Treatment Follow -upa 
Study Week Wk 106 
& 
108 Wk 
110 Wk 
117 Wk 
123 Wk 
130 
Study Day  736 
& 
750 764 813 855 904 
Visit Window+/ - Days  2 7 7 7 7 
      
Outpatient Visit  Xb Xb X Xb X 
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X Blood Draw (Fasting)e Chemistry Panel   X X X X 
CBC with Differentialc Xd X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37491]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testf  X X X X 
Archived Serum & Plasma Samplesg   X  X 
Urinalysis  Xi Xi Xi Xi 
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Diet/Alcohol Counselingi  X X X X Schedule of procedures table added 
for [ADDRESS_37867] treatment follow-
up subsequent to the 52 week 
extended treatment period.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
13  Adverse Events  X X X X X 
Concomitant Medication  X X X X X 
 
Appendix C: 
Pharmacokinetic 
Sampling Schedule Week  Wk 
76 Wk 
104 Wk 
117 
Study Day  D526 D722 D813  
Visit 
Window +/ - 
Days 2 2 7 
Time Point  Pre-dose  Pre-
dose Anytime  
 A PK sampling scheduled was 
added for the 52 week extended 
treatment period.  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
14  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication Familial Chylomicronemia Syndrome  
Study  Objectives To evaluate the safety and efficacy of dosing and extended dosing with volanesorsen 
(volanesorsen sodium 300 mg) in patients with FCS  
Study Design This is a multi-center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll  over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll  over FCS patients  
All patients will receive volanesorsen [ADDRESS_37868] -treatment follow-up period.  
Number of  Patient s Up to a pproximately 70 patients dosed 
Study Population Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed and 
dated) and any authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS  304801-
CS16 (index studies) with an acceptable safety profile, per Sponsor and 
Investigator judgement.  
 Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the following criteria in order to enter into the open- label study:  
a. History of chylomicronemia as evidenc ed by [CONTACT_37754] (a creamy top layer after ultracentrifugation of a fasting blood 
sample) or documentation of fasting TG measurement ≥ 880 mg/dL 
(10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of the 
following: 
• Confirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-causing 
genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LP L activity of ≤ 20% of normal in medical 
history.  Note:  testing of LPL activity should not be performed to 
confirm eligibility for the study 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-
CS16 index study   
4. Able and willing to participate in a 78-week study  
Inclusion Criteria:  Continued  Study Populat ion Continued  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]  25 May 2018  
15  Inclusion Criteria: Continued  
5. Satisfy 1 of the following:
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal
occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral
oophorectomy), post -menopausal (defined as 12 months of spontaneous
amenorrhea in females > 55 years of age or, in females  ≤ 55 years, 12
months of spontaneous amenorrhea without an alternative medical causeand FSH levels in the postmenopausal range for the laboratory involved),
abstinent*, or if engaged in sexual relations of child-bearing potential,
patient is using an acc eptable contraceptive method (refer to
Section  6.3.1 ) from time of signing the inform
ed consent form until [ADDRESS_37869] dose of Stud
y Drug administration
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations
with a female o f child -bearin g
 potential, patient is utilizing an acceptable
contraceptive method (refer to Section  6.3.1 ) from the time of signing the
informed consent form until [ADDRESS_37870] dose of Study Drug
administration
* Abstinence is only acceptabl
e as true abstinence, i.e., when this is in line
with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial and withdraw al are not acceptable 
methods of contraception  
Exclusion Criteria : 
1.Diabetes mellitus with any of the following:
a.Newly diagnosed within 12 weeks of Qualification
b.HbA1c ≥ 9.0% at Qualification
c.Recent change in anti -diabetic pharmacotherapy (chang e in dosage or
addition of new medication within 12 weeks of Qualification [with the
exception of ± 10 units of insulin])
d.Anticipated need to change dose or type of medication during the  treatment
period of the Study (with the exc eption of ± 10 units of insulin)
e.Current use of GLP -1 agonists
2.Severe hypertriglyceridemia other than due to familial chylomicronemiasyndrome
3.Active pancreatitis within 4 weeks prior to Qualification
4.History within 6 months of Qualification of acute or unstable cardiac ischemia(myocardial infarction, acute coronary syndrome, new onset angina), stroke,transient ischemic attack or unstable congestive cardiac failure requiring a
change in medication or major surgery within 3 months of Qualification
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
16  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued 
5. Any of the following laboratory value s at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which case 
total bilirubin must be ≤ 3 mg/dL 
• ALT > 2.[ADDRESS_37871]  
• AST > 2.[ADDRESS_37872]  
b. Renal: 
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein 
on urine dipstick.  In the event of a positive test eligibility may be 
confirmed by a quantitative total urine protein measurement of 
< 500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥ trace positive) 
for blood on urine dipstick.  In the event of a positive test eligibility may be confirm ed with urine microscopy showing ≤ 5 
red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault for 
estimation  of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL -C > 130 mg/dL  at Qualification  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP >  160/100 mm Hg) 
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding 
diathesis or coagulopathy or clinically -significant abnormality in coagul ation 
parameter s at Qualification  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_37873] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the 
skin or carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another  investigational drug, biological agent, or device within 1  
month of Qualification , or 5 half -lives of investigational agent, whichever is 
longer 
13. Unwilling to comply with lifestyle requirements ( Section  6.3) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]  25 May 2018  
17  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued  
14.Use of any of the following:
a.Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a
stable dose for at least 3 months prior to Qualification  and d ose and regimen
expected  to remain constant during the treatment period.  Patients taking
OTC omega -3 fatty acids should make every effort to remain on the same
brand throughout the study
b.Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to
Qualification
c.Systemic corticosteroids or anabolic steroids within 6 weeks prior to
Qualification unless approved by [CONTACT_37755]
d.Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on
a stable dose for at least [ADDRESS_37874] 4  weeks
prior to Qualification  and dose and regimen expected to remain constant
during the treatment period
f.Glybera gene therapy within  2 years prior to Qualification
g.Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822])unless on a stable dose for at least [ADDRESS_37875] 4 weeks prior to Qualification
(Occasional or intermittent use of over-the -counter medications will be
allowed at Investigator’s discretion)
15. Bl ood donation of 50 to 499 mL within 30 days of Qualification  or of >  499 mL
within 60 days of Qualification
16.Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS  304801
or placebo)
17.Have any other conditions, including new  or worsening of existing condition,
which, in the opi[INVESTIGATOR_37492], or could interfere with the patient participating in orcompleting the study
Treatment Group  Volanesorsen 300 mg once per week 
Study Drug Administration  Volanesorsen will be administered as subcutaneous (SC ) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency 
will be allowed for safety or tolerability after consultation with the Sponsor Medical 
Monitor. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
18  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The d ose of 300 mg once weekly was chosen for the double -blinded 
placebo-controlled Phase 3 in
dex studies ( ISIS 304801-CS6  and ISIS  304801-CS16 ) 
based on the pharmacodynamic and safety analysis of the Phase 2 studies 
(Section  2.4) which included a subset of 
patients with FCS .  The same dose of [ADDRESS_37876] of the following periods: 
• A qualification period of up to 2  weeks (unless  approved by [CONTACT_1034]).  
Please refer to Section  4.1 and Appendix A  
o A 52 -week treatment per iod
 during which vola
ne
sorsen will be 
administered as a once weekly SC injection  
o Option to participate in an extended treatment period (up to an 
additional 52 weeks) 
o A 26-week post -treatment follow-up period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to lipid data through the last patient’s Week [ADDRESS_37877] . 
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events (AE) , concomitant 
medication/procedure information, lipid panel, blood viscosity, volanesorsen plasma 
concentr ations, immunogenicity (IM) testing , platelet aggregation, liver/spleen 
magnetic resonance imaging (MRI ), ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in 
Appendix A .  Dietary counseling wil l be repeated at intervals throughout the 
treatment and follow -up period and a daily food/drink diary will be completed  for the 
week prior to each quarterly visit by [CONTACT_6904] .  Following the Week [ADDRESS_37878] the option to continue dosing for up to an additional 52 weeks . 
Patients not to continuing dosing will enter a 26- week pos t-treatment follow-up 
period. 
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by [CONTACT_37686] (including independently adjudicated events of acute pancreatitis and MACE), withdrawals due to adverse events, and changes in laboratory and other safety parameters.  
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
19  PROTOCOL SYNOPSIS Continued  
Planned Analyses  Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis and 
MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory tests (serum chemistry,  hematology, coagulation, 
urinalysis) 
• Echocardiography 
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs 
• Platelet aggregation (may be evaluated)  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the 
treatment period  
• Percent change and change from baseline in other fasting lipid measurements including total cholesterol, non-high -density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein-cholester ol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low-density lipoprotein- cholesterol (VLDL -C), and LDL -C 
• Percent change from baseline in fasting total apolipoprotein C-III (apoC-III) 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ -5D, SF-36) 
• Adjudi cated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of volanesorsen 
as follows : trough levels  (pre-dose) throughou
t treatment and post- treatment levels 
during the post -treatment follow-up period .  In a subset of patients, more frequent 
assessment of plasma concentrations of volanesorsen will be performed to determine 
volanesorsen pharmacokinetic parameters .  Plasma sample collection time points are 
detailed in Appendix A  and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open-label study . 
Sponsor  Akcea Therapeutics , Inc. 
Collaborator Ionis Pharmaceuticals,  Inc. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
20  STUDY DESIGN AND TREA TMENT SCHEMA  
 
  
QUALIFICATION  PERIOD  
Weeks -2 to -1 
EARLY TERMINATION 
(ET) 
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post -treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at specified 
time points  
EXTENDED TREATMENT PERIOD  
Weeks [ADDRESS_37879] -TREATMENT FOLLOW -UP 
Weeks 53 to 78* 
(Treatment Period Post Treatment 
Follow -Up) 
 
And Weeks 105 to 130 
(Extended Treatment Period Post 
Treatment Follow -Up) 
 
Safety, efficacy, PK and PD assessments  
* If needed, the post -treatment follow- up 
period will be extended (with patients 
monitored every 6 weeks) until apoC -III 
levels return to baseline values  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
21  STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_37880]  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
ET early termination  
FAS full analysis set 
FCS Familial Chylomicronemia Syndrome  
GCP  Good Clinical Practice  
GLP -1 glucagon -like peptide -1 
GPI[INVESTIGATOR_37445]1  Glycosylphosphatidylinositol -anchored HDL -binding Protein 1  
HAPI  [INVESTIGATOR_37451]1c  Glycated Hemoglobi n 
HDL  High -Density Lipoprotein  
HDL -C High -Density Lipoprotein -Cholesterol  
hsCRP  High -sensitivity C -reactive protein  
ICH International Conference on Harmonization  
IDL Intermediate density  lipoprotein  
IEC Independent  Ethics Committee  
IM immunogenicity  
Index  Studies  ISIS 304801 -CS6 and ISIS 304801 -CS16  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
22  Abbreviation/Acronym  Definition  
INR International Normalized Ratio  
IRB Institutional  Review Board  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_37881] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_37882]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]  25 May 2018  
23  1. OBJECTIVES
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen  in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATI ONALE
2.1 Overview of Disease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and risk or history of pancreatitis .  It is a rare autosomal 
recessive disease that can be diagnosed ei ther in childhood or adulthood.  
Fasting plasma triglyceri de (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10-fold to 100-fold above normal 
(1,500 to 15,000 mg/dL), 
despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily 
calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in infancy or childhood with 
frequent and 
severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37493], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011) .  Physical examination 
frequently reveals eruptive xanthomas, lipemia retinalis and hepatosplenomegaly, and plasma from 
patients appears lactescent, interfering with determination of other laboratory parameters (Tremblay et al. 
2011).  
Patients with fasting triglyceride levels >  10 mmol/L  probably have a component of chylomicronemia .  
Cli
nical diagnosis would include  evidence of clinical features of chylomicronemia syndrome and 
secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus (T2DM) , hypothyroidism, poor 
diet, alcohol use, nephrotic syndrome or use of associated medications should be ruled out .  The diagnosis 
of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37454] (LPL) enzyme activity in post  heparin plasma ( Brunzell 1999-2011). 
Patients with FCS carry a heavy burden of medical complications, the  most serious, as described above, 
being an extreme risk of recurrent and potentially fatal
 pancreatitis.   Due to the recurrent epi[INVESTIGATOR_37455], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine 
pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  While the pathophysiology 
underlying chylomicron-related pancreatitis has not 
been completely elucidated, 1 hypothesi
s is that large 
chylomicrons lodged in pancreatic capi[INVESTIGATOR_37494] d to pancreatic lipase, with the subsequent 
release of free fatty acids through the hydrolysis of chylomicron -associated TGs.  High concentrations of 
free fatty acids are thought to damage pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; 
Berglund et al. 2012). 
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity.  LPL normally functions to hydrolyze 
triglycerides (TG)  in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, skeletal 
muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL is regulated by a 
number of key genes, and loss -of-function mutations in one of these genes, or the LPL gene itself, results 
in FCS (Surendran et al. 2012).  In addition to loss of function mutations, null mutations, and nonsense 
mutati ons in the LPL gene, other genes currently identified in FCS patients, and known to directly 
influence LPL activity include: apolipoprotein  C-II (APOC2) a cofactor for LPL (Schuster et al. 2011); 
apolipoprotein A -V (APOA5)  an enhancer of LPL activity  (Schaap et al. 2004); lipase maturation F actor 
1 (LMF1), a transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
24  glycosylphosphatidylinositol -anchored HDL -binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37495] a plat form for LPL -mediated processing of chylomicrons ( Beigneux et al. 2007). 
2.2 Therapeutic Rationale  
Apolipoprotein C -III (Ap oC-III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein sy
nthesized principally in the liver ( Ooi et al. 2008; Figure 1).  Ap oC-III is a major regulator 
of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] ( Chan  et al. 2008).  It is 
a component of triglyceride -rich lipoproteins (TRLs) and a potent inhibitor of 
LPL (Lemieu
x et al. 2003).  
At higher concentrations apoC -III also inhibits hepatic lipase activity ( Kinnunen and Ehnolm  1976), an 
enzyme which plays an important role in the conversion of dense very-low-density lipoprotein ( VLDL ) to 
intermediate density lipoprotein ( IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of 
HDL ( Brown et al. 2010) .  In addition, increased apoC -III content adversely affects apoE- mediated 
hepatic uptake of TG-rich remnants ( Mann et al. 1997 ).  Thus, elevated plasma apoC -III levels are 
associated with impaired hydrolysis and retarded clearance of TG-rich particles, resulting in the 
accumulation of lipoprotein-triglyceride ( VLDL -TG) and chylomicrons in plasma and the development of 
hypertriglyceri demia ( Ito et al. 1990). 
 
Figure 1 Ap oC-III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL = high -density lipoprotein, 
HL = hepatic lipase, IDL = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr = LDL receptor, LPL  = lipoprotein lipase,  LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL = very low -density lipoprotein. 
Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  Ap oC-III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in inhibiting LPL, 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
25  apoC -III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by [CONTACT_37758] . 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or nonsense 
mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; Pollin et al.
 2008; 
Petersen et al. 2010).  A novel nonsense mutation in the apoC -III gene was ident
ified in the heritability 
and phenotype intervention (HAPI) heart
 study in Old Order Amish that results in lower plasma apoC-III 
and TG levels and lower LDL -C, increased HDL -C and reduced atherosclerosis (Pollin  et al. 2008).  In 
another study involving a group of 214 Ashkenazi Jews of advanced age (had passed or nearly reached 
100 years of age), genotype analysis revealed a polymorphism in the apoC -III gene (APOC3 -641CC 
genotype) with a clear pattern of age-dependent frequency that w as associated with significantly lower 
levels of apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006) .  
In contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC -
III polymo rphisms associated with higher plasma TG have also been recently described ( Petersen  et al. 
2010).  In a cohort of lean (mean body mass index [BMI]  = 24.7 ± 3.6 kg/m2) Asian Indians, carriers of 
apoC -III variant alleles (C -482T, T -455C, or both) were noted to have significantly higher plasma apoC -
III and TG levels, and decreased ability to clear postprandial plasma TG from the circulation .  Taken 
together, the available data strongly support the development of a therapy that reduces plasma apoC -III 
levels i n order to reduce the very high circulating triglyceride and chylomicron levels that are 
accompanied by [CONTACT_37690].  
Given the profound reductions in TGs observed with  volanesorsen  treatment in FCS patients who have no 
detectable LPL activity (See Section  2.3.4), and the mechanistic data available to date on apoC -III 
function, potential mechanisms that explain how apoC -III inhibition results in triglyceride reduction in 
FCS patients  include:  (1) enhancing the  very small residual amounts of LPL activity that  these patients 
may have, below the limit of detection of the assay in many cases (2) potentially enhanced activity of 
other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial 
lipase (Kinnunen and Ehnolm  1976), and (3) apoC -III interaction  with Apolipoprotein E ( apoE ), an 
important factor in liver reuptake of lipid particl
es by [CONTACT_37691] -mediated uptake of lipid particles in 
the liver ( Breyer et al. 1999 ), and therefore, reduc ing apoC -III might enhance apoE -mediated uptake of 
lipid particles.  Volanesorsen -mediated reduction of apoC -III could be contributing to one or all of these 
mechanisms resulting in the observed potent and sustained reductions in TG.  
Through a novel apoC -III lowering mechanism of action, volanesorsen may provide the potential to 
m
anage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action 
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human apoC -III.  It 
is complement
ary to a region within the 3 ʹ untranslated region of the apoC-III messenger ribonucleic acid 
(mRNA ) and binds to the mRNA by [CONTACT_37692].  The hybridization (binding) of 
volanesorsen to the cognate mRNA , results  in the RNase H1- mediated degradation of the apoC-III 
mRNA, thus preventing production of the apoC-III protein .  Maximal antisense -mediated reduction of 
target mRNA levels is ty pi[INVESTIGATOR_37497] 90%  of control levels in sensitive tissues (Crooke  and 
Bennett 1996 ; Zhang et al. 2010).  Furthermore, reduction in target mRNA levels using thi
s approach 
correlates directly  wi
th a subsequent reduction in target protein levels.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]  25 May 2018  
26  2.3.2 Chemistry  
Chemically, volanesorsen  is a synthetic oligomer of 20 nucleotides (i.e., a 20 -mer) that are connected 
sequentially by [CONTACT_37693] .  The nucleotide sequence of  volanesorsen  (Figure 2 ) is 
complementary to a 20-nucleotide stretch within the 3 ʹ untranslated region of the apoC-III mRNA 
transcript at base position 489 -508.  Structurally, the oligonucleotide has 3  regions .  Two (2) of them, the  
5 nucleot ides at the 5′ end and the  5 nucleotides at the 3′ end, are  composed of 2ʹ- O-(2-methoxyethyl)  
(MOE) -modified ribonucleotides .  These MOE -modified nucleotides confer (1) increased affinity to the 
target mRNA ( Altmann  et al. 1996; McKay  et al. 1999), (2) increased resistance to exonucleases and 
endonu
cleases (thereby [CONTACT_37759]) ( Geary et al. 2003), an
d (3) amelioration of  some of 
the high dose toxicities thereby [CONTACT_37760] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 10 oligodeoxynucleotides .  
This chimeric design is called a MOE -Gapmer, and volanesorsen  employs  this chimeric structure to 
enable use of the RNase H 1-mechanism for  antisense activity .  This is because while the 2 ʹ-MOE 
modification confers increased stability and  affinity, it does not support RNase H 1 catalysis of RNA 
hybridized to 2ʹ-MOE -modified nucleotides ( McKay  et al. 1999).  This is caused by [CONTACT_37694] 2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 
enzymes ( Inoue  et al. 1987 ; Monia  et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides 
flanking the phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2 ʹ-MOE 
chemistry are preserved while also retaining RNase H1 recognition.  
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides 
(MOE -Gapmer) .  The 
sequence of volanesorsen  is shown  
2.3.3 Preclinical Experience  
Inhibition of apoC -III using volanesorsen  has been shown to potently r
educe hepatic apoC -III mRNA as 
well 
as plasma apoC-III protein and TG in a dose - and time -dependent fashion in several species, 
including human apoC -III transgenic mice, and other rodent and monkey models .  Treatment with 
volanesorsen  also resulted in reduced VLDL and chylomicron TG and reduced postprandial TG in 
hypertriglyceridemic monkeys  (Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen  have  been asse
ssed in mice, rats, and 
cynomolgus monkeys .  Gen eral toxicity studies with volanesorsen  for up to 39 weeks of treatment 
followed by [CONTACT_8622] a 20-week recovery period are complete.  The preclinical toxicology program for 
volanesorsen  consists of single dose safety pharmacology studies in the monkey (cardiovascular) and 
2ʹ-MOE  
 2ʹ-Deoxy  
 2ʹ-MOE  
(RNase H 1 
 Sensitive)  
A  G  C 
 T 
T 
 C  T 
 T 
G  
T 
C  
C 
A 
G  
C 
 T 
T  
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
27  mouse (neurobehavioral and pulmonary assessment studies), in vitro  and in vivo genetic toxicity 
assessment, repeat dose fertility and/or developmental reproductive toxicology studies in the mouse and 
rabbit and evaluation in the in vitro huma n Ether -á-go-go-related gene (hERG) assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with those 
expected for the 2′ -MOE -class of ASOs.  Treatment -related findings included effects consistent with drug 
accumulatio n in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents 
and monkeys and complement activation and reductions in platelet counts in the monkey .  In the mouse 
and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated 
with any findings that could be considered related to the pharmacologic inhibition of apoC -III for up to [ADDRESS_37883] effects in safety pharmacology studies (in vitro  and in vivo ) and was 
non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or embryo/fetal 
development in the mouse or rabbit reproductive toxicity studies .  In these studies, volanesorsen  was 
detected in placental tissue but not in fetal tissue indicating that little, if any, drug  was able to cross the 
placenta to reach the fetus.  Reduction of apoC -III mRNA (64% in males and 47% in females) also did 
not affect fertility or cause untoward effects on emb ryo/fetal development in mice.  
Detailed information concerning the precli nical studies conducted with volanesorsen can be found in the 
volanesorsen  Investigator’s Brochure.  
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found in the 
volanesorsen  Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double blinded and 
placebo controlled.  The total exposures comprise 99 patients and healthy volunteers administered 
volanesorsen  from 50 to 400 mg subcutaneously up to 3 months (compared to 37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinica
 lly meaningful reductions in fasting plasma 
apoC -III and TG (~80% and 70%, respectively,  mean reduction from baseline with 300 mg dose) with a 
very high degree of consistency of response between the different patient groups.  This includes healthy 
volunteers, patients with moderate to severe hypertriglyceridemia not on background TG -lowering 
therapy, patients with moderate to severe hypertriglyceridemia on a background stable fibrate therapy  
(Gaudet et al. 2015) , patie
nts with FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an open -label 
fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 3 patients achieved 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
28  TG levels below or close to 500 mg/dL during the dosing period out to Day  92 (Figure 3).  Two (2) of the 
FCS patients had an absolute reductio n in fasting TG in excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_37884] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine aminotransferase 
[ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_37885] -treatment period and 
was not associated with platelet -related adverse events  (AEs) .  In the blinded ongoing clinical trials of 
ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less 
than 50,000/mm3 in the  absence of major bleeding or clinically -relevant non-major bleeding and had 
Study Drug paused as per the monitoring and stoppi[INVESTIGATOR_37498] ( Section  8.6.3).   Platelet 
counts recovered following suspension 
of dosing.  
The most frequently obse rved AEs with vo
lanesorsen  were local reactions at the injection site.  L ocal 
cutaneous reactions at the injection site defined as those events presenting as either pain, tenderness,  
erythema,  pruritus or swelling occurring on the day of injection and persisting for at least 2 days were 
infrequent (~15% of injections), were almost always mild, resolved spontaneously, were non -progressive, 
and were not associated with systemic sequelae.  
2.[ADDRESS_37886] Level (NOAEL ) was defined by [CONTACT_37762] .  No nonclinical findings were considered 
to be  related to the pharmacologic inhibition of apoC -III. 
The safety data to date suggest that volanesorsen  has been well-tolerated  at dose levels up to 300 mg  in 
patients with high triglycerides (including  type 2 diabetes patients and administration  in combination with 
fibrates and statins) with the most common AEs being local to the injection site and predominantly mild.  
A pooled analysis of safety for the  Phase 2  studies did not demonstrate any clear difference in safety or 
tolerability between the different doses tested (100 mg, 200 mg, and 300 mg per week for 13 weeks) . 
Analysis of the cohorts in which volanesorsen  was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, apoC-III, wi th 
a clear difference in the TG -lowering effect between the different doses in the 100  mg to 300 mg dose 
range as compared to placebo . 
In addition to the nonclini cal and clinical experience of volanesorsen, t he dose  and schedule of 
administration is suppor ted by [CONTACT_37697] 2′ -MOE -
modified ASOs that have been safely administered intravenously and subcutaneously in multiple clinical 
studies at doses up to 1000 mg and for treatment durations that exceed 24 m onths  (Santos et al. 201 5). 
3. EXPERIMENTAL PLAN 
3.1 Study
 Design 
This is an open-label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients  
Up to a pproximately [ADDRESS_37887] of the following periods:  
3.4.1  Qualification  
A qualification period of up to 2 weeks (unless approved by [CONTACT_1034])  is given to complete 
qualification assessments outlined in the Schedule of Procedures .  Please refer to Section 4.1 and 
Appendix A.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
30  3.4.2 Treatment  
The treatment period is 52 weeks.  Eligible patients  will report to the Study Center for assessments at 
specified  intervals throughout the 52-week treatment period  as detailed in the Schedule o f Procedures 
(Appendix A ).  During the treatment period, volanesorsen  is administered by  [CONTACT_37763].  
3.4.[ADDRESS_37888] 9 Study Center visits on 
Weeks 53, 54, 55, 56, 57, 58, 65, 71 , and 78 (Weeks 53, 54, 55, 56, 57, 58, and 71 may be conducted by a 
home healthcare nurse).  
3.[ADDRESS_37889] (DSMB) will review (as needed)  safety, tolerability 
and efficacy data collected on volanesorsen during this study .  Based on its ongoing assessment of the 
safety and tolerability of volanesorsen , the DSMB will provide reco mmendations to the Sponsor for 
modifying, stoppi[INVESTIGATOR_10483].  Details on the safety assessments, frequency of 
review and meeting schedules are outlined in the DSMB Charter and/or  the statistical analysis plan 
(SAP ). 
4. PATIENT  ENROL LMENT  
4.1 Qualification 
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center’s written 
independent ethics committee/institutional review board (IEC/IRB) approval of the protocol, informed consent form,  and all other patient  information . 
Patients or their legally acceptable representatives must sign the consent form  before any  study -specific 
procedures or evaluations  related to this open-label study are performed .   
During the qualification period,  the el igibility of the patient to enroll  in the open -label study will be 
determined .  Final assessments from the ISIS 304801- CS6 or ISIS 304801-CS16 stud ies may be used for 
qualification.  A period  of up to 2 weeks after completion of the ISIS 304801-CS6 or  ISIS 304801-CS16 
index studies (unless approved by [CONTACT_16049]) is given to complete qualification.  Qualified patients will 
retain the unique  patient  identification number  that was assigned to them  during the ISIS 304801-CS6 or 
ISIS 304801- CS16 index studies.  The patient identification number will be used to identify the patient  
throughout the extension trial and must be used on all stud y documentation related to that patient.  The 
patient  identification number must remain constant throughout the extension trial. 
ISIS [ADDRESS_37890] been 
completed and after the Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  
No patient may begin treatm
ent prior
 to enrollment . 
Eligible patients will be enrolled using an 
Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY 
To be eligible to participate in this study candidates must meet the following eligibility criteria within [ADDRESS_37891] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801 -CS6 or ISIS 304801-CS16 (index 
studies)  with an acceptable safety profile, per Sponsor and Investigator judgement . 
 
Group 2:   Patients who enrolled in ISIS 304801-CS16 must also meet the following criteria in 
order to enter  into the open -label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a creamy 
top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG 
measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of the following:  
• Confirmed homozygote, compound heterozygote or double heterozygote for known loss -
of-function mutations in Type 1-causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or 
LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal  in medical history.  Note: testing of 
LPL activity should not be performed to confirm eligibility for the study . 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  ISIS 304801-CS16 index study 
4. Able and willing to participate in a 78- week study  
5. Satisfy 1 of the following:  
a. Females:  Non -pregnant and non-lact ating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post -menopausal (defined as 
12 months of spontaneous amenorrhea in females >  55 years of age or, in females ≤  55 years, 
12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels 
in the postmenopausal range for the laboratory involved), abstinent *, or if engaged in sexual 
relations of child -bearing potential, patient is using an acceptable contr aceptive method (refer 
to Section 6.3.1 ) from time of signing the
 informed consent form until [ADDRESS_37892] 
dose of Study Drug administration.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
32  b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child-
bearing potential, patient is utilizing an acceptable contraceptive method (refer to 
Section  6.3.1) from the time of signing the informed consent form until [ADDRESS_37893] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception 
5.2 Exclusion Criteria   
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of Qualification  
b. HbA1c ≥ 9.0% at Qualification  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of Qualification [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the  treatment period of the 
Study (with the exception of ± 10 units of insuli n) 
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to Qualification 
4. History within 6 months of Qualification of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or unstable congestive cardiac failure requiring a change in medication or major surgery within 3 
months of Qualification  
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation 
of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL 
• ALT > 2.[ADDRESS_37894]  
• AST > 2.[ADDRESS_37895]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for protein on urine dipstick.  In 
the event of a positive test eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently p ositive (2 out of 3 consecutive tests ≥  trace positive) for blood on urine 
dipstick.  In the event of a positive test eligibility may be confirmed with urine 
microscopy showing ≤  5 red blood cells per high power field 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
33  • Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault < 50 mL/min (MDRD or CKD -EPI [INVESTIGATOR_37446] -
Gault for estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL -C > 130 mg/dL at Qualification 
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia  (platelet count <  100,000/mm
3) or bleeding diathesis or 
coagulopathy or clinically -significant abnormality in coagulation parameters at Qualification  
8. History of heart failure with NYHA greater than Class II  
9. Active infectio n requiring systemic antiviral or antimicrobial therapy that will not be completed 
prior to Study Day [ADDRESS_37896] for human immunodeficiency virus (HIV), hepatitis C or 
chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1 month of 
Qualification, or 5 half -lives of investigational agent, whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section  6.3) 
14. Use of any 
of t
he following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable dose for at 
least 3 months prior to Qualification and dose and regimen expected to remain constant 
during the treatment period.  Patients taking OTC omega -3 fatty acids should make every 
effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification unless 
approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable dose 
for at least [ADDRESS_37897] 4  weeks prior to 
Qualification and dose and regimen expected to remain constant during the treatment period 
f. Glybera gene therapy within 2 years prior to Qualification  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable 
dose for at least [ADDRESS_37898] 4 weeks prior to Qualification  (Occasional or 
intermittent use of over -the-counter medications will be allowed at Investigator’s discretion) 
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of > 499 mL within 60  days 
of Qualification  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS  304801 or placebo)  
17. Have any other condi tions, including new  or worsening of existing condition, which, in the 
opi[INVESTIGATOR_37450], or could interfere with the patient participating in or completing the study 
6. STUDY PROCEDURES 
6.[ADDRESS_37899] 
patient’s Week [ADDRESS_37900].  
During the treatment period, p atients will report to the study center for clinic visits a minimum of  5 t imes 
during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be administered once 
weekl y (Section  8.1).  Collection and measurement of vital signs, clinical laborato
ry parameters 
(including hematology, serum chemistry, and urinalysis), AEs, concom
itant medication/procedure 
information, lipid panel, blood viscosity, volanesorsen  plasma concentrations,  immunogenicity (IM) 
testing , platelet aggregation, liver/spleen MRI, ECGs, echocardiograms and quality of life assessments 
will be performed according to the schedule of procedures in Appendix A .  Adverse events at the 
injection site should be collected as adverse events.  Dietary counseling will be reinforc ed at intervals 
throughout the treatment and follow -up period and all patients will complete a daily food diary  for one 
week prior to their quarterly visit .  All blood and urine samples should be collected  prior to volanesorsen  
administration.  Blood sampling  at Weeks 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 
23, 24, [ADDRESS_37901] assessments and procedures done during W eeks 
54-104 as per the Schedule of Procedures in Appendix A .  Asses
sments and procedures may be conducted 
by [CONTACT_5640] a home healthcare service or the Study Center, however the patient will be required to visit the 
study center approximately every 3 months .  Study Drug will be administered once weekly unless the 
patient is on a biweekly dosing schedule for safety reasons (Section  8.1).  Collection and measurement of 
vital signs, clinical laboratory parameters (i
ncluding hematology, serum chemistry, and urinal ysis), AEs, 
concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, IM 
testing , ECGs, and physical examinations will be performed according to the S chedule of Procedures in 
Appendix A .  Adverse events at the injection site should be collected as adverse events.  Dietary 
counseling will be reinforced at intervals throughout the extended treatment period.  All blood and urine 
samples should be collected prior to volanesorsen administrati on.  Blood sampling at Weeks 53, 54, 55, 
56, 57, 58, 59, 60, 61, 62,63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 79, 80, 81, 82, 83, 84, 85, 
86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, and [ADDRESS_37902] be fasted prior to drawing 
all blood samples and samples drawn locally shoul d also  be sent to the central laboratory for analysis 
whenever possible.  Dosing instructions and training will be provided to the patient where applicable.  
6.1.4 Pharmacokinetic (PK) Subgroup  
A subgroup of patients wi
ll participate in an extended PK collection.  Patients in this subgroup will have 
more frequent PK sampl
ing over a 24- hour period following the first dose on Study  Day [ADDRESS_37903] -dose blood draw after 
dosing on Day 1.  The detailed PK sampling schedules are outlined in Appendix C. 
Participation in the PK subgroup is optional  for 
sites and patients, and consent  may be withdrawn for the 
subgroup-specific procedures (e.g. , multiple blood draws for PK) without being withdrawn from the 
study .  If a patient withdraws consent from the subgroup procedures, he/she should remain on study and 
continue to follow al l the non -subgroup assessments and procedures as outlined in Appendix  A. 
6.1.[ADDRESS_37904] 9 Study 
Center visits on Weeks 53, 54, 55, 56, 57, 58, 65, 71 , and 78 (Week s 53, 54, 55, 56,  57, 58, and 71 may 
be conducted by a home healthcare nurse). An additional [ADDRESS_37905] 9 Study Center visits on Weeks 105, 106, 107, 108, 109, 110, 
117, 118, and 1 25 (Weeks 105, 106, [ADDRESS_37906] of these analytes is  contained in 
Appendix B. 
Each time a hematol
ogy lab is drawn and sent to the central laboratory for analysis an additional sample 
should be collected in parallel and analyzed locally.  In the event that  both the central and local sample 
are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated 
within [ADDRESS_37907] be reviewed by [CONTACT_37764].  All platelet count results will be promptly reviewed by [CONTACT_37765] a stoppi[INVESTIGATOR_1877] , or the dose reduction rule of 100,000/mm3, or the dose pause rule of 
75,000/mm3. 
Any case of a platelet count < 50,000/mm3 shoul d be reported in an expedited fashion to the Sponsor.  
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A ).  Vital signs should include weight, blood pressure, pulse rate, respi[INVESTIGATOR_37499].  Blood pressure and pulse rate will be recorded after the patient has been in a sitting position 
for at least 5 minutes.  Semi -supi[INVESTIGATOR_37460] (preferentially on the left arm) .  Height will be measured at  the Day 1  visit. 
[IP_ADDRESS]  Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events will be recorded.  Physical exams should also include skin 
examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be taken, if possible.  
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37701] (for ISIS 304801-CS16 roll  over patients) and repeated at Week 52.  Images will be 
evaluated by [CONTACT_37766], blinded to the patient’s treatment assignment. 
6.2.[ADDRESS_37908] ECGs performed 
in triplicate at Week s 76, 104 and 130. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
37  6.2.5  MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is  not 
contraindicated, e.g., patients having metal implants . 
MRIs will be conducted using standardized procedures and settings .  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF -36) at Week 1, Week  13, 
Week  26, and Week 52. During the post -treatment follow -up, patients will complete an EQ -5D and SF -[ADDRESS_37909] -treatment follow -up period. 
6.2.8  Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7-day food diary prior to Week 1, Week 13, Week  26, 
Week [ADDRESS_37910] -treatment follow -up, patients will complete a 7 -day food diary prior to 
Week s 65 and 78. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to 
provide diet/alcohol counseling for visits that are conducted by a clinical service.  
3. In addition to the 7 -day f ood diary and the diet /alcohol counseling during clinic visits, telephone 
calls from a dietitian or qualified study personnel to assess as to how each patient is maintaining 
their diet will be conducted randomly during the treatment and post treatment fol low-up periods.  
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2) 
Patient records will be reviewed for incidents of acute pancreatitis occurring up to [ADDRESS_37911] refrain from sperm/egg donation and either 
be abstinent or, if engaged in sexual relations of child- bearing potential, practice effective contraception 
from the time of signing the informed consent form until at lea st [ADDRESS_37912]’s last dose of study treatment.  
For t he purposes of this Study , women of childbearing potential are defined as any female who has 
experienced menarche, and who does not meet 1 of the following conditions:  
•Postmenopausal:  12 months of spontaneous amenorrhea in females > 5 5 years of age or, in
females ≤  55 years, 12  months of spontaneous amenorrhea without an alternative medical
cause and  FSH levels in the postmenopausal range for the laboratory involved
•6 weeks after surgical bilateral oophorectomy with or without hysterectomy
•Post hysterectom y
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
•Effectiv e male contraception includes a vasectomy wi th negative semen  analysis at follow -up, or 
the us e of c on
doms together w ith spermicidal f oam/gel/film/ cream/suppository.  Mal e patien ts 
must al so en courage their f emale partner t o use effective contracepti on from t he time  of signing 
the 
informe d consent unt il 3 months after t he patien t’s last dose of st udy t reatment .  Effective 
contraceptive for t
he female partner includes: surgical sterilization (e.g., bilateral tubal ligation), 
hormonal contraception, intrauterine contraception/device, or barrier methods (female condom*, 
diaphragm, s ponge, cervical c ap) together  with sp ermicidal foam/gel/film/cream/suppository . 
Male patien ts with partners t hat a re pregnant m ust us e condoms t o ensure that  the fetus is  not 
exposed to the Study
 Drug.
For female patien ts: 
•Using 1 or more of the following acceptable methods of contraception:  surgical  sterilization
(e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 2
barrier methods (a combination of male or female condom * with diaphragm, sponge, or cervical
cap) together with spermicidal foam/gel/film/c ream/suppository.
*Note: A female condom and a male condom should not be used together as friction between the two can
result in either product failing. 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual 
lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods 
of contraception  
6.3.[ADDRESS_37913] 10 hours and preferably not more than 12 hours  before 
visits requiring fasted blood sampling.  
All pat ients will be encouraged to follow a diet comprising ≤  [ADDRESS_37914] will explain that the patient is in a clinical trial and that 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
39  serum lipase and/or amylase measures should be done in order  to adjudicate the event, based on Atlanta 
Classification ( Banks et al. 2013).  If serum or amylase activity is less than 3  x upper limit of normal 
(ULN), imaging, 
preferably contrast -enhanced computed tomography, should be considered  to confirm 
the diagnosis  of acute pancreatitis per the Atlanta Criteria. 
7. STUDY DRUG  
7.[ADDRESS_37915] 
(ISIS  304801)  characteristics are listed in Table  1. 
Volanesorsen  (ISIS 304801)  is contained in glass prefilled syringes (PFS).  Volanesorsen  and its storage 
and preparation instructions will be provided by [CONTACT_16015] .  Volanesorsen  must be stored 
securely at 2 °C to 8 °C and be protected from light.  
Table  1 Volanesorsen (ISIS 304801) Characteristics  
Strength 200 mg/mL  
Volume/Formulation 1.5 mL solution per PFS  
Dose  300 mg once weekly 
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return /destruction of volanesorsen  
provided by [CONTACT_1034] .  The S tudy Center  must return all unused volanesorsen  to the Sponsor  or 
designee.  All used syringes must be disposed of as per  the site’s hazardous waste destruction policy.  
8. TREATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen  will be administered subcutaneously as a single 1.5 mL 300 mg 
injection once weekly for Weeks 1 -52.  Patients entering this ISIS 304801 -CS7 study on a reduced dose 
or dose frequency of Study Drug ( volanesorsen ), for safety or tolerability reasons in their index study 
(ISIS 304801 -CS6 or ISIS 304801-CS16) , will receive  a reduced dose or dose frequency of  volanesorsen 
for continued safety or tolerability as outlined in Sections 8.[ADDRESS_37916] 2  days apart.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
40  Please refer to the Study Drug Manual  provided by [CONTACT_37705].  
8.2 Other Protocol-Required Drugs  
There are no other protocol -required drugs.  
8.3 Other Protocol-Requi red Treatment Procedures  
There are no other protocol required treatment procedures for this study.  
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study.  
8.5 Safety Monitoring Rules  
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure . 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_37917] measurement prior to Day 1  (e.g., qualification assessments or assessments from  the final visits of 
ISIS 304801-CS6 and ISIS 304801-CS16  index studies if used for qualification) . 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are provided 
for the monitoring of selected parameters chosen  based on preclinical and clinical observations.  
Confirmation Guidance :  At any time during the study (Treatment or Post -Treatment P eriods), the initial 
clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37463] (ideally in the same laboratory that performed the initial 
measurement) on new specimens.  All new specimen collections should take place as soon as possible 
(ideally within 3 days of the initial collection).  For stoppi[INVESTIGATOR_004], if the initial laboratory result is 
observed during the Treatment Period, the results from the retest must be available prior  to administering 
the next  dose of volanesorsen . 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirmation of additional lab values.  
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37501] -
dosed until the re -test results are available.  In general, patien ts who do not meet the stoppi[INVESTIGATOR_37502].  However, the Investigator and the Sponsor Medical Monitor (or 
appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is 
appropriate .  Reduction in dose  or dose frequency may also be initiated as noted in Section  8.7.  If any of 
the stoppi[INVESTIGATOR_37466] (refer to Sections 8.6.1 to 8.6.3 ) are met, the patien t will be dose 
paus
ed or permanently discontinued (as d
escribed in the stoppi[INVESTIGATOR_37503]) from further 
treatment with volanesorsen  and evaluated fully as outlined below and in consultation with the Sponsor 
Medical Monitor or appropriately qualified designee and will be followed up in accordance with Section  8.8 of the protocol.  
8.5.1  Safety Monitoring for Liver Chemistry Tests 
The fol l
owing rules are adapted from the draft guidance for industry, “Drug-Induced Liver Injury:  
Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S.  Department of Health and Human Services, Food 
ISIS [ADDRESS_37918] measurement that is >  [ADDRESS_37919]  (or the greater of [ADDRESS_37920] if the baseline value was > ULN)  at any time during the study ( Treatment or Post-Treatment 
Period ), the initial measurement(s) should be confirmed as described above .  Additional confirmatory 
measurements should also be performed if ALT or AST levels increase to [ADDRESS_37921]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_37922] (or the 
greater of [ADDRESS_37923] if the baseline value was >  ULN)  should have their liver 
chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio ( INR) and total 
bilirubin) retested at least once-weekly until ALT and AST levels become ≤ 1.[ADDRESS_37924] or 1.2 x  baseline 
value  if the baseline value was > ULN. 
Further Investigation into Liver Chemistry Elevations :  For patients with confirmed ALT or AST levels > 
[ADDRESS_37925]  (or the greater of [ADDRESS_37926] if the baseline value was > ULN), the following 
evaluations should be performed:  
1. Obtain a more detailed history of symptoms and prior and concurrent diseases  
2. Obtain further history for  concomitant drug use (including nonprescription medications, herbal 
and dietary supplement preparations), alcohol use, recreational drug use, and special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel 
4. Serology for vi ral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV antibody 
panel)  
5. Serology for autoimmune hepatit is (e.g., antinuclear antibody [ANA] ) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or MRI 
scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical 
Monitor .  Repetition of the above evaluations should be considered if a patient ’s ALT and/or AST levels 
reach [ADDRESS_37927] be documented in the patient’s 
medical records.  
Due to the [ADDRESS_37928] with the study patients.  However, if the above options are not possib le, a temporary interruption 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
42  of study treatment will be planned with a prompt blood draw upon the patient’s return which must be 
reported and reviewed by [CONTACT_37768].  
The tests outlin ed in Table  2 should also be pe rformed as soon as possible.   Additional lab tests will be 
determined by [CONTACT_37769] .  
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor (See 
also Stoppi[INVESTIGATOR_10020] s Section  8.6.3 ). 
Table  2 Labs to Be Performed in the Event of a Platelet Count Less than the Lower Limit of Normal (x2) or < 100,000/mm
3 (x1)* 
*In patients who have any 2 occurrences  (consecutive or non-consecutive)  of platelet count less than the 
lower limit of normal or who have any 1 occurrence of platelets < 100,000/mm3.  Labs only need to be 
performed once.  Labs may be collected over multiple visits, if blood requirements are a concern, as per investigat or discretion.  
Note:  The following labs may change as additional data is assessed, and sites will be updated regarding 
any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV  
Parvo B19  
Auto -antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
43  8.5.3 Safety Monitoring for Minor Bleeding Events  
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -relevant, 
non-major ble
eding events (which are defined in Section 8.6.3), for 
example excess bruising, petechiae, 
gingival bleeding on brushing t
eeth.  If a m inor bleeding event occurs, the Investigator must notify the 
Sponsor Medical Monitor and additional testing of coagulation parameters activated partial 
thromboplastin time (aPTT ), prothrombin time ( PT), INR  and platelet count should be performed.  
8.5.[ADDRESS_37929] to notify the Investigator if a patient has a low -
density lipoprotein-cholesterol ( LDL -C) > 160 mg/dL (>  130 mg/dL for patients with T2DM) on 2 
consecutive visits.  If this occurs, LDL -C value s for this patient will be unblinded for the remainder of the 
study and the Investigator will be encouraged to initiate/adjust treatment to lower LDL -C according to 
country -specific guidelines (e.g., initiate statin therapy or in crease the statin dose for patients who are 
already on treatment).  
8.5.[ADDRESS_37930] practice 
guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In addition, patients 
who are not on insulin but use a glucometer should also bring their  glucometer and/or glucometer log 
printout to every clinic visit. 
• The Investigator  or delegate will review the glucometer reading or printout at every clinic visit to 
evaluate if fasting pre-breakfast self- monitored plasma glucose values exceed threshold values as 
per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose  and /or oral antidiabetic  therapy, as well 
as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator  or delegate will ask patients at every clinic visit if they made changes in their 
insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic epi[INVESTIGATOR_1865].  
o Patients will be instructed on the monitoring and management of hypoglycemic epi[INVESTIGATOR_37504] t. 
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37506] ≤  70 mg/dL (≤ 3.9 
mmol/L ). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
44  8.5.7  Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as one in which the patient requi res assistance of 
another person to obtain treatment for the event and has a plasma glucose level ≤  70 mg/dL (≤ 3.9 
mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or buccal or intramuscular 
glucagon.  
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at 
risk for injury to themselves or others.  Note that “requires assistance” means that the patient could not 
help himself or herself.  Someone being kind that assists spontaneously the patient when not necessary 
does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take immediate action 
to confirm the patient’s glucose level and treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there are certain 
classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or 
tingling, pale skin, shakine ss or tremulousness, increased appetite, anxiousness or nervousness, 
lightheadedness or dizziness, sweating, and weakness.  Coma could occur if blood sugar correction is not 
performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood glucose 
using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.   
If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for 
example,  then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature 
of treatment should be noted, and especially if any blood glucose result was before or after treatment.  It 
would be helpful for the patient to note if a contributory factor (e.g., missed or reduced meals, 
unaccustomed physical activity) occurred earlier in the day of the event.  
8.5.[ADDRESS_37931] dose titration and/or addition of any other anti -hyperglycemic agent(s) will not be allowed during 
the course of the study, unless specific threshold values are met at Week 13 or later and confirmed on subsequent testing (ideally within [ADDRESS_37932]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should self -
monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  If a fasting  
pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should check it again on the following [ADDRESS_37933] the Investigator and an unscheduled central laboratory FPG measurement and HbA1c should be performed.  
The threshold values are defined as: 
• FPG > 270 mg/dL (15.0 mmol/L)  
• HbA1c > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 1% from 
baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
45  In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no 
reasonable explanation exists for insufficient glucose control and in particular that:  
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_37934])  
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency 
(e.g., surgery, infection), the Investigator can take appropriate measures for glycemic control  
• Compliance to treatment is appropriate 
• Compliance to diet and lifestyle is appropriate  
If any of the above can reasonably explain the insufficient glycemic control, the Investigator should consider the following:  
• Investigation and treatment of intercurrent disease (to be reported in adverse event  (AE)/concomitant medication parts of the e-CRF) 
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to die t and lifestyle recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  If none 
from the above -mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c 
under the threshold values, additional medication may be introduced at the Investigator’s discretion and 
according to local guidelines after discussion with the Sponsor Medical Monitor.  
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended te
 mporarily 
until the patient is clinically stable.  The suitability of the patient for continued dosing and the need for any modification to treatment schedule (refer to Section  8.7) will be det
ermined by [CONTACT_37770]
y Medical Monitor . 
8.[ADDRESS_37935] measurement prior to Day 1.  
8.6.1  Stoppi[INVESTIGATOR_37508], and the  event is without an alternative 
explanation as discussed with the Sponsor Medical Monitor, dosing of a patient  with volanesorsen  
will be stopped permanently ; values that are not confirmed due to failure to retest or missing lab values 
will be presumed con firmed : 
1. ALT or AST >  [ADDRESS_37936] >  [ADDRESS_37937] , which is confirmed and persists for ≥  [ADDRESS_37938] >  [ADDRESS_37939] (or the greater of [ADDRESS_37940] if the baseline value was 
> ULN) , which is confirmed  and total bilirubin >  [ADDRESS_37941]  or INR > 1.[ADDRESS_37942] >  [ADDRESS_37943] (or the greater of [ADDRESS_37944] if the baseline value was 
> ULN), which is confirmed, and the new appearance (i.e., onset coincides with the changes in 
hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, 
rash, or eosinophi lia (>  ULN) felt by [CONTACT_37708]  
8.6.[ADDRESS_37945] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 3 criteria 
below, dosing of a patient with volanesorsen  may be stopped  temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL (26.5 μmol/L) and 
≥ 40% above baseline creatinine values and > ULN 
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24 hour)  
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault ≤ 40 mL/min that is confirmed by a 24-hour urine collection  
The possible dosing re -initiation or follow -up schedule for any events meeting either of these criteria will 
be determined by [CONTACT_37771] . 
8.6.3  Stoppi[INVESTIGATOR_10020] s for Platelet Count Results  
Actions to be taken in the event of a low platelet count are summarized in  Table  3 below.  
In the event of a platelet count less than 75,000/mm
3 that is associated with  major bleeding or clinically -
relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t with volanesorsen  
will be stopped permanently .  The follow -up 
schedule for any events meeting  this stoppi[INVESTIGATOR_37509].   
In the event of any platelet count les s than 5 0,000/mm3, or a rate of decline ≥  50% between two 
consecutive assessments, irrespective of the platelet level,  or a platelet count less than 75 ,000/mm3 that 
occurs while the patient is on dosing at 300 mg every 2 weeks, then dosing of a patient with volanesorsen will be stopped permanently .  Platelet count will be monitored as outlined in Table  3. 
Administration of steroids is recommended for patients whose platelet count is less than 50,000/mm
3.  
Recovery in platelet count may  be accelerated by [CONTACT_37711].  Treatment 
guidelines for immune thrombocytope nia (Provan et al.  2010) recommend Dexamethasone 40 mg daily 
for 4 days every 2 -4 weeks for 1 -4 cycles; Prednis(ol)one 0.5-2 m
g/kg/d for 2- 4 weeks then taper; or 
Methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone).   In order to reduce the 
unlikel y but potential increased risk of pancreatitis during the period of corticosteroid therapy, 
triglyceride levels will be monitored weekly , and AE monitoring will continue, during corticosteroid 
treatment and the laboratory alert will be changed from an increase of 2,000 to 500 mg/dL during that 
period. 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or clinically -
relevant  non-major bleeding (defined below;  Schulman et al. 2005), dosing of a patient with volanesorsen  
should be suspended temporarily until the platelet count h
as recovered to> 100,000/mm3.  If dosing is 
continued it should be at a reduced dose frequency of 300 mg every 2 weeks (refer to Section  8.7).  The 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
47  suitability of the patient for continued dosing will be determined by [CONTACT_37772]’s 
platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of dosing.  
If after the first dosing rechallenge  the platelet count again falls below 75,000/mm
3, then dosing of the 
patient with Study Drug will be s topped permanently.  
Definition of Major Bleeding Events  (Schulman et al . 2005): 
• Fatal bleeding, and/or  
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with compartment syndrome, and/or  
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or 
leading  to transfusion of 2 or more units of whole or red cells  
Definition of Clinically -Relevant, Non -Major Bleeding Events  (Schulman et al . 2005):  
1. Multiple -source bleeding  
2. Spontaneous hematoma >  25 cm2 
3. Excessive wound hematoma (not injection site related)  
4. Macroscopic hematuria (spontaneous or lasting > 24 hours if associated with an intervention)  
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis  
6. Bleeding after venipuncture for >  [ADDRESS_37946] be documented in 
the patient’s medical records.  Monitor every 1 week unless 
otherwise specified 
Obtain additional lab tests  
(Table 2) if 2 occurrences  consecutive 
or non-cons
ecutive of platelet count 
140K - > 100K/mm3 or 1 occurrence 
of platelet count ≤ 100K/mm3.  Labs 
only need to be performed once.   Labs 
may be collected over multiple visits, if blood requirements are a concern, as 
per Investigator discretion.  
> 100K/mm3 Weekly 300 mg Study Drug administration   
100K/mm3 - >75K/mm3 Permanently r educe dose frequency to 300 mg 
every 2  weeks    
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
48  Platelet Count on Rx  Drug Dose Monitoring  
75K/mm3 - >50K/mm3 • If occurs while on dose of 300 mg every 
2 weeks then permanently discontinue 
Study Drug, otherwise dose pause. 
• When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks only 
if approved by [CONTACT_37773]  • Monitor every 2 -3 days until 
2 successive values are 
> 75K/mm
3 then monitor every 1 
week  
• Consider discontinuation of antiplatelet agents/NSAIDS/ anticoagulant medication  
< 50K/mm3 or a rate of decline ≥ 
50% between two consecutive assessments, irrespective of the platelet level  Permanently discontinue Study Drug   • Monitor daily until 2 successive values show improvement then monitor every 2- 3 days until 
2 successive values are >  75K/mm
3 
then monitor every 1 week  
• Patient should be evaluated by a hematologist to provide diagnostic and therapeutic management  
• Steroids recommended *.  It is 
strongly recommended that, unless the patient has a medical 
contraindication to receiving 
glucocorticoids, the patient receives glucocorticoid therapy to reverse the platelet decline.   
• Monitor triglyceride levels weekly and continue AE monitoring during 
steroid therapy  
• Discontinue antiplatel et agents/ 
NSAIDS/ anticoagulant medication 
while platelet count is<  50K/mm
3 if 
possible 
Legend:  
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune 
thrombocytopenia (Provan et al. 2010) recomm
end Dexamethas
one 40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; 
Prednis(ol)one 0.5-2 m
g/kg/d for 2-4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days (note :  may require 
continu ation with oral steroids after Methylprednisolone).   In order to reduce the unlikely but potential increased risk of 
pancreatitis during the period of corticosteroid therapy, triglyceride levels will be monitored weekly, and AE monitoring 
will continue,  during corticosteroid treatment  and the laboratory alert will be changed from an increase of 2,000 to 500 
mg/dL during that period . 
8.[ADDRESS_37947] be made in accordance with Section 8.6.3 and Table  3 
(above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose frequency will 
be allowed for safety and tolerability .  Any proposed adjustment to treatment schedule must be discussed 
with, and approved by, the Study Medical Monitor prior to initiation.  Up to [ADDRESS_37948] permanently discontinue study treatment for any of the following:  
• The patien t becomes pregnant .  Report the pregnancy according to instructions in Sec tion 9.5.4  
• The patien t withdraws consent 
• The patien t experiences an AE that 
necessitates permanent discontinuation of study treatment  
• The patien t develops laboratory test abnormalities that meet any of the sto ppi[INVESTIGATOR_37510] 8.[ADDRESS_37949] 6 weeks after discontinuing Study Drug .  
Following this period, if  the platelet count is stable (at least 3  consecutive values that are stable as 
determined by [CONTACT_37683] > 100,000/mm3), the next platelet count should be taken 
within at least [ADDRESS_37950] 12  weeks after discontinuing Study 
Drug .  Patients  should also be strongly encouraged to attend applicable landmark visits at Week s 12, 13, 
25, 26, and 50, 52 (calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and 
conduct safety assessments in accordance with the S chedule of Procedures in Appendix  A.  Any patient 
who discontinues  treatment after Week 44 should also be strongly encouraged to 
attend a final follow -up 
visit ( Week 78 visit assessments) approximately [ADDRESS_37951] dose of Study Drug , in addition 
to the applicable landmark visits . 
If the patient declines or is unable to participate in the above , an early te
rmination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and ideally 
within [ADDRESS_37952] 6 
weeks after discontinuing Study Drug .  Following this period, if t
he platelet count is stable (at least 3 
consecutive values that are stable as determined by [CONTACT_37683] >  100,000/mm3), 
the next platelet count should be taken within at least [ADDRESS_37953] 1 2 
weeks after discontinuing Study Drug .  Patients  should also be encouraged to undergo a final  follow -up 
visit ( Week 78, see Appendix A ) prior to leaving the study.  
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange for the 
patient to have appropriate follow -up until the AE has resolved or stabilized.  
8.[ADDRESS_37954] be withdrawn from the study for any of the following:  
• Withdrawal of consent  
• The patient  is unwilling or unable to comply with the protocol  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
50  Other reasons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance  
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to the date 
of withdrawal .  All information,  including the reason for withdrawal from study, must be record ed in the  
CRF. 
Any patient  who withdraws consent to partic ipate in the study will be removed from further treatment and 
study observation immediately upon the date of request .  These patient s should be encouraged to 
complete the ET study procedures and observations  at the time of withdrawal  (see Section 8.8 and 
Appendix A ). 
For patients
 withdra
wn for re
asons other than withdrawal of consent every effo rt should be made to 
complete the early termination study procedures and observations  at the time of withdrawal  (see 
Section  8.8 and Appendix A). 
8.[ADDRESS_37955] be recorded on the patient ’s CRF .  
AEs related to administration of these therapi[INVESTIGATOR_37478].  
8.10.1  Concomitant Therapy  
A concomitant therapy is any non -protocol specified drug or substance  (includ ing over -the-counter 
medications, herbal medications and vitamin supplements) administered between signing informed 
consent and completion of the post -treatment follow -up period.  All concomitant medications/treatments 
and significant non-drug therapi[INVESTIGATOR_014] (including supplements and assistive devices) received by a patient , 
including changes in the patient’s current medications, must be recorded in the patient’s source 
documents and CRF .  Patients taking over the counter ( OTC ) omega -3 fatty acids should make every 
effort to remain on the same brand throughout the study.  
Allowed Concomitant Therapy  
Any medications deemed necessary by [CONTACT_37713].  
Disallowed Concomitant Therapy  
No lipid lowering therapi[INVESTIGATOR_014] ( e.g., fibrates, niacin, fish oil or other products containing omega -3 fatty acids 
[including OTC preparations] ), -glucagon-like peptide -1 (GLP -1) agonists , Glybera, or systemic 
corticosteroids may be started  or adjusted  after baseline Qualification.  Doses of existing  oral anti -diabetic 
medication, oral contraceptives, hormone replacement therapy,  anticoagulants, or drugs or dietary 
supplements with potential lipid -altering effects should not be adjusted .  Study patients are prohibited 
from receiving other experimental agents during the study .  This includes marketed agents at 
experimental dosages that are being tested for the treatment of hypertriglyceridemia.  
ISIS 304801-CS7 CONFIDENTIAL Amendment 9 
Protocol - [LOCATION_009]  25 May 2018 
 
51  Patients should consult with the Site Investigator or designee prior to initiating any new medication, 
including non-prescription or herbal compounds or any other non-drug therapy. 
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) or 
diagnostic assessment (e.g., blood  gas measurement, bacterial c ultures) performed between signing of 
informed consent and Week 78 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 8.11 Treatment Compliance 
Compliance with treatment dosing is to be monitored and recorde d by [CONTACT_37714].  The Study 
Center staff is required to doc ument the receipt, dispensing, a nd return/destruction of volanesorsen.  
Patients that are self-administering volanesorsen at home must record treatment in a dosing diary that will 
be reviewed periodically by [CONTACT_37774] y Center staff and the Clinical  Monitor. 
9. SERIOUS AND NON-SERIOUS ADVERSE EVENT REPORTING 9.[ADDRESS_37956] of the clinical t rial. 
9.2 Regulatory Requirements 
The Sponsor is responsible for regulatory submissions and repor ting to the Investigators of serious 
adverse events (SAEs) including suspected unexpected serious ad verse reactions (S[LOCATION_003]Rs) per the 
International Conference on Harmonization (ICH) guidelines E2A and ICH E6 (R2).  Country-specific 
regulatory requirements will be f ollowed in accordance with loc al country regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any SAE 
according to applicable regula tions.  The Independent DSMB will be notified of any SAE as specified in 
the DSMB charter. 
In addition to the Investigator ’s assessment of relatedness, the Sponsor or designee will evaluate the 
available information and perform an independent assessment of relatedness.  While the Sponsor may 
upgrade an Investigator’s decision it is not permissible to dow ngrade the Investigator’s opi[INVESTIGATOR_37479]  a S[LOCATION_003]R. 
The following table identifies th e SAEs that the Sponsor or designee will not report on an individual basis 
in an expedited manner because they are anticipated to occur in  the study population independent of 
volanesorsen exposure.  The Investigator still has the responsi bility to report all SAEs to the Sponsor as 
described in Sections 9.4.1  to [IP_ADDRESS] . 
Table 4 Expected Event for the Protocol Defined Population by P referred Term and the 
Expected Incidence 
Preferred Term Expected Incidence in the Protocol Defined 
Population ( Gaudet et al. 2010  and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis acute, 
pancreatitis chronic, pancreatitis necrotizing, pancreatitis relapsing 0.2-0.35 events per patient-year  
 
ISIS 304801-CS7 CONFIDENTIAL Amendment 9 
Protocol - [LOCATION_009]  25 May 2018 
 
52  Fatal pancreatitis associated events will be considered as unex pected and are reportable.  The Sponsor and 
DSMB will monitor non-fatal pancreatitis associated SAEs using the incidence rate of the event compared 
to the rate expected in a non- volanesorsen exposed population.  If the aggregate analysis indicates that an 
event is occurring significantly m ore frequently or at a greate r severity than expected, then the event will 
be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37775] a 
reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37718] a S[LOCATION_003]R the event will be re ported. 
9.3 Definitions 
9.3.1 Adverse Event 
An adverse event is any unfavorable and unintended sign (includ ing a clinically-significant abnormal 
laboratory finding, for example ), symptom, or disease temporall y associated with the study or use of 
investigational drug product, whe ther or not the AE is considered related to the investigational drug 
product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction 
An adverse reaction is any adver se event caused by [CONTACT_37719] . 
A suspected adverse reaction is a ny adverse event for which there is a reasonable possibility that 
volanesorsen drug caused the adverse event.  A suspected advers e reaction implies a lesser degree of 
certainty about causality than an adverse reaction. 
9.3.3 Serious Adverse Event (SAE) 
A serious adverse event is any adverse event that in the view of either the Investigator or Sponsor, meets 
any of the following criteria: 
• Results in death 
• Is life threatening:  that is, poses an immediate risk of death at the time of the event 
An AE or suspected adverse reaction is considered “life-threate ning” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient at i mmediate risk of death.  It does not include 
an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused death. 
• Requires inpatient hospi[INVESTIGATOR_37511] 
• Hospi[INVESTIGATOR_37512] 24 h ours to a medical facility and does 
not always qualify as an AE 
• Results in a persistent or significant incapacity or substantia l disruption of the ability to conduct 
normal life functions 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
53  • Resul ts in congenital anomaly or birth defect in the offspring of the patient (whether the patient  is 
male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not require 
hospi[INVESTIGATOR_37513], based upon appropriate medical judgment, 
they may jeopardize the patient and may require medical or surgical intervention to prevent one 
of the outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse  
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the study 
(i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the 
pre-existing condition worsened.  The Investi gator should always group signs and symptoms into a single 
term that constitutes a  single unifying diagnosis  if possible.  
9.4.[ADDRESS_37957] of patient  safety, and in order to fulfill regulatory requirements , all SAEs (regardless of 
their relationship to volanesorsen ) should be reported to the Sponsor  or designee within 24 hours of the 
Study Center ’s first knowledge of the  event .  The collection of SAEs will begin after the patient signs the 
informed consent form and stop at the  end of the patient ’s follow -up period which is defined as the Week 
[ADDRESS_37958] the patient’s  last protocol -specified follow-up visit will be evaluated by [CONTACT_37776] .  If the Investigator and Sponsor agree the patient’s  condition is unlikely to 
resolve, the Investigator and Sponsor will deter mine the follow -up requirement.  
9.4.2  Non-Serious Adverse Events 
The recording of non-serious AEs will begin after the patient  signs the informed consent form and will 
stop at the end of the patient ’s follow -up period, which is defined  as the Week [ADDRESS_37959] all observed or volunteered AEs on the Adverse Event Case 
Report Form.  
9.4.3  Evaluation of Adverse Events (Serious and Non -Serious)  
The Investigator’s opi[INVESTIGATOR_37514]: 
[IP_ADDRESS]  Relationship to the Study Drug  
The event’s relationship to volanesorsen  is characterized by 1 of the following:  
• Related:   There is clear evidence that the event is related to the use of volanesorsen , e.g., 
confirmation by [CONTACT_37777] 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
54  • Possible:   The event cannot be explained by [CONTACT_102]’s medical condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event and 
volanesorsen  administration 
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesors en administration and/or exposure suggests that a causal relationship  is unlikely (For 
reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_102]’s underlying medical condition, 
concomitant therapy, or other causes, and therefore, the Investigator believes no relationship 
exists between the event and volanesorsen  
[IP_ADDRESS]  Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Term inology Criteria 
for Adver
se Events (CTCAE) Version 4.03, June 2010 (refer to Appendix  D).  Any AE not listed
 in 
Appendix D will be graded as 
follows:  
• Mild:   The event is easily tolerated
 by [CONTACT_10553]’s usual daily 
activities  
• Moderate:  The event causes the patient more discomfort and interrupts the patient’s usual daily 
activities  
• Severe:  The event is incapacitating and causes considerable interference with the patient’s usual 
daily activities  
If the event is an SAE, then all applicable seriousness criteria must be  indicated (criteria listed in 
Section  9.3.3). 
[IP_ADDRESS]  Action Taken with Volaneso rsen 
Act
ion taken with volanesorsen  due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen  administration and dose  
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted  
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted  or 
delayed due to the AE  and restarted at the same dose  
• Reduced schedule:   Dosing frequency was reduced  
[IP_ADDRESS]  Treatment G iven for Adverse Event  
Any treatment (e.g., medications or procedures) given for the AE should be recorded on the Adverse 
Event Case Report Form ( treatment  should also be recorded on the concomitant treatment  or ancillary 
procedures  CRF as appropriate). 
[IP_ADDRESS]  Outcome of the Adverse E vent 
If the event is a non -serious AE then the event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from  the trial and the AE continues  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
55  • Recovered:  Patient recovered completely from the AE  
• Became Serious:  The event became serious (the date that the event became serious should be 
recorded as the Resolution Date of that AE and the Onset  Date of  the corresponding SAE)  
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:  SAE continuing  
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer meets 
serious criteria and should be captured as an AE on the non -serious AE eCRF (the SAE resolution 
date should be entered as the date of onset of that AE)  
• Recovered:  Patient recovered completely from the SAE (the date of recovery should be entered 
as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be ente red as the SAE resolution date)  
9.4.4  Adjudication Committees  
All SAEs that occur during the study that are consistent with a m ajor acute cardiovascular event  (MACE) 
will be adjudicated by a blinded, independent committee as outlined in the MACE Adjudication Charter.  
All AEs and SAEs that occur during the study that are consistent with an event of acute pancreatitis will 
be adjudicated by 
a blinded, indepe ndent committee according to the Atlanta classification of acute 
pancreatitis ( Banks et al. 2013) and as 
outlined in the Pancreatitis Adjudication Charter .  In addition, data 
for 
prior epi[INVESTIGATOR_37482]’s medical chart and these events will also be adjudicated.  
9.[ADDRESS_37960] results may, in the opi[INVESTIGATOR_689], constitute or 
be associated with an AE.  Examples of these include abnormal laboratory results that are associated with 
symptoms, or require treatment, e.g., bleeding due  to thrombocytopenia, tetany due to hypocalcemia, or 
cardiac arrhythmias due to hyperkalemia .  Whenever possible, the underlying diagnosis should be listed 
in preference to  abnormal laboratory values as AEs.  Clinically -significant abnormalities will be 
monitored by [CONTACT_37722] .  Laboratory abnormalities deemed not 
clinically -significant  (NCS) by [CONTACT_37723].  Similarly, laboratory 
abnormalities reported as AEs by [CONTACT_37724].  
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed clinical 
laborat ory reports will serve as source documents and should include the Investigator’s assessment of 
clinical significance of out of range/abnormal laboratory values . 
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, 
even if the patient  is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
56  • The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was 
on a waiting list to be scheduled) prior to obtaining the patient’s  consent to participate in the 
study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37515]’s  consent to participate in the study and the timing of the procedure or 
treatment 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the 
intervention or hospi[INVESTIGATOR_063] 
9.5.3  Dosing Errors 
Volanesorsen dosing  errors should be documented as Protocol Deviations .  A brief description should be 
provided in the deviation, including whether the patient  was symptomatic (list symptoms) or 
asymptomatic, and the ev ent accidental or intentional. 
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose of
  
volanesorsen  that exceeds protocol specifications and the patient  is symptomatic, then the symptom(s) 
should be documented as an AE and be reported per Section  9.4. 
Should an overdose o
ccur , the Investigator or designee should refer to the Guidance to Investigator’s 
section of the Investigator’s Brochure and contact [CONTACT_37725] [ADDRESS_37961] 
learning of the occurrence of pregnancy .  Follow -up information including delivery or termination is 
reported on Follow -up Pregnancy Forms and reported within 24 hours.  
Payment for all aspects of obstetrical care, child or related care will be the patient’s responsibility.  
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow -up), a pregnancy 
test will be performed .  The patient  with a confirmed pregnancy will be immediately withdrawn from 
treatment with volanesorsen .  However, the patient  will be encouraged to complete the post -treatment 
follow -up portion of the study to the extent that study procedures do not interfere with the  pregnancy .  
Regardless of continued study participation, the study physician will assist the patient in getting 
obstetrical care and the progress of the pregnancy will be followed until the outcome of the pregnancy is 
known (i.e., delivery, elective termination, or spontaneous abortion) .  If the pregnancy results i n the birth 
of a child, the Study Center  and Sponsor may require access to the mother and infant’s medical records 
for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed until the 
outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion) .  If the 
pregnancy results in the birth of a child,  the Study Center and Sponsor may request access to the 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
57  mother and infant’s medical records for an additional 8 weeks after birth .  Follow -up will be 
performed to the extent permitted by [CONTACT_37726] . 
10. STATISTICAL CONSIDE RATIONS  
10.1 Study Endpoints 
For fasting lipid measurement s, the values at Month 3 analysis time point are defined as the average of 
Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 analysis time point 
is at the end of Month 6 are define d as the average of Week 25 (Day  169) and Week 26 (Day 176) fasting 
assessments, and the values at the Mo nth 12 analysis time point are defined as the average of Week 50 
(Day 344) and Week  52 (Day 358) fasting assessments.  
10.1. 1 Efficacy Endpoints  
• Percent  change and absolute change  from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change  from baseline in other fasting lipid measurements including total 
cholesterol, non-HDL -C, apoB, HDL -C, apolipoprotein A -1 (apoA -1), VLDL -C, and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C -III 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ-5D, SF-36)  
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1. 2 Safety Endpoints  
• Adverse events including adjudicated events of pancreatitis and MACE  
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hemat ology,  coagulation,  urinalysis)  
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications 
• MRIs 
• Platelet aggregation (may be evaluated)  
10.2 Sample Size  
No sample size calculations were performed as this is an open-label study . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
58  10.3 Populations  
Full Analysis Set (FAS) :  All patients who are enrolled  and received at least [ADDRESS_37962] a baseline TG assessment.  The FAS represents the practically -feasible intent -to-treat (ITT) 
population as delineated in ICH Guideline E9.  
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_37963] efficacy and PD assessments.  
The detailed criteria will be specified and finalized prior to the final database lock . 
Safety Set:  All patients who are enrolled  and receive at least 1 dose of volanesorsen . 
PK Population :  All patients who are enrolled, recei ve at least [ADDRESS_37964] dose PK sample collected , analyzed , and reported . 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis . 
For fasting lipid measu rements , 2 baselines are defined for each patient  in Groups 1 and 2:  Group 1 ( ISIS 
304801-CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the baseline in this open -label 
study, which is defined as the average of Day [ADDRESS_37965] measurement prior to 
Day 1  (e.g., qualification assessments or assessments from final visit of the ISIS 304801-CS6 or 
ISIS 304801- CS16 index studies if used for qualification) . 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or ISIS 
304801-CS16 index study will be the ISIS 304801-CS6 or  ISIS 304801-CS16 index study baseline .  For 
patients on placebo in the ISIS 304801- CS6 or ISIS 304801-CS16 index study, baseline will be the last 
non-missing assessment prior to the first dose of Study Drug .  Details will be provided in the SAP. 
10.[ADDRESS_37966] patient’s Week [ADDRESS_37967] error, interquar tile 
range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and 
counts and percentages for categorical variables will be used to summarize most data by [CONTACT_37727] 304801-CS6 or ISIS 304801- CS16 
index studies, and pooled treatment naïve group which includes patients on placebo in index studies .  
Where appropriate, p -values will be reported .  All statistical tests will be conducted using 2 -sided t ests 
with 5% Type I error  rates unless otherwise stated.  
TG related endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will be 
assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK endpoints will  be 
assessed in the PK Set as applicable.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
59  10.6.1 Demographic and Baseline Characteristics  
Demographic and baseline characteristics will be summarized using descriptive statistics by [CONTACT_17674] .  The patient disposition will be summarized  by [CONTACT_6654] .  All 
patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of Study Drug received will be  summarized by [CONTACT_14459] . 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA preferred 
term, and treatment group of the index studies.   Narratives of treatment -emergent  deaths, serious and 
significant AEs, including early withdrawals due to AEs, will also be provide d. 
All treatment-emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all treatment -
emergent  serious AEs, and all treatment-emergent  serious AEs potentially related to Study Drug will be 
summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_1570] , MedDRA preferred term and 
severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_1570].  
Laboratory tests to ensure patient safety including chemistry panel, complete blood  count (CBC) with 
differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37778]. 
These safety variables will also be presented as change and percent change from baseline over time after 
Study Drug administratio n, as appropriate.  
Vital signs , weight , ECG measures, echocardiography assessments, and MRI assessments will be 
tabulated by [CONTACT_1570] . 
10.6.3 Efficacy Analysis  
Percent change and change  from baseline to Month 3, Month 6, and Month 12 in fasting TG  will be 
summarized by [CONTACT_1570] .  Response rate of patients with fasting plasma TG < 750 mg/dL or 
achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and Month 12 will be 
summarized .  Response analysis will also be conducted using  a range of fasting plasma TG thresholds for 
determination of responder status . 
Percent change and change  from baseline to Month 3, Month 6, and Month 12 will also be summarized 
by [CONTACT_37779]- HDL -C, apoB,  HDL -C, apoA -1, 
VLDL -C, and LDL -C, total cholesterol, and fasting  total apoC -III. 
The incremental effects of volanesorsen  on lipid measures  will be explored  and the association between 
changes in lipid parameters and total amount of drug received will be examined, as appropriate . 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event rate, 
quality of life assessments, and comparison of other symptoms including eruptive xanthomas and lipemia 
retinalis  will be s ummarized by [CONTACT_1570] . 
Additional details of the analyses to be conducted will be provided in the SAP.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
60  10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis  
For all patients, pre -dose and post -treatment volanesorsen pl asma concentrations will be summarized 
using descriptive statistics by [CONTACT_37780].  
For patients in the PK subgroup only, non-compartmental PK  analysis of volanesorsen will be carried out 
on each individual patient data set using data col lected  in the open- label study from the intensive  PK 
subgroup, following a single -dose (i.e., single -dose PK) or multiple dose s (i.e., steady -state PK), 
depending on their earlier treatment in the index studies  (Group 1 and 2 patients) .  On Week [ADDRESS_37968] treatment of 
volanesorsen (single -dose PK), while patients who received volanesorsen in the index studies had been on 
volanesorsen treatment for 12 months (ISIS 304801- CS6) or 6 months (ISIS 304801-CS16) , thus the PK 
data collected from these patients reflect steady -state PK.  The maximum observed drug concentration 
(Cmax) and the time taken to reach C max (T max) will be obtained directly from the concentra tion-time data.  
Area under the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24h) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration (CL 0-24h 
/F) will be calculated from C L0-24h /F = Actual Dose/AUC 0-24h.  Mean residence time (MRT) from time 
zero to 24 hours after the SC administration  will be calculated from the equation, MRT 0-24h = AUMC 0-24h 
/AUC 0-24h, where AUMC 0-24h is the area under the moment plasma concentration -time curve from time 
zero to [ADDRESS_37969] . 
Plasma PK parameters will be summarized using descr iptive statistics  by [CONTACT_37780].  
Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK /PD, and covariate analysis may be performed if deemed appropriate, and results will 
be reported separately. 
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not evaluable, and 
when applicable, titer of anti -volanesorsen  antibodies) before, during, and after treatment with Study 
Drug  (volanesorsen ) (i.e., sample [anti-drug antibody]  ADA status) will be listed by [CONTACT_37731] 304801-CS6 or ISIS 304801-CS16 (Groups 1 and 2) and study day.  Subject ADA status 
(positive/negative or not evaluable) for all evaluable patients, along with the study day associated  with the 
first positive IM status emerged (T first, i.e., onset of ADA development), the last positive IM status 
observed (T last), the last ADA sample collection day,  and subject - peak titer if applicable, will be  listed by 
[CONTACT_37732] 304801-CS6 and ISIS  304801-CS16 (Groups 1 and 2) and study day .  
Subjects with positive anti- volanesorsen  antibody status may be further classified (when applicable) as 
being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjects with antibody negative, positive, and 
unknown sta tus by [CONTACT_1570].  Furthermore, onset and t iter of the ADA response,  if applicable, will 
be summarized as median, quartiles (25% and 75%), and range . 
Additional details regarding the IM data analysis will be described in the SAP. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
61  Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., 
%change in fasting TG from baseline at 3 -, 6-, and 12 -month endpoints), safety, and PK (e.g., C trough) 
measures will be evaluated using graphical analysis and statistical analysis.  These analyses will be either 
conducted and included in the study report, or data pooled and analyzed from all available Phase 2 and 3 
studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient 
population, based on an English version provided by [CONTACT_1034] . 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written informed 
consent from the patient after adequate explanation of the aims, methods, anticipated benefits, and 
potential hazards of the study and before any protocol -specific qualification procedures or any Study 
Drug  are administered .  The patient  must be given sufficient time to consider whethe r to participate in the 
study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her primary care 
physician  should be documented in the patient ’s medical records and the informed consent form should 
be signed and personally dated by [CONTACT_37781] (not necessarily an Investigator) .  The original signed informed consent form should be 
retained in  the Study Master File and in any other locations required by  [CONTACT_10569], and a copy of 
the signed consent form should be provided to the patient . 
11.[ADDRESS_37970] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  October  2002 
the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands 
of national drug and data protection laws and other applicable regulatory requirem ents will be strictly 
followed.  
11.3 Independent Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent  form, other written patient  information, and any 
proposed advertising material must be submitted to the IEC/IRB for written ap proval .  A copy of the 
written approval of the protocol and informed consent form must be received by [CONTACT_37782] s into the study and shipment of volanesorsen .  A copy of the written approval of 
any other items/materials that must be approved by [CONTACT_37783]/IRB must also be received b y 
the Sponsor  before recruitment of patients into the study and shipment of Study Drug.  The Investigator’s 
Brochure must be submitted to the IEC/IRB for acknowledgement.  
The Investigat or must submit to and, where necessary, obtain approval from the  IEC/IRB, for all 
subsequent protocol amendments and changes to the informed consent document .  The Investigator 
should notify the IEC/IRB of deviations from the protocol in accordance with ICH GCP  Section  4.5.2.  
The Investigator should also notify the IEC/IRB  of serious adve rse events occurring at the Study Center 
and other adverse event reports received from the Sponsor , in accordance with local procedures. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
62  The I nvestigator will be responsible for obtaining annual IEC/IRB approval/renewal throughout the 
duratio n of the study .  Copi[INVESTIGATOR_5699]’s reports, all IEC/IRB  submissions and the IEC/IRB 
continuance of approval must be sent t o the Sponsor . 
11.[ADDRESS_37971] ensure that the patient ’s confidentiality is maintained .  On the case report forms 
(CRF) or other documents submitted to the Sponsor , patient s should be identified by [CONTACT_37784] a 
patient  study number only .  Documents that are not  for submission to the Sponsor  (e.g. , signed informed 
consent forms) should be kept in strict confidence by [CONTACT_737].  
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the Investigator 
and institution permit a uthorized representatives of the company, of the r egulatory agency(s), and the 
IEC/IRB direct access to review the patient ’s original medical records for verification of study -related 
procedures and data .  Direct access includes examining, analyzing, verifying, and reproducing any 
records and reports that are important to the evaluation of the study.  The Investigator is obligated to 
inform and obtain the consent of the patient to permit named representatives to have access to his/her 
study -related records without violating the confidentiality of the patient. 
12. ADMINISTRATIVE AND LEG AL OBLIGATIONS  
12.[ADDRESS_37972] be obtained for all protocol amendments and amendments to the informed consent 
document .  The regulatory authority and IEC/IRB must be informed of all amendments and give approval 
for any amendments likely to affect the safety of the patient s or the conduct of the trial .  The Investigator  
must  send a copy of the approval letter from the IEC/IRB  to the Sponsor . 
12.[ADDRESS_37973].  The Investigator/Sponsor should notify the IEC/IRB in writing of the trial’s completion or 
early termination and send a copy of the notification to the Sponsor.  
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application will be 
used for this study.  
The Investigator  should ensure that all  appropriately qualified persons to whom he/she has del egated trial 
duties  are recorded on a Sponsor -approved Delegation of Site Responsibilities Form . 
Source documents are original documents, data, and records from which the patient’s CRF data are 
obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs may not be used as source 
documents.  
The Investigator and S tudy Center staffs are responsible for maintaining a comprehensive and centralized 
filing system of all study -related (essential) documentation  in accordance with Section  8 of the ICH 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
63  Guidelines E6  (R2), suitable for inspection at any time by [CONTACT_37736]/or 
applicable reg ulatory authorities.  Elements should include:  
• Patient files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_31653] 
• Study files containing the protocol with all amendments, Investigator’s Brochure, copi[INVESTIGATOR_10468] -
study documentation and all correspondence to and from the IEC/IRB  and the Sponsor  
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, volane sorsen  
Accountability Record, Return of volanesorsen  for Destruction, final study volanesorsen  
reconciliation, and all volanesorsen -related correspondence 
In addition, all original source documents supporting entries in the CRF s must be maintained and be 
readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  and the 
Investigator .  Should the Investigator wish to assign the study records to another party or move them to 
another location, he/she must notify the Sponsor . 
12.[ADDRESS_37974], inspecting the various 
records of the trial (e.g., CRF s and other pertinent data) provided that patient  confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular interv als throughout the study to 
verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to 
local regulations on the conduct of clinical research .  The monitor should have access to patient  medical 
records and other study -related records needed to verify the entries on the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by 
[CONTACT_10576]’s  Clinical Quality Assurance Department .  Inspection of Study Center  
facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study -related records will occur 
to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory 
requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data 
received by [CONTACT_1034] .  During this review, patient  data will be checked for consistency, omissions, and 
any apparent discrepancies .  In addition, the data will be reviewed for adherence to the protocol and GCP .  
To resolve any questions arising from the clinical data management review process, data queries and/or 
Study Center  notifications will be sent to the Study Center  for completion and return to Sponsor . 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures will 
indicate that the principal Investigator [INVESTIGATOR_37485] , the data queries, and 
the Study Center notifications, and agrees with the content.  
ISIS [ADDRESS_37975] use 
voca bulary and language that are clearly understood.  
12.6 Compensation for Injury  
The Sponsor  maintains appropriate insurance coverage for clinical trials and will follow applicable local 
compensation laws.  Patients will be treated a nd/or compensated for any study -related illness/injury in 
accordance with the information provided in the Compensation for Injury section of the Informed Consent 
document.
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
65  13. REFERENCES 
Altmann KH, Fabbrot D, Dean NM, et al . Second generation of antisense oligonucleotides:  from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: [ADDRESS_37976] for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Derve nis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high- density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons . Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of  hypertriglyceridemia: An endocrine 
society clinical practice guideline . J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: [ADDRESS_37977] of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B- containing lipoproteins . Circ Res 
2010; 107: 357-364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pag on RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C- III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract  2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev  Pharmacol Toxicol 1996; 
36: 107 -129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al . Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; [ADDRESS_37978] 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial . Gene Therapy 2013; 20: 361- 369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371 ; 23 Dec 2014; 2200 -2206 . 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolip oprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5): 438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′- O-(2-
methoxyethyl) modified antisense oligonucleotide: compar ison across species . Drug Metab Dispos 2003; 31: 
1419 -1428.  
Graham MJ, Lee RG, Bell TA , et al. Antisense oligonucleotide inhibition of apolipoprotein C- III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479 -1490 . 
Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468 -479. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
66  Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327 -330. 
Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 A ug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase . FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12 -week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: [ADDRESS_37979] AA, Yen FT, et al. Inhibitory effects of specific apolip oprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE] -[ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligon ucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715 -1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small  apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin Sci (Lond)  2008; 114: 611 -624. 
Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver dis ease. N Engl J 
Med 2010; 362: 1082 -1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702 -1705.   
Provan D, Stasi R, Newland AC , et al. Inter national consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with familial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur Heart J  2015 Mar; 36(9): 566- 575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PC, Voshol  PJ, et al. ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: [ADDRESS_37980], APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia . J Internal Med 2012; 272: 185 -196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487]  2011; 5: 37 -44. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol - [LOCATION_009]   25 May 2018  
 
67  Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: [ADDRESS_37981] -Treatment Follow -Up 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
69  Appendix  A Schedule of Procedure s – Qualification through Treatment Period 
Study Period  Quala Treatment Period  
Study Week -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12 
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -14 to -7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 
Visit Window+/ - Days  0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Informed Consent  X                       
Outpatient Visit X X Xj Xj X
j Xj Xj Xj X Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X 
Inclusion/Exclusion Criteria  X                       
Medical Historyq X                       
Vital Signs + body weight (+ height on Day 1 only)  X X  X  X   X     X    X     X 
Physical Examination  X X       X     X    X     X 
12- lead ECG (triplicate)  X        X     X    X     X 
MRI (liver/spleen)  X                      Xk 
Echocardiography  X             Xk         Xk Blood Draw (Fasting)c Chemistry Panel  X X  X  X   X  X   X  X  X  X   X 
CBC with Differentialb X X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  
Serum Lipid Panel  X X  X  X  X X    X X    X    X X 
Blood viscosityr  X       X     X         X 
Platelet aggregationr X X       X     X         X 
Coagulation (aPTT, PT, INR)  X     X   X     X    X     X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37488] X       X     X         X 
Sedimentation Rate   X       X     X         X 
Complement (C5a, Bb)   X       X     X         X 
Plasma PK - Volanesorsen   Xl X X  X   X     X    X     X 
Anti-Volanesorsen Antibodies   X  X  X   X     X    X     X 
FSH (women only, if applicable)  X                       
Serum Pregnancy Testd X   X  X   X  X   X  X  X  X   X 
Archived Serum & Plasma Samplese  X    X   X     X         X 
Troponin Io X                       
Platelet Bound Autoantibod iesr  X                      
Archive blood sample for potential gene sequencing 
related to hypertriglyceridemia (Group 2 if not available 
from index study)g X                       
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
70  Appendix  A Schedule of Procedures  - Qualification through Treatment Period Continued  
Study Period  Quala Treatment Period  
Study Week -2 to -1 Wk 
1 W
k 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12 
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day -14 to 
 -7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 
Visit Window+/ - Days  0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Urinalysisc X Xm  X  X   Xm  Xm   Xm  Xm  Xm  Xm   Xm 
Fundus Photographyf X                      Xk 
Genetic testing for FCS diagnosis (if not 
available in medical history)g X                       
Weekly Study Drug:  SC Injection   X  X X X X X X X X X X X X X X X X X X X X 
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X       X     X         X 
Food/Drink Diary (quarterly)h  X       X     X         X 
Diet/Alcohol Counselingi X X  X  X   X     X    X     X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
71  Appendix  A Schedule of Procedures – Post-Treatment Follow -up  
Study Period  Post Treatment Follow -upp 
Study Week Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Outpatient Visit  Xj Xj X Xj X 
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X Blood Draw (Fasting)c Chemistry Panel   X X X X 
CBC with Differentialb Xs X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testd  X X X X 
Archived Serum & Plasma Samplese   X  X 
Urinalysisc  Xm Xm Xm Xm 
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Food/Drink Diary (quarterly)h   X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication  X X X X X 
Legend : 
a Qualification procedures performed (Please refer to Sections 3.4 , 4.1, and 6.1.2 ) 
b Each time a hematology
 lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in 
parallel and analyzed locally.   In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or 
clumped blood samples) another sample must be repeated withi n [ADDRESS_37982] be reviewed by [CONTACT_37785].  All platelet count results will be promptly reviewed by [CONTACT_37786] a stoppi[INVESTIGATOR_1877] , or the dose  reduction rule of 100 ,000/mm3, or the dose pause rule of 
75,000/ mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor 
c Blood samples to be collected after an overnight fast of at least 10 hours and pref erably not more than 12 hours.  During 
treatment period urine and blood samples will be collected prior to Study Drug administration.  Does not apply to 24-hour PK 
blood draw  
d Females of childbearing potential only 
e Serum and plasma samples will be colle cted and stored for follow -up exploration of laboratory findings and/or adverse events 
(e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clin ical studies of volanesorsen 
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug (Group 2 ISIS 
304801-CS16 roll  over patients ) and repe 
ated at Week 52 (Please refer to Section  [IP_ADDRESS] ) 
g Genetic te
sting can be conducted for study Qualification  (Group 2 ISIS 304801-CS16 roll  over patients ); genetic testing will only 
be conducted if allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
72  h In addition to diary, patients will be contact[CONTACT_37787]  
i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone vis its) will also be 
performed by [CONTACT_37743]  
j Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37744]  
k A ± 7 -day window is allowed for MRI, echocardiography procedures and fundus photography 
l Full or abbreviated PK profile (see Appendix C) 
m Expanded urinalysis (see Appendix B) 
n HbA1c only 
o All abnormal troponin samples will be rerun at the central laboratory and also analyzed for CK -MB  
p If needed, the post -treatment follow-up period will be extended (with patients monitored every 6 weeks) until apoC-III levels 
return to baseline values  
q Patient charts will be reviewed in order to collect data for events of acute pancreatitis or suspected pancreatitis in the patient’s 
medical history.  Chart  review may be conducted at any time during the study.  These events will be adjudicated in the same 
manner as for events of pancreatitis during the study  
r May be done.  Blood viscosity and platelet aggregation in volanesorsen-treatment naïve patients only 
s Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of schedul ing
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
73  Appendix  A Schedule of Procedures  – Extended Treatment Period  
Study Pe riod Extended Treatment Period  
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62  Mo 15  
Wk 64 Wk 66 
& 68  Wk 
70 Wk 72 
& 74  Mo 18  
Wk 76 Wk 78 
& 80  Wk 
82 Wk 84, 86 , 
& 88  Mo 21  
Wk 90 Wk 92 
& 94  Wk 
96 Wk 98, 
100 & 
102 Mo 24  
Wk 104  
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 568  582, 596 & 
610 624 638 & 
652 666 680, 694 
& 708  722 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X 
Vital Signs (+ body weight)     X    X    X    X 
Physical Examination         X        X 
12- lead ECG (triplicate)         X        X 
Urinalysis (including P/C ratio)   X  X  X  X  X  X  X  X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X 
CBC with Differentiala X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  
Serum Lipid Panel    X    X    X    X 
Coagulation (aPTT, PT, INR)     X    X    X    X 
Troponin I     X    X    X    X 
Plasma PK - ISIS 304801c        X        X 
Anti-ISIS 304801 Antibodies         X        X 
Serum Pregnancy Testd  X  X  X  X  X  X  X  X 
Weekly Study Drug: SC Injection X X X X X X X X X X X X X X X X 
Diet/Alcohol Counselinge    X    X    X    X 
Adverse Events  X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X 
Legend : 
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. In the event that 
both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_37983] be 
reviewed by [CONTACT_37788].  All platelet count results will be promptly reviewed by [CONTACT_37789] 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
74  if the count has met a stoppi[INVESTIGATOR_1877] , or the dose reduction rule of 100,000/mm3, or the dose pause rule of 75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be 
reported in an expedited fashion to the Sponsor 
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatment period urine and blood samples will be 
collected prior to Study  Drug administration  
c Abbreviated PK collection (see Appendix C) 
d Females of childbearing potential only 
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the  Study Center as arranged by [CONTACT_37790] 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
75   
Appendix  A Schedule of Procedures – Extended Treatment Period (Post-Treatment Follow -Up)  
Study Period  Post Treatment Follow -upa 
Study Week Wk 106  
& 
108 Wk 
110 Wk 
117 Wk 
123 Wk 
130 
Study Day  736 
& 
750 764 813 855 904 
Visit Window+/ - Days  2 7 7 7 7 
Outpatient Visit  Xb Xb X Xb X 
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X Blood Draw (Fasting)e Chemistry Panel   X X X X 
CBC with Differentialc Xd X X X X 
Serum Lipid Panel    X  X 
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
Serum Pregnancy Testf  X X X X 
Archived Serum & Plasma Samplesg   X  X 
Urinalysis  Xh Xh Xh Xh 
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events  X X X X X 
Concomitant Medication  X X X X X 
Legend : 
a If needed, the post -treatment follow-up period will be extended (with patients monitored every 6 weeks) until apoC-III 
levels return to baseline values  
b Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37748]   
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected 
in parallel and analyzed locally.   In the event that both the central and local sample are unreportable (e.g., due to hemolyzed 
or clumped blood samples) another sample must be repeated within [ADDRESS_37984] be reviewed by  [CONTACT_37791].  All platelet count results will be promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877] , or the dose reduction rule of 100,000/mm
3, or the dose 
pause rule of 75,000/ mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor 
d Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling  
e Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During 
treatment period urine and blood samples will be collected prior to Study Drug administration.  Does not apply to 24-hour PK blood draw  
f Females of childbearing potential only 
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse 
events (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of kidney function, 
measurement of antibodies, etc.) in this or subsequent clinical studies of volanesorsen 
h Expanded urinalysis (see Appendix B)  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
76  i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be 
performed by [CONTACT_37750] [ADDRESS_37985] of Laboratory Analytes 
Based on emerging data from this or  future studies, additional tests not listed below may be performed on 
stored samples to better characterize the profile of volanesorsen  or other similar oligonucleotides . 
Clinical Chemistry Panel  
• Sodium 
• Potassium  
• Chloride 
• Bicarbonate 
• Total protein  
• Albumin 
• Calcium 
• Magnesium 
• Phosphorus 
• Glucose  
• BUN  
• Creatinine 
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) bilirubin  
• Indirect (unconjugated) 
bilirubin 
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL -C 
• HDL -C 
• Triglycerides 
• Non-HDL -C 
• VLDL -C 
• apoA-1 
• apoB 
• apoC-III 
 Hematology  
• Red blood cells  
• Hemoglobin 
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (%  and 
absolute) 
• Neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes  
• Monocytes 
 
Pharmacokinetics1  
& Immunogenicity 
• Volanesorsen levels in plasma  
• Anti-volanesorsen antibodies 
in plasma  
 
Other Assessments  
• hsCRP 
• Sedimentation Rate  
• C5a, Bb  
• Troponin I2 
• CK-MB2 
• Platelet Bound Autoantibodies
3 
• De-lipi[INVESTIGATOR_37489]  
• HbA1c , FPG  
• Blood viscosity3 Urinalysis  
• Color 
• Appearance 
• Specific gravity 
• pH 
• Protein 
• Blood 
• Ketones 
• Urobilinogen 
• Glucose  
• Bilirubin 
• Leukocyte esterase 
• Nitrate  
• Microscopic examination4 
 
Additional  Measures for Expanded 
Urinalysis  
• Total protein (quantitative)  
• Microalbumin 
• β2-microglobulin 
 
Platelet Function  
• Platelet aggregation3 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, 
stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay development and/or 
validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_37986] -treatment follow -up period as noted in the 
tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 7 
Time Point  Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Anytime  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D2 D22 D50 D85 D176 D260 D358 D449 D540 
Visit Window 
+/- Days  [ADDRESS_37987]-dose Pre-dose Pre-dose Pre-dose Pre-
dose Pre-
dose Pre-
dose Anytime  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24 -hour PK profile beginning on Study  Day 1.  
Participation is optional  
 PK Sampling Schedule (Extended Treatment Period)  
Week  Wk 
76 Wk 
104 Wk 
117 
Study Day  D526  D722  D813  
Visit Window 
+/- Days  [ADDRESS_37988] abnormalities are based 
upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010  
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
80  Appendix  D Grading Scale for Adverse Events Relating to Laboratory Abnormalities  Continued  
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 9  
Protocol  - [LOCATION_009]   25 May 2018  
 
81  Appendix  D Grading Scale for Adverse Events Relating to Laboratory Abnormalities Continued  
 
 
 

Sponsor:  
Akcea Th
erapeutics, Inc.  
[ADDRESS_37989], 9th Floor,  [LOCATION_011], MA 
[ZIP_CODE] Collaborator:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_37990]  
Carlsbad, CA  [ZIP_CODE]  
ISIS 304801- CS7 
The APPROACH  Open- Label Study  
Volanesorsen (ISIS 304801)
An Open- Label Study of Volanesorsen Administered Subcutaneously 
to Patient s
 with Familial Chylomicronemia Syndrome (FCS) 
Protocol Amendmen
t 8 – [ADDRESS_37991] No:  2015- 0037
55-21 

ISIS [ZIP_CODE] l-CS7 
Protocol CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 8 
21 November 2018 
An Open-Label Study of Volanesorsen Administered Subcutaneously 
to Patients with Familial Chylomicronemia Syndrome (FCS) 
Protocol Amendment 8 -21 November 2018 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Protocol Amendment 6: 
Protocol Amendment 7: 
Approved by: 
[CONTACT_37673], Inc. 
[ADDRESS_37992], 9th Floor 
[LOCATION_011], MA [ZIP_CODE] 
Telephone:  [ADDRESS_37993] 2015 
2 February 2016 
22 April 2016 
9 May 2016 
6 June 2016 
6 July 2016 
18 November 2016 
7 April 2017 
Akcea Therapeutics, Inc. 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
3   
Ionis  Protocol Number:  ISIS [ADDRESS_37994] No:  2015- 003755 -21 
Clinical Phase:  3  
 
The APPROACH  Open- Label Study  
Volanesorsen (ISIS 304801)  
An Open- Label Study of Volanesorsen Administered Subcutaneously 
to Patients with Familial Chylomicronemia Syndrome (FCS)  
 
Trial Sponsor:  [ADDRESS_37995], ,9th Floor  
[LOCATION_011], MA [ZIP_CODE]  
Telephone:
Key Sponsor Contact:   
 
[CONTACT_37793], Inc.  
[ADDRESS_37996], 9th Floor  
[LOCATION_011], MA [ZIP_CODE]  
Telephone:
Email:
Collaborator : Ionis Pharmaceuticals,  Inc. 
[ADDRESS_37997]  
Carlsbad, CA [ZIP_CODE]  
Date:  [ADDRESS_37998] of the clinical 
investigation without the prior written consent of Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, 
Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
4  Protocol Signature [CONTACT_10669]:  ISIS 304801- CS7 
Protocol Title:  An Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients 
with Familial Chylomicronemia Syndrome (FCS)  
Amendment: Amendment 8 
Date: [ADDRESS_37999] read and understand the attached clinical protocol , entitled “An Open -
Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) ”, dated  [ADDRESS_38000] the study as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n Good 
Clinical Practice (E6)  (R2). 
I agree to ensure that the confidential information contained in this document will not be used for any 
purpose other than the evaluation or conduct of the clinical investigation with out the prior written 
consent of Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc .   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month  YYYY) 
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
5  TABLE OF CONTENTS  
Page  
PROTOCOL AMENDMENT  ..................................................................................................... 10 
PROTOCOL SYNOPSIS  ............................................................................................................ 20 
STUDY DESIGN AND TRE ATMENT SCHEMA  ................................................................... 26 
STUDY GLOSSARY ................................................................................................................... 27 
1. OBJECTIVES  ................................................................................................................. 29 
2. BACKGROUND AND RATIONALE  .......................................................................... 29 
2.1 Overview of Disease  .................................................................................................................. 29 
2.2 Therapeutic Rationale  ............................................................................................................... 30 
2.3 Volanesorsen  ............................................................................................................................. 31 
2.3.1  Mechanism of Action  ........................................................................................................ 31 
2.3.2 Chemistry  .......................................................................................................................... 32 
2.3.3  Preclinical Experience  ........................................................................................................ 32 
2.3.4  Clinical Experience  ............................................................................................................. 33 
2.4 Rationale for Dose and Schedule of Administration  ................................................................. 35 
3. EXPERIMENTAL PLAN  .............................................................................................. 36 
3.1 Study Design  .............................................................................................................................. 36 
3.2 Number o f Study Centers  .......................................................................................................... 36 
3.3 Number of Patients  ................................................................................................................... 36 
3.4 Overall Study Duration and Follow -up ...................................................................................... 36 
3.4.1  Group 1 and 2 Patients (participated in ISIS  304801- CS6 or ISIS 304801 –CS16 index 
study):  Qualification  ......................................................................................................... 36 
3.4.2  Group 3 Patients (did not participate in an index study):  Screening/Qualification  ......... [ADDRESS_38001]  ............................................................................................ 37 
4. PATIENT ENROLLMENT ........................................................................................... 37  
4.1 Screening/Qualification  ............................................................................................................. 37 
4.2 Enrollment  ................................................................................................................................. 38 
5. PATIENT ELIGIBILITY .............................................................................................. 38 
5.1 Inclusion Criteria  ........................................................................................................................ 38 
5.2 Exclusion Criteria for Group 1 (ISIS 304801 -CS6) and Group 2 (ISIS  304801 -CS16) Index St u
dy 
Roll- over Pati ents  ...................................................................................................................... 39 
6. STUDY PROCEDURES  ................................................................................................ 42 
6.1 Study Schedule  .......................................................................................................................... 42 
6.1.1  Qual ification (Groups 1 and 2)  .......................................................................................... 42 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
6  6.1.2  Screening and Qualification (Group 3)  .............................................................................. 42 
6.1.3  Treatment Period  .............................................................................................................. 42 
6.1.4  Extended Treatment Period  .............................................................................................. 43 
6.1.5  Pharmacokinetic (PK) Subgroup  ........................................................................................ [ADDRESS_38002] -Treatment Period  ...................................................................................................... 43 
6.2 Additional Study Assessments  ................................................................................................... 44 
6.2.1  Laboratory Asses sments  .................................................................................................... 44 
6.2.2  Physical Exams and Vital Signs  .......................................................................................... 44 
[IP_ADDRESS]  Eruptive Xanthoma  ..................................................................................................... 44 
[IP_ADDRESS]  Lipemia Retinalis  ........................................................................................................ 44 
6.2.3  Echocardiography  .............................................................................................................. 45 
6.2.4  ECG....................................................................................................................................  45 
6.2.5  MRI...................................................................................................................................  45 
6.2.6  Quality of L ife Assessments  ............................................................................................... 45 
6.2.7  Disease Symptom Diary  ..................................................................................................... 45 
6.2.8  Diet Monitoring  ................................................................................................................. 45 
6.2.9  Family History  .................................................................................................................... 45 
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2 and 3)  ..... [ADDRESS_38003] -Treatment Follow- up Period ............... 60 
8.9 Withdrawal of Patients from the Study ..................................................................................... 60 
8.10  Concomitant Therapy and Procedures  ...................................................................................... 61 
8.10.1  Concomitant Therapy  ........................................................................................................ 61 
8.10.2  Concomitant Procedures  ................................................................................................... 62 
8.11  Treatment Compliance  .............................................................................................................. 62 
9. SERIOUS AND NON- SERI OUS ADVERSE EVENT REPORTING  ....................... 62 
9.1 Sponsor Review of Safety Information  ...................................................................................... 62 
9.2 Regulatory Requirements  .......................................................................................................... 62 
9.3 Definitions  ................................................................................................................................. 63 
9.3.1  Adverse Event  .................................................................................................................... 63 
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ......................................................... 63 
9.3.3  Serious Adverse Event (SAE).............................................................................................. 63 
9.4 Monitoring and Recording Adverse Events  ............................................................................... 64 
9.4.1  Serious Adverse Events  ..................................................................................................... 64 
9.4.2  Non -Serious Adverse Events  ............................................................................................. 64 
9.4.3  Evaluation of Adverse Events (Serious and Non -Serious)  ................................................. 65 
[IP_ADDRESS]  Relationship to the Study Drug .................................................................................. 65 
[IP_ADDRESS]  Severity  ....................................................................................................................... 65 
[IP_ADDRESS]  Action Taken with Volanesorsen  ................................................................................ 65 
[IP_ADDRESS]  Treatment Given for Adverse Event  ........................................................................... 66 
[IP_ADDRESS]  Outcome of the Adverse Event  .................................................................................. 66 
9.4.4  Adjudication Committees  .................................................................................................. 66 
9.5 Procedures for Handling Special Situations ............................................................................... 66 
9.5.1  Abnorm alit
ies of Laboratory Tests  .................................................................................... 66 
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ...................... 67 
9.5.3  Treatment  Errors  ............................................................................................................... 67 
9.5.4  Contraception and Pregnancy  ........................................................................................... 67 
10. STATISTICAL CONSIDERATIONS  .......................................................................... 68 
10.1  Study Endpoints  ......................................................................................................................... 68 
10.1.1  Efficacy Endpoints  ............................................................................................................. 68 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
8  10.1.2  Safety Endpoints  ................................................................................................................ 69 
10.2  Sample Size  ................................................................................................................................ 69 
10.3  Populations  ................................................................................................................................ 69 
10.4  Definition of Baseline  ................................................................................................................ 69 
10.5  Interim Analysis  ......................................................................................................................... 70 
10.6  Planned Methods of Analysis  .................................................................................................... 70 
10.6.1  Demographic and Baseline Characteristics  ....................................................................... 70 
10.6.2  Safety Analysis  ................................................................................................................... 70 
10.6.3  Efficacy Analysis ................................................................................................................. 71 
10.6.4  Pharmacokinetic and Immunogenicity Analysis  ................................................................ 71 
[IP_ADDRESS]  Pharmacokinetic Analysis  ........................................................................................... 71 
[IP_ADDRESS]  Immunogenicity Analysis  ............................................................................................ 72 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. [ADDRESS_38004] of the Study  ..................................................................................................... 73 
11.3  Independent Ethics Committee/Institutional Review Board  .................................................... [ADDRESS_38005] of Laboratory Analytes ........................................................................................ 88 
Appendix C           Pharmacokinetic Sampling Schedule ......................................................................... 90 
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities  .................. 92 
TABLE OF TABLES  
Page  
Table 1  Volanesorsen (ISIS 304801) Characteristics  ...................................................................... 47 
Table 2  Labs to Be Performed in the Event of a Platelet Count Less than the Lower Limit 
of Normal (x2) or < 100,000/mm3 (x1)*  ........................................................................... 52 
Table 3  Actions in Patients with Low Platelet Count or Drop in Platelet Count  ........................... 58 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
9  Table 4  Expected Event for the Protocol Defined Population by [CONTACT_37794]  ........................................................................................................... 63 
 
TABLE OF FIGURES  
Page  
Figure 1  ApoC -III Regulates Lipoprotein Metabolism by [CONTACT_37675]  ............................ 30 
Figure 2  Design of Chimeric 2ʹ -MOE Phosphorothioate Oligonucleotides  
(MOE- Gapmer).  The sequence of volanesorsen is shown  ............................................... 32 
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ............................ 34 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
10  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open -Label Study of Volanesorsen  Administered Subcutaneously to 
Patient s with Familial Chylomicronemia Syndrome (FCS)  
Amendment Number:  8 
Amendment Date:  21 November  2018  
 
The purpose of this protocol amendment is to implement the following modifications to Prot ocol ISIS 
304801- CS7 Amendment 7 dated 7 April 2017 : 
• To add the option for patients to receive a study drug dose reduction as either 300 mg every 
two w eeks (prefilled syringe) or 150 mg once -weekly  (vial presentation) , to clarify that 
discontinuation from the treatment period will be required for any patients who are on a dose 
pause for ≥ 3 months, and to remove the references to landmark visits (if patient stops drug 
treatment  then they enter the follow-up period).  
Minor changes (not included in the list of changes below) have been made throughout the protocol  to 
correct errors and/or to improve the overall clarity of the original protocol but these changes do not 
impact subject safety, exposure, or the overall study design.  
The following table provides a summary list of major changes to the protocol, additions  are indicated as 
underline and deletions are indicated as strikethrough : 
Protocol 
Section Description of Change  Rationale  
Section 2.3.4 
Clinical experience  Volanesorsen has been evaluated in one Phase 1 study 
and two Phase 2 studies, all double blinded and placebo 
controlled.  The total exposures comprise 99 patients and 
healthy volunteers administered volanesorsen from 50 to 
400 mg subcutaneously up to 3 months (compared to 37 
administered placebo). The clinical experience with 
volanesorsen includes clinical trials in healthy subjects, 
patients with hypertriglyceridemia, FCS, or familial partial 
lipodystrophy . Overall, [ADDRESS_38006] 1 dose of 
volanesorsen. Ninety -five (95) patients with FCS have 
been enrolled in studies, all showing clinically meaningful 
reductions in plasma triglyceride. Patients with FCS 
continue on treatment in the open-label extension (OLE) 
and triglyceride reductions persist at similar levels as 
reported in earlier studies.  
In the completed Phase [ADDRESS_38007] on the 
renal (serum creatinine, proteinuria) or hepatic systems 
(alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], bilirubin). There was a reduction 
(mean reduction < 30%) in platelets in volanesorsen vs. 
placebo with mean nadirs for all doses remaining above 
the lower limit of normal (LLN). The most frequently 
reported adverse events (AEs) were mild, non-
progressive events at the injection site. In Phase 2, a 
single serious adverse event (SAE) of secondary serum 
sickness- like reaction was reported as related to Study 
Drug.  
... 
In clinical studies conducted to date volanesorsen has 
been well -tolerated and has shown a favorable safety 
profile.  There has been no clinical or laboratory evidence 
of drug -drug interactions.  
In the completed studies there have been no 
volanesorsen associated laboratory abnormalities 
suggestive of an effect on the renal (serum creatinine, 
proteinuria) or hepatic systems (alanine 
aminotransferase [ALT], aspartate aminotransferase 
[AST], bilirubin).  In Phase [ADDRESS_38008] -treatment period 
and was not associated with plat elet-related adverse 
events (AEs).  In the blinded ongoing clinical trials of ISIS 
304801, 2 patients of 142 dosed (as of February 29, 
2016) had a decrease in platelet count to less than 
50,000/mm3 in the absence of major bleeding or 
clinically -relevant non-major bleeding and had Study 
Drug paused as per the monitoring and stoppi[INVESTIGATOR_37516] (Section 8.6.3).  Platelet counts recovered 
following suspension of treatment . 
The most frequently observed AEs with volanesorsen 
were local reactions at the injection site.  Local 
cutaneous reactions at the injection site defined as those 
events presenting as either pain, tenderness, erythema, 
pruritus or swelling occurring on the day of injection and 
persisting for at least 2 days were infrequent (~15% of 
injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not 
associated with systemic sequelae.  
In the completed pooled Phase 3 studies (ISIS 304801-
CS6 (hereafter CS6) and ISIS 304801-CS16 (hereafter 
CS16), the most common AEs associated with 
volanesorsen administration were tolerability at the 
injection site and platelet reductions. The majority of the 
injection site AEs were mild, none were severe, and the 
incidence appeared to decrease over time. No deaths 
have been associated with volanesorsen treatment to 
date. No cardiac toxicity was associated with 
volanesorsen treatment. There were no abnormal QTc 
findings and no study -drug related adjudicated major 
adverse cardiac events (MACE). There is no evident 
association between volanesorsen treatment and 
changes in renal or liver functions.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
12  In conclusion,t  The safety profile of volanesorsen has 
been well -described in this development program, which 
has identified 3 safety risks: thrombocytopenia (an 
identified risk), constitutional symptoms (flu-like reactions 
and influenza-like illness), and injection site reactions (a 
tolerability signal). Spontaneous, mild to severe 
thrombocytopenia has been described in the FCS patient 
population (Gaudet et al. 2017),but is increased by 
[CONTACT_37676]. Less frequent and less 
pronounced platelet declines were also observed with 
volanesorsen treatment in the hypertriglyceridemic (HTG) 
population of CS16. When fully complied with, frequent 
monitoring for this effect and appropriate dose 
adjustments have been successful both in preventing or 
promptly detecting the occurrence of severe platelet 
declines and often in retaining patients on treatment.  
Section 2.4  
Rationale for 
Dose and Schedule of 
Administration  The dose and schedule selected for this study is 300 mg 
per week for 52 weeks.  The dose of 300 mg per week and dose reduction to 300 mg every 2 weeks ( delivered 
as either a single 300- mg dose or as 150 mg once-
weekly , respectively ) are is supported by [CONTACT_37795] 3 clinical data.  
… 
Non nonclinical findings were not considered to be 
related to the pharmacologic inhibition of apoC -III. Language added to specify dose 
reductions   as either 300 mg every 
2 weeks or 150 mg weekly according to patient’s tolerability on 
the 300 mg dose, given similar 
extents of triglyceride lowering anticipated based on population pharmacokinetic/pharmacodynamic 
model based simulations.  
Section 3.4.[ADDRESS_38009] -treatment evaluation period is 
of 13 weeks  and, consists consisting  of 7 Study Center 
visits on Weeks  53, 54, 55, 56, 57, 58, and 65 (Weeks 
53, 54, 55, 56, 57, and 58 may be conducted by a home healthcare nurse). Patients who complete, or terminate 
early from, the extended treatment period without 
subsequently participating in an expanded access 
program will enter a 13-week post -treatment evaluation 
period consisting of 7 Study Center visits on Weeks 105, 
106, 107, 108, 109, and 110 (which may be conducted by 
a home healthcare nurse), and Week 117 (Appendix A).   Language added to specify that patients who discontinue from treatment during treatment period 
of the study , who previously would 
have been followed for landmark visits, will now enter into the 13-week follow -up period  
Section 6.1.3 Treatment 
Period 
Synopsis, 
Study  Visits 
and 
Procedures  Collection and measurement of race and ethnicity , vital 
signs, clinical laboratory parameters (including 
hematology, serum chemistry, and urinalysis), adverse 
events (AE), concomitant medication/procedure information, lipid panel, bl ood viscosity, volanesorsen 
plasma concentrations, immunogenicity (IM) testing, platelet aggregation, liver/spleen magnetic resonance 
imaging (MRI), ECGs, echocardiograms and quality of 
life assessments will be performed according to the schedule of procedures in Appendix A.  To add a specification that race and ethnicity are to be collected.  
Section 6.2. 1 
Laboratory Assessments  Should a patient experience constitutional or flu-like 
symptoms after Study Drug administration, investigators 
may consider additional laboratory assessments.  For 
example, plasma and serum samples may be drawn for 
complement (Total C3, C4, C5a and Bb), hsCRP and for 
cytokine analysis.  To add additional laboratory assessments permi tted for safety 
purposes  
Section 7.1 Volanesorsen Description  … 
Volanesorsen (ISIS 304801) is contained in glass prefilled syringes (PFS ) or in glass vials . 
Table 1 Volanesorsen (ISIS 304801) Characteristics  To add details of study drug 
preparation to be used in the open-label extension phase  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
13   Study Drug  ISIS 304801 
Prefilled 
Syringe ISIS 304801  
Vial* 
Strength  300 mg  200 mg  
Volume / 
Formulation  1.5 mL  
200 mg/mL ISIS 
304801  1.0 mL  
200 mg/mL ISIS 
304801  
Dose  300 mg / 1.5 mL  150 mg / 0.[ADDRESS_38010] be disposed of as per the 
site’s hazardous waste destruction policy.  Specified disposal of study drug preparation to be used in the open-label extension phase  
Section 8.1 
Volanesorsen 
Administration  For each individual patient, volanesorsen  will be 
administered subcutaneously  as a single 1.5 mL 300 mg 
injection once weekly for Weeks 1- 52, and patients wi ll 
continue to receive Study Drug as a single 300 mg/1.5 
mL injection once -weekly for Weeks  53-104 of the study.   
Patients entering this ISIS 304801-CS7 study on a reduced dose or dose frequency of Study Drug 
(volanesorsen), for safety or tolerability reas ons in their 
index study (ISIS 304801-CS6 or ISIS 304801 -CS16), 
will receive a reduced dose or dose frequency of 
volanesorsen for continued safety or tolerability as 
outlined in Sections 8.5 and 8.6.  Patients on dose 
reduction will receive either 300 mg/1 .5 mL injections 
every 2 weeks or 150 mg/0.75 mL injections 
once-weekly .  Treatment with  a 150 mg dose during the 
study will use the glass vials containing 200 mg/mL of 
volanesorsen.  Patients entering this CS7 study having 
dose or dose frequency reduced in the CS16 index study 
after 13  weeks of treatment, as outlined in CS16 
Amendment 4 Section 8.7, can receive the 300 mg once 
weekly dose of volanesorsen.  Treatment  
Patients should rece ive 1 dose per week, unless on a 
dose reduction of 300 mg every 2 weeks,  with weeks 
always defined relative to Study Day  1.   
… Added language detailing dose 
reduction options.  
Section 8.5. [ADDRESS_38011] ed study centers.  
… 
Due to the [ADDRESS_38012] with the study patients.  However, if the above options are not possible, 
a temporary interruption of study treatment will be Additional point -of-care platelet 
function testing may be conducted on patients at participating study 
centers.  
 
Included an additional blood draw 
to assess platelet count prior to any 
travel that would result in missing a weekly monitoring visit.   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
14  planned with a platelet count drawn within 3 -5 days prior 
to departure and a prompt blood draw upon the patient’s 
return which must be reported and reviewed by [CONTACT_37796] . 
 
Patients on dose pause should be monitored as per the 
platelet monitoring rules outlined in Section 8.8.1 until 
Study Drug administration is resumed.  
8.5.4  Safety 
Monitoring for 
Constitutional 
Symptoms  Should a patient experience constitutional or flu-like 
symptoms after Study Drug administration, investigators 
may consider additional laboratory assessments.  For 
example, plasma and serum samples may be drawn for 
complement (Total C3, C4, C5a and Bb), hsCRP , and for 
cytokine analysis.  To add additional laboratory assessments perm itted for safety 
purposes  
Section 8.6.3 Stoppi[INVESTIGATOR_37517] 50,000/mm3, 
or a platelet count less than 75,000/mm3 that occurs 
while the patient is treated  at 300 mg every 2 weeks or 
150 mg once -weekly  then treatment  of a patient with 
volanesorsen will be stopped permanently.  
… 
In the event of a platelet count less than 75,000/mm3, 
and in the absence of major bleeding or clinically -relevant 
non-major bleeding (defined below; Schulman et al. 
2005), treatment  of a patient with volanesorsen should be 
suspended temporarily until the platelet count has 
recovered to ≥ 100,000/mm3.  If do sing is continued 
treatment  is reinitiated , it should be at a reduced dose 
frequency of 300 mg every 2 weeks or 150 mg once -
weekly  every week (refer to Section 8.7).  
 
Table [ADDRESS_38013] be documented in the patient’s medical records.  Monitor every 1 
week unless otherwise specified 
In addition, 
platelet function 
may be evaluated 
during the study 
by [CONTACT_37680], 
using an 
approved point -
of-care diagnostic 
device, in some 
patients.  This 
additional 
functional testing 
may be 
performed at 
selected study 
centers.  
Patients on dose 
pause should be 
monitored as per 
the platelet 
monitoring rules 
outlined in 
Section 8.8.1 until 
Study Drug 
administration is 
resumed.  
Obtain additional 
lab tests 
(Table 2) if 
2 occurrences 
(consecutive or 
non-c onsecutive) 
of platelet c ount  
140K - 
>100K/mm3 or 1
occurrence of
platelet count ≤100K/mm
3.  Labs
only need to be
performed once.
Labs may becollected overmultiple visits, ifbloodrequirements area concern, as perInvestigatordiscretion.
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
16  > 100K/mm3 Once -weekly 300 
mg Study Drug 
administration   
100K/mm3 - 
> 75K/mm3 Permanently 
reduce dose frequency to 300 mg every 
2 weeks  or 
150 mg once-
weekly.    
75K/mm3 
- > 50K/mm3 • If occurs 
while on dose of 300 mg every 2 weeks or 150 mg once-
weekly  then 
permanently discontinue Study Drug, otherwise dose pause. If dose pause 
is ≥ [ADDRESS_38014] 
discontinue 
treatment 
and enter the 
follow up 
period.  
• When platelet 
count returns to > 100K/mm
3 
restart treatment  at 
dose frequency of 300 mg every 2 weeks or 
150 mg once-
weekly  only if 
approved by  
[CONTACT_37682] 2 -3 
days until 
2 successive 
values are > 75K/mm
3 then 
monitor every 1 week  
Consider discontinuation of antiplatelet 
agents/NSAIDS/ 
anticoagulant medication  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
17  ≤ 50K/mm3 Permanently 
discontinue Study 
Drug and the 
patient will enter 
the follow up 
period . • Monitor daily until 2 successive values show improvement 
then monitor 
every  
2-3 days until 
2 successive 
values are > 75K/mm
3 then 
monitor every 1 
week  
• Patient should 
be evaluated by a hematologist to provide diagnostic and therapeutic 
management  
• Steroids 
recommended*.  
It is strongly 
recommended that, unless the patient has a medical 
contraindication 
to receiving glucocorticoids, the patient receives glucocorticoid therapy to reverse the 
platelet decline.   
• Monitor triglyceride levels weekly and c ontinue 
AE monitoring during steroid 
therapy  
Discontinue 
antiplatelet agents/ NSAIDS/ anticoagulant medication while platelet count is < 50K/mm
3 if 
possible  
 
Section 8.7 
Adjustment of Dose Frequency  Other dose adjustments, including dose interruptions, and/or decreasing the dose to 150 mg once-weekly  or 
the dose frequency to 300 mg every 2 other  weeks  will 
be allowed for safety and tolerabil ity. Addition of dose reduction options to allow for safety and tolerability  
 
Discontinuation of patients from the 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
18  … 
Patients may be dose paused in response to AEs after 
consultations with, and the Study Medical Monitor is 
informed. If a patient is dose paused for ≥ [ADDRESS_38015] been on dose 
pause and off study drug for >[ADDRESS_38016] permanently discontinue study treatment for any of the following:  
… 
•The patient is dose-paused for ≥ [ADDRESS_38017] discontinue the treatment period and enter the 
follow -up period . Added new treatment discontinuation criterion consistent 
with other protocol changes.  
Section 8.8.1 
Follow -up Visits  
for Early Termination from Treatment 
Period Patients should be strongly encouraged to attend 
applicable landmark visits at Weeks 12, 13, 25, 26 and 
50, 52 of Randomized Treatment period (calculated 
based on the time elapsed since Day 1) and at Weeks 
64, 65, 77, [ADDRESS_38018] safety assessments in 
accordance with the schedule of procedures in Appendi x 
A. Any patient who discontinues treatment after Week 44 
should also be strongly encouraged to attend a final follow -up visit (Week 65 visit assessments) 
approximately [ADDRESS_38019] dose of Study 
Drug , in addition to the applicable landmark vi sits. 
 
… 
A patient who discontinues early from treatment with 
stable platelet counts above the LLN at the time of 
treatment discontinuation will have platelet counts drawn 
every [ADDRESS_38020] -treatment 
follow -up period.  
Section 13 REFERENCES  Gaudet D, Baass A, Tremblay K, et al. Natural History 
(up to 15 years) of Platelet Count in 84 Patients wi th 
Familial Hyperchylomicronemia Due to Lipoprotein 
Lipase Deficiency. Journal of Clinical Lipi[INVESTIGATOR_37444] 2017; 
11(3): 797-798.  Addition of reference  
Section 14 APPENDICES  Appendix A Schedule of Procedures  
Added platelet function analysis to extended treatment period table.  
Footnote i: Genetic testing can be conducted for study qualification (Group 2 [ISIS 304801-CS16 roll -over 
patients] and Group 3); genetic testing will only be conducted if allowed in the geographic region and only after the patient has given specific writt en informed 
consent for genetic testing. A blood sample for potential 
gene sequencing may be collected at timepoints other 
than Screening or Qualification Visits. Footnote g: May be 
done  Clarification that blood sampling for gene sequencing may occur during 
the study.  
Indication that platelet function may be assessed.  
 
Section [ADDRESS_38021] of Laboratory Analytes  
Platelet Function  
Platelet aggregation3 
Platelet function5 Addition of laboratory analyte to measure platelet function.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
19  Footnote 5: May be done using a point -of-care device on 
site. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
20  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of treatment  and extended treatment  with 
volanesorsen in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll-over  FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll-over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_38022] -treatment evaluation period  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 Groups 2 and 3 :  Patients must also meet the following c riteria in order 
to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37797] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of 
the following:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal in medical 
history . Note: testing of LPL activity should not be performed to 
confirm eligibility for the study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
21  PROTOCOL SYNOPSIS Continued 
Study Population Continued  c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the 
ISIS 304801-CS16 index study   
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this open -label study  
4. Able and willing to participate in a 65-week studyInclusion Criteria:  
Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., tubal 
occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), 
post-menopausal (defined as 12 months of spontaneous amenorrhea in 
females > 55 years of age or, in females ≤ 55 years, 12 months of 
spontaneous amenorrhea without an alternative medical cause and FSH 
levels in the postmenopausal range for the laboratory involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 
6.3.1
) from time of signing the informed consent form until [ADDRESS_38023] dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual relations with 
a female of child-bearing potential, patient is utilizing an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38024] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of  a trial and withdrawal are not acceptable 
methods of contraception  
Exclusion Criteria  for Group 1 (ISIS 304801-CS6 ) and Group 2  
(ISIS 304801-CS16 ) Index Study Roll-over Patients  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37518], or could interfere with the patient participating in or completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section 6.3) 
Exclusion Criteria for Group 3 (patients who did not participate in an index study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening  
c. Recent change in anti- diabetic pharmacotherapy (change in dosage or 
addition of new medication within 12 weeks of screening [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the treatment period of the Study (with the exception of ± 10 uni ts of insulin)  
e. Current use of GLP -1 agonists  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
22  PROTOCOL SYNOPSIS Continued 
Study Population Continued  2. Severe hypertriglyceridemia other than due to familial chylomicronemia 
syndrome  
3. Active pancreatitis within 4 weeks prior to screening Exclusion 
Criteria for Group 3 (patients who did not participate in an index study)  
Continued  
4. History within 6 months of screening of acute or unstable cardiac ischemia (myocardial infarction, acute coronary syndrome, new onset 
angina), stroke, transient ischemic attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery within 3 months 
of screening  
5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless  prior 
diagnosis and documentation of Gilbert’s syndrome in which 
case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38025]  
• AST > 2.[ADDRESS_38026]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive 
test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Platelet count < lower limit of normal ( LLN) for the central 
laboratory (i.e., < 140,000/mm
3) 
d. Cardiac Troponin I >  ULN at Screening  
e. LDL-C > 130 mg/dL at Screening  
f. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for 
inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or clinically -significant 
abnormality in coagulation parameters at Screening  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38027] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
23  PROTOCOL SYNOPSIS Continued 
 11. Malignancy within 5 years, except for basal or squamous cell 
carcinoma of the skin or carcinoma in situ  of the cervix that has been 
successfully treated  
 12. Treatment with another investigational drug, biological agent,  or device 
within 1 month of screening, or 5 half -lives of investigational agent, whichever 
is longer   
Exclusion Criteria for Group 3 (patients who did not participate in an index 
study)  Continued  
13. Unwilling to comply with lifestyle requirements ( Sectio n 6.3) 
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to screening and dose and 
regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable dose for at least [ADDRESS_38028] 4 weeks prior to screening and dose and regimen expected to remain 
constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_38029] 4 weeks prior to screening 
(Occasional or intermittent use of over -the-counter medications will be 
allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening or of > 499 mL within 60 days of scr eening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37519], or could interfer e with the patient participating in or completing the study  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
24  PROTOCOL SYNOPSIS Continued 
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 and 3 studies  (Section 2.4 ) which included a subset of patients 
with FCS .  The same dose of [ADDRESS_38030] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study) :  A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]) .  Please refer to 
Section 4.1 and Appendix A  
• Group 3 patients (did not participate in an index study) :  An up to 
8-week screening and qualification period, including a diet 
stabilization period of at least 6 weeks  (screening and diet 
stabilization period may be reduced, per Sponsor approval, if the 
patient is following a diet for optimal control of TGs and disease management prior to screening) .  Please refer to Section 6.1.2  and 
Appendix A  
• All patients:  
o A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
o Option to participate in an extended treatment period (up to an additional 52 weeks)  
o A 13-week post -treatment evaluation period or expanded 
access program  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38031] . 
Collection and measurement of  race and ethnicity,  vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events  (AE), concomitant medication/procedure 
information, lipid panel, blood viscosity, volanesorsen plasma concentrations, 
immunogenicity (IM) testing, platelet aggregation,  liver/spleen magnetic 
resonance imaging ( MRI), ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A .  Dietary counseling will be repeated at intervals throughout the 
treatment and follow -up period  and a daily food/drink  diary will be completed 
for the week prior to each quarterly visit by [CONTACT_6904] .  Follo wing the 
Week  [ADDRESS_38032] -treatment evaluation period. 
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen will be ass essed by 
[CONTACT_37798] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and other safety parameters.  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Change in blood viscosity (may be evaluated) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of volanesorsen will be performed to determine volanesorsen pharmacokinetic  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
26  PROTOCOL SYNOPSIS Continued 
 parameters.  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Akcea Therapeutics , Inc.  
Collaborator  Ionis Pharmaceuticals, Inc.  
STUDY DESIGN AND TREA TMENT SCHEMA  
 
  
SCREENING PERIOD  
Weeks -8 to -2 (Group 3 patients only)  
QUALIFICATION PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION (ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanes orsen.  Routine safety 
assessments.  PK and PD/efficacy 
assessments at specified time points  
POST -TREATMENT 
EVALUATION PERIOD  
Weeks [ADDRESS_38033] 
the option of 
participating in an 
expanded access 
program or 
continuing 
treatment  for up to 
an additional 52 
weeks until an 
expanded access 
program is 
approved and 
available in their 
country  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
27  STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP alkaline Phosphatase  
ALT alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38034]  
IXRS  Interactive Voice/Web -Response System  
LDL low-density lipoprotein  
LDL-C low-density lipoprotein -cholesterol  
LMF1  lipase maturation f actor [ADDRESS_38035] lipoprotein lipase  
MACE  major acute cardiovascular ev ent 
MOE  2ʹ-O-(2-methoxyethyl)  
MRI magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS not clinically -significant  
NOAEL  no-observed -adverse -effect level  
non-HDL-C non-high -density lipoprotein -cholesterol  
OTC over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE serious  adverse event  
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38036]  upper limit of normal  
VLDL  very -low-density lipoprotein  
VLDL -C very -low-density lipoprotein -cholesterol  
VLDL -TG lipoprotein -triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
29  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of treatment and extended treatment 
with volanesorsen  in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATI ONALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756], and risk or history of pancreatitis .  It is a rare autosomal 
recessive disease that can be diagnosed ei ther in childhood or adulthood.  
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100 -fold above normal 
(1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily 
calorie intake) ( Brunzell 1999 -2011) .  Patients with FCS often present in infancy or childhood with 
frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999 -2011; Tremblay et al. 2011 ).  Physical examinati on 
frequently reveals eruptive xanthomas, lipemia retinalis and hepatosplenomegaly, and plasma from 
patients appears lactescent, interfering with determination of other laboratory parameters (Tremblay et 
al. 2011).  
Patients with fasting triglyceride levels  > 10 mmol/L  probably have a co mponent of chylomicronemia.  
Clinical diagnosis would include  evidence of clinical features of chylomicronemia syndrome and 
secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM) , hypothyroidism, poor  
diet, alcohol use, nephrotic syndrome or use of associated medications should be ruled out .  The 
diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37521] (LPL) enzyme activity in post  heparin pl asma ( Brunzell 1999 -2011 ). 
Patients with FCS carry a heavy burden of medical complications, the  most serious , as described above,  
being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent epi[INVESTIGATOR_37455], these patients may also develop chronic pancreatitis and signs of exocrine or 
endocrine pancreatic insufficiency, including diabet es mellitus ( Gaudet et al. 2013 ).  While the 
pathophysiology underlying chylomicron -related pancreatitis has not been completely elucidated, 1 
hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37522], 
with the  subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  
High concentrations of free fatty acids are thought to damage pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009 ; Berglund et al. 2012).  
The eti ology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride 
clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG)  in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, skeletal 
muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL is regulated by a 
number of key genes, and loss -of-function mutations in one of these genes, or the LPL gene itself, results 
in FCS ( Surendran et al. 2012 ).  In addition to loss of function mutations, null mutations, and nonsense 
mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include:  apolipoprotein  C-II (APOC2) a c ofactor for LPL ( Schuster et al. 2011 ); 
apolipoprotein A -V (APOA5)  an enhancer of LPL activity  (Schaap et al. 2004 ); lipase maturation F actor 1 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
30  (LMF1), a transmembrane protein involved in LPL maturation ( Doolittle et al. 2009 ); 
glycosylphosphatidylinositol-anchored HDL -binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37495] a platform for LPL -mediated processing of chylomicrons ( Beigneux et al. 2007 ). 
2.2 T herapeutic Rationale  
Apolipoprotein C -III (ApoC-III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008 ; Figure 1 ).  ApoC-III is a major regulator 
of lipoprotein metabolism and plays a pi[INVESTIGATOR_37523] l evels (Chan  et al. 2008 ).  It is 
a component of triglyceride -rich lipoproteins (TRLs) and a potent inhibitor of LPL ( Lemieux et al. 2003) .  
At higher concentrations apoC -III also inhibits hepatic lipase activity ( Kinnunen and Ehnolm  1976 ), an 
enzyme which plays an important role in the conversion of dense very -low-density lipoprotein ( VLDL ) to 
intermediate density lipoprotein ( IDL) and to LDL ( Mendivil et al. 2010 ), as well as in the remodeling of 
HDL ( Brown et al. 2010) .  In addition, in creased apoC -III content adversely affects apoE -mediated 
hepatic uptake of TG -rich remnants ( Mann et al. 1997) .  Thus, elevated plasma apoC -III levels are 
associated with impaired hydrolysis and retarded clearance of TG- rich particles, resulting in the 
accumulation of lipoprotein -triglyceride ( VLDL -TG) and chylomicrons in plasma and the development of 
hypertriglyceridemia ( Ito et al. 1990 ). 
 
Figure 1 Ap oC-III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP-binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, CETP  = 
cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high -density lipoprotein, HL  = hepatic lipase, IDL  = 
intermediate- density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, LDL  = low-density lipoprotein, LDLr 
= LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated receptor, SR- B1 = scavenger receptor B -1, TG  = 
triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
31  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC-III is a prominent 
component of TRL (e.g., VLDL and chylomicrons) .  In addition to its role in inhibiting LPL, apoC -III inhibits 
TRL remnant (TG -depleted remnant lipopro tein) uptake by [CONTACT_37799] . 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with  gain of function mutations ( Atzmon et al. 2006 ; Pollin et 
al. 2008 ; Petersen et al. 2010 ).  A novel nonsense mutation in the apoC -III gene was identified in the 
heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower 
plasma apoC -III and TG levels and lower LDL -C, increased HDL -C and reduced atherosclerosis ( Pollin  et al. 
2008) .  In another study involving a group  of 214 Ashkenazi Jews of advanced age (had passed or nearly 
reached 100 years of age), genotype analy sis revealed a polymorphism in the apoC -III gene (APOC3 -
641CC genotype) with a clear pattern of age -dependent frequency that was associated with significantly 
lower levels of apoC -III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 
2006) .  In contrast to the Amish and Ashkenazi apoC -III polymorphisms associated with lower plasma TG, 
apoC -III polymorphisms associated with higher plasma TG have also been recently described 
(Petersen  et al. 2010 ).  In a cohort of lean (mean body mass index [BMI]  = 24.7 ± 3.6 kg/m2) Asian 
Indians, carriers of apoC -III variant alleles (C -482T, T -455C, or both) were noted to have significantly 
higher plasma apoC -III and TG levels, and decreased ability to clear postprandial plasma TG from the 
circulation .  Taken together, the available data strongly support the development of a therapy that 
reduces plasma apoC -III levels in order to reduce the very high circulating triglyceride and chylomicron 
levels that are accompanied by [CONTACT_37690].  
Given the profound reductions in TGs observed with  volanesorsen  treatment in FCS patients who have 
no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to date on apoC -III 
function, potential mechanisms that explain how apoC -III inhibition results in triglyceride reduction in 
FCS patients include:  (1) enhancing the  very small residual amounts of LPL  activity that these patients 
may have, below the limit of detection of the assay in many cases (2) potentially enhanced activity of 
other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or 
endothelial lipase  (Kinnunen and Ehnolm  1976 ), and  (3) apoC -III interact ion with  Apolipoprotein  E 
(apoE ), an important factor in liver reuptake of lipid particles by [CONTACT_37691] -mediated uptake of lipid 
particles in the liver ( Breyer et al. 1999 ), and therefore, reduc ing apoC -III might enhance apoE -mediated 
uptake of lipid particles .  Volanesorsen -mediated  reduction of apoC -III could be contributing to one or 
all of these mechanisms resulting in the observed potent and sustained reductions in TG.  
Through a novel apoC -III lowering mechanism of action, volanesorsen  may provide the potential to 
manage triglyce ride levels in FCS patients.  
2.3 Volanesorsen 
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO)  drug targeted to human apoC-III.  
It is complementary to a region within the 3 ʹ untranslated region  of the apoC-III messenger ribonucleic 
acid ( mRNA ) and binds to the mRNA by [CONTACT_37800].   The hybridization (binding) of 
volanesorsen to the cognate mRNA , results  in the RNase H 1-mediated degradation of the apoC -III 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
32  mRNA, thus preventing production o f the apoC-III protein .  Maximal a ntisense -mediated reduction of 
targe t mRNA levels is typi[INVESTIGATOR_37497] 9 0% of control levels in sensitive tissues ( Crooke  and 
Bennett 1996 ; Zhang et al. 2010) .  Furthermore, reduction in target mRNA levels using this approach 
correlates directly  with a subsequent reduction in target protein levels.  
2.3.2 Chemistry  
Chemically, volanesorsen  is a synthe
tic oligomer of 20 nucleotides (i.e., a 20 -mer) that are connected 
sequentially by [CONTACT_37693] .  The n ucleotide sequence of  volanesorsen  (Figure 2 ) is 
complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the apoC-III mRNA 
transcript at base position 489 -508.  Structurally, the oligonucleotide has 3  regions .  Two (2) of them, 
the 5 nucleot ides at the 5 ʹ end and the 5 nucleotides at the 3 ʹ end, are composed of 2 ʹ-O-(2-
methoxyethyl)  (MOE
)-modified ribonucleotides .  These MOE- modified nucleotides confer (1) increased 
affinity to the target mRNA ( Altmann  et al. 1996 ; McKay  et al. 1999), (2) increased resistance to 
exonucleases and endonucleases (thereby [CONTACT_37759])  (Geary et al. 2003 ), and (3) 
amelioration of some of the high dose toxicities thereby [CONTACT_37801] n antisense drugs containing phosphorothioate modified 
oligodeoxynucleotides (DNA) ( Henry et al. 2000 ).  The third region, the central portion of the 
oligo nucleotide, is composed of 10 oligodeoxynucleotides .  This chimeric design is called a MOE -
Gapmer, and volanesorsen  employs  this chimeric structure to enable use of the RNase H 1-mechanism 
for antisense activity .  This is because while the 2 ʹ-MOE modification confers increased stability and  
affinity, it does not support RNase H 1 catalysis of RNA hybridized to 2 ʹ-MOE -modified nucleotides 
(McKay  et al. 1999 ).  This is caused by [CONTACT_37802] 2 ʹ-
alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H1 enzymes ( Inoue  et al. 1987 ; Monia  et al. 1993 ).  
By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the phosphorothioate oligodeoxynucleotide 
core, the beneficial attributes of the 2 ʹ-MOE chemistry are preserved while also retaining RNase H 1 
recognition.  
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphor
othioate  Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen is shown  
 
2.3.3 Preclinical Experience  
Inhibition of apoC -III using volanesorsen  has been shown to potently reduce hepatic apoC -III mRNA as 
well as plasma apoC -III protein and TG in a dose - and time -dependent fashion in several species, 
2ʹ-MOE  
 2ʹ-Deoxy  
 2ʹ-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
 C  T   
T 
G   
T 
C   
C 
A 
G   
C 
 T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
33  including human apoC -III transgenic mice, and other rodent and monkey models .  Treatment with 
volanesorsen  also resulted in reduced VLDL and chylomicron TG and reduced postprandial TG in 
hypertriglyceridemic monk eys (Graham et al. 2013 ). 
The pharmacokinetics (PK) and toxicity of volanesorsen  have been assessed in mice, rats, and 
cynomolgus monkeys .  General toxicity studies with volanesorsen  for up to 39 weeks of treatment 
followed by [CONTACT_8622] a 20 -week recovery period are complete.  The preclinical toxicology program for 
volanesorsen  consists of single dose safety pharmacology studies in the monkey (cardiovascular) and 
mouse (neurobehavioral and pulmonary assessment studies), in vitro  and in vivo  genetic toxicity 
assessment, repeat dose fertility and/or developmental reproductive toxicology studies in the mouse 
and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatm
ent-related findings in mice and monkeys were generally consistent with those 
expected for the 2 ʹ-MOE- class of ASOs .  Tr
eatment- related findings included effects consistent with drug 
accumulation in tissues in rodents and monkeys, s pecies -dependent proinflammatory response in 
rodents and monkeys and complement activation and reductions in platelet counts in the monkey .  In 
the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not 
associated wit h any findings that could be considered related to the pharmacologic inhibition of apoC -III 
for up to [ADDRESS_38037] effects in safety pharmacology studies ( in vitro  and in vivo) and was 
non-genotoxic ( in vitro and in vivo) .  Volanesorsen  had no effects on fe rtility or embryo/fetal 
development in the mouse or rabbit reproductive toxicity studies .  In these studies, volanesorsen  was 
detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC -III mRNA (64% in males and 47% in females) also did not 
affect fertility or cause untoward effects on emb ryo/fetal development in mice.  
Detailed information concerning the preclinical studies conducted with volanesorsen  can be found in the 
volanesorsen  Investigator’s Brochure.  
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen  can be found  in the 
volanesorsen  Investigator’s Brochure .  A summary is included below.  
The clinical experience with volanesorsen includes clinical trials in healthy subjects, patients with 
hypertriglyceridemia, FCS, or familial partial lipodystrophy. Overall, [ADDRESS_38038] 1 dose of 
volanesorsen. Ninety -five (95) patients with FCS have been enrolled in studies, all showing clinically 
meaningful reductions in plasma triglyceride. Patients with FCS continue on treatment in the open -label 
extension (OLE) and triglyceride reductions persist at similar levels as reported in earlier studies.  
In the completed Phase [ADDRESS_38039] on the renal (serum creatinine, proteinuria) 
or hepatic systems (alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin). There 
was a reduction (mean reduction < 30%) in platelets  in volanesorsen vs. placebo with mean nadirs for all 
doses remaining above the lower limit of normal (LLN). The most frequently reported adverse events 
(AEs) were mild, non -progressive events at the injection site. In Phase 2, a single serious adverse event 
(SAE) of secondary serum sickness -like reaction was reported as related to Study Drug.  All clinical trials 
of volanesorsen  have shown large and clinically meaningful reductions in fasting plasma apoC -III and TG 
(~80% and 70% , respectively,  mean reduction from baseline with 300 mg dose) with a very high degree 
of consistency of response between the different patient groups .  This includes healthy volunteers, 
patients with moderate to severe hypertriglyceridemia not on background TG -lowering therapy, 
patie nts with moderate to severe hypertriglyceridemia on a background stable fibrate therapy  (Gaudet  
et al. 2015) , patients with FCS, and patients with T2DM.  
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen in an open -label 
fashion .  These patients had a mean baseline fasting TG level of 1,844 mg/dL and all 3 patients achieved 
TG levels below or close to 500 mg/dL during the treatment  period out to D ay 92 (Figure 3 ).  Two (2) of 
the FCS patients had an absolute reduction in fasting TG in excess of 1,500  mg/dL  (Gaudet  et al. 2014 ). 
 
Figure 3 Fasting Triglycerides in Patients with FCS Treated with Volanesorsen 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
35   
In the completed pooled Phase 3 studies (ISIS 304801 -CS6 (hereafter  referred to as  CS6) and ISIS 
304801- CS16 (hereafter  referred to as  CS16), the most common AEs associated with volaneso rsen 
administration were tolerability at the injection site and platelet reductions. The majority of the  
injection site AEs were mild, none were severe, and the incidence appeared to decrease over time. No 
deaths have been associated with volanesorsen treatment to date. No cardiac toxicity was associated 
with volanesorsen treatment. There were no abnormal QTc findings and no study -drug related 
adjudicated major adverse cardiac events (MACE). There is no evident association between 
volanesorsen treatment and  changes in renal or liver functions.  
The safety profile of volanesorsen has been well- described in this development program, which has 
identified 3 safety risks: thrombocytopenia (an identified risk), constitutional symptoms (flu -like 
reactions and influe nza-like illness), and injection site reactions (a tolerability signal). Spontaneous, 
mild -to-severe thrombocytopenia has been described in the FCS patient population ( Gaudet et al. 2017 ) 
but is increased by [CONTACT_37676]. Less frequent and l ess pronounced platelet declines 
were also observed with volanesorsen treatment in the hypertriglyceridemic (HTG) population of CS16. When fully complied with, frequent monitoring for this effect and appropriate dose adjustments have been successful both in preventing and promptly detecting the occurrence of severe platelet declines 
and often in retaining patients on treatment.  
2.4 Rationale for Dose and Schedule of Administration  
The dose and schedule selected for this study is 300 mg per week for 52 weeks .  The dose of 300  mg per 
week and dose reduction to 300 mg every 2 weeks ( delivered as either a single 300 mg dose or as 
150 mg once -weekly , respectively ) are supported by [CONTACT_37803] [ADDRESS_38040] Level ( NOAEL ) was 
defined by [CONTACT_37804].  Nonclinical findings were not considered to be related to the pharmacologic inhibition 
of apoC -III. 
The safety data to date suggest that volanesorsen  has been well-tolerated  at dose levels up to 300  mg in 
patients with high triglycerides (including type 2 diabetes patients and administration  in combination 
with fibrates and statins) with the most common AEs being local to the injection site and predominantly 
mild .  A pooled analysis of safety for the  Phase 2  studies did not demonstrate any clear dif ference in 
safety or tolerability between the different doses  tested (100  mg, 200 mg, and 300 mg per week for 13 
weeks). 
Analysis of the cohorts in which volanesorsen  was studied at different doses demonstrates 
dose -dependent pharmacology with respect to p harmac odynamic (PD) effect on the target, apoC -III, 
with a clear difference in the TG -lowering effect between the different doses in the [ADDRESS_38041] been administered intravenously and subcutaneously in multiple clinical 
studies at doses up to 1200 mg and for treatment durations that exceed 24  months  (Santos et al. 2015 ). 
3. EXPERIMENTAL PLAN  
3.1 Study Design  
This is an open -label study of:  
Group 1:  ISI S 304801- CS6 (index study) roll -over  FCS patients  
Group 2:  ISIS 304801- CS16 (index study) roll-over  FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801- CS6 or  
ISIS 304801- CS16 index studies  
Up to a pproximately [ADDRESS_38042] of the following periods:  
3.4.1  Group 1 and 2 Patients (participated in ISIS  304801- CS6 or ISIS 304801 –CS16 index study):  
Qualification  
A period of up to 2 weeks  (unle ss approved by [CONTACT_1034]) is given to complete qualification 
assessments outlined in the Schedule of Procedures .  Please refer to Section 4.1  and Appendix A . 
3.4.2  Group 3 P atients (did not participate in an index study):  Screening/Qualification  
An up to [ADDRESS_38043] 6 
weeks  (screening and diet stabilization period may be reduced, per Sponsor app roval, if the patient  is 
following a diet for optimal control of TGs and disease management prior to screening .  Please refer to 
Section 6 .1.2 and Appendix A . 
3.4.3 Treatment  
The treatment period is 52  weeks .  Eligible patients  will report to the Study Center  for assessments at 
specified  intervals throughout the 52-week treatment period  as detailed in the Schedule o f Procedures 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
37  (Appendix A ).  During the treatment period, volanesorsen  is administered by  [CONTACT_37805].treatmenttreatment 
3.4.[ADDRESS_38044] ing of 7 Study Cen ter visits on Weeks  53, 54, 55, 56, 57, 58 , and 65 
(Weeks  53, 54, 55, 56, 57, and 58 may be conducted by a home healthcare nurse) . Patients who 
complete, or terminate early from, the extended treatment period without subsequently participating in 
an expanded access program will enter a [ADDRESS_38045]- treatment evaluation period consis ting of 7 
Study Center visits on Weeks 105, 106, 107, 108, 109, and 110 (which may be conducted by a home 
healthcare nurse), and Week 117 (Appendix A ). 
3.[ADDRESS_38046] (DSMB) will review (as needed)  safety, tolerability 
and efficacy data collected on volanesorsen  during this stu dy.  Based on its ongoing assessment of the 
safety and tolerability of volanesorsen , the DSMB will provide recommendations to the Sponsor for 
modifying, stoppi[INVESTIGATOR_10483] .  Details on the safety assessments, frequency of 
review and meeting schedules are outlined in the DSMB Charter and /or the statistical analysis plan 
(SAP). 
4. PATIENT  ENROL LMENT  
4.1 Screening/ Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the protocol, 
informed consent form,  and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study -specific 
procedures or evaluations  related to this open -label study are performed .   
Groups 1 and 2 (Qualification):  During the qualification period,  the eligibility of the patient  to enroll  in 
the open -label study will be determined .  Final assessments from the ISIS 304801 -CS6 or ISIS 304801-
CS16 stud ies may be used for qualification .  A period  of up  to 2 weeks  after completion of the ISIS 
304801- CS6 or  ISIS 304801- CS16  index studies (unless approved by [CONTACT_16049]) is given to complete 
qualification.  Qualified patients will retain the unique  patient  identification number that was assigned 
to them  during the ISIS [ADDRESS_38047] remain constant 
throughout the extension trial. 
Group 3 (Screening and Qualification):  At the time of consent, the patient  will be considered enrolled 
into the study and will be assigned a unique screening number before any study procedures, including 
ISIS [ADDRESS_38048] be given a new screening number.  Screening numbers and 
patient  identification numbers, once  assigned, will not be re -used.  
4.2 Enrollment  
Patient s will be enroll ed into the treat ment phase of the study after all Screeni ng (Group3) and 
qualification assessments have been completed and after the Investigator has verified that they are 
eligible per criteria in Sections 5.1 and 5.2.  No p
atient may be gin treatment prior to enrollment . 
Eligible patients will b
e enrolled u sing an Interactive Vo ice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria within [ADDRESS_38049] give written in formed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801 -CS6 or ISIS 304801- CS16 (index studies)  
with an acceptable safety profile, per Sponsor and Investigator judgement . 
Groups 2 and 3:   Patients must also meet the following criteria in order to enter  into the open -
label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10  mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) 
supported by [CONTACT_37685] 1 of the following:  
• Confirmed homozygote, compound heterozygote or double heterozygote for known 
loss-of-function mutations in Type 1 -causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or 
LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal in medical history .  Note: testing of 
LPL activity should not be performed to confirm eligibility for the study  
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  
 ISIS 304801- CS16 index study  
Group 3:  F asting TG ≥ 750 mg/dL  at Screening for this open -label study  
4. Able and willing to participate in a 65 -week study  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
39  5. Satisfy 1 of the following:  
a. Females:  Non -pregnant and non -lactating; surgically sterile (e.g., t ubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post -menopausal (defined 
as 12 months of spontaneous amenorrhea in females >  55 years of age or, in females ≤ 55 
years, 12 months of spontaneous amenorrhea without an alternati ve medical cause and FSH 
levels in the postmenopausal range for the laboratory involved), abstinent *, or if engaged in 
sexual relations of child- bearing potential, patient is using an acceptable contraceptive 
method (refer to Section 6.3.1 ) from time of si gning the informed consent form until [ADDRESS_38050] dos e of Study Drug administration.  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual relations with a female of child -
bearing potential, patient is utilizing an acceptable contraceptive method (refer to Section 
6.3.1 ) from the time of signing the informed consent form until [ADDRESS_38051] dose 
of Study Dru g administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred 
and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, 
post -ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are 
not acceptable methods of contraception  
5.2 Exclusion Criteria  for Group 1 (ISIS 304801- CS6) and Group 2 (ISIS  304801 -CS16) I ndex Study 
Roll-over Patients  
1. Have any new condition or worsening of e xisting condition which in the opi[INVESTIGATOR_37524], or could interfere with the patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration o f the study ( Section  6.3). 
Exclusion Criteria for Group 3 (patients who did not participate in an index study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of screening [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the  treatment period of the 
Study ( with the exception of ± 10 units of insulin ) 
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
40  4. History within 6 months of s creening of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or 
unstable congestive cardiac failure requiring a change in medication or major surgery within 3 
months of  screening 
5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be  
≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38052]  
• AST > 2.[ADDRESS_38053]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for protein on urine dipstick.  In 
the event of a positive test eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace positive) for blood on urine 
dipstick.  In the event of a positive test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or CKD -EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after discussion with Sponsor 
Medical Monitor)  
c. Platelet count < LLN for the central laboratory (i.e., < 140,000/mm
3) 
d. Cardiac Troponin I >  ULN at Screening  
e. LDL-C > 130 mg/dL at Screening  
f. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], 
would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or clinically -significant abnormality in coagulation 
parameters at Screening  
8. History of heart failure with NYHA greater than Clas s II 
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38054] for human immunodeficiency virus (HIV), hepatitis C or chronic 
hepatitis B  
11. Malignancy w ithin 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma 
in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1 -month of 
screening, or 5 half-lives of investigational agent, whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3 ) 
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable dose for at 
least  3 months prior to screening and dose and regimen expected to remain constant during 
the treatment period.  Patients taking OTC omega -3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening unless 
approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unle ss on a stable dose 
for at least [ADDRESS_38055] 4  weeks prior to screening 
and dose and regimen expected to remain constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a 
stable dose for at least [ADDRESS_38056] 4 weeks prior to screening (Occasional or intermittent use of over -the-counter medications will be allowed at Investigator’s 
discretion ) 
15. Blood donation of 50 to 499 mL within 30 days of screening or of >  499 mL within 60  days of 
screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS  304801 or placebo)  
ISIS [ADDRESS_38057] any other conditions, which, in the opi[INVESTIGATOR_37525], or could interfere with the patient participating in or 
completing the study  
6. STUDY PROCEDURES  
6.1 Study Schedule 
All required study procedures are outlined in Appendices  A, B, C, and D. 
6.1.1  Qualification  (Groups 1 and 2)  
Please refer to Section 4.1  and Appendix A . 
6.1.2  Screening and Qualification  (Group 3)  
Before any study -specific procedures or evaluations are initiated, patients must sign and date the 
informed consent form.  An [ADDRESS_38058] 6  weeks 
(screening and diet stabilization period may be reduced, per Sponsor approval, if the patient  is following 
a diet for optimal control of TGs and disease management prior to screening ) is given to perform the 
screening evaluations.  The qualification  assessments will be performed at Week -[ADDRESS_38059] patient’s Week [ADDRESS_38060].  
During the treatment period , patients will report to the study center for clinic visits a minimum of 5 
times during Weeks 1 -52 (see Schedule of Procedures in Appendix A ).  Study Drug will be administered 
once weekly  unless the patient is on a biweekly treatment  schedule for safety reasons (Section  8.1).  
Collection and measurement of race and ethnicity, vital signs, clinical laboratory parameters (including 
hematology, serum chemistry, and urinalysis), AEs, concomitant medication/procedure information, 
lipid panel, blood viscosity, volanesorsen  plasma concentrations,  immunogenicity  (IM)  testing , platelet 
aggregation, liver/spleen MRI, ECGs, echocardiograms and quality of life assessments  will b e performed 
according to the schedule of procedures in Appendix A .  Adverse events at the injection site should be 
collected as AEs.  Dietary counseling will be re inforc ed at intervals throughout the treatment and follow -
up period  and all patients will complete a daily food diary  for one week prior to their quarterly visit .  All 
blood and urine samples should be collected  prior to volanesorsen  administration .  Blood sampling at 
Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, [ADDRESS_38061] the option of continuing treatment for up to an additional 52 weeks until an  expanded 
access program  is approved and available in their country.  
During the extended treatment period, patients will report to the study center for clinic visits during 
Weeks 54 -104 (see Schedule of Procedures in Appendix A).  Study Drug will be administered once 
weekly  unless the patient is on a biweekly treatment schedule for safety reas ons (Section 8.1 ).  
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum 
chemistry, and urinalysis), AEs, concomitant medication/procedure information, lipid panel, 
volanesorsen plasma concentrations, IM te sting, ECGs, and physical examinations will be performed 
according to the S chedule of Procedures in Appendix A .  Adverse events at the injection site should be 
collected as adverse events.  Dietary counseling will be reinforced at intervals throughout the extended 
treatment period.  All blood and urine samples should be collected prior to volanesorsen administration.  Blood sampling at Weeks 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65,  66, 67, 68, 69, 70, 71, 72, 73, 74, 
75, 77, 78, 79, 80, 81, 82, 83, [ADDRESS_38062] be fasted prior to drawing all blood samples and samples drawn locally should also  be 
sent to the central laboratory for analysis  whenever possible .  Treatment instructions and training will 
be provided to the patient where applicable.  
6.1.5 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection .  Patients in this subgroup will have 
more frequent PK sampling over a [ADDRESS_38063] -dose blood draw 
after treatment  on Day 1.  The detailed PK sampling schedules are outlined in Appendix C . 
Participation in the PK subgroup  is optional  for sites and patients,  and consent may be withdrawn for 
the subgroup -specific procedures (e.g. , multiple blood draws for PK) without being withdrawn from the 
study .  If a patient withdraws consent from the subgroup procedures, he/she should remain on study 
and continue to follow all the non -subgroup assessments and procedures as outlined in Appendix A.  
6.1.[ADDRESS_38064]- treatment e valuation period c onsists of 7 Study C enter visits o n Weeks 53, 54, 55, 56, 
57, and 58 (which may be conducted by a home healthcare nurse), and Week [ADDRESS_38065]- treatment evaluation period consisting of 7 Study Center visits on Weeks 105, 106, 107, 108, 
109, and 110 (which may be conducted by a home healthcare nurse), and Week [ADDRESS_38066] of these analytes  is contained 
in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample 
should be collected in parallel and analyzed locally.  In the event that both the central and local sample 
are unreportable (e.g., due to hemolyzed or clumped blood samples ) another sample must be repeated 
within [ADDRESS_38067] be reviewed by [CONTACT_37806].  All platelet count results will be promptly reviewed by [CONTACT_37807] a stoppi[INVESTIGATOR_1877] , or the dose reduction rule of 100 ,000/mm3, or the 
dose pause rule of 75,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor.  
Should a patient exper ience constitutional or flu- like symptoms after Study Drug administration, 
investigators may  consider additional laboratory assessments.  For example, plasma and serum samples 
may be drawn for complement (Total C3, C4, C5a and Bb), hsCRP  and for cytokine analysis.  
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures (Appendix 
A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37526] .  
Blood pressure and pulse rate will be recorded after the patient has been in a sitting position for at least 
5 minutes .  Semi -supi[INVESTIGATOR_37527] (preferentially on the left arm) .  Height will be measured at  the Day 1  visit. 
[IP_ADDRESS]  Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events  will be recorded.  Physical exams should also 
include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be taken, if possible.  
[IP_ADDRESS]  Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37701] (for ISIS 304801- CS16 roll-over  patients) and repeated at Week 52.   Images will be 
evaluated by [CONTACT_37808], blinded to the patient’s treatment assignment.  
ISIS [ADDRESS_38068] ECGs performed in triplicate at Week 76 and W eek 104.  
6.2.5  MRI  
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants . 
MRIs will be conducted using standardized procedures and settings .  MRIs will be read by  [CONTACT_37767] . 
6.2.6 Quality of Life Assessments 
All patients will complete Quality of Life Questionnaires (EQ-5D and SF -36) at Week 1, Week  13, 
Week 26, Week 52, and Week [ADDRESS_38069] -treatment follow -up period  (Week 65) . 
6.2.8  Diet Monitoring  
The diets of patien ts enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, Week 26, 
Week 52 , and Week 65.  
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to 
provide diet/alcohol counseling for visits that are conducted by a clinical service.   Patients in the 
Extended Treatment Period will receive diet/alcohol counseling by [CONTACT_37809].  
3. In addition to the 7 -day food diary and the diet /alcohol counseling during clinic visits, telephone 
calls from a dietitian or qualified study personnel to assess as to how each patient is maintaining 
their diet may  be conducted randomly during the treatment and post treatment follow -up 
periods.  
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
46  6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2 and 3)  
Patient records will be reviewed for incidents of acute pancreatitis occurring up to [ADDRESS_38070] refrain from sperm/egg donation and either 
be abstinent† or, if engaged in sexual relations of child -bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_38071]’s last dose of study treatment.  
For the purpo ses of this Study , women of childbearing potential are defined as any female who has 
experienced menarche , and who does not meet 1 of the following conditions:  
• Postmenopausal:  12  months of spontaneous amenorrhea in females >  55 years of age or, in 
females ≤  55 years, 12  months of spontaneous amenorrhea without an alternative medical 
cause  and FSH levels in the postmenopausal range for the laboratory involved  
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy  
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows:  
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen  analysis at follow -up, or 
the use of condoms together with spermicidal foam/gel/film/  cream/suppository .  Male patients 
must also encourage their female partner to use effective contrac eption from the time of 
signing the informed consent until  3 months after the patien t’s last dose of study treatment.  
Effective contraceptive for the female partner includes: surgical sterilization (e.g., bilateral tubal 
ligation), hormonal contraception, intrauterine contraception/device, or barrier methods 
(female condom *, diaphragm, sponge, cervical cap) together with spermicidal 
foam/gel/film/cream/suppository .  Male patien ts with partners that are pregnant must use 
condoms to ensure that the fetus is not exposed to the Study Drug. 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical sterilization 
(e.g., bilateral tubal ligation), hormonal contraception , intrauterine contraception/device, or any 
2 barrier methods (a combination of male or female condom * with  diaphragm , sponge, or 
cervical cap)  together with spermicidal foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
47  † Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual 
lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the d uration of a trial and withdrawal are not acceptable 
methods of contraception  
6.3.[ADDRESS_38072] 10 hours and preferably not more than 12 hours  before 
visits requiring  fasted blood sampling.  
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38073] will explain that the patient is in a clinical trial and that 
serum lipase and/or amylase measures should be done in order  to adjudicate the event, based on 
Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 3  x upper limit of 
normal ( ULN) , imaging, preferably contrast -enhanced computed tomography, should be considered  to 
confirm the diagnosis  of acute pancreatitis per the Atlanta Criteria. 
7. STUDY DRUG
7.[ADDRESS_38074] (ISIS 304801) characteristics are li sted in Table 1. 
Volanesorsen (ISIS  304801) is c ontained in g lass p refilled s yringes ( PFS) or in g lass vials .  Volanesorsen 
and it s storage and p reparation in structions w ill be p rovided b y the S ponso r or designee .  Volanesorsen 
must be stored securely a t 2 to 8°C a nd b e protected f rom l ight. 
Table 1 Volanesor
sen (ISIS  304801)  Characteristics  
Study Drug  ISIS 304801 Prefilled Syringe  ISIS 304801 Vial  
Strength  300 mg  200 mg  
Volume / Formulation  1.5 mL  
200 mg/mL ISIS 304801  1.0 mL  
200 mg/mL ISIS 304801  
Dose  300 mg / 1.5 mL 150 mg / 0.75 mL  
Route of Administration Subcutaneous injection Subcutaneous injection 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801 ) in 
accordance with specific country regulatory requirements.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
48  7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return /destruction of volanesorsen  
provided by [CONTACT_1034] .  The S tudy Center  must return all u nused volanesorsen  to the Sponsor  or 
designee .  All used syringes or vials must be disposed of as per the site’s hazardous waste destruction 
policy.  
8. T REATMENT OF PATIENT S 
8.1 Volanesorsen Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 300 mg 
injection once weekly for Weeks 1 -52, and patients will continue to receive S tudy Drug as a single 
300 mg/1.5 mL injection once -weekly for Weeks  53-104 of the study . Patients entering this ISIS 304801 -
CS7 study on a reduced dose or dose frequency of Study Drug ( volanesorsen ), for safety or tolerability 
reasons in  their index study (ISIS 304801 -CS6 or ISIS 304801 -CS16) , will receive  a reduced dose or dose 
frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.5  and 8.6.  
Patients on dose reduction will receive either 300  mg/1.5 mL injections every 2 weeks or 150 mg/0.75 
mL injections once -weekly.  Treatment with  a 150 mg dose during the study will use the glass vials 
containing 200  mg/mL of volanesorsen.    
Patients should receive [ADDRESS_38075] 2  days apart.  
Please refer to the Study Drug Manual  provided by [CONTACT_37705].  
8.2 Other Protocol -Required Drugs  
There are no other protocol -required drugs.  
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treat ment procedures for this study.  
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study.  
8.5 Safety Monitoring Rules  
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure . 
For the purposes of safety monitoring, baseline is defined as  the average of Day [ADDRESS_38076] measurement prior to Day 1  (e.g., qualification assess ments or assessments from  the final 
visits of ISIS 304801- CS6 and ISIS 304801- CS16  index studies if used for qualification) . 
ISIS [ADDRESS_38077] monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of s elected parameters chosen based on preclin ical and clinical 
observations.  
Confirmation Guidance :  At any time during the study (Treatment or Post-Tr eatment P eriods), the initial 
clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37463] (ideally in the same laboratory that performed the initial 
measurement) on new specimens .  All new specimen collections should take place as soon as possible 
(ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], i f the initial laboratory result is 
observed during the Treatment Period, the results from the retest must be available p rior to 
administering the next dose of volanesorsen . 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of 
additional lab values.  
Re-treatment Guidance :  Patien ts with initial laboratory test values that reac h a stoppi[INVESTIGATOR_37528] -dosed until the re -test results are available .  In general, patien ts who do not meet the stoppi[INVESTIGATOR_37529] -test may continue treatment .  However, the Investigator and the Sponsor Medical 
Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of 
the patien t is appropriate .  Reduction in dose or dose frequency may also be initiated as noted in 
Section 8.7 .  If any of the stoppi[INVESTIGATOR_37466] (refer to Sections 8.6.1  to 8.6.3 ) are met, the 
patien t will be dose paused or permanently discontinued (as described in the stoppi[INVESTIGATOR_37530]) from further treatment with volanesorsen , and evaluated fully as outlined below and in 
consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed 
up in accordance with Section 8.8  of the protocol.  
8.5.1  Safety Monitoring for Liver Chemistry Tests  
The f ollowing rules are adapted from the draft guidance for industry, “Drug -Induced Liver Injury: 
Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S . Department of Health and Human Services, Food 
and Drug Administration, July [ADDRESS_38078] measurement that is > [ADDRESS_38079]  (or the greater of [ADDRESS_38080] if the baseline value  was >  ULN)  at any time during the study ( Treatment or Post -Treatment Period ), 
the initial measurement(s) should be confirmed as described above .  Additional  confirmatory 
measurements should also be performed if ALT or AST levels increase to [ADDRESS_38081] . 
Frequency of Repeat Measurements :  Patien ts wit h confirmed A LT or AST levels >  [ADDRESS_38082] (or the 
greater of [ADDRESS_38083] if the baseline value  was >  ULN)  should have their liver chemistry 
tests (ALT, AST, alkaline phosphatase ( ALP), international normalized ratio ( INR) and total bi lirubin) 
retested at least once- weekly until ALT and AST levels become ≤ 1.[ADDRESS_38084] or 1.2 x  baseline value  if the 
baseline value  was >  ULN. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
50  Further Investigation into Liver Chemistry Elevations :  For patien ts wit h confirmed ALT or AST levels >  [ADDRESS_38085] ( or the great er of [ADDRESS_38086] if the baseline value  was >  ULN), the following 
evaluations should be performed:  
1.Obtain a more detailed history of symptoms and prior and concurrent diseases
2.Obtain further history for concomitant drug use (includi ng nonprescription medications, herbal
and dietary suppleme nt preparations), alcohol use, recreational drug use, and special diets
3.Obtain a history for exposure to environmental chemical agents and travel
4.Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV antibody panel)
5.Serology for autoimmune hepatit is (e.g., antinuclear antibody [ANA] )
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or MRI 
scans, may be performed at th e discretion of the Investigator, in consultation with the Sponsor Medical 
Monitor .  Repetition of the above evaluations should be considered if a patient’s ALT and/o r AST levels 
reach [ADDRESS_38087] be documented in the 
patient’s medical record s. 
Due to the [ADDRESS_38088] with the study patients.  However, if the above options are not possible, a 
tempora ry interruption of study treatment will be planned with a platelet count drawn within 3 -5 days 
prior to departure and a prompt blood draw upon the patient’s return which must be reported and 
reviewed by [CONTACT_37810]. 
Patients on dose pause should be monitored as per the platelet monitoring rules outlined in Section  8.8.1 until Study Drug administration is resumed.  
The tests outlin ed in  Table 2 should also be performed as soon as possible.   Additional lab tests will be 
determined by [CONTACT_37769].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
51  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor 
(See also Stoppi[INVESTIGATOR_37468] 8.6.3).   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
52  Table 2 Labs to Be Performed in the Event of a Platelet C ount Less than the Lower Limit of 
Normal (x2) or < 100,000/mm3 (x1)*  
*In patients who have any 2 occurrences  (consecutive or non -consecutive)  of platelet count less than
the lower limit of normal or who have any 1 occurrence of platelets <  100,000/mm3.  Labs only need to
be performed once.  Labs may be collected over  multiple visits, if blood requirements are a concern, as
per Investigator discretion .
Note:  The following labs may change as additional data is assessed, and sites will be updated regarding
any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti-PF4 assay  
Anti-ASO antibody  
8.5.3 Safety Monitoring for Minor Bleeding Events  
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -relevant , 
non-major bleeding events (which are defined in Section 8.6.3), for example excess bruising, petechiae, 
ISIS [ADDRESS_38089] notify the 
Sponsor Medical Monitor and additional testing of coagulation parameters activated partial 
thromboplastin time (aPTT ), prothrombin time ( PT), INR  and platelet count should be performed.  
8.5.4  Safety Monitoring for Constitutional Symptoms  
Patients will be instructed to promptly report any signs of symptoms of fever or constitutional  
symptoms that may arise during the study and the Investigator should closely evaluate all potential causes, includ ing concomitant illness .  Patients that experience persistent constitutional symptoms , 
should be discussed with the Sponsor Medical Monitor or designee to determine whether additional monitoring or laboratory tests are required.  
Should a patien t experience constitutional or flu -like symptoms after Study Drug administration, 
investigators may  consider additional laboratory assessments.  For example, plasma and serum samples 
may be drawn for complement (Total C3, C4, C5a and Bb), hsCRP , and for cytokine analy sis. 
8.5.[ADDRESS_38090] to notify the Investigator if a patient has a low-
density lipoprotein -cholesterol ( LDL-C) > 160 mg/dL (>  130 mg/dL for patients with T2DM) on 2 
conse cutive visits .  If this occurs, LDL -C value s for this patient will be unblinded for the remainder of the 
study and the Investigator will be encouraged to initiate/adjust treatment to lower LDL -C according to 
country -specific guidelines (e.g., initiate statin therapy or increase the statin dose for patients  who are 
already on treatment).  
8.5.[ADDRESS_38091] practice 
guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In addition, 
patients who are not on insulin but use a glucometer should also bring their  glucometer and/or 
glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic visit to 
evaluate if fasting  pre-breakfast self-monitored plasma glucose values exceed threshold values 
as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose  and /or oral antidiabetic  therapy, as well 
as any hypo glycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in their 
insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic epi[INVESTIGATOR_1865].  
o Patients will be instructed on the monitoring and management of hypoglycemic epi[INVESTIGATOR_37470].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37531]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37532] ≤  70 mg/dL (≤ 3.9 
mmol/L ). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
54  o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF.  
8.5.7  Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient requires assistance of 
another person to obtain treatment for the event and has a plasma glucose level ≤ 70 mg/dL (≤ 3.9 
mmol/L).   The rescue treatment of hypoglycemia may include IV glucose or  buccal or intramuscular 
glucagon.  
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473] -treatment and which were thus thought to place 
patients at risk for injury to them selves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the patient 
when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE only if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take immediate 
action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypo glycemia may vary greatly from patient to patient.  However, there are certain 
classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or 
tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could occur if blood sugar correction is not 
performed.  
If patients suspec t they might be having a hypoglycemia reaction, they should check their blood glucose 
using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.   
If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and 
nature of treatment should be noted, and especially if any blood glucose result was before or after treatment.  It would be helpful for the patient to note if a contributory factor (e.g., missed or reduced 
meals, unaccustomed physical activity) occurred earlier in the day of the event.  
8.5.[ADDRESS_38092] dose titration and/or addition of any other anti-hyperglycemic agent(s) will not be allowed 
during the course of the study, unless specific threshold values are met at Week 13 or later and confirmed on subsequent testing (ideally within [ADDRESS_38093]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should self -
monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  If a fasting 
pre-breakfast SMPG value exceeds the specific glycemic limit, the patie nt should check it again on the 
following [ADDRESS_38094] the Investigator and an unscheduled central laboratory FPG measurement and HbA1c should b e performed.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
55  The threshold values are defined as:  
• FPG >  270 mg/dL (15.0 mmol/L)  
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 1% from 
baseline (for patients with baseline HbA1c ≥ 8 and < 9%)  
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no 
reasonable explanation exists for insufficient glucose control and in particular that:  
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38095]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measures for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate  
If any of the above can reasonably explain the insufficient glycemic control, the Investigator should 
consider the following:  
• Investigation and treatment of intercurrent disease (to be reported in adverse event (AE)/concomitant  medication parts of the e-CRF)  
• Stress on the absolute need to be compliant to treatment  
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to die t and lifestyle recommendations  
An FPG/HbA1c follow -up assessment should be arranged after appropriate action has been taken.  If 
none from the above -mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor.  
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], treatment  with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued treatment 
and the need for any modification to treatment schedule (refer to Section 8.7 ) will be determined by [CONTACT_37707]. 
8.[ADDRESS_38096] measurement prior to Day 1.  
8.6.1  Stoppi[INVESTIGATOR_10453], and the event is without an alternative 
explanation as discussed w ith the Sponsor Medical Monitor,  treatment  of a patient  with volanesorsen  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
56  will be stopped permanently ; values that are not confirmed due to failure to retest or missing lab values 
will be presumed confirmed: 
1. ALT or AST >  [ADDRESS_38097] >  [ADDRESS_38098] , which is confirmed and persists for ≥  [ADDRESS_38099] >  [ADDRESS_38100] (or the greater of [ADDRESS_38101] if the baseline value was >  
ULN) , which is confirmed and total bilirubin >  [ADDRESS_38102]  or INR  > 1.[ADDRESS_38103] >  [ADDRESS_38104] (or the greater of [ADDRESS_38105] if the baseline value was >  
ULN), which is confirmed, and the new  appearance (i.e., onset coinci des with the changes in 
hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, 
rash, or eosinophi lia (>  ULN) felt by [CONTACT_37708]  
8.6.[ADDRESS_38106] Results 
In the event of a persistent elevation that is observed over 2 consec utive weeks, for any of the 3 criteria 
below, treatment  of a patient with volanesorsen  may be stopped  temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria :  ≥ 0.3 mg/dL (26.5 μmol/L) and 
≥ 40% above baseline creatinine values and > ULN 
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24 -hour)  
3. Estimated creatinine clearance calculated accordin g to the formula of Cockcroft and Gault ≤ 40 
mL/min that is confirmed by a 24 -hour urine collection  
The possible treatment  re-initiation or follow -up schedule for any events meeting either of these criteria 
will be determined by [CONTACT_37811] . 
8.6.3  Stoppi[INVESTIGATOR_10020] s for Platelet Count Results  
Actions to be taken in the event of a low platelet count are summarized in  Table 3  below.  
In the event of a platelet count less than 75,000/mm3 that is associated with major bleeding or clinically -
relevant  non-major bleeding (defined below; Schulman et al. 2005 ), treatment  of a patien t with 
volanesorsen  will be stopped permanently .  The follow -up schedule for any events meeting this stoppi[INVESTIGATOR_37533].   
In the event of any platelet count less than 50,000/mm3, or a platelet count less than 75,000/mm3 that 
occurs while the patient is treated  at 300 mg every 2 weeks or 150 mg once -weekly then treatment  of a 
patient with volanesorsen  will be stopped permanently .  Platelet count will be monitored  as outlined in 
Table  3. 
Administration of steroids is recomm ended for patients whose platelet count is less than 50,000/mm3.  
Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytope nia ( Provan et al.  2010) recommend Dexamethasone 40 mg da ily 
for 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2 -4 weeks then taper; or 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
57  Methylprednisolone 30 mg/kg/day for 7 days  
(note: may require continuation with oral steroids after methylprednisolone) .  Triglyceride levels will be 
monitored weekly, and AE monitoring will continue, during cortiscosteroid treatment and the laboratory 
alert will be changed  from an increase of 2,000 to 500 mg/dL during that period.  
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or clinically -
relevant  non-major bleeding (defined below;  Schulman et al. 2005 ), treatment  of a patient with 
volanesorsen  should  be suspended temporarily until the platelet count has recovered to  
> 100,000/mm3.  If treatment is reinitiated  it should be at a reduced dose frequency of 300 mg every 2 
weeks  or 150  mg once -weekly  (refer to Section 8.7 ).  The suitability of the patient for continued 
treatment  will be determined by [CONTACT_37812]’s platelet count, whether any 
bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of treatment. 
If after the first treatment re-challenge  the platelet count again falls below 75,000/mm
3, then treatment 
of the patient with Study Drug will be s topped permanently.  
Definition of Major Bleeding Events  (Schulman et al . 2005 ): 
• Fatal bleeding, and/or  
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], intraocular, 
retroperitoneal, intraarterial or pericardial, or intramuscular with compartment syndrome, 
and/or  
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24  hours, or 
leading to transfusion of 2 or more units of whole or red cells  
Definition of Clinically -Relevant, Non -Major Bleeding Events  (Schulman et al . 2005): 
1. Multiple -source bleeding 
2. Spontaneous hematoma >  25 cm2 
3. Excessive wound hematoma (not injection site related)  
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an intervention)  
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis  
6. Bleeding after ven ipuncture for >  [ADDRESS_38107] be documented in the patient’ s medical records.  Monitor every [ADDRESS_38108]
s (Table  2) if 
2 occurrences  consecutive or non-
consecutive) of platelet count 140K - 
>100K/mm3 or 1 occurrence of platelet
count ≤ 100K/mm3.  Labs only need to be
performed once.   Labs may be collected
over multiple visits, if blood requirementsare a concern, as per Investigator
discretion.
>100K/mm3Once -weekly 300 mg Study  Drug 
administration  
100K/mm3 - >75K/ mm3 Permanently reduce dose frequency to 300 mg every 2 weeks  or 150 mg 
once-weekly  
75K/mm3 - >50K/ mm3 •If occurs while on dose of 300 mgevery 2  weeks or 150 mg
once-weekly then permanently
discontinue Study Drug, otherwisedose pause. If dose pause is
≥ [ADDRESS_38109]
discontinue treatment and enter the
follow up period.
•When platelet count returns to
>100K/mm
3 restart treatment  at
dose frequency of 300 mg every 2
weeks or 150 mg once-weekly in
consultation with the Sponsor
Medical Monitor•Monitor every 2-3 days until2 successive values are >  75K/mm
3 
then monitor every 1 week
•Consider  discontinuation of
antiplatelet agents/NSAIDS/
anticoagulant medication
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
59  Platelet Count on Rx  Drug Dose Monitoring  
≤ 50K/mm3 Permanently discontinue Study Drug 
and the patient will enter the follow up 
period  •Monitor daily until 2 successive values
show improvement then monitor every2-3 days until 2 successive values are
> 75K/mm
3 then monitor every 1 week
•Patient should be evaluated by [CONTACT_37813]
•Steroids recommended*.  It is stronglyrecommended that, unless the patient
has a medical contr aindication to
receiving glucocorticoids, the patientreceives glucocorticoid therapy to
reverse the platelet decline.
•Monitor triglyceride levels weekly and
continue AE monitoring during steroid
therapy
•Discontinue antiplatelet agents/
NSAIDS/ anticoagulant medication while
platelet count is  < 50K/mm3 if possible
*Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for
immune thrombocytopenia ( Provan et al. 2010) recommend dexamethasone 40 mg daily for 4 days every
2-4 weeks for 1- 4 cycles; prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or methylprednisolone
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methylprednisolone)
8.[ADDRESS_38110] be made i n accordance with Section 8.6.3 and 
Table 3 (above). 
Other d ose adjustmen
ts, including dose interruptions, and/or decreasing the dose to [ADDRESS_38111] be discussed with, and approved by, the Study 
Medical Monitor prior to initiation .  Up to 2 adjustments in the treatment schedule may be allowed . 
Patients may be dose paused in response to AE s, and the  Study Medical Monitor  is informed. If a patient 
is dose paused for ≥ [ADDRESS_38112] permanently discontinue study treatment for any of the following:  
•The patien t becomes pregnant .  Report the pregnancy according to instructions in Section  9.5.4.
•The patien t withdraws consent .
•The patien t experiences an AE  that necessitates permanent discontinuation of study treatment .
•The patien t develops laboratory test abnormalities that meet any of the stoppi[INVESTIGATOR_37477]  8.6.
•The patient is dose paused for ≥ [ADDRESS_38113] 6 weeks after discontinuing Study Drug.  
Following this period, if the platelet count is stable (a t least 3  consecutive values that are stable as 
determined by [CONTACT_37683] >  100,000/mm3), the next platelet count should be 
taken within at least [ADDRESS_38114] 12  weeks after discontinuing 
Study Drug.  Any pa tient who discontinues  treatment after  Week 44 should also be strongly encouraged 
to attend  a final follow -up visit ( Week 65 visit assessments) approximately [ADDRESS_38115] 12 weeks after discontinuing Study Drug.  
If the patient declines or is unable to participate in the above , an early termination (ET) visit 
(Week 52 visit assessments ) should be performed at the time of withdrawal, at a minimum, and ideally 
within [ADDRESS_38116] 6 w eeks aft er discontinuing Study D rug.  Following t his p eriod, if the platelet c ount is s table (a t least 
3 consecutive v alues th at are stable a s determined b y the Sponsor Medical Monitor a nd > 
100,000/mm3), the next platelet c ount should b e taken wi thin a t least [ADDRESS_38117] 1 2 weeks a fter d iscontinuing Study D rug.  Patients should als o be e ncouraged t o 
undergo a final follow -up visit ( Wee k 65 or W eek 1 17 if ter minating f rom th e Extended Treatment 
Follow -Up P eriod) , see Appendi x A) prior t o leaving the s tudy. 
If a patient withdra
ws due to an AE at any time during the study, the Investigator should arrange for the 
patient to have appropriate follow -up until the AE has resolved or stabilized.  
8.[ADDRESS_38118] be withdrawn from the study for any of the following:  
•Withdrawal of consent
•The patient  is unwilling or unable to comply with the protocol
Other r easons for withdrawal of patient s from the study might include:  
•At the discretion of the Investigator for medical reasons
•At the discretion of the Investigator or Sponsor for noncompliance
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
61  • Significant protocol deviation 
All efforts will be made to complete and report the observations as thoroughly as possible up to the 
date of withdrawal.  All information,  including the reason for withdrawal from s tudy, must be record ed 
in the  CRF. 
Any patient  who withdraws consent to participate in the study will be removed from further treatment 
and study observation immediately upon the date of request .  These patient s should be encouraged to 
complete the ET  study procedures and observations  at the time of withdrawal ( see Section 8.8  and 
Appendix A ). 
For patient s withdrawn for reasons other than withdrawal of consent , every effo rt should be made to 
complete the  early termination study procedures and observations  at the time of withdrawal  (see 
Section 8.8  and Appendix  A). 
8.[ADDRESS_38119] be recorded on the patient ’s CRF.  
AEs related to administration of these therapi[INVESTIGATOR_37478]. 
8.10 .1 Concomitant Therapy  
A concomitant therapy is any non -protocol specified drug or substance  (including over -the-counter 
medications, herbal medications and vitamin supplements) administered between signing informed 
consent and completion of the post- treatment follow- up period .  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient, including changes in the patient’s current medications,  must be recorded 
in the patient’s source documents and CRF .  Patients taking over the counter (OTC ) omega -3 fatty acids 
should make every effort to remain on the same brand throughout the study.  
Allowed Concomitant Therapy  
Any medications deemed necessary by [CONTACT_37814].  
Disallowed Concomitant Therapy  
No lipid lowering therapi[INVESTIGATOR_014] ( e.g., fibrates, niacin, fish oil or other products containing omega- 3 fatty 
acids  [including over -the-counter  preparations] ), -glucagon- like peptide -1 (GLP-1) agonists , Glybera, or 
systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of existing  oral 
anti-diabetic medication, oral contraceptives, hormone replacement therapy,  anticoagulants, or drugs 
or dietary supplements wit h potential lipid -altering effects should not be adjusted .  Study patients are 
prohibited from receiving other experimental agents during the study .  This includes marketed agents at 
experimental dosages that are being tested for the treatment of hypertrig lyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non -prescription or herbal compounds or any other non -drug therapy.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
62  8.10 .2 Concomitant Procedures  
A concomitant procedure is any t herapeutic intervention (e.g., surgery/biopsy, physical therapy) or 
diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between signing of 
informed consent and Week 65 (or Week 117 if patient enters the extended treatment peri od) visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study.  
8.11  Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37815].  The Study 
Center staff is required to document the receipt, dispensing, and return /destruction  of volanesorsen .  
Patient s that are self-administering volanesorsen  at home must record treatment in a dosing diary that 
will be reviewed periodically by [CONTACT_37715].  
9. SERIOUS AND NON -SERIOUS ADVERSE EVENT R EPORTING  
9.[ADDRESS_38120] of the clinical trial.  
9.2 Regulatory Requirements  
The Sponsor  is responsible for regulatory su bmissions and reporting to the I nvestigators of serious 
adverse events (SAEs) including suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) per the 
International Co nference on Harmonization (ICH) guidelines E2A and ICH E6  (R2).  Country -specific 
regulatory requirements will be followed in accordance with local country regulations and guidelines.  
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) wi ll be notified of any SAE 
according to applicable regulations .  The I ndependent DSMB  will be notified of any SAE as specified in 
the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the  Sponsor  or designee  will evaluate the 
available information and perform an independent assessment of relatedness.  While  the Sponsor may 
upgrade an Investigator ’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37534] a S[LOCATION_003]R.  
The following table  identifies the SAEs  that the S ponsor or designee  will not report on an individual basis 
in an expedited manner because they are anticipated to occur in the study population independent of  
volanesorsen  exposure .  The I nvestigator still has the responsibility to report all SAEs to the Sponsor as 
described in Sections 9.4 .1 to [IP_ADDRESS]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
63  Table 4 Expected Event for the Protocol Defined Population by [CONTACT_37716]  (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable .  The Sponsor  
and DSMB  will monitor  non-fatal pancreatitis associated SAEs  using the incidence rate of the event 
compared to the rate expected in a non -volanesorsen  exposed population .  If the aggregate analysis 
indicates that an event is occurring significantly more frequently  or at a greater severity  than expected , 
then the event will be reported.  
SAEs not specified in the table will be evaluated on case by [CONTACT_37717] a 
reasonable possibility that the drug caused the event .  If the event is consid ered by [CONTACT_37816] a S[LOCATION_003]R  the event will be reported.  
9.3 Definitions 
9.3.1  Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the study or use of 
investigational drug product, whether or not the AE is considered related to the investigational drug product.  
9.3.2  Adverse Reaction and Suspected Adverse Reaction 
An adverse reac tion is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen  drug caused the adverse event .  A suspected adverse reaction implies a lesser degree of 
certainty about causality than an adverse reaction.  
9.3.3  Serious Adverse Event (SAE)  
A serious adverse event is any adverse event that in the view of either the Investigator or Sponsor, 
meets any of the following criteria:  
• Results in death  
• Is life threate ning:  that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life -threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not include 
an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused 
death . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
64  • Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility and does 
not always qualify as an AE 
• Results in a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions  
• Results in congenital anomaly or birth defect in the offspring of the patient (whether the patient  
is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_37535] c onsidered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient  and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition .  Examples of such medical events include  
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development o f 
drug dependency or drug abuse  
9.4 Monitoring and Recording Adverse Events  
Any p re-existing conditions or signs and/or symptoms present in a patient  prior to the start of the study 
(i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless 
the pre -existing condition worsened .  The Investigator  should always group signs and symptoms into a 
single term that constitutes a  single unifying diagnosis if possible.  
9.4.[ADDRESS_38121] of patient  safety, and in order to fulfill regulatory requirements , all SAEs (regardless of 
their relationship to volanesorsen ) should be reported to the Sponsor  or designee  within 24 hours of the 
Study Center ’s first knowledge of the  event .  The collection of SAEs will begin after the patient  signs the 
informed consent form and stop at the  end of the patient ’s follow -up period which is defined as the 
Week 65  visit (or Week 117 if patient enters the extended treatment period) .  When  the Investigator is 
reporting by [CONTACT_756], it is important to speak to someone in person versus leaving a message.  An 
Initial Serious Adverse Event Form should be completed and a copy should be faxed to the Sponsor  or 
designee . 
Detailed information shou ld be actively sought and included on Follow -Up Serious Adverse Event Forms 
as soon as additional information becomes available .  All SAEs will be followed until resolution .  SAEs 
that remain ongoing past the patient ’s last protocol -specified follow -up vis it will be evaluated by [CONTACT_37776] .  If the Investigator and Sponsor agree the patient ’s condition  is unlikely to 
resolve, the Investigator and Sponsor will deter mine the follow -up requirement.  
9.4.2  Non -Serious Adverse Events  
The recording of non -serious AEs will begin after the patient  signs the informed consent form and will 
stop at the end of the patient ’s follow -up period, which is defined  as the Week 65 visit (or Week 117 if 
patient enters the extended treatment period).  The Investigator will monitor each patient  closely and 
record all observed or volunteered AEs on the Adverse Event Case Report Form.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
65  9.4.3  Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_37536] : 
[IP_ADDRESS]  Relationship to the Study Drug  
The event’s relationship to volanesorsen  is characterized by 1 of the following:  
• Related:  There is clear evidence that the event is related to the use of volanesorsen , e.g., 
confirmation by [CONTACT_37817] 
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event and 
volanesorsen  administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., concomitant medications or ongoing medical conditions) or the temporal relationship to  
volanesorsen  administration and/or exposure suggests that a causal relationship  is unlikely (For 
reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:  The event can be readily explained by [CONTACT_102] ’s underlying medical condition, 
concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS]  Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D) .  Any AE not listed in Appendix D 
will be graded as follows:  
• Mild:  The event is easily tolerated by [CONTACT_37721] ’s usual daily 
activities  
• Moderate:  The event causes the  patient  more discomfort and interrupts the patient ’s usual 
daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the patient ’s 
usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be  indicated (criteria listed in Section  
9.3.3 ). 
[IP_ADDRESS]  Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following:  
• None:  No changes were made to volanesorsen administration and dose  
• Permanently Discontinued:  Volanesorsen  was discontinued and not restarted  
• Temporarily Interrupted, restarted – same dose:  Treatment was temporarily interrupted  or 
delayed due to the AE and restarted at the same dose  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
66  • Reduced schedule:  Treatment  frequency was reduced  
[IP_ADDRESS]  Treatment Given fo r Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE should be recorded  on the A dverse 
Event Case Report Form ( treatment should also be recorded on the concomitant treatment  or ancillary 
procedures  CRF as appropriate ). 
[IP_ADDRESS]  Outcome of the Adverse E vent  
If the event is a non -serious AE then the event’s outcome is charac terized by 1 of the following:  
• AE Persists:   Patient terminates from  the trial and the AE continues  
• Recovered:   Patient r ecovered comp letely from the AE  
• Became Serious:   The event became serious (the date that the event became serious should be 
recorded as the Resolution Date of that AE and the Onset Date of the corresponding SAE)  
• Change in Severity  (if applicable):   AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following:  
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer meets 
serious criteria and should be captured as an AE on the non -serious AE eCRF (the SAE resolution 
date should be entered as the date of onset of that AE)  
• Recovered:   Patient recovered completely  from the SAE (the date of recovery should be entered 
as the SAE resolution da te) 
• Fatal:  Patient died (the date of death should be entered as the SAE resolution date)  
9.4.4  Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  (MACE) 
will be adjudicated by a blinded, independent committee as outlined in the MACE Adjudication Charter.  
All AEs and SAEs that occur during the study that are consistent with an event of acute pancreatitis will 
be adjudicated by a blinded, independent committee according to the Atlanta classification of acute 
pancreatitis ( Banks et al. 2013 ) and as outlined in the Pancreatitis Adjudication Charter.  In addition, 
data for prior epi[INVESTIGATOR_37537]’s medical chart and these events w ill also be adjudicated.  
9.[ADDRESS_38122] results may, in the opi[INVESTIGATOR_689], constitute 
or be associated with an AE.  Examples of these include abnormal laboratory results that are associated 
with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, tetany due t o 
hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
67  diagnosis should be listed in preference to  abnormal laboratory values as AEs .  Clinically -significant 
abnormalities will be monitored by [CONTACT_37818] .  Laboratory 
abnormalities deemed not clinically -significant  (NCS) by [CONTACT_37723] .  
Similarly,  laboratory abnormalities reported as AEs by [CONTACT_37819].  
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed clinical 
laboratory reports will serve as source documents  and should include the Investigator’s assessment of 
clinical significance of out of range/abnormal laboratory values . 
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely s cheduled treatment will not be considered an SAE, 
even if the patient  is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or 
was on a waiting list to b e scheduled) prior to obtaining the patient ’s cons ent to participate in 
the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37515] ’s consent to participate in the study and the timin g of the procedure or 
treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for 
the int ervention or hospi[INVESTIGATOR_063]  
9.5.3  Treatment  Errors  
Volanesorsen treatment errors should be documented as Protocol Devi ations .  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list symptoms) or 
asymptomatic, and the ev ent accidental or intentional.  
Treatment  details should be captured on the Treatment Case Report Form .  If the patient  takes a dose of 
volanesorsen  that exceeds protocol specifications and the patient  is symptomatic, then the symptom(s) 
should be documented as an AE and be reported per Section 9.4 . 
Should an overdose occur , the Investigator or designee should refer to the Guidance to Investigator’s 
section of the Investigator’s Brochure and  contact [CONTACT_37725] [ADDRESS_38123] learning of the occurrence of pregnancy .  Follow -up information including delivery or 
termination is reported on Follow -up Pregnancy Forms and reported within 24 hours.  
Payment for all aspects of obstetrical care, child or related care will be th e patien t’s responsibility.  
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow -up), a pregnancy 
test will be performed .  The patient  with a confirmed pregnancy will be immediately withdrawn from 
treatment with volanesors en.  However, the patient  will be encouraged to complete the post-treatment 
follow -up portion of the study to the extent that study procedures do not interfere with the pregnancy .  
Regardless of continued study participation, the study physician will assis t the patient  in getting 
obstetrical care and the progress of the pregnancy will be followed until the outcome of the pregnancy 
is known (i.e., delivery, elective termination, or spontaneous abortion) .  If the pregnancy results i n the 
birth of a child, the  Study Center  and Sponsor may require access to the mother and infant’s medical 
records for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed until the 
outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion) .  If the 
pregnancy results in the birth of a child,  the Study Center and Sponsor may request access to the 
mother and infant’s medical records for an additional 8 weeks afte r birth .  Follow -up will be performed 
to the extent permitted by [CONTACT_37726] . 
10. STATISTICAL CONSIDE RATIONS 
10.1 Study Endpoints  
For fasting lipid measurement s, the values at Month 3 analysis time point are defined as  the average of 
Week 12 (Day 78) and Week 13 (Day 85) fasting assessments , the values of Month 6 analysis time point 
is at the end of Month 6 are defined as the average of Week 25 (Day  169) and Week 26 (Day 176) fasting 
assessments, and the values at the M onth 12 analysis time point are defined as the average of Week 50 
(Day 344 ) and Week  52 (Day 358) fasting assessments.  
10.1. 1 Efficacy Endpoints  
• Percent change  and absolute change  from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change  and change  from baseline in other fasting lipid measurements including total 
cholesterol, non -HDL-C, apoB, HDL -C, apolipoprotein A -1 (apoA -1), VLDL -C, and LDL -C 
• Percent change from baseline  in fasting  total apolipoprotein C -III 
• Change in blood viscosity (may be evaluated ) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
69  10.1. 2 Safety Endpoints  
• Adverse  events  including adjudicated events of pancreatitis and MACE  
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation,  urinalysis)  
• Echocardiography  
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
10.2 Sample Size  
No sample size calculations were performed as this is an open -label study . 
10.3 Populations  
Full Analysis Set (FAS) :  All patients who are enrolled  and received at least [ADDRESS_38124] a baseline TG assessment.  The FAS represents the practically -feasible intent -to-treat (ITT) 
population as delineated in ICH Guideline E9.  
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38125] efficacy and PD 
assessments.  The detailed criteria will be specified and finalized prior to the final database lock . 
Safety Set:  All pati ents who are enrolled  and receive at least 1 dose of volanesorsen . 
PK Population :  All patients who are enrolled, recei ve at least [ADDRESS_38126] dose  PK sample collected , analyzed , and reported . 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis . 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2 :  Group 1 ( ISIS 
304801- CS6) or Group 2 ( ISIS 304801- CS16 ) index stud y baseline and the baseline in this open -label 
study, which is defined as the average of Day [ADDRESS_38127] measurement prior to 
Day 1 (e.g., qualification assessments or assessments from final visit of the ISIS 304801 -CS6 or 
ISIS 304801- CS16 index studies if used for qualification) .  For Group [ADDRESS_38128] patient’s Week [ADDRESS_38129] error, 
interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous 
variables, and counts and percentages for categorical variables will be used to summarize most data by 
[CONTACT_37820] 304801 -CS6 or ISIS 304801 -CS16 
index studies, and pooled treatment naive group which including patients on placebo in index studies 
and Group 3 pati ents .  Where appropriate, p -values will be reported .  All statistical tests will be 
conducted using 2 -sided tests with 5% Type I error  rates unless otherwise stated.  
TG related  endpoints will be assessed in the F AS and PPS , and all other efficacy endpoints  will be 
assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK endpoints will be 
assessed in the PK Set as applicable.  
10.6.1 Demographic and Baseline Characteristics  
Demographic and baseline characteristics will be summarized using descriptive statistics by [CONTACT_14454].  The patient disposition will be summarized  by [CONTACT_14454].  All 
patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatmen t duration and amount of Study Drug received will be  summarized by [CONTACT_37821]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA preferred  
term , and treatment group  of the index studies.   Narratives of treatment -emergent deaths, serious and 
significant AEs, including early withdrawals due to AEs, will also be provided.  
All treatment- emergent  AEs, all treatment- emergent AEs potentially related to Study Drug, all 
treatment- emergent  serious AE s, and all treatment- emergent serious AEs potentially related to Study 
Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_1570], MedDRA preferred term and 
severity . 
Independently adjudicated events of MACE and pancreat itis will be summarized by [CONTACT_1570].  
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) with 
differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37778] . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
71  These safety variables will also be presented as change and percent change from baseline over time 
after Study Drug administration, as appropriate.  
Vital sign s, weight , ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_1570] . 
10.6.3 Efficacy Analysis  
Percent change  and change  from baseline  to Month 3, Month 6, and Month 12 in fasting TG will be 
summarized by [CONTACT_1570] .  Response rate of pa tients with fasting plasma TG <  750 mg/dL or 
achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and Month 12 will be 
summarized .  Response analysis will also be conducted using a range of fasting plasma TG thresholds for 
determina tion of responder status . 
Percent change  and change  from baseline  to Month 3, Month 6, and Month 12 will also be summarized 
by [CONTACT_37822] -HDL-C, apoB, HDL -C, apoA -1, VLDL -C, 
and LDL -C, total cholesterol , and fasting total  apoC -III. 
The incremental effects of volanesorsen  on lipid measures  will be explored  and the association between 
changes in lipid parameters and total amount of drug received will be examined, as appropriate . 
Frequency and se verity of patient reported abdominal pain, adjudicated  acute pancreatitis event rate,  
quality of life assessments , and comparison of other symptoms including eruptive xanthomas and 
lipemia retinalis  will be summarized by [CONTACT_1570] . 
Additional details  of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis  
For all patients, pre -dose and post -treatment volanesorsen  plasma concentrations will be summarized 
using descriptive statistics  by [CONTACT_37823]. 
For patients in the PK subgroup only, non -compartmental PK analysis of volanesorsen will be carried out 
on each individual patient data set using data collected  in the open -label study from the intensive PK 
subgroup, following a single -dose (i.e., single -dose PK) or multiple dose s (i.e., steady -state PK), 
depending on their earlier treatment in the index studies  (Group 1 and 2 patients) .  On Week 1  Day 1 of 
the open -label study, patients who received placebo in the index study (and all patients in Group 3) will 
receive the first treatment of volanesorsen (single -dose PK), while  patients who received volanesorsen 
in the index studies  had been on volanesors en treatment for 12 months  (ISIS  304801 -CS6) or 6 months 
(ISIS 304801- CS16) , thus the PK data collected from these patients reflect steady -state PK.  The 
maximum observed drug concentration (C max) and the time taken to reach C max (Tmax) will be obtained 
directly from the concentration -time data .  Area under the plasma concentration -time curve from time 
zero to 24  hours ( AUC 0-24h) will be calculated using the linear trapezoidal rule .  Apparent systemic 
(plasma) clearance after SC administration (C L0-24h /F) will be calculated from  
CL0-24h/F = Actual Dose/AUC 0-24h.  Mean residence time (MRT) from time zero to 24 hours after the SC 
administration  will be calculated from the equation,  
MRT 0-24h = AUMC 0-24h/AUC 0-24h, where AUMC 0-24h is the area under the  moment plasma concentration -
ISIS [ADDRESS_38130] . 
Plasma PK parameters will be summarized using descriptive statistics  by [CONTACT_37780] .  
Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK /PD, and covariate analysis may be performed if deemed appropriate, and results will 
be reported separ ately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not evaluable, 
and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after treatment with 
Study Drug ( volanesorsen ) (i.e., sample [anti -drug antibody]  ADA status) will be listed by [CONTACT_37824] 304801 -CS6 or ISIS 304801- CS16  (Groups 1 and 2) and study day .  Subject ADA 
status (positive/negative or not evaluable) for all evaluable patients, along with the study day associated  
with the first positive IM status emerged (T first, i.e., onset of ADA development), the last positive IM 
status observed (T last), the la st ADA sample collection day,  and subject - peak titer if applicable, will be 
listed by [CONTACT_37732]  304801 -CS6 and  ISIS 304801 -CS16  (Groups 1 and 2) and  
study day .  Subjects with positive anti -volanesorsen  antibody status may be fur ther classified (when 
applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjects with antibody negative, positive, and 
unknown status  by [CONTACT_1570] .  Furthermore, onset and t iter of the ADA response,  if applicable, 
will be summarized as median, quartiles (25% and 75%), and range . 
Additional details regarding the IM data analysis will be described in the SAP . 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., % 
change in fasting TG from baseline at 3 -, 6-, and 12 -month  endpoints), safety, and PK (e.g., C trough ) 
measures will be evaluated using graphical analysis and statistical analysis .  These analyses will be either 
conducted and included in the study report, or data pooled and analyzed from all available Phase 2 and 
3 studies  and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient 
population , based on an English version provided by [CONTACT_1034] . 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written informed 
consent from the patient  after adequate explanation of the aims, methods, anticipated benefits, and 
potential hazards of the study and before any protocol -specific qualification procedures or any Study 
Drug are administered .  The patient  must be given sufficient time to consider whether to participate in 
the study.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
73  The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her primary 
care physician  should be documented in the patient ’s medical records and the informed consent form 
should be signed and personally dated by [CONTACT_37825] (not necessarily an I nvestigator) .  The original signed informed consent for m should 
be retained in  the Study Master File and in any other locations required by  [CONTACT_10569], and a 
copy of the signed consent form should be provided to the patient . 
11.[ADDRESS_38131] of the Study  
The Guidelines of the World Medical Associ ation (WMA) Declaration of Helsinki dated  October  2002 the 
applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands of 
national drug and data protection laws and other applicable regulatory requirem ents will be s trictly 
followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent  form, other written patient  information, and any 
proposed advertising material must be submitted to the IEC/IRB  for written approval.  A copy of the 
written approval of the protocol and informed consent form must be received b y the Sponsor  before 
recruitment of patient s into the study and shipment of  volanesorsen .  A copy of the written approval of 
any other items/materials that must be approved by [CONTACT_37826]/IRB must also be received 
by [CONTACT_37827] s into the study and shipment of Study Drug.  The 
Investigato r’s Brochure must be submitted to the IEC/IRB for acknowledgement.  
The I nvestigator must submit to and, where necessary, obtain approval from the  IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document .  The Investigator 
should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  E6 (R2) Section  4.5.2 .  
The Investigator should also notify the IEC/IRB  of serious adve rse events occurring at the Study Center  
and other adverse event reports received from the Sponsor , in accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout the 
duratio n of the study .  Copi[INVESTIGATOR_1093] I nvestigator’s reports, all IEC/IRB submissions and the IEC/IRB  
continuance of approval must be sent t o the Sponsor . 
11.[ADDRESS_38132] ensure that the patient ’s confidentiality is maintained .  On the case report forms  
(CRF) or other documents submitted to the Sponsor , patient s should be identified by [CONTACT_37784] 
a patient  study number only .  Documents that are not for submission t o the Sponsor  (e.g., signed 
informed consent forms) should be kept in strict confidence by [CONTACT_737].  
In compliance with Federal and local regulations/ICH E6 (R2)  Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB  direct access to review the patient ’s original medical records for verification 
of study -related procedures and data .  Direct access includes examining, analyzing, verifying, and 
reproducing any records and reports that are important to the evaluation of the study .  The Investigator 
is obligated to inform and obtain the consent of the patient  to permit named representatives to have 
access to his/her study -related records without violating the confidentiality of the patient . 
ISIS [ADDRESS_38133] be obtained for all protocol amendments and amendments to the informed consent 
document .  The regulatory authority and  IEC/IRB must be informed of all amendments and give approval 
for any amendments likely to affect the safety of the patient s or the conduct of the trial .  The 
Investigator must  send a copy of the approval letter from the IEC/IRB t o the Sponsor . 
12.[ADDRESS_38134] .  The Inves tigator/Sponsor should notify the IEC/IRB in writing of the trial’s completion or 
early termination and send a copy of the notification to the Sponsor.  
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application will be used for this study.  
The Investigator should ensure that all appropriately qualified persons to whom he/she has del egated 
trial duties  are recorded on a Sponsor -approved Delegation of Site Responsibilities Form . 
Source doc uments are original documents, data, and records from which the patient ’s CRF data are 
obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and 
pharmacy records, d iaries, imaging , and correspondence .  In this study, CRFs may not be used as source 
documents.  
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with Section 8  of 
ICH E6 (R2), suitable for inspection at any time by [CONTACT_37736]/or applicable  
regulatory authorities .  Elements should include:  
• Patient  files containing completed CRFs, informed consents, and supporting copi[INVESTIGATOR_31653]  
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_10468] -
study documentation and all correspondence to and from the IEC/IRB  and the Sponsor  
• If volanesorsen supplies are  maintained at the Study Center, proof of receipt , volanesorsen  
Accountability Record, Return of volanesorsen  for Destruction, final study volanesorsen 
reconciliation, and all volanesorsen -related correspondence  
In addition, all original source documents supporting entries in the CRFs must be maintained and be 
readily available.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
75  No study document should be destroyed without prior written agreement between the Sponsor or  and 
the Investigator .  Should the I nvestigator wish to assign the study records to another party or move 
them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_38135], inspecting the 
various records of the trial (e.g., CRFs and other pertinent data) provided that patient  confidentiality is 
respected.  
The Sponsor monitor is responsible for inspecting the CRFs at regular intervals throughout the study to 
verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence 
to local regulations on the conduct of clinical research .  The monitor should have access t o patient  
medical records and other study -related records needed to verify the entries on the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in com pleting CRFs, are resolved. 
In accordance with ICH E6 (R2) and the Sponsor’s audit plans, this study may be selected for audit by 
[CONTACT_10576]’s  Clinical Quality Assurance Department .  Inspection of Study Center  
facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study -related records will occur 
to evaluate the trial conduct and compliance with the protocol, ICH E6 (R2), and applicable regulatory 
requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  
data received by [CONTACT_1034] .  During this review, patient  data will be checked for consistency, 
omissions, and any apparent discrepancies .  In addition, the data will be reviewed for adherence to the 
protocol and GCP .  To resolve any questions arising from the clinical data management review process, 
data queries and/or Study Center  notifications will be sent to the Study Center  for completion and 
return t o Sponsor . 
The Principal Investigator [INVESTIGATOR_37484].  These signatures will 
indicate that the principal Investigator [INVESTIGATOR_37485], the data queries, and 
the Study Center  notifications, and agrees with the content.  
12.[ADDRESS_38136] use 
vocabulary and language that are clearly understood.  
12.6 Compensation for Injury  
The Sponsor  maintains appropriate insurance coverage for clinical trials and will follow applicable local 
compensation laws .  Patient s will be treated a nd/or compensated for any study -related illness/injury in 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
76  accordance with the information provided in the Compensation for Injury section of the Informed 
Consent document.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
77  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al . Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176.  
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions  by [CONTACT_5757] . Gut 2013; 62:  
102- 111.  
Beigneux AP, Davies BS, Gin P, et al . Glycosylphosphatidylinositol -anchored high- density lipoprotein- binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons . Cell Metab 2007 Ap r; 5(4): 279 -291. 
Berglund L, Brunzell JD, Goldberg AC, et al . Evaluation and treatment of hypertriglyceridemia: An endocrine society 
clinical practice guideline . J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al . Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of particle 
size. J Lipid Res 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al . Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high- density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364.  
Brunzell JD. Familial lipoprotein lipase deficiency . In Pag on RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF. An ABC of apolipoprotein C -III: a clinically useful new cardiovascular risk 
factor? Int J Clin Pract  2008; 62 (5): 799- 809.  
Crooke ST and Benne tt CF . Progress in antisense oligonucleotide therapeutics . Ann Rev  Pharmacol Toxicol 1996; 
36: 107 -129.  
Doolittle MH, Neher SB, Ben -Zeev O, et al . Lipase maturation factor 1 (LMF1): Membrane topology and interaction 
with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; [ADDRESS_38137] 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al . Efficacy and long- term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open- label trial . Gene Therapy 2013 ; 20: 361- 369.  
Gaudet D, Brisson, D Tremblay K, et al . Targeting APOC3 in the Familia l Chylomicronemia Syndrome . N Engl J Med 
371; 23  Dec 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438- 447. 
Gaudet D, Baass A, Trembla y K, et al. Natural History (up to 15 years) of Platelet Count in 84 Patients with Familial 
Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency. Journal of Clinical Lipi[INVESTIGATOR_37444] 2017; 11(3): 797- 798.  
Geary RS, Yu RZ
, Watanabe T, et al . Pharmacokinetics  of a tumor necrosis factor -alpha phosphorothiate 2 ʹ-O-(2-
methoxyethyl) 
modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
78  Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipo protein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479 -1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468 -479.  
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327 -330.  
Ito Y, Azrolan N, O'Conne ll A, et al . Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic 
mice . Science 1990 Aug 17; 249: [ADDRESS_38138] of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasm a hepatic lipase . FEBS Lett  1976; 65: 354 –357.  
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12 -week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: [ADDRESS_38139] AA, Yen FT, et al . Inhibitory effects of specific apolipoprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McK ay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al . Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239- 245.  
Monia BP, Lesni
k EA, Gonzalez C, et al . Evaluation of 2 ʹ-modified o
ligonucleotides containing 2 ʹ-deoxy gaps as 
a
ntisense i nhibitors of gene expression. J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Ba
rrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin Sci (Lond)  2008; 114: 611 -624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082 -1089.  
Pollin TI, Damcott CM, Shen H, et al . A null mutation in human APOC3 confers a favorable plasma lipid profile and 
apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune  thrombocytopenia. Blood 2010;  115:  168- 186.  
Santos RD, Duell PB, East C, et al . Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur Heart J  2015 Mar; 36(9) : 566-575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PC, Voshol  PJ, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ADDRESS_38140] 2005; 3(4):  692- 694.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
79  Schuster KB, Wilfert W, Evans D, et al . Identification of mutations in the lipoprotein lipase (LPL) and apolipoprotein 
C-II (APOC2) g enes using denaturing high performance liquid chromatography (DHPLC) . Clinica Chimia Acta 2011; 
412: 240- 244.  
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients with 
severe hypertriglyceridaemia . J Internal Med 2012; 272: 185- 196.  
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent  plasma and severe hypertriglyceridemia . 
J Clin Lipi[INVESTIGATOR_37487]  2011; 5: 37 -44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice. Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al . Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684 -4692.  
 
 
 
 
  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  21 November  2018  
80  14. APPENDICES
Appendix A  Schedule of Procedures  
ISIS 304801- CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
81   
Appendix A  Schedule of Procedure s 
Study Period  Screen/  
Run Ina Quala Treatment Period  Post 
Treatment 
Follow -up 
Study Week  -8 to 
 -2 -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 44
9 
Visit Window+/ - Days  0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent  X X                          
Outpatient Visit  X X X Xl Xl Xl Xl Xl Xl X Xl Xl Xl Xl X Xl Xl Xl X Xl Xl Xl Xl X Xl Xl X 
Inclusion/Exclusion Criteria  X X                          
Medical Historyb X                           
Vital Signs + body weight  
(+ height on Day 1 only)  X X X  X  X   X     X    X     X   X 
Physical Examination  X  X       X     X    X     X   X 
12- lead ECG (triplicate)  X         X     X    X     X   X 
MRI (liver/spleen)  X                      Xm    
Echocardiography  X             Xm         Xm    Blood Draw (Fasting)d Chemistry Panel  X X X  X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialc X X X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  X 
Serum Lipid Panel  X X X  X  X  X X    X X    X    X X   X 
Blood viscositye   X       X     X         X    
Platelet aggregatione  X X       X     X         X    
Coagulation (aPTT, PT, INR)  X X     X   X     X    X     X    
Hepatitis B, C, HIV  X                           
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37538]1c   X       X     X         X   X 
Sedimentation Rate    X       X     X         X   X 
Complement (C5a, Bb)    X       X     X         X   X 
Troponin I  X  X       X     X         X   X 
Platelet Bound Autoantibod iese   X                         
Plasma PK - Volanesorsen    Xn X X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies    X  X  X   X     X    X     X   X 
ISIS 304801- CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
82  Study Period  Screen/  
Run Ina Quala Treatment Period  Post 
Treatment 
Follow -up 
Study Week  -8 to 
 -2 -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 44
9 
Visit Window+/ - Days  0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
FSH (women only, if applicable)  X                           
Serum Pregnancy Testf X X   X  X   X  X   X  X  X  X   X  X X 
Appendix A  Schedule of Procedures  Continued 
Study Period  Screen/  
Run Ina Quala Treatment Period  Post Treatment 
Follow -up 
Study Week  -8 to 
 -2 -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 
Wk 
12 Wk 
13    Wk 
25 Wk 
26        Wk 
50 Wk 52  
or ET     
Study Day  -56 to 
-15 -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 Blood Draw 
(Fasting)d Archive blood sample for potential 
gene sequencing related to 
hypertriglyceridemia (Group 3; 
Group 2 if not  available from index 
study)i X                         
Archived Serum & Plasma 
Samplesg   X    X   X     X         X   X 
Urinalysisd X X Xo  X  X   Xo  Xo   Xo  Xo  Xo  Xo   Xo  Xo Xo 
Fundus Photographyh X                      Xm    
Genetic testing for FCS diagnosis (if 
not available in medical history)i X                          
Once -weekly Study Drug:  SC Injection    X  X X X X X X X X X X X X X X X X X X X X    
Symptom Diary (weekly)  X X X  X X X X X X X X X X X X X X X X X X X X X X X 
ISIS 304801- CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
83  Study Period  Screen/  
Run Ina Quala Treatment Period  Post Treatment 
Follow -up 
Study Week  -8 to 
 -2 -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 
Wk 
12 Wk 
13    Wk 
25 Wk 
26        Wk 
50 Wk 52  
or ET     
Study Day  -56 to 
-15 -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Quality of Life Assessment(s)    X       X     X         X   X 
Food/Drink Diary (quarterly)j   X       X     X         X   X 
Diet/Alcohol Counselingk X X X  X  X   X     X    X     X  X X 
Adverse Events X X X  X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X  X X X X X X X X X X X X X X X X X X X X X X X 
a Screening and Qualification  (Group 3) procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Patient charts will be reviewed in order to collect data for events of acute pancreatitis or suspected pancreatitis in the patient’s medical history.  Chart review may be 
conducted at any time during the study.  These events will be adjudicated in the same manner as for events of pancreatitis during the study  
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.   In the 
event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38141] be reviewed by [CONTACT_37745] .  All platelet count results will be promptly reviewed by 
[CONTACT_37792] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, or the dose pause rule of 75,000/mm3.  Any case of a 
platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor   
ISIS 304801- CS7 CONFIDENTIAL  Amendment [ADDRESS_38142] 10 hours  and preferably not more than 12 hours .  During treatment period urine and blood 
samples will be collected prior to Study Drug  administration .  Does not  apply to 24-hour PK blood draw  
e May be done.  Blood viscosity and platelet aggregation in volanesorsen-treatment naïve patients  only 
f Females of childbearing pot ential only  
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney f unction, measurement of antibodies, etc.) in this or subsequent clinical studies of 
volanesorsen  
h If possible, fundus photography should be completed prior to administration of the first dose of Study Drug ( Group 2 [ISIS 304801-CS16 roll-over patients ] and 
Group 3)  and repeated at Week 52 (Please refer to Section [IP_ADDRESS] ) 
i Genetic testing can be conducted for study qualification (Group 2 [ISIS 304801-CS16 roll-over  patients ] and Group 3) ; genetic testing will only be conducted if 
allowed in the geographic  region and only after the patient has given specific written informed consent for genetic testing.  A blood sample for potential gene 
sequencing may be collected at timepoints other than Screening or Qualification Visits.  
j In addition to diary, patients will be contact[CONTACT_37787]  
k To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
l Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
m A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
n Full or abbreviated PK profile (see Appendix C ) 
o Expanded urinalysis (see Appendix B ) 
  
ISIS 304801- CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
85  Appendix A  Schedule of Procedures  – Extended Treatment Period  
Study Period  Treatment Period  Post -Treatment 
Follow -up 
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62 Mo 15  
Wk 64 Wk 66 
& 68  Wk 
70 Wk 72 
& 74 Mo 18  
Wk 76  Wk 78 
& 80  Wk 
82 Wk 84, 
86, & 88  Mo 21  
Wk 90 Wk 92 
& 94  Wk 
96 Wk 
98, 
100 & 
102 Mo 24  
Wk 
104 Wk 
106 
& 
108 Wk 
110 Mo 27  
Wk 
117 
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 56
8  582, 596 
& 610  624 638 & 
652 666 680, 
694 & 
708 722 736  
& 
750 764 813 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf X 
Vital Signs (+ body weight)     X    X    X    X   X 
Physical Examination         X        X    
12- lead ECG (triplicate)         X        X    
Urinalysis(including P/C ratio)   X  X  X  X  X  X  X  X  X X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X  X X 
CBC with Differentiala X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  X 
Serum Lipid Panel    X    X    X    X   X 
Coagulation (aPTT, PT, INR)     X    X    X    X    
Troponin I     X    X    X    X   X 
Plasma PK - ISIS 304801c        X        X   X 
Anti-ISIS  [ADDRESS_38143] specified windows to allow flexibility of scheduling.  
Once -weekly Study Drug: SC 
Injection X X X X X X X X X X X X X X X X    
Diet/Alcohol Counselinge    X    X    X    X    
Adverse Events  X X X X X X X X X X X X X X X X X X X 
ISIS 304801- CS7 CONFIDENTIAL  Amendment [ADDRESS_38144] -Treatment 
Follow -up 
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62 Mo 15  
Wk 64 Wk 66 
& 68  Wk 
70 Wk 72 
& 74 Mo 18  
Wk 76  Wk 78 
& 80  Wk 
82 Wk 84, 
86, & 88  Mo 21  
Wk 90 Wk 92 
& 94  Wk 
96 Wk 
98, 
100 & 
102 Mo 24  
Wk 
104 Wk 
106 
& 
108 Wk 
110 Mo 27  
Wk 
117 
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 56
8  582, 596 
& 610  624 638 & 
652 666 680, 
694 & 
708 722 736  
& 
750 764 813 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X 
  
ISIS 304801- CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
87  Appendix A  Schedule of Procedures – Extended Treatment Period  Continued 
Legend Text  
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38145] be reviewed by [CONTACT_37745].  All platelet count results will 
be promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877] , or the dose reduction rule of 100,000/mm
3, or the dose pause rule 
of 75,000/mm3.  Any case of a platelet count < 50, 000/mm3 should be reported in an expedited fashion to the Sponsor .  
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatment period urine and blood 
samples will be collected prior  to Study Drug administration  
c Abbreviated PK collection (see Appendix C ) 
d Females of childbearing potential only  
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
g     May be done  
 
ISIS [ADDRESS_38146] of Laboratory Analytes  
Based on emerging data from this or future studies, additional tests not listed below may be performed 
on stored samples t o better characterize the  profile of volanesorsen  or other similar oligonucleotides . 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN  
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT 
• AST 
• Alkaline phosphatase  Screening Tests  (Group 3)  
• Hepatitis B surface antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women only)  
• Serum βhCG (women only)  
 
Coagulation 
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL-C 
• Triglycerides  
• Non- HDL-C 
• VLDL -C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit 
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other A ssessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• Troponin I2 
• CK-MB2 
• Platelet Bound Autoantibodies
3 
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  
• Blood viscosity3 Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood  
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
4 
 
Additional Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
Platelet Function  
• Platelet aggregation3 
• Platelet Function5 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_38147] -treatment follow- up period  as 
noted in the tables below . 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52  
 
PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_38148]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52  
 
PK Sampling Schedule (Extended Treatment Period) 
Week  Wk 
76 Wk 
104 Wk 
117 
Study Day  D526  D722  D813  
Visit Window 
+/- Days  [ADDRESS_38149] abnormalities are based 
upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010  
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
94  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities  Continued 
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol   21 November  2018  
 
95  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities  Continued 
 
 
 

 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38150] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38151] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 8  - [LOCATION_009] – [ADDRESS_38152] No:  2015-003755-21 
 
 
 

ISIS [ZIP_CODE] l -CS7 
Protocol -[LOCATION_009] CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 8 
IO April 2017 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 8 -[LOCATION_009] -10 April 2017 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Protocol Amendment 6: 
Protocol Amendment 7: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38153] 2016 
16 September 2016 
3 February 2017 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_38154] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor: Ionis Pharmaceuticals,  Inc. 
[ADDRESS_38155] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] Fax:  
Key Sponsor Contact:  [CONTACT_37829].D. 
[ADDRESS_38156] Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator: Akcea Therapeutics  
[ADDRESS_38157] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38158] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 8 - [LOCATION_009]  
Date:    [ADDRESS_38159] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38160] the study as 
described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_38161] ................................................................................35  
4. PATIENT ENROLLMENT ........................................................................................... 36  
4.1 Qualification  ..................................................................................................................36  
4.2 Enroll ment  .....................................................................................................................36  
5. PATIENT ELIGIBILITY  .............................................................................................. 36  
5.1 Inclusion Criteria  ...........................................................................................................36  
5.2 Exclusion Criteria  ..........................................................................................................37  
6. STUDY PROCEDURES  ................................................................................................ 40  
6.1 Study Schedule  ..............................................................................................................40  
6.1.1  Qualification  ...........................................................................................................40  
6.1.2  Treatment Period  ....................................................................................................40  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_38162]- Treatment Period  ............................................................................................41  
6.2 Additional Study Assessments  .......................................................................................41  
6.2.1  Laboratory Assessments  .........................................................................................41  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
6  6.2.2  Physical Exams and Vital Signs  .............................................................................41  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................42  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................42  
6.2.3  Echocardiography ...................................................................................................42  
6.2.4  ECG  ........................................................................................................................42  
6.2.5  MRI  ........................................................................................................................42  
6.2.6  Quality of Life Assessments  ...................................................................................42  
6.2.7  Disease Symptom Diary  .........................................................................................42  
6.2.8  Diet Monitoring  ......................................................................................................42  
6.2.9  Family History  ........................................................................................................43  
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2) ..[ADDRESS_38163]- Treatment Follow -up Period .56  
8.9 Withdrawal of Patients from the Study  ..........................................................................56  
8.10  Concomitant Therapy and Procedures ...........................................................................57  
8.10.1  Concomitant Therapy .............................................................................................57  
8.10.2  Concomitant Procedures .........................................................................................57  
8.11  Treatment Compliance  ...................................................................................................57  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ...................... 58  
9.1 Sponsor Review of Safety Information .........................................................................58  
9.2 Regulatory Requirements  ..............................................................................................58  
9.3 Definitions  .....................................................................................................................59  
9.3.1  Advers e Event  ........................................................................................................59  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................59  
9.3.3  Serious Adverse Event (SAE) ................................................................................59  
9.4 Monitoring and Recording Adverse Events  ...................................................................60  
9.4.1  Serious Adverse Events ..........................................................................................60  
9.4.2  Non-Serious Adverse Events ..................................................................................60  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................60  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................60  
[IP_ADDRESS]  Severity  ............................................................................................................61  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................61  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................61  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................61  
9.4.4  Adjudication Committees  .......................................................................................62  
9.5 Procedures for Handling Special Situations ..................................................................62  
9.5.1  Abnormalities of Laboratory Tests .........................................................................62  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............63  
9.5.3  Dosing Errors .........................................................................................................63  
9.5.4  Contraception and Pregnancy .................................................................................63  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 64  
10.1  Study Endpoints  .............................................................................................................64  
10.1.1  Efficacy Endpoints .................................................................................................64  
10.1.2  Safety Endpoints  .....................................................................................................64  
10.2  Sample Size  ....................................................................................................................65  
10.3  Populations .....................................................................................................................65  
10.4  Definition of Baseline  ....................................................................................................65  
10.5  Interim Analysis  .............................................................................................................65  
10.6  Planned Methods of Analysis ........................................................................................66  
10.6.1  Demographic and Baseline Characteristics  ............................................................66  
10.6.2  Safety Analysis  .......................................................................................................66  
10.6.3  Efficacy Analysis  ...................................................................................................67  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
8  10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................67  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................67  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................68  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. [ADDRESS_38164] of the Study .........................................................................................69  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38165] of Laboratory Analytes  .............................................................................81  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................83  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......85  
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics .........................................................45  
Table 2  Labs to Be Performed in the Event of a Platelet Count Less than the 
Lower Limit of Normal (x2) or < 100,000/mm3 (x1)* ..........................................48  
Table 3  Actions in Patients with Low Platele t Count .........................................................54  
Table 4  Expected Event for the Protocol Defined Population by [CONTACT_37674]  ...................................................................................58
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  ...............29  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  (MOE -Gapmer).  The sequence of volanesorsen is shown ....................................31
 
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ...............33  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 8 
Protocol - [LOCATION_009]  10 April 2017 
 
9  PROTOCOL AMENDMENT 
 
Protocol Number: ISIS 304801-CS7 
Protocol Title: An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 
Amendment Number:  8 - [LOCATION_009] 
Amendment Date: 10 April 2017 
 
The purpose of this protocol amendment is to imp lement the following modifications to Protocol 
ISIS 304801-CS7 Amendment 7 dated 3 February 2017:  
1. To update the platelet safety monitoring rules shown in Table 3. 
2. To assess acute pancreatitis in me dical history in Group 2 patients. 
3. Added archive blood sample for pot ential gene sequencing related to 
hypertriglyceridemia (Group 2 if not available from index study). 
4  Added Troponin I and platelet bound autoanti body testing at baseline (may be done) to 
provide added patient safety; blood viscosity (m ay be done) to assess potential benefit of 
ISIS 304801 administration; and platelet aggr egation (may be done) to assess platelet 
function. 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design. 
The following table provides a summary list of major changes to the protocol, additions are indicated as underline and deletions  are indicated as strikethrough: 
Protocol 
Section Description of Change Rationale 
Section 3.4.[ADDRESS_38166] 69 Study Center visits on Weeks 53, 54, 55, 56, 57, 58, 65, 71, and 78 
(Weeks 53, 54, 55, 56, 57, 58, and 71 may be conducted by a home healthcare 
nurse). 
 To provide added 
patient safety 
regarding platelet 
count reductions 
and ISIS 304801 dose exposure 
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
10  Protocol 
Section Description of Change  Rationale  
Synopsis  
Section 5.1 
Inclusion Criteria 3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or 
ISIS 304801-CS16 (index studies) with an acceptable safety profile, per 
Sponsor and Investigator judgement.  
Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the following criteria in order to enter into the open-label study:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinem ia) supported by [CONTACT_37685] 1 of  the 
following:  
• Confirmed homozygote, compound heterozygote or double heterozygote for known loss -of-function mutations in Type 1- causing 
genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal  in medical history. 
Note: testing of LPL activity should not be performed to confirm 
eligibility for the study  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS  304801-
CS16 index study   
4. Able and willing to part icipate in a 78-week study  To clarify that 
either genetics or 
LPL activity can 
be used as an 
inclusion criteria and that LPL 
activity should not 
be performed unless already in medical history  
6.1.2 
Treatment 
Period During the treatment period, patients will report to the study center for clinic 
visits a minimum of 5 times during Weeks 1- 52 (see Schedule of Procedures in 
Appendix A).  Study Drug will be administered once weekly unless the patient is on a biweekly dosing schedule for safety reasons (Section 8.1).  Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs, concomitant 
medication/procedure information, lipid panel , blood viscosity, volanesorsen 
plasma concentrations, i mmunogenicity (IM) testing,  platelet aggregation, 
liver/spleen MRI, ECGs, echocardiograms and quality of life assessments will 
be performed according to the schedule of procedures in Appendix A.  Adverse 
events at the injection site should be collected as adverse events.  Dietary 
counseling will be reinforced at intervals throughout the treatment and follow -up 
period and all patients will complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected prior to volanesors en administration.  Blood sampling at Weeks 2, 3, 4, 5, 6, [ADDRESS_38167] be fasted prior to drawing 
all blood samples and samples drawn locally should also be sent to the central laboratory for analysis whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given [ADDRESS_38168]-treatment evaluation period or will participate in an 
expanded access program pending approval by [CONTACT_1026]/IEC, and the appropriate regulatory authorities.  The 26-week period consists of at least 69 
Study Center visits on Weeks 53, 54, 55, 56, 57, 58 , 65, 71, and 78 (Weeks  53, 
54, 55 , 56, 57, 58, and 71 may be conducted by a home healthcare nurse), as 
outlined in the Schedule of Procedures in Appendix A . To provide added patient safety regarding platelet count reductions 
and ISIS 304801 
dose exposure  
 
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 8 
Protocol - [LOCATION_009]  10 April 2017 
 
11  Protocol 
Section Description of Change Rationale 
6.2.1 
Laboratory Assessments Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.  In the event that both the c entral and local sample are unreportable 
(e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within 1-week and the result must be reviewed by [CONTACT_37785].  All platelet count 
results will be promptly reviewed by t he Investigator to determine if the count 
has met a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, and 
determined not to have met a stoppi[INVESTIGATOR_37539] 75,000/mm3. 
If there is no reportable platelet count with in [ADDRESS_38169] platelet count, 
the Investigator will contac t the patient to hold dosing until a new platelet count 
is obtained and reviewed. 
All platelet count results will be promptly  reviewed by [CONTACT_37831] t the stoppi[INVESTIGATOR_37540] 75,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited 
fashion to the Sponsor. To provide added patient safety regarding platelet 
count reductions, 
ISIS 304801 
dose exposure, 
and treatment 
recommendations 
6.2.10 Chart 
Review for 
Incidents of 
Acute 
Pancreatitis in 
Medical 
History 
(Group 2) Added 
6.2.10 Chart Review for Incidents of Ac ute Pancreatitis in Medical History 
(Group 2) 
Patient records will be reviewed for incidents of acute pancr eatitis occurring up 
to 5 years prior to screening and information relating to these events will be 
collected for independent adjudication. To assess acute 
pancreatitis in 
medical history in 
Group 2 patients 
8.1 Volanesorsen 
Administration Removed 
Every effort should be made to ensure the previous week’s dose is given [ADDRESS_38170] be documented in the patient’s medical records. 
Due to the [ADDRESS_38171] with the study patients.  However, 
if the above options are not possible,  a temporary interruption of study 
treatment will be planned with a prompt  blood draw upon the patient’s return 
which must be reported and reviewed by [CONTACT_37832]. To provide added 
patient safety regarding platelet 
count reductions, 
ISIS 304801 
dose exposure, 
and treatment 
recommendations 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
12  Protocol 
Section Description of Change  Rationale  
8.5.2 Safety 
Monitoring for  
Platelet Count  
Results  
Continued  The tests outlined in Table 2 should also be performed as soon as possible.   
Additional lab tests will be determined by [CONTACT_37833].  
Any case of a platelet count < 50,000/mm3 should be reported in an expedited 
fashion to the Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
Table 2  Labs to Be Performed in the Event of a Platelet Count Less than the 
Lower Limit of Normal (x2) or < 100,000/mm3 (x1)* 
*In patients who have any 2 occurrences (consecutive or non -consecutive) of 
platelet count less than the lower limit of normal or who have any 1 occurrence 
of platelets <  100,000/mm3.  Labs only need to be performed once.  Labs may 
be collected over multiple visits, if blood r equirements are a concern, as per 
Investigator discretion.  
Note:  The following labs may change as additional data is assessed, and 
sites will be updated regarding any changes . To provide added 
patient safety regarding platelet 
count reductions, ISIS 304801 dose exposure, 
and treatment 
recommendations 
 Added Table 2:  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central 
lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinoge n 
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
13  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37541] a low platelet count are summarized in 
Table 2 3 below.  
In the event of a platelet count less than 75,000/mm3 that is associated with 
major bleeding or clinically -relevant non-major bleeding (defined below; 
Schulman et al. 2005), dosing of a patient with volanesorsen will be stopped 
permanently.  The follow -up schedule for any events meeting this stoppi[INVESTIGATOR_37542].  
In the event of any platelet count less than 50,000/ mm3, or a rate of decline 
≥ 50% between two consecutive assessments, irrespective of the platelet level , 
or a platelet count less than 75,000/mm3 that occurs while the patient is on 
dosing at 300 mg every 2 weeks  or 150 mg every week  then dosing of a patient 
with volanesorsen will be stopped permanently.  Platelet count will be monitored 
as outlined in Table 3. daily until 2 successive values show improvement then 
monitored every 2-3 days until platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is 
less than 2550,000/mm3.  Recovery in platelet count may be accelerated by 
[CONTACT_37711].  Treatment guidelines for immune 
thrombocytopenia (Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; Prednis(ol)one 0 .5-2 mg/kg/d 
for 2-4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:  may require continuation with oral steroids after methylprednisolone).   In 
order to reduce the unlikely  but potential increased risk of pancreatitis during 
the period of corticosteroid therapy, triglyceride levels will be monitored weekly , 
and AE monitoring will continue, during corticosteroid treatment and the 
laboratory alert will be changed from an increase of 2,000 to 500 mg/dL during 
that period.  
In the event of a platelet count less than 75,000/mm3, and in the absence of 
major bleeding or clinically -relevant non-major bleeding (defined below; 
Schulman et al. 2005), dosing of a patient with volanesorsen should be 
suspended temporarily until the platelet count has recovered to > 100,000/mm3.  
If dosing is continued it should be at a reduced dose frequency of 300 mg every 
2 weeks or a reduced dose of 150 mg per week  (refer to Section 8.7).  The 
suitability  of the patient for continued dosing will be determined by [CONTACT_37834]’s platelet count, 
whether any bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of dosing.  
If after the first dosing rechallenge the platelet count again falls below 75,000/mm
3, then dosing of the patient with Study Drug will be stopped 
permanently.  
Following a rechallenge platelet count should be tested every week until count 
is stable.  
Any unreportable platelet count result must be rechecked and determined not to 
have met a stoppi[INVESTIGATOR_10450].  
If there is no reportable platelet count within [ADDRESS_38172] the patient to hold dosing until a new platelet count 
is obtained and reviewed.  To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
14  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37543] 23 Actions in Patients with Low Platelet Count  
Platelet C ount 
on Rx  Drug Dose Monitoring  
Normal range, 
> 140K/mm3 Study D rug administration is 
contingent on the availability 
of the immediately preceding 
test result.  An interpretable 
platelet v alue must be 
available within [ADDRESS_38173] 
be documented in the 
patient’s medical records.  
No action  Monitor every 1 week 
unless otherwise 
specified 
Obtain addi tional lab 
tests (Table 2) if 
2 occurrences  
consecutive or non-
consecutive) of 
platelet count 140K - 
> 100K/mm3 or 
1 occurrence of 
platelet count 
≤100K/mm3.  Labs 
only need to be 
performed once.   Labs 
may be collected over 
multiple visits, if blood 
requirements are a 
concern, as per 
Investigator discretion  
Monitor every 2 weeks  
> 100K /mm3-
140K/mm3 Weekly 300 mg S tudy Drug 
administration No action  Closer observation  
Monitor every 1 week 
until stable*  
75K-100K/mm3 - 
75K/mm3 Permanently reduce dose 
frequency to 300 mg every 2 weeks or reduce dose to 
150 mg weekly  Closer observation  
Monitor every 1 week  
50K-75K/mm3 - 
50K/m m3 If occurs while on dose of 300 mg every 2 weeks or 
150 mg every week  then 
permanently discontinue 
Study Drug, otherwise dose 
pause.  
When platelet count returns to > 100K/mm
3 restart 
dosing at dose frequency of 
300 mg every 2 weeks or 
150 mg weekly  only if 
approved by [CONTACT_37835] 2-3 days until 
2 successive values 
are >  75K/mm
3 then 
monitor every 
1 weekshow 
improvement  
Consider discontinuation of 
antiplatelet 
agents/NSAIDS/ anticoagulant medication  
 To provide added 
patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
15  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37543] 23 Actions in P atients with Low Platelet Count Continued  
Platelet C ount 
on Rx  Drug Dose Monitoring  
25K-< 50K/mm3 
or a rate of 
decline ≥  50% 
between two consecutive 
assessments, irrespective of the platelet level  Permanently discontinue Study Drug  Closer observation  
• Moni tor daily until 
2 successive values 
show improvement then monitor every 
2-3 days until 
2 successive values 
are >  75K/mm3 then 
monitor every 1 week  
platelet count stable  
• Patient should be 
evaluated by a 
hematologist to 
provide diagnostic 
and therapeutic 
management  
• Steroids 
recommended if 
platelet count is 
< 50K/mm3*.  It is 
strongly 
recommended that, 
unless the patient has 
a medical 
contraindication to 
receiving 
glucocorticoids, the 
patient receives 
glucocorticoid therapy 
to reverse the platelet 
decline.   
• Monitor triglyceride 
levels weekly and 
continue AE 
monitoring during 
steroid therapy  
• Discontinue 
antiplatelet 
agents/NSAIDS/antico
agulant medication while platelet count < 50K/mm
[ADDRESS_38174] ions, 
ISIS 304801 dose exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
16  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37544] 23 Actions in Patients with Low Platelet Count  Continued  
Platelet Co unt 
on Rx  Drug Dose Monitoring  
< 25K/mm3 Permanently discontinue 
Study Drug  Closer observation:  
Monitor daily until 
2 successive values 
show improvement then 
monitor every 2-3 days 
until platelet count 
stable 
Steroids 
recommended**  
Consider need for 
hospi [INVESTIGATOR_37545]/NSAIDS/anticoa
gulant medication while 
platelet count 
< 50K/mm3 if possible  
* At least 3 consecutive values measured weekly that are stable as 
determined by [CONTACT_37836] > 100,000/mm3 
**Recovery in platelet count may be accelerated by [CONTACT_37837].  Treatment guidelines for immune thrombocytopenia 
(Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days 
every 2 -4 weeks for  1-4 cycles ; Prednis(ol)one 0.5-2 mg/kg/d for 2 -4 
weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days 
(note:   may require continuation with oral steroids after methyl 
prednisolone).  I n order to reduce the unlikely but potential increased risk 
of pancrea titis during the period of corticosteroid therapy, triglyceride 
levels will be monitored weekly , and AE monitoring will continue,  during 
corticosteroid treatment  and the laboratory alert will be changed from an 
increase of 2,000 to 500 mg/dL during that period . 
 To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations  
Synopsis  
10.1.1 Efficacy Endpoints  • Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid measurements including total cholesterol, non-HDL -C, apoB, HDL -C, 
apolipoprotein A -1 (apoA -1), VLDL-C, and LDL-C 
• Percent c hange from baseline in fasting total apolipoprotein C -III 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  To assess 
potential benefit of ISIS 304801 
administration  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
17  Protocol 
Section Description of Change  Rationale  
Synopsis  
10.1.2 Safety 
Endpoints  • Adverse events including adjudicated events of pancreatitis and MACE  
• Vital signs and weight  
• Physical examinations   
• Clinical laboratory tests (serum chemistry, hematology, coagulation, 
urinalysis)  
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  To assess platelet 
function following ISIS 304801 
administration  
Appendix A  Removed W eek 2.5  
 
CBC with Differential  
c Each time a hematology lab is drawn and sent to the central laboratory 
for analysis an additional sample should be collected in parallel and analyzed locally. In the event that  both the central and local sample are 
unreportable (e.g. , due to hemolyzed or clumped blood samples) 
another sample must be repeated within [ADDRESS_38175] be 
reviewed by [CONTACT_37838] e.  All platelet count results will be promptly reviewed 
by [CONTACT_37700] a stoppi[INVESTIGATOR_1877], or 
the dose reduction rule of 100,000/mm3, or the  and determined not to 
have met a stoppi[INVESTIGATOR_10450].  If  there is no 
reportable platelet count within [ADDRESS_38176] the patient to hold dosing until a new platelet 
count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37839][INVESTIGATOR_37546] 
75,000/ mm3.  In the event of any platelet count less than 50,000/mm3 or 
a rate of decline ≥ 50% between two consecutive assessments, 
irrespective of the platelet level, then dosing of a patient with Study Drug 
(ISIS 304801 or placebo) will be stopped permanently.   Any case of a 
platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
 
Added:  
Medical Historyq 
Blood Viscosityr 
Platelet Aggregationr 
Platelet Bound Autoantibodiesr 
Archive blood sample for potential gene sequencing related to 
hypertriglyceridemia (Group [ADDRESS_38177] udy) g 
Xs 
q Patient charts will be reviewed in order to collect data for events of acute pancreatitis or suspected pancreatitis in the patient’s medical history.  Chart review may be conducted at any time during the study.  These events will be adjudicated in the same manner as for events of 
pancreatitis during the study  
r May be done.  Blood viscosity and plate let aggregation in 
volanesorsen-treatment naïve patients only  
s Platelets are assessed each calendar week, visits do not have 
specified windows to allow flexibility of scheduling  To provide added patient safety regarding platelet 
count reductions, 
ISIS 304801 dose exposure, and treatment 
recommendations  
Medical history, 
blood viscosity and potential gene sequencing to 
assess potential benefit of ISIS 304801 
administration  
Platelet aggregation to 
assess platelet function following ISIS 304801 administration  
ISIS 304801-CS7 CONFIDENTIAL Amendment 8 
Protocol - [LOCATION_009]  10 April 2017 
 
18  Protocol 
Section Description of Change Rationale 
Appendix B  Added : 
Troponin I2 
CK-MB2 
Platelet Bound Autoantibodies3 
Blood Viscosity3 
Platelet Aggregation3 
 
2 All abnormal troponin samples will be rerun at the central laboratory and 
also analyzed for CK-MB 
3 May be done To provide added 
patient safety regarding platelet 
count reductions, 
ISIS 304801 dose 
exposure, and 
treatment 
recommendations 
Blood viscosity to 
assess potential 
benefit of 
ISIS 304801 
administration 
Platelet 
aggregation to 
assess platelet 
function following 
ISIS 304801 
administration 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
19  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll  over FCS patients  
All patients will receive volanesorsen [ADDRESS_38178]-treatment evaluation period or will participate in an expanded 
access program pending approval by [CONTACT_1026]/IEC, and the appropriate 
regulatory authorities.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 
Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet 
the following criteria in order to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of 
the following:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LM F1) 
• Post heparin plasma LPL activity of ≤ 20% of normal  in medical 
history .  Note:  testing of LPL activity should not be performed 
to confirm eligibility for the study  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the 
ISIS 304801-CS16 index study   
4. Able and willing to participate in a 78-week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
20  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females  ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medical cause and FSH levels in the 
postmenopausal range for the laboratory involved), abstinent*, or if 
engaged in sexual relations of child-bearing potential, patient is 
using an acceptable contraceptive method (refer to Section 6.3.1 ) 
from time of signing the informed consent form until [ADDRESS_38179] dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38180] dose of Study Drug administration 
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria : 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of Qualification  
b. HbA1c ≥  9.0% at Qualification  
c. Recent change in anti- diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of Qualification  [with 
the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment per iod of the Study (with the exception of ± 10 units of 
insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to Qualification  
4. History withi n 6 months of Qualification  of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery  within 3 months 
of Qualification  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
21  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued  
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which 
case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38181]  
• AST > 2.[ADDRESS_38182]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive  
test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL-C > 130 mg/dL at Qualification  
e. Any other laboratory abnormalities which, in the o pi[INVESTIGATOR_37547], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding 
diathesis or coagulopathy or clinically -significant abnormality in 
coagulation parameter s at Qualification  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38183] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been successfully 
treated  
12. Treatment with another investigational drug, biological agent, or device 
within 1 month  of Qualification , or 5 half -lives of investigational agent, 
whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3)  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
22  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued  
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to Qualification a nd dose 
and regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least [ADDRESS_38184] 
4 weeks prior to  Qualification a nd dose and regimen expected to 
remain constant during the treatment period  
f. Glybera gene therapy within 2 years prior to Qualification 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_38185] 4 weeks prior to 
Qualification (Occasional or intermittent use of over -the-counter 
medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of 
> 499 mL within 60 days of Qualification  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS  304801 or placebo)  
17. Have any other conditions, including new  or worsening of existing 
condition , which, in the opi[INVESTIGATOR_37548], or could interfere with the 
patient participating in or completing the study  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
23  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- control
led Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a s
ubset of patients with 
FCS.  The same dose of [ADDRESS_38186] of the following periods:  
• A q ualification period of up to 2 weeks (unless approved by t
 he 
Sponsor) .  Please refer to Section 4.1 and Appendix A  
• A 52-week t
reatment period dur
ing 
which volanesorsen will be 
administered as a once weekly SC injection  
• An at least  26-week post -treatment evaluation period  
The patients, I nvestigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38187] . 
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, blood 
visco sity, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
platelet aggregation, liver/spleen magnetic resonance imaging ( MRI), ECGs, 
echocardiograms and quality of life assessments will be performed according 
to the schedule of procedures in A ppendix A .  Dietary counseling will be 
repeated at intervals throughout the treatment and follow -up period  and a 
daily food/drink  diary will be completed for the week prior to each quarterly 
visit by [CONTACT_6904] .  Following the Week  [ADDRESS_38188] -treatment evaluation period or will participate in an 
expanded access program pending approval by [CONTACT_1026]/IEC, and the 
appropriate regulatory authorities . 
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen will be assessed by [CONTACT_37840] (including independently adjudicated events of acute pancreatitis and MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
24  PROTOCOL SYNOPSIS Continued  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during 
the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol  (non-HDL -C), apolipoprotein B [apoB] , high -
density lipoprotein- cholester ol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : tr
ough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of volanesorsen will be performed to determine volanesorsen pharmacokinetic parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
25  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
QUALIFICATION PERIOD 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks 53 to 78* 
Safety, efficacy, PK and PD assessments  
* If needed, the post -treatment follow -up 
period will be extended (with patients 
monitored every 6 weeks) until apoC -III 
levels return to baselin e values  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
26  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38189]  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
ET early termination  
FAS full analysis set 
FCS Familial Chylomicronemia Syndrome  
GCP  Good Clinical Practice  
GLP -1 glucagon -like peptide -1 
GPI[INVESTIGATOR_37445]1  Glycosylphosphatidylinositol -anchored HDL -binding Protein 1  
HAPI  [INVESTIGATOR_37451]1c  Glycated Hemoglobi n 
HDL  High -Density Lipoprotein  
HDL -C High -Density Lipoprotein -Cholesterol  
hsCRP  High -sensitivity C -reactive protein  
ICH International Conference on Harmonization  
IDL Intermediate density lipoprotein  
IEC Independent  Ethics Committee  
IM immunogenicity  
Index  Studies  ISIS 304801 -CS6 and ISIS 304801 -CS16  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
27  STUDY GLOSSARY Continued  
Abbreviation/Acronym  Definition  
INR International Normalized Ratio  
IRB Institutional  Review Board  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_38190] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical  Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38191]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
28  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATI ONALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37549] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated 
epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination f
requently reveals eru ptive xanthomas, lipemia 
retinalis and hepatospl
enomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L pr
obably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and p
otentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothes is is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology 
of extreme hypertriglycerid
emia in FCS is considered to be ineffective triglyceride 
clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutat
ions, null mutations, and nonsense mutations in the L
PL gene, other genes currently 
identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
29  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1  (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL- mediated processing of chylomi crons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; F
igure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] (Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) a
nd a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III a
lso inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as wel l as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37841]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
30  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC-I II inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects wi
th gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonse
nse mutation in the apoC- III gene was 
identified in the heritabilit
y and phenotype intervention (HAPI) heart study in Old Order Amish 
that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly low er levels of 
apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasm a TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37690].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS p
 atients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available t
o 
date on apoC-III function, potential mechani
sms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an i 
mportant factor in liver
 reuptake of 
lipid particles by [CONTACT_37691]- mediated u
ptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing a
poC- III might enhance apoE -medi ated uptake of 
lipid p
articles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of 
action, volanesorsen  may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
31  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the 
RNase H1- mediated degradatio n of the ap oC-III mRNA, thus preventing production of the 
apoC-III protein .  Maximal antisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37554] 90% of control levels in sensitive tissues (Crooke and Bennett 1996;  
Zhang et al. 2010).  Furthermore, reduction in target mRNA levels usi ng this approach correlates 
directly  with a subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic o
ligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37843] l
inkages.  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resist
ance to exonucleases and en donucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37844] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability  and affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate O
ligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
32  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volaneso rsen has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hype rtriglyceridemic monkeys  (Graham et al. 2013). 
The phar
macokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral an d pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay. 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, s pecies -dependent 
proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_38192] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross t he placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
33  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below. 
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clini cally meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients 
with 
FCS, and patients with T2DM
. 
In a Phase 2 study, 3 patients w
ith FCS were treated with 300 mg/wk volanesorsen  in an 
open -label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_38193] on the renal (serum creati nine, proteinuria) or hepatic systems ( alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_38194]- treatment period and was not associated with platelet- related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of 
February  29, 2016) had a decrease in platelet count to less than 50,000/mm3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing
. 
The most frequently observed 
AEs with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_38195] Level ( NOAEL ) 
was defined by [CONTACT_37845] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of s afety for the  Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience o
 f volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
35  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients 
Up to approximately [ADDRESS_38196]-treatment evaluation period 
or will participate in an expanded access program pending approval by [CONTACT_1026]/IEC, and the 
appropriate regulatory authorities. 
3.[ADDRESS_38197] of the following periods: 
3.4.1 Qualification  
A qualification period of up to 2 weeks  (unless approved by [CONTACT_37846]) is given to complete 
qualification  assessments outlined in the Schedule of Procedures .  Please refer to Section 4.1 and  
Appendix A . 
3.4.2 Trea
tment  
The tr
eatment 
period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_38198] 9 Study Cen ter 
visits on Weeks 53, 54, 55, 56, 57, 58, 65, 71, and 78 (Weeks  53, 54, 55, 56, 57, 58, and 71 may 
be conducted by a home healthcare nurse) . 
3.[ADDRESS_38199] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
36  recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  
study- specific procedures or evaluations related to this open- label study are performed .   
During the qualification period, the eligibility of the patient to enroll in the open- label study will 
be determined .  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may 
be used for qualification.  A period of up to 2 weeks after completion of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_38200] been completed and after the Investigator has verified that they are eligible per criteria in 
Sections 5.1 and 5.2.  No patient  may 
begin treatme nt prior to enrollment. 
Eligible patients will b
e enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria within [ADDRESS_38201] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. 
 Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the following 
criteria in order to enter  into the open- label Study:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
37  a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Synd rome (Type 1 Hyperlipoproteinemia) 
supported by [CONTACT_37685] 1 of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal in medical history .  Note: 
testing of LPL activity should not be performed to confirm eligibility for the 
study. 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  ISIS 304801-CS16 index 
study 
4. Able and willing to participate in a 78-week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post-menopaus al 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to 
Section 6.3.1) from time
 
of signing the infor
med consent form until [ADDRESS_38202] dos e of Study Drug 
administration. 
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing po 
tential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form un til [ADDRESS_38203] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
5.2 Exclusion Criteria   
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of Qua lification  
b. HbA1c ≥ 9.0% at Qualification  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of Qualification  [with the exception of ± 10 units of 
insulin]) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
38  d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
e. Current use of GLP- 1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to Qualification  
4. History within 6 months of Qualification  of acute or unstable cardiac ischemia 
(myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient 
ischemic attack or unstable congestive cardiac failure requiring a change in medication or 
major surgery within 3 months of Qualification  
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and 
documentation of Gilbert’s syndrome in which case total bilirubin must be  
≤ 3 mg/dL 
• ALT > 2.[ADDRESS_38204] 
• AST  > 2.[ADDRESS_38205] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein measurement of <  500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥ trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated creatinine clearance calcul ated according to the formula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37446]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor) 
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL- C > 130 mg/dL at Qualification  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of thrombocytopenia (platelet count <  100,000/mm
3) or bleeding diathesis or 
coagulopathy or clinically -significant abnormality in coagulation parameters at 
Qualification  
8. History of heart failure with NYHA greater than Class II  
ISIS [ADDRESS_38206] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1 month 
of Qualification , or 5 half-lives of investigational agent, whichever is longer 
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable 
dose for at least 3 months prior to Qualification  and dose and regimen expected to 
remain constant during the treatment period.  Patients taking OTC omega- 3 fatty 
acids should make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification  
unless approved by [CONTACT_37755] 
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least [ADDRESS_38207] 4 weeks prior to 
Qualification  and dose and regimen expected t o remain constant during the treatment 
period 
f. Glybera gene therapy within 2 years prior to Qualification  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least [ADDRESS_38208] 4 weeks prior to Qualification  (Occasional 
or intermittent use of over-the-counter medications will be allowed at Inve stigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of >  499 mL within 
60 days of Qualification  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
40  16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
17. Have any other condi tions, including new or worsening of existing condition, which, in 
the opi[INVESTIGATOR_37556], or could interfere with the patient participating in or completing the study  
6. STUDY PROCEDURES  
6.[ADDRESS_38209] patient’s Week [ADDRESS_38210]. 
During the treatment period , patients will report to the study center for
  clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekl y (Section 8.1).  Collection and measurement of 
vital signs, clinical 
laboratory parameters (including hematol
ogy, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, blood viscosity, volanesorsen  
plasma concentrations, immunogenicity  (IM)  testing , platelet aggregation, liver/spleen MRI, 
ECGs, echocardiograms and quality of life assessments  will be performed according to the 
schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be re inforced at intervals throughout the treatment 
and follow-up period and all patients will complete a daily food diary  for one week prior to their 
quarterly visit.  All blood and urine samples s hould be collected  prior to volanesorsen  
administration .  Blood sampling  at Week s 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 
21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, and [ADDRESS_38211] be fasted prior to drawing all blood samples and samples 
drawn locally should also be sent to the central laboratory for analysis whenever possible.  
Dosing instructions and training will be provided to the patient where applicable. 
All reasonable attempts should be made to ensure
 compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
41  6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampl
ing over a 24-hour period following the first dose on 
Study Day [ADDRESS_38212]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the P
K subgroup is optional for sites and patients, and  consent may be withdrawn 
for t
he subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures as outlined in Appendix A . 
6.1.[ADDRESS_38213]- treatment evaluation period  or will participate in an expanded access program pending 
approval by [CONTACT_1026]/IEC, and the appropriate regulatory authorities.  The 26- week period 
consists of at least 9 Study Center visits on Weeks 53, 54, 55, 56, 57, 58, 65, 71, and 78 
(Week s 53, 54, 55, 56, 57, 58, and 71 may be conducted by a home healthcare nurse) , as outlined 
in the Schedule of Procedures in Appendix A. 
6.[ADDRESS_38214] of these analytes  is 
contained in Appendix B . 
Each ti
me a hematolog
y lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed locally.  In the event that both the central and 
local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample 
must be repeated within [ADDRESS_38215] be reviewed by [CONTACT_37848].  All platelet count results will be 
promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877], or the 
dose reduction rule of 100,000/mm
3, or the dose pause rule of 75 ,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
42  [IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37559]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 roll over patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment assignment.  
6.2.[ADDRESS_38216] 5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, 
Week 65 , and Week 78. 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, Week [ADDRESS_38217]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be mo nitored as follows: 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, Week 65, and Week 78. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
43  2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post treatment follow -up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
6.2.10 Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2) 
Patient records will be reviewed for incidents of acute pancreatitis occurring up to [ADDRESS_38218] refrain from s perm/egg donation and 
either be abstinent † or, if enga
ged in sexual relations of child-bearing potential, practice effective 
contraception fro
m the time of signing the informed consent form until at least [ADDRESS_38219]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
44  includes: surgic al sterilization (e.g., bilateral tubal ligation), hormonal contraception, 
intrauterine contraception/device, or barrier methods (female condom*, diaphragm , 
sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
* Note : A female condom and a m ale condom should not be used together as friction between the 
two can result in either product failing . 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstine nce (e.g., calendar, ovulation, symptothermal, 
post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception 
6.3.[ADDRESS_38220] 10 hours and preferably not more than 12 hours 
before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38221] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amy
lase activity is less than 
3 x upper limit of normal ( ULN ), ima
ging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_38222] (ISIS 304801) char acteristics are listed in Table 1 . 
Volanesorsen  (ISIS 304801)
 is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2 °C to 8 °C and be protected from light. 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]  10 April 2017  
45  Table 1 Volanesorsen (ISIS 304801) Characteristics 
Strength 200 mg/mL 
Volume/Formulation  1.5 mL solution per PFS 
Dose  300 mg once weekly  
Route of Administration  SC 
7.2 Packaging and Labeling  
The
 Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and retur n/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS
8.1 Volanesorsen  Administration
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly f
or Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on 
a reduced dose or dose frequency of Study Drug ( volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_38223] 
2 days apart.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol-r equired drugs. 
8.3 Other Protocol -Required T
reatment Procedures  
There are no other protocol required treatment procedures for this study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
46  8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 
8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_38224] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods ), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new sp ecimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may also be initiated as noted in 
Section 8.7.  If any of the stoppin g c
riteria described below 
(refe
r to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapte
d from the draft guidance for industry, “Drug- Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to 
guidance in  Section 8.[ADDRESS_38225] measurement that is > [ADDRESS_38226]  (or the greater of [ADDRESS_38227] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) s hould be confirmed as described above.  
ISIS [ADDRESS_38228]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_38229] (or 
the greater of [ADDRESS_38230] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_38231] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_38232]  (or the greater of [ADDRESS_38233] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a patient ’s ALT and/or AST levels reach [ADDRESS_38234] be documented in the patient’s medical records. 
Due to the [ADDRESS_38235] with the study patients.  However, if the above options are not possible, a temporary interruption of study treatment will be planned with a prompt blood draw 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
48  upon the patient’s return which must be reported and reviewed by [CONTACT_37851]. 
The tests outlin ed in Table 2  should also be performed as soon as possible.  A dditional lab tests 
will be determined by [CONTACT_37852].  Any case of a platelet count < 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3). 
Table 2 Labs to Be Perform ed in the Event of a Platelet Count Less than the Lower 
Limit of Normal (x2) or < 100,000/mm3 (x1)*  
*In patients who have any 2 occurrences (consecutive or non-consecutive) of platelet count less 
than the lower limit of normal or who have any 1 occurrence of platelets < 100,000/mm3.  Labs 
only need to be performed once.  Labs may be collected over multiple visits, if blood 
requirements are a concern, as per investigator discretion. 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
49  8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or 
clinically -relevant , non- majo
r bleeding events (which are defined in Section 8.6.3), for
 example 
excess bruising, pe
techiae, gingival bleeding on brushing teeth.  If a m inor bleeding event 
occurs, the Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), 
INR and platelet count should be performed. 
8.5.[ADDRESS_38236] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_38237] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values  exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] ≤ 70 mg /dL (≤ 3.9 mmol/L). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
50  o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as one in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to pat ient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reactio n, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it 
is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day of the event.  
8.5.[ADDRESS_38238] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within [ADDRESS_38239]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_38240] the Investigator and an unscheduled central laboratory FPG measurement and HbA1c should be performed. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
51  The threshold values are defined as:  
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38241]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can r easonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  (AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow- up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be
  suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be
 
determined by [CONTACT_37853] . 
8.[ADDRESS_38242] measurement prior to Day 1.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
52  8.6.1 Stoppi[INVESTIGATOR_10453], an d the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presume d confirmed : 
1. ALT or AST >  [ADDRESS_38243] >  [ADDRESS_38244] , which is confirmed and persists for ≥ [ADDRESS_38245] >  [ADDRESS_38246] (or the greater of [ADDRESS_38247] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_38248]  or INR  > 1.[ADDRESS_38249] >  [ADDRESS_38250] (or the greater of [ADDRESS_38251] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_38252] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24 hour) 
3. Estimated creatinin e clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by  [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 3 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen w
ill be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any plate
let count less than 5 0,000/mm3, or a rate of decline ≥ 50% between two  
consecutive assessments, irrespective of the platelet level,  or a platelet count less than 
75,000/mm3 that occurs while the patient is on dosing at 300 mg every 2 weeks, then dosing of a 
patient with volanesorsen will be stopped permanently.  Platelet count will be monitored  as 
outlined in Table 3. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
53  Administration of steroids is recommended for patients whose platelet count is less than 
50,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily f
or 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone).  I n order to reduce 
the unlikely but potential increased risk of pancreatitis during the period of corticosteroid 
therapy, triglyceride levels will be monitored weekly , and AE monitoring will continue, during 
corticosteroid treatment and the laboratory alert will be changed from an increase of 2,000 to 
500 mg/dL during that period . 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspende
d temporarily until the platelet count has re covered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks (refer to Section 8.7).  The suitability of the patient for continued dosing will be 
determined by [CONTACT_37857]’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If aft er the first dosing rechal
lenge the platelet count again falls below 75,000/mm3, then dosing 
of the patient with Study Drug will be s topped permanently. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding  in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related)  
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > [ADDRESS_38253] be documented in the patient’s 
medical records. Monitor every 1 week unless 
otherwise specified 
Obtain additional lab tests  
(Table 2) if 2 occurrences 
consecutive or non- consecutive of 
platelet count 140K - > 100K/mm
3 
or 1 occurrence of platelet count 
≤ 100K/mm3.  Labs only need to 
be performed once.  Labs may be 
collected over multiple visits, if 
blood requirements are a concern, 
as per Investigator discretion. 
> 100K/mm3 Weekly 300 mg Study Drug administration  
100K/mm3 - >75K/mm3 Permanently reduce dose frequency to 
300 mg every 2 weeks   
75K/mm3 - >50K/mm3 • If occurs while on dose of 300 mg 
every 2 weeks then permanently 
discontinue Study Drug, otherwise 
dose pause. 
• When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks 
only if approved by [CONTACT_37858]  • Monitor every 2-3 days until 
2 successive values are 
> 75K/mm3 then monitor every 
1 week 
• Consider discontinuation of 
antiplatelet agents/NSAIDS/ 
anticoagulant medication 
< 50K/mm3 or a rate of 
decline ≥ 50% between 
two consecutive 
assessments, irrespective of the platelet level Permanently discontinue Study Drug   • Monitor daily until 2 successive 
values show improvement then 
monitor every 2-3 days until 2 successive values are > 75K/mm
3 then monitor every 
1 week 
• Patient should be evaluated by a 
hematologist to provide diagnostic and therapeutic management 
• Steroids recommended if platelet 
count is < 50K/mm
3*.  It is 
strongly recommended that, 
unless the patient has a medical 
contraindication to receiving 
glucocorticoids, the patient 
receives glucocorticoid therapy to reverse the platelet decline.   
• Monitor triglyceride levels weekly 
and continue AE monitoring during steroid therapy  
• Discontinue antiplatelet agents/ 
NSAIDS/ anticoagulant 
medication while platelet count is< 50K/mm
3 if possible 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
55  Table 3  Actions in Patients with Low Platelet Count Continued  
Legend:  
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) reco
mmend Dexamethasone 40 mg 
daily for 4 days every 
2-4 w eeks for 1-4 cyc
les; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methyl  prednisolone) .  In order 
to reduce the unlikely but potential increased risk of  pancreatitis during the period of corticosteroid therapy, 
triglyceride levels will be monitored weekly, and AE monitoring will continue,  during corticosteroid treatment  and 
the laboratory alert will be changed from an increase of 2,000 to 500 mg/dL during that period. 
 
8.[ADDRESS_38254] be made in accordance with Section 8.6.3 and 
Table 3 (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
schedule must be discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to [ADDRESS_38255] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy accordi
 ng to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t ex
periences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities tha t meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_38256] 6 weeks aft
er 
discontinuing Study Drug.  Following this per
iod, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_37683] 
> 100,000/mm3), the next platelet count should be taken within at least [ADDRESS_38257] 12  weeks after discontinuing Study Drug .  Patients  should also be 
strongly encouraged to attend applicable landmark visits at Week s 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and conduct 
safety assessments in accordance with the Schedule of P rocedures in Appendix A .  Any patient 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
56  who discontinues treatment after  Week 44 should also be strongly encouraged to attend a final 
follow-up visit ( Week 78 visit assessments) approximately [ADDRESS_38258] dose of 
Study Drug , in addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_38259] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 
consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_38260] 1 2 weeks after discontinuing Study Drug.  
Patients  should also be encouraged to undergo a final  follow-up visit ( Week 78, see Appendix A ) 
prior to leaving the study.  
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_38261] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons  
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in t he study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s w
ithdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination stud y procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
ISIS [ADDRESS_38262] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing 
informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin,  fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline Qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents dur ing the 
study.  This includes marketed agents at experimental dosages that are being tested for the treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non- prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cult ures) performed between 
signing of informed consent and Week 78 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37815] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that will be reviewed periodic ally by [CONTACT_37860].  
ISIS [ADDRESS_38263] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adver se reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IR B)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the 
Investigator’s opi[INVESTIGATOR_37567] a S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not
  report on an 
individual basis in an expedited manner because they are anticipated to occur in the study population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 4 Expected
 Event for the Protocol Defined Population by [CONTACT_37861]  (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAE s using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
59  9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facilit y 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
60  9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnos is if possible. 
9.4.[ADDRESS_38264] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_38265] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_38266] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible :  The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
61  • Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Advers
e Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not liste
d in Appendix D wi
ll be graded as follows: 
• Mild:   The event is easily 
tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Vola nesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
62  • Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on  the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of  death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will
 be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and a
s outlined in the Pancreatitis 
Adjudication Charte
r.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudi cated.  
9.[ADDRESS_38267] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these includ e abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s assessment of clinical significance of out of range/abnormal laboratory values . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
63  9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the 
procedure or treatment 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a d
 ose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdos
e occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_38268] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed .  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
ISIS [ADDRESS_38269] the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or 
spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day  169) and 
Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoin ts 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol,  non- HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreat itis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
65  • Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and received at least [ADDRESS_38270] a baseline TG assessment .  The FAS represents the practically -feasible 
intent- to-treat (ITT) population as delineated in ICH Guideline E9.  
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38271] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_38272] dose PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_38273] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 inde x study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline will be the last non -missing assessment prior to the first dose of Study Drug .  Details 
will be provided in the SAP. 
10.[ADDRESS_38274] patient’s Week [ADDRESS_38275] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_37868] 304801-CS6 or ISIS 304801-CS16 index studies, and 
pooled treatment naïve group which includes  patients on placebo in index studies.  Where 
appropriate, p- values will be reported .  All statistical tests will be conducted using 2-sided tests 
with 5% Type I error rates unless otherwise stated.  
TG related endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will 
be assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK 
endpoints will be assessed in the PK Set as applicable. 
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_14454] .  The patient disposition will be summarized  by [CONTACT_14459] .  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_14453]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. 
All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reac tions (I SRs) will be summarized by [CONTACT_1570] , MedDRA preferred term 
and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_6490]. 
Laboratory tests to ensure patient safety including chemistry panel, co mplete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37869] . 
These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug a dmin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_1570] . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
67  10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] .  Response rate of patients with fasting plasma TG 
< 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and 
Month 12 will be summarized .  Response analysis will also be conducted using a range of fasting 
plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37870]-H DL-C, apoB, 
HDL -C, apoA- 1, VLDL -C, and LDL-C, total cholesterol, and fasting total apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug receive d will be examined, as 
appropriate. Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_1570] . 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics  by [CONTACT_37780].  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single-dose PK) or multiple doses (i.e., 
steady -state PK), depending on their earlier treatment in the index studies (Group 1 and 
2 patients) .  On Week [ADDRESS_38276] treatment of volanesorsen (single -dose PK), while patients who 
received volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16) , thus the PK data collected from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C
max) and the time 
taken to reach C max (Tmax) will be obtained directly from the concentr ation -time data .  Area under 
the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24h) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24h /F) will be calculated from CL 0-24h /F = Actual Dose/AUC 0-24h.  Mean residence time 
(MRT) from time zero to 24 hours after the SC administration  will be calculated from the 
equation, MRT 0-24h = AUMC 0-24h /AUC 0-24h, where AUMC 0-24h is the area under the moment 
plasma concentration -time curve from time zero to [ADDRESS_38277]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
68  Plasma PK parameters will be summarized using descriptive statistics  by [CONTACT_3148] g roup and IM 
status .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day associated with the first positive IM status emerged (T
first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the last ADA sample 
collection day, and subject - peak titer if applicable, will be listed by [CONTACT_37872] 304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day .  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropria te. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by  [CONTACT_1570] .  Furthermore, onset and t iter of the ADA 
response, if applicable, will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., %change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis  and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical recor ds and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
ISIS [ADDRESS_38278] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration  of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the w ritten approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  Th e Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_38279] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records  without violating the 
confidentiality of the patient . 
ISIS [ADDRESS_38280] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_38281].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage 
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial  duties are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized fi ling system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB  and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence 
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
71  No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the I nvestigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_38282], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical  data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed 
for adh erence to the protocol and GCP.  To resolve any questions arising from the clinical data 
management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investig ator will sign and date the indicated places on the CRF .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_38283] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for Injury section of the Informed Consent document. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
72  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62: 
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tr emblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec 2014; 2200- 2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol - [LOCATION_009]   10 April 2017  
 
73  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of  human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussar d AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Character ization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipop rotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors  of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolip oprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mip omersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PC, Voshol  PJ, et al . ApoAV reduces plasma t riglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation o f the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice. Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_38284]- Treatment Follow -up 
 
ISIS 304801-CS7 CONFIDENTIAL Amendment 8 
Protocol - [LOCATION_009]  10 April 2017 
 
76  Appendix A Schedule of Procedures – Qu alification through Treatment Period 
Study Period Quala Treatment Period 
Study Week -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3 Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6 Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12 
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET 
Study Day -14 to -
7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 
Visit Window+/- Days 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Informed Consent X                       
Outpatient Visit X X Xj Xj Xj Xj Xj Xj X Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X 
Inclusion/Exclusion Criteria X                       
Medical Historyq X                       
Vital Signs + body weight (+ height on Day 1 only) X X  X  X   X     X    X     X 
Physical Examination X X       X     X    X     X 
12- lead ECG (triplicate) X        X     X    X     X 
MRI (liver/spleen) X                      Xk 
Echocardiography X             Xk         Xk Blood Draw (Fasting)c Chemistry Panel X X  X  X   X  X   X  X  X  X   X 
CBC with Differentialb X X 
Platelets are assessed each calendar week, visits do not ha ve specified windows to allow flexibility of scheduling.  
Serum Lipid Panel X X  X  X  X X    X X    X    X X 
Blood viscosityr  X       X     X         X 
Platelet aggregationr X X       X     X         X 
Coagulation (aPTT, PT, INR) X     X   X     X    X     X 
hsCRP, HbA1c, FPG, and de-lipi[INVESTIGATOR_37570] X       X     X         X 
Sedimentation Rate  X       X     X         X 
Complement (C5a, Bb)  X       X     X         X 
Plasma PK - Volanesorsen  Xl X X  X   X     X    X     X 
Anti-Volanesorsen Antibodies  X  X  X   X     X    X     X 
FSH (women only, if applicable) X                       
Serum Pregnancy Testd X   X  X   X  X   X  X  X  X   X 
Archived Serum & Plasma Samplese  X    X   X     X         X 
Troponin Io X                       
Platelet Bound Autoantibodiesr  X                      
Archive blood sample for potential gene sequencing 
related to hypertriglyceridemia (Group 2 if not 
available from index study)g X                       
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  - [LOCATION_009]   10 April 2017  
 
77  Appendix A  Schedule of Procedures  - Qualification  through Treatment Period  Continued  
Study Period  Quala Treatment Period  
Study Week  -2 to -1 Wk 
1 W
k 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Stud y Day  -14 to  
 -7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 
Visit Window+/ - Days  0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Urinalysisc X Xm  X  X   Xm  Xm   Xm  Xm  Xm  Xm   Xm 
Fundus Photographyf X                      Xk 
Genetic testing for FCS diagnosis (if not 
available in medical history)g X                       
Weekly Study Drug:  SC Injection  X  X X X X X X X X X X X X X X X X X X X X 
Symptom Diary (weekly) X X  X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X       X     X         X 
Food/Drink Diary (quarterly)h  X       X     X         X 
Diet/Alcohol Counselingi X X  X  X   X     X    X     X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X 
 
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  - [LOCATION_009]   10 April 2017  
 
78  Appendix A  Schedule of Procedures – Post -Treatment Follow -up  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Informed Consent       
Outpatient Visit  Xj Xj X Xj X 
Inclusion/Exclusion Criteria       
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X 
MRI (liver/spleen)       
Echocardiography       Blood Draw (Fasting)c Chemistry Panel   X X X X 
CBC with Differentialb Xs X X X X 
Serum Lipid Panel    X  X 
Coagulation (aPTT, PT, INR)       
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
FSH (women only, if applicable)       
Serum Pregnancy Testd  X X X X 
Archived Serum & Plasma Samplese   X  X 
Troponin Io      
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  - [LOCATION_009]   10 April 2017  
 
79  Appendix A  Schedule of Procedures – Post -Treatment Follow -up Continued  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Urinalysisc  Xm Xm Xm Xm 
Fundus Photographyf      
Genetic testing for FCS diagnosis 
(if not available in medical 
history)g      
Weekly Study Drug:  SC Injection      
Symptom Diary (weekly) X X X X X 
Quality of Life Assessment(s)    X  X 
Food/Drink Diary (quarterly)h   X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication  X X X X X 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  - [LOCATION_009]   10 April 2017  
 
80  Appendix A  Schedule of Procedures Continued  
a Qualification procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Each time a hematology lab is drawn and sent to t
he central 
laboratory for analysis an additional sample should 
be collected in parallel and analyzed locally.   In the event that both the central and local sample are unreportable 
(e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38285] be reviewed by [CONTACT_37848].  All 
platelet count results will be promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_10035], or the dose reduction rule of 100,000/mm3, or the dose pause rule of 75,000/ mm3.  Any case of a platele t 
count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
c Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatment period urine and blood samples will be collected prior to Study Drug administration.  Does not 
apply to 24-hour PK blood draw  
d Females of childbearing potential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or 
adverse events (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of 
kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of volanesorsen  
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug (Group 2 ISIS 304801-CS16 roll  over patients ) and repeated 
at Week 52 (Please refer to Section [IP_ADDRESS]) 
g Genetic testing can be conduct
ed for study Qualification  (Group 2 ISIS 304801-CS16 roll  over patients ); genetic 
testing will only be conducted if allowed in the geographic region and only after the patient has given specific 
written informed consent for genetic testing  
h In addition to diary, patients will be contact[CONTACT_37787]  
i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will 
also be performed by [CONTACT_37743]  
j Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
k A ± 7 -day window is allowed for MRI, echocardiography procedures and fundus photography  
l Full or abbreviated PK profile (see Appendix C ) 
m Expanded urinalysis (see Appendix B ) 
n HbA1c only  
o All abnormal troponin sa
mpl
es will be rerun at the central laboratory and also analyzed for CK -MB 
p If needed, the post -treatment follow -up period will be extended (with patients  monitored every 6 weeks) until 
apoC -III levels return to baseline values  
q Patient charts will be reviewed in order to collect data for events of acute pancreatitis or suspected pancreatitis in the patient’s medical history.  Chart  review may be conducted at any time during the study.  These events will be 
adjudicated in the same manner as for events of pancreatitis during the study  
r May be done.  Blood viscosity and platelet aggregation in volanesorsen-treatment naïve patients  only 
s Platelets are assess ed each calendar week, visits do not have specified windows to allow flexibility of scheduling  
  
ISIS [ADDRESS_38286] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium 
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• Troponin I2 
• CK-MB2 
• Platelet Bound Autoantibodies
3 
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  
• Blood viscosity3 Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
4 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
Platelet Function  
• Platelet aggregation3 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
developm ent and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_38287]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window 
+/- Days  [ADDRESS_38288]-dose Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_38289] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  - [LOCATION_009]   10 April 2017  
 
87  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 8  
Protocol  - [LOCATION_009]   10 April 2017  
 
88  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 

 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38290] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38291] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 7  – [ADDRESS_38292] No:  2015-003755-21 
 
 
 

ISIS [ZIP_CODE] l-CS7 
Protocol CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 7 
7 April 2017 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 7 -7 April 2017 
Protocol History: 
Original Protocol: 
Protocol Amendment 1 : 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Protocol Amendment 6: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38293] 2015 
2 February 2016 
22 April 2016 
9 May 2016 
6 June 2016 
6 July 2016 
18 November 2016 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_38294] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor: Ionis Pharmaceuticals,  Inc. 
[ADDRESS_38295] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] Fax:  
Key Sponsor Contact:  [CONTACT_37829].D. 
[ADDRESS_38296] Carlsbad, CA [ZIP_CODE] Phone: 
Collaborator: Akcea Therapeutics  
[ADDRESS_38297] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38298] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protoc ol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 7 
Date:  [ADDRESS_38299] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38300] the study as 
described herein . 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation with out the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .....................................................................................................10  
PROTOCOL SYNOPSIS  ............................................................................................................22  
STUDY DESIGN AND TREATMENT SCH EMA  ...................................................................28  
STUDY GLOSSARY ...................................................................................................................29  
1. OBJECTIVES  ..................................................................................................................31  
2. BACKGROUND AND RATIO NALE  ...........................................................................31  
2.1 Overview of Disease  ......................................................................................................31  
2.2 Therapeutic Rationale  ....................................................................................................32  
2.3 Volanesorsen  ..................................................................................................................33  
2.3.1  Mechan ism of Action  .............................................................................................33  
2.3.2  Chemistry  ...............................................................................................................34  
2.3.3  Preclinical Experience  ............................................................................................35  
2.3.4  Clinical Experience ................................................................................................36  
2.4 Rationale for Dose and Schedule of Administration .....................................................37  
3. EXPERIMENTAL PLAN ...............................................................................................38  
3.1 Study Design  ..................................................................................................................38  
3.2 Number of Study Centers ..............................................................................................38  
3.3 Number of Patients ........................................................................................................38  
3.4 Overall Study Duration and Follow-up .........................................................................38  
3.4.1  Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification  ....................................................................................38  
3.4.2  Group 3 Patients (did not participate in an index study):   Screening/Qualification  ..........................................................................................[ADDRESS_38301] ................................................................................39  
4. PATIENT ENROLLMENT ............................................................................................39  
4.1 Screening/Qualification  .................................................................................................39  
4.2 Enrollment .....................................................................................................................40  
5. PATIENT ELIGIBILITY  ...............................................................................................40  
5.1 Inclusion Criteria  ...........................................................................................................40  
5.2 Exclusion Criteria for Group 1 (ISIS 304801-CS6) and Group 2 (ISIS  304801-CS16) 
Index Study Roll-over Patients ......................................................................................41  
6. STUDY PROCEDURES  .................................................................................................44  
6.1 Study Schedule ..............................................................................................................44  
6.1.1  Qualification (Groups 1 and 2) ...............................................................................44  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
6  6.1.2  Screening and Qualification (Group 3) ..................................................................44  
6.1.3  Treatment Period  ....................................................................................................44  
6.1.4  Extended Treatment Period  ....................................................................................45  
6.1.5  Pharmacoki netic (PK) Subgroup ............................................................................[ADDRESS_38302]- Treatment Period  ............................................................................................46  
6.2 Additional Study Assessments  .......................................................................................46  
6.2.1  Laboratory Assessments  .........................................................................................46  
6.2.2  Physical Exams and Vital Signs  .............................................................................46  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................46  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................47  
6.2.3  Echocardiography ...................................................................................................47  
6.2.4  ECG  ........................................................................................................................47  
6.2.5  MRI  ........................................................................................................................47  
6.2.6  Quality of L ife Assessments ...................................................................................47  
6.2.7  Disease Symptom Diary  .........................................................................................47  
6.2.8  Diet Monitoring  ......................................................................................................47  
6.2.9  Family History  ........................................................................................................48  
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History  
(Group 2 and 3) ......................................................................................................[ADDRESS_38303]- Treatment Follow -up Period .60  
8.9 Withdrawal of Patients from the Study  ..........................................................................61  
8.10  Concomitant Therapy and Procedures ...........................................................................61  
8.10.1  Concomitant Therapy .............................................................................................61  
8.10.2  Concomitant Procedures .........................................................................................62  
8.11  Treatment Compliance  ...................................................................................................62  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  .......................62  
9.1 Sponsor Review of Safety Information .........................................................................62  
9.2 Regulatory Requirements  ..............................................................................................62  
9.3 Definitions  .....................................................................................................................63  
9.3.1  Adverse Event  ........................................................................................................63  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................64  
9.3.3  Serious Adverse Event (SAE) ................................................................................64  
9.4 Monitoring and Recording Adverse Events ...................................................................64  
9.4.1  Serious Adverse Events ..........................................................................................64  
9.4.2  Non-Serious Adverse Events ..................................................................................65  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................65  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................65  
[IP_ADDRESS]  Severity  ............................................................................................................65  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................66  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................66  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................66  
9.4.4  Adjudication Committees  .......................................................................................67  
9.5 Procedures for Handling Special Situations ..................................................................67  
9.5.1  Abnormalities of Laboratory Tests .........................................................................67  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............67  
9.5.3  Dosing Errors .........................................................................................................68  
9.5.4  Contraception and Pregnancy .................................................................................68  
10. STATISTICAL CONSIDERATIONS  ...........................................................................69  
10.1  Study Endpoints  .............................................................................................................69  
10.1.1  Efficacy Endpoints .................................................................................................69  
10.1.2  Safety Endpoints  .....................................................................................................69  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
8  10.2  Sample Size  ....................................................................................................................69  
10.3  Populations .....................................................................................................................70  
10.4  Definition of Baseline  ....................................................................................................70  
10.5  Interim Analysis  .............................................................................................................70  
10.6  Planned Methods of Analysis ........................................................................................70  
10.6.1  Demographic and Baseline Characteristics  ............................................................71  
10.6.2  Safety Analysis  .......................................................................................................71  
10.6.3  Efficacy Analysis  ...................................................................................................71  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................72  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................72  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................72  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ..............................................[ADDRESS_38304] of the Study .........................................................................................73  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38305] of Laboratory Analytes  .............................................................................86  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................88  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnor malities ......90  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics .........................................................49  
Table 2  Labs to Be Performed in the Event of a Platelet Count Less than the 
Lower Limit of Normal (x2) or < 100,000/mm3 (x1)* ..........................................53  
Table 3  Actions in Patients with Low Platelet Count or Drop in Platelet Count  ................59  
Table 4  Expected Event for the Protocol Defined Population by [CONTACT_37674]  ...................................................................................63
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
9   
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  ...............32  
Figure 2  Design of Chimeric 2ʹ- MOE Pho sphorothioate Oligonucleotides 
(MOE -Gapmer).  The sequence of volanesorsen is shown ....................................34  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ...............36  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 7 
Protocol  7 April 2017 
 
10  PROTOCOL AMENDMENT 
 
Protocol Number:  ISIS 304801-CS7 
Protocol Title:  An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 
Amendment Number:  7 
Amendment Date:  7 April 2017 
 
The purpose of this protocol amendment is to imp lement the following modifications to Protocol 
ISIS 304801-CS7 Amendment 6 dated 18 November 2016: 
1. To update the platelet safety monitoring rules shown in Table [ADDRESS_38306] activity of ≤  20% of normal in medical histor y as an inclusion criteria for 
Group 2 and 3 patients as has been allowed for Group 1 patients. 
3. To add platelet count < lower limit of  normal (LLN) for the central laboratory 
 (i.e., < 140,000/mm3) for Group 3 patients. 
4. To assess acute pancreatitis in me dical history in Group 2 patients. 
5. Added archive blood sample for pot ential gene sequencing related to 
hypertriglyceridemia (Group 3; Group 2 if not available from index study) 
6. Added blood viscosity (may be done) to assess potential benefit of ISIS 304801 
administration and platelet aggregation (m ay be done) to assess platelet function. 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design. 
The following table provides a summary list of major changes to the protocol, additions are indicated as underline and deletions  are indicated as strikethrough: 
Protocol 
Section Description of Change Rationale 
Section 3.4.[ADDRESS_38307]-treatment evaluation period is 13 weeks and consists of 4 Study 
Center visits on Weeks 54, 56, 58, and 65 (Weeks 54, 56, and 58 may be 
conducted by a home healthcare nurse). 
 
Is The post-treatment evaluation period is 13 weeks and consists of 7 Study 
Center visits on Weeks 53, 54, 55, 56, 57, 58, and 65 (Weeks 53, 54, 55, 
56, 57, and [ADDRESS_38308] ed by a home healthcare nurse). To provide added 
patient safety 
regarding platelet 
count reductions 
and ISIS 304801 dose exposure 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
11  Protocol 
Section Description of Change  Rationale  
Synopsis  
Section 5.1 
Inclusion Criteria 3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 (index studies) with an acceptable safety profile, per 
Sponsor and Investigator judgement.  
Groups 2 and 3:  Patients must also meet the following criteria in order to enter into the open-label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG meas urement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) supported  by [CONTACT_37685] 1  
of the following:  
• Confirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal in 
medical history.  Note: testing of LPL activity should not 
be performed to confirm eligibility for the study  
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS 304801-CS16 index study  
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this open -label 
study  To add LPL activity of ≤ 20% of normal in medical history 
as an inclusion 
criteria for 
Group 2 and 3  
patients as has 
been allowed for 
Group 1 patients  
Synopsis  
5.2 Exclusion Criteria for 
Group 3  5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and docume ntation of Gilbert’s syndrome in which 
case total bilirubin must be  
≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38309]  
• AST > 2.[ADDRESS_38310]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or 
CKD-EPI [INVESTIGATOR_37446] -Gault for 
estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Platelet count < lower limit of normal (LLN) for the central 
laboratory (i.e., < 140,000/mm3) 
dc. Cardiac Troponin I >  ULN at Screening  
ed. LDL-C > 130 mg/dL at Screening  
fe. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37547], would make the patient unsuitable for inclusion
 To provide added patient safety regarding platelet count reductions, and ISIS 304801 
dose exposure  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
12  Protocol 
Section Description of Change  Rationale  
Synopsis  
6.1.3 
Treatment Period During the treatment period, patients will report to the study center for clinic visits a minimum of 5 times during Weeks 1- 52 (see Schedule of 
Procedures in Appendix A).  Study Drug will be administered once weekly unless the patient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital signs, clinical laboratory 
parameters (including hematology, serum chemistry, and urinalysis), AEs, 
concomitant medication/procedure information, lipid panel, blood 
viscosity , volanesorsen plasma concentrations, immunogenicity (IM) 
testing,  platelet aggregation , liver/spleen MRI, ECGs , echocardiograms 
and quality of life assessments will be performed according to the schedule 
of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events.  Dietary counseling will be reinforced at 
intervals throughout the treatment and follow -up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.   All 
blood and urine samples should be collected prior to volanesorsen 
administration.  Blood sampling at Weeks 2, 3, 4, [ADDRESS_38311] be fasted prior to 
drawing all blood samples and samples drawn locally should also be sent to the central laboratory for analysis whenever possible.  Every effort should 
be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.   Dosing instructions and training will be provided to 
the patient where applicable.  To provide added patient safety regarding platelet count reductions 
and ISIS 304801 
dose exposure  
6.14 Extended 
Treatment Period During the extended treatment period, patients will report to the study center for clinic visits during Weeks 54- 104 (see Schedule of Procedures in 
Appendix A).  Study Drug will be administered once weekly unless the patient is on a biweekly dosing schedule for safety reasons (Section 8.1).  
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), AEs, concomitant medication/procedure information, lipid panel, volanesorsen plasma conc entrations, IM testing, ECGs, and physical examinations will be 
performed according to the Schedule of Procedures in Appendix A.  
Adverse events at the injection site should be collected as adverse events.  
Dietary counseling will be reinforced at interval s throughout the extended 
treatment period.  All blood and urine samples should be collected prior to 
volanesorsen administration.  Blood sampling at Weeks 53, 54, [ADDRESS_38312] be fasted prior to drawing all blood samples and samples drawn locally should also be sent to the central laboratory for analysis whenever possible.  Every effort should be made to ensure the previous 
week ’s dose is given [ADDRESS_38313] treatment 
evaluation period consists of 7 Study Center visits on Weeks  53, 54, 55 , 
56, 57, and 58 (which may be conducted by a home healthcare nurse), and 
Week [ADDRESS_38314] treatment evaluation period consisting of 7 Study 
Center visits on Weeks 105, 106, 107, 108, 109, and 110 (which may be 
conducted by a home healthcare nurse), and Week 117 as outlined in the 
Schedule of Procedures in Appendix A.  To provide added patient safety regarding platelet count reductions 
and ISIS 304801 
dose exposure  
6.2.1 
Laboratory Assessments  Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.  In the event that both the central and local sample are unreportable 
(e.g., due to hemolyzed or clumped blood samples) another sample mu st 
be repeated within 1-week  and the result must be reviewed by [CONTACT_37876].  All platelet count results will be promptly reviewed by [CONTACT_37741] a stoppi [INVESTIGATOR_1877], or the 
dose reduction rule of 100,000/mm
3, and determined not to have met a 
stoppi[INVESTIGATOR_37571] 
75,000/mm3. 
If there is no reportable platelet count within [ADDRESS_38315] the patient to hold dosing until a new 
platelet count is obtained and reviewed.  
All platelet count results will be promptly reviewed by [CONTACT_37877][INVESTIGATOR_37572] 75,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an 
expedited fashion to the Sponsor.  To provide added 
patient safety regarding platelet 
count reductions, 
ISIS 304801 dose exposure, and treatment 
recommendations  
6.2.10 Chart 
Review for 
Incidents of 
Acute Pancreatitis in Medical History  Added 
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History 
(Group 2 and 3) To assess acute 
pancreatitis in 
medical h istory  in 
Group 2 patients  
8.1 
Volanesorsen 
Administration  Removed  
Every effort should be made to ensure the previous week’s dose is given [ADDRESS_38316] be documented in the patient’s medical 
records.  
Due to the [ADDRESS_38317] with the study patients.  However, if the above options are not 
possible, a temporary interruption of study treatment will be planned 
with a prompt blood draw upon the patient’s return which must be 
reported and reviewed by [CONTACT_37832].  
The tests outlined in Table 2 should also be performed as soon as possible.  Additional lab tests will be determined by [CONTACT_37878].  
Any case of a platelet count < 50,000/mm
3 should be reported in an 
expedited fashion to the Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
15  Protocol 
Section Description of Ch ange  Rationale  
8.5.2 Safety 
Monitoring for Platelet Count Results Continued  Table 2  Labs to Be Performed in the Event of a Platelet Count Less than 
the Lower Limit of Normal (x2) or < 100,000/mm3 (x1)* < 75,000/mm3 
*In patients who have any 2 occurrences (consecutive or non -
consecutive) of platelet count less than the lower limit of normal or 
who have any 1 occurrence of platelets <  100,000/mm3.  Labs only 
need to be performed once.  Labs may be collected over multiple 
visits, if blood requirements are a concern, as per Investigator  
discretion.  
Note:  The following labs may change as additional data is assessed, 
and sites will be updated regarding any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Helicobacter pylori (IgG serum test)  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti-PF4 assay  
Anti-ASO antibody  
 To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
16  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37573] a low platelet count are summarized in 
Table 3 below.  
In the event of a platelet count less than 75,000/mm
3 that is associated with 
major bleeding or clinically -relevant non-major bleeding (defined below; 
Schulman et al. 2005), dosing of a patient with volanesorsen will be stopped 
permanently.  The follow -up schedule for any events meeting this stoppi[INVESTIGATOR_37574].  
In the event of any platelet count less than 2550,000/mm3, or a platelet count 
less than 75,000/mm3 that occurs while the patient is on dosing at 300 mg 
every 2 weeks or 150 mg every week  then dosing of a patient with 
volanesorsen will be stopped permanently.  Platelet count will be monitored as outlined in Table 3. daily until 2 successive values show improvement then 
monitored every 2-3 days until platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is less than 2550,000/mm
3.  Recovery in platelet count may be accelerated 
by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; Prednis(ol)one 0.5 2 mg/kg/d for 2-4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note: may require continuation with oral steroids after methylprednisolone).   
Triglyceride levels will be monitored weekly, and AE monitoring will continue, 
during cortiscosteroid treatment and the laboratory alert will be changed from 
an increase of 2,000 to 500 mg/dL during that period.  
In the event of a platelet count less than 75,000/mm3, and in the absence of 
major bleeding or clinically -relevant non-major bleeding (defined below; 
Schulman et al. 2005), dosing of a patient with volanesorsen should be suspended temporarily until the platelet count has recovered to > 100,000/mm
3.  If dosing is continued it should be at a reduced dose 
frequency of 300 mg every 2 weeks or a reduced dose of 150 mg per week  
(refer to Section 8.7).  The suitability of the patient for continued dosing will be determined by [CONTACT_37879]’s platelet count, whether any bleeding events were experienced by 
[CONTACT_102], and the speed of recovery of platelet count upon holding of dosing.  
If after the first dosing rechallenge the platelet count again falls below 75,000/mm
3, then dosing of the patient with Study Drug will be stopped 
permanently.  
Following a rechallenge platelet count should be tested every week until 
count is stable.  
Any unreportable platelet count result must be rechecked and determined not 
to have met a stoppi[INVESTIGATOR_10450].  
If there is no reportable platelet count within [ADDRESS_38318] the patient to hold dosing until a new platelet 
count is obtained and reviewed.  To provide added patient safety regarding platelet count reductions, 
ISIS 304801 
dose exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
17  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37575]:  
Table 3 Actions in Patients with Low Platelet Count  
Platelet 
Count on Rx  Drug Dose Monitoring  
Normal range, > 140K/mm
3 No action  Monitor every 2 weeks  
100K -
140K/mm3 No action  Closer observation  
Monitor every 1 week until 
stable*  
75K-
100K/mm3 Permanently reduce 
dose frequency to 300 mg every 2 weeks  
or reduce dose to 
150 mg weekly  Closer observation  
Monitor every  1 week  
50K-75K/mm3 If occurs while on dose 
of 300  mg every 
2 weeks or 150 mg 
every week then permanently 
discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to >  100K/mm
3 
restart dosing at dose frequency of 300 mg 
every 2 weeks or 
150 mg weekly only if 
approved by [CONTACT_37835] 2-3 days until 2 successive values show 
improvement  
Consider discontinuation of antiplatelet agents/NSAIDS/  
anticoagulant medication  
25K-50K/mm3 If occurs while on dose of 300  mg every 
2 weeks or 150 mg 
every week then permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to >  100K/mm
3 
restart dosing at dose 
frequency of 300 mg 
every 2 weeks or 
150 mg weekly only if 
approved by [CONTACT_37880] 2 successive values show 
improvement then monitor 
every 2 -3 days until platelet 
count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet 
count <  50K/mm
3 if possible 
 To provide added patient safety regarding platelet count reductions, 
ISIS 304801 
dose exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
18  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37576] 3 Actions in Patients with Low Platelet Count  Continued  
Platelet 
Count on Rx  Drug Dose Monitoring  
< 25K/mm3 Permanently 
discontinue 
Study  Drug  Closer observation:  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until platelet count stable  
Steroids recommended**  
Consider need for hospi[INVESTIGATOR_37577]/NSAIDS/anticoagulant medi cation while platelet count 
< 50K/mm
3 if possible  
* At least 3 consecutive values measured weekly that are stable as determined by [CONTACT_37683] >  100,000/mm
3 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia 
(Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1-4 cycles; Prednis(ol) one 0.5- 2 mg/kg/d for 2 -4 
weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days ( note :  
may require continuation with oral steroids after methyl prednisolone)   
  
ISIS [ADDRESS_38319] be documented in the patient’s medical records. Monitor every 1 week unless otherwise specified  
Obtain additional lab tests 
(Table 2 ) if 2 occurrence s 
consecutive or non-consecutive)  of platelet 
count 140K - > 100K/mm
3 
or 1 occurrence of platelet 
count ≤  100K/mm3.  Labs 
only need to be performed 
once.   Labs may be 
collected over multiple 
visits, if blood requirements 
are a concern, as per Investigator discretion.  
> 100K/mm3 Weekly 300 mg Study 
Drug administration  
100K/mm3 - 
> 75K/mm3 Permanently reduce dose frequency to 300 mg every 2  weeks   
75K/mm3 - 
> 50K/mm3 • If occurs while on dose of 300 mg every 2 weeks then 
permanently discontinue Study Drug, otherwise dose pause  
• When platelet count returns to > 100K/mm
3 
restart dosing at dose 
frequency of 300 mg 
every 2 weeks only if 
approved by [CONTACT_37858]  • Monitor every 2-3 days until 2 successive 
values are >75K/mm
3 
then monitor every 1 week  
• Consider discontinuation of antiplatelet agents/NSAIDS/ 
anticoagulant 
medication  
 
 To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
20  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37578] 3  Actions in Patients with Low Platelet Count or Drop in Platelet 
Count  Continued  
Platelet 
Count on Rx  Drug Dose Monitoring  
≤ 50K/mm3 Permanently discontinue 
Study Drug  • Monitor daily until 
2 successive values show 
improvement then monitor every 2-3 days until 2 successive values 
are >  75K/mm
3 then 
monitor every 1 week  
• Patient should be 
evaluated by a 
hematologist to provide diagnostic and therapeutic management  
• Steroids recommended*.  
It is strongly 
recommended that, unless the patient has a medical contraindication 
to receiving 
glucocorticoids, the patient receives glucocorticoid therapy to 
reverse the platelet 
decline.   
• Monitor triglyceride levels weekly and continue AE monitoring during steroid 
therapy  
• Discontinue antiplatelet agents/ NSAIDS/ 
anticoagulant medication while platelet count is< 50K/mm
3 if possible 
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia 
(Provan et al. 2010) recommend dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1-4 cycles; prednis(ol)one 0.5-2 mg/kg/d for 2-
4 weeks then taper; or methylprednisolone 30 mg/kg/day for 7 days 
(note:  may require continuation with oral steroids after 
methylprednisolone)  To provide added patient safety regarding platelet count reductions, 
ISIS [ADDRESS_38320] of patient safety, and in order to fulfill regulatory requirements, all SAEs (regardless of their relationship to volanesorsen) should be reported to the Sponsor or designee within 24 hours of the Study Center’s first knowledge of the event .  The collection of SAEs will begin after the 
patient signs the informed consent form and stop at the end of the patient’s follow -up period which is defined as the Week 65 visit (or Week 117 if 
patient enters the extended treatment period).  When the Investigator is 
reporting by [CONTACT_756], it is important to speak to someone in person versus 
leaving a message.  An Initial Serious Adverse Event Form should be 
completed and a copy should be faxed to the Sponsor or designee.  To provide consistent SAE reporting rules  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 7 
Protocol  7 April 2017 
 
21  Protocol 
Section Description of Change Rationale 
Synopsis 
10.1.1 
Efficacy Endpoints • Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the 
treatment period 
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non-HDL-C, apoB, HDL-C, 
apolipoprotein A-1 (apoA-1), VLDL-C, and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C-III 
• Change in blood viscosity (may be evaluated) 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate • Other symptoms: eruptive xanthoma, lipemia retinalis To assess 
potential benefit of ISIS 304801 
administration 
Synopsis 
10.1.2 Safety 
Endpoints • Adverse events including adjudica ted events of pancreatitis and MACE 
• Vital signs and weight 
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, 
urinalysis) 
• Echocardiography 
• Electrocardiograms (ECGs) • Use of concomitant medications 
• MRIs • Platelet aggregation (may be evaluated)  To assess platelet 
function following ISIS 304801 
administration 
Appendix A Removed Week 2.5 
CBC with Differential 
c Each time a hematology lab is drawn and sent to the central laboratory 
for analysis an additional sample should be collected in parallel and 
analyzed locally.  In the event that both the central and local sample are 
unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38321] t he patient to hold dosing until a new 
platelet count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37881] a stoppi[INVESTIGATOR_37579], and to determine whether the 
rate of decline is suggestive that the patient could be approaching the 
or the dose reduction rule of 100,000/mm3, or the dose pause rule of 
75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be 
reported in an expedited fashion to the Sponsor 
Added:  Blood Viscosity and Platelet Aggregation 
e May be done.  Blood viscosity and platelet aggregation in 
volanesorsen-treatment naïve patients only 
Added:  Archive blood sample for potential gene sequencing related to 
hypertriglyceridemia (Group 3; Group 2 if not available from index study) To provide added 
patient safety 
regarding platelet 
count reductions, 
ISIS 304801 dose 
exposure, and 
treatment recommendations. 
Blood viscosity 
and potential 
gene sequencing 
to assess 
potential benefit of 
ISIS 304801 
administration. 
Platelet 
aggregation to 
assess platelet 
function following 
ISIS 304801 administration. 
Appendix B Added Blood Viscosity and Platelet Aggregation To assess 
potential benefit of 
ISIS 304801 
administration 
To assess platelet 
function following 
ISIS 304801 administration 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
22  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll-over  FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll-over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_38322] -treatment evaluation period  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and  any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 Groups 2 and 3 :  Patients must also meet the following criteria in order 
to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of 
the following:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal in medical 
history . Note: testing of LPL activity should not  be pe rformed to 
confirm eligibility for the study  
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS  304801-CS16 index study   
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this open -label 
study  
4. Able and willing to participate in a 65-week study  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
23  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non -pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females  ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in 
sexual relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1)  from time 
of signing 
the informed consent form
 until [ADDRESS_38323] 
dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations w
ith a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_38324] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and 
withdraw al are not acceptable methods of contraception  
Exclusion Criteria  for Group 1 (ISIS 304801-CS6 ) and Group 2  
(ISIS 304801-CS16 ) Index Study Roll-over Patients  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37580], or could interfere with the patient participating in or completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the 
study ( Section 6.3 ) 
Exclusion Criteria for Group 3 (patients who did not participate in an index 
study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening  
c. Recent change in anti- diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of screening [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment period of the Study (with the exception of ± 10 uni ts of 
insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
24  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria for Group 3  (patients who did not participate in an index 
study)  Continued  
4. History within 6 months of screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset 
angina), stroke, transient ischemic  attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery within 3 months 
of screening  
5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38325]  
• AST > 2.[ADDRESS_38326]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive 
test eligibility may be confirmed with urine microscopy 
showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estim ation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor)  
c. Platelet count < lower limit of normal ( LLN) for the central 
laboratory (i.e., < 140,000/mm
3) 
d. Cardiac Troponin I >  ULN at Screening  
e. LDL-C > 130 mg/dL at Screening  
f. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or c linically -significant 
abnormality in coagulation parameters at Screening  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38327] for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been success fully 
treated  
12. Treatment with another investigational drug, biological agent,  or device 
within 1 month of screening, or 5 half -lives of investigational agent, 
whichever is longer  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
25  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria for Group 3  (patients who did not participate in an index 
study)  Continued  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to screening and dose and 
regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to 
screening unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least [ADDRESS_38328] 4 weeks prior to screening and dose and regimen expected to remain 
constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_38329] 4 weeks prior to screening (Occasional or intermittent use of over -the-counter medications will be 
allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening or of 
> 499 mL within 60 days of screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] 
(ISIS 304801 or placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37519], or could interfere with the patient participating in or completing the study  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
26  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studi
es (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a subset of patients wi
th 
FCS.  The same dose of [ADDRESS_38330] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 
index study) :  A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]) .  Please refer to 
Section 4.1 and Appendix A  
• Group 3 patients (did not participat
e in an index study) :  An 
up to 
8-week screening and qualification period, including a diet 
stabilization period of at least 6 weeks  (screening and diet 
stabilization period may  be reduced, per Sponsor approval, if the 
patient is following a diet for optimal control of TGs and disease 
management prior to screening) .  Please refer to Section 6.1.2  and 
Appendix A  
• All patients:  
o A 52-week tr
eatment perio
d during whic
h volanesorsen will be 
administered as a once weekly SC injection  
o Option to participate in an extended treatment period (up to an 
additional 52 weeks)  
o A 13-week post -treatment evaluation period or expanded 
access program  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38331] . 
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, blood 
viscosity, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
platelet aggregation,  liver/spleen magnetic resonance imaging ( MRI), ECGs, 
echocardiograms and quality of life assessments will be performed according 
to the schedule of procedures in Appendix A .  Dietary counseling wil l be 
repeated at intervals throughout the treatment and follow -up period  and a 
daily food/drink  diary will be completed for the week prior to each quarterly 
visit by [CONTACT_6904] .  Following the Week  [ADDRESS_38332] -treatment evaluation 
period . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
27  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37840] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatiti s 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during 
the treatment period  
• Percent change and change from baseline in other fasting lipid measurements including t otal cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from bas eline in fasting total apolipoprotein C -III 
(apoC -III) 
• Change in blood viscosity (may be evaluated) 
• Quality of Life questionnaires (EQ -5D, SF-36)  
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of volanesorsen as follows : trough l 
evels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
28  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
SCREENING PERIOD  
Weeks -8 to -2 (Group 3 patients only)  
QUALIFICATION PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION (ET) 
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety 
assessments.  PK and PD/efficacy 
assessments at specified time points  
POST -TREATMENT 
EVALUATION PERIOD  
Weeks [ADDRESS_38333] 
the option of 
participating in an 
expanded access 
program or  
continuing dosing 
for up to an 
additional 52 weeks 
until an expanded 
access program is 
approved and 
available in their 
country.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
29  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38334]  
IXRS  Interactive Voice/Web -Response System  
LDL  low-density lipoprotein  
LDL -C low-density lipoprotein -cholesterol  
LMF1  lipase maturation f actor [ADDRESS_38335] lipoprotein lipase  
MACE  major acute cardiovascular ev ent 
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  no-observed -adverse -effect level  
non-HDL -C non-high-density lipoprotein -cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38336]  upper limit of normal  
VLDL  very-low-density lipoprotein  
VLDL -C very-low-density lipoprotein -cholesterol  
VLDL -TG lipoprotein -triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
31  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATI ONALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37581] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  P atients with FCS often present in 
infancy or childhood with fr
equent and severe abdominal pain, repetitive col
icky pain, repeated 
epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appear 
s lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels > 10 mmol/L probably have a co mpone
nt of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancr
eatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron -related pancreatitis has not been completely 
elucidated, 1 hy 
pothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylo micron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology of extreme hypertri
glyceridemia 
in FCS is considered to be ineffe ctive triglyceride 
clearance, due to an extremely low level of LPL act
ivity.  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting t riglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
32  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinosi
tol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37582] a platform for LPL-mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator 
of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] 
(Chan  et 
al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  
At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnune
n and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of
 dense very-low-density lipoprotein ( VLDL ) to in termediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants 
(Mann et al. 1997).  Thus, elevated plasm
a apoC- III levels are associated 
with impaired hydrolysis and retarded 
clearance of TG -rich particles, resulting in 
the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyce ridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase,  LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
33  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutat
ions ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense m
utation in the apoC- III gene was 
identified in the heritability and phenotype inter
vention (HAPI) heart study in Old Order Amish 
that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype 
analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age- dependent frequency that was associated with significantly lower levels of 
apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC- III polymorphisms associated with higher plasma TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III le vels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37690].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no dete ctable 
LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III fun
ction, potential mechanisms that explain how a
poC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small res idual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endotheli al lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an i
mportant factor in l
iver reuptake of 
lipid pa
rt
icles by [CONTACT_37691]- mediated uptake of lipid par
ticles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhan
ce apoE -mediated uptake of 
lipid particles .  Volanesor
sen-mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen ma
y provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to hum an 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
34  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.[ADDRESS_38337]
sorsen is a synthetic oligomer of 20 nucleot ides (i.e
., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The 
nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base po sition 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonu
cleases (thereby 
[CONTACT_37882])  (Geary et al. 2003), and (3) amelioration of some of the
 high dose 
toxicities thereby [CONTACT_37883] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that a re not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core
, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MO
E-Gap
mer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
35  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesors en has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apo C-III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys  (Graham et al. 2013). 
The pharma
cokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral an d pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay. 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, s pecies -dependent 
proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_38338] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross t he placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
36  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below. 
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinicall y meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS
, and patients with T2DM. 
In a Pha
se 2 study, 3 patients with FC
S were treated with 300 mg/wk volanesorsen  in an 
open -label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_38339] on the renal (serum creati nine, proteinuria) or hepatic systems ( alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_38340]- treatment period and was not associated with platelet- related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of 
February  29, 2016) had a decrease in platelet count to less than 50,000/mm3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The m
ost frequently observed AE s with vo
lanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_38341] Level ( NOAEL ) 
was defined by [CONTACT_37845] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of s afety for the  Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of vol anesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
38  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll-over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll -over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or  
ISIS 304801-CS16 index studies 
Up to approximately [ADDRESS_38342] of the following periods: 
3.4.1 Group 1 and 2 P atients (participated in ISIS  304801-CS6 or ISIS  304801–CS16 
index study):  Qualification  
A period of up to 2 weeks  (unless approved by [CONTACT_1034]) is given to  complete  qualification  
assessments outlined in the Schedule of Procedures.  Please refer to Section 4.1 and  Appendix A . 
3.4.2 Group 3 P atients (did
 not participate in 
an 
index study):  Screening/Qualification  
An up to 8- week screening and qualification period, i ncluding a diet stabilization period of at 
least 6 weeks  (screening and diet stabilization period may be reduced, per Sponsor approval, if 
the patient  is following a diet for optimal control of TGs and disease management prior to 
screening.  Please refer to Section 6.1.2 and Appendix A. 
3.4.3 Treatment  
The 
treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at sp ecified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
ISIS [ADDRESS_38343]-treatment evaluation period is 13 weeks and consists of 7 Study Cen ter visits on 
Weeks  53, 54, 55, 56, 57, 58, and 65 (Weeks 53, 54, 55, 56, 57, and 58 may be conducted by a 
home healthcare nurse) . 
3.[ADDRESS_38344] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and mee ting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Screening/ Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations related to this open- label study are performed .   
Groups 1 and 2 (Qualification):  During the qualification period, the eligibility of the patient to 
enroll in the open- label study will be determined .  Final assessments from the ISIS 304801-CS6 
or ISIS 304801-CS16 studies may be used for qualification .  A period of up to 2 weeks after 
completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  
identification number that was assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient identification number will be used to identify the 
patient  throughout the extensio n trial and must be used on all study documentation related to that 
patient .  The patient  identification number must remain constant throughout the extension trial. 
Group 3 (Screening and Qualification):  At the time of consent, the patient will be considered enrolled into the study and will be assigned a unique screening number before any study procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This number will be used to identify the patient throughout the trial and must be used on all study documentation related to that patient.  The screening number and patient identification number must remain constant throughout the entire trial.  In the event the patient is re-consented and re- screened the patient must be given a 
new screening number.  Screening numbers and patient  identification numbers, once assigned, 
will not be re -used. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
40  4.2 Enrollment  
Patient s will be enroll ed into the treatment ph as e of the study after all  Screening (Group3) and 
qualification assessments have been completed and after the Investigator has verified that they 
are eligible per criteria in Sections 5.1 and 5.2.  No patient  may be
gin treatment prior to 
enrollment. 
Eligible patients will be en
rolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_38345] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. 
Groups 2 and 3:  Patients must also meet the following criteria in order to enter  into the 
open- label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measur ement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal in medical history.  Note: 
testing of LPL activity should not be performed to confirm eligibility for the study 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  
 ISIS 304801-CS16 index study 
Group 3:  F asting TG ≥ 750 mg/dL at Screening for this open -label study  
4. Able and willing to participate in a 65 -week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
41  5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, 
patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing t
he informed consent f
orm until [ADDRESS_38346] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of 
child -bearing potential, patie
nt is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38347] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception  
5.2 Exclusion Criteria  for Group 1 (ISIS 304801- CS6) and Group 2 
(ISIS  304801- CS16 ) Index Study Roll- over Patients  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the patient participating in or completing the study.  
2. Unwilling to comply with lif estyle requirements for t
 he duration of the study 
(Section  6.3). 
Exclusion Criter
ia for Group 3 (patients who did not participate in an index study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening 
b. HbA1c ≥ 9.0% at Screening 
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of screening [with the exception of ± 10 units of insulin]) 
d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
e. Current use of GLP- 1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
42  4. History within 6 months of screening of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack 
or unstable congestive cardiac failure requiring a change in medication or major surgery within 3 months of screening 
5. Any of the following laboratory values at Screening 
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be  ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38348] 
• AST > 2.[ADDRESS_38349] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein measurement of <  500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥ trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with 
urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated  creatinine clearance calculated according to the formula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37446]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monit or) 
c. Platelet count < lower limit of normal (LLN) for the central laboratory (i.e., 
< 140,000/mm
3) 
d. Cardiac Troponin I >  ULN at Screening  
e. LDL- C > 130 mg/dL at Screening  
f. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of bleeding diathesis or coagulopathy or clinically- significant abnormality in 
coagulation parameters at Screening  
8. History of he art failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day [ADDRESS_38350] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1 -month 
of screening, or 5 half-lives of investigational agent, whichever is longer 
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable 
dose for at least 3 months prior to screening and dose and regimen expected to remain 
constant during the treatment period.  Patients taking OTC omega-3 fatty acids should make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening unless 
approved by [CONTACT_37755] 
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least [ADDRESS_38351] 4 weeks prior to 
screening and dose and regimen expected to remain constant during the treatment period 
f. Glybera gene therapy within 2 years prior to screening 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least [ADDRESS_38352] 4 weeks prior to screening (Occasional or 
intermittent use of over -the-counter medications will be allowed at Investigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of screening or of > 499 mL within 
60 days of screening  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
44  16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37548], or could interfere with the patient participating 
in or completing the study 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, C, and D . 
6.1.1 Qualification  (Groups 1 and 2) 
Please refer to Section 4.1 and Appe
ndix A. 
6.1.2 Scr
eening and Qualification  (Group 3) 
Before any study -specific procedures or evaluations are in itiated, patients must sign and date the 
informed consent form.  An 8-week period, including a diet stabilization period of at least 6 weeks (screening and diet stabilization period may be reduced, per Sponsor approval, if the 
patient  is following a diet for optimal control of TGs and disease management prior to screening ) 
is given to perform the screening evaluations.  The qualification  assessments will be performed 
at Week -[ADDRESS_38353] patient’s Week [ADDRESS_38354]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 t
imes during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  unless the patient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital signs, clinical lab
oratory parameters 
(including hematology, serum chemistry, and urinalysis), AEs , co
ncomitant 
medication/pro cedure information, lipid panel, blood viscosity, volanesorsen plasma 
concentrations, immunogenicity (IM)  testing , platelet aggregation, liver/spleen MRI, ECGs, 
echocardiograms and quality of life assessments  will be performed according to the schedule of 
procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be re inforc ed at intervals throughout the treatment and follow-up 
period and all patients will complete a daily food diary  for one week prior to their quarterly visit.  
All blood and urine samples should be collected  prior to volanesorsen administration .  Blood 
sampling  at Week s 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, a nd [ADDRESS_38355] the option of continuing dosing for up to an additional 52 weeks until an 
expanded access program  is approved and available in their country.  
During the extended treatment period, patients will report to the study center for clinic visits 
during Weeks 54-104 (see Schedule of Procedu
res in Appendix A ).  Study Drug will be 
administered once weekly  unless the patient is on a biweekly dosing schedule for safety reasons  
(Section 8.1).  Collection and measuremen
t of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry
, and urinalysis), AEs, concomitant 
medication/procedure information, lipid panel, volanesorsen plasma concentrations, IM testing , 
ECGs, and physical examinations will be performed according to the S chedule of Procedures in 
Appendix A .  Adverse events at the injection site should be collected as adverse events.  Dietary 
counseling will be reinforced at i ntervals throughout the extended treatment period.  All blood 
and urine samples should be collected prior to volanesorsen administration.  Blood sampling at 
Weeks 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, a nd 
[ADDRESS_38356] be fasted prior to drawing all blood samples and samples drawn locally should also be sent to the central laboratory for analysis  whenever possible .  Dosing 
instructions and training will be provided to the patient where applicable.  
6.1.5 Pharmacokinetic (PK) Subgroup 
A subgr
oup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a
 24-hour period following the first dose on 
Study Day [ADDRESS_38357]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the PK subgroup is
 optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A. 
ISIS [ADDRESS_38358]- treatment evaluation period consists of 
7 Study Center visits on Weeks 53, 54, 55, 56, 57, and 58 (which may be conducted by a home 
healthcare nurse) , and Week [ADDRESS_38359]- treatment 
evaluation period consisting of 7 Study Center visits on Weeks 105, 106, 107, 108, 109, and 110 (which may be conducted by a home healthcare nurse), and Week [ADDRESS_38360]
awn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed locally.  In the event that both the central and 
local sample are unreportable (e.g.,  due to hemolyzed or clumped blood samples ) another sample 
must be repeated within 1- week and the result must be reviewed by [CONTACT_37785].  All platelet count results will be 
promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877], or the 
dose reduction rule of 100,000/mm3, or the dose pause rule of 75 ,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressur e and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37559]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be taken, if possible. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
47  [IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 roll -over patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment assignm ent. 
6.2.[ADDRESS_38361] ECGs performed in triplicate at 
Week 76 and Week 104. 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767] . 
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_38362]- treatment follow-up period (Week 65). 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualif ied study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service.  Patients in the Extended Treatment Period will receive diet/alcohol counseling by 
[CONTACT_37884]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
48  3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet may  be conducted randomly duri ng the treatment and 
post treatment follow -up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
6.2.10 Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2 and 3) 
Patient records will be reviewed for incidents of acute pancreatitis occurring up to [ADDRESS_38363] r
 efrain from sperm/egg donation and 
either be abstinent† or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of 
signing the informed consent form until at least [ADDRESS_38364]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen  analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or barrier methods (female 
condom *, diaphragm, 
sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
ISIS [ADDRESS_38365] use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used together as friction between 
the two can result in either product failing. 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
6.3.[ADDRESS_38366] 10 hours and preferably not more than 12 hours before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38367] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum 
or amylase activity is less than 
3 x upper limit of normal
 (ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_38368] ( ISIS 304801) characteristics are listed in  Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2  to 8 °C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  7 April 2017  
50  7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS
8.1 Volanesorsen  Administration
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for
 Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on 
a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_38369] 
2 days apart.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol-r equired drugs. 
8.3 Othe r Protocol -Required T
reatment Procedures  
There are no other protocol required treatment procedures for this study. 8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_38370] measurement prior to Day 1  (e.g., qualification assessments or 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
51  assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected para meters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts wh o do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may also be initiated as noted in 
Section 8.7.  If any of the stoppi[INVESTIGATOR_37583] 
(refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose pa
used or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guida
nce for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,
” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to 
guidance in  Section 8.[ADDRESS_38371] measurement 
that is > [ADDRESS_38372]  (or the greater of [ADDRESS_38373] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels incr ease 
to [ADDRESS_38374]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_38375] (or 
the greater of [ADDRESS_38376] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatas e (ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_38377] or 1.2 x baseline value if the baseline value was > ULN . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
52  Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_38378]  (or the greater of [ADDRESS_38379] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases  
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemic al agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a patient ’s ALT and/or AST levels reach [ADDRESS_38380] be documented in the patient’s medical records. 
Due to the [ADDRESS_38381] with the study patients.  Howev er, if the above options are not 
possible, a temporary interruption of study treatment will be planned with a prompt blood draw upon the patient’s return which must be reported and reviewed by [CONTACT_37768]. 
The test s outlin ed in Table 2 should also be performed as soon as possible.  A dditional lab tests 
will be determined by [CONTACT_37852].  Any case of a platelet count < 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
53  Table 2 Labs to Be Performed in the Event of a Platelet C ount Less than the Lower 
Limit of Normal (x2) or < 100,000/mm3 (x1)*  
*In patients who have any 2 occurrences (consecutive or non-consecutive) of platelet count less 
than the lower limit of normal or who have any 1 occurrence of platelets < 100,000/mm3.  Labs 
only need to be performed once.  Labs may be collected  over multiple visits, if blood 
requirements are a concern, as per Investigator discretion . 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti-PF4 assay  
Anti-ASO antibody  
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
54  8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding e
vents (which are defined in Section 8.6.3), for ex
ample excess 
bruising, petechiae, gi
ngival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin time (aPTT ), prot hrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_38382] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country -specific guidelines (e.g., initiate statin therapy or increase 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_38383] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate wil l ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37504] t. 
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
55  o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient require s 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or buccal or intramuscular glucagon. 
The definition of severe symptomati c hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place 
patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient pr esents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example,  then obtain and record a blood glucose value as soon as possible 
thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day of the event.  
8.5.[ADDRESS_38384] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within 1- week of the initial test).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_38385] the Investigator and an unscheduled central laboratory FPG measurement and HbA1c should be performed. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
56  The threshold values are defined as: 
• FPG > 270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38386]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonab ly explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event (AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need t o be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be sus
 pended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
dete
rmined by [CONTACT_37885] . 
8.[ADDRESS_38387] measurement prior to Day 1.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
57  8.6.1 Stoppi[INVESTIGATOR_10453], and the  event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_38388] >  [ADDRESS_38389] , which is confirmed and persists for ≥ [ADDRESS_38390] >  [ADDRESS_38391] (or the greater of [ADDRESS_38392] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_38393]  or INR  > 1.[ADDRESS_38394] >  [ADDRESS_38395] (or the greater of [ADDRESS_38396] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_38397] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37886]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 3  below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stoppe
d permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37584] b e determined by [CONTACT_37887].  
In the event of any platelet c
ount less than 50,000/mm3, or a platelet count less than 75,000/mm3 
that occurs while the patient is on dosing at 300 mg every 2 weeks then d osing of a patient with 
volanesorsen will be stopped permanently.  Platelet count will be monitored  as outlined in 
Table 3. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
58  Administration of steroids is recommended for patients whose platelet count is less than 
50,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 day
s every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:  may require continuation with oral steroids after methylprednisolone).  Triglyceride levels 
will be monitored weekly, and AE monitoring will continue, during cortiscosteroid treatment and the labor atory alert will be changed  from an increase of 2,000 to 500 mg/dL during that period. 
In the event of a platelet count less than 75,000/mm
3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporar
ily until the platelet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks  (refer to Section 8.7).  The suitability of the patient for continued dosing will be 
determined by [CONTACT_37888] c
onsultation with the Study Medical Monitor and will be based 
on factors such as the original rate of decline in the patient’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding 
of dosing. 
If after the first dosing rechallenge 
the platelet count again falls below 75,000/mm3, then dosing 
of the patient with Study Drug will be s topped perm anently.  
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous re ctal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis  
6. Bleeding after venipuncture for > [ADDRESS_38398] be documented in the patient’s medical records.  Monitor every 1 week unless otherwise specified  
 
Obtain additional lab tests ( Table  2) if 
2 occurrences  consecutive or non-
c
onsecutive) of platelet count 140K - 
> 100K/mm3 or 1 occurrence of platelet 
count ≤ 100K/mm3.  Labs only need to be 
performed once.   Labs may be collected 
over multiple visits, if blood requirements 
are a concern, as per Investigator  
discretion.  
> 100K/mm3 Weekly 300 mg Study Drug 
administration   
100K/mm3 - >75K/ mm3 Permanently reduce dose frequency to 300 mg every 2 weeks   
75K/mm3 - >50K/ mm3 • If occurs while on dose of 300 mg 
every 2  weeks then permanently 
discontinue Study Drug, otherwise dose pause  
• When platelet count returns to > 100K/mm
3 restart dosing at dose 
frequency of 300 mg every 2 weeks 
only if approved by [CONTACT_37858]  • Monitor every 2-3 days until 2 successive values are >  75K/mm
3 
then monitor every 1 week  
• Consider discontinuation of antiplatelet agents/NSAIDS/ anticoagulant medication  
≤ 50K/mm3 Permanently discontinue Study Drug • Monitor daily until 2 successive values show improvement then monitor every 2-3 days until 2 successive values are 
> 75K/mm
3 then monitor every 1 week  
• Patient should be evaluated by a 
hematologist to provide diagnostic and 
therapeutic management  
• Steroids recommended*.  It is strongly 
recommended that, unless the patient 
has a medical contraindication to receiving glucocorticoids, the patient receives glucocorticoid therapy to reverse the platelet decline.   
• Monitor triglyceride levels weekly and continue AE monitoring during steroid therapy  
• Discontinue antiplatelet agents/ 
NSAIDS/ anticoagulant medication while 
platelet count is  < 50K/mm3 if possible  
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al. 2010) recommend dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1- 4 cycles; predni
s(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper ; or methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methylprednisolone)  
ISIS [ADDRESS_38399] be made in accordance with Section 8.6.3 and 
Table 3 (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
schedule must be discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to [ADDRESS_38400] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions
  in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that
 necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi [INVESTIGATOR_37565]  8.[ADDRESS_38401] 6 weeks af
ter discontinuing Study 
Drug .  Following this period, if the platelet count is stable (at 
least 3  consecutive values that are 
stable as determined by [CONTACT_1034] M edical Monitor and > 100,000/mm3), the next platelet 
count should be taken within at least [ADDRESS_38402] 12 weeks 
after discontinuing Study Drug .  Patients  should also be strongly encouraged to attend applicable 
landmark visits at Week s 12, 13, 25, 26, and 50, 52 (calculated based on the time elapsed since 
Day 1) to collect  fasting lipid panels and conduct safety assessments in accordance with the 
Schedule of Procedures in Appendix A .  Any patient who discontinues treatment after  Week 44 
should also be strongly encouraged to attend a final fol
low-up visit ( Week 65 visit assessments) 
approximately [ADDRESS_38403] dose of Study Drug, in addition to the applicable landmark visits . 
If the patient declines or is unable to participate in the above, 
an early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_38404] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 consecut
ive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_38405] 1 2 weeks after discontinuing Study Drug.  
Patients  should also be encouraged to undergo a final  follow-up visit ( Week 65 (or Week 117 if 
terminating from the Extended T reatment Follow- Up P eriod), see Appendix A ) prior to leaving 
the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to  have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_38406] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate i n the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal (see Section 8.8 and Appendix A ). 
For patient s wit
hdrawn for reasons othe
r tha
n withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_38407] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A conc omitant therapy is any non -protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing 
informed consent and completion of the post- treatment follow -up period.  All c oncomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
62  recorded in the patient’s source documents and CRF.  P atients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera,  
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the treatment of hypertriglyceridemia.  
Patien ts should consult with the Site Investigator or designee prior to initiating any new 
medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between signing of informed consent and Week 65 (or Week 117 if patient enters the extended treatment 
period) visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON-S ERIOUS ADVERSE EVENT  REPORTING  
9.[ADDRESS_38408] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
63  E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE accord ing to applicable regulations .  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
indivi
dual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the respons ibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 4 Expected Event for 
the Protocol Defined Population by [CONTACT_37889] D efined 
Pop
ulation  (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
64  9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm  requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existin g conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the pre-existing condition worsened.  The Investigator should al ways group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_38409] of patient  safety, and in order to fulfill regulatory requirements, all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
65  begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week 65 visit (or Week 117 if patient enters the 
extended treatment period) .  When  the Investigator is reporting by [CONTACT_756], it is important to 
speak to someone in person versus leaving a message.  An  Initial Serious Adverse Event Form 
should be completed and a copy should be faxed to the Sponsor or designee . 
Detailed information shou ld be actively sought and included on Follow-Up Serious Adverse 
Event Forms as soon as additional information becomes available.  All SAEs will be followed 
until resolution.  SAEs that remain ongoing past the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week 65 visit 
(or Week 117 if patient enters the extended treatment period).  The Investigator will monitor 
each patient  closely and record all observed or volunteered AEs on the Adverse Event Case 
Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_37585]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Adver
se Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not list
ed in Appendix D w
ill be graded as follows: 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
66  • Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Vo lanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Ons et Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely  from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
67  • Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent w ith a major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be  adjudic
ated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as
 outlined in the Pancreatitis 
Adjudication Charter.  
In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_38410] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as sou rce documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routin ely scheduled treatment will not be considered 
an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_37586] 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
68  9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient takes a dose 
of volanes
orsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose oc
cur, the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_38411] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnanc y will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37890]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
69  10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in othe r fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Change in blood viscosity (may be evaluated ) 
• Quality of Life  questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical exami nations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
70  10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and received at least [ADDRESS_38412] a baseline TG assessment .  The FAS represents the practically -feasible 
intent- to-treat (ITT) population as delineated in ICH Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38413] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_38414] dose PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_38415] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification).  
For Group [ADDRESS_38416] patient’s Week [ADDRESS_38417] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_37891] 304801- CS6 or ISIS  304801-CS16 index studies, and pooled 
treatment naive group which including patients on placebo in index studies and Group 3 patients.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
71  Where appropriate, p- values will be reported .  All statistical tests will be conducted using 2 -sided 
tests with 5% Type  I error  rates unless otherwise stated.  
TG related  endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will 
be assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK 
endpoints will be assessed in t he PK Set as applicable.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_14454] .  The patient disposition will be summarized  by [CONTACT_14459] .  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_14453]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_1570] , MedDRA preferred term 
and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_6490]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37869] . 
These safety variables will also be presented as change and percent change from baseline over time after Study Drug admin istration, as appropr iate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_1570] . 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] .  Response rate of pa tients with fasting plasma TG 
< 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a range of fasting 
plasma TG thresholds for determination of responder status. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
72  Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37870]- HDL -C, apoB, 
HDL -C, apoA- 1, VLDL -C, and LDL-C, total cholesterol, and fasting total apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_1570] . 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics  by [CONTACT_37780].  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single-dose PK) or multiple doses (i.e., 
steady -state PK), dependi ng on their earlier treatment in the index studies (Group 1 and 2 
patients) .  On Week 1  Day 1 of the open- label study, patients who received placebo in the index 
study (and all patients in Group 3) will receive the first treatment of volanesorsen (single -dose 
PK), while  patients who received volanesorsen in the index studies had been on volanesorsen 
treatment for 12 months (ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data 
collected from these patients reflect steady -state PK .  The maximum o bserved drug 
concentration (C max) and the time taken to reach C max (Tmax) will be obtained directly from the 
concentration -time data .  Area under the plasma concentration -time curve from time zero to 
24 hours ( AUC 0-24h) will be calculated using the linear trapezoidal rule.  Apparent systemic 
(plasma) clearance after SC administration (CL 0-24h /F) will be calculated from  
CL 0-24h/F = Actual Dose/AUC 0-24h.  Mean residence time (MRT) from time zero to 24 hours after 
the SC administration  will be calculated from the equation,  
MRT 0-24h = AUMC 0-24h/AUC 0-24h, where AUMC 0-24h is the area under the moment plasma 
concentration -time curve from time zero to [ADDRESS_38418]. 
Plasma PK parameters will be summarized using descriptive statistics  by [CONTACT_37892] .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not evaluable, and when appli cable, titer of anti -volanesorsen  antibodies) before, during, and after 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
73  treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable 
patients, along with the study day associated with the first positive IM status emerged (T first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the last ADA sample 
collection day, and subject - peak titer if applicable, will be listed by [CONTACT_37872]  304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day .  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as  the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by  [CONTACT_1570] .  Furthermore, onset and t iter of the ADA 
response, if applicable, will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal t o notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an I nvestigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569], and a copy of the signed consent form should be provided to the patient . 
11.[ADDRESS_38419] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
74  as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any propose d advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator ’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_38420] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification  of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS  
12.[ADDRESS_38421] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
ISIS [ADDRESS_38422]  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_38423].  The Investigator /Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence.  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section  8 of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_38424], inspecting 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
76  the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; 
and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study- related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed  on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_38425] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated and/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for Injury section of the Informed Consent document. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
77  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Ef fect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B-containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM,  Ooi MM, Watts GF. An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107-129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review  of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therap y for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec 2014; 2200- 2206. 
Gaudet D, Alexander V, Bak er BF, et al. Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl ) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
78  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expres sion in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Despré s JP. Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibi tory effects of specific apolipoprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipopr otein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants i n nonalcoholic fatty liver disease. N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PC, Voshol  PJ, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standa rdization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al . Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar  S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009;  195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
79   
  
 
  
 
14. APPENDICES  
   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol   7 April 2017  
 
80   
  
 
  
 
Appendix A  Schedule of Procedures 
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7 
Protocol   7 April 2017  
 
81  Appendix A  Schedule of Procedures 
Study Period  Screen/  
Run Ina Quala Treatment Period  Post 
Treatment 
Follow -up 
Study Week  -8 to 
 -2 -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 44
9 
Visit Window+/ - Days  0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent  X X                          
Outpatient Visit  X X X Xl Xl Xl Xl Xl Xl X Xl Xl Xl Xl X Xl Xl Xl X Xl Xl Xl Xl X Xl Xl X 
Inclusion/Exclusion Criteria  X X                          
Medical Historyb X                           
Vital Signs + body weight  
(+ height on Day 1 only)  X X X  X  X   X     X    X     X   X 
Physical Examination  X  X       X     X    X     X   X 
12- lead ECG (triplicate)  X         X     X    X     X   X 
MRI (liver/spleen)  X                      Xm    
Echocardiography  X             Xm         Xm    Blood Draw (Fasting)d Chemistry Panel  X X X  X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialc X X X 
Platelets are assessed each calendar week, visits do n ot have specified windows to allow flexibility of scheduling.  X 
Serum Lipid Panel  X X X  X  X  X X    X X    X    X X   X 
Blood viscositye   X       X     X         X    
Platelet aggregatione  X X       X     X         X    
Coagulation (aPTT, PT, INR)  X X     X   X     X    X     X    
Hepatitis B, C, HIV  X                           
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37538]1c   X       X     X         X   X 
Sedimentation Rate    X       X     X         X   X 
Complement (C5a, Bb)    X       X     X         X   X 
Troponin I  X  X       X     X         X   X 
Platelet Bound Autoantibod iese   X                         
Plasma PK - Volanesorsen    Xn X X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies    X  X  X   X     X    X     X   X 
FSH (women only, if applicable)  X                           
Serum Pregnancy Testf X X   X  X   X  X   X  X  X  X   X  X X 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7 
Protocol   7 April 2017  
 
82  Appendix A  Schedule of Procedures  Continued  
Study Period  Screen/  
Run Ina Quala Treatment Period  Post Treatment 
Follow -up 
Study Week  -8 to 
 -2 -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 
Wk 
12 Wk 
13    Wk 
25 Wk 
26        Wk 
50 Wk 52  
or ET     
Study Day  -56 to 
-15 -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 Blood Draw 
(Fasting)d Archive blood sample for potential 
gene sequencing related to 
hypertriglyceridemia (Group 3; 
Group 2 if not  available from index 
study)i X                         
Archived Serum & Plasma 
Samplesg   X    X   X     X         X   X 
Urinalysisd X X Xo  X  X   Xo  Xo   Xo  Xo  Xo  Xo   Xo  Xo Xo 
Fundus Photographyh X                      Xm    
Genetic testing for FCS diagnosis (if 
not available in medical history)i X                          
Weekly Study Drug:  SC Injection    X  X X X X X X X X X X X X X X X X X X X X    
Symptom Diary (weekly)  X X X  X X X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)    X       X     X         X   X 
Food/Drink Diary (quarterly)j   X       X     X         X   X 
Diet/Alcohol Counselingk X X X  X  X   X     X    X     X  X X 
Adverse Events X X X  X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X  X X X X X X X X X X X X X X X X X X X X X X X 
a Screening and Qualification  (Group 3) procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Patient charts will be reviewed i
n order to c
ollect data for events of acute pancreatitis or suspected pancreatitis in the patient’s medical history.  Chart review may be 
conducted at any time during the study.  These events will be adjudicated in the same manner as for events of pancreatitis during the study  
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.   In the 
event that both the central and local sample ar e unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38426] be reviewed by [CONTACT_37848].  All platelet count results will be promptly reviewed by [CONTACT_37893] a stoppi[INVESTIGATOR_1877] , or the dose reduction rule of 100,000/mm3, or the dose pause rule of 75,000/mm3.  Any case of a 
platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor   
ISIS [ADDRESS_38427] 10 hours  and preferably not more than 12 hours .  During treatm ent period urine and blood 
samples will be collected prior to Study Drug  administration .  Does not  apply to 24-hour PK blood draw  
e May be done.  Blood viscosity and platelet aggregation in volanesorsen-treatment naïve patients  only 
f Females of childbearing pot ential only  
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney f unction, measurement of antibodies, etc.) in this or subsequent clinical studies of 
volanesorsen  
h If possible, fundus photography should be completed prior to administration of the first dose of Study Drug ( Group 2 [ISIS 304801-CS16 roll-over patients ] and 
Group 3)  and 
repeated at Week 52 (Please refer to Section [IP_ADDRESS]) 
i Genetic testing can 
be conducted for study qualification (Group 2 [ISIS 304801-CS16 roll-over  patients ] and Group 3) ; genetic testing will only be conducted if 
allowed in the geographic  region and only after the patient has given specific written informed consent for genetic testing  
j In addition to diary, patients will be contact[CONTACT_37787]  
k To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
l Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
m A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
n Full or abbreviated PK profile (see Appendix C ) 
o Expanded urinalysis (see Appendix B ) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7 
Protocol   7 April 2017  
 
84  Appendix A  Schedule of Procedures  – Extended Treatment Period  
Study Period  Treatment Period  Post-Treatment 
Follow -up 
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62 Mo 15  
Wk 64 Wk 66 
& 68  Wk 
70 Wk 72 
& 74 Mo 18  
Wk 76  Wk 78 
& 80  Wk 
82 Wk 84, 
86, & 88  Mo 21  
Wk 90 Wk 92 
& 94  Wk 
96 Wk 
98, 
100 & 
102 Mo 24 
Wk 
104 Wk 
106 
& 
108 Wk 
110 Mo 27  
Wk 
117 
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 56
8  582, 596 
& 610  624 638 & 
652 666 680, 
694 & 
708 722 736  
& 
750 764 813 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf X 
Vital Signs (+ body weight)     X    X    X    X   X 
Physical Examination         X        X    
12- lead ECG (triplicate)         X        X    
Urinalysis(including P/C ratio)   X  X  X  X  X  X  X  X  X X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X  X X 
CBC with Differentiala X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  X 
Serum Lipid Panel    X    X    X    X   X 
Coagulation (aPTT, PT, INR)     X    X    X    X    
Troponin I     X    X    X    X   X 
Plasma PK - ISIS 304801c        X        X   X 
Anti-ISIS  304801 Antibodies         X        X   X 
Serum Pregnancy Testd  X  X  X  X  X  X  X  X  X X 
Weekly Study Drug: SC Injection  X X X X X X X X X X X X X X X X    
Diet/Alcohol Counselinge    X    X    X    X    
Adverse Events  X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7 
Protocol   7 April 2017  
 
85  Appendix A  Schedule of Procedures – Extended Treatment Period  Continued  
Legend Text  
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated 
within [ADDRESS_38428] be reviewed by [CONTACT_37848].  All platelet count results will be 
promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100 ,000/mm3, or the dose pause rule of 
75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatment period urine and blood 
samples will be collected prior to Study Drug administration  
c Abbreviated PK collection (see Appendix C ) 
d Females 
of chi
ldbearing potential only  
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37894] 304801-CS7 CONFIDENTIAL Amendment [ADDRESS_38429] of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better character ize the profile of volanes orsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel 
• Sodium 
• Potassium 
• Chloride 
• Bicarbonate 
• Total protein 
• Albumin 
• Calcium 
• Magnesium 
• Phosphorus 
• Glucose 
• BUN 
• Creatinine 
• Uric Acid 
• Total bilirubin 
• Direct (conjugated) 
bilirubin 
• Indirect (unconjugated) bilirubin 
• ALT 
• AST 
• Alkaline phosphatase Screening Tests (Group 3) 
• Hepatitis B surface antigen 
• Hepatitis C antibody 
• HIV antibody 
• FSH (women only) 
• Serum βhCG (women 
only) 
 
Coagulation 
• aPTT (sec) 
• PT (sec) 
• INR 
 
Lipid Panel 
• Total Cholesterol 
• LDL-C 
• HDL-C 
• Triglycerides 
• Non-HDL-C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC-III 
 Hematology 
• Red blood cells 
• Hemoglobin 
• Hematocrit 
• MCV, MCH, MCHC 
• Platelets 
• White blood cells 
• WBC Differential (% 
and absolute) 
• Neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes 
• Monocytes 
 
Pharmacokinetics1  
& Immunogenicity 
• Volanesorsen levels in 
plasma 
• Anti-volanesorsen antibodies in plasma 
 
Other Assessments 
• hsCRP 
• Sedimentation Rate 
• C5a, Bb 
• Troponin I2 
• CK-MB2 
• Platelet Bound 
Autoantibodies3 
• De-lipi[INVESTIGATOR_37489] 
• HbA1c, FPG 
• Blood viscosity
3 Urinalysis 
• Color 
• Appearance 
• Specific gravity 
• pH 
• Protein 
• Blood 
• Ketones 
• Urobilinogen 
• Glucose 
• Bilirubin 
• Leukocyte esterase 
• Nitrate 
• Microscopic examination
4 
 
Additional Measures for 
Expanded Urinalysis 
• Total protein (quantitative) 
• Microalbumin 
• β2-microglobulin 
 
Platelet Function 
• Platelet aggregation
3 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabo lite assessments, IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents 
[ADDRESS_38430]-treatment follow-up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup) 
Week Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day D1 D22 D50 D85 D176 D260 D358 D449 
Visit Window 
+/- Days 0 2 2 2 2 3 2 7 
Time Point Pre-dose Pre-dose Pre-dose Pr e-dose Pre-dose Pre-dose Pre-dose Anytime 
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52 
 PK Sampling Schedule (PK Subgroup only*) 
Week Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day D1 D2 D22 D50 D85 D176 D260 D358 D449 
Visit Window 
+/- Days [ADDRESS_38431]-dose Pre-
dose Pre-
dose Pre-
dose Pre-
dose Pre-
dose Pre-
dose Anytime 
* Patients at selected sites will be asked to participate in the extended 24-hour PK profile beginning on 
Study Day 1.  Partic ipation is optional 
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52 
 PK Sampling Schedule (Extended Treatment Period) 
Week Wk 
76 Wk 
104 Wk 
117 
Study Day D526 D722 D813 
Visit Window 
+/- Days [ADDRESS_38432] abnormalities are 
based upon the Common Terminology Criteria for Adv erse Events (CTCAE) Version 4.03, 
June 2010 
 
 
  

ISIS 304801-CS7 CONFIDENTIAL Amendment 7 
Protocol  7 April 2017 
 
92  Appendix D Grading Scale for Adverse Events  Relating to Laboratory Abnormalities 
Continued 
 
 
  

ISIS 304801-CS7 CONFIDENTIAL Amendment 7 
Protocol  7 April 2017 
 
93  Appendix D Grading Scale for Adverse Events  Relating to Laboratory Abnormalities 
Continued 
 
  

 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38433] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38434] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 7  - [LOCATION_009] – [ADDRESS_38435] No:  2015-003755-21 
 
  

ISIS 304801-CS7 
Protocol -[LOCATION_009] CONFIDENTIAL 
ISIS 304801-CS7 
The APPROAC H Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 7 
3 February 2017 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 7 -[LOCATION_009] -3 February 2017 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Protocol Amendment 6: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38436] 2016 
16 September 2016 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_38437] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor: Ionis Pharmaceuticals,  Inc. 
[ADDRESS_38438] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact: , Ph.D. 
[ADDRESS_38439] 
Carlsbad, CA [ZIP_CODE] 
Phone:  
Collaborator: Akcea Therapeutics  
[ADDRESS_38440] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38441] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 7 - [LOCATION_009]  
Date:    [ADDRESS_38442] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38443] the study as 
described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation with out the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_38444] ................................................................................29  
4. PATIENT ENROLLMENT ........................................................................................... 30  
4.1 Qualification  ..................................................................................................................30  
4.2 Enroll ment  .....................................................................................................................30  
5. PATIENT ELIGIBILITY  .............................................................................................. 30  
5.1 Inclusion Criteria  ...........................................................................................................30  
5.2 Exclusion Criteria  ..........................................................................................................31  
6. STUDY PROCEDURES  ................................................................................................ 34  
6.1 Study Schedule  ..............................................................................................................34  
6.1.1  Qualification  ...........................................................................................................34  
6.1.2  Treatment Period  ....................................................................................................34  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_38445]- Treatment Period  ............................................................................................35  
6.2 Additional Study Assessments  .......................................................................................35  
6.2.1  Laboratory Assessments  .........................................................................................35  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
6  6.2.2  Physical Exams and Vital Signs  .............................................................................35  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................36  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_38446]- Treatment Follow -up Period .48  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
7  8.9 Withdrawal of Patients from the Study  ..........................................................................49  
8.10  Concomitant Therapy and Procedures ...........................................................................49  
8.10.1  Concomitant Therapy .............................................................................................49  
8.10.2  Concomitant Procedures .........................................................................................50  
8.11  Treatment Compliance  ...................................................................................................50  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ...................... 50  
9.1 Sponsor Review of Safety Information .........................................................................50  
9.2 Regulatory Requirements  ..............................................................................................50  
9.3 Definitions  .....................................................................................................................51  
9.3.1  Adverse Event  ........................................................................................................51  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................51  
9.3.3  Serious Adverse Event (SAE) ................................................................................52  
9.4 Monitoring and Recording Adverse Events ...................................................................52  
9.4.1  Serious Adverse Events ..........................................................................................52  
9.4.2  Non-Serious Adverse Events ..................................................................................53  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................53  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................53  
[IP_ADDRESS]  Severity  ............................................................................................................53  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................54  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................54  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................54  
9.4.4  Adjudication Committees  .......................................................................................55  
9.5 Procedures for Handling Special Situations ..................................................................55  
9.5.1  Abnormalities of Laboratory Tests .........................................................................55  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............55  
9.5.3  Dosing Errors .........................................................................................................56  
9.5.4  Contraception and Pregnancy .................................................................................56  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 57  
10.1  Study Endpoints  .............................................................................................................57  
10.1.1  Efficacy Endpoints .................................................................................................57  
10.1.2  Safety Endpoints  .....................................................................................................57  
10.2  Sample Size  ....................................................................................................................57  
10.3  Populations .....................................................................................................................57  
10.4  Definition of Baseline ....................................................................................................58  
10.5  Interim Analysis  .............................................................................................................58  
10.6  Planned Methods of Analysis ........................................................................................58  
10.6.1  Demographic and Baseline Characteristics  ............................................................59  
10.6.2  Safety Analysis  .......................................................................................................59  
10.6.3  Efficacy Analysis  ...................................................................................................59  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................60  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
8  [IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................60  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................60  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. [ADDRESS_38447] of the Study .........................................................................................61  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38448] of Laboratory Analytes  .............................................................................74  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................76  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......78  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics .........................................................38  
Table 2  Actions in Patients with Low Platele t Count .........................................................47  
Table 3  Expected Event for the Protocol Defined Population by [CONTACT_37895]  ...................................................................................51  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  ...............23  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer).  The sequence of volanesorsen is shown ....................................25  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ...............27  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 7
Protocol - [LOCATION_009]  3 February 2017
 
9  PROTOCOL AMENDMENT 
 
Protocol Number: ISIS 304801-CS7 
Protocol Title: An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 
Amendment Number:  7 - [LOCATION_009] 
Amendment Date: 3 February 2017 
 
The purpose of this protocol amendment is to imp lement the following modifications to Protocol 
ISIS 304801-CS7 Amendment 6 dated 16 September 2016:  
1. To exclude enrollment of FCS patients in th is open-label study who did not participate in 
the ISIS 304801-CS6 or ISIS 304801-CS16 index studies 
2. To add post heparin plasma LPL activity of ≤ 20% of normal in medical history as an 
inclusion criteria for ISIS 304801-CS16 (Group 2) patients as has been allowed for 
ISIS 304801–CS6 (Group 1) patients 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
The following table provides a summary list of major changes to the protocol: 
Protocol Section Description of Change Rationale 
Protocol Synopsis: 
Study Design 
3.1  Study Design  Was 
This is a multi-center open-label study of: 
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS 
patients 
Group 3:  FCS patients who did not participate in the 
ISIS 304801-CS6 or ISIS 304801-CS16 index studies 
 
Is 
This is a multi-center open-label study of: 
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS 
patients To exclude 
enrollment of FCS patients who did 
not participate in 
an index study 
from this open 
label study 
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 7
Protocol - [LOCATION_009]  3 February 2017
 
10  Protocol Section Description of Change Rationale 
Protocol Synopsis: 
Study Population 
5.1  Inclusion Criteria  Was 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 
or ISIS 304801-CS16 (index studies) with an acceptable 
safety profile, per Sponsor and Investigator judgement. 
 
Groups 2 and 3:  Patients must also meet the following criteria 
in order to enter into the open-label study: 
a. History of chylomicronemia as evidenced by 
[CONTACT_37684] (a creamy top layer 
after ultracentrifugation of a fasting blood sample) or 
documentation of fast ing TG measurement ≥ 880 mg/dL 
(10 mmol/L) 
b. A diagnosis of Familial Chylomicronemia Syndrome 
(Type 1 Hyperlipoproteinemia) by [CONTACT_37896]: 
• Confirmed homozygote, compound heterozygote or 
double heterozygote for known loss-of-function 
mutations in Type 1-causing genes (such as LPL, 
apoC-II, GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at 
Screening for the ISIS 304801-CS16 index study  Group 3:  Fasting TG ≥  750 mg/dL at Screening for this 
open-label study  
 
Is 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 
or ISIS 304801-CS16 (index studies) with an acceptable 
safety profile, per Sponsor and Investigator judgement. 
 Group 2:  Patients who enrolled in ISIS 304801-CS16 must 
also meet the following criteria in order to enter into the open-
label study: 
a. History of chylomicronemia as evidenced by 
[CONTACT_37684] (a creamy top layer 
after ultracentrifugation of a fasting blood sample) or 
documentation of fast ing TG measurement ≥ 880 mg/dL 
(10 mmol/L) 
b. A diagnosis of Familial Chylomicronemia Syndrome 
(Type 1 Hyperlipoproteinemia) by [CONTACT_37896]: 
• Confirmed homozygote, compound heterozygote or 
double heterozygote for known loss-of-function 
mutations in Type 1-causing genes (such as LPL, 
apoC-II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal 
in medical history 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS 304801-CS16 index study  To define the 
inclusion criteria for each group of 
patients. 
To add LPL activity 
of ≤ 20% of normal 
in medical history as an inclusion 
criteria for Group 2 
patients as has 
been allowed for 
Group 1 patients 
Protocol Synopsis:  
Study Population 
5.2  Exclusion Criteria Was (noted throughout Exclusion Criteria) 
Screening* *(Group 3) or Qualificat ion (Groups 1 and 2) 
 
Is (noted throughout Exclusion Criteria) 
Qualification To distinguish that 
patients who are rolling over from an 
index study will 
have Qualification 
assessments  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
11  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:  
Study Visit Schedule 
and Procedures  
3.[ADDRESS_38449] of the following periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study):  A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please 
refer to Section  4.1 and Appendix A.  
• Group 3 patients (did not participate in an index study):  An up to 8-week screening and qualification period, including a diet stabilization period of at least 6 weeks  (screening and 
diet stabilization period may be reduced, per Sponsor 
approval, if the patient is following a diet for optimal control 
of TGs and disease management prior to screening).  
Please refer to Section 6.1.2 and Appendix A.  
• All patients:  
o A 52-week treatment period during which 
volanesorsen will be administered as a once weekly SC injection  
A 13-week post -treatment evaluation period  
 
Is 
The study for an individual patient will generally consist of the following periods:  
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer to Section 4.1 and Appendix A.   
• A 52-week treatment period during which volanesorsen will 
be administered as a once weekly SC injection  
• A 13-week post -treatment evaluation period  To remove FCS 
patients who did 
not participate in 
an index study 
from the study 
schedule  
4.1  
Screening/Qualification  Was 
Groups 1 and 2 (Qualification):  During the qualification period, the eligibility of the patient to enroll in the open- label study will be 
determined.  Final assessments from the ISIS 304801-CS6 or 
ISIS 304801-CS16 studies may be used for qualification.  A  period 
of up to 2 weeks after completion of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies (unless approved by [CONTACT_429]) is given to complete qualification.  Qualified patients will 
retain the unique patient identification number that was assigned 
to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index 
studies.  The patient identification number will be used to identify the patient throughout the extension trial and must be used on all 
study documentation related to that patient.  The patient 
identification number must remain constant throughout the 
extension trial.  
Group 3 (Screening and Qualification):  At the time of consent, the 
patient will be considered enrolled into the study and will be assigned a unique screening number before any st udy 
procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This number will be used to identify the patient throughout the trial and must be used on all study 
documentation related to that patient.  The screening number and 
patient identification number must remain constant throughout the entire trial.  In the event the patient is re-consented and re-screened the patient must be given a new screening number.  
Screening numbers and patient identification numbers, once 
assigned, will not be re-used.  To remove FCS 
patients who did 
not participate in 
an index study 
from Screening/ 
Qualification  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
12  Protocol Section  Description of Change  Rationale  
4.1  
Screening/Qualification 
Continued  Is 
During the qualification period, the eligibility of the patient to enroll 
in the open-label study will be determined.  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may be used for qualification.  A period of up to 2 weeks after completion 
of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies 
(unless approved by [CONTACT_1034]) is given to complete qualification.  Qualified patients will retain the unique patient identification number that was assigned to them during the 
ISIS 304801-CS6 or ISIS 304801-CS16 index studies.  The 
patient identification number will be used to identify the patient 
throughout the extension trial and must be used on all study documentation related to that patient.  The patient identification number must remain constant throughout the extension trial.  To remove FCS 
patients who did 
not participate in 
an index study 
from Screening/ 
Qualification  
6.1.1  Screening  
6.1.2  Screening and 
Qualification (Group 3)  Was 
6.1.1  Qualification (Groups 1 and 2)  
Please refer to Section 4.1 and Appendix A.  
 
6.1.2  Screening and Qualification (Group 3)  
Before any study -specific procedures or evaluations are initiated, 
patients must sign and date the informed consent form.  An 
8-we ek period, including a diet stabilization period of at least 
6 weeks (screening and diet stabilization period may be reduced, 
per Sponsor approval, if the patient is following a diet for optimal 
control of TGs and disease management prior to screening) is 
given to perform the screening evaluations.  The qualification assessments will be performed at Week -2 to -1, ideally after 
patient eligibility has been determined, and on Study  Day 1.  
Abnormal screening results may be retested for review by [CONTACT_37897] 
6.1.1  Qualification  
Please refer to Section 4.1 and Appendix A.  To remove FCS 
patients who did 
not participate in an index study from Screening/ Qualification  
Section 10.3 Populations  Updated:  
Full Analysis Set (FAS):  All patients who are enrolled and 
received at least [ADDRESS_38450] a baseline 
TG assessment.   
 
PK Population:  All patients who are enrolled, receive at least 
[ADDRESS_38451] a 
baseline TG 
assessment and clarified the PK 
Population  
 
   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
13  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll  over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll  over FCS patients  
All patients will receive volanesorsen [ADDRESS_38452] -treatment evaluation period or will participate in an expanded 
access program pending approval by [CONTACT_1026]/IEC, and the appropriate 
regulatory authorities.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 
Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet 
the following criteria in order to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by  [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia)  by [CONTACT_37898]:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal  in medical 
history  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-CS16 index study   
4. Able and willing to participate in a 78-week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
14  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females >  55 years of age or, in 
females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the 
postmenopausal range for the laboratory involved), abstinent*, or if 
engaged in sexual relations of child-bearing pot ential, patient is 
using an acceptable contraceptive method (refer to Section 6.3.1 ) 
from time of signing the informed consent form until [ADDRESS_38453] dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in s exual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38454] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria : 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of Qualification  
b. HbA1c ≥  9.0% at Qualification  
c. Recent change in anti-diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of Qualification  [with 
the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment period of the Study (with the exception of ± 10 units of 
insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to Qualification  
4. History within 6 months of Qualification  of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery within 3 months 
of Qualification  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
15  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued  
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which 
case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38455]  
• AST > 2.[ADDRESS_38456]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive  
test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL-C > 130 mg/dL at Qualification  
e. Any other laboratory abnormalities which, in the o pi[INVESTIGATOR_37547], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding 
diathesis or coagulopathy or clinically -significant abnormality in 
coagulation parameter s at Qualification  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38457] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been successfully 
treated  
12. Treatment with another investigational drug, biological agent, or device 
within 1 month  of Qualification , or 5 half -lives of investigational agent, 
whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
16  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria : Continued  
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to Qualification a nd dose 
and regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least [ADDRESS_38458] 
4 week s prio r to Qualification a nd dose and regimen expected to 
remain constant during the treatment period  
f. Glybera gene therapy within 2 years prior to Qualification 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_38459] 4 weeks prior to 
Qualification (Occasional or intermittent use  of over -the-counter 
medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of 
> 499 mL within 60 days of Qualification  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or placebo)  
17. Have any other conditions, including new  or worsening of existing 
condition , which, in the opi[INVESTIGATOR_37548], or could interfere with the patient participating in or completing the study  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the Sponsor Medical Monitor.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
17  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double -blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a subset of patients with 
FCS.  The same dose of [ADDRESS_38460] of the following 
periods:  
• A q ualification period of up to 2 weeks (unless approved by [CONTACT_429]) .  Please refer to Section 4.1 and Appendix A  
• A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
• An at least  26-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38461] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_38462] -
treatment evaluation period 
or will participate in an expanded access program 
pending approval by [CONTACT_1026]/IEC, and the appropriate regulatory authorities . 
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37798] (including independently adjudicated events of acute pancreatitis and MACE), withdrawals due to adverse events, and changes in laboratory and other safety parameters.  
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
18  PROTOCOL SYNOPSIS Continued  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during 
the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB] , high -
density lipoprotein- cholester ol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
19  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
QUALIFICATION PERIOD 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessment s.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks 53 to 78* 
Safety, efficacy, PK and PD assessments  
* If needed, the post -treatment follow -up 
period will be extended (with patients 
monitored every 6 weeks)  until apoC -III 
levels return to baseline values  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
20  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38463]  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
ET early termination  
FAS full analysis set 
FCS Familial Chylomicronemia Syndrome  
GCP  Good Clinical Practice  
GLP -1 glucagon -like peptide -1 
GPI[INVESTIGATOR_37445]1  Glycosylphosphatidylinositol -anchored HDL -binding Protein 1  
HAPI  [INVESTIGATOR_37451]1c  Glycated Hemoglobi n 
HDL  High -Density Lipoprotein  
HDL -C High -Density Lipoprotein -Cholesterol  
hsCRP  High -sensitivity C -reactive protein  
ICH International Conference on Harmonization  
IDL Intermediate density lipoprotein  
IEC Independent  Ethics Committee  
IM immunogenicity  
Index  Studies  ISIS 304801 -CS6 and ISIS 304801 -CS16  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
21  STUDY GLOSSARY Continued  
Abbreviation/Acronym  Definition  
INR International Normalized Ratio  
IRB Institutional  Review Board  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_38464] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38465]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
22  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eru ptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunze ll 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated , 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss -of-function mutations in one of these genes, or 
the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes curre ntly 
identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
23  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL- mediated processing of ch ylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] (Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hyd rolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
24  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC-I II inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly low er levels of 
apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasm a TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), a nd the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -medi ated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen  may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
25  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the 
RNase H1- mediated degradatio n of the ap oC-III mRNA, thus preventing production of the 
apoC-III protein .  Maximal antisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37554] 90% of control levels in sensitive tissues (Crooke and Bennett 1996;  
Zhang et al. 2010).  Furthermore, reduction in target mRNA levels using this approach correlates 
directly  with a subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37844] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability  and affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
26  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hype rtriglyceridemic monkeys  (Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral an d pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay. 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, s pecies -dependent 
proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_38466] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross t he placenta to reach the fetus .  Reduction of apoC-III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on embryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
27  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below. 
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an 
open -label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_38467] on the renal (serum creati nine, proteinuria) or hepatic systems ( alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_38468]- treatment period and was not associated with platelet- related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of 
February  29, 2016) had a decrease in platelet count to less than 50,000/mm3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_38469] Level ( NOAEL ) 
was defined by [CONTACT_37845] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of s afety for the  Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
29  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients 
Up to approximately [ADDRESS_38470]-treatment evaluation period 
or will participate in an expanded access program pending approval by [CONTACT_1026]/IEC, and the 
appropriate regulatory authorities. 
3.[ADDRESS_38471] of the following periods: 
3.4.1 Qualification  
A qualification period of up to 2 weeks  (unless approved by [CONTACT_1034]) is given to complete 
qualification  assessments outlined in the Schedule of Procedures .  Please refer to Section 4.1 and  
Appendix A . 
3.4.2 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_38472] 6 Study Cen ter 
visits on Weeks 54, 56, 58 , 65, 71, and 78 (Weeks 54, 56, 58, and 71 may be conducted by a 
home healthcare nurse) . 
3.[ADDRESS_38473] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of  the safety and tolerability of volanesorsen, the DSMB will provide 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
30  recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  
study- specific procedures or evaluations related to this open- label study are performed .   
During the qualification period, the eligibility of the patient to enroll in the open- label study will 
be determined .  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may 
be used for qualification.  A period of up to 2 weeks after completion of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_38474] been co mpleted and after the Investigator has verified that they are eligible per criteria in 
Sections 5.1 and 5.2.  No patient  may begin treatment prior to enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_38475] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. 
 Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the following 
criteria in order to enter  into the open- label Study:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
31  a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicrone mia Syndrome (Type 1 Hyperlipoproteinemia) 
by [CONTACT_37898]: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal in medical history  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  ISIS 304801-CS16 index 
study 
4. Able and willing to participate in a 78-week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_38476] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38477] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception  
5.2 Exclusion Criteria   
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of Qualificat ion 
b. HbA1c ≥ 9.0% at Qualification  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of Qualification  [with the exception of ± 10 units of 
insulin]) 
d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
32  e. Current use of GLP- 1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks  prior to Qualification  
4. History within 6 months of Qualification  of acute or unstable cardiac ischemia 
(myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient 
ischemic attack or unstable congestive cardiac failure requiring a change in medication or major surgery within 3 months of Qualification  
5. Any of the following laboratory values at Qualification  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be  ≤ 3 mg/dL 
• ALT > 2.[ADDRESS_38478] 
• AST  > 2.[ADDRESS_38479] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine 
dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein measurement of <  500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥ trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with 
urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated creatinine clearance calcul ated according to the formula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37446]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor) 
c. Cardiac Troponin I >  ULN at Qualification  
d. LDL- C > 130 mg/dL at Qualification  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of thrombocytopenia (platelet count <  100,000/mm
3) or bleeding diathesis or 
coagulopathy or clinically -significant abnormality in coagulation parameters at 
Qualification  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day [ADDRESS_38480] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1 month 
of Qualification , or 5 half-lives of investigational agent, whichever is longer 
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable 
dose for at least 3 months prior to Qualification  and dose and regimen expected to 
remain constant during the treatment period.  Patients taking OTC omega- 3 fatty 
acids sho uld make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to Qualification  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to Qualification  
unless ap proved by [CONTACT_37755] 
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least [ADDRESS_38481] 4 weeks prior to 
Qualification  and dose and regimen expected to remain constant during the treatment 
period 
f. Glybera gene therapy within 2 years prior to Qualification  
g. Oral anticoagulants (e.g. , warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least [ADDRESS_38482] 4 months prior 
to Qualification  and dose and regimen expected to remain constant during the 
treatment period  
i. Plasma apheresis within 4 weeks prior to Qualification  or planned during the study 
j. Prior exposure to ISIS 304801 
k. Any other medication unless stable at leas t 4 weeks prior to Qualification  (Occasional 
or intermittent use of over-the- counter medications will be allowed at Investigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of Qualification  or of >  499 mL within 
60 days of Qualification  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
ISIS [ADDRESS_38483] patient’s Week [ADDRESS_38484]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure informatio n, lipid panel, volanesorsen p lasma concentrations,  
immunogenicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All bloo d and urine 
samples should be collected  prior to volanesorsen administration .  Blood sampling  at Week s 2.5, 
4, 6, 8, 10, 12, 15, 17, 19, 21, 23, 25, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, a nd [ADDRESS_38485] be fasted prior to drawing all blood samples and samples drawn locally should also 
be sent to  the central laboratory for analysis  whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given 7 days prior to a scheduled clinic visit.  Dosing 
instructions and training will be provided to the patient where applicable. 
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_38486]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without bei ng 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_38487]- treatment evaluation period  or will participate in an expanded access program pending 
approval by [CONTACT_1026]/IEC, and the appropriate regulatory authorities.  The 26- week  period 
consists of at least 6 Study Center visits on Weeks 54, 56, 58, 65, 71, and 78 ( Week s 54, 56, 58, 
and 71 may be conducted by a home healthcare nurse) , as outlined in the Schedule of Procedures 
in Appendix A. 
6.[ADDRESS_38488] of these analytes  is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed locally.  In the event that both the central and 
local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38489] the patient to hold dosing until a new platelet count is obtained and reviewed. 
All platelet count results will be promptly reviewed by [CONTACT_37900][INVESTIGATOR_37587] 75,000/mm
3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight,  blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37588] (preferentially on the left arm).  Height will be measured at  
the Day 1  visit. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
36  [IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37559]/duration of the events will be recorded.  Physical exams 
should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 roll over patients) and repeated at Week 52.   
Images will be eval uated by [CONTACT_37702], blinded to the patient’s treatment 
assignment.  
6.2.[ADDRESS_38490] 
5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, 
Week 65 , and Week 78. 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, Week [ADDRESS_38491]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, Week 65, and Week 78. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
37  2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post 
treatment follow -up periods. 
6.2.[ADDRESS_38492] refrain from sperm/egg donation and 
either be abstinent † or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_38493]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patie nts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, 
intrauterine contraception/device, or barrier methods (female condom *, diaphragm, 
sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus i s not 
exposed to the Study Drug . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
38  For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are 
not acceptable methods of contraception 
6.3.[ADDRESS_38494] 10 hours and preferably not more than 12 hours 
before vis its requiring  fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38495] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification  (Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_38496] (ISIS 304801) characteristics are listed in Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2 °C to 8 °C and be protected from light. 
Table 1 Volanesorsen (ISIS 304801) Characteristics 
Strength 200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
39  7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_38497] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treat ment procedures for this study. 
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
ISIS [ADDRESS_38498] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index s tudies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Gui dance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laborat ory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during th e Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request 
confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether 
additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may also be initiated as noted in Section 8.7.  If any of the stoppi[INVESTIGATOR_37466] 
(refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with 
Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury:  P
remarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in  Section 8.[ADDRESS_38499] measurement that is > [ADDRESS_38500]  (or the greater of [ADDRESS_38501] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase to [ADDRESS_38502]. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
41  Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_38503] (or 
the greater of [ADDRESS_38504] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly  until ALT and AST levels become 
≤ 1.[ADDRESS_38505] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_38506]  (or the greater of [ADDRESS_38507] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_38508] . 
8.5.2 Safety Monitoring for Platelet Count Results  
Actions to be taken in the event of reduced platelet count are shown in Table 2 in Section 8.6.3. 
Additional lab tests will be determined by [CONTACT_37901] .  
Any case of a platelet count < 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or 
clinically -relevant , non- major bleeding events (which are defined in Section 8.6.3), for example 
excess bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), 
INR and platelet count should be performed. 
8.5.[ADDRESS_38509] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs , LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the sta tin dose for patients who are already on treatment).  
8.5.[ADDRESS_38510] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate wil l ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37504] t. 
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as one in which the patient requi res 
assistance of another person to obtain treatment for the event and has a plasma glucose level ≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptoma tic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place 
patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
43  patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there a re 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood 
glucose may be low.  Common symptoms include headache, heart pounding, confusion, 
disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, 
anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could 
occu r if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do  so.  If there is doubt about safety they should treat the event first, using some sugar, 
milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_38511] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or later and confirmed on subsequent testing (i deally within [ADDRESS_38512]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-bre akfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_38513] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
The threshold values are defined as: 
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38514]) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
44  • Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the 
Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_38515] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_38516] >  [ADDRESS_38517] , which is confirmed and persists for ≥ [ADDRESS_38518] >  [ADDRESS_38519] (or the greater of [ADDRESS_38520] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_38521]  or INR  > 1.[ADDRESS_38522] >  [ADDRESS_38523] (or the greater of [ADDRESS_38524] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37903]  
8.6.[ADDRESS_38525] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24 hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or  follow-up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a l ow platelet count are summarized in  Table 2 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37589].  
In the event of any platelet count less than 50,000/mm3, or a rate of decline ≥ 50% between two  
consecutive assessments, irrespective of the platelet level,  then dosing of a patient with 
volanesorsen will be stopped permanently.  Platelet count will be monitored daily until 
2 successive values show improvement then monitored every 2-3 days until platelet count is 
stable.  
Administration of steroids is recommended for patients whose platelet count is le ss than 
25,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks  for 1 -4 cycles ; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone).  I n order to reduce 
the unlikely but potential increased risk of pancreat itis during the period of corticosteroid 
therapy, triglyceride levels will be monitored weekly during corticosteroid treatment and the laboratory alert will be changed from an increase of 2,000 to 500 mg/dL during that period. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
46  In the event of a platelet co unt less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks or a reduced dose of 150 mg per week (refer to Section 8.7) .  The suitability of the 
patient for continued dosing will be determined by [CONTACT_37904]’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If after the first dosing rechallenge the platelet count again falls below 75,000/mm
3, then dosing 
of the patient with Study Drug will be s topped permanently. 
Following a rechallenge platelet count should be tested every week until count is stable.  
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450].  If there is no reportable platelet count within [ADDRESS_38526] the patient to hold dosing until a new platelet count is obtained and reviewed. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whol e or red cells  
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
47  Table 2 Actions in Patients with Low Pla telet Count  
Platelet C ount on Rx  Drug Dose Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every 1 week  until stable*  
75K-100K/mm3 Permanently reduce dose frequency to 
300 mg every 2 weeks  or reduce dose to 
150 mg weekly  Closer observation  
Monitor every  1 week  
50K-75K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37905] 2-3 days until 2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/NSAIDS/ 
anticoagulant medication  
25K-50K/mm3 or a rate of 
decline ≥  50% between 
two consecutive 
assessments, irrespective of the platelet level  Permanently discontinue Study Drug   Closer observation  
Monitor daily until 2 successive 
values show improvement then 
monitor every 2-3 days until 
platelet count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet count < 50K/mm
3 if possible  
< 25K/mm3 Permanently discontinue Study Drug Closer observation:  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Steroids recommended* * 
Consider need for hospi[INVESTIGATOR_37590]/NSAIDS/anticoagulant 
medication while platelet count 
< 50K/mm
3 if possible  
* At least 3 consecutive values measured weekly  that are stable as determined by [CONTACT_37906] > 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 w eeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methyl  prednisolone) .  In order 
to reduce the unlikel y but potential increased risk of  pancreatitis during the period of corticosteroid therapy, 
triglyceride levels will be monitored weekly during corticosteroid treatment  and the laboratory alert will be 
changed from an increase of 2,000 to 500 mg/dL during that period . 
 
8.[ADDRESS_38527] be made in accordance with Section 8.6.3 and 
Table 2  (above).  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
48  Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
schedule must be discussed with, and approved by, the Study Medical Monitor prior to initiation.  
Up to [ADDRESS_38528] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_38529] 6 weeks after 
discontinuing Study Drug.  
Following this period, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_37683] 
> 100,000/mm3), the next platelet count should be taken within at least [ADDRESS_38530] 12  weeks after discontinuing Study Drug .  Patients  should also be 
strongly encouraged to attend applicable landmark visits at Week s 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and conduct 
safety assessments in accordance with the Schedule of P rocedures in Appendix A .  Any patient 
who discontinues treatment after  Week 44 should also be strongly encouraged to attend a final 
follow-up visit ( Week 78 visit assessments) approximately [ADDRESS_38531] dose of 
Study Drug , in addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_38532] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
ISIS [ADDRESS_38533] 1 2 weeks after discontinuing Study Drug.  
Patients  should also be encouraged to undergo a final  follow-up visit ( Week 78, see Appendix A ) 
prior to leaving the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_38534] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include: 
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_38535] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (i ncluding supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
50  Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline Qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initia ting any new 
medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment ( e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 78 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that will be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_38536] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) i ncluding suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
51  Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Invest igator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anti cipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 3 Expected Event for the Protocol Defined Population by [CONTACT_37889] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
52  A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threateni ng:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate 
medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm  requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existin g conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should al ways group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_38537] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_38538] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is u nlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_38539] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious) 
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes 
no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is eas ily tolerated by [CONTACT_37721] ’s usual 
daily activities  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
54  • Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing  was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
55  9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_38540] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatme nt, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant ab normalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_37907].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or electi ve procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_37586] 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
56  9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_38541] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the  pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or 
spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
57  10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are define d as the average of Week 25 (Day  169) and 
Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are 
defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent  change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and received at least [ADDRESS_38542] a baseline TG assessment .  The FAS represents the practically -feasible 
intent- to-treat (ITT) population as delineated in ICH Guideline E9. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
58  Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38543] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_38544] dose PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseli ne and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_38545] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placeb o in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline will be the last non -missing assessment prior to the first dose of Study Drug .  Details 
will be provided in the SAP. 
10.5 Interim Analysis  
An interim analysis may be conducted after the las t patient’s Week [ADDRESS_38546] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variab les, and counts and percentages for categorical 
variables will be used to summarize most data by [CONTACT_37868] 304801-CS6 or ISIS 304801-CS16 index studies, and 
pooled treatment naïve group which includes  patients on placebo in index studies.  Where 
appropriate, p- values will be reported .  All statistical tests will be conducted using 2 -sided tests 
with 5% Type I error rates unless otherwise stated.  
TG related endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will 
be assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK 
endpoints will be assessed in the PK Set as applicable. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
59  10.6.1 Demographic and Baseline Characteristics 
Demogra phic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_14454] .  The patient disposition will be summarized  by [CONTACT_14459] .  All patients enrolled will be included in a summary of patient disposition. 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_14453]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term, and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. 
All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_1570] , MedDRA preferred term 
and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_6490]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized  by [CONTACT_37869] . 
These safety variables will also be presented as change and percent change from baseline over time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MR I assessments  will be 
tabulated by [CONTACT_1570] . 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] .  Response rate of patients with fasting plasma TG 
< 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a range of fasting 
plasma TG thresholds for determination of responder status. 
Percent change  and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37870]- HDL -C, apoB, 
HDL -C, apoA- 1, VLDL -C, and LDL-C, total cholesterol, and fasting total apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
60  Frequency and severity of patient reported abdominal pain, adjudic ated acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_1570] . 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics  by [CONTACT_37780].  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single-dose PK) or multiple doses (i.e., 
steady -state PK), depending on their earlier treatment in the index studies (Group 1 and 
2 patients) .  On Week [ADDRESS_38547] treatment of volanesorsen (single -dose PK), while patients who 
received volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16) , thus the PK data collected from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C max) and the time 
taken to reach C max (Tmax) will be obtained directly from the concentration -time data .  Area under 
the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24h) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24h /F) will be calculated from CL 0-24h /F = Actual Dose/ AUC 0-24h.  Mean residence time 
(MRT) from time zero to 24 hours after the SC administration  will be calculated from the 
equation, MRT 0-24h = AUMC 0-24h /AUC 0-24h, where AUMC 0-24h is the area under the moment 
plasma concentration -time curve from time zero to  [ADDRESS_38548]. 
Plasma PK parameters will be summarized using descriptive statistics  by [CONTACT_37908] .  Addi tional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day associated with the first positive IM status emerged (T
first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the last ADA sample 
collection day, and subject - peak titer if applicable, will be listed by [CONTACT_37872] 304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day .  Subjects with 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
61  positive anti-volanesorsen antibody status may be further classified (when applicable) as being 
either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropria te. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by  [CONTACT_1570] .  Furthermore, onset and t iter of the ADA 
response, if applicable, will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e. g., IM status) and selected efficacy 
(e.g., %change in fasting TG from baseline at 3-, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whether to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by  [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_38549] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
62  the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must al so be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the  IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also noti fy the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_38550] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., sign ed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_38551] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_38552].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
63  12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study fi les containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volane sorsen  Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_38553], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
64  The Investigator agrees to cooperate with the monitor to ensur e that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by [CONTACT_10576]’s C linical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, 
ICH GCP, and appl icable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any appare nt discrepancies .  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Ce nter for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_38554] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage f or clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
65  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processi ng of chylomicrons . Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED,  Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial  
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet ], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress  in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of  Biological Chemistry 2009; [ADDRESS_38555] 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia  Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhib ition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation i n 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol - [LOCATION_009]   3 February 2017  
 
66  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasm a lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulma n S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatograp hy (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisso n D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells  and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_38556]- Treatment Follow -up 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
69  Appendix A  Schedule of Procedures – Qualification  through Treatment Period  
Study Period  Quala Treatment Period  
Study Week  -2 to -1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -14 to -7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 
Visit Window+/ - Days  0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Informed Consent  X                        
Outpatient Visit  X X Xj Xj Xj Xj Xj Xj Xj X Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X 
Inclusion/Exclusion Criteria  X                        
Vital Signs + body weight  
(+ height on Day 1 only)  X X   X  X   X     X    X     X 
Physical Examination  X X        X     X    X     X 
12- lead ECG (triplicate)  X         X     X    X     X 
MRI (liver/spleen)  X                       Xk 
Echocardiography  X              Xk         Xk Blood Draw (Fasting)c Chemistry Panel  X X   X  X   X  X   X  X  X  X   X 
CBC with Differentialb X X  X X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel  X X   X  X  X X    X X    X    X X 
Coagulation (aPTT, PT, INR)  X      X   X     X    X     X 
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37488] X        X     X         X 
Sedimentation Rate   X        X     X         X 
Complement (C5a, Bb)   X        X     X         X 
Plasma PK - Volanesorsen   Xl X  X  X   X     X    X     X 
Anti-Volanesorsen Antibodies   X   X  X   X     X    X     X 
FSH (women only, if applicable)  X                        
Serum Pregnancy Testd X    X  X   X  X   X  X  X  X   X 
Archived Serum & Plasma 
Samplese  X     X   X     X         X 
Troponin Io X                        
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
70  Appendix A  Schedule of Procedures  - Qualification  through Treatment Period  Continued  
Study Period  Quala Treatment Period  
Study Week  -2 to -1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day  -14 to -
7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 
Visit Window+/ - Days  0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Urinalysisc X Xm   X  X   Xm  Xm   Xm  Xm  Xm  Xm   Xm 
Fundus Photographyf X                       Xk 
Genetic testing for FCS diagnosis (if 
not available in medical history)g X                        
Weekly Study Drug:  SC Injection  X  X X X X X X X X X X X X X X X X X X X X X 
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X        X     X         X 
Food/Drink Diary (quarterly)h  X        X     X         X 
Diet/Alcohol Counselingi X X   X  X   X     X    X     X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X X 
 
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
71  Appendix A  Schedule of Procedures – Post -Treatment Follow -up  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Informed Consent       
Outpatient Visit  Xj Xj X Xj X 
Inclusion/Exclusion Criteria       
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X 
MRI (liver/spleen)       
Echocardiography      Blood Draw (Fasting)c Chemistry Panel   X X X X 
CBC with Differentialb X X X X X 
Serum Lipid Panel    X  X 
Coagulation (aPTT, PT, INR)       
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
FSH (women only, if applicable)       
Serum Pregnancy Testd  X X X X 
Archived Serum & Plasma Samplese   X  X 
Troponin Io      
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
72  Appendix A  Schedule of Procedures – Post -Treatment Follow -up Continued  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Urinalysisc  Xm Xm Xm Xm 
Fundus Photographyf      
Genetic testing for FCS diagnosis 
(if not available in medical 
history)g      
Weekly Study Drug:  SC Injection      
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Food/Drink Diary (quarterly)h   X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication  X X X X X 
ISIS 304804 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
73  Appendix A  Schedule of Procedures Continued  
a Qualification procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should 
be collected in parallel and analyzed locally. In the event that both the central and local sample are unreportable 
(e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within [ADDRESS_38557] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be promptly reviewed by [CONTACT_37909][INVESTIGATOR_37587] 75,000/ mm
3.  In the event of any platelet count less than 
50,000/mm3 or a rate of decline ≥  50% between two consecutive assessments, irrespective of the platelet level, 
then dosing of a patient with Study Drug (ISIS 304801 or placebo) will be stopped permanently.  Any case of a 
platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
c Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  
During treatment period urine and blood samples will be collected prior to Study Drug administration.  Does not apply to 24-hour PK blood draw  
d Females of childbearing potential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laborator y findings and/or 
adverse events (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of 
kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of  volanesorsen  
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug (Group 2 ISIS 304801-CS16 roll  over patients ) and repeated at Week 52 (Please refer to Section [IP_ADDRESS]) 
g Genetic testing can be conducted for study Qualification  (Group 2 ISIS 304801-CS16 roll  over patients ); genetic 
testing will only be conducted if allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing  
h In addition to diary, patients will be contact[CONTACT_37910]  
i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37743]  
j Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
k A ± 7 -day window is allowed for MRI, echocardiography procedures and fundus photography  
l Full or abbreviated PK profile (see Appendix C ) 
m Expanded urinalysis (see Appendix B ) 
n HbA1c only  
o All abnormal troponin samples will be rerun at the central laboratory and also analyzed for CK -MB 
p If needed, the post -treatment follow -up period will be extended (with patients monitored every 6 weeks) until 
apoC -III levels return to baseline values  
  
ISIS [ADDRESS_38558] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte  esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_38559]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window 
+/- Days  [ADDRESS_38560]-dose Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_38561] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
80  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 7  
Protocol  - [LOCATION_009]   3 February 2017  
 
81  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 Adverse Event Mild Moderate Severe 
Urine 
Prote inuria 
Adults 1 + prote inuria; 2+ prote inuria; Urinary prote in g/24 hrs; urinary protein < 1.0 g/24 hrs urinary protein 1.0 - 3.4 g/24 hrs; 
Children -Urine PIC (Protein /Creat inine) Urine P/C >1.9 ratio 0.5 - 1.9 
Gross hema turia; transfusion, 
Asymp tomatic; clinical or diagnostic IV medications or 
Symp tomat ic; urina ry cathe ter or hospi[INVESTIGATOR_37591] ; Hematur ia observat ions only; interven tion not bladder irrigation indicated elective endoscop ic, radiologic indicated or operat ive intervention 
indicated 
tGrading for this paramete r is derived from the Toxicity Grad ing Scale for Healthy Adult and Adol escent Volun teers Enrolled in 
Preventi ve V accine Clinical Trials, Sept 2007 
*Grading for this parameter is derived from the Division of AIDS (DAIDS) Table for Grad ing the Seve rity of Adult and Pediatric 
Adverse Events Version 2.0, Nov 2014 
tModifi ed for consistency with the ADA and Endocrine Society Guidelines (Seaqu ist ER, Anderson J, Childs B, et al. 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Associa tion and The Endocrine Society. 
Diabetes Care 2013 ;36: 1384 -95) 
 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38562] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38563] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 6 - Netherlands  – [ADDRESS_38564] No:  2015-003755-21 
 
 
 

ISIS [ZIP_CODE] I-CS7 
Protocol -Netherlands CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 6 
11 April 2017 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 6 -Netherlands -11 April 2017 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38565] 2015 
2 February 2016 
22 April 2016 
9 May 2016 
6 June 2016 
6 July 2016 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands  11 April 2017  
3Ionis Protocol Number:  ISIS 304801-CS7 
Protocol Amendment
 [ADDRESS_38566] No:   2015-003755-21 
C
linical Phase:  3 
The APPROACH Open- Label Study 
Volanesorsen (ISIS 304801)
An Open- Label Study o f Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Trial Sponsor: Ionis
 Pharmaceuticals,  Inc. 
[ADDRESS_38567] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] Fax:  
Key Sponsor Contact: , Ph.D. 
[ADDRESS_38568] Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator: Akcea Therapeutics  
[ADDRESS_38569] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38570] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protoc ol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 6 Netherlands  
Date:  [ADDRESS_38571] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38572] the study as 
described herei n. 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
 
 
ISIS [ADDRESS_38573] ................................................................................43  
4. PATIENT ENROLLMENT ........................................................................................... 43  
4.1 Qualification  ..................................................................................................................43  
4.2 Enroll ment  .....................................................................................................................43  
5. PATIENT ELIGIBILITY  .............................................................................................. 43  
5.1 Inclusion Criteria  ...........................................................................................................43  
5.2 Exclusion Criteria for Group 1 (ISIS 304801-CS6) and Group 2 (ISIS 304801-CS16) 
Index Study Roll-over Patients ......................................................................................44  
6. STUDY PROCEDURES  ................................................................................................ 45  
6.1 Study Schedule  ..............................................................................................................45  
6.1.1  Qualification  ...........................................................................................................45  
6.1.2  Treatment Period  ....................................................................................................45  
6.1.3  Extended Treatment Period  ....................................................................................45  
6.1.4  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_38574]- Treatment Period  ............................................................................................46  
6.2 Additional Study Assessments  .......................................................................................47  
6.2.1  Laboratory Assessments  .........................................................................................47  
6.2.2  Physical Exams and Vital Signs  .............................................................................47  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................47  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................47  
6.2.3  Echocardiography ...................................................................................................47  
6.2.4  ECG  ........................................................................................................................48  
6.2.5  MRI  ........................................................................................................................48  
6.2.6  Quality of L ife Assessments ...................................................................................48  
6.2.7  Disease Symptom Diary  .........................................................................................48  
6.2.8  Diet Monitoring  ......................................................................................................48  
6.2.9  Family History  ........................................................................................................48  
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2) ..[ADDRESS_38575]- Treatment Follow -up Period .62  
8.9 Withdrawal of Patients from the Study  ..........................................................................62  
8.10  Concomitant Therapy and P rocedures  ...........................................................................62  
8.10.1  Concomitant Therapy .............................................................................................63  
8.10.2  Concomitant Procedures .........................................................................................63  
8.11  Treatment Compliance  ...................................................................................................63  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ...................... 64  
9.1 Sponsor Review of Safety Information .........................................................................64  
9.2 Regulatory Requirements  ..............................................................................................64  
9.3 Definitions  .....................................................................................................................65  
9.3.1  Adverse Event  ........................................................................................................65  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................65  
9.3.3  Serious Adverse Event (SAE)  ................................................................................65  
9.4 Monitoring and Recording Adverse Events ...................................................................66  
9.4.1  Serious Adverse Events ..........................................................................................66  
9.4.2  Non-Serious Adverse Events ..................................................................................66  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................66  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................66  
[IP_ADDRESS]  Severity  ............................................................................................................67  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................67  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................67  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................67  
9.4.4  Adjudication Committees  .......................................................................................68  
9.5 Procedures for Handling Special Situations ..................................................................68  
9.5.1  Abnormalities of Laboratory Tests .........................................................................68  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............69  
9.5.3  Dosing Errors .........................................................................................................69  
9.5.4  Contraception and Pregnancy .................................................................................69  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 70  
10.1  Study Endpoints  .............................................................................................................70  
10.1.1  Efficacy Endpoints .................................................................................................70  
10.1.2  Safety Endpoints .....................................................................................................70  
10.2  Sample Size  ....................................................................................................................71  
10.3  Populations .....................................................................................................................71  
10.4  Definition of Baseline  ....................................................................................................71  
10.5  Interim Analysis  .............................................................................................................71  
10.6  Planned Methods of Analysis  ........................................................................................72  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
8  10.6.1  Demographic and Baseline Characteristics  ............................................................72  
10.6.2  Safety Analysis  .......................................................................................................72  
10.6.3  Efficacy Analysis  ...................................................................................................73  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................73  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................73  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................74  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. [ADDRESS_38576] of the Study .........................................................................................75  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38577] of Laboratory Analytes  .............................................................................87  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................89  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......91  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics .........................................................50  
Table 2  Labs to Be Performed in the Event of a Platelet Count Less than the 
Lower Limit of Normal (x2) or < 100,000/mm3 (x1)* ..........................................54  
Table 3  Actions in Patients with Low Platele t Count or Drop in Platelet Count ................60  
Table 4  Expected Event for the Protocol Defined Population by [CONTACT_37674]  ...................................................................................64
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
9  TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  ...............36  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown ....................................38  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ...............40  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands  11 April 2017  
10  PROTOCOL AMENDMENT  
Protocol Number:  ISIS 304801- CS7 
Protoco
l Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously 
to Patients with Familial Chylomicronemia Syndrome (F CS) 
Amendment Number:  
Amendment Date:  6 - Netherlands 
11 April 2017 
The purpose of this protocol amendment is to implement the following modification s to Protocol 
ISIS 304801-CS7 Amendment 5 dated 6 July 2016: 
1. To update the platelet safety monitoring rules shown in Table 3.
2. To exclude enrollment of FCS patients in this open-label study who did not participate in
the ISIS  304801-CS6 or ISIS 304801- CS16 index studies .
3. To add post heparin plasma LPL activity of ≤ 20% of normal in medical history as an
inclusion criteria for ISIS 304801-CS16 (Group 2) patients as has been allowed for
ISIS 304801-CS6 (Group 1) patients.
4. To allow patients who complete the 52-week treatment period to participate in an
expanded access program or continue dosing for up to an additional [ADDRESS_38578]- treatment
evaluation period.
5. Added archive blood sample for potential gene sequencing related to
hypertriglyceridemia (Group 2 if not available from index study).
6. Added:  Troponin I, platelet bound autoantibody testing at baseline (may be done), and
Table 2 Labs  to be performed in the event of a platelet count Less than the Lower Limit
of Normal (x2) or < 100,000/mm
3 (x1)  to provided added patient safety; blood viscosity
(may be done) to assess potential benefit of ISIS 304801 administration; and platelet
aggregation (may be done) to assess platelet function.
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of the original protocol but these changes do not impact subject safety, exposure, or the overall study design. 
The following table  provides a summary list of major changes to the protocol, additions are 
indicated as underline and deletion
s are indicated as strikethrough : 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
11  Protocol 
Section Description of Change  Rationale  
Synopsis  
Section 3.1 
Study Design  
 This is a multi -center open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll-over  FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll-over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 
or ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_38579] -treatment evaluation 
period  To exclude enrollment of FCS patients in this open-label study 
who did not 
participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 
index studies . 
Synopsis  
Section 5.1 
Inclusion Criteria 3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or 
ISIS 304801-CS16 (index studies) with an acceptable safety profile, 
per Sponsor and Investigator judgement.  
 Groups 2 and 3:  Patients who enrolled in ISIS 304801-CS16 must 
also meet the following criteria in order to enter into the open -label  
study:  
 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at ScreeningQualification  for 
the ISIS  304801-CS16 index study  Group 3:  Fasting TG ≥ 750 
mg/dL at Screeningfor this open-label study  To exclude enrollment of FCS 
patients in this 
open-label study who did not participate in the 
ISIS 304801-CS6 or 
ISIS 304801-CS16 
index studies . 
Synopsis  
Section 5.1 Inclusion Criteria b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of 
the following:  
• Confirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal in medical 
history. Note: testing of LPL activity should not be performed to 
confirm eligibility for the study  To add LPL activity 
of ≤ 20% of normal in medical history 
as an inclusion 
criteria for Group 2 
patients as has been allowed for 
Group 1 patients . 
Synopsis  
Section 5.2 
Exclusion Criteria Exclusion Criteria for Group 3 (patients who did not participate in an 
index study)  
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening  
c. Recent change in anti- diabetic pharmacotherapy (change in 
dosage or addition of new medication within 12 weeks of screening 
[with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment period of the Study (with the exception of ± 10 units of 
insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia 
syndrome  
3. Active pancreatitis within 4 weeks prior to screening  To exclude enrollment of FCS 
patients in this 
open-label study who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies . 
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
12  Protocol 
Section Description of Change  Rationale  
Synopsis  
Section 5.2 
Exclusion Criteria 
Continued  4. History within 6 months of screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset 
angina), stroke, transient ischemic attack or unstable congestive 
cardiac failure requiring a change in medication or major surgery within 
3 months of screening  
5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN) , unless prior 
diagnosis and documentation of Gilbert’s syndrome in which 
case total bilirubin must be  
≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38580]  
• AST > 2.[ADDRESS_38581]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine protein 
measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive 
test e ligibility may be confirmed with urine microscopy 
showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the 
formula of Cockcroft and Gault <  50 mL/min (MDRD or CKD-
EPI [INVESTIGATOR_37592]-Gault for 
estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening  
d. LDL-C > 130 mg/dL at Screening  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37547], would make the patient unsuitable for 
inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or clinically -significant 
abnormality in coagulation parameters at Screening  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that 
will not be completed prior to Study Day [ADDRESS_38582] for human immunodeficiency virus 
(HIV), h epatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell 
carcinoma of the skin or carcinoma in situ  of the cervix that has been 
successfully treated  
12. Treatment with another investigational drug, biological agent, or device 
within 1-month of screening, or 5 half -lives of investigational agent, 
whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) To exclude 
enrollment of FCS patients in this open-label study 
who did not 
participate in the 
ISIS 304801-CS6 or 
ISIS 304801-CS16 
index studies . 
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
13  Protocol 
Section Description of Change  Rationale  
Synopsis  
Section 5.2 
Exclusion Criteria 
Continued  14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates 
unless on a stable dose for at least 3 months prior to screening 
and dose and regimen expected to remain constant during the 
treatment period.  Patients taking OTC omega- 3 fatty acids should 
make every effort to remain on the same brand throughout  the 
study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior 
to screening unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least [ADDRESS_38583] 
4 weeks prior to screening and dose and regimen expected to 
remain constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and 
api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_38584] 4 weeks prior to 
screening (Occasional or intermittent use of over -the-counter 
medications  will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening or of 
> 499 mL within 60 days of screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] 
(ISIS 304801 or placebo)  
17. Have  any other conditions, which, in the opi[INVESTIGATOR_37593], or could 
interfere with the patient participating in or completing the study  To exclude 
enrollment of FCS patients in this open-label study 
who did not 
participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 
index studies . 
 
  
ISIS [ADDRESS_38585] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study):   A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]).  Please refer to 
Secti on 4.1 and Appendix A  
• Group 3 patients (did not participate in an index study):  An up to 
8-week screening and qualification period, including a diet stabilization 
period of at least 6 weeks (screening and diet stabilization period may 
be reduced, per Sponsor approval, if the patient is following a diet for 
optimal control of TGs and disease management prior to screening).  
Please refer to Section 6.1.2 and Appendix A  
• All patients:  
o A 52-week treatment period during which volanesorsen will be 
administered as  a once weekly SC injection  
o Option to participate in an extended treatment period (up to an 
additional 52 weeks)  
o A 13-week post -treatment evaluation period or expanded access 
program  
The patients, Investigators, study staff, and the Sponsor will remain bli nded 
to lipid data through the last patient’s Week [ADDRESS_38586].  
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events (AE), concomitant medication/procedure information, lipid panel, blood 
viscosity, volanesorsen plasma concentrations, immunogenicity (IM) 
testing , platelet aggregation , liver/spleen magnetic resonance imaging 
(MRI), ECGs, echocardiograms and quality of life assessments will be performed according to the schedule of procedures in Appendix A.  Dietary 
counseling will be repeated at intervals throughout the treatment and follow -
up period and a daily food/drink diary will be completed for the week prior to 
each quarterly visit by [CONTACT_6904].  Following the Week  [ADDRESS_38587] -treatment evaluation period is 13 weeks and consists of 27 Study 
Center visits on Weeks  53, 54, 55, 5 6, 57, 58 , and 65 (Weeks 53, 54, 55, 
56, 57, and 58 may be conducted by a home healthcare nurse).  To provide added patient safety regarding plat elet 
count reductions 
and ISIS 304801 
dose exposure. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
15  Protocol 
Section Description of Change  Rationale  
Sectio n 4.1 
Qualification  Group 3 (Screening and Qualification):  At the time of consent, the patient 
will be considered enrolled into the study and will be assigned a unique 
screening number before any study procedures, including screening 
procedures, are performed.  At the time of enrollment, patients will be 
assigned a unique patient identification number.  This number will be used 
to identify the patient throughout the trial and must be used on all study 
documentation related to that patient.  The screening number and patient 
identification number must remain constant throughout the entire trial.  In 
the event the patient is re-consented and re- screened the patient must be 
given a new screening number.  Screening numbers and patient 
identification numbers, once assigned, will not be re-used.  To exclude 
enrollment of FCS patients in this open-label study 
who did not 
participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 
index studies . 
Section 6.1 
Study Schedule  6.1.2 Screening and Qualification (Group 3)  
Before any study -specific procedures or evaluations are initiated, patients 
must sign and date the informed consent form.  An 8-week period, including 
a diet stabilization period of at least 6 weeks (screening and diet 
stabilization period may be reduced, per Sponsor approval, if the patient is 
following a diet for optimal control of TGs and disease management prior to 
screening) is given to perform the screening evaluations.  The qualification 
assessments will be performed at Week -2 to -1, ideally after patient  
eligibility has been determined, and on Study  Day 1.  Abnormal screening 
results may be retested for review by [CONTACT_37911]-label study 
who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies . 
Section 6.1. 2 
Treatment 
Period During the treatment period, patients will report to the study center for clinic 
visits a minimum of 5 times during Weeks 1- 52 (see Schedule of 
Procedures in Appendix A).  Study Drug will be administered once weekly unless the patient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinaly sis), AEs, 
concomitant medication/procedure information, lipid panel, blood viscosity , 
volanesorsen plasma concentrations, immunogenicity (IM) testing,  platelet 
aggregation, liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as 
adverse events.  Dietary counseling will be reinforced at intervals 
throughout the treatment and follow -up period and all patients w ill complete 
a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected prior to volanesorsen administration.  
Blood sampling at Weeks 2, 3, 4, 5, 6, [ADDRESS_38588] be fasted prior to drawing all blood 
samples and samples drawn locally should also be sent to the central laboratory for analysis whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given [ADDRESS_38589] the option of continuing dosing for up to an additional 
52 weeks until an expanded access program is approved and available in 
their country.  
During the extended treatment period, patients will report to the study center 
for clinic visits during Weeks 54-104 (see Schedule of Procedures in 
Appendix A).  Study Drug will be administered once weekly unless the pat ient 
is on a biweekly dosing schedule for safety reasons (Section 8.1).  Collection 
and measurement of vital signs, clinical laboratory parameters (including 
hematology, serum chemistry, and urinalysis), AEs, concomitant 
medication/procedure information, l ipid panel, volanesorsen plasma 
concentrations, IM testing, ECGs, and physical examinations will be 
performed according to the Schedule of Procedures in Appendix A.  Adverse 
events at the injection site should be collected as adverse events.  Dietary 
couns eling will be reinforced at intervals throughout the extended treatment 
period.  All blood and urine samples should be collected prior to 
volanesorsen administration.  Blood sampling at Weeks 53, 54, 55, 56, 57, 
58, 59, 60, 61, 62,63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 79, 
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 
101, 102, and [ADDRESS_38590] -treatment  
evaluation period consists of 4 7 Study Center visits on Weeks 53, 54, 55, 56, 
57, and 58 (which may be conducted by a home healthcare nurse), and 
Week [ADDRESS_38591] -treatment evaluation period consisting of 7 Study Center visits 
on Weeks 105, 106, 107, 108, 109, and 110 (which may be conducted  by a 
home healthcare nurse), and Week 117 as outlined in the Schedule of 
Procedures in Appendix A.  To allow patients who complete the 52-week treatment 
period to participate 
in an expanded 
access program or 
continue dosing for 
up to an additional 
52 weeks  until an  
expanded access program  is approved 
and available in their country.  
 
To provide added 
patient safety regarding platelet count reductions and 
ISIS 304801 dose 
exposure. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
17  Protocol 
Section Description of Change  Rationale  
Section 6.2.1 
Laboratory Assessments  Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.  In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be 
repeated within 1-week and determined not to have met a stoppi[INVESTIGATOR_37594].   
If there is no reportable platelet count within [ADDRESS_38592] the patient to hold dosing until a new platelet 
count is obtained and reviewed.  
All platelet count results will be promptly reviewed by [CONTACT_37912] a stoppi[INVESTIGATOR_37595], or the dose 
reduction  rule and to determine whether the rate of decline is suggestive that 
the patient could be approachingof 100,000/mm3, or the dose pause rule of 
75,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an 
expedited fashion to the Sponsor.  To provide added 
patient safety regarding platelet count reductions, 
ISIS [ADDRESS_38593] ECGs performed in triplicate at 
Week  76 and Week 104.  To provide patient safety during the Extended Treatment Period. 
Section 6.2.8 Diet 
Monitoring  2. Patients will receive diet/alcohol counseling by [CONTACT_37913].  Qualified s tudy 
personnel will telephone the patient to provide diet/alcohol counseling for visits that are conducted by a clinical service.   Patients in the Extended 
Treatment Period will receive diet/alcohol counseling by [CONTACT_37914].  
3. In addition to the 7 -day food diary and the diet /alcohol counseling during 
clinic visits, telephone calls from a dietitian or qualified study personnel to 
assess as to how each patient is maintaining their diet will may be 
conducted randomly during the treatment and post treatment follow -up 
periods.  To provide 
diet/alcohol 
counseling  during 
the Extended 
Treatment Period. 
Section 6.2.10 Chart Review for Incidents of 
Acute 
Pancreatitis in Medical History  
(Group 2) 6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History 
(Group 2)  
Patient records will be reviewed for incidents of acute pancreatitis occurring 
up to 5 years prior to Qualification and information relating to these events 
will be collected for independent adjudication.  To assess acute 
pancreatitis in medical h istory  in 
Group 2 patients . 
Section 8.1 Volanesorsen Administration  Every effort should be made to ensure the previous week’s dose is given [ADDRESS_38594] be documented in the 
patient’s medical records.  
Due to the [ADDRESS_38595] with the study patients.  
However, if the above options are not possible, a temporary interruption of 
study treatment will be planned with a prompt blood draw upon the 
patient’s return which must be reported and reviewed by [CONTACT_37915].  
The tests outlined in Table 2 should also be performed as soon as 
possible.   Additional lab tests will be determined by [CONTACT_37916].  
Any case of a platelet count < 50,000/mm3 should be reported in an 
expedited fashion to the Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
19  Protocol 
Section Descr iption of Change  Rationale  
Section 8.5.2 
Safety Monitoring for Platelet Count 
Results 
Continued  Added Table 2 : 
Table 2  Labs to Be Performed in the Event of a Platelet Count Less than 
the Lower Limit of Normal (x2) or < 100,000/mm
3 (x1)* 
*In patients who have any 2 occurrences (consecutive or non -consecutive) 
of platelet count less than the lower limit of normal or who have any 
1 occurrence of platelets < 100,000/mm3.  Labs only need to be performed 
once.  Labs may be collected over multiple visits, if bloo d requirements are 
a concern, as per investigator discretion.  
Note:  The following labs may change as additional data is assessed, 
and sites will be updated regarding any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen 
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for Qualification) 
Rubella  
CMV  
EBV 
Parvo B19 
Helicobacter pylori (IgG serum test)  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti-PF4 assay  
Anti-ASO antibody  
 To provide added patient safety  
regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations . 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
20  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37573] a low platelet count are summarized in Table 23 below.  
In the event of a platelet count less than 75,000/mm3 that is associated with 
major bleeding or clinically -relevant non-major bleeding (defined below; 
Schulman et al . 2005), dosing of a patient with volanesorsen will be stopped 
permanently.  The follow -up schedule for any events meeting this stoppi[INVESTIGATOR_37596].  
In the event of any  platelet count less than 2550,000/mm3, or a platelet count 
less than 75,000/mm3 that occurs while the patient is on dosing at 300 mg 
every 2 weeks or 150 mg every week  then dosing of a patient with 
volanesorsen will be stopped permanently.  Platelet count  will be monitored 
as outlined in Table 3. daily until 2 successive values show improvement 
then monitored every 2-3 days until platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is less than 2550,000/mm
3.  Recovery in platelet count may be accelerated 
by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; Prednis(ol)one 0. 5 2 mg/kg/d 
for 2-4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note: may require continuation with oral steroids after methylprednisolone).   
Triglyceride levels be monitored weekly, and AE monitoring will continue, 
during corticosteroid treatment and the laboratory alert will be changed from 
an increase of 2,000 to 500 mg/dL during that period.  
In the event of a platelet count less than 75,000/mm3, and in the absence of 
major bleeding or clinically -relevant non-major bleeding (defined below; 
Schulman et al. 2005), dosing of a patient with volanesorsen should be 
suspended temporarily until the platelet count has recovered to 
> 100,000/mm3.  If dosing is continued it should be at a reduced dose 
frequency of 300 mg every 2 weeks or a reduced dose of 150 mg per week  
(refer to Section 8.7).  The suitability of the patient for continued dosing will 
be determined by [CONTACT_37917]’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of 
dosing.  
If after the first dosing rechallenge the platelet count again falls below 75,000/mm
3, then dosing of the patient with Study Drug will be stopped 
permanently.  
Following a rechallenge platelet count should be tested every week until 
count is stable.  
Any unreportable platelet count result must be rechecked and determined 
not to have met a stoppi[INVESTIGATOR_007] r ule before dosing can continue.  
If there is no reportable platelet count within [ADDRESS_38596] the patient to hold dosing until a new 
platelet count is obtained and reviewed.  To provide added 
patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
21  Protocol 
Section Description of Change  Rationale  
Section 
8.6.3 Stoppi[INVESTIGATOR_37597]:  
Table 2 Actions in Patients with Low Platelet Count   
Platelet 
Count on Rx  Drug Dose Monitoring  
Normal range, > 140K/mm
3 No action  Monitor every 2 weeks  
100K -
140K/mm3 No action  Closer observation  
Monitor every 1 week until 
stable*  
75K-
100K/mm3 Permanently reduce 
dose frequency to 300 
mg every 2 weeks  or 
reduce dose to 150 mg 
weekly  Closer  observation  
Monitor every  1 week  
50K-75K/mm3 If occurs while on dose of 300  mg every 
2 weeks or 150 mg 
every week then permanently 
discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to >  100K/mm
3 
restart dosing at dose frequency of  300 mg 
every 2 weeks or 
150 mg weekly only if 
approved by [CONTACT_37835] 2-3 days until 2 successive values show 
improvement  
Consider discontinuation of antiplatelet agents/NSAIDS/  
anticoagulant medication  
25K-50K/mm3 If occurs while on dose of 300  mg every 
2 weeks or 150 mg 
every week then permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to >  100K/mm
3 
restart dosing at dose 
frequency of 300 mg 
every 2 weeks or 
150 mg weekly only if 
approved by [CONTACT_37880] 2 successive values show 
improvement then monitor 
every 2 -3 days until platelet 
count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet 
count <  50K/mm
3 if possible 
 To provide added 
patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
22  Protocol 
Section Description of Change  Rationale  
Section 
8.6.3 Stoppi[INVESTIGATOR_37598] 2 Actions in Patients with Low Platelet Count  Continued  
Platelet 
Count on Rx  Drug Dose Monitoring  
< 25K/mm3 Permanently discontinue 
Study  Drug  Closer observation:  
Monitor daily until 2 successive 
values show improvement then 
monitor every 2-3 days until platelet count stable  
Steroids recommended**  
Consider need for hospi[INVESTIGATOR_37577]/NSAIDS/anticoagulant medication while platelet count 
< 50K/mm
3 if possible  
* At least 3 consecutive values measured weekly that are stable as determined by [CONTACT_37683] >  100,000/mm
3 
** Recovery in platelet count may be accelerated by [CONTACT_37837].  Treatment guidelines for immune thrombocytopenia 
(Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1-4 cycles; Prednis(ol) one 0.5- 2 mg/kg/d for 
2-4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days 
(note :  may require continuation with oral steroids after methyl 
prednisolone)  To provide added patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
23  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37599]: 
 
Table [ADDRESS_38597] be documented in the patient’s  medical records.  Monitor every 1 week unless otherwise specified  
Obtain additional lab tests 
(Table 2 ) if 2 occurrence s 
consecutive or non-consecutive)  of platelet 
count 140K - > 100K/mm
3 
or 1 occurrence of platelet 
count ≤  100K/mm3.  Labs 
only need to be performed 
once.   Labs may be 
collected over multiple visits, if blood requirements 
are a concern, as per Investigator discretion.  
> 100K/mm3 Weekly 300 mg Study 
Drug administration   
100K/mm3 - 
> 75K/mm3 Permanently reduce dose frequency to 300 mg 
every 2 weeks   
75K/mm3 - 
> 50K/mm3 • If occurs while on dose 
of 300 mg every 2 weeks then 
permanently discontinue Study Drug, 
otherwise dose pause  
• When platelet count 
returns to >  100K/mm
3 
restart dosing at dose frequency of 300 mg 
every 2 weeks only if 
approved by [CONTACT_37858]  • Monitor every 2-3 days 
until 2 successive 
values are >75K/mm
3 
then monitor every 1 week  
• Consider 
discontinuation of 
antiplatelet agents/NSAIDS/ anticoagulant 
medication  
 To provide added 
patient safety regarding platelet count reductions, 
ISIS 304801 dose 
exposure, and treatment recommendations . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
24  Protocol 
Section Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37600] 3  Actions in Patients with Low Platelet Count or Drop in Platelet 
Count  Continued  
Platelet 
Count on Rx  Drug Dose Monitoring  
≤ 50K/mm3 Permanently discontinue Study Drug  • Monitor daily until 2 successive values 
show improvement then monitor every 2-3 days until 2 successive values 
are >  75K/mm
3 then 
monitor every  1 week  
• Patient should be 
evaluated by a 
hematologist to provide diagnostic and therapeutic management  
• Steroids recommended*.  
It is strongly 
recommended that, unless the patient has a medical contraindication 
to receiving 
glucocorticoids, the patient receives glucocorticoid therapy to 
reverse the platelet 
decline.   
• Monitor triglyceride levels weekly and continue AE monitoring during steroid 
therapy  
• Discontinue antiplatelet agents/ NSAIDS/ 
anticoagulant medication while platelet count is< 50K/mm
3 if possible 
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010) recommend dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1-4 cycles; prednis(ol)one 0.5-2 mg/kg/d for 
2-4 weeks then taper; or methylprednisolone 30 mg/kg/day for 7 days 
(note:  may require continuation with oral steroids after methylprednisolone)  To provide added patient safety regarding platelet count reductions, 
ISIS 304 801 dose 
exposure, and 
treatment recommendations . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
25  Protocol 
Section Description  of Change  Rationale  
Synopsis  
Section 
10.1.1 Efficacy Endpoints  • Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from basel ine in other fasting lipid 
measurements including total cholesterol, non-HDL -C, apoB, HDL -C, 
apolipoprotein A -1 (apoA -1), VLDL -C, and LDL -C 
• Percent change from baseline in fasting total apolipoprotein C -III 
• Change in blood viscosity (may be evaluated)  
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  Blood viscosity added to assess 
potential benefit of ISIS 304801 
administration. 
 
Synopsis  
Section 
10.1.2 Safety  
Endpoints  • Adverse events including adjudicated events of pancreatitis and MACE  
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis)  
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  Platelet 
aggregation added to assess platelet function 
following 
ISIS 304801 
administration. 
Section 10.3 Populations  Full Analysis Set (FAS):  All patients who are enrolled and received at least 
[ADDRESS_38598] a baseline TG assessment.  The FAS 
represents the practically -feasible intent -to-treat (ITT) population as 
delineated in ICH Guideline E9.  
Per Protocol Set (PPS):  Subset of the FAS who received [ADDRESS_38599] efficacy and PD assessments.  The detailed criteria will be specified and finalized prior to the final database lock. 
Safety  Set:  All patients who are enrolled and receive at least 1 dose of 
volanesorsen.  
PK Population:  All patients who are enrolled, receive at least [ADDRESS_38600] a baseline TG 
assessment and 
clarified the PK Population. 
Section 10.4 Definition of Baseline  Definitions of baseline are given below for the purposes of the final analysis.  
For fasting lipid measurements , 2 baselines are defined for each patient in 
Groups 1 and 2:  Group 1 (ISIS 304801-CS6) or Group 2 (ISIS 304801-CS16) index study baseline and the baseline in this open- label study, which 
is defined as the average of Day [ADDRESS_38601] 
measurement prior to Day 1 (e.g., qualification assessments or assessments from final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if 
used for qualification).   For Group [ADDRESS_38602] 
dose of Study  Drug.  To exclude enrollment of FCS patients in this open-label 
study who did not 
participate in the ISIS 304801-CS6 
or ISIS 304801-
CS16 index 
studies . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
26  Protocol 
Section Description of Change  Rationale  
Appendix A  Removed Screening period (Group 3)  
Removed Week 2.5  
 
Added:  Medical History  
b Patient charts will be reviewed in order to collect data for events of 
acute pancreatitis or suspected pancreatitis in the patient’s medical 
history.  Chart review may be conducted at any time during the study.  These events will be adjudicated in the same manner as for events of pancreatitis during the study  
 
CBC with Differential  
c Each time a hematology lab is drawn and sent to the central laboratory 
for analysis an additional sample should be collected in parallel and 
analyzed locally.   In the event that both the central and local sample are 
unreportable (e.g., due to hemolyzed or clumped blood samples) 
another sample must be repeated within [ADDRESS_38603] the patient to hold dosing until a new 
platelet count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37918] a stoppi[INVESTIGATOR_1877], and to determine whether the 
rate of decline is suggestive that the patient could be approaching the 
or the dose reduction rule of 100,000/mm3, or the dose pause rule of 
75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be 
reported in an expedited fashion to the Sponsor  
 
Added:   Troponin I  
 Added:   Blood Viscosity, Platelet Aggregation , Platelet Bound 
Autoantibodies  
e May be done.  Blood viscosity and platelet aggregation in 
volanesorsen-treatment naïve patients only  
 
Added:   archive blood sample for potential gene sequencing related to 
hypertriglyceridemia (Group 2 if not available from index study)  Added troponin, 
platelet bound autoantibodies, and modified CBC 
blood draws t o 
provide added 
patient safety regarding platelet 
count reductions, 
ISIS 304801 dose exposure, and treatment 
recommendations . 
 
Added patient 
chart review, 
blood viscosity and potential gene sequencing 
to assess 
potential benefit of ISIS 304801 administration. 
 Added platelet 
aggregation to 
assess platelet function following ISIS 304801 
administration. 
Appendix A  Added: 
Appendix A Schedule of Procedures  – Extended Treatment Period Table 
and Legend. To allow patients 
who complete the 52-week treatment period 
to participate in an 
expanded access 
program or 
continue dosing for up to an 
additional 
52 weeks until an  
expanded access program  is 
approved and available in their country.  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 6 
Protocol - Netherlands  11 April 2017 
 
27  Protocol 
Section Description of Change Rationale 
Appendix B  Removed Screening Tests (Group 3) 
 
Added : 
Troponin I2 
CK-MB2 
Platelet Bound Autoantibodies3 
Blood Viscosity3 
Platelet Aggregation3 
 2 All abnormal troponin samples will be rerun at the central laboratory and 
also analyzed for CK-MB 
3 May be done Added troponin, 
CK-MB, and platelet bound 
autoantibodies, 
provide added 
patient safety. 
Added Blood 
Viscosity to 
assess potential 
benefit of 
ISIS 304801 administration 
Added Platelet 
Aggregation to 
assess platelet 
function following 
ISIS 304801 administration. 
Appendix C  Added: 
Appendix C PK Sampling Schedule (E xtended Treatment Period) Table. To collect 
intermittent PK 
data in patients 
who enter the 
extended treatment period. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
28  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll-over  FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll-over FCS patients  
All patients will receive volanesorsen [ADDRESS_38604] -treatment evaluation period  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 
Group 2:  Patients who enrolled in ISIS 304801-CS16  must  also meet 
the following criteria in order to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of 
the following:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤20% of normal in medical 
history . Note: testing of LPL activity should not be performed to 
confirm eligibility for the study  
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Qualification  for 
the ISIS  304801-CS16 index study   
4. Able and willing to participate in a 65-week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
29  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in 
sexual relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1) from time 
of si
gning the informed consent for
m until [ADDRESS_38605] 
dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relati ons
 with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_38606] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and 
withdrawal are not acceptable methods of contraception  
Exclusion Criteria  for Group 1 (ISIS 304801-CS6 ) and Group 2  
(ISIS 304801-CS16 ) Index Study Roll-over Patients  
1. Have any new condition or worsening of existing condition which in the 
opi[INVESTIGATOR_37601], or could interfere with the patient participating in or completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the 
study ( Section 6.3 ) 
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the Sponsor Medical Monitor.  
Rationale for Dose and Schedule Selection  The dose of 300 mg once weekly was chosen for the double- blinded 
placebo- controlled Phase 3 i 
ndex studies (ISIS 304801-CS6 and 
ISIS 304801-CS16) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies ( Section 2.4) which included a s
ubset of patients with 
FCS.  The same dose of [ADDRESS_38607] of the following periods:  
• A qualification period of up to 2 weeks (unless approved by
  [CONTACT_429]) .  Please refer to Section 4.1 and Appendix A  
o A 
52-week treatment per
io
d during which volanesorsen will be 
administered as a once weekly SC injection  
o Option to participate in an extended treatment period (up to an additional 52 weeks)  
o A 13-week post -treatment evaluation period or expanded 
access program  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38608] . 
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, blood 
viscosity, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
platelet aggregation, liver/spleen magnetic resonance imaging ( MRI), ECGs, 
echocardiograms and quality of life assessments will be performed according 
to the schedule of procedures in Appendix A .  Dietary counseling will be 
repeated at intervals throughout the treatment and follow -up period  and a 
daily food/drink  diary will be completed for the week prior to each quarterly 
visit by [CONTACT_6904] .  Following the Week  [ADDRESS_38609] -treatment evaluation 
period . 
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by [CONTACT_37840] (including independently adjudicated events of acute pancreatitis and MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
31  PROTOCOL SYNOPSIS Continued  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications 
• MRIs  
• Platelet aggregation (may be evaluated)  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during 
the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -densit y lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Change in blood viscosity (may be evaluated) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of volanesorsen as follows : tr 
ough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of volanesorsen will be performed to determine volanesorsen pharmacokinetic parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
32  STUDY DESIGN AND TREAT MENT SCHEMA  
 
  
QUALIFICATION PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION (ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety 
assessments.  PK and PD/efficacy 
assessments at specified time points  
POST -TREATMENT 
EVALUATION PERIOD  
Weeks [ADDRESS_38610] 
the option of 
participating in an 
expanded access 
program or 
continuing dosing 
for up to an 
additional 52 weeks 
until an expanded 
access program is 
approved and 
available in their 
country.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
33  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38611]  
IXRS  Interactive Voice/Web -Response System  
LDL  low-density lipoprotein  
LDL -C low-density lipoprotein -cholesterol  
LMF1  lipase maturation f actor [ADDRESS_38612] lipoprotein lipase  
MACE  major acute cardiovascular ev ent 
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  no-observed -adverse -effect level  
non-HDL -C non-high-density lipoprotein -cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38613]  upper limit of normal  
VLDL  very-low-density lipoprotein  
VLDL -C very-low-density lipoprotein -cholesterol  
VLDL -TG lipoprotein -triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
35  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATI ONALE  
2.1 Overview of Disease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37549] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination f
requently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plas
ma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L 
probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activi ty in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and p
otentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis h as not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology 
of extreme hypertriglycerid
emia in FCS is considered to be ineffective triglyceride 
clearance,  due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutat
ions, null mutations, and nonsense mutations in the L
PL gene, other genes currently 
identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
36  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a plat form for LPL -mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; F
igure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] (Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) a
nd a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III a
lso inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceri demia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37919]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase,  LSR  = lipolysis -stimulated  
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
37  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects wi
th gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et 
al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritabilit
y and phenotype intervention (HAPI) heart study in Old Order Amish 
that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In ano ther study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype 
analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that w as associated with significantly lower levels of 
apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC- III polymo rphisms associated with higher plasma TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels i n order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37690].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanis 
ms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients  include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in live
r reuptake of 
lipid particles by [CONTACT_37691]-mediate
d uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing a
poC- III might enhance apoE -mediated uptake of 
lipid
 particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of 
action, volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37692].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
38  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels u
sing this approach correlates directly  with a 
subsequent reduction in target protein levels.  
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic o
ligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37843] l
inkages.  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resist
ance to exonucleases and en donucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2 ʹ-MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate O
ligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
39  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volaneso rsen has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatmen t with volanesorsen also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The phar
macokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the i n vitro  human  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_38614] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotox ic (in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
40  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clini cally meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering ther apy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients 
with 
FCS, and patients with T2DM
. 
In a Phase 2 study, 3 patients w
ith FCS were treated with 300 mg/wk volanesorsen  in an 
open-l abel fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_38615] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_38616]- treatment  period and was not associated with platelet- related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosi
ng. 
The most frequently observe
d AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_38617] Level ( NOAEL ) 
was defined by [CONTACT_37921] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well-tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen wa s studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience o
 f volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
42  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISI S 304801-CS6 (index study) roll-over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll -over FCS patients  
Up to approximately [ADDRESS_38618] of the following periods: 
3.4.1 Qualification  
A Qualification period of up to 2 weeks  (unless approved by [CONTACT_37922]) is given to complete 
qualification  assessments outlined in the Schedule of Procedures .  Please refer to Section 4.1 and  
Appendix A . 
3.4.2 Tr
eatment  
The tr
eatment 
period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_38619]-treatment evaluation period is 13 weeks and consists of 7 Study Cen ter visits on 
Weeks  53, 54, 55, 56, 57, 58, and 65 (Weeks 53, 54, 55, 56, 57, and 58 may be conducted by a 
home healthcare nurse) . 
3.[ADDRESS_38620] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483] .  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives  must sign the consent form before any  study-
specific procedures or evaluations  related to this open- label study are performed .   
During the qualification period, the eligibility of the patient to enroll in the open- label study will 
be determined .  Final a ssessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may 
be used for qualification.  A period of up to 2 weeks after completion of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete 
qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_38621] been completed and after the Investigator has verified that they are eligible per criteria in 
Sections 5.1 and 5.2.  No patient  may 
begin treatme nt prior to enrollment. 
Eligible  patients will b
e enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria within [ADDRESS_38622] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
44  3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. 
Group 2:  Patients who enrolled in ISIS 304801-CS16 must also meet the following 
criteria in order to enter  into the open- label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/d L (10  mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) supported by [CONTACT_37685] 1 of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of- function mutatio ns in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤20% of normal in medical history.  Note: 
testing of LPL activity should not be performed to confirm eligibility for the study 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Qualification  for the ISIS 304801-CS16 
index study 
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to 
Section 6.3.1) from time
 
of signing the infor
med consent form until [ADDRESS_38623] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing po 
tential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38624] dose of Study Drug administration. 
*Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
5.2 Exclusion Criteria  for Group 1 (ISIS 304801- CS6) and Group 2 
(ISIS  304801- CS16 ) Index Study Roll- over Patients  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the patient participating in or completing the study.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
45  2. Unwilling to comply with lifestyle requirements for the duration of the study 
(Section  6.3). 
6. STUDY PROCEDURES  
6.[ADDRESS_38625] patient’s Week [ADDRESS_38626]. 
During the treatment period , patients will report to the study center for clin
 ic visits a minimum of 
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  unless the patient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital 
signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urina
lysis), AEs , concomitant 
medication/proced ure information, lipid panel, blood viscosity, volanesorsen plasma 
concentrations, immunogenicity (IM)  testing , platelet aggregation, liver/spleen MRI, ECGs, 
echocardiograms and quality of life assessments  will be performed according to the schedule of 
procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be re inforc ed at intervals throughout the treatment and follow-up 
period and all patients will complete a daily food diary  for one week prior to their quarterly visit.  
All blood and urine samples should be collected  prior to volanesorsen administration .  Blood 
sampling at Week s 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, a nd [ADDRESS_38627] the option  of continuing dosing for up to an additional 52 weeks until an 
expanded access program  is approved and available in their country. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands  11 April 2017  
46  During the extended treatment period, patients will report to the study center for clinic visits 
during Weeks 54-104 (see Schedule of Procedures in Appendix A ).  Study Drug will be 
administered once weekly  unless the p
atient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), AEs, concomitant 
medication/procedure information, lipid panel, volanesorsen plasma concentrations, IM testing , 
ECGs, and physical examinations will be performed according to the S chedule of Procedures in 
Appendi x A.  Adverse events at the injection site should be collected as adverse events.  Dietary 
counseling will be reinforced at intervals throughout the extended treatment period.  All blood 
and urine samples should be collected prior to volanesorsen administration.  Blood sampling at 
Weeks 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, a nd 
[ADDRESS_38628] be fasted prior to drawing all blood samples and samples drawn locally should also be sent to the central laboratory for analysis  whenever possible .  Dosing 
instructions and training will be provided to the patient where applicable. 
6.1.4 Pharmacokinetic (PK) Subgroup 
A s
ubgroup of patients will participate in an extended PK collection .  Patients in this subgroup 
will have more
 frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_38629]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the PK subgroup i
s optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A. 
6.1.[ADDRESS_38630]- treatment evaluation  period consists of 
7 Study Cent
er visits on Weeks 53, 54, 55, 56, 57, and 58 (which may be conducted by a home 
healthcare nurse) , and W eek [ADDRESS_38631]- treatment 
evaluat
ion period consisting of 7 Study Center visits on Weeks 105, 106, 107, 108, 109, and 
110 (which m ay be  conducted b y a hom e healthcare nurse), and Week [ADDRESS_38632] of these analytes  is 
contained in Appendix B . 
Ea
ch time a hema
tology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed locally.  In the event that both the central and 
local sample are unreportable (e.g., due to hemolyzed or clumped blood samples ) another sample 
must be repeated within 1- week and the result must be reviewed by [CONTACT_37923] d osing can continue.  All platelet count results will be 
promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877], or the 
dose reduction rule of 100,000/mm3, or the dose pause rule of 75 ,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A ).  
Vital signs shoul
d include weight, blood pressure, pulse rate , respi[INVESTIGATOR_697] a nd 
body temperature.  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37602] (preferentially on the left arm).  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At ea
ch visit, patients will be asked whether they have had any epi[INVESTIGATOR_37559]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 roll -over patients) and repeated at Week 52.  
Images will be evaluated b y an independent assessor, blinded to the patient’s treatment 
assignment.  
6.2.[ADDRESS_38633] ECGs performed in triplicate at 
Week 76 and Week 104. 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_38634]- treatment follow-up period (Week 65). 
6.2.8 Diet Monitoring  
The diets of patien ts enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to provide diet/alcohol counseling for visits that are conducted by a clinical service.  Patients in the Extended Treatment Period will receive diet/alcohol counseling by 
[CONTACT_37884]. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet may  be conducted randomly during the treatment and 
post treatment follow -up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
6.2.10 Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 2)  
Patient records will be reviewed for incidents of acute pancreatitis occurring up to [ADDRESS_38635] refrain from sperm/egg donation and 
either be abstinent† or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_38636]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patie nts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, 
intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus i s not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used together as friction between 
the two can result in either product failing. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
50  † Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
6.3.[ADDRESS_38637] 10 hours and preferably not more than 12 hours before vis its requiring  fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38638] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification  (Banks et al. 2013 ).  If se
rum or amylase activity is less than 
3 x upper limit of norm
al (ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_38639] (ISIS 304801) characteristics are listed in  Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2  to 8 °C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands  11 April 2017  
51  8. T REATMENT OF PATIENTS
8.1 Volanesorsen  Administration
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once wee
kly for Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on 
a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their  index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_38640] 
2 days apart.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs.  
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 
8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_38641] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen colle ctions should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
ISIS [ADDRESS_38642] confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may also be initiated as noted in 
Section 8.7.  If any of the stoppi[INVESTIGATOR_37603] 
(refer to Sections 8.6.1 to 8.6.3) a re met,
 the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from
 the draft guidance for industry, “Drug- Induced Liver 
Injury: Pre marketing Clin
ical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to 
guidance in  Section 8.[ADDRESS_38643] measurement that is >  [ADDRESS_38644]  (or the greater of [ADDRESS_38645] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmato ry measurements should also be performed if ALT or AST levels increase 
to [ADDRESS_38646]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_38647] (or 
the greater of [ADDRESS_38648] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_38649] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_38650]  (or the greater of [ADDRESS_38651] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
53  4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a patient ’s ALT and/or AST levels reach [ADDRESS_38652] be documented in the patient’s medical records. 
Due to the [ADDRESS_38653] with the study patients.  However, if the above options are not possible, a temporary interruption of study treatment will be planned with a prompt blood draw upon the patient’s return which must be reported and reviewed by [CONTACT_37768]. 
The tests outlin ed in Table 2 should also be performed as soon as possible.  A dditional lab tests 
will be determined by [CONTACT_37852].  Any case of a platelet count < 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
54  Table 2 Labs to Be Performed in the Event of a Platelet C ount Less than the Lower 
Limit of Normal (x2) or < 100,000/mm3 (x1)*  
*In p atients who have any 2 occurrences (consecutive or non-consecutive) of platelet count less 
than the lower limit of normal or who have any 1 occurrence of platelets < 100,000/mm3.  Labs 
only need to be performed once.  Labs may be collected  over multiple visits, if blood 
requirements are a concern, as per investigator discretion. 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for Qualification ) 
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti-PF4 assay  
Anti-ASO antibody  
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
55  8.5.3 Safety Monitoring for Minor Bleeding Events  
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major blee
ding events (which are defined in Section 8.6.3), for
 example excess 
bruising, petechiae
, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_38654] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or in crease 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_38655] 
practice guidelines  and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer and/or glucometer log printout to every clinic visit.  
• The Investigator or de legate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined 
as typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
56  o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF.  
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to  patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice f or example, then obtain and record a blood glucose value as soon as possible 
thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day of the event.  
8.5.[ADDRESS_38656] dose titration and/or addition of any other anti- hyperglycemic agent(s) w ill not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within 1- week of the initial test).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_38657] the Investigator and an unscheduled central laboratory FPG measurement and HbA1c should be performed. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
57  The threshold values are defi ned as:  
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38658]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of th e above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event (AE)/concomitant medication parts of the e -CRF)  
• Stress on  the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be
  suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be
 
determined by [CONTACT_37853] . 
8.[ADDRESS_38659] measurement prior to Day 1.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
58  8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_38660] >  [ADDRESS_38661] , which is confirmed and persists for ≥ [ADDRESS_38662] >  [ADDRESS_38663] (or the greater of [ADDRESS_38664] if the baseline 
value was > ULN) , which is confirmed  and total bilirubin >  [ADDRESS_38665]  or INR  > 1.[ADDRESS_38666] >  [ADDRESS_38667] (or the greater of [ADDRESS_38668] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic en zymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_38669] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinin e clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by  [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 3 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen w
ill be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any plate
let count less than 50,000/mm3, or a platelet count less than 75,000/mm3 
that occurs while the patient is on dosing at 300 mg every 2 weeks then d osing of a patient with 
volanesorsen will be stopped permanently.  Platelet count will be monitored as outlined in 
Table 3. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
59  Administration of steroids is recommended for patients whose platelet count is less than 
50,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily f
or 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone).  Triglyceride 
levels be monitored weekly, and AE monitoring will continue, during corticosteroid treatment 
and the laboratory alert will be changed from an increase of 2,000 to 500 mg/dL during that 
period. 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the pla telet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks  (refer to Section 8.7).  The suitability of the patient for continued dosing will be 
determined by [CONTACT_37924]’s platelet count, whether any bleeding 
events were experienced by [CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If after the first dosing rech
allenge the platelet count again falls below 75,000/mm3, then dosing 
of the patient with Study Drug will be s topped permanently. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessi ve wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipunctu re for >  [ADDRESS_38670] be documented in the 
patient’ s medical records.  Monitor every 1 week unless otherwise specified  
 
Obtain additional lab tests (Table 2) if 
2 occurrences  consecutive or 
non-consecutive) of platelet  count 140K - 
> 100K/mm
3 or 1 occurrence of platelet 
count ≤  100K/mm3.  Labs only need to be 
performed once.   Labs may be collected 
over multiple visits, if blood requirements 
are a concern, as per investigator discretion.  
> 100K/mm3 Weekly 300 mg Study Drug 
administration   
100K/mm3 - > 75K/mm3 Permanently reduce dose frequency to 300 mg every 2 weeks   
75K/mm3 - > 50K/mm3 • If occurs while on dose of 300 mg every 2  weeks then permanently 
discontinue Study Drug, otherwise dose pause  
• When platelet count returns to 
> 100K/mm
3 restart dosing at dose 
frequency of 300 mg every 2 weeks 
only if approved by [CONTACT_37858]  • Monitor every 2-3 days until 2 successive values are >  75K/mm
3 
then monitor every 1 week  
• Consider discontinuation of antiplatelet agents/NSAIDS/ anticoagulant 
medication  
≤ 50K/mm3 Permanently discontinue Study Drug • Monitor daily until 2 successive values 
show improvement then monitor every 
2-3 days until 2 successive values are 
>75K/mm3 then monitor every 1 week  
• Patient should be evaluated by a 
hematologist to provide diagnostic and 
therapeutic management  
• Steroids recommended*.  It is strongly recommended that, unless the patient 
has a medical contraindication to 
receiving glucocorticoids, the patient receives glucocorticoid therap y to 
reverse the platelet decline  
• Monitor triglyceride levels weekly and 
continue AE monitoring during steroid 
therapy  
• Discontinue antiplatelet agents/ NSAIDS/ anticoagulant medication while platelet count is<  50K/mm
3 if possible 
* Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010) recommend dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1- 4 cycles; 
prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks  then taper; or methylprednisolone 
30 mg/kg/day for 7 days ( note:   may require continuation with oral steroids after methylprednisolone)  
ISIS [ADDRESS_38671] be made in accordance with Section 8.6.3 and 
Table 3 (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safet y and tolerability.  Any proposed adjustment to treatment 
schedule must be discussed with, and approved by, the Study Medical Monitor prior to initiation.  
Up to [ADDRESS_38672] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregna ncy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
•
 The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abn ormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_38673] 6 weeks after discontinuing Study 
Drug .  Following this period, if the platelet count is stable (at least 3  consecutive values that are 
stable as determined by [CONTACT_37925] M edical Monitor and > 100,000/mm3), the next platelet 
count should be taken within at least [ADDRESS_38674] 12 weeks 
after discontinuing Study Drug .  Patients  should also be strongly encouraged to attend applicable 
landmark visits at Week s 12, 13, 25, 26, and 50, 52 (calculated based on the time elapsed since 
Day 1) to collect  fasting lipid panels and conduct safety assessments in accordance with the 
Schedule of Procedures in Appendix A .  Any patient who discontinues treatment after  Week 44 
should also be strongly encourage
d to attend a final follow-up visit ( Week 65 visit assessments) 
approximately [ADDRESS_38675] dose of Study Drug, in addition to the applicable landmark visits . 
If the patient declines or is unable to p
articipate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_38676] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 
consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_38677] 1 2 weeks after discontinuing Study Drug.  
Patients  should also be encouraged to undergo a final  follow-up visit ( Week 65 (or Week 117 if 
terminating from the Extended T reatment Follow- Up P eriod), see Appendix A ) prior to leaving 
the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patien t to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_38678] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participat e in the s tudy will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal (see Section 8.8 and Appendix A ). 
For patien
ts withdrawn for rea
sons ot
her than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_38679] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
63  8.10.1 Concomitant Therapy 
A conc omitant therapy is any non -protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing 
informed consent and completion of the post- treatment follow -up period.  All c oncomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543].  
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid- altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the treatment of hypertriglyceridemia.  
Patients  should consult with the Site Investigator or designee prior to initiating any new 
medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between signing of informed consent and Week 65 (or Week 117 if patient ent ers the extended treatment 
period) visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center  staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
ISIS [ADDRESS_38680] of the clinical trial.  
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) pe r the International Conference on Harmonization (ICH) guidelines E2A and ICH 
E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will
  not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study population independent of volanesor sen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table [ADDRESS_38681]
ed Event for the Protocol Defined Population by [CONTACT_37861]  (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the ev ent will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
65  9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that, had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility and does not always qualify as an AE 
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
66  9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_38682] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week 65 visit (or Week 117 if patient enters the 
extended treatment period) .  When  the Investigator is reporting by [CONTACT_756], it is important to 
speak to someone in person versus leaving a message.  An  Initial Serious Adverse Event Form 
should be completed and a copy should be faxed to the Sponsor or designee . 
Detailed information should be actively sought and included on Follow-Up Serious Adverse Event Forms as soon as additional information becomes available.  All SAEs will be followed until resolution.  SAEs that remain ongoing past the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week 65 visit 
(or Week 117 if patient enters the extended treatment period).  The Investigator will monitor 
each patient  closely and record all observed or volunteered AEs on the Adverse Event Case 
Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non -Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
67  • Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medicatio ns or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is 
unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Advers
e Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not liste
d in Appendix D wi
ll be graded as follows: 
• Mild:   The event is easily 
tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Vol anesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same d ose:  Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
68  • Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will
 be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) a
nd as outlined in the Pancre atitis 
Adjudication Char
ter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_38683] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associ ated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be listed in preference to  abnormal laboratory val ues as AEs .  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
69  9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or electi ve procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a d
 ose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdos
e occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_38684] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the  pregnancy.  Regardless of continued study participation, the study 
ISIS [ADDRESS_38685] the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or 
spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are define d as the average of Week 25 (Day  169) and 
Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent  change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Change in blood viscosity (may be evaluated ) 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis) 
• Echocardiography 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
71  • Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
• Platelet aggregation (may be evaluated)  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and received at least [ADDRESS_38686] a baseline TG assessment .  The FAS represents the practically -feasible 
intent- to-treat (ITT) population as delineated in ICH Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38687] 
efficacy and PD assessments .  The detailed criteria will be specif ied and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_38688] dose  PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_38689] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification).   
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 in dex study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline will be the last non -missing assessment prior to the first dose of Study  Drug . 
10.[ADDRESS_38690] patient’s Week [ADDRESS_38691] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_37891] 304801- CS6 or ISIS 304801-CS16 index studies, and pooled 
treatment naive group which including patients on placebo in index studies.  Where appropriate, p-values will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% 
Type  I error  rates unless otherwise stated.  
TG related  endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will 
be assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK 
endpoints will be assessed in the PK Se t as applicable.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_14454] .  The patient disposition will be summarized  by [CONTACT_14459].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_14453]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. 
All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_1570] , MedDRA preferred term 
and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_6490]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37869] . 
These safety variables will also be presented as change and percent change from baseline over time after Study Drug admin istration, as appropr iate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_1570] . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
73  10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] .  Response rate of pa tients with fasting plasma TG 
< 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and 
Month 12 will be summarized .  Response analysis will also be conducted using a range of fasting 
plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37870]- HDL -C, apoB, 
HDL -C, apoA- 1, VLDL -C, and LDL-C, total cholesterol, and fasting total apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_1570] . 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics  by [CONTACT_37780].  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single-dose PK) or multiple doses (i.e., 
steady -state PK), dependi ng on their earlier treatment in the index studies (Group 1 and 
2 patients) .  On Week [ADDRESS_38692] treatment of volanesorsen (single -dose PK), while patients who 
received volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16) , thus the PK data collected from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C max) and the time 
taken to reach C max (Tmax) will be obtained directly from the concentration -time data .  Area under 
the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24h) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24h /F) will be calculated from CL 0-24h/F = Actual Dose/AUC 0-24h.  Mean residence time 
(MRT) from time zero to 24 hours after the SC administration  will be calculated from the 
equation, MRT 0-24h = AUMC 0-24h/AUC 0-24h, where AUMC 0-24h is the area under the moment 
plasma concentration -time curve from time zero to [ADDRESS_38693]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
74  Plasma PK parameters will be summarized using descriptive statistics  by [CONTACT_37892] .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/ PD, and covariate analysis may be performed if  deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day associated with the first positive IM status emerged (T
first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the last ADA sample 
collection  day,  and subject - peak titer if applicable, will be listed by [CONTACT_37872]  304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day .  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized  as the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by  [CONTACT_1570] .  Furthermore, onset and t iter of the ADA 
response, if applicable, will be summarized as median, quartiles (25% and 75%), and ran ge. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
ISIS [ADDRESS_38694] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising ma terial must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure mus t be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures. 
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_38695] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification  of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
ISIS [ADDRESS_38696] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_38697].  The Investigator /Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence.  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section  8 of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
77  No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_38698], inspecting the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study- related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed  on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_38699] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for Injury section of the Informed Consent document.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
78  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second gene ration of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Ef fect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containin g lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Wa tts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modif ied antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and  humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - Netherlands   11 April 2017  
 
79  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expressi on in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP. Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibito ry effects of specific apolipoprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene v ariants in nonalcoholic fatty liver disease. N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patien ts with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37926] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, H eemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyce ridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_38700] 
Treatment 
Follow-up 
Study Week -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3 Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6 Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12 Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET 
Study Day -14 to  
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 44
9 
Visit Window+/- Days 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent X                          
Outpatient Visit X X Xl Xl Xl Xl Xl Xl X Xl Xl Xl Xl X Xl Xl Xl X Xl Xl Xl Xl X Xl Xl X 
Inclusion/Exclusion Criteria X                          
Medical Historyb                           
Vital Signs + body weight  
(+ height on Day 1 only) X X  X  X   X     X    X     X   X 
Physical Examination  X       X     X    X     X   X 
12- lead ECG (triplicate)         X     X    X     X   X 
MRI (liver/spleen)                       Xm    
Echocardiography              Xm         Xm    Blood Draw (Fasting)d Chemistry Panel X X  X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialc X X 
Platelets are assessed each calendar week , visits do not have specified windows to allow flexibility of scheduling. X 
Serum Lipid Panel X X  X  X  X X    X X    X    X X   X 
Blood viscositye  X       X     X         X    
Platelet aggregatione X X       X     X         X    
Coagulation (aPTT, PT, INR) X     X   X     X    X     X    
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]  X       X     X         X   X 
Sedimentation Rate  X       X     X         X   X 
Complement (C5a, Bb)  X       X     X         X   X 
Troponin I  X       X     X         X   X 
Platelet Bound Autoantibodiese  X                         
Plasma PK - Volanesorsen  Xn X X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies  X  X  X   X     X    X     X   X 
Serum Pregnancy Testf X   X  X   X  X   X  X  X  X   X  X X 
  
ISIS [ADDRESS_38701] Treatment 
Follow -up 
Study Week  -2 to 
 -1 Wk 
1 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 
Wk 
12 Wk 
13    Wk 
25 Wk 
26        Wk 
50 Wk 52  
or ET     
Study Day  -14 to 
-7 1 2 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 Blood Draw 
(Fasting)d Archive blood sample for 
potential gene sequencing 
related to hypertriglyceridemia 
(Group 2 if not available from 
index study)i X X                         
Archived Serum & Plasma 
Samplesg  X    X   X     X         X   X 
Urinalysisd X Xo  X  X   Xo  Xo   Xo  Xo  Xo  Xo   Xo  Xo Xo 
Fundus Photographyh X                      Xm    
Genetic testing for FCS diagnosis (if 
not available in medical history)i X                          
Weekly Study Drug:  SC Injection   X  X X X X X X X X X X X X X X X X X X X X    
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X       X     X         X   X 
Food/Drink Diary (quarterly)j  X       X     X         X   X 
Diet/Alcohol Counselingk X X  X  X   X     X    X     X  X X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X X X X 
a Qualification procedures performed (Please refer to Section s 3.4.1 , 4.1, and 6.1.1) 
b Patient charts wil
l be reviewed i
n order to collect data for events of acute pancreatitis or suspected pancreatitis in the patient’s medical history.  Chart review may 
be conducted at any time during the study.  These events will be adjudicated in the same manner as for events of pancreatitis  during the study  
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.   In 
the event that both the central and local sample are unreportable (e.g. , due to hemolyzed or clumped blood samples) another sample must be repeated within 
[ADDRESS_38702] be reviewed by [CONTACT_37848].  All platelet count results will be promptly 
reviewed by [CONTACT_37927] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100,000/mm3, or the dose pause rule of 75,000/mm3.  
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor   
ISIS [ADDRESS_38703] 10 hours  and preferably not more than 12 hours .  During treatment period urine and blood 
samples will be collected prior to Study Dru g administration .  Does not  apply to 24-hour PK blood draw  
e May be done.  Blood viscosity and platelet aggregation in volanesorsen-treatment naïve patients  only 
f Females of childbearing pot ential only  
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of 
volanesorsen  
h If possible, fundus photography should be completed prior to administration of the first dose of Study Drug ( Group 2 [ISIS 304801-CS16 roll-over patient s]) 
and repeated at Week 52 (Please refer to Section [IP_ADDRESS]) 
i Genetic t
esting can be conducted for study qualification (Group 2 [ISIS 304801-CS16 roll-over  patients ]); genetic testing will only be conducted if allowed in 
the geographic region and only after the patient has given specific written informed consent for genetic testing  
j In addition to diary, patients will be contact[CONTACT_37787]  
k To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
l Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
m A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
n Full or abbreviated PK profile (see Appendix C ) 
o Expanded urinalysis (see Appendix B ) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6 
Protocol  - Netherlands   11 April 2017  
 
85  Appendix A  Schedule of Procedures  – Extended Treatment Period  
Study Period  Treatment Period  Post-Treatment 
Follow -up 
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62 Mo 15  
Wk 64 Wk 66 
& 68  Wk 
70 Wk 72 
& 74 Mo 18  
Wk 76  Wk 78 
& 80  Wk 
82 Wk 84, 
86, & 88  Mo 21  
Wk 90 Wk 92 
& 94  Wk 
96 Wk 
98, 
100 & 
102 Mo 24  
Wk 
104 Wk 
106 
& 
108 Wk 
110 Mo 27  
Wk 
117 
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 56
8  582, 596 
& 610  624 638 & 
652 666 680, 
694 & 
708 722 736  
& 
750 764 813 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf X 
Vital Signs (+ body weight)     X    X    X    X   X 
Physical Examination         X        X    
12- lead ECG (triplicate)         X        X    
Urinalysis(including P/C ratio)   X  X  X  X  X  X  X  X  X X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X  X X 
CBC with Differentiala X 
Platelets are assessed each calendar week, visits do not have specified windows to allow flexibility of scheduling.  X 
Serum Lipid Panel    X    X    X    X   X 
Coagulation (aPTT, PT, INR)     X    X    X    X    
Troponin I     X    X    X    X   X 
Plasma PK - ISIS 304801c        X        X   X 
Anti-ISIS  304801 Antibodies         X        X   X 
Serum Pregnancy Testd  X  X  X  X  X  X  X  X  X X 
Weekly Study Drug: SC Injection  X X X X X X X X X X X X X X X X    
Diet/Alcohol Counselinge    X    X    X    X    
Adverse Events  X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6 
Protocol  - Netherlands   11 April 2017  
 
86  Appendix A  Schedule of Procedures – Extended Treatment Period  Continued  
Legend Text  
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated 
within [ADDRESS_38704] be reviewed by [CONTACT_37848].  All platelet count results will be 
promptly reviewed by [CONTACT_37792] a stoppi[INVESTIGATOR_1877], or the dose reduction rule of 100 ,000/mm3, or the dose pause rule of 
75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatme nt period urine and blood 
samples will be collected prior to Study Drug administration  
c Abbreviated PK collection (see Appendix C ) 
d Fem
ales of
 childbearing potential only  
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37894] [ADDRESS_38705] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides . 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium 
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• Troponin I2 
• CK-MB2 
• Platelet Bound 
Autoantibodies3 
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  
• Blood viscosity3 Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
4 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
Platelet Function  
• Platelet aggregation3 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_38706]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_38707]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52  
 PK Sampling Schedule (Extended Treatment Period)  
Week  Wk 
76 Wk 
104 Wk 
117 
Study Day  D526  D722  D813  
Visit Window 
+/- Days  [ADDRESS_38708] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol  - Netherlands   11 April 2017  
 
93  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol  - Netherlands   11 April 2017  
 
94  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 

 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38709] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38710] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 6  – [ADDRESS_38711] No:  2015-003755-21 
 
 
 

ISIS 304801-CS7 
Protocol CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 6 
18 November 2016 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 6-18 November 2016 
Protocol History: 
Original Protocol: 
Protocol Amendment 1 : 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38712] 2015 
2 February 2016 
22 April2016 
9 May 2016 
6June2016 
6July2016 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_38713] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor: Ionis Pharmaceuticals,  Inc. 
[ADDRESS_38714] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:  [CONTACT_37829].D. 
[ADDRESS_38715] 
Carlsbad, CA [ZIP_CODE] 
Phone:  
Collaborator: Akcea Therapeutics  
[ADDRESS_38716] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38717] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 6 
Date:  [ADDRESS_38718] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38719] the study 
as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .................................................................................................... 10  
PROTOCOL SYNOPSIS  ........................................................................................................... 15  
STUDY DESIGN AND TREATMENT SCHEMA  .................................................................. 21  
STUDY GLOSSARY .................................................................................................................. 22  
1. OBJECTIVES  ................................................................................................................. 24  
2. BACKGROUND AND RATIO NALE  .......................................................................... 24  
2.1 Overview of Disease  ......................................................................................................24  
2.2 Therapeutic Rationale  ....................................................................................................25  
2.3 Volanesorsen  ..................................................................................................................26  
2.3.1  Mechanism of Action  .............................................................................................26  
2.3.2  Chemistry  ...............................................................................................................27  
2.3.3  Preclinical Experience  ............................................................................................28  
2.3.4  Clinical Experience ................................................................................................29  
2.4 Rationale for Dose and Schedule of Administration .....................................................30  
3. EXPERIMENTAL PLAN .............................................................................................. 31  
3.1 Study Design  ..................................................................................................................31  
3.2 Number of Study Centers ..............................................................................................31  
3.3 Number of Patients ........................................................................................................31  
3.4 Overall Study Duration and Follow-up .........................................................................31  
3.4.1  Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification  ....................................................................................31  
3.4.2  Group 3 Patients (did not participate in an index study):  Screening/ Qualification  ...........................................................................................................[ADDRESS_38720] ................................................................................32  
4. PATIENT ENROLLMENT ........................................................................................... 32  
4.1 Screening/Qualification  .................................................................................................32  
4.2 Enrollment .....................................................................................................................33  
5. PATIENT ELIGIBILITY  .............................................................................................. 33  
5.1 Inclusion Criteria  ...........................................................................................................33  
5.2 Exclusion Criteria for Group 1 (ISIS 304801-CS6) and Group 2 (ISIS 304801-CS16) Index Study Roll-over Patients  ......................................................................................34
 
6. STUDY PROCEDURES  ................................................................................................ 36  
6.1 Study Schedule ..............................................................................................................36  
6.1.1  Qualification (Groups 1 and 2) ...............................................................................37  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
6  6.1.2  Screening and Qualification (Group 3) ..................................................................37  
6.1.3  Treatment Period  ....................................................................................................37  
6.1.4  Extended Treatment Period  ....................................................................................38  
6.1.5  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_38721]- Treatment Period  ............................................................................................38  
6.2 Additional Study Assessments  .......................................................................................39  
6.2.1  Laboratory Assessments  .........................................................................................39  
6.2.2  Physical Exams and Vital Signs  .............................................................................39  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................39  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................39  
6.2.3  Echocardiography ...................................................................................................40  
6.2.4  ECG  ........................................................................................................................40  
6.2.5  MRI  ........................................................................................................................40  
6.2.6  Quality of L ife Assessments ...................................................................................40  
6.2.7  Disease Symptom Diary  .........................................................................................40  
6.2.8  Diet Monitoring  ......................................................................................................40  
6.2.9  Family History  ........................................................................................................40  
6.2.10  Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 3) ..[ADDRESS_38722]- Treatment Follow -up Period .53  
8.9 Withdrawal of Patients from the Study  ..........................................................................54  
8.10  Concomitant Therapy and P rocedures  ...........................................................................54  
8.10.1  Concomitant Therapy .............................................................................................54  
8.10.2  Concomitant Procedures .........................................................................................55  
8.11  Treatment Compliance  ...................................................................................................55  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ...................... 55  
9.1 Sponsor Review of Safety Information .........................................................................55  
9.2 Regulatory Requirements  ..............................................................................................55  
9.3 Definitions  .....................................................................................................................56  
9.3.1  Adverse Event  ........................................................................................................56  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................56  
9.3.3  Serious Adverse Event (SAE)  ................................................................................57  
9.4 Monitoring and Recording Adverse Events ...................................................................57  
9.4.1  Serious Adverse Events ..........................................................................................57  
9.4.2  Non-Serious Adverse Events ..................................................................................58  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................58  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................58  
[IP_ADDRESS]  Severity  ............................................................................................................58  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................59  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................59  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................59  
9.4.4  Adjudication Committees  .......................................................................................60  
9.5 Procedures for Handling Special Situations ..................................................................60  
9.5.1  Abnormalities of Laboratory Tests .........................................................................60  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............60  
9.5.3  Dosing Errors .........................................................................................................61  
9.5.4  Contraception and Pregnancy .................................................................................61  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 62  
10.1  Study Endpoints  .............................................................................................................62  
10.1.1  Efficacy Endpoints .................................................................................................62  
10.1.2  Safety Endpoints .....................................................................................................62  
10.2  Sample Size  ....................................................................................................................62  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
8  10.3  Populations .....................................................................................................................63  
10.4  Definition of Baseline  ....................................................................................................63  
10.5  Interim Analysis  .............................................................................................................63  
10.6  Planned Methods of Analysis  ........................................................................................63  
10.6.1  Demographic and Baseline Characteristics  ............................................................64  
10.6.2  Safety Analysis  .......................................................................................................64  
10.6.3  Efficacy Analysis  ...................................................................................................64  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................65  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................65  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................65  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. [ADDRESS_38723] of the Study .........................................................................................66  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38724] of Laboratory Analytes  .............................................................................79  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................81  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......83  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics .........................................................42  
Table 2  Labs to Be Performed in the Event of a Platelet Count < 75,000/mm3 .................46  
Table 3  Actions in Patients with Low Platelet Count  .........................................................52  
Table 4  Expected Event for the Protocol Defined Population by [CONTACT_37895]  ...................................................................................56  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
9  TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  ...............25  
Figure 2  Design of Chimeric 2ʹ- MOE Pho sphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown ....................................27  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  ...............29  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
10  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered 
Subcutaneously to Patient s with Familial Chylomicronemia 
Syndrome (F CS) 
Amendment Number:  6 
Amendment Date:  18 November 2016 
 
The purpose of this protocol amendment is to implement the following modification s to Protocol 
ISIS 304801-CS7 Amendment 5 dated 6 July 2016: 
1. To allow patients who complete the 52- week treatment period to participate in an 
expanded access program or continue dosing for up to an additional [ADDRESS_38725] treatment 
evaluation period. 
2. The following assessment s were added:  Troponin I; labs to be performed in the event of 
a platelet count < 75,000/mm3; platelet bound autoantibody testing at baseline  (may be 
done); plus medical history, hepatitis B, C, and HIV at Screening (Group 3 patients) . 
Minor changes (not included in the list of changes below) have been made throughout the 
protocol to correct errors and/or to improve the overall clarity of the original protocol but t hese 
changes do not impact subject safety, exposure, or the overall study design. 
The following table provides a summary list of major changes to the protocol: 
Protocol Section  Description of Change  Rationale  
Protocol Synopsis:    
Study Design  
Study Visit  Schedule 
and Procedures  
3.[ADDRESS_38726] -Treatment  
Period Was: 
Following the Week [ADDRESS_38727] treatment evaluation period.  
Is: 
Following the Week [ADDRESS_38728] -treatment evaluat ion period.  To allow patients the 
option of continuing 
treatment with 
volanesorsen after 
completion of the 52-week open-label 
treatment period.  
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
11  Protocol Section  Description of Change  Rationale  
For con sistency with the above changes:  
appropriate wording was added to the following sections : 
Protocol Synopsis:  Study Visit Schedule and Procedures  
Study Design and Treatment Schema  
6.2.[ADDRESS_38729] -Treatment Follow -up Period  
8.10.2  Concomitant Procedures  
9.4.2  Non-Serious Adverse Events  
and the following table and footnotes were added to Appendix A:  Schedule of Procedures : 
Appendix A  Schedule of Procedures – Extended Treatment Period  
Study Period  Treatment Period  Post -Treatment 
Follow -up 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
60 
& 
62 Mo 
15 
Wk 
64 Wk 
66 
& 
68 Wk 
70 Wk 
72 
& 
74 Mo 
18 
Wk  
76 Wk 
78 
& 
80 Wk 
82 Wk 
84, 
86 
& 
88 Mo 
21 
Wk 
90 Wk 
92 
& 
94 Wk 
96  Wk 
98, 
100 
& 
102 Mo 
24 
Wk 
104 Wk 
106 
& 
108 Wk 
110 Mo 
27 
Wk 
117 
Study Day  372 
& 
386 400  414 
& 
428  442 456 
& 
470 484  498 
& 
512 526 540 
& 
554 568  582, 
596 
& 
610 624 638 
& 
652 666 680, 
694 
& 
708 722 736  
& 
750 764 813 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf X 
Vital Signs (+ body 
weight)     X    X    X    X   X 
Physical Examination         X        X    
12- lead ECG (triplicate)         X        X    
Urinalysis  (including 
P/C ratio)   X  X  X  X  X  X  X  X  X X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X  X X 
CBC with Differentiala X X X X X X X X X X X X X X X X X X X 
Serum Lipid 
Panel    X    X    X    X   X 
Coagulation (aPTT, PT, INR)     X  
  X    X    X    
Troponin I     X    X    X    X   X 
Plasma PK -  
ISIS 304801c        X        X   X 
Anti-ISIS 304801 
Antibodies         X        X   X 
Serum 
Pregnancy Testd  X  X  X  X  X  X  X  X  X X 
Weekly Study Drug: SC Injection  X X X X X 
X X X X X X X X X X X    
Diet/Alcohol 
Counselinge    X    X    X    X    
Adverse Events  X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
12  Protocol Section  Description of Change  Rationale  
Appendix A  Schedule of Procedures – Extended Treatment Period Continued  
Legend Text  
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample 
should be collected in parallel and analyzed locally.  In the event that both the central and local sample are 
unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within 
[ADDRESS_38730] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be promptly reviewed by [CONTACT_37909][INVESTIGATOR_37604] 75,000/mm
3.  Any case of a 
platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
b Blood samples to be collected after an overnight fast of at least  10 hours and preferably not more than 
12 hours.  During treatment period urine and blood samples will be collected prior to Study Drug 
administration  
c Abbreviated PK collection (see Appendix C)  
d Females of childbearing potential only  
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as 
arranged by [CONTACT_37928] C :  Phar macokinetic Sampling Schedule:  
Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52  
PK Sampling Schedule:  Extended Treatment Schedule  
Week  Wk 
76 Wk 
104 Wk 
117 
Study Day  D526  D722  D813  
Visit Window 
+/- Days  [ADDRESS_38731] the option of continuing dosing for up to 
an additional 52 weeks until an expanded access program is 
approved and available in their country.  
During the extended treatment period, patients will report to the study center for clinic visits during Weeks 54- 104 (see 
Schedule of Procedures in Appendix A).  Study Drug will be administered once weekly unless the patient is on a 
biweekly dosing schedule for safety reasons  (Section 8.1 ).  
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and 
urinalysis), AEs, concomitant medication/procedure 
information, lipid panel, volanesorsen plasma conc entrations, IM testing, ECGs, and physical 
examinations will be performed according to the schedule of 
procedures in Appendix A.  To outline the procedures to be performed during the 
extended treatment 
period.  
ISIS [ADDRESS_38732] be fasted prior to drawing all blood samples and samples drawn locally should also be sent to the central 
laboratory for analysis whenever possible.  Every effort 
should be made to ensure the previous week’s dose is given 
[ADDRESS_38733] -Treatment  
Period Added : 
Patients who complete, or terminate early from, the 
extended treatment period without subsequently 
participating in an expanded access program will enter a 
13-week post -treatment evaluation period consisting of 
4 Study Center visits on Weeks 106, 108, and 110 (which 
may be conducted by a home healthcare nurse), and 
Week  117 as outlined in the Schedule of Procedures in 
Appendix A . To describe the follow -up 
visits for patie nts that 
terminate early from the 
extended treatment 
period . 
6.2.10  Chart Review 
for Incidents of Acute 
Pancreatitis in Medical  
History (Group 3)  
Appendix A:  Schedule 
of Procedures  Added: 
Patient records will be reviewed for incidents of acute 
pancreatitis occurring up to [ADDRESS_38734] acute 
pancreatitis medical 
history events on patients that did not 
participate in an index 
study ( ISIS 304801-CS6 
or ISIS 304801-CS16) . 
8.5.2  Safety 
Monitoring for Platelet  
Count Results  Added: 
Table 2  Labs to Be Performed in the Event of a Platelet 
Count < 75,000/mm3. 
Note:  The following labs may change as additional data is 
assessed, and sites will  be updated regarding any changes . 
To Be Performed at Local Lab  
Peripheral smear (should be performed locally, fixed and 
sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Fibrinogen 
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
 
 To increase platelet 
count monitoring for 
safety purposes . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
14  Protocol Section  Description of Change  Rationale  
8.5.2  Safety 
Monitoring for Platelet  
Count Results  
Continued  To Be Performed at Central Lab  Continued  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella 
CMV  
EBV 
Parvo B19  
Helicobacter pylori (IgG serum test)  
Auto- antibody screen:  
Antiphospholipid  
Rheumatoid factor 
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
 To increase platelet count monitoring for 
safety purposes . 
Section 10.3  
Populations  Updated:  
Full Analysis Set (FAS):  All patients who are e nrolled and 
received at least [ADDRESS_38735] a 
baseline TG assessment.  
PK Population:  All patients who are enrolled, receive at 
least [ADDRESS_38736] a baseline TG 
assessment and clarified 
the PK Population.  
Section 10.4  
Definition of Baseline  Added:  
For Group [ADDRESS_38737] 
dose of Study Drug.  To add the baseline 
definition for Group 3 
patients.  
Appendix A:  Schedule 
of Procedures  
Appendix B:  List of 
Laboratory Analytes  Added: 
Troponin I at Screening (Group 3 patients only) and 
Weeks  13, 26, 52, and 65 (All abnormal troponin samples 
will be rerun at the central laboratory and also analyzed for 
CK-MB). 
Platelet bound autoantibody testing at baseline (may be 
done) . 
Medical history, hepatitis B, C, and HIV at S creening 
(Group 3 patients only) . To ensure that Troponin I 
is monitored in patients 
that did not previously 
receive volanesorsen 
(i.e., Group 3 patients 
and placebo patients from the index studies) 
consistently with what 
was done in the 
ISIS 304801-CS6 index 
study.  
To increase platelet count monitoring for safety purposes . 
To make the eligibility criteria for the Group 3 patients consistent with those for t he 
ISIS 304801-CS6 index 
study patients.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
15  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll-over  FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll-over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_38738] -treatment evaluation period  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 Groups 2 and 3 :  Patients must also meet the following criteria in order 
to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37898]:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS  304801-CS16 index study   
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this open -label 
study  
4. Able and willing to participate in a 65-week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
16  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in sexual relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_38739] 
dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_38740] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria  for Group 1 (ISIS 304801-CS6 ) and Group 2 (ISIS  304801-
CS16 ) Index Study Roll-over Patients  
1. Have  any new condition or worsening of existing condition which in the 
opi[INVESTIGATOR_37601], or could interfere with the patient participating in or completing the study  
2. Unwilling to comply with lifest yle requirements for the duration of the 
study ( Section 6.3 ) 
Exclusion Criteria for Group 3 (patients who did not participate in an index 
study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of screening [with the 
exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment period of the Study (with the exception of ± 10 units of insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
17  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria for Group 3 (patients who did not participate in an index 
study)  Continued  
4. History within 6 months of screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset 
angina), stroke, transient ischemic attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery within 3 months 
of screening  
5. Any of the following laboratory values at Screening  
a. Hepatic : 
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38741]  
• AST > 2.[ADDRESS_38742]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive 
test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening  
d. LDL-C >  130 mg/dL at Screening  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for 
inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or clinically -significant 
abnormality in coagulation parameters at Screening  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38743] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix th at has been successfully 
treated  
12. Treatment with another investigational drug, biological agent,  or device 
within 1 month of screening, or 5 half -lives of investigational agent, 
whichever is longer  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
18  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria for Group 3 (patients who did not participate in an index 
study)  Continued  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to screening and dose and 
regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout  the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to 
screening unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least [ADDRESS_38744] 4 weeks prior to screening and dose and regimen expected to remain 
constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_38745] 4 weeks prior to screening 
(Occasional or intermittent use of over -the-counter medicat ions will be 
allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening or of 
> 499 mL within 60 days of screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] 
(ISIS 304801 or placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37519], or could interfere with the patient participating in or completing the study  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
19  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a subset of patients with 
FCS.  The same dose of [ADDRESS_38746] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study) :  A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]) .  Please refer to 
Section 4.1 and Appendix A  
• Group 3 patients (did not participate in an index study) :  An up to 
8-week screening and qualification period, including a diet 
stabilization period of at least 6 weeks  (screening and diet 
stabilization period may be reduced, per Sponsor approval, if the 
patient is following a diet for optimal control of TGs and disease 
management prior to screening) .  Please refer to Section 6.1.2  and 
Appendix A  
• All patients:  
o A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
o Option to participate in an extended treatment period (up to an 
additional 52 weeks)  
o A 13-week post -treatment evaluation period or expanded 
access program  
The patient s, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38747] . 
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, 
volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_38748] -treatment evaluation period. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
20  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37840] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-c holesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC-III)  
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesor sen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc. 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
21  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
SCREENING PERIOD  
Weeks -8 to -2 (Group 3 patients only)  
QUALIFICATION PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION (ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety 
assessments.  PK and PD/efficacy 
assessments at specified time points  
POST -TREATMENT 
EVALUATION PERIOD  
Weeks [ADDRESS_38749] 
the option of 
participating in an 
expanded access 
program or 
continuing dosing 
for up to an 
additional 52 weeks 
until an expanded 
access program is 
approved and 
available in their 
country.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
22  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38750]  
IXRS  Interactive Voice/Web -Response System  
LDL  low-density lipoprotein  
LDL -C low-density lipoprotein -cholesterol  
LMF1  lipase maturation f actor [ADDRESS_38751] lipoprotein lipase  
MACE  major acute cardiovascular ev ent 
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  no-observed -adverse -effect level  
non-HDL -C non-high-density lipoprotein -cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38752]  upper limit of normal  
VLDL  very-low-density lipoprotein  
VLDL -C very-low-density lipoprotein -cholesterol  
VLDL -TG lipoprotein -triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
24  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis .  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37605] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes m ellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of 
chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etio logy of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride 
clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_37606], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a co factor for LPL ( Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
25  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasm a triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] 
(Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC -III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
26  Mechanistically, FCS  is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apo C-III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a p olymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma TG have also been recently described (Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown 
of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid partic les by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
27  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity , it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
28  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volan esorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  Gen eral toxicity studies with volanesorsen for up to 39 weeks of 
treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardio vascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  huma n  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_38753] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotox ic (in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
29  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen  from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an 
open -label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_38754] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_38755] -treatment period and was not associated with platelet -related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_38756] Level ( NOAEL ) 
was defined by [CONTACT_37921] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date s uggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
31  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll-over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll -over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or  
ISIS 304801-CS16 index studies 
Up to approximately [ADDRESS_38757] of the following periods: 
3.4.1 Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification  
A period of up to 2 weeks  (unless approved by [CONTACT_1034]) is given to complete  qualification  
assessments outlined in the Schedule of Procedures.  Please refer to Section 4.1 and  Appendix A . 
3.4.2 Group 3 P atients (did not participate in an index study):  Screening/Qualification  
An up to 8- week screening and qualification period, including a diet stabilization period of at 
least 6 weeks  (screening and diet stabilization period may be reduced, per Sponsor approval, if 
the patient  is following a diet for optimal control of TGs and disease management prior to 
screening.  Please refer to Section 6.1.2 and Appendix A. 
3.4.3 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
ISIS [ADDRESS_38758]-treatment evaluation period is 13 weeks and consists of 4 Study Cen ter visits on 
Weeks  54, 56, 58, and 65 (Weeks 54, 56, and 58 may be conducted by a home healthcare nurse) . 
3.[ADDRESS_38759] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen , the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistic al analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Screening/ Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open- label study are performed .   
Groups 1 and 2 (Qualification):  During the qualification period, the eligibility of the patient to 
enroll in the open- label study will be determined .  Final assessments from the ISIS 304801-CS6 
or ISIS 304801-CS16 studies may be used for qualification .  A period of up to 2 weeks after 
completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  
identification number that was assig ned to them during the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies .  The patient identification number will be used to identify the 
patient  throughout the extension trial and must be used on all study documentation related to that 
patient .  The patient  identification number must remain constant throughout the extension trial. 
Group 3 (Screening and Qualification):  At the time of consent, the patient will be considered enrolled into the study and will be assigned a unique screening number before any study procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This number will be used to identify the patient throughout the trial and must be used on al l study documentation related to that patient.  
The screening number and patient identification number must remain constant throughout the entire trial.  In the event the patient is re -consented and re- screened the patient must be given a 
new screening num ber.  Screening numbers and patient  identification numbers, once assigned, 
will not be re -used. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
33  4.2 Enrollment  
Patient s will be enroll ed into the treatment phase of the study after all  Screening (Group3) and 
qualification assessments have been completed and after the Investigator has verified that they 
are eligible per criteria in Sections 5.1 and 5.2.  No patient  may begin treatment prior to 
enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_38760] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. Groups 2 and 3:  Patients must also meet the following criteria in order to enter  into the 
open- label Study:  
a. History of chylomicronemia as eviden ced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoprotei nemia) 
by [CONTACT_37898]: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol /L) at Screening for the  
 ISIS 304801-CS16 index study 
Group 3:  F asting TG ≥ 750 mg/dL at Screening for this open -label study  
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating ; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
34  involved), abstinent*, or if engaged in sexual relations of child-bearing potential, 
patient is using an acceptable contr aceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_38761] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38762] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the 
preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception 
5.2 Exclusion Criteria  for Group 1 (ISIS 304801- CS6) and Group 2 (ISIS 304801-
CS16 ) Index Study Roll- over Patients  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section  6.3). 
Exclusion Criteria for Group 3 (patients who did not participate in an index study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening 
b. HbA1c ≥ 9.0% at Screening 
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of screening [with the exception of ± 10 units of insulin]) 
d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
4. History within 6 months of screening of acute or unstable cardiac ischemia (myocardial 
infarctio n, acute coronary syndrome, new onset angina), stroke, transient ischemic attack 
or unstable congestive cardiac failure requiring a change in medication or major surgery 
within 3 months of screening 
5. Any of the following laboratory values at Screening 
a. Hepatic:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
35  • Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and 
documentation of Gilbert’s syndrome in which case total bilirubin must be  
≤ 3 mg/dL 
• ALT > 2.[ADDRESS_38763] 
• AST > 2.[ADDRESS_38764] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine 
dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein measurement of <  500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥  trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with 
urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated creatinine clearance calculated according to the f ormula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37446]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor) 
c. Cardiac Troponin I >  ULN at Screening  
d. LDL- C > 130 mg/dL at Screening  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of bleeding diathesis o r coagulopathy or clinically- significant abnormality in 
coagulation parameters at Screening  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day [ADDRESS_38765] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix tha t has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1-month 
of screening, or 5 half-lives of investigational agent, whichever is longer 
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
36  14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable 
dose for at least 3 months prior to screening and dose and regimen expected to remain 
constant during the treatment period.  P atients taking OTC omega -3 fatty acids should 
make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening unless 
approved by [CONTACT_37755] 
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least [ADDRESS_38766] 4 weeks prior to 
screening and dose and regimen expected to remain constant during the treatment period 
f. Glybera gene therapy within 2 years prior to screening 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least [ADDRESS_38767] 4 weeks prior to screening (Occasional or 
intermittent use of over -the- counter medications will be allowed at Investigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of screening or of > 499 mL within 
60 days of screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37548], or could interfere with the patient participating in or completing the study 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, C, and D . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
37  6.1.1 Qualification  (Groups 1 and 2) 
Please refer to Section 4.1 and Appendix A . 
6.1.2 Screening and Qualification  (Group 3) 
Before any study -specific procedures or evaluations are initiated, patients must sign and date the 
informed consent form.  An 8-week period, including a diet stabilization period of at least 
6 weeks (screening and diet stabilization period may be reduced, per Sponsor approval, if the 
patient  is following a diet for optimal control of TGs and disease management prior to screening ) 
is given to perform the screening evaluations.  The quali fication  assessments will be performed 
at Week -[ADDRESS_38768] patient’s Week [ADDRESS_38769]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  unless the patient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), AEs , concomitant 
medication/proced ure information, lipid panel, volanesorsen plasma concentrations,  
immunogenicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesorsen administration .  Blood sampling  at Week s 2.5, 
4, 6, 8, 10, 12, 15, 17, 19, 21, 23, 25, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, a nd [ADDRESS_38770] be fasted prior to drawing all blood samples and samples drawn locally should also 
be sent to the central laboratory for analysis  whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given [ADDRESS_38771] the option of continuing dosing for up to an additional 52 weeks until an 
expanded access program  is approved and available in their country. 
During the extended treatment period, patients will report to the study center for clinic visits 
during Weeks 54-104 (see Schedule of Procedures in Appendix A ).  Study Drug will be 
administered once weekly  unless the patient is on a biweekly dosing schedule for safety reasons 
(Section 8.1).  Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), AEs, concomitant 
medication/procedure information, lipid panel, volanesorsen plasma concentrations, IM testing , 
ECGs, and physical examinations will be performed according to the S chedule of Procedures in 
Appendix A .  Adverse events at the injection site should be collected as adverse events.  Diet ary 
counseling will be reinforced at intervals throughout the extended treatment period.  All blood 
and urine samples should be collected prior to volanesorsen administration.  Blood sampling at 
Weeks 54, 56, 58, 60, 62, 66, 68, 70, 72, 74, 78, 80, 82, 84, 86, 88, 92, 94, 96, 98, 100, a nd [ADDRESS_38772] be fasted  prior to drawing all blood samples and samples drawn locally 
should also be sent to the central laboratory for analysis  whenever possible.  Every effort should 
be made to ensure the previous week’s dose is given 7 days prior to a scheduled clinic visit.  
Dosing instructions and training will be provided to the patient where applicable. 
6.1.5 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_38773]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures ( e.g., multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in App endix A. 
6.1.[ADDRESS_38774]- treatment evaluation period consists of 
4 Study Center visits on Weeks 54, 56, and 58 (which may be conducted by a home healthcare nurse), and Week [ADDRESS_38775]- treatment evaluation 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
39  period consisting of 4 Study Center visits on Weeks 106, 108, and 110 (which may be conducted 
by a home healthcare nurse), and Week [ADDRESS_38776] of these analytes  is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally.  In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or clumped blood samples ) another sample 
must be repeated within 1-week and determined not to have met a stoppi[INVESTIGATOR_37607].  
If there is no reportable platelet count within [ADDRESS_38777] the patient to hold dosing until a new platelet count is obtained and reviewed. 
All platelet count results will be promptly reviewed by [CONTACT_37900][INVESTIGATOR_37587] 75,000/mm
3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37559]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas .  If a patient 
experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37929] (for ISIS 304801-CS16 roll -over patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment 
assignment.  
ISIS [ADDRESS_38778] ECGs performed in triplicate at 
Week 76 and Week 104. 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e .g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37703].  
6.2.6 Quality of Life Assessments  
All patients will c omplete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_38779]- treatment follow-up period (Week 65). 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week  1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service.   
Patients in the Extended Treatment Period will receive diet/alcohol counseling by 
[CONTACT_37884]. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet may  be conducted randomly during the treatment and 
post treatment follow -up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
41  6.2.10 Chart Review for Incidents of Acute Pancreatitis in Medical History (Group 3)  
Patient records will be reviewed for incidents of acute pancreatitis o ccurring up to [ADDRESS_38780] refrain from sperm/egg donation and 
either be abstinent† or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_38781]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppo sitory .  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or barrier methods (female condom *, diaphragm, 
sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
42  condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used together as friction between 
the two can result in either product failing. 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdr awal are not 
acceptable methods of contraception  
6.3.[ADDRESS_38782] 10 hours and preferably not more than 12 hours 
before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38783] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_38784] (ISIS 304801) characteristics are listed in  Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored s ecurely at 2  to 8 °C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
43  7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on 
a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outline d in Sections 8.[ADDRESS_38785] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to  the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_38786] measurement prior to Day 1  (e.g., qualification assessments or 
asses sments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
ISIS [ADDRESS_38787] monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collec tion) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed  below, the Sponsor may request 
confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Redu ction in dose or dose frequency 
may also be initiated as noted in Section 8.7.  If any of the stoppi[INVESTIGATOR_37466] 
(refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with 
Section 8.8 of t he protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services,  Food and Drug Administration, July 2009.  For a definition of Baseline please refer to 
guidance in  Section 8.[ADDRESS_38788] measurement that is > [ADDRESS_38789]  (or the greater of [ADDRESS_38790] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase to [ADDRESS_38791]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_38792] (or 
the greater of [ADDRESS_38793] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_38794] or 1.2 x baseline value if the baseline value was > ULN . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
45  Further Investigation into Liver Chemistry Elevations:  For patien ts with confirm ed ALT or AST 
levels > [ADDRESS_38795]  (or the greater of [ADDRESS_38796] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepa tic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_38797] . 
8.5.2 Safety Monito ring for Platelet Count Results  
Actions to be taken in the event of reduced platelet count are shown in Table 3 in Section 8.6.3. 
The tests outlin ed in Table 2 should also be performed as soon as possible.  A dditional lab tests 
will be determined by [CONTACT_37852] .  
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
46  Table 2 Labs to Be Performed in the Event of a Platelet C ount < 75,000/mm3 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab 
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Helicobacter pylori (IgG serum test)  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
 
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
ISIS [ADDRESS_38798] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_38799] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -moni tored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37608] y experience.  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and ma nagement of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37609]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] 
≤ 70 mg/dL (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic even t is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
48  ≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular  glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatl y from patient to patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood 
glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could 
occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_38800] dose titration and/or addition of any other anti- hypergl ycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within 1- week of the initial test).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_38801] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
The threshol d values are defined as:  
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
49  In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38802]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1 c follow -up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_38803] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failur e to 
retest or missing lab values will be presumed confirmed : 
ISIS [ADDRESS_38804] >  [ADDRESS_38805] >  [ADDRESS_38806] , which is confirmed and persists for ≥ [ADDRESS_38807] >  [ADDRESS_38808] (or the greater of [ADDRESS_38809] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_38810]  or INR  > 1.[ADDRESS_38811] >  [ADDRESS_38812] (or the greater of [ADDRESS_38813] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coi ncides 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_38814] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 3   below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any platelet count less than 25 ,000/mm3, or a platelet count less than 75,000/mm3 
that occurs while the patient is on dosing at 300 mg every 2 weeks or 150 mg every week then 
dosing of a patient with volanesorsen will be stopped permanently.  Platelet count will be 
monitored daily until 2 successive values show improvement then monitored every 2-3 days until 
platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is less than 
25,000/mm3.  Recovery in platelet coun t may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
51  0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:  may require continuation with oral steroids after methylprednisolone). 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks or a reduced dose of 150 mg per week (refer to Section 8.7) .  The suitability of the 
patient for continued dosing will be determined by [CONTACT_37904]’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of 
recovery of platelet count upon holding of dos ing. 
If after the first dosing rechallenge the platelet count again falls below 75,000/mm
3, then dosing 
of the patient with Study Drug will be s topped permanently. 
Following a rechallenge platelet count should be tested every week until count is stable. 
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450].  
If there is no reportable platelet count within [ADDRESS_38815] the patient to hold dosing until a new platelet count is obtained and reviewed. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
52  Table 3 Actions in Patients with Low Platelet Count  
Platelet C ount on Rx  Drug Dose Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every 1 week  until stable*  
75K-100K/mm3 Permanently reduce dose frequency to 
300 mg every 2  weeks  or reduce dose to 
150 mg weekly  Closer observation  
Monitor every  1 week  
50K-75K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/ mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37905] 2-3 days until 2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/N SAIDS/ 
anticoagulant medication  
25K-50K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37930] 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant 
medication while platelet count < 50K/mm
3 if possible  
< 25K/mm3 Permanently discontinue Study Drug Closer observation:  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Steroids recommended* * 
Consider need for hospi[INVESTIGATOR_37590]/NSAIDS/anticoagulant 
medication while platelet count 
< 50K/mm
3 if possible  
* At least 3 consecutive values measured weekly  that are stable as determined by [CONTACT_37906] > 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 w eeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methyl prednisolone)  
 
8.[ADDRESS_38816] be made in accordance with Section 8.6.3 and 
Table 3  (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
ISIS [ADDRESS_38817] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_38818] 6 weeks after 
discontinuing Study Drug.  Following this period, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_37683] 
> 100,000/mm
3), the next platelet count should be taken within at least [ADDRESS_38819] 12  weeks after discontinuing Study Drug .  Patients  should also be 
strongly encouraged to attend applicable landmark visits at Week s 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and conduct 
safety assessments in accordance with the Schedule of P rocedures in Appendix A .  Any patient 
who discontinues treatment after  Week 44 should also be strongly encouraged to attend a final 
follow-up visit ( Week 65 visit asse ssments) approximately [ADDRESS_38820] dose of 
Study Drug , in addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be perf ormed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_38821] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_38822] 1 2 weeks after discontinuing Study Drug.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
54  Patients  should also be encouraged to undergo a final  follow-up visit ( Week 65 (or Week 117 if 
terminating from the Extended T reatment Follow- Up P eriod), see Appendix A ) prior to leaving 
the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_38823] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the d iscretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from s tudy, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to com plete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_38824] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
55  Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin,  fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents dur ing the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non- prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cult ures) performed between 
signing of informed consent and Week 65 (or Week 117 if patient enters the extended treatment 
period) visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must re cord treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_38825] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
56  Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In additi on to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 4 Expected Event for the Protocol Defined Population by [CONTACT_37931] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events  including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37932] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
57  A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event that  in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life -threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death , are not life-threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes list ed in this definition .  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug  dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not re corded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_38826] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
ISIS [ADDRESS_38827] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week 65 visit 
(or Week 117 if patient enters the extended treatment period).  The Investigator will monitor 
each patient  closely and record all observed or volunteered AEs on the Adverse Event Case 
Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_37585]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Inves tigator believes 
no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
59  • Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on  the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
60  • Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of  death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudi cated.  
9.[ADDRESS_38828] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these includ e abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the 
procedure or treatment 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
61  • The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_38829] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs whil e on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow-up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37933]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
62  10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are 
defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
63  10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and received at least [ADDRESS_38830] a baseline TG assessment .  The FAS represents the practically -feasible 
intent- to-treat (ITT) population as delineated in ICH Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38831] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_38832] dose PK sample collected , analyzed, and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_38833] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification).  
For Group [ADDRESS_38834] patient’s Week [ADDRESS_38835] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for c ategorical 
variables will be used to summarize most data by [CONTACT_37891] 304801- CS6 or ISIS 304801-CS16 index studies, and pooled 
treatment naive group which including patients on placebo in index studies and Group 3 patients.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
64  Where appropriate, p- values will be reported .  All statistical tests will be conducted using 2 -sided 
tests with 5% Type I error  rates unless otherwise stated.  
TG related  endpoints will be assessed in the F AS and PPS, and all other efficacy endpoints will 
be assessed in the FAS .  All safety assessments will be performed on the Safety Set .  PK 
endpoints will be assessed in the PK Set as applicable. 
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characte ristics will be summarized using descriptive statistics by 
[CONTACT_14454] .  The patient disposition will be summarized  by [CONTACT_14459] .  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_14453]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_1570] , MedDRA preferred term 
and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_6490]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37934] g roup. 
These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated  by [CONTACT_1570] . 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] .  Response rate of pa tients with fasting plasma TG 
< 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and 
Month 12 will be summarized .  Response analysis will also be conducted using a range of fasting 
plasma TG thresholds for determination of responder status. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
65  Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37870]- HDL -C, apoB, 
HDL -C, apoA- 1, VLDL -C, and LDL-C, total cholesterol, and fasting total apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_1570] . 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics  by [CONTACT_37780].  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single-dose PK) or multiple doses (i.e., 
steady -state PK), depending on their earlier treatment in the index studies (Group 1 and 2 
patients) .  On Week 1  Day 1 of the open- label study, patients who received placebo in the index 
study (and all patients in Group 3) will receive the first treatment of volanesorsen (single -dose 
PK), while  patients who received volanesorsen in the index studies had been on volanesorsen 
treatment for 12 months (ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data 
collected from these patients reflect steady -state PK .  The maximum observed drug 
concentration (C max) and the time taken to reach C max (Tmax) will be obtained directly from the 
concentration -time data .  Area under the plasma concentration -time curve from time zero to 
24 hours ( AUC 0-24h) will be calculated using the linear trapezoidal rule .  Apparent systemic 
(plasma) clearance after SC administration (CL 0-24h /F) will be calculated from  
CL 0-24h/F = Actual Dose/AUC 0-24h.  Mean residence time (MRT) from time zero to 24 hours after 
the SC administration  will be calculated from the equation,  
MRT 0-24h = AUMC 0-24h/AUC 0-24h, where AUMC 0-24h is the area under the moment plasma 
concentration -time curve from time zero to [ADDRESS_38836]. 
Plasma PK parameters will be summarized using descr iptive statistics  by [CONTACT_37892] .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
66  treatment with Study Drug  (volanesor sen) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable 
patients, al ong with the study day associated with the first positive IM status emerged (T first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the last ADA sample 
collection day, and subject - peak titer if applicable, will be listed by [CONTACT_37872]  304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day .  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized  as the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by  [CONTACT_1570] .  Furthermore, onset and t iter of the ADA 
response, if applicable, will be summarized as median, quartiles (25% and 75%), and ran ge. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Inve stigator) .  The original signed 
informed consent form should be retained in the Study Master File and in any other locations 
required by [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_38837] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
67  as well as the demands of national drug and data protection laws an d other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising mater ial must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_38838] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification  of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_38839] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
ISIS [ADDRESS_38840]  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_38841].  The Investigator /Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence.  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section  8 of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Cen ter, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
  
ISIS [ADDRESS_38842], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study- related records will occur to evaluate the tri al conduct and compliance with the protocol, 
ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37610] d or reviewed the data on the CRF , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_38843] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
70  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50:  168-176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline . J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pago n RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pr act 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
intera ction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, B risson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Feder ation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
71  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate  than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Bio l Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Und erstanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and manageme nt of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lip ase-mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprot ein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertrigl yceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
72   
  
 
  
 
14. APPENDICES  
   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
73   
  
 
  
 
Appendix A  Schedule of Procedures 
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
74  Appendix A  Schedule of Procedures 
Study Period  Screen/  
Run Ina Quala Treatment Period  Post 
Treatment 
Follow -up 
Study Week  -8 to -2 -2 to 
 -1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent  X X                           
Outpatient Visit  X X X Xl Xl Xl Xl Xl Xl Xl X Xl Xl Xl Xl X Xl Xl Xl X Xl Xl Xl Xl X Xl Xl X 
Inclusion/Exclusion Criteria  X X                           
Medical Historyb X                            
Vital Signs + body weight  
(+ height on Day 1 only)  X X X   X  X   X     X    X     X   X 
Physical Examination  X  X        X     X    X     X   X 
12- lead ECG (triplicate)  X          X     X    X     X   X 
MRI (liver/spleen)  X                       Xm    
Echocardiography  X              Xm         Xm    Blood Draw (Fasting)d Chemistry Panel  X X X   X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialc X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel  X X X   X  X  X X    X X    X    X X   X 
Coagulation (aPTT, PT, INR)  X X      X   X     X    X     X    
Hepatitis B, C, HIV  X                            
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]    X        X     X         X   X 
Sedimentation Rate    X        X     X         X   X 
Complement (C5a, Bb)    X        X     X         X   X 
Troponin I  X  X        X     X         X   X 
Platelet Bound Autoantibod iese   X                          
Plasma PK - Volanesorsen    Xn X  X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies    X   X  X   X     X    X     X   X 
FSH (women only, if 
applicable)  X                            
Serum Pregnancy Testf X X    X  X   X  X   X  X  X  X   X  X X 
Archived Serum & Plasma 
Samplesg   X     X   X     X         X   X 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6 
Protocol   18 November 2016  
 
75  Appendix A  Schedule of Procedures  Continued  
Study Period  Screen/  
Run Ina Quala Treatment Period  Post 
Treatment 
Follow -up 
Study Week  -8 to -2 -2 to -
1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 28  
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET 
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Urinalysisd X X Xo   X  X   Xo  Xo   Xo  Xo  Xo  Xo   Xo  Xo Xo 
Fundus Photographyh X                       Xm    
Genetic testing for FCS diagnosis (if 
not available in medical history)i X                           
Weekly Study Drug:  SC Injection   X  X X X X X X X X X X X X X X X X X X X X X    
Symptom Diary (weekly)  X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)    X        X     X         X   X 
Food/Drink Diary (quarterly)j   X        X     X         X   X 
Diet/Alcohol Counselingk X X X   X  X   X     X    X     X  X X 
Adverse Events X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
a Screening and Qualification  (Group 3) procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Patient charts will be reviewed in order to collect data for events of acute pancreatitis or suspected pancreatitis in the patient’s medical history.  Chart review 
may be conducted at any time during the study.  These events will be adjudicated in the same manner as for events of pancreatitis during the study  
c Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that  both the central and local sample are unreportable (e.g. , due to hemolyzed or clumped blood samples) another sample must be repeated 
within [ADDRESS_38844] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37909][INVESTIGATOR_37604] 75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
  
ISIS [ADDRESS_38845] 10 hours  and preferably not more than 12 hours .  During treatment period urine and blood 
samples will be collected prior to Study Drug  administration .  Does not  apply to 24-hour PK blood draw  
e May be done  
f Females of childbearing pot ential only  
g Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or su bsequent clinical studies of  
volanesorsen  
h If possible, fundus photography should be completed prior to administration of the first dose of Study Drug ( Group 2 [ISIS 304801-CS16 roll-over patients ] and 
Group 3)  and repeated at Week 52 (Please refer to Section [IP_ADDRESS] ) 
i Genetic testing can be conducted for study qualification (Group 2 [ISIS 304801-CS16 roll-over  patients ] and Group 3) ; genetic testing will only be conducted if 
allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing  
j In addition to diary, patients will be contact[CONTACT_37787]  
k To reinforce compliance to the diet  and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
l Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
m A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
n Full or abbreviated PK profile (see Appendix C ) 
o Expanded urinalysis (see Appendix B ) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6 
Protocol   18 November 2016  
 
77  Appendix A  Schedule of Procedures  – Extended Treatment Period  
Study Period  Treatment Period  Post-Treatment 
Follow -up 
Study Week  Wk 54 
& 56  Wk 
58 Wk 60 
& 62 Mo 15  
Wk 64 Wk 66 
& 68  Wk 
70 Wk 72 
& 74 Mo 18  
Wk 76  Wk 78 
& 80  Wk 
82 Wk 84, 
86, & 88  Mo 21  
Wk 90 Wk 92 
& 94  Wk 
96 Wk 98, 
100 & 
102 Mo 24  
Wk 
104 Wk 
106 
& 
108 Wk 
110 Mo 27  
Wk 117 
Study Day  372 & 
386 400 414 & 
428  442 456 & 
470 484 498 & 
512 526 540 & 
554 568  582, 596 
& 610  624 638 & 
652 666 680, 
694 & 
708 722 736  
& 
750 764 813 
Visit Window+/ - Days  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Outpatient Visit  Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf Xf X Xf Xf X 
Vital Signs (+ body weight)     X    X    X    X   X 
Physical Examination         X        X    
12- lead ECG (triplicate)         X        X    
Urinalysis(including P/C ratio)   X  X  X  X  X  X  X  X  X X Blood Draw (Fasting)b Chemistry Panel  X  X  X  X  X  X  X  X  X X 
CBC with Differentiala X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel    X    X    X    X   X 
Coagulation (aPTT, PT, INR)     X    X    X    X    
Troponin I     X    X    X    X   X 
Plasma PK - ISIS 304801c        X        X   X 
Anti-ISIS  304801 Antibodies         X        X   X 
Serum Pregnancy Testd  X  X  X  X  X  X  X  X  X X 
Weekly Study Drug: SC Injection  X X X X X X X X X X X X X X X X    
Diet/Alcohol Counselinge    X    X    X    X    
Adverse Events  X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6 
Protocol   18 November 2016  
 
78  Appendix A  Schedule of Procedures – Extended Treatment Period  Continued  
Legend Text  
a Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g., due to hemolyzed or c lumped blood samples) another sample must be repeated 
within [ADDRESS_38846] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37909][INVESTIGATOR_37611] e of decline is suggestive that 
the patient could be approaching the dose pause rule of 75,000/mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
b Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During treatment period urine and blood 
samples will be collected prior to Study Drug administration. 
c Abbreviated PK collection (see Appendix C ) 
d Females of childbearing potential only  
e To reinforce compliance to the diet and alcohol restrictions  
f Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37894] [ADDRESS_38847] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Screening Tests  (Group 3)  
• Hepatitis B surface 
antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women only)  
• Serum βhCG (women 
only)  
 
Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• Troponin I2 
• CK-MB2 
• Platelet Bound 
Autoantibodies3 
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic 
examination4 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_38848]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52  
 
PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65# 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_38849]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
# Week 65 PK collection will be omitted for patients continuing to receive volanesorsen beyond Week 52 
 
PK Sampling Schedule (Extended Treatment Period)  
Week  Wk 
76 Wk 
104 Wk 
117 
Study Day  D526  D722  D813  
Visit Window 
+/- Days  [ADDRESS_38850] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
85  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 6  
Protocol   18 November 2016  
 
86  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 Adverse Event Mild Moderate Severe 
Urine 
Prote inuria 
Adults 1 + prote inuria; 2+ prote inuria; Urinary prote in g/24 hrs; urinary protein < 1.0 g/24 hrs urinary protein 1.0 - 3.4 g/24 hrs; 
Children -Urine PIC (Protein /Creat inine) Urine P/C >1.9 ratio 0.5 - 1.9 
Gross hema turia; transfusion, 
Asymp tomatic; clinical or diagnostic IV medications or 
Symp tomat ic; urina ry cathe ter or hospi[INVESTIGATOR_37591] ; Hematur ia observat ions only; interven tion not bladder irrigation indicated elective endoscop ic, radiologic indicated or operat ive intervention 
indicated 
tGrading for this paramete r is derived from the Toxicity Grad ing Scale for Healthy Adult and Adol escent Volun teers Enrolled in 
Preventi ve V accine Clinical Trials, Sept 2007 
*Grading for this parameter is derived from the Division of AIDS (DAIDS) Table for Grad ing the Seve rity of Adult and Pediatric 
Adverse Events Version 2.0, Nov 2014 
tModifi ed for consistency with the ADA and Endocrine Society Guidelines (Seaqu ist ER, Anderson J, Childs B, et al. 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Associa tion and The Endocrine Society. 
Diabetes Care 2013 ;36: 1384 -95) 
 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38851] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38852] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 6 - [LOCATION_009] – [ADDRESS_38853] No:  2015-003755-21 
 
 
 

ISIS [ZIP_CODE] l-CS7 
Protocol -[LOCATION_009] CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment 6 
16 September 2016 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 6-[LOCATION_009]- 16 September 2016 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38854] 2016 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_38855] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_38856] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:  , Ph.D.  
[ADDRESS_38857] 
Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator:  Akcea Therapeutics  
[ADDRESS_38858] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38859] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 6 - [LOCATION_009]  
Date:    [ADDRESS_38860] read and understand the att ached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38861] the study 
as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................13  
STUDY DESIGN AND TREATMENT SCHEMA  ...................................................................19  
STUDY GLOSSARY ...................................................................................................................20  
1. OBJECTIVES  .....................................................................................................................22  
2. BACKGROUND AND RATIO NALE  ..............................................................................22  
2.1 Overview of Disease  ......................................................................................................22  
2.2 Therapeutic Rationale  ....................................................................................................23  
2.3 Volanesorsen  ..................................................................................................................24  
2.3.1  Mechanism of Action  .............................................................................................24  
2.3.2  Chemistry  ...............................................................................................................25  
2.3.3  Preclinical Experience  ............................................................................................26  
2.3.4  Clinical Experience ................................................................................................27  
2.4 Rationale for Dose and Schedule of Administration .....................................................28  
3. EXPERIMENTAL PLAN ..................................................................................................29  
3.1 Study Design  ..................................................................................................................29  
3.2 Number of Study Centers ..............................................................................................29  
3.3 Number of Patients ........................................................................................................29  
3.4 Overall Study Duration and Follow-up .........................................................................29  
3.4.1  Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification  ....................................................................................29  
3.4.2  Group 3 Patients (did not participate in an index study):  Screening/Qualification [ADDRESS_38862] ................................................................................30  
4. PATIENT ENROLLMENT ...............................................................................................30  
4.1 Screening/Qualification  .................................................................................................30  
4.2 Enrollment .....................................................................................................................31  
5. PATIENT ELI GIBILITY  ..................................................................................................31  
5.1 Inclusion Criteria  ...........................................................................................................31  
5.2 Exclusion Criteria  ..........................................................................................................32  
6. STUDY PROCEDURES  ....................................................................................................34  
6.1 Study Schedule ..............................................................................................................34  
6.1.1  Qual ification (Groups 1 and 2) ...............................................................................35  
6.1.2  Screening and Qualification (Group 3) ..................................................................35  
6.1.3  Treatment Period  ....................................................................................................35  
6.1.4  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_38863]- Treatment Period  ............................................................................................36  
6.2 Additional Study Assessments  .......................................................................................36  
6.2.1  Laboratory Assessments  .........................................................................................36  
6.2.2  Physical Exams and Vital Signs  .............................................................................36  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................37  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_38864]- Treatment Follow -up Period .50  
8.9 Withdrawal of Patients from the Study  ..........................................................................50  
8.10  Concomitant Therapy and Procedures ...........................................................................50  
8.10.1  Concomitant Therapy .............................................................................................51  
8.10.2  Concomitant Procedures .........................................................................................51  
8.11  Treatment Compliance  ...................................................................................................51  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................51  
9.1 Sponsor Review of Safety Information .........................................................................51  
9.2 Regulatory Requirements  ..............................................................................................52  
9.3 Definitions  .....................................................................................................................52  
9.3.1  Adverse Event  ........................................................................................................52  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................53  
9.3.3  Serious Adverse Event (SAE) ................................................................................53  
9.4 Monitoring and Recording Adverse Events ...................................................................53  
9.4.1  Serious Adverse Events ..........................................................................................54  
9.4.2  Non-Serious Adverse Events ..................................................................................54  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................54  
[IP_ADDRESS]  Relationship to the Study Drug  ........................................................................54  
[IP_ADDRESS]  Severity  ............................................................................................................55  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................55  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................55  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................55  
9.4.4  Adjudication Committees  .......................................................................................56  
9.5 Procedures for Handling Special Situations ..................................................................56  
9.5.1  Abnormalities of Laboratory Tests .........................................................................56  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............56  
9.5.3  Dosing Errors .........................................................................................................57  
9.5.4  Contraception and Pregnancy .................................................................................57  
10. STATISTICAL CONSIDERATIONS  ..............................................................................58  
10.1  Study Endpoints  .............................................................................................................58  
10.1.1  Efficacy Endpoints .................................................................................................58  
10.1.2  Safety Endpoints  .....................................................................................................58  
10.2  Sample Size  ....................................................................................................................58  
10.3  Populations .....................................................................................................................59  
10.4  Definition of Baseline  ....................................................................................................59  
10.5  Interim Analysis  .............................................................................................................59  
10.6  Planned Methods of Analysis ........................................................................................59  
10.6.1  Demographic and Baseline Characteristics  ............................................................60  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
8  10.6.2  Safety Analysis  .......................................................................................................60  
10.6.3  Efficacy Analysis  ...................................................................................................60  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................61  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................61  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................61  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_38865] of the Study .........................................................................................63  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38866] of Laboratory Analytes  .............................................................................75  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................77  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......79  
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ................................................................ 40  
Table 2  Actions in Patients With Low Platele t Count ............................................................... 48  
Table 3  Expected Event for the Protocol Defined Population by [CONTACT_37935]  ................................................................................................. 52  
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 23  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown ................................... 25  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  .............. 27 
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 6
Protocol - [LOCATION_009]  16 September 2016
 
9  PROTOCOL AMENDMENT 
 
Protocol Number: ISIS 304801-CS7 
Protocol Title: An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 
Amendment Number:  6 - [LOCATION_009] 
Amendment Date: [ADDRESS_38867] been made: 
1. In order to reduce the unlikel y but potential increased risk  of pancreatitis during the 
period of corticosteroid therapy, triglycerid e levels will be monitored weekly during 
corticosteroid treatment and the laborato ry alert will be changed from 2,000 to 
500 mg/dL during this period. 
2. To increase the post-treatment follow-up peri od from [ADDRESS_38868]-treatment evaluation period or will participate in an expanded access program  pending approval by [CONTACT_1026]/IEC, and the 
appropriate regulat ory authorities. 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
The following table provides a summary list of major changes to the protocol: 
Protocol Section Description of Change Rationale 
Protocol Synopsis: 
Study Design 
Protocol Synopsis:  
Study Visit 
Schedule and 
Procedures 
3.1  Study Design  Was: 
Following the Week [ADDRESS_38869]-
treatment evaluation period. 
 
Is: 
Following the Week [ADDRESS_38870]-treatment evaluation period or will participate in 
an expanded access program pending approval by [CONTACT_37936]/IEC, and the appropriate  regulatory authorities. To follow guidance provided by [CONTACT_37937]-treatment follow-up 
period until apoC-III levels 
return to baseline values 
To provide an expanded 
access program as an option 
for patients that may be 
benefiting from active drug 
treatment 
Protocol Synopsis: 
Study Population 
5.1  Inclusion 
Criteria Was: 
4. Able and willing to participate in a 65-week study  
Is: 
4. Able and willing to participate in a 78-week study To follow guidance provided 
by [CONTACT_37937]-treatment follow-up 
period until apoC-III levels 
return to baseline values 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
10  Protocol Section  Description of Change  Rationale  
Study Design and 
Treatment Schema  
Appendix A   
Schedule of  
Procedures  Was:  
 
Study Period  Post Treatment 
Follow -up 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 
Study Day  372 
& 
386 400 449 
Visit Window+/ - Days  2 7 7 
Informed Consent     
Outpatient Visit  Xj Xj X 
Inclusion/Exclusion Criteria     
Vital Signs + body weight  
(+ height on Day 1 only)    X 
Physical Examination    X 
12- lead ECG (triplicate)    X 
MRI (liver/spleen)     
Echocardiography     Blood Draw (Fasting)c Chemistry Panel   X X 
CBC with Differentialb X X X 
Serum Lipid Panel    X 
Coagulation (aPTT, PT, 
INR)    
hsCRP, HbA1c, FPG, 
and de -lipi[INVESTIGATOR_37490]    X 
Sedimentation Rate    X 
Complement (C5a, Bb)    X 
Plasma PK - 
Volanesorsen    X 
Anti-Volanesorsen 
Antibodies    X 
FSH (women only, if 
applicable)     
Serum Pregnancy Testd  X X 
Archived Serum & 
Plasma Samplese   X 
Troponin Io    
Urinalysisc  X
m X
m 
Fundus Photographyf    
Genetic testing for FCS 
diagnosis (if not available in 
medical history)g    
Weekly Study Drug:  SC 
Injection     
Symptom Diary (weekly)  X X X 
Quality of Life 
Assessment(s)    X 
Food/Drink Diary 
(quarterly)h   X 
Diet/Alcohol Counselingi  X X 
Adverse Events  X X X 
Concomitant Medication  X X X To follow guidance provided 
by [CONTACT_37937]-treatment follow -up 
period until apoC -III levels 
return to baseline values  
 
ISIS 304801-CS7 CONFIDENTIAL Amendment 6
Protocol - [LOCATION_009]  16 September 2016
 
11  Protocol Section Description of Change Rationale 
Study Design and 
Treatment Schema  
Appendix A 
Schedule of 
Procedures Continued  Is: 
 
Study Period Post Treatment Follow-upp
Study Week Wk 
54
&
56 Wk
58 Wk
65 Wk
71 Wk
78 
Study Day 372
&
386400 [ZIP_CODE]
1 540 
Visit Window+/- Days 2 7 7 7 7 
Informed Consent      
Outpatient Visit Xj Xj X Xj X 
Inclusion/Exclusion Criteria      
Vital Signs + body weight  
(+ height on Day 1 only)   X  X 
Physical Examination   X  X 
12- lead ECG (triplicate)   X  X 
MRI (liver/spleen)      
Echocardiography      Blood Draw (Fasting)c Chemistry Panel  X X X X 
CBC with Differentialb X X X X X 
Serum Lipid Panel   X  X 
Coagulation (aPTT, PT, 
INR)      
hsCRP, HbA1c, FPG, 
and de-lipi[INVESTIGATOR_37490]   X  
X 
Sedimentation Rate   X  X 
Complement (C5a, Bb)   X  X 
Plasma PK - Volanesorsen   X  X 
Anti-Volanesorsen 
Antibodies   X  X 
FSH (women only, if applicable)      
Serum Pregnancy Testd X X X X 
Archived Serum & Plasma Samples
e   X  X 
Troponin Io      
Urinalysisc  Xm Xm Xm Xm 
Fundus Photographyf      
Genetic testing for FCS 
diagnosis (if not available in 
medical history)g      
Weekly Study Drug:  SC 
Injection      
Symptom Diary (weekly) X X X X X 
Quality of Life 
Assessment(s)   X  X 
Food/Drink Diary (quarterly)
h   X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication X X X X X 
p  If needed, the post-treatment follow-up period will be 
extended (with patients monitored every 6 weeks) until 
apoC-III levels return to baseline values To follow guidance provided 
by [CONTACT_37938]-treatment follow-up 
period until apoC-III levels 
return to baseline values 
  
ISIS 304801-CS7 CONFIDENTIAL Amendment [ADDRESS_38871]-
Treatment Period  Was: 
After completion of the Week- [ADDRESS_38872]-treatment evaluation period.  This period consists of 4 Study Cent er visits on Weeks 54, 56, and 
58 (which may be conducted by a home healthcare nurse), and Week 65 as outlined in the Schedule of Procedures in 
Appendix A. 
 
Is: 
After completion of the Week [ADDRESS_38873]-treatment evaluation period 
or will participate in an expanded access program pending approval by [CONTACT_1026]/IEC, and the appropriate regulatory 
authorities.  The 26-week period consists of at least 6 Study 
Center visits on Weeks 54, 56, 58, 65, 71, and 78 (Weeks 54, 56, 58, and 71 may be conducted by a home healthcare 
nurse), as outlined in the Schedule of Procedures in 
Appendix A. To follow guidance provided 
by [CONTACT_37938]-treatment follow-up 
period until apoC-III levels 
return to baseline values 
To provide an expanded 
access program as an option 
for patients that may be 
benefiting from active drug 
treatment 
For consistency with the above changes, Week  78 was added to the following sections: 
6.2.[ADDRESS_38874]-Treatment Follow-up Period  
8.10.2  Concomitant Procedures 9.4.1  Serious Adverse Events 
9.4.2  Non-Serious Adverse Events  
Appendix C  Pharmacokinetic Sampling Schedule  
8.6.3  Stoppi[INVESTIGATOR_37612] 2  Actions in 
Patients with Low 
Platelet Count Was: 
Administration of steroids is recommended for patients whose 
platelet count is less than 25,000/mm3.  Recovery in platelet count 
may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia (Provan et al. 
2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 
2-4 weeks then taper; or Meth ylprednisolone 30 mg/kg/day for 
7 days ( note:   may require continuation with oral steroids after 
methylprednisolone). 
 
Is: 
Administration of steroids is recommended for patients whose 
platelet count is less than 25,000/mm3.  Recovery in platelet count 
may be accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia (Provan et al. 
2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 
2-4 weeks then taper; or Meth ylprednisolone 30 mg/kg/day for 
7 days ( note:   may require continuation with oral steroids after 
methylprednisolone).  In order to reduce the unlikely but potential 
increased risk of pancreatitis duri ng the period of corticosteroid 
therapy, triglyceride levels will be monitored weekly during corticosteroid treatment and the laboratory alert will be changed 
from an increase of 2,000 to 500 mg/dL during that period. To follow guidance provided by [CONTACT_37939] 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
13  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll  over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll  over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_38875] -treatment evaluation period or will participate in an expanded 
access program pending approval by [CONTACT_1026]/IEC, and the appropriate 
regulatory authorities.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria: 
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 Groups 2 and 3 :  Patients must also meet the following criteria in order 
to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by [CONTACT_37898]:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS  304801-CS16 index study   
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this open -label 
study  
4. Able and willing to participate in a 78-week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
14  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females  ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medical cause and FSH levels in the 
postmenopausal range for the laboratory involved), abstinent*, or if 
engaged in sexual relations of child-bearing potential, patient is 
using an acceptable contraceptive method (refer to Section 6.3.1 ) 
from time of signing the informed consent form until [ADDRESS_38876] dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38877] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdraw al are not acceptable methods of contraception  
Exclusion Criteria  
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening*  
b. HbA1c ≥ 9.0% at Screening*  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of screening*  [with the 
exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment period of the Study (with the exception of ± 10 units of 
insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia 
syndrome  
3. Active pancreatitis within 4 weeks prior to screening*  
4. History within 6 months of screening*  of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery within 3 months 
of screening*  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
15  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria  Continued  
5. Any of the following laboratory values at Screening*  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which 
case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_38878]  
• AST > 2.[ADDRESS_38879]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive 
test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening*  
d. LDL-C > 130 mg/dL at Screening*  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding 
diathesis or coagulopathy or clinically -significant abnormality in 
coagulation parameters at Screening*  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_38880] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been successfully 
treated  
12. Treatment with another investigational drug, biological agent, or device 
within 1-month of screening* , or 5 half -lives of investigational agent, 
whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
16  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria  Continued  
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to screening*  and dose 
and regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
screening*  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to 
screening*  unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least 3 months prior to screening*  and 
dose and regimen expected to remain stable throughout the study  
e. Antihypertensive medication unless on a stable dose for at least 
4 weeks prior to screening*  and dose and regimen expected to remain 
constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening*  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least 4 weeks prior to 
screening*  and regular clinical monitoring is performed  
h. Tamoxifen, estrogens or progestins unless on a stable dose for at 
least 4 months prior to screening*  and dose and regimen expected to 
remain constant during the treatment period  
i. Plasma apheresis within 4 weeks prior to screening*  or planned 
during the study  
j. Prior exposure to ISIS [ADDRESS_38881] 4 weeks prior to 
screening*  (Occasional or intermittent use of over -the-counter 
medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening*  or of 
> 499 mL within 60 days of screening*  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or placebo)  
17. Have any other conditions, including new  or worsening of existing 
condition , which, in the opi[INVESTIGATOR_37548], or could interfere with the patient participating in or completing the study  
*(Group 3) or Qualification (Groups 1 and 2)  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
17  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a subset of patients with 
FCS.  The same dose of [ADDRESS_38882] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study) :  A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]) .  Please refer to 
Section 4.1 and Appendix A  
• Group 3 patients (did not participate in an index study) :  An up to 
8-week screening and qualification period, including a diet 
stabilization period of at least 6 weeks  (screening and diet 
stabilization period may be reduced, per Sponsor approva l, if the 
patient is following a diet for optimal control of TGs and disease management prior to screening) .  Please refer to Section 6.1.2  and 
Appendix A  
• All patients:  
o A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
o An at least  26-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_38883] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_38884] -
treatment evaluation period or will participate in an expanded access program 
pending approval by [CONTACT_1026]/IEC, and the appropriate regulatory authorities . 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
18  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37840] (including independently adjudicated events of  acute pancreatitis  and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during 
the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB] , high -
density lipoprotein- cholester ol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF-36)  
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
19  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
SCREENING PERIOD  
Weeks -8 to -2 (Group 3 patients only)  
QUALIFICATION  
PERIOD 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks 53 to 78* 
Safety, efficacy, PK and PD assessments  
* If needed, the post -treatment follow -up 
period will be extended (with patients 
monitored every 6 weeks) until apoC -III 
levels return to baseline values  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
20  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_38885]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_38886] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_38887]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
22  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIONALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed either in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily calor ie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011).  
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancr eatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al.  2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: 
apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
23  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] 
(Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
24  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein profile and increased longevity (A tzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma TG have also been recently described (Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
25  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the 
RNase H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the 
apoC-III protein .  Maximal antisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37554] 90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al.  
2010).  Furthermore, reduction in target mRNA levels using this approach correlates directly  
with a subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleot ides at  the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased  resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
26  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_38888] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, 
drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on embryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
27  2.3.4 Clinical Experience  
Detailed information concerning the clinical stu dies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exp osures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an 
open- label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_38889] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_38890]- treatment period and was not associated with platelet -related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_38891] Level ( NOAEL ) 
was defined by [CONTACT_37921] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combina tion with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different  doses tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exce ed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
29  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or  
ISIS 304801-CS16 index studies 
Up to approximately [ADDRESS_38892]- treatment evaluation period 
or will participate in an expanded access program pending approval by [CONTACT_1026]/IEC, and the 
appropriate regulatory authorities. 
3.[ADDRESS_38893] of the following periods: 
3.4.1 Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification  
A period of up to 2 weeks  (unless approved by [CONTACT_1034]) is given to complete  qualification  
assessments outlined in the Schedule of Procedures.  Please refer to Section 4.1 and  Appendix A . 
3.4.2 Group 3 P atients (did not participate in an index study):  Screening/Qualification  
An up to 8- week screening and qualification period, including a diet stabilization period of at 
least 6 weeks  (screening and diet stabilization period may be reduced, per Sponsor approval, if 
the patient  is following a diet for optimal control of TGs and disease management prior to 
screening.  Please refer to Section 6.1.2 and Appendix A. 
3.4.3 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
ISIS [ADDRESS_38894] 6 Study Cen ter 
visits on Weeks 54, 56, 58 , 65, 71, and 78 (Weeks 54, 56, 58, and 71 may be conducted by a 
home healthcare nurse) . 
3.[ADDRESS_38895] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and mee ting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Screening/ Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open- label study are performed .   
Groups 1 and 2 (Qualification):  During the qualification period, the eligibility of the patient to 
enroll in the open- label study will be determined .  Final assess ments from the ISIS 304801-CS6 
or ISIS 304801-CS16 studies may be used for qualification .  A period of up to 2 weeks after 
completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  
identification number that was assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient identification number will be used to identify the 
patient  throughout the extension trial and must be used on all study documentation related to that 
patient .  The patient  identification number must remain constant throughout the extension trial. 
Group 3 (Screening and Qualification):  At the time of consent, the patient will be considered enrolled into the study and will be assigned a unique screening number before any study procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This number will be used to identify the patient throughout the trial and must be used on all study documentation related to that patient.  The screening number and patient identification number must remain constant throughout the entire trial.  In the event the patient is re-consented and re- screened the patient must be given a 
new screening number.  Screening numbers and patient  identification numbers, once assigned, 
will not be re -used. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
31  4.2 Enrollment  
Patient s will be enroll ed into the treatment ph ase of the study after all  Screening (Group3) and 
qualification assessments have been completed and after the Investigator has verified that they 
are eligible per criteria in Sections 5.1 and 5.2.  No patient  may begin treatment prior to 
enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_38896] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement.  Groups 2 and 3:  Patients must also meet t he following criteria in order to enter  into the 
open- label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measu rement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37898]: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1 -causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  
 ISIS 304801-CS16 index study 
Group 3:  F asting TG ≥ 750 mg/dL at Screening for this open -label study  
4. Able and willing to participate in a 78-week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defin ed as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
32  medical cause and  FSH levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, 
patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_38897] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of 
child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_38898] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception  
5.2 Exclusion Criteria   
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening * 
b. HbA1c ≥ 9.0% at Screening*  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of screening*  [with the exception of ± 10 units of 
insulin]) 
d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
e. Current use of GLP- 1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening*  
4. History within 6 months of screening*  of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack 
or unstable congestive cardiac failure requiring a change in med ication or major surgery 
within 3 months of screening*  
5. Any of the following laboratory values at Screening*  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and 
documentation of Gilbert’s syndrome in which case total bilirubin must be  
≤ 3 mg/dL 
• ALT > 2.[ADDRESS_38899] 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
33  • AST > 2.[ADDRESS_38900] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine 
dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein  measurement of < 500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥ trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with 
urine microscopy showing ≤ 5 red blood cells per high powe r field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37446]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening * 
d. LDL- C > 130 mg/dL at Screening*  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of thrombocytopenia (platelet count <  100,000/mm
3) or bleeding diathesis or 
coagulopathy or clinically -significant abnormality in coagulation parameters at 
Screening*  
8. History of heart failure with NYHA grea ter than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day [ADDRESS_38901] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1-month 
of screening* , or 5 half-lives of investigational agent, whichever is longer 
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a sta ble 
dose for at least 3 months prior to screening*  and dose and regimen expected to 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
34  remain constant during the treatment period.  Patients taking OTC omega- 3 fatty 
acids should make every effort to remain on the same brand throughout the study 
b. Nicotinic  acid or derivatives of nicotinic acid within 4 weeks prior to screening* 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening*  
unless approved by [CONTACT_37755] 
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least 3 months prior to screening*  and dose and regimen expected to 
remain stable throughout the study 
e. Antihypertensive medication unless on a stable dose for at least 4 weeks prior to 
screening*  and dose and regimen expected to remain constant during the treatment 
period 
f. Glybera gene therapy within 2 years prior to screening* 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least 4 weeks pr ior to screening* and regular clinical monitoring is 
performed  
h. Tamoxifen, estrogens or progestins unless on a stable dose for at least 4 months prior 
to screening*  and dose and regimen expected to remain constant during the treatment 
period 
i. Plasma ap heresis within 4 weeks prior to screening* or planned during the study 
j. Prior exposure to ISIS [ADDRESS_38902] 4 weeks prior to screening*  (Occasional 
or intermittent use of over-the- counter medications will be allow ed at Investigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of screening*  or of >  499 mL within 
60 days of screening*  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
17. Have any other conditions, including new or worsening of existing condition, which, in 
the opi[INVESTIGATOR_37556], or could interfere with the patient participating in or completing the study 
*(Group 3) or Qualification (Groups 1 and 2) 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, C, and D . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
35  6.1.1 Qualification  (Groups 1 and 2) 
Please refer to Section 4.1 and Appendix A . 
6.1.2 Screening and Qualification  (Group 3) 
Before any study -specific procedures or evaluations are initiated, patients must sign and date the 
informed consent form.  An 8-week period, including a diet stabilization period of at least 
6 weeks (screening and diet stabilization period may be reduced, per Sponsor approval, if the 
patient  is following a diet for optimal control of TGs and disease management prior to screening ) 
is given to perform the screening evaluations.  The qualification  assessme nts will be performed 
at Week -[ADDRESS_38903] patient’s Week [ADDRESS_38904]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Secti on 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunogenicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesorsen administration.  Blood sampling  at Week s 2.5, 
4, 6, 8, 10, 12, 15, 17, 19, 21, 23, 25, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, a nd [ADDRESS_38905] be fasted prior to drawing all blood samples and samples drawn locally should also 
be sent to the central laboratory for analysis  whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given 7 days prior to a scheduled clinic visit.  Dosing 
instructions and training will be provided to the patient where applicable. 
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.4 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
ISIS [ADDRESS_38906]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_38907]- treatment evaluation period  or will participate in an expanded access program pending 
approval by [CONTACT_1026]/IEC, and the appropriate regulatory authorities.  The 26- week period 
consists of at least 6 Study Center visits on Weeks 54, 56, 58, 65, 71, and 78 ( Week s 54, 56, 58, 
and 71 may be conducted by a home healthcare nurse) , as outlined in the Schedule of Procedures 
in Appendix A. 
6.[ADDRESS_38908] of these analytes  is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed locally.  In the event that both the central and 
local sample are unreportable (e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within 1-week and determined not to have met a stoppi[INVESTIGATOR_37607].  
If there is no reportable platelet count within [ADDRESS_38909] the patient to hold dosing until a new platelet count is obtained and reviewed. 
All platelet count results will be promptly reviewed by [CONTACT_37900][INVESTIGATOR_37587] 75,000/mm
3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37613] 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
37  always be measured on the same arm (preferentially on the left arm) .  Height w ill be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37559]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 rollover patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatm ent 
assignment.  
6.2.[ADDRESS_38910] 5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, 
Week 65 , and Week 78. 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants . 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37703].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality o f Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, Week [ADDRESS_38911]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
38  1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, Week 65, and Week 78. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service.  
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post treatment follow -up periods. 
6.2.[ADDRESS_38912] refrain from sperm/egg donation and 
either be abstinent † or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_38913]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patie nt’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
39  intrauterine contraception/device, or barrier methods (female condom*, diaphragm, 
sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
* Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
† Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdr awal are not 
acceptable methods of contraception  
6.3.[ADDRESS_38914] 10 hours and preferably not more than 12 hours 
before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_38915] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_38916] (ISIS 304801) characteristics are listed in  Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
40  Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength 200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_38917] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
41  8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to  the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_38918] measurement prior to Day 1  (e.g., qualification assessments or 
asses sments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collec tion) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed  below, the Sponsor may request 
confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Redu ction in dose or dose frequency 
may also be initiated as noted in Section 8.7.  If any of the stoppi[INVESTIGATOR_37466] 
(refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with 
Section 8.8 of t he protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in  Section 8.[ADDRESS_38919] measurement that is > [ADDRESS_38920]  (or the greater of [ADDRESS_38921] if the baseline val ue was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase 
to [ADDRESS_38922]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_38923] (or 
the greater of [ADDRESS_38924] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_38925] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts wit h confirmed ALT or AST 
levels > [ADDRESS_38926]  (or the greater of [ADDRESS_38927] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ations, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_38928] . 
8.5.2 Safety Monitoring for Platelet Count Results  
Actions to be taken in the event of reduced platelet count are shown in Table 2 in Section 8.6.3. 
Additional lab tests will be determined by [CONTACT_37940] .  
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
43  parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet  count should be performed. 
8.5.[ADDRESS_38929] to notify the Investigator if a patient has 
a low-density lipoprote in-cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust trea tment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_38930] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or de legate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37614].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37609]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] 
≤ 70 mg/dL  (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
44  8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of s evere symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place 
patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  Ho wever, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood 
glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could 
occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_38931] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within 1- week of the initial test).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_38932] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
45  The threshold values are defined as: 
• FPG > 270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_38933]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonab ly explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable.  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_38934] measurement prior to Day 1.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
46  8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_38935] >  [ADDRESS_38936] , which is confirmed and persists for ≥ [ADDRESS_38937] >  [ADDRESS_38938] (or the greater of [ADDRESS_38939] if the baseline 
value was > ULN) , which is confirmed and total bilirubin > [ADDRESS_38940]  or INR  > 1.[ADDRESS_38941] >  [ADDRESS_38942] (or the greater of [ADDRESS_38943] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_38944] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinin e clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by  [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 2 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any platelet count less than 5 0,000/mm3, or a rate of decline ≥ 50% between two  
consecutive assessments, irrespective of the platelet level,  then dosing of a patient with 
volanesorsen will be stopped permanently.  Platelet count will be monitored daily until 
2 successive val ues show improvement then monitored every 2-3 days until platelet count is 
stable.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
47  Administration of steroids is recommended for patients whose platelet count is less than 
25,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone).  I n order to reduce 
the unlikely but potential increased risk of pancreatitis during the period of corticosteroid therapy, triglyceride levels will be monitored weekly during corticosteroid treatment and the laboratory alert will be changed from an increase of 2,000 to 500 mg/dL during that period. 
In the event of a pl atelet count less than 75,000/mm
3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks or a reduced dose of 150 mg per week (refer to Section 8.7) .  The suitability of the 
patient for continued dosing will be determined by [CONTACT_37941]’s 
platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of 
recovery of platelet co unt upon holding of dosing. 
If after the first dosing rechallenge the platelet count again falls below 75,000/mm3, then dosing 
of the patient with Study Drug will be s topped permanently. 
Following a rechallenge platelet count should be tested every week until count is stable. 
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450].  
If there is no reportable platelet count within [ADDRESS_38945] the patient to hold dosing until a new platelet count is obtained and reviewed. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related)  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
48  4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
Table 2 Actions in Patients with Low Platelet Count  
Platelet C ount on Rx  Drug Dose Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every 1-week  until stable*  
75K-100K/mm3 Permanently reduce dose frequency to 
300 mg every 2  weeks  or reduce dose to 
150 mg weekly  Closer observation  
Monitor every  1-week  
50K-75K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37905] 2-3 days until 
2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/NSAIDS/  
anticoagulant medication  
25K-50K/mm3 or a rate of 
decline ≥  50% between 
two consecutive 
assessments, irrespective of the platelet level  Permanently discontinue Study Drug   Closer observation  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant 
medication while platelet count 
< 50K/mm3 if possible  
< 25K/mm3 Permanently discontinue Study Drug Closer observation:  
Monitor daily until 2 successive 
values show improvement then 
monitor every 2-3 days until 
platelet count stable  
Steroids recommended* * 
Consider need for hospi[INVESTIGATOR_37590]/NSAIDS/anticoagulant 
medication while platelet count 
< 50K/mm3 if possible  
* At least 3 consecutive values measured weekly  that are stable as determined by [CONTACT_37906] > 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 w eeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methyl  prednisolone) .  In order 
to reduce the unlikel y but potential increased risk of  pancreatitis during the period of corticosteroid therapy, 
triglyceride levels will be monitored weekly during corticosteroid treatment  and the laboratory alert will be 
changed from an increase of 2,000 to 500 mg/dL during that period . 
ISIS [ADDRESS_38946] be made in accordance with Section 8.6.3 and 
Table 2 (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
schedule must be discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to [ADDRESS_38947] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormaliti es that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_38948] 6 weeks after 
discontinuing Study Drug.  Following this period, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_37683] 
> 100,000/mm
3), the next platelet count should be taken within at least [ADDRESS_38949] 12  weeks after discontinuing Study Drug .  Patie nts should also be 
strongly encouraged to attend applicable landmark visits at Week s 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and conduct 
safety assessments in accordance with the Schedule of P rocedures in Appendix A .  Any patient 
who discontinues treatment after  Week 44 should also be strongly encouraged to attend a final 
follow-up visit ( Week 78 visit assessments) approximately [ADDRESS_38950] dose of 
Study Drug , in addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_38951] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_38952] 1 2 weeks after discontinuing Study Drug.  
Patients  should also be encouraged to undergo a final  follow-up visit ( Week 78, see Appendix A ) 
prior to leaving the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_38953] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion  of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdraw al.  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of reque st.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to com plete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_38954] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
51  8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega- 3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti-diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non -prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 78 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_38955] of the clinical trial. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
52  9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements will be followed in accordance wit h local country 
regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedite d manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 3 Expected Event for the Protocol Defined Population by [CONTACT_37889] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected  and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37932] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
ISIS [ADDRESS_38956]. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility th at 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of e ither the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE 
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important me dical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
ISIS [ADDRESS_38957] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_38958] the patient ’s last protocol- specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Event s 
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week 78 visit.  
The Investigator will monitor each  patient  closely and recor d all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
55  [IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Vo lanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non-serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
56  • Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_38959] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or requ ire treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant ( NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
57  • The prescheduled or elective procedure or routine ly scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_38960] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
58  Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are 
defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
59  10.3 Populations 
Full Analysis Set (F AS):  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_38961] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who  are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_38962] 1 evaluable PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_38963] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in t he ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline for safety will be the last non- missing assessment prior to the first dose of Study Drug . 
10.[ADDRESS_38964] patient’s Week [ADDRESS_38965] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for c ategorical 
variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoi nts will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be assessed in the PK Set as applicable.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
60  10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_37942].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echoc ardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] o f the index studies.  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, 
Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a 
range of fasting plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37947]-HDL -C, apoB, HDL-C, apoA-1, VLDL-C, and LDL-C, total cholesterol, and fasting total 
apoC- III. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
61  The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be  summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification for Group 1 and 2 patients by [CONTACT_37949]  304801- CS6 and ISIS 304801-CS16 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single- dose PK) or multiple doses (i.e., 
steady -state PK), depending on their earlier treatment in the index studies (Group 1 and 2 
patients) .  On Week 1  Day 1 of the open- label study, patients who received placebo in the index 
study (and all patients in Group 3) will receive the first treatment of volanesorsen (single -dose 
PK), while  patients who received volanesorsen in the index studies had been on volanesorsen 
treatment for 12 months (ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data 
collected from these patients reflect steady -state PK .  The maximum observed drug 
concentration (C max) and the time taken to reach C max (Tmax) will be obtained directly from the 
concentration -time data .  Area under the plasma concentration -time curve from time zero to 
24 hours ( AUC 0-24hr) will be calculated using the linear trapezoidal rule.  Apparent systemic 
(plasma) clearance after SC administration (CL 0-24hr /F0-24hr) will be calculated from  
CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean residence time (MRT) from time zero to 
24 hours after the SC administration  will be calculated from the equation,  
MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the  moment plasma 
concentration -time curve from time zero to [ADDRESS_38966]. 
Plasma PK parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_37732] 304801 -CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
62  listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable 
patients, along with the study day a ssociated  with the first positive IM status emerged (T first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the duration of ADA 
response (number of days between T first and T last) if appropriate , the last ADA sample collectio n 
day, and subject - peak titer if applicable, will be listed by [CONTACT_37950] 304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day.  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized  as the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable,  
will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., %change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
  
ISIS [ADDRESS_38967] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form m ust be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_38968] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
ISIS [ADDRESS_38969] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_38970].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi [INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Stu dy Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
65  No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the I nvestigat or wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_38971], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug sto rage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management revi ew will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To r esolve any questions arising from the clinical data 
management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37616] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_38972] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated and/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
66  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al . Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipopr oteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle  MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein  lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antis ense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
67  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expressi on in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP. Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486]. Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibito ry effects of specific apolipoprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprot ein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol C hem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37951] g very low density  
lipoprotein -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Stan dardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfer t W, Evans D, et al . Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemela ar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemi a. J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica  2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
68   
  
 
  
 
14. APPENDICES  
   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol - [LOCATION_009]   16 September 2016  
 
69   
  
 
  
 
Appendix A  Schedule of Procedures 
 
Screen/Run In through Treatment Period  
Post- Treatment Follow -up 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
70  Appendix A  Schedule of Procedures – Screen/Run In through Treatment Period  
Study Period  Screen/  
Run Ina Quala Treatment Period  
Study Week  -8 to -2 -2 to -
1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 
Visit Window+/ - Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Informed Consent  X X                        
Outpatient Visit  X X X Xj Xj Xj Xj Xj Xj Xj X Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X 
Inclusion/Exclusion Criteria  X X                        
Vital Signs + body weight  
(+ height on Day 1 only)  X X X   X  X   X     X    X     X 
Physical Examination  X X X        X     X    X     X 
12- lead ECG (triplicate)  X X         X     X    X     X 
MRI (liver/spleen)  X                       Xk 
Echocardiography  X              Xk         Xk Blood Draw (Fasting)c Chemistry Panel  X X X   X  X   X  X   X  X  X  X   X 
CBC with Differentialb X X X  X X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel  X X X   X  X  X X    X X    X    X X 
Coagulation (aPTT, PT, INR)  X X      X   X     X    X     X 
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37617] X        X     X         X 
Sedimentation Rate    X        X     X         X 
Complement (C5a, Bb)    X        X     X         X 
Plasma PK - Volanesorsen    Xl X  X  X   X     X    X     X 
Anti-Volanesorsen Antibodies    X   X  X   X     X    X     X 
FSH (women only, if applicable)  X X                        
Serum Pregnancy Testd X X    X  X   X  X   X  X  X  X   X 
Archived Serum & Plasma 
Samplese   X     X   X     X         X 
Troponin Io X X                        
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
71  Appendix A  Schedule of Procedures  - Screen/Run In through Treatment Period  Continued  
Study Period  Screen/  
Run Ina Quala Treatment Period  
Study Week  -8 to -2 -2 to -
1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  
Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 
Visit Window+/ - Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
Urinalysisc X X Xm   X  X   Xm  Xm   Xm  Xm  Xm  Xm   Xm 
Fundus Photographyf X                       Xk 
Genetic testing for FCS diagnosis (if 
not available in medical history)g X                        
Weekly Study Drug:  SC Injection   X  X X X X X X X X X X X X X X X X X X X X X 
Symptom Diary (weekly)  X X X  X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)    X        X     X         X 
Food/Drink Diary (quarterly)h   X        X     X         X 
Diet/Alcohol Counselingi X X X   X  X   X     X    X     X 
Adverse Events X X X  X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X  X X X X X X X X X X X X X X X X X X X X X 
 
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
72  Appendix A  Schedule of Procedures – Post -Treatment Follow -up  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Informed Consent       
Outpatient Visit  Xj Xj X Xj X 
Inclusion/Exclusion Criteria       
Vital Signs + body weight  
(+ height on Day 1 only)    X  X 
Physical Examination    X  X 
12- lead ECG (triplicate)    X  X 
MRI (liver/spleen)       
Echocardiography      Blood Draw (Fasting)c Chemistry Panel   X X X X 
CBC with Differentialb X X X X X 
Serum Lipid Panel    X  X 
Coagulation (aPTT, PT, INR)       
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]    X  X 
Sedimentation Rate    X  X 
Complement (C5a, Bb)    X  X 
Plasma PK - Volanesorsen    X  X 
Anti-Volanesorsen Antibodies    X  X 
FSH (women only, if applicable)       
Serum Pregnancy Testd  X X X X 
Archived Serum & Plasma Samplese   X  X 
Troponin Io      
 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
73  Appendix A  Schedule of Procedures – Post -Treatment Follow -up Continued  
Study Period  Post Treatment Follow -upp 
Study Week  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
71 Wk 
78 
Study Day  372 
& 
386 400 449 491 540 
Visit Window+/ - Days  2 7 7 7 7 
Urinalysisc  Xm Xm Xm Xm 
Fundus Photographyf      
Genetic testing for FCS diagnosis 
(if not available in medical 
history)g      
Weekly Study Drug:  SC Injection      
Symptom Diary (weekly)  X X X X X 
Quality of Life Assessment(s)    X  X 
Food/Drink Diary (quarterly)h   X  X 
Diet/Alcohol Counselingi  X X X X 
Adverse Events X X X X X 
Concomitant Medication  X X X X X 
ISIS 304804 -CS7 CON FIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
74  Appendix A  Schedule of Procedures Continued  
a Screening (Group 3) and Qualification  procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should 
be collected in parallel and analyzed locally. In the event that both the central and local sample are unreportable 
(e.g., due to hemolyzed or clumped blood samples) another sample must be repeated within 1-week  and 
determined not to have met a stoppi[INVESTIGATOR_10450].  If there is no reportable platelet count within [ADDRESS_38973] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be promptly reviewed by [CONTACT_37909][INVESTIGATOR_37587] 75,000/ mm
3.  In the event of any platelet count less than 
50,000/mm3 or a rate of decline ≥  50% between two consecutive assessments, irrespective of the platelet level, 
then dosing of a patient with Study Drug (ISIS 304801 or placebo) will be stopped permanently.  Any case of a 
platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
c Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  
During treatment period urine and blood samples will be collected prior to Study Drug administration.  Does not apply to 24-hour PK blood draw  
d Females of childbearing potential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laborator y findings and/or 
adverse events (e.g., measurement of cytokine and/or chemokine levels, measurement of additional markers of 
kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of  volanesorsen  
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug 
(Group 2 [ISIS 304801-CS16 rollover patients] and Group 3)  and repeated at Week 52 (Please refer to 
Section [IP_ADDRESS]) 
g Genetic testing can be conducted for study qualification (Group 2 [ISIS 304801-CS16 rollover patients] and Group 3); genetic testing will only be conducted if allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing  
h In addition to diary, patients will be contact[CONTACT_37910]  
i To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37743]  
j Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
k A ± 7 -day window is allowed for MRI, echocardiography procedures and fundus photography  
l Full or abbreviated PK profile (see Appendix C ) 
m Expanded urinalysis (see Appendix B ) 
n HbA1c only  
o All abnormal troponin samples will be rerun at the central laboratory and also analyzed for CK -MB 
p If needed, the post -treatment follow -up period will be extended (with patients monitored every 6 weeks) until 
apoC -III levels return to baseline values  
  
ISIS [ADDRESS_38974] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte  esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_38975]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 Wk 
78 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  D540 
Visit Window 
+/- Days  [ADDRESS_38976]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_38977] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804 -CS7 CON FIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
81  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CON FIDENTIAL  Amendment 6  
Protocol  - [LOCATION_009]   16 September 2016  
 
82  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 Adverse Event Mild Moderate Severe 
Urine 
Prote inuria 
Adults 1 + prote inuria; 2+ prote inuria; Urinary prote in g/24 hrs; urinary protein < 1.0 g/24 hrs urinary protein 1.0 - 3.4 g/24 hrs; 
Children -Urine PIC (Protein /Creat inine) Urine P/C >1.9 ratio 0.5 - 1.9 
Gross hema turia; transfusion, 
Asymp tomatic; clinical or diagnostic IV medications or 
Symp tomat ic; urina ry cathe ter or hospi[INVESTIGATOR_37591] ; Hematur ia observat ions only; interven tion not bladder irrigation indicated elective endoscop ic, radiologic indicated or operat ive intervention 
indicated 
tGrading for this paramete r is derived from the Toxicity Grad ing Scale for Healthy Adult and Adol escent Volun teers Enrolled in 
Preventi ve V accine Clinical Trials, Sept 2007 
*Grading for this parameter is derived from the Division of AIDS (DAIDS) Table for Grad ing the Seve rity of Adult and Pediatric 
Adverse Events Version 2.0, Nov 2014 
tModifi ed for consistency with the ADA and Endocrine Society Guidelines (Seaqu ist ER, Anderson J, Childs B, et al. 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Associa tion and The Endocrine Society. 
Diabetes Care 2013 ;36: 1384 -95) 
 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_38978] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_38979] 
Cambridge, MA  [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 5 - [LOCATION_009] – [ADDRESS_38980] No:  2015-003755-21 
 
 
 

ISIS 304801-CS? 
Protocol- [LOCATION_009] CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801) Amendment [ADDRESS_38981] 2016 
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 5-[LOCATION_009]- [ADDRESS_38982] 2016 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_38983]  2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_38984] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_38985] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:  [CONTACT_37829].D.  
[ADDRESS_38986]  
Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator:  Akcea Therapeutics  
[ADDRESS_38987] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_38988]  2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 5 - [LOCATION_009]  
Date:    [ADDRESS_38989] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_38990] the study as 
described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_38991]  2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................20  
STUDY DESIGN AND TREATMENT SCHEMA  ...................................................................26  
STUDY GLOSSARY ...................................................................................................................27  
1. OBJECTIVES  .....................................................................................................................29  
2. BACKGROUND AND RATIO NALE  ..............................................................................29  
2.1 Overview of Disease  ......................................................................................................29  
2.2 Therapeutic Rationale  ....................................................................................................30  
2.3 Volanesorsen  ..................................................................................................................31  
2.3.1  Mechanism of Action  .............................................................................................31  
2.3.2  Chemistry  ...............................................................................................................32  
2.3.3  Preclinical Experience  ............................................................................................33  
2.3.4  Clinical Experience ................................................................................................34  
2.4 Rationale for Dose and Schedule of Administration .....................................................35  
3. EXPERIMENTAL PLAN ..................................................................................................36  
3.1 Study Design  ..................................................................................................................36  
3.2 Number of Study Centers ..............................................................................................36  
3.3 Number of Patients ........................................................................................................36  
3.4 Overall Study Duration and Follow-up .........................................................................36  
3.4.1  Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study): Qualification  .....................................................................................36  
3.4.2  Group 3 Patients (did not participate in an index study): Screening/Qualification  [ADDRESS_38992] ................................................................................37  
4. PATIENT ENROLLMENT ...............................................................................................37  
4.1 Screening/Qualification  .................................................................................................37  
4.2 Enrollment .....................................................................................................................37  
5. PATIENT ELI GIBILITY  ..................................................................................................38  
5.1 Inclusion Criteria  ...........................................................................................................38  
5.2 Exclusion Criteria  ..........................................................................................................39  
6. STUDY PROCEDURES  ....................................................................................................41  
6.1 Study Schedule  ..............................................................................................................41  
6.1.1  Qualification (Groups 1 and 2) ...............................................................................41  
6.1.2  Screening and Qualification (Group 3) ..................................................................41  
6.1.3  Treatment Period  ....................................................................................................42  
6.1.4  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_38993]- Treatment Period  ............................................................................................43  
6.2 Additional Study Assessments  .......................................................................................43  
6.2.1  Laboratory Assessments  .........................................................................................43  
6.2.2  Physical Exams and Vital Signs  .............................................................................43  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................43  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_38994]- Treatment Follow -up Period .56  
8.9 Withdrawal of Patients from the Study  ..........................................................................57  
8.10  Concomitant Therapy and Procedures ...........................................................................57  
8.10.1  Concomitant Therapy .............................................................................................57  
8.10.2  Concomitant Procedures .........................................................................................58  
8.11  Treatment Compliance ...................................................................................................58  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................58  
9.1 Sponsor Review of Safety Information .........................................................................58  
9.2 Regulatory Requirements  ..............................................................................................58  
9.3 Definitions  .....................................................................................................................59  
9.3.1  Adverse Event  ........................................................................................................59  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................59  
9.3.3  Serious Adverse Event (SAE) ................................................................................60  
9.4 Monitoring and Recording Adverse Events ...................................................................60  
9.4.1  Serious Adverse Events ..........................................................................................60  
9.4.2  Non-Serious Adverse Events ..................................................................................61  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................61  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................61  
[IP_ADDRESS]  Severity  ............................................................................................................61  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................62  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................62  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................[ADDRESS_38995]  2016  
 
8  10.6.2  Safety Analysis  .......................................................................................................67  
10.6.3  Efficacy Analysis  ...................................................................................................67  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................68  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................68  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................68  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_38996] of the Study .........................................................................................70  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_38997] of Laboratory Analytes  .............................................................................80  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................82  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......84  
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ................................................................ 46  
Table 2  Actions in Patients With Low Platele t Count ............................................................... 55  
Table 3  Expected Event for the Protocol Defined Population by [CONTACT_37935]  ................................................................................................. 59  
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 30  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown ................................... [ADDRESS_38998]  2016  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered 
Subcutaneously to Patient s with Familial Chylomicronemia 
Syndrome (FC S) 
Amendment Number:  5 - [LOCATION_009]  
Amendment Date:  [ADDRESS_38999] 2016 
 
The purpose of this protocol amendment is to implement the following modification s to Protocol 
ISIS 304801- CS7 Amendment 4 dated 6 June 2016: 
1. To enroll FCS patients in this open- label study  who did not participate in the 
ISIS 304801–CS6 or ISIS 304801–CS16 index studies. 
For clari ty, the protocol now specifies 3 patient g roups, with assignment based on prior 
involvement in index studies of ISIS 304801: 
Group 1:  ISIS 304801-CS6 (index study) rollover FCS patients Group 2:  ISIS 304801-CS16 (index study) rollover FCS patients Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies 
2. To remove language that indicates  that lipoprotein lipase (LPL) activity can be measured 
if needed for study qualification for patients in Groups 2 and 3. 
3. To add language to indicate that a second Study Drug rechallenge will not be allowed  
following a platelet count decrease below 75,000/mm
3. 
4. To provide clarification s to the pl atelet safety monitoring rules in Table 2. 
5. To add language to indicate that patients who discontinue early from Study Drug, or the 
study,  should be followed as per the platelet monitoring rules shown in Ta ble [ADDRESS_39000] 12 weeks after 
discontinuing Study Drug. 
6. Followin g guidance provided by [CONTACT_37952] 
a. Following guidance provided by [CONTACT_37952], the complete stop of Study Drug in 
patients whose platelet threshold is below 25,000/mm3 will be changed to below 
50,000/mm3 
ISIS [ADDRESS_39001]  2016  
 
10  b. T o add a criteria for treatment discontinuation:  patient participation to the trial must 
be stopped if a decrease in platelets greater than or equal to 50% between two 
consecutive assessments is observed, irrespective of the platelet level  
c. To add in the footnote to Appendix A that in the event of any platelet count less than 
50,000/mm3 or a rate of decline ≥ 50% between two  consecutive assessments, 
irrespective of the platelet level, then dosing of a patient with Study Drug (ISIS  304801 or placebo) will be stopped permanently 
d. To add in the Exclusion Criteria patients that already had thrombocytopenia 
e. To add language to exclude patients that meet the Exclusion Criteria of their index 
study 
Minor changes (not included in the list of changes below) have been made throughout the 
protocol to correct errors and/or to improve the overall clarity of the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
The following table provides a summary list of majo r changes to the protocol: 
Protocol Section  Description of Change  Rationale  
Protocol Title pages  
Signature [CONTACT_38021] :  
Title, Study Population,  
Rationale for Dose and 
Schedule Selection, Study Visit Schedule 
and Procedures, 
Statistical 
Considerations  
5.1  Inclusion Criteria “Extension” was removed from the study title. To note that 
FCS patients 
who did not 
participate in an 
index study will 
also be enrolled . 
Protocol Synopsis:  
Study Design  
3.1  Study Design  Was: 
This is a multi -center open- label extension study of ISIS 304801-CS6 
and ISIS 304801-CS16 
 
Is: 
This is a multi -center open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients  
Group 3:  FCS  patients who did not participate in the  
ISIS 304801-CS6 or ISIS 304801-CS16 index studies  To distinguish 
patients who 
participated in 
an index study 
from those who 
did not . 
  
ISIS [ADDRESS_39002]  2016  
 
11  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:  
Study Population  
5.1  Inclusion Criteria Inclusion Criteria  
Was: 
3. Satisfactory completion of ISIS 304801-CS6 or ISIS 304801- CS16 
(index studies) with an acceptable safety profile, per Sponsor and 
Investigator judgement.  Patients who are enrolled in ISIS 304801-CS16 must also meet the following criteria in order to 
enter into the Extension Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37797] (a creamy top layer after 
ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL 
(10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by [CONTACT_37953] t 1 of the 
following:  
• Confirmed homozygote, compound heterozygote or 
double heterozygote for known loss -of-function mutations 
in Type 1-causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal  
c. Fasting TG  ≥ 750 mg/dL (8.4 mmol/L) at Screening for the 
ISIS 304801-CS16 study  
 
Is: 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or 
ISIS 304801-CS16 (index studies) with an acceptable safety 
profile, per Sponsor and Investigator judgement.  
 
Groups  2 and 3:  Patients must also meet the following criteria in 
order to enter into the open-label study:  
a. History of chylomicronemia as evidenced by [CONTACT_37954] (a creamy top layer after 
ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL 
(10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37955]:  
• Confirmed homozygote, compound heterozygote or 
double heterozygote for known loss -of-function mutations 
in Type 1-causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening 
 for the ISIS  304801 -CS16 index study  
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this  open-label study  To define the 
inclusion criteria 
for each Group of patients . 
LPL removed to 
avoid the 
production of heparin induced anti-platelet 
antibodies . 
  
ISIS [ADDRESS_39003]  2016  
 
12  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:   
Study Population  
5.2  Exclusion Criteria  Exclusion Criteria  
Was: 
1. Have any new condition or worsening of existing condition which 
in the opi[INVESTIGATOR_37601], or could interfere with the patient 
participating in or completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section 6.3)  
 
Is: 
Exclusion Criteria  
1. Diabetes mellitus with any of the follow ing: 
a. Newly diagnosed within 12 weeks of screening*  
b. HbA1c ≥ 9.0% at Screening*  
c. Recent change in anti -diabetic pharmacotherapy (change in 
dosage or addition of new medication within 12 weeks of 
screening*  [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during 
the treatment period of the Study [with the exception of ± 10 units of insulin]  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening*  
4. History within 6 months of screening*  of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina),  stroke, transient ischemic attack or unstable 
congestive cardiac failure requiring a change in medication or 
major surgery within 3 months of screening*  
5. Any of the following laboratory values at Screening*  
a. Hepatic:  
• Total bilirubin > upper limit of n ormal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in 
which case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_39004]  
• AST > 2.[ADDRESS_39005]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) 
for protein on urine dipstick.   In the event of a positive 
test eligibility may be confirmed by a quantitative total 
urine protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a 
positiv e test eligibility may be confirmed with urine 
microscopy showing ≤  5 red blood cells per high power 
field 
• Estimated creatinine clearance calculated according to 
the formula of Cockcroft and Gault <  50 mL/min (MDRD 
or CKD -EPI [INVESTIGATOR_37446]-
Gault for estimation of GFR in patients with low body 
weight after discussion with Sponsor Medical Monitor)  To define the 
exclusion 
criteria for each 
Group of 
patients and to make the eligibility criteria 
for the Group [ADDRESS_39006]  2016  
 
13  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:   
Study Population 
Continued  
5.2  Exclusion Criteria  
Continued  Exclusion Criteria  
Is: Continued  
c. Cardiac Troponin I >  ULN at Screening*  
d. LDL-C > 130 mg/dL at Screening*  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37547], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia (platelet count < 100,000/mm3) or 
bleeding diathesis or coagulopathy or clinically -significant 
abnormality in coagulation parameters at Screening*  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial 
therapy that will not be completed prior to Study Day [ADDRESS_39007] for human immunodeficiency 
virus (HIV), hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell 
carcinoma of the skin or carcinoma in situ  of the cervix that has 
been successfully treated  
12. Treatment with another investigational drug, biological agent, or 
device within 1- month of screening* , or 5 half -lives of 
investigational agent, w hichever is longer  
13. Unwilling to comply with lifestyle requirements (Section 6.3)  
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or 
fibrates unless on a stable dose for at least 3 months prior to 
screening*  and dose and regimen expected to remain 
constant during the treatment period.  Patients taking OTC 
omega-3 fatty acids should make every effort to remain on 
the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening*  
c. Systemic corticosteroids or anabolic steroids within 6 weeks 
prior to screening*  unless approved by [CONTACT_37956]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37618]) unless on a stable dose for at least 3 months prior 
to screening*  and dose and regimen expected to remain 
stable throughout the study  
e. Antihypertensive medication unless on a stable dose for at least 4 weeks prior to screening*  and dose and regimen 
expected to remain constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening*  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least 4 weeks 
prior to screening*  and regular clinical monitoring is 
performed  
h. Tamoxifen, estrogens or progestins unless on a stable dose 
for at least 4 months prior to screening*  and dose and 
regimen expected to remain constant during the treatment period  
i. Plasma apheresis within 4 weeks prior to screening*  or 
planned during the study  To define the 
exclusion 
criteria for each Group of patients and to 
make the 
eligibility criteria for the Group [ADDRESS_39008]  2016  
 
14  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:   
Study Population 
Continued  
5.2  Exclusion Criteria  
Continued  Exclusion Criteria  
Is: Continued  
j. Prior exposure to ISIS [ADDRESS_39009] 4 weeks prior to 
screening*  (Occasional or intermittent use of over -the-counter 
medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening*  or of 
> 499 mL within 60 days of screening*  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] 
(ISIS 304801 or placebo)  
17. Have any other conditions, including new  or worsening of existing 
condition , which, in the opi[INVESTIGATOR_37619], or could in terfere 
with the patient participating in or completing the study  
*(Group 3) or Qualification (Groups 1 and 2)  To define the 
exclusion 
criteria for each Group of patients and to 
make the 
eligibility criteria for the Group 3 patients 
consistent with 
those for the Group 1 index 
study patients .  
Protocol Synopsis:  
Study Visit Schedule and Procedures  
3.4  Overall Study 
Duration and Follow -up 
Appendix A  Was: 
The study for an individual patient will generally consist of the following 
periods:  
A qualification period of up to 2 weeks (unless approved by [CONTACT_429]).  Please refer to Section 4.[ADDRESS_39010] -treatment evaluation period  
 
Is:  
The study for an individual patient will generally consist of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or ISIS 304801-CS16 index study):  A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer 
to Section  4.1 and Appendix A . 
• Group 3 patients (did not participate in an index study):  An 
up to 8-week screening and qualification period, including a 
diet stabilization period of at least 6 weeks (screening and diet stabilizat ion period may be reduced, per Sponsor 
approval, if the patient is following a diet for optimal control of TGs and disease management prior to screening).  Please refer to Section 6.1.2 and Appendix A.  
• All patients:  
o A 52-week treatment period during which volanesorsen 
will be administered as a once weekly SC injection  
o A 13-week post -treatment evaluation period  To distinguish 
the Screening/  
Qualification 
period for patients who 
participated in 
an index study from those who 
did not . 
4.1  
Screening/Qualification  Group 3 (Screening and Qualification):  At the time of consent, the 
patient will be considered enrolled into the study and will be assigned 
a unique screening number before any study procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This 
number will be used to identify the patient throughout the trial and 
must be used on all study documentation related to that patient.  The screen ing number and patient identification number must remain 
constant throughout the entire trial.  In the event the patient is 
re-consented and re-screened the patient must be given a new 
screening number.  Screening numbers and patient identification 
numbers , once assigned, will not be re-used To define the 
enrollment 
criteria for patients who did not participate in an index study . 
ISIS [ADDRESS_39011]  2016  
 
15  Protocol Section  Description of Change  Rationale  
6.1.2  Screening and 
Qualification (Group 3)  Before any study -specific procedures or evaluations are initiated, 
patients must sign and date the informed consent form.  An 8-week period, including a diet stabilization period of at least 6  weeks 
(screening and diet stabilization period may be reduced, per Sponsor approval, if the patient is following a diet for optimal control of TGs and 
disease management prior to screening) is given to perform the 
screening evaluations.  The qualification assessments will be performed at Week -2 to -1, ideally after patient eligibility has been 
determined, and on Study  Day 1.  Abnormal screening results may be 
retested for review by [CONTACT_37957] . 
8.6.3   Stoppi[INVESTIGATOR_37620]: 
If after the first dosing rechallenge the platelet count again falls below 
75,000/mm3, then dosing of the patient must be held until the platelet 
count again returns to at least 100,000/mm3.  The suitab ility of the 
patient for continued dosing and the need for any further modification 
to treatment schedule or dose (refer to Section 8.7) will be re -
examined by [CONTACT_37958] (at least) the factors mentioned above.  
If after the second rechallenge the platelet count falls below 
75,000/mm3 and is subsequently confirmed (see Section 8.5), dosing 
with volanesorsen will be stopped permanently.  The follow -up 
schedule for any events meeting this stoppi[INVESTIGATOR_37621].  
 
Is: 
If after the first dosing rechallenge the platelet count again falls below 
75,000/mm3, then dosing of the patient with Study Drug will be 
stopped permanently.  Text was 
removed as a 
second Study  Drug 
rechallenge will 
not be allowed 
following a platelet count decrease below 75,000/mm
3. 
8.6.3   Stoppi[INVESTIGATOR_37622] 2  Actions in 
Patients with Low 
Platelet Count  Platelet C ount  
on Rx  Drug Dose Monitoring  
Normal range, 
> 140K/mm3 No action  Monitor every 2 weeks  
100K -
140K/mm3 No action  Closer observation  
Monitor every  
1-week  until 
stable*  
75K-100K/mm3 Permanently  reduce 
dose frequency to 300mg every 2 weeks or reduce dose to 
150 mg weekly  Closer observation  
Monitor every 
1-week  
 To provide clarification to 
the platelet 
safety 
monitoring rules . 
 
Note:  Changes 
are reflected as bold underlined text. 
  
ISIS [ADDRESS_39012]  2016  
 
16  Protocol Section  Description of Change  Rationale  
8.6.3 Stoppi[INVESTIGATOR_37623] 2  Actions in 
Patients with Low 
Platelet Count  
Continued  Platelet C ount 
on Rx  Drug Dose Monitoring  
50K-75K/mm3 If occurs while on 
dose of 300 mg every 
2 weeks or 150 mg 
every week then 
permanently 
discontinue Study 
Drug, otherwise dose 
pause.  
Dose pause  
When platelet count returns to >  100K/mm3 
restart dosing at dose 
frequency of 300 mg 
every 2 weeks or 
150 mg weekly only if 
approved by [CONTACT_37835] 2-3 days until 
2 successive 
values show 
improvement  
Consider discontinuation of 
antiplatelet 
agents/NSAIDS/  
anticoagulant 
medication  
25K-50K/mm3 
or a rate of 
decline ≥  50% 
between 2 consecutive 
assessments, 
irrespective of 
the platelet 
level Permanently 
discontinue Study Drug    Closer  observation  
Monitor daily until 2 successive 
values show improvement then monitor every 2 3 days until 
platelet count 
stable 
Discontinue 
antiplatelet agents/NSAIDS/an
ticoagulant 
medication while platelet count < 50K/mm
3 if 
possible  
 To provide 
clarification to 
the platelet 
safety 
monitoring rules  
 
Note:  Changes 
are reflected as bold underlined 
text 
  
ISIS [ADDRESS_39013]  2016  
 
17  Protocol Section  Description of Change  Rationale  
8.6.3 Stoppi[INVESTIGATOR_37623] 2  Actions in 
Patients with Low 
Platelet Count  
Continued  < 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count 
stable 
Steroids 
recommended* * 
Consider need for 
hospi[INVESTIGATOR_37624]/NSAIDS/anticoagulant 
medication while 
platelet count < 50K/mm
3 if 
possible  
* At least 3 consecutive values measured weekly that are 
stable as determined by [CONTACT_1034] M edical Monitor and 
> 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37959].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010) recommend Dexamethasone 
40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; Prednis(ol)one 
0.5-2 mg/kg/ d for 2 -4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days (note: may require continuation with oral 
steroids after methyl prednisolone)  To provide 
clarification to 
the platelet 
safety 
monitoring rules  
 
Note:  Changes 
are reflected as bold underlined 
text 
8.8.1  Follow -up Visits 
for Early Termination from Treatment Period  Was:  
Any patient who discontinues early from the Treatment Period should 
be strongly encouraged to attend applicable landmark visits at Weeks  
2, 13, 25, 26, and 51, 52 (calculated based on the time elapsed 
since Day 1) to collect fasting lipid panels and conduct safety assessments in accordance with the schedule of procedures in Appendix A.  Any patient who discontinues treatment after Week 44 should also be strongly encouraged to attend a final follow -up visit 
(Week 65 visit assessments) approximately [ADDRESS_39014]  2016  
 
18  Protocol Section  Description of Change  Rationale  
8.8.1  Follow -up Visits 
for Early Termination 
from Treatment Period 
Continued  Is: 
Any patient who discontinues early from the Treatment Period should 
be followed as per the platelet monitoring rules shown in Table [ADDRESS_39015] 6 weeks after discontinuing Study Drug.  Following this period, if  the platelet count is stable (a t least 
3 consecutive values that are stable as determined by [CONTACT_37859] >  100,000/mm
3), the next platelet count should 
be taken within at least [ADDRESS_39016] 12 weeks after discontinuing Study Drug.  Patients should also 
be strongly encouraged to attend applicable landmark visits at 
Weeks  12, 13, 25, 26, and 50, 52 (calculated based on the time 
elapsed since Day 1) to collect fasting lipid panels and conduct safety assessments in accordance with the schedule of procedures in 
Appendix A.  Any patient who discontinues treatment after Week 44 
should also be strongly encouraged to attend a final follow -up visit 
(Week 65 visit assessments) approximately [ADDRESS_39017] -Treatment 
Follow -up Period  Was:  
The patient who requests to withdraw from the study during the Post -
Treatment Follow -up Period should be encouraged to undergo a final 
follow -up visit (Week 65, see Appendix A) prior to leaving the study.  
 
Is: 
The patient who requests to withdraw from the study during the Post -
Treatment Follow -up Period should be encouraged to follow the 
platelet monitoring rules shown in Table [ADDRESS_39018] 
6 weeks after discontinuing Study Drug.   Following this period, if the 
platelet count is stable ( at least 3 consecutive values that are stable as 
determined by [CONTACT_37960] >  100,000/mm3), the 
next platelet count should be taken within at least [ADDRESS_39019] 12 weeks after discontinuing Study  Drug.  Patients should also be encouraged to undergo a final 
follow -up visit (Week 65, see Appendix A) prior to leaving the study.  To provide 
guidance to the platelet safety 
monitoring rules for patients that discontinue 
early from the 
Post-Treatment Follow -up 
Period. 
8.6.3  
Stoppi[INVESTIGATOR_37625] 2  
Actions in Patients with 
Low Platelet Count  Was:  
In the event of any platelet count less than 25,000/mm3, or a platelet 
count less  than 75,000/mm3 that occurs while the patient is on dosing 
at 300 mg every 2 weeks or 150 mg every week, then dosing of a patient with volanesorsen  will be stopped permanently . 
 
Is: 
In the event of any platelet count less than 50,000/mm3, or a rate of 
decline ≥ 50% between two consecutive assessments, irrespective of 
the platelet level,  then dosing of a patient with volanesorsen will be 
stopped permanently . To follow 
guidance provided by [CONTACT_37961][INVESTIGATOR_37626] . 
Appendix A  Added to Footnote “ b”: 
In the event of any platelet count less than 50,000/mm3 or a rate of 
decline ≥  50% between two consecutive assessments, irrespective of 
the platelet level, then dosing of a patient with Study Drug 
(ISIS 304801 or placebo) will be stopped permanently.  To follow 
guidance 
provided by [CONTACT_37962][INVESTIGATOR_37627]  A. 
  
ISIS [ADDRESS_39020]  2016  
 
19  Protocol Section  Description of Change  Rationale  
Protocol Synopsis : 
Study Population  
5.2 
Exclusion Criteria   Exclusion Criteria  
Was:  
7. History of bleeding diathesis or coagulopathy or clinically -
significant abnormality in coagulation parameters at Screening 
 
Is: 
7. History of thrombocytopenia (platelet count <  100,000/mm3) or 
bleeding diathesis or coagulopathy or clinically -significant 
abnormality in coagulation parameters at Screening  To exclude 
patients with a 
history of 
thrombocytopeni
a because it sometimes seems to be 
associated with 
patients suffering from hyperchylomicro
nemia  
  
ISIS [ADDRESS_39021]  2016  
 
20  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_39022]-treatment evaluation period.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 
Groups 2 and 3 :  Patients must also meet the following criteria in order 
to enter  into the open-l abel s tudy:  
a. History of chylomicro nemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by [CONTACT_37898]:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1)  
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS  304801-CS16 index study   
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this open -label 
study  
4. Able and willing to participate in a 65-week study  
  
ISIS [ADDRESS_39023]  2016  
 
21  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in sexu al relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39024] 
dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_39025] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria  
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening*  
b. HbA1c ≥ 9.0% at Screening*  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of screening*  [with the 
exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the treatment period of the Study (with the exception of ± 10 units of insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening*  
4. History within 6 months of screening*  of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or unstable congestive cardiac failure requiring a change in medication or major  surgery within 3 months 
of screening*  
  
ISIS [ADDRESS_39026]  2016  
 
22  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria Continued  
5. Any of the following laboratory values at Screening*  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which 
case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_39027]  
• AST > 2.[ADDRESS_39028]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive  
test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening*  
d. LDL-C > 130 mg/dL at Screening*  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37547], would make the patient unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of thrombocytopenia (platelet count < 100,000/mm
3) or bleeding 
diathesis or coagulopathy or clinically -signifi cant abnormality in 
coagulation parameters at Screening*  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_39029] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been successfully 
treated  
12. Treatment with another investigational drug, biological agent, or device 
within 1-month of screening* , or 5 half -lives of investigational agent, 
whichever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
  
ISIS [ADDRESS_39030]  2016  
 
23  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria Continued  
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to screening*  and dose 
and regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
screening*  
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to 
screening*  unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least 3 months prior to screening*  and 
dose and regimen expected to remain stable throughout the study  
e. Antihypertensive medication unless on a stable dose for at least 
4 weeks prior to screening*  and dose and regimen expected to remain 
constant during the treatment  period  
f. Glybera gene therapy within 2 years prior to screening*  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least 4 weeks prior to 
screening*  and regular clinical monitoring is performed  
h. Tamoxifen, estrogens or progestins unless on a stable dose for at 
least 4 months prior to screening*  and dose and regimen expected to 
remain constant during the treatment period  
i. Plasma apheresis within 4 weeks prior to screening*  or planned 
during the study  
j. Prior exposure to ISIS [ADDRESS_39031] 4 weeks prior to 
screening*  (Occasional or intermittent use of over -the-counter 
medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening*  or of 
> 499 mL within 60 days of screening*  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or placebo)  
17. Have any other conditions, including new  or worsening of existing 
condition , which, in the opi[INVESTIGATOR_37548], or could interfere with the patient participating in or completing the study  
*(Group 3) or Qualification (Groups 1 and 2)  
Treatment Group  Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
  
ISIS [ADDRESS_39032]  2016  
 
24  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a subset of patients with 
FCS.  The same dose of [ADDRESS_39033] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study) :  A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]) .  Please refer to 
Section 4.1 and Appendix A  
• Group 3 patients (did not participate in an index study) :  An up to 
8-week screening and qualification period, including a diet 
stabilization period of at least 6 weeks  (screening and diet 
stabilization period may be reduced, per Sponsor approval, if the 
patient is following a diet for optimal control of TGs and disease 
management prior to screening) .  Please refer to Section 6.1.2  and 
Appendix A  
• All patients:  
o A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
o A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_39034] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed  for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39035]  2016  
 
25  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37840] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laborator y and 
other safety parameters.  
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during 
the treatment per iod 
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB] , high -
density lipoprotein- cholester ol (HDL -C), apolipoprotein A -1 [apoA-1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS [ADDRESS_39036]  2016  
 
26  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
SCREENING PERIOD  
Weeks -8 to -2 (Group  3 patients only)  
QUALIFICATION  
PERIOD 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks [ADDRESS_39037]  2016  
 
27  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39038]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39039] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39040]  2016  
 
29  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis .  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37628] e dietary fat restriction (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering w ith 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancr eatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al.  2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: 
apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS [ADDRESS_39041]  2016  
 
30  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] 
(Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS [ADDRESS_39042]  2016  
 
31  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein profile and increased longevity (A tzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma TG have also been recently described (Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS [ADDRESS_39043]  2016  
 
32  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleot ides at  the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased  resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS [ADDRESS_39044]  2016  
 
33  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39045] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, 
drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on embryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS [ADDRESS_39046]  2016  
 
34  2.3.4 Clinical Experience  
Detailed information concerning the clinical stu dies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exp osures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an 
open- label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39047] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_39048]- treatment period and was not associated with platelet -related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the i njection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39049] Level ( NOAEL ) 
was defined by [CONTACT_37921] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in com bination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the diffe rent doses tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exce ed 
24 months ( Santos et al. 2015). 
ISIS [ADDRESS_39050]  2016  
 
36  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or  
ISIS 304801-CS16 index studies 
Up to approximately [ADDRESS_39051] of the following periods: 
3.4.1 Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification  
A period of up to 2 weeks  (unless approved by [CONTACT_1034]) is given to complete  qualification  
assessments outlined in the Schedule of Procedures.  Please refer to Section 4.1 and  Appendix A . 
3.4.2 Group 3 P atients (did not participate in an index study):  Screening/Qualification  
An up to 8- week screening and qualification period, including a diet stabilization period of at 
least 6 weeks  (screening  and diet stabilization period may be reduced, per Sponsor approval, if 
the patient  is following a diet for optimal control of TGs and disease management prior to 
screening.  Please refer to Section 6.1.2 and Appendix A. 
3.4.3 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule o f Procedures ( Appendix A).  During the treatment period, volane sorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_39052] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen , the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistic al analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Screening/ Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open- label study are performed .   
Groups 1 and 2 (Qualification):  During the qualification period, the eligibility of the patient to 
enroll in the open- label study will be determined .  Final assessments from the ISIS 304801-CS6 
or ISIS 304801-CS16 studies may be used for qualification .  A period of up to 2 weeks after 
completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  
identification number that was assig ned to them during the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies .  The patient identification number will be used to identify the 
patient  throughout the extension trial and must be used on all study documentation related to that 
patient .  The patient  identification number must remain constant throughout the extension trial. 
Group 3 (Screening and Qualification):  At the time of consent, the patient will be considered enrolled into the study and will be assigned a unique screening number before any study procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This number will be used to identify the patient throughout the trial and must be used on al l study documentation related to that patient.  
The screening number and patient identification number must remain constant throughout the entire trial.  In the event the patient is re -consented and re- screened the patient must be given a 
new screening num ber.  Screening numbers and patient  identification numbers, once assigned, 
will not be re -used. 
4.2 Enrollment  
Patient s will be enroll ed into the treatment phase of the study after all  Screening (Group3) and 
qualification assessments have been completed and after the Investigator has verified that they 
are eligible per criteria in Sections 5.1 and 5.2.  No patient  may begin treatment prior to 
enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
ISIS [ADDRESS_39053] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. 
 Groups 2 and 3:  Patients must also meet the following criteria in order to enter  into the 
open- label Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicrone mia Syndrome (Type 1 Hyperlipoproteinemia) 
by [CONTACT_37898]: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  
 ISIS 304801-CS16 index study 
Group 3:  F asting TG ≥ 750 mg/dL at Screening for this open -label study  
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Fema les:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory 
involved), abstinent *, or if engaged in sexual relations of child-bearing potential, 
patient is using an accept able contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39054] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
ISIS [ADDRESS_39055]  2016  
 
39  to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_39056] dose of Study Drug administration. 
* Abstinence is only acceptable as  true abstinence, i.e., when this is in line with the 
preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post-ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawa l are not acceptable methods of contraception  
5.2 Exclusion Criteria   
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening * 
b. HbA1c ≥ 9.0% at Screening*  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medication within 12 weeks of screening*  [with the exception of ± 10 units of 
insulin]) 
d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
e. Current use of GLP- 1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening*  
4. History within 6 months of screening*  of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack 
or unstable congestive cardiac failure requiring a change in medication or major surgery 
within 3 months of screeni ng* 
5. Any of the following laboratory values at Screening*  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and 
documentation of Gilbert’s syndrome in which case total bilirubin must be  ≤ 3 mg/dL 
• ALT > 2.[ADDRESS_39057] 
• AST > 2.[ADDRESS_39058]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine 
dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein measurement of <  500 mg/[ADDRESS_39059]  2016  
 
40  • Persistently positive (2 out of 3 consecutive tests ≥ trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with 
urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated creatinine clearance calculated a ccording to the formula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37629]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor) 
c. Cardiac Troponin I >  ULN at  Screening * 
d. LDL- C > 130 mg/dL at Screening*  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of thrombocytopenia (platelet count <  100,000/mm3) or bleeding diathesis or 
coagulopathy or clinically -significant abnormality in coagulation parameters at 
Screening*  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day [ADDRESS_39060] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix that has been successfully treated  
12. Treatment with another investigational drug, biological agent, or device within 1-month 
of screening* , or 5 half-lives of investigational agent, whi chever is longer  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable 
dose for at least 3 months prior to screening*  and dose and regimen expected to 
remain constant during the treatment period.  Patients taking OTC omega- 3 fatty 
acids should make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening* 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening*  
unless approved by [CONTACT_37963] [ADDRESS_39061]  2016  
 
41  d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least 3 months prior to screening*  and dose and regimen expected to 
remain stable throughout the study 
e. Antihypertensive medication unless on a stable dose for at least 4 weeks prior to 
screening*  and dose and regimen expected to remain constant during the tre atment 
period 
f. Glybera gene therapy within 2 years prior to screening* 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least 4 weeks prior to screening* and regular clinical monitoring is 
performed  
h. Tamoxifen, estrogens or progestins unless on a stable dose for at least 4 months prior 
to screening*  and dose and regimen expected to remain constant during the treatment 
period 
i. Plasma apheresis within 4 weeks prior to screening* or planned dur ing the study  
j. Prior exposure to ISIS [ADDRESS_39062] 4 weeks prior to screening*  (Occasional 
or intermittent use of over-the- counter medications will be allowed at Investigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of screening*  or of >  499 mL within 
60 days of screening*  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
17. Have any other conditions, including new or worsening of existing condition, which, in 
the opi[INVESTIGATOR_37556], or could interfere with the patient participating in or completing the study  
*(Group 3) or Qualification (Groups 1 and 2) 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, C, and D . 
6.1.1 Qualification  (Groups 1 and 2) 
Please refer to Section 4.1 and Appendix A. 
6.1.2 Screening and Qualification  (Group 3) 
Before any study -specific procedures or evaluations are initiated, patients must sign and date the 
informed consent form.  An 8-week period, including a diet stabilization period of at least 
ISIS [ADDRESS_39063]  2016  
 
42  6 weeks (screening and diet stabilization period may be reduced, per Sponsor approval, if the 
patient  is following a diet for optimal control of TGs and disease management prior to screening ) 
is given to perform the screening evaluations.  The qualification  assessments will be performed 
at Week -[ADDRESS_39064] patient’s Week [ADDRESS_39065]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunogenicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse 
events at the injection site should be collected as adverse events .  Dietary counseling will be 
reinforc ed at intervals throughout the treatme nt and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesorsen administration .  Blood sampling  at Week s 2.5, 
4, 6, 8, 10, 12, 15, 17, 19, 21, 23, 25, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, a nd [ADDRESS_39066] be fasted prior to drawing all blood samples and samples drawn locally should also 
be sent to the central laboratory for analysis  whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given 7 days prior to a scheduled clinic visit.  Dosing 
instructions and training will be provided to the patient where applicable. 
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.4 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extende d PK collection .  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_39067]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
ISIS [ADDRESS_39068]  2016  
 
43  withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_39069]- treatment evaluation period .  This period consists of 4 Study Center visits on Weeks 54, 56, 
and 58 (which may be conducted by a home healthcare nurse) , and Week [ADDRESS_39070] of these analytes  is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analy zed locally.  In the event that both the central and 
local sample are unreportable (e.g., due to hemolyzed or clumped blood samples ) another sample 
must be repeated within 1-week and determined not to have met a stoppi[INVESTIGATOR_37607].  
If there is no reportable platelet count within [ADDRESS_39071] the patient to hold dosing until a new platelet count is obtained and reviewed. 
All platelet count results will be promptly reviewed by [CONTACT_37964][INVESTIGATOR_37587] 75,000/mm3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate, respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (pr eferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
ISIS [ADDRESS_39072]  2016  
 
44  [IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 rollover patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment 
assignment.  
6.2.[ADDRESS_39073] 
5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, and 
Week 65 . 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767]. 
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_39074]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be mo nitored as follows: 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to provide diet/alcohol counseling for visits that are conducted by a clinical service. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post treatment follow -up periods. 
ISIS [ADDRESS_39075] refrain from sperm/egg donation and 
either be abstinent * or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_39076]’s last dose of study 
treatment.  
For the purposes of this Study , women of chil dbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patien ts must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partner s that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
ISIS [ADDRESS_39077]  2016  
 
46  *Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the patient.  Periodic abstinence (e.g.,  calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception  
6.3.[ADDRESS_39078] 10 hours and preferably not more than 12 hours 
before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39079] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39080] (ISIS 304801) characteristics are listed in  Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength 200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
ISIS [ADDRESS_39081]  2016  
 
47  7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on 
a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_39082] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug  Manual  provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ sectio n of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_39083] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
ISIS [ADDRESS_39084] monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical  and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37630] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confir mation of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may als o be initiated as noted in Section 8.7.  If any of the stoppi[INVESTIGATOR_37466] 
(refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with 
Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in  Section 8.[ADDRESS_39085] measurement that is > [ADDRESS_39086]  (or the greater of [ADDRESS_39087] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase to [ADDRESS_39088]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39089] (or 
the greater of [ADDRESS_39090] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_39091] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39092]  (or the greater of [ADDRESS_39093] if the baseline value was 
> ULN ), the following evaluations should be performed: 
ISIS [ADDRESS_39094]  2016  
 
49  1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV Ig M, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at  the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a patient ’s ALT and/or AST levels reach [ADDRESS_39095] . 
8.5.2 Safety Monitoring for Platelet Count Results  
Actions to be taken in the event of reduced platelet count are shown in Table 2  in Section 8.6.3. 
Additional lab tests will be determined by [CONTACT_37901] .  
Any case of a platelet count < 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_39096] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
ISIS [ADDRESS_39097]  2016  
 
50  to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin dose for patients  who are already on treatment).  
8.5.[ADDRESS_39098] 
practice guidelines and bring their glucometer  or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in th eir insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37609]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] 
≤ 70 mg/dL (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL (≤ 3.9 mmol/L).   The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]- treatment and which were thus thought to place 
patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessa ry does not qualify as “requires assistance.”  
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take immediate action to confirm the patient’s  glucose level and  treat the patient accordingly.  
ISIS [ADDRESS_39099] a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_39100] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or later and confirmed on subsequent testing (ideally within [ADDRESS_39101]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting pre- breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_39102] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
The threshold values are defined as: 
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (fo r patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually  measured in the fasting condition (i.e., after at least [ADDRESS_39103]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control 
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
ISIS [ADDRESS_39104]  2016  
 
52  If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of inte rcurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate act ion fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Sect ion 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_39105] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_39106] >  [ADDRESS_39107] , which is confirmed and persists for ≥ [ADDRESS_39108] >  [ADDRESS_39109] (or the greater of [ADDRESS_39110] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_39111]  or INR  > 1.[ADDRESS_39112] >  [ADDRESS_39113] (or the greater of [ADDRESS_39114] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37965] [ADDRESS_39115] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37966] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initia tion or follow-up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 2  below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any platelet count les s than 50,000/mm3, or a rate of decline ≥ 50% between two  
consecutive assessments, irrespective of the platelet level,  then dosing of a patient with 
volanesorsen will be stopped permanently.  Platelet count will be monitored daily until 
2 successive values  show improvement then monitored every 2-3 days until platelet count is 
stable.  
Administration of steroids is recommended for patients whose platelet count is less than 25,000/mm
3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:  may require continuation with oral steroids after methylprednisolone). 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks or a reduced dose of 150 mg per we ek (refer to Section 8.7) .  The suitability of the 
patient for continued dosing will be determined by [CONTACT_37879]’s platele t count, whether any bleeding events were experienced by [CONTACT_102], and the speed of 
recovery of platelet count upon holding of dosing. 
ISIS [ADDRESS_39116] dosing rechallenge the platelet count again falls below 75,000/mm3, then dosing 
of the patient with  Study Drug will be s topped permanently. 
Following a rechallenge platelet count should be tested every week until count is stable. 
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450].  
If there is no reportable platelet count within [ADDRESS_39117] the patient to hold dosing until a new platelet count is obtained and reviewed. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in h emoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis  
6. Bleeding after venipuncture for > [ADDRESS_39118]  2016  
 
55  Table 2 Actions in Patients with Low Platelet Count  
Platelet C ount on Rx  Drug Dose Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every 1-week  until stable*  
75K-100K/mm3 Permanently reduce dose frequency to 
300 mg every 2  weeks  or reduce dose to 
150 mg weekly  Closer observation  
Monitor every  1-week  
50K-75K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37967] 2-3 days until 2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/NSAIDS/  
anticoagulant medication  
25K-50K/mm3 or a rate of 
decline ≥  50% between 
two consecutive 
assessments, irrespective of 
the platelet level  Permanently discontinue Study Drug   Closer observation  
Monitor daily until 2 successive 
values show improvement then 
monitor every 2-3 days until 
platelet count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant  
medication while platelet count < 50K/mm3 if possible  
< 25K/mm3 Permanently discontinue Study Drug Closer observation:  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Steroids recommended* * 
Consider need for hospi[INVESTIGATOR_37590]/NSAIDS/anticoagulant 
medication while platelet count 
< 50K/mm
3 if possible  
* At least 3 consecutive values measured weekly  that are stable as determined by [CONTACT_37906] > 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 w eeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methyl  prednisolone)  
 
8.[ADDRESS_39119] be made in accordance with Section 8.6.3 and 
Table 2  (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability .  Any proposed adjustment to treatment 
ISIS [ADDRESS_39120] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39121] 6 weeks after 
discontinuing Study Drug.  Following this period, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_37683] 
> 100,000/mm
3), the next platelet count should be taken within at least [ADDRESS_39122] 12  weeks after discontinuing Study Drug .  Patients  should also be 
strongly encouraged to attend applicable landmark visits at Week s 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and conduct 
safety assessments in accordance with the S chedule o f Procedures in Appendix A .  Any patient 
who discontinues treatment after  Week 44 should also be strongly encouraged to attend a final 
follow-up visit ( Week 65 visit assessments) approximately [ADDRESS_39123] dose of 
Study Drug , in addition to the applicable landmark visits . 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_39124] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_39125]  2016  
 
57  Patients  should also be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A ) 
prior to leaving the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39126] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion  of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdraw al.  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of reque st.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to com plete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_39127] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega- [ADDRESS_39128]  2016  
 
58  Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti-diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non -prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_39129] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements will be followed in accordance wit h local country 
regulations and guidelines. 
ISIS [ADDRESS_39130]  2016  
 
59  Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedite d manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 3 Expected Event for the Protocol Defined Population by [CONTACT_37889] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected  and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37932] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.[ADDRESS_39131]  2016  
 
60  A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility th at 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of e ither the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE 
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important me dical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_39132] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
ISIS [ADDRESS_39133] the patient ’s last protocol- specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Event s 
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week 65 visit.  
The Investigator will monitor each  patient  closely and recor d all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
ISIS [ADDRESS_39134]  2016  
 
62  • Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Vo lanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non-serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following:  
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
ISIS [ADDRESS_39135]  2016  
 
63  • Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.4.4 Adjudication  Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter .  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_39136] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -signif icant  (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37483] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
ISIS [ADDRESS_39137]  2016  
 
64  • The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_39138] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional [ADDRESS_39139]  2016  
 
65  10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are 
defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.[ADDRESS_39140]  2016  
 
66  10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39141] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who  are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_39142] 1 evaluable PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_39143] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in t he ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline for safety will be the last non- missing assessment prior to the first dose of Study Drug . 
10.[ADDRESS_39144] patient’s Week [ADDRESS_39145] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for c ategorical 
variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoi nts will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be assessed in the PK Set as applicable.  
ISIS [ADDRESS_39146]  2016  
 
67  10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_37942].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echoc ardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_37948].  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, 
Month 6, and Month [ADDRESS_39147]  2016  
 
68  The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be  summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification for Group 1 and 2 patients by [CONTACT_37949]  304801- CS6 and ISIS 304801-CS16 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single- dose PK) or multiple doses (i.e., 
steady -state PK), depending on their earlier treatment in the index studies (Group 1 and 2 
patients) .  On Week 1  Day 1 of the open- label study, patients who received placebo in the index 
study (and all patients in Group 3) will receive the first treatment of volanesorsen (single -dose 
PK), while  patients who received volanesorsen in the index studies had been on volanesorsen 
treatment for 12 months (ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data 
collected from these patients reflect steady -state PK .  The maximum observed drug 
concentration (C max) and the time taken to reach C max (Tmax) will be obtained directly from the 
concentration -time data .  Area under the plasma concentration -time curve from time zero to 
24 hours ( AUC 0-24hr) will be calculated using the linear trapezoidal rule.  Apparent systemic 
(plasma) clearance after SC administration (CL 0-24hr /F0-24hr) will be calculated from  
CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean residence time (MRT) from time zero to 
24 hours after the SC administration  will be calculated from the equation,  
MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the  moment plasma 
concentration -time curve from time zero to [ADDRESS_39148]. 
Plasma PK parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_37732] 304801 -CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
ISIS [ADDRESS_39149]  2016  
 
69  listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable 
patients, along with the study day a ssociated  with the first positive IM status emerged (T first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the duration of ADA 
response (number of days between T first and T last) if appropriate , the last ADA sample collectio n 
day, and subject - peak titer if applicable, will be listed by [CONTACT_37950] 304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day.  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized  as the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable,  
will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., % chang e in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
  
ISIS [ADDRESS_39150] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form m ust be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_39151] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
ISIS [ADDRESS_39152] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_39153].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi [INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Stu dy Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
ISIS [ADDRESS_39154]  2016  
 
72  No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the I nvestigat or wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_39155], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug sto rage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and a grees with the content.  
12.[ADDRESS_39156] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS [ADDRESS_39157]  2016  
 
73  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve path way for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions  by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Ap r; 5(4): 279 -291. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washingt on, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaud et D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces  plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther  2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS [ADDRESS_39158]  2016  
 
74  Ito Y, Azrolan N, O'Connell A, et al. Hyper triglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486]. Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ , Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lip oprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Duf our S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al. ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee o n Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Ac ta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and r isk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling  in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37968]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_39159]  2016  
 
76   
  
 
  
 
Appendix A  Schedule of Procedures 
 
 
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol - [LOCATION_009] 19 Augus t2016
 
77  Appendix A Schedule of Procedures 
Study Period Screen/ 
Run Ina Quala Treatment Period Post Treatment 
Follow-up 
Study Week -8 to -2 -2 to -
1 Wk
1 Wk 
2.5Wk
4 Wk
6 Wk
8 Wk 
10Month 3 Wk 
15
&
17 Wk 
19 Wk 
21
&
23 Month 6 Wk 
28
& 
30 Wk
32 Wk 
34
&
36 Wk
38 Wk 
40 
& 
42 Wk
44 Wk 
46 
& 
48 Month 12 Wk 
54
&
56 Wk 
58Wk 
65 Wk
12 Wk
13 Wk 
25 Wk
26 Wk 
50 Wk 52
or ET 
Study Day -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99
&
113127141
&
155169 176190
& 
204 218232
&
246260274
&
288302316
& 
330344 358 372
&
386400 449 
Visit Window+/- Days 0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent X X                           
Outpatient Visit X X X XjXjXj Xj Xj XjXjX Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X Xj Xj X 
Inclusion/Exclusion Criteria X X                           
Vital Signs + body weight  
(+ height on Day 1 only) X X X   X  X   X     X    X     X   X 
Physical Examination X X X        X     X    X     X   X 
12- lead ECG (triplicate) X X         X     X    X     X   X 
MRI (liver/spleen) X                       Xk    
Echocardiography X              Xk         Xk    Blood Draw (Fasting)c Chemistry Panel X X X   X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialb X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel X X X   X  X  X X    X X    X    X X   X 
Coagulation (aPTT, PT, INR) X X      X   X     X    X     X    
hsCRP, HbA1c, FPG, and de-lipi[INVESTIGATOR_37489] X
n Xn X        X     X         X   X 
Sedimentation Rate   X        X     X         X   X 
Complement (C5a, Bb)   X        X     X         X   X 
Plasma PK - Volanesorsen   Xl X  X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies   X   X  X   X     X    X     X   X 
FSH (women only, if applicable) X X                           
Serum Pregnancy Testd X X    X  X   X  X   X  X  X  X   X  X X 
Archived Serum & Plasma Samples
e   X     X   X     X         X   X 
Troponin Io X X                           
 
ISIS [ADDRESS_39160]  2016  
 
78  Appendix A  Schedule of Procedures  Continued  
Study Period  Screen/  
Run Ina Quala Treatment Period  Post Treatment 
Follow -up 
Study Week  -8 to -2 -2 to -
1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Urinalysisc X X Xm   X  X   Xm  Xm   Xm  Xm  Xm  Xm   Xm  Xm Xm 
Fundus Photographyf X                       Xk    
Genetic testing for FCS 
diagnosis (if not available in medical history)g X                           
Weekly Study Drug:  SC Injection    X  X X X X X 
X X X X X X X X X X X X X X X X    
Symptom Diary (weekly)  X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)    X       
 X     X         X   X 
Food/Drink Diary (quarterly)h   X        X     X         X   X 
Diet/Alcohol Counselingi X X X   X  X   X     X    X     X  X X 
Adverse Events X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
a Screening (Group 3) and Qualification  procedures performed (Please refer to Section s 3.4, 4.1, and 6.1.2 ) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g. , due to hemolyzed or clumped blood samples) another sample must be repeated 
within 1-week  and determined not to have met a stoppi[INVESTIGATOR_10450].  If there is no reportable platelet count within [ADDRESS_39161] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37909][INVESTIGATOR_37604] 75,000/ mm3.  In the event of any platelet count less than 50,000/mm3 or a rate of decline ≥  50% 
between two consecutive assessments, irrespective of the platelet level, then dosing of a patient with Study Drug (ISIS 304801 or placebo) will be stopped 
permanently.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the Sponsor  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment [ADDRESS_39162] 10 hours and preferably not more than 12 hours.  During tre atment period urine and blood 
samples will be collected prior to Study Drug administr ation.  Does not apply to 24-hour PK blood draw 
d Females of childbearing potential only 
e Serum and plasma samples will be collected and stored for follo w-up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of ki dney function, measurement of anti bodies, etc.) in this or subs equent clinical studies of  
volanesorsen 
f If possible, fundus photography should be completed prior to  administration of the first dose of Study Drug (Group 2 [ISIS 30 4801-CS16 rollover patients] and 
Group 3) and repeated at Week 52 (Please refer to Section [IP_ADDRESS] ) 
g Genetic testing can be conducted for stud y qualification (Group 2 [ISIS 304801-CS16  rollover patients] and Group 3); genetic testing will only be conducted if 
allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing 
h In addition to diary, patients will be contact[CONTACT_37969] s during the study to review their current eating and drinking habits 
i To reinforce compliance to the diet and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be pe rformed by [CONTACT_37828] 
j Assessments and procedures to be conducted by [CONTACT_5640] a home he althcare nurse, or the Study Cent er as arranged by [CONTACT_37970] 
k A ± 7-day window is allowed for MRI, echocardiography procedures and fundus photography l Full or abbreviated PK profile (see Appendix C ) 
m Expanded urinalysis (see Appendix B) n HbA1c only o All abnormal troponin samples will be rerun at t he central laboratory and also analyzed for CK-MB 
 
ISIS [ADDRESS_39163] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_39164]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_39165]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_39166] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June [ADDRESS_39167]  2016  
 
87  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 Adverse Event Mild Moderate Severe 
Urine 
Prote inuria 
Adults 1 + prote inuria; 2+ prote inuria; Urinary prote in g/24 hrs; urinary protein < 1.0 g/24 hrs urinary protein 1.0 - 3.4 g/24 hrs; 
Children -Urine PIC (Protein /Creat inine) Urine P/C >1.9 ratio 0.5 - 1.9 
Gross hema turia; transfusion, 
Asymp tomatic; clinical or diagnostic IV medications or 
Symp tomat ic; urina ry cathe ter or hospi[INVESTIGATOR_37591] ; Hematur ia observat ions only; interven tion not bladder irrigation indicated elective endoscop ic, radiologic indicated or operat ive intervention 
indicated 
tGrading for this paramete r is derived from the Toxicity Grad ing Scale for Healthy Adult and Adol escent Volun teers Enrolled in 
Preventi ve V accine Clinical Trials, Sept 2007 
*Grading for this parameter is derived from the Division of AIDS (DAIDS) Table for Grad ing the Seve rity of Adult and Pediatric 
Adverse Events Version 2.0, Nov 2014 
tModifi ed for consistency with the ADA and Endocrine Society Guidelines (Seaqu ist ER, Anderson J, Childs B, et al. 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Associa tion and The Endocrine Society. 
Diabetes Care 2013 ;36: 1384 -95) 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc. 
[ADDRESS_39168] Carlsbad, CA  [ZIP_CODE] Collaborator:
Akcea Therapeutics
[ADDRESS_39169]
Cambridge, MA [ZIP_CODE]
 
 
ISIS 304801-CS7 
 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients wi th Familial Chylomicronemia 
Syndrome (FCS) 
 
Protocol Amendment 5 – [ADDRESS_39170] No:  2015-003755-21  
 
 
 

ISIS 304804-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
2   
 
ISIS 304801-CS7 
 
The APPROACH Open-Label Study 
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients wi th Familial Chylomicronemia 
Syndrome (FCS) 
 
Protocol Amendment 5 – 6 July 2016 
  
Protocol History: 
Original Protocol:  [ADDRESS_39171] 2015 
Protocol Amendment 1: 2 February 2016 
Protocol Amendment 2: 22 April 2016 
Protocol Amendment 3: 9 May 2016 Protocol Amendment 4: 6 June 2016 
 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_39172] Carlsbad, CA  [ZIP_CODE] 
______________________ 
MD, MBA 
 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_39173] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open -Label Study  
Volanesorsen (ISIS 304801)  
An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_39174] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:   [CONTACT_37829].D.  
[ADDRESS_39175] 
Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator:  Akcea Therapeutics  
[ADDRESS_39176] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_39177] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open- Label Study of Volanesorsen  Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Amendment:  Amendment 5 
Date:    [ADDRESS_39178] read and understand the attached clinical protocol , entitled “An 
Open -Label Study of Volanesorsen  Administered Subcutaneously to Patients with Familial 
Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_39179] the study as 
described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharm aceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................18  
STUDY DESIGN AND TREATMENT SCH EMA  ...................................................................24  
STUDY GLOSSARY  ...................................................................................................................25  
1. OBJECTIVES  .....................................................................................................................27  
2. BACKGROUND AND RATIONALE  ..............................................................................27  
2.1 Overview of Disease  ......................................................................................................27  
2.2 Therapeutic Rationale  ....................................................................................................28  
2.3 Volanesorsen  ..................................................................................................................29  
2.3.1  Mechanism of Action  .............................................................................................29  
2.3.2  Chemistry  ...............................................................................................................30  
2.3.3  Preclinical Experience  ............................................................................................31  
2.3.4  Clinical Experience  ................................................................................................32  
2.4 Rationale for Dose and Schedule of Administration .....................................................33  
3. EXPERIMENTAL PLAN  ..................................................................................................34  
3.1 Study Design ..................................................................................................................34  
3.2 Number o f Study Centers ..............................................................................................34  
3.3 Number of Patients  ........................................................................................................34  
3.4 Overall Study Duration and Follow- up .........................................................................34  
3.4.1  Group 1 and 2 Patients (participated in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification ....................................................................................34  
3.4.2  Group 3 Ppgatients (did not participate in an index study):  Screening/Qualification  ..........................................................................................[ADDRESS_39180] ................................................................................35  
4. PATIENT ENROLLMENT  ...............................................................................................35  
4.1 Screening/Qualification  .................................................................................................35  
4.2 Enrollment .....................................................................................................................35  
5. PATIENT ELIGIBILITY  ..................................................................................................36  
5.1 Inclusion Criteria  ...........................................................................................................36  
5.2 Exclusion Criteria for Group 1 (ISIS 304801-CS6) and Group 2 (ISIS 304801-CS16) 
Index Study Roll -over Patients  ......................................................................................37  
6. STUDY PROCEDURE S ....................................................................................................40  
6.1 Study Schedule ..............................................................................................................40  
6.1.1  Qualification (Groups 1 and 2) ...............................................................................40  
6.1.2  Screening and Qualification (Group 3)  ..................................................................40  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
6  6.1.3  Treatment Period  ....................................................................................................40  
6.1.4  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_39181]-Treatment Period  ............................................................................................41  
6.2 Additional Study Assessments .......................................................................................41  
6.2.1  Laboratory Assessments .........................................................................................41  
6.2.2  Physical Exams and Vital Signs  .............................................................................41  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................42  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_39182]- Treatment Follow -up Period  .54 
8.9 Withdrawal of Patients from the Study  ..........................................................................55  
8.10  Concomitant Therapy and Procedures ...........................................................................55  
8.10.1  Concomitant Therapy .............................................................................................55  
8.10.2  Concomitant Procedures .........................................................................................56  
8.11  Treatment Compliance  ...................................................................................................56  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................56  
9.1 Sponsor Review of Safety Information .........................................................................56  
9.2 Regulatory Requirements  ..............................................................................................56  
9.3 Definitions  .....................................................................................................................57  
9.3.1  Adverse Event ........................................................................................................57  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................57  
9.3.3  Serious Adverse Event (SAE)  ................................................................................58  
9.4 Monitoring and Recording Adverse Events  ...................................................................58  
9.4.1  Serious Adverse Events  ..........................................................................................58  
9.4.2  Non-Serious Adverse Events ..................................................................................59  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................59  
[IP_ADDRESS]  Relationship to the Study Drug  ........................................................................59  
[IP_ADDRESS]  Severity  ............................................................................................................59  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................60  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................60  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................60  
9.4.4  Adjudication Committees  .......................................................................................61  
9.5 Procedures for Handling Special Situations ..................................................................61  
9.5.1  Abnormalities of Laboratory Tests .........................................................................61  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments ............61  
9.5.3  Dosing Errors  .........................................................................................................62  
9.5.4  Contraception and Pregnancy .................................................................................62  
10. STATISTICAL CONSIDER ATIONS  ..............................................................................63  
10.1  Study Endpoints .............................................................................................................63  
10.1.1  Efficacy Endpoints .................................................................................................63  
10.1.2  Safety Endpoints .....................................................................................................63  
10.2  Sample Size  ....................................................................................................................63  
10.3  Populations .....................................................................................................................64  
10.4  Definition of Baseline ....................................................................................................64  
10.5  Interim Analysis  .............................................................................................................64  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
8  10.6  Planned Methods of Analysis ........................................................................................64  
10.6.1  Demographic and Baseline Characteristics  ............................................................65  
10.6.2  Safety Analysis  .......................................................................................................65  
10.6.3  Efficacy Analysis  ...................................................................................................65  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................66  
[IP_ADDRESS]  Pharmacokinetic Analysis ................................................................................66  
[IP_ADDRESS]  Immunogenicity Analysis ................................................................................66  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_39183] of the Study .........................................................................................67  
11.3  Independent Ethics Committee/Institutional Review Board .........................................[ADDRESS_39184] of Laboratory Analytes  .............................................................................78  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................80  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities ......82  
 
TABLE OF TABLES  
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics  ................................................................ 45  
Table 2  Actions in Patients With Low Platele t Count ............................................................... 53  
Table 3  Expected Event for the Protocol Defined Population by [CONTACT_37935] ................................................................................................. 57  
 
TABLE OF FIGURES  
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 28  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown  ................................... 30  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  .............. 32   
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
9  PROTOCOL AMENDMENT 
 
Protocol Number: ISIS 304801-CS7 
Protocol Title: An Open-Label Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 
Amendment Number:  5 
Amendment Date: 6 July 2016 
 
The purpose of this protocol amendment is to imp lement the following modifications to Protocol 
ISIS 304801-CS7 Amendment 4 dated 6 June 2016: 
1. To enroll FCS patients in this open la bel study who did not participate in the 
ISIS 304801–CS6 or ISIS 304801–CS16 index studies. 
For clarity, the protocol now specifies 3 patient groups, with assignment based on prior 
involvement in index studies of ISIS 304801: 
Group 1:  ISIS 304801-CS6 (index study) rollover FCS patients 
Group 2:  ISIS 304801-CS16 (index study) rollover FCS patients 
Group 3:  FCS patients who did not pa rticipate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies 
2. To remove language that indicates that li poprotein lipase (LPL) activ ity can be measured 
if needed for study qualification for patients in Groups 2 and 3. 
3. To add language to indicate that a second Study Drug rech allenge will not be allowed 
following a platelet co unt decrease below 75,000/mm3. 
4. To provide clarifications to the platelet safety monitoring rules in Table 2. 
5. To add language to indicate that patients who discontinue  early from Study Drug, or the 
study, should be followed as per the platelet monitoring rules shown in Table [ADDRESS_39185] 12 weeks after discontinuing Study Drug. 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
The following table  provides a summary list of major changes to the protocol: 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
10  Protocol Section  Description of Change  Rationale  
Protocol Title pages  
Signature [CONTACT_38021] :  
Title, Study Population,  
Rationale for Dose and 
Schedule Selection, 
Study Visit Schedule 
and Procedures, Statistical 
Considerations  
5.1  Inclusion Criteria “Extension” was removed from the study title  To note that 
FCS patients 
who did not 
participate in an index study will 
also be enrolled  
Protocol Synopsis:  
Study Design  
3.1  Study Design  Was: 
This is a multi -center open- label extension study of ISIS 304801-CS6 
and ISIS 304801-CS16 
 
Is: 
This is a multi -center open- label study of:  
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients  
Group 3:  FCS patients who did not participate in the  
ISIS 304801-CS6 or ISIS 304801-CS16 index studies  To distinguish 
patients who 
participated in 
an index study 
from those who 
did not  
Protocol Synopsis:  
Study Population  
5.1  Inclusion Criteria Was: 
3. Satisfactory completion of ISIS 304801-CS6 or ISIS 304801- CS16 
(index studies) with an acceptable safety profile, per Sponsor and 
Investigator judgement.  Patients who are enrolled in ISIS 304801-CS16 must also meet the following criteria in order to 
enter into the Extension Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37971] (a creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL 
(10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by [CONTACT_37972] 1 of the 
following:  
• Confirmed homozygote, compound heterozygote or double heterozygote for known loss -of-function mutations 
in Type 1-causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-CS16 study  To define the 
inclusion criteria 
for each Group 
of patients  
LPL removed to 
avoid the 
production of 
heparin induced anti-platelet 
antibodies  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
11  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:  
Study Population 
Continued  
5.1  Inclusion Criteria 
Continued  Is: Continued  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or 
ISIS 304801-CS16 (index studies) with an acceptable safety profile, per Sponsor and Investigator judgement.  
 
Groups 2 and 3:  Patients must also meet the following criteria in 
order to enter into the open-label study:  
a. History of chylomicronemia as evidenced by [CONTACT_37973] (a creamy top layer after ultracentrifugation of a fasting blood sample) or 
documentation of fasting TG measurement ≥ 880 mg/dL 
(10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37898]:  
• Confirmed homozygote, compound heterozygote or 
double heterozygote for known loss -of-function mutations 
in Type 1-causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening 
for the ISIS  304801-CS16 index study  
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for this 
open-label study  To define the 
inclusion criteria 
for each Group of patients  
LPL removed to 
avoid the 
production of heparin induced anti-platelet 
antibodies 
Continued  
Protocol Synopsis:   
Study Popu lation  
5.2  Exclusion Criteria  Was: 
Exclusion Criteria  
1. Have any new condition or worsening of existing condition which 
in the opi[INVESTIGATOR_37601], or could interfere with the patient participating  in or completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of 
the study (Section 6.3)  
 
Is: 
Exclusion Criteria for Group 1 (ISIS 304801-CS6) and Group 2 
(ISIS 304801-CS16) I ndex Study Roll-over Patients 
1. Have any new condition or worsening of existing condition which 
in the opi[INVESTIGATOR_37631], or could interfere with the patient 
participating in or completing the study  
2. Unwilling to comply with lifestyle requir ements for the duration of 
the study (Section 6.3)  
 
Exclusion Criteria for Group 3 (patients who did not participate in 
an index study)  
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening 
c. Recent change in anti -diabetic pharmacotherapy (change in 
dosage or addition of new medication within 12 weeks of screening [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during 
the treatment  period of the Study [with the exception of 
± 10 units of insulin]  
e. Current use of GLP -1 agonists
 To define the exclusion criteria for each 
Group of patients and to make the 
eligibility criteria 
for the Group 3 patients consistent with those for the 
Grou p 1 index 
study patients  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
12  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:   
Study Population 
Continued  
5.2  Exclusion Criteria  
Continued  Is: Continued  
Exclusion Criteria for Group 3 (patients who did not participate in 
an index study)  
2. Severe hypertriglyceridemia other than due to familial 
chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
4. History within 6 months of screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack or unstable congestive cardiac failure requiring a change in medication or major surgery within 3 months of screening  
5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in 
which case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_39186]  
• AST > 2.[ADDRESS_39187]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) 
for protein on urine dipstick.   In the event of a positive 
test eligibility may be confirmed by a quantitative total urine protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a 
positive test eligibility may be confirmed with urine microscopy showing ≤  5 red blood cells per high power 
field 
• Estimated creatinine clearance calculated according to 
the formula of Cockcroft and Gault <  50 mL/min (MDRD 
or CKD -EPI [INVESTIGATOR_37446] -
Gault for estimation of GFR in patients with low body 
weight after discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening  
d. LDL-C > 130 mg/dL at Screening  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37547], would make the patient 
unsuitable for inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or clinically -
significant abnormality in coagulation parameters at Screening 
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial 
therapy that will not be completed prior to Study Day [ADDRESS_39188] for human immunodeficiency 
virus (HIV), hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell 
carcinoma of the skin or carcinoma in situ  of the cervix that has 
been successfully treated  
12. Treatment with another investigational drug, biological agent, or 
device within 1- month of screening, or 5 half -lives of 
investigational agent, whichever is longer  
13. Unwilling to comply with lifestyle requirements (Section 6.3)  To define the 
exclusion 
criteria for each Grou p of 
patients and to 
make the 
eligibility criteria for the Group 3 patients 
consistent with 
those for the Group 1 index study patients 
Continued  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
13  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:   
Study Population 
Continued  
5.2  Exclusion Criteria  
Continued  Is: Continued  
Exclusion Criteria for Group 3 (patients who did not participate in 
an index study)  Continued  
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or 
fibrates unless on a stable dose for at least 3 months prior to 
screening and dose and regimen expected to remain 
constant during the treatment period.  Patients taking OTC 
omega-3 fatty acids should make every effort to remain on 
the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks 
prior to screening  
c. Systemic corticosteroids or anabolic steroids within 6 weeks 
prior to screening unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapin e and 
clozapi[INVESTIGATOR_050]) unless on a stable dose for at least [ADDRESS_39189] 4 weeks prior to screening and dose and regimen 
expected to remain constant during the treatment period  
f. Glybera gene therapy within 2 years prior to screening  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, 
and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_39190] 4 weeks prior to 
screening (Occasional or intermittent use of over -the-counter 
medications will be allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening or of 
> 499 mL within 60 days of screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37632], or could interfere with the patient participating in or completing the study  To define the 
exclusion 
criteria for each 
Group of 
patients and to make the eligibility criteria 
for the Group 3 
patients consistent with those for the Group 1 index 
study patients 
Continued  
Protocol Synopsis:  
Study Visit Schedule 
and Procedures  
3.4  Overall Study 
Duration and Follow -up 
Appendix A  Was: 
The study for an individual patient will generally consist of the following 
periods:  
A qualification period of up to 2 weeks (unless approved by [CONTACT_429]).  Please refer to Section 4.[ADDRESS_39191] -treatment evaluation period  To distinguish 
the Screening/  
Qualification 
period for patients who 
participated in 
an index study from those who 
did not  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
14  Protocol Section  Description of Change  Rationale  
Protocol Synopsis:  
Study Visit Schedule 
and Procedures  
Continued  
3.4  Overall Study 
Duration and Follow -up 
Continued  
Appendix A  Continued  Is: Continued  
The study for an individual patient will generally consist of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or ISIS 304801-CS16 index study):  A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer 
to Section  4.1 and Appendix A . 
• Group 3 patients (did not participate in an index study):  An up to 8-week screening and qualification period, including a diet stabilization period of at least 6 weeks (screening and diet stabilization period may be reduced, per Sponsor 
approval, if the patient is following a diet for optimal control  of 
TGs and disease management prior to screening).  Please 
refer to Section 6.1.2 and Appendix A.  
• All patients:  
o A 52-week treatment period during which volanesorsen 
will be administered as a once weekly SC injection  
o A 13-week post -treatment evaluation period  To distinguish 
the Screening/  
Qualification period for 
patients who participated in an index study 
from those who 
did not  
Continued  
4.1  Screening /  
Qualification  Group 3 (Screening and Qualification):  At the time of consent, the 
patient will be considered enrolled into the study and will be assigned 
a unique screening number before any study procedures, including 
screening procedures, are performed.  At the time of enrollment, 
patients will be assigned a unique patient identification number.  Thi s 
number will be used to identify the patient throughout the trial and must be used on all study documentation related to that patient.  The 
screening number and patient identification number must remain 
constant throughout the entire trial.  In the event the patient is re-consented and re-screened the patient must be given a new screening number.  Screening numbers and patient identification numbers, once assigned, will not be re-used To define the 
enrollment 
criteria for 
patients who did 
not participate in 
an index study  
6.1.2  Screening and Qualification (Group 3)  Before any study -specific procedures or evaluations are initiated, 
patients must sign and date the informed consent form.  An 8-week period, including a diet stabilization period of at least 6  weeks 
(screening and diet stabilization period may be reduced, per Sponsor approval, if the patient is following a diet for optimal control of TGs and disease management prior to screening) is given to perform the 
screening evaluations.  The qualification assessments will be 
performed at Week -2 to -1, ideally after patient eligibility has been 
determined, and on Study  Day 1.  Abnormal screening results may be 
retested for review by [CONTACT_37974]  
8.6.3   Stoppi[INVESTIGATOR_37620]: 
If after the first dosing rechallenge the platelet count again falls below 75,000/mm3, then dosing of the patient must be held until the platelet 
count again returns to at least 100,000/mm3.  The suitability of the 
patient for continued dosing and the need for any further modification to treatment schedule or dose (refer to Section 8.7) will be re -
examined by [CONTACT_37975] (at least) the factors mentioned above.  
If after the second rechallenge the platelet count falls below 
75,000/mm3 and is subsequently confirmed (see Section 8.5), dosing 
with volanesorsen will be stopped permanently.  The follow -up 
schedule for any events meeting this stoppi[INVESTIGATOR_37633].  Text was removed as a 
second 
Study  Drug 
rechallenge will not be allowed 
following a 
platelet count decrease below 
75,000/mm
3 
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
15  Protocol Section Description of Change Rationale 
8.6.3  Stoppi[INVESTIGATOR_37634]: 
If after the first dosing rechallenge the platelet count again falls below 75,000/mm3, then dosing of the patient with Study Drug will be 
stopped permanently. Text was removed as a second 
Study Drug 
rechallenge will 
not be allowed 
following a 
platelet count 
decrease below 
75,000/mm
3  
8.6.3  Stoppi[INVESTIGATOR_37635] 2  Actions in 
Patients with Low 
Platelet Count Platelet Count 
on Rx Drug Dose Monitoring 
Normal range, 
> 140K/mm3 No action Monitor every 2 weeks 
100K-140K/mm3 No action Closer observation 
Monitor every  
1-week until 
stable*  
75K-100K/mm3 Permanently  reduce 
dose frequency to 
300mg every 2 weeks 
or reduce dose to 
150 mg weekly Closer observation 
Monitor every 
1-week 
50K-75K/mm3 If occurs while on 
dose of 300 mg every 
2 weeks or 150 mg 
every week then 
permanently 
discontinue Study 
Drug, otherwise dose 
pause. 
Dose pause 
When platelet count 
returns to > 100K/mm3 
restart dosing at dose frequency of 300 mg 
every 2 weeks or 150 mg weekly only if 
approved by [CONTACT_37976] 
2-3 days until 
2 successive 
values show 
improvement 
Consider 
discontinuation of 
antiplatelet 
agents/NSAIDS/ 
anticoagulant 
medication 
 To provide 
clarification to 
the platelet 
safety 
monitoring rules 
 Note:  Changes 
are reflected as 
bold underlined 
text 
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
16  Protocol Section Description of Change Rationale 
8.6.3 Stoppi[INVESTIGATOR_37636] 2  Actions in 
Patients with Low 
Platelet Count Continued Platelet Count 
on Rx Drug Dose Monitoring 
25K-50K/mm3 If occurs while on dose of 300 mg every 2 weeks or 150 mg 
every week then 
permanently 
discontinue Study 
Drug, otherwise dose 
pause. 
When platelet count 
returns to > 100K/mm
3 
restart dosing at dose frequency of 300 mg 
every 2 weeks or 
150 mg weekly only if 
approved by [CONTACT_37977] 
2 successive 
values show 
improvement then 
monitor every 
2 3 days until 
platelet count 
stable 
Discontinue 
antiplatelet 
agents/NSAIDS/an
ticoagulant 
medication while 
platelet count 
< 50K/mm3 if 
possible 
< 25K/mm3 Permanently discontinue Study Drug Closer observation: 
Monitor daily until 
2 successive 
values show 
improvement then 
monitor every 
2-3 days until 
platelet count 
stable 
Steroids 
recommended** 
Consider need for 
hospi[INVESTIGATOR_37637]/NSAIDS/an
ticoagulant 
medication while 
platelet count 
< 50K/mm3 if 
possible 
* At least 3 consecutive values measured weekly that are 
stable as determined by [CONTACT_37683] 
> 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37959].  Treatment guidelines for immune thrombocytopenia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2-4 weeks for 
1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2-4 weeks then taper; 
or Methylprednisolone 30 mg/kg/day for 7 days (note: may require 
continuation with oral steroids after methyl prednisolone) To provide 
clarification to the platelet 
safety 
monitoring rules 
 
Note:  Changes 
are reflected as 
bold underlined 
text 
Continued 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
17  Protocol Section  Description of Change  Rationale  
8.8.1  Follow -up Visits 
for Early Termination 
from Treatment Period  Was:  
Any patient who discontinues early from the Treatment Period should 
be strongly encouraged to attend applicable landmark visits at Weeks  
2, 13, 25, 26, and 51, 52 (calculated based on the time elapsed 
since Day 1) to collect fasting lipid panels and conduct safety 
assessments in accordance with the schedule of procedures in Appendix A.  Any patient who discontinues treatment after Week 44 should also be strongly encouraged to attend a final follow -up visit 
(Week 65 vis it assessments) approximately [ADDRESS_39192] 
dose of Study Drug, in addition to the applicable landmark visits.  
 
Is: 
Any patient who discontinues early from the Treatment Period should 
be followed as per the platelet monitoring rules shown in Table [ADDRESS_39193] 6 weeks after discontinuing Study Drug.  Following this period, if  the platelet count is stable (a t least 
3 consecutive values that are stable as determined by [CONTACT_37859] >  100,000/mm3), the next platelet count should 
be taken within at least [ADDRESS_39194] 12 weeks after discontinuing Study Drug.  Patients should also be strongly encouraged to attend applicable landmark visits at 
Weeks  12, 13, 25, 26, and 50, 52 (calculated based on the time 
elapsed since Day 1) to collect fasting lipid panels and conduct safety 
assessments in accordance with the schedule of procedures in Appendix A.  Any patient who discontinues treatment after Week 44 
should also be strongly encouraged to attend a final follow -up visit 
(Week 65 visit assessments) approximately [ADDRESS_39195] -Treatment 
Follow -up Period  Was:  
The patient who requests to withdraw from the study during the Post -
Treatment Follow -up Period should be encouraged to undergo a final 
follow -up visit (Week 65, see Appendix A) prior to leaving the study.  
 
Is: 
The patient who requests to withdraw from the study during the Post -
Treatment Follow -up Period should be encouraged to follow the 
platelet monitoring rules shown in Table [ADDRESS_39196] 
6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable ( at least 3 consecutive values that are stable as 
determined by [CONTACT_37960] >  100,000/mm3), the 
next platelet count should be taken within at least [ADDRESS_39197] 12 weeks after discontinuing Study  Drug.  Patients should also be encouraged to undergo a final 
follow -up visit (Week 65, see Appendix A) prior to leaving the study.  To provide 
guidance to the 
platelet safety 
monitoring rules 
for patients that discontinue early from the Post-Treatment 
Follow -up 
Period 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
18  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label  Study of Volanesorsen Administered Subcutaneously to 
Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study  Objective s To evaluate the safety and efficacy of dosing and extended dosing with 
volanesorsen (volanesorsen sodium 300 mg) in patients with FCS  
Study Design  This is a multi -center open- label study  of: 
Group 1:  ISIS 304801-CS6  (index study) roll over FCS patients  
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients  
Group 3:  FCS patients who did not participate in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies  
All patients will receive volanesorsen [ADDRESS_39198]-treatment evaluation period.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6  or 
ISIS 304801-CS16  (index studies)  with an acceptable safety profile, per  
Sponsor  and Investigator judg ement . 
 
Grou ps 2 and 3 :  Patients must also meet the following criteria in order 
to enter  into the open-l abel s tudy:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by [CONTACT_37898]:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1)  
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for 
the ISIS  304801-CS16 index study   
Group 3:  Fasting TG ≥ 750 mg/dL at Screening for t his open -label 
study  
4. Able and willing to participate in a 65-week study  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
19  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females  ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent*, or if engaged in 
sexual relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39199] 
dose of Study Drug administration  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_39200] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in 
line with the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria  for Group 1 (ISIS 304801-CS6 ) and Group 2 (ISIS  304801-
CS16 ) Index Study Roll-over Patients  
1. Have any new condition or worsening of existing condition which in the 
opi[INVESTIGATOR_37638], or could interfere with the patient participating in or 
completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the 
study (Section 6.3)  
Exclusion Criteria for Group 3 (patients who did not participate in an index 
study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening  
b. HbA1c ≥ 9.0% at Screening  
c. Recent change in anti -diabetic pharmacotherapy (change in dosage 
or addition of new medication within 12 weeks of screening [with the exception of ± 10 units of insulin])  
d. Anticipated need to change dose or type of medication during the 
treatment period of the Study (with the exception of ± 10 units of insulin)  
e. Current use of GLP -1 agonists  
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
20  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria for Group 3 (patients who did not participate in an index 
study)  Continued  
4. History within 6 months of screening of acute or unstable cardiac 
ischemia (myocardial infarction, acute coronary syndrome, new onset 
angina), stroke, transient ischemic attack or unstable congestive cardiac 
failure requiring a change in medication or major surgery within 3 months 
of screening  
5. Any of the following laboratory values at Screening  
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior 
diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL  
• ALT > 2.[ADDRESS_39201]  
• AST > 2.[ADDRESS_39202]  
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥  1+) for 
protein on urine dipstick.  In the event of a positive test 
eligibility may be confirmed by a quantitative total urine 
protein measurement of <  500 mg/24 hrs  
• Persistently positive (2 out of 3 consecutive tests ≥  trace 
positive) for blood on urine dipstick.  In the event of a positive 
test eligibility may be confirmed with urine mi croscopy 
showing ≤  5 red blood cells per high power field  
• Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault <  50 mL/min (MDRD or  
CKD-EPI [INVESTIGATOR_37446] -Gault 
for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor)  
c. Cardiac Troponin I >  ULN at Screening  
d. LDL-C > 130 mg/dL at Screening  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37447], would make the patient unsuitable for 
inclusion  
6. Uncontrolled hypertension (BP >  160/100 mm Hg)  
7. History of bleeding diathesis or coagulopathy or clinically -significant 
abnormality in coagulation parameters at Screening  
8. History of heart failure with NYHA greater  than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day [ADDRESS_39203] for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Malignancy within 5 years, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been successfully 
treated  
12. Treatment with another investigational drug, biological agent, or device within 1-month of screening,  or 5 half -lives of investigational agent, 
whichever is longer  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
21  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Exclusion Criteria for Group 3 (patients who did not participate in an index 
study)  Continued  
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following:  
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless 
on a stable dose for at least 3 months prior to screening and dose and 
regimen expected to remain constant during the treatment period.  
Patients taking OTC omega-3 fatty acids should make every effort to 
remain on the same brand throughout the study  
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to 
screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to 
screening unless approved by [CONTACT_37755]  
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) 
unless on a stable dose for at least [ADDRESS_39204] 4 weeks prior to screening and dose and regimen expected to remain 
constant during the treatment period  
f. Glybera gene therapy within 2 years prior t o screening  
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on a stable dose for at least [ADDRESS_39205] 4 weeks prior to screening 
(Occasional or intermittent use of over -the-counter medications will be 
allowed at Investigator’s discretion)  
15. Blood donation of 50 to 499 mL within 30 days of screening or of 
> 499 mL within 60 days of screening  
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] 
(ISIS 304801 or placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37519], or coul d 
interfere with the patient participating in or completing the study  
Treatment Group Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the Sponsor Medical Monitor.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
22  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6  and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies  (Section 2.4) which included a subset of patients with 
FCS.  The same dose of [ADDRESS_39206] of the following 
periods:  
• Group 1 and 2 patients (participated in ISIS 304801-CS6 or 
ISIS 304801-CS16 index study) :  A qualification period of up to 
2 weeks (unless approved by [CONTACT_1034]) .  Please refer to 
Section 4.1 and Appendix A  
• Group 3 patients (did not participate in an index study) :  An up to 
8-week screening and qualification period, including a diet 
stabilization period of at least 6 weeks  (screening and diet 
stabilization period may be reduced, per Sponsor approval, if the 
patient is following a diet for optimal control of TGs and disease 
management prior to screening) .  Please refer to Section 6.1.2  and 
Appendix A  
• All patients:  
o A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
o A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_39207] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39208] -treatment 
evaluation period.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
23  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37798] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planned Analyses  Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatit is 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprote in C-III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement  of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an open -label study . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
24  STUDY DESIGN AND TREATMENT SCHEMA  
 
  
SCREENING PERIOD  
Weeks -8 to -2 (Group 3 patients only)  
QUALIFICATION  
PERIOD 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATM ENT EVALUATION 
PERIOD 
Weeks 53 to 65  
Safety, efficacy, PK and PD assessments  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
25  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39209]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39210] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39211]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
27  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of dosing and extended dosing 
with volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance,  due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
28  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a plat form for LPL -mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] (Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceri demia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase,  LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
29  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish 
that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In ano ther study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that w as associated with significantly lower levels of 
apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC- III polymo rphisms associated with higher plasma TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels i n order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients  include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]-mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37692].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
30  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl) (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for  antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37978] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2 ʹ-MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
31  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volan esorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  Gen eral toxicity studies with volanesorsen for up to 39 weeks of 
treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardio vascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  huma n  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39212] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the preclinical s tudies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
32  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an 
open -label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39213] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_39214] -treatment period and was not associated with platelet -related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39215] Level ( NOAE L) 
was defined by [CONTACT_37921] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect betwee n the different doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
34  3. EXPERIMENTAL PLAN 
3.1 Study Design 
This is an open-label study of: 
Group 1:  ISIS 304801-CS6 (index study) roll over FCS patients 
Group 2:  ISIS 304801-CS16 (index study) roll over FCS patients 
Group 3:  FCS patients who did not part icipate in the ISIS 304801-CS6 or  
ISIS 304801-CS16 index studies 
Up to approximately [ADDRESS_39216] of the following periods: 
3.4.1 Group 1 and 2 Patients (participate d in ISIS 304801-CS6 or ISIS 304801–CS16 
index study):  Qualification 
A period of up to 2 weeks (unless approved by [CONTACT_3433] e Sponsor) is given to complete qualification 
assessments outlined in the Schedule of Procedures.  Please refer to Section 4.1  and Appendix A . 
3.4.2 Group 3 Patients (did not par ticipate in an index study):  Screening/Qualification 
An up to 8-week screening and qualification peri od, including a diet stab ilization period of at 
least 6 weeks (screening and diet stabilization period may be reduced, per Sponsor approval, if 
the patient is following a diet for optimal cont rol of TGs and disease management prior to 
screening.  Please refer to Section 6.1.2  and Appendix A. 
3.4.3 Treatment 
The treatment period is 52 weeks.  Eligible patients will report to the Study Center for 
assessments at specified intervals throughout th e 52-week treatment period as detailed in the 
Schedule of Procedures (Appendix A).  Duri ng the treatment peri od, volanesorsen is 
administered by [CONTACT_37979]. 
3.4.[ADDRESS_39217] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesor sen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Screening/ Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of t he 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open- label study are performed .   
Groups 1 and 2 (Qualification):  During the qualification period, the eligibility of the patient to 
enroll in the open- label study will be determined .  Final assessments from the ISIS 304801-CS6 
or ISIS 304801-CS16 studies may be used for qualification .  A period of up to 2 weeks after 
completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  
identification number that was assigned to them  during the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies .  The patient identification number will be used to identify the 
patient  throughout the extension trial and must be used on all study documentation related to that 
patient .  The patient  identification number must remain constant throughout the extension trial. 
Group 3 (Screening and Qualification):  At the time of consent, the patient will be considered enrolled into the study and will be assigned a unique screening number before any study procedures, including screening procedures, are performed.  At the time of enrollment, patients will be assigned a unique patient identification number.  This number will be used to identify the patient throughout the trial and must be used on al l study documentation related to that patient.  
The screening number and patient identification number must remain constant throughout the entire trial.  In the event the patient is re -consented and re- screened the patient must be given a 
new screening num ber.  Screening numbers and patient  identification numbers, once assigned, 
will not be re -used. 
4.2 Enrollment  
Patient s will be enroll ed into the treatment phase of the study after all  Screening (Group3) and 
qualification assessments have been completed and after the Investigator has verified that they 
are eligible per criteria in Sections 5.1 and 5.2.  No patient  may begin treatment prior to 
enrollment. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
36  Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_39218] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Groups 1 and 2:  Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 
(index studies) with an acceptable safety profile, per Sponsor and Investigator judgement. 
 Groups 2 and 3:  Patients must also meet the following criteria in order to enter  into the 
open- label Study:  
a. History of chylomicro nemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) 
by [CONTACT_37898]: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
c. Group 2:  Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening f or the  
 ISIS 304801-CS16 index study 
Group 3:  F asting TG ≥ 750 mg/dL at Screening for this open -label study  
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH levels in the postmenopausal range for the laboratory involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39219] dos e of Study Drug 
administration.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
37  b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of 
child -bearing potent ial, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_39220] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i. e., when this is in line with the 
preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post-ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception 
5.2 Exclusion Criteria  for Group 1 (ISIS 304801- CS6) and Group 2 (ISIS 304801-
CS16 ) Index Study Roll- over Patients  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section  6.3). 
Exclusion Criteria for Group 3 (patients who did not participate in an index study ) 
1. Diabetes mellitus with any of the following:  
a. Newly diagnosed within 12 weeks of screening 
b. HbA1c ≥ 9.0% at Screening 
c. Recent change in anti -diabetic pharmacotherapy (change in dosage or addition of new 
medic ation within 12 weeks of screening [with the exception of ± 10 units of insulin]) 
d. Anticipated need to change dose or type of medication during the treatment period of 
the Study (with the exception of ± 10 units of insulin) 
e. Current use of GLP- 1 agonis ts 
2. Severe hypertriglyceridemia other than due to familial chylomicronemia syndrome  
3. Active pancreatitis within 4 weeks prior to screening  
4. History within 6 months of screening of acute or unstable cardiac ischemia (myocardial 
infarction, acute coronary syndrome, new onset angina), stroke, transient ischemic attack 
or unstable congestive cardiac failure requiring a change in medication or major surgery 
within 3 months of screening 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
38  5. Any of the following laboratory values at Screening 
a. Hepatic:  
• Total bilirubin > upper limit of normal (ULN), unless prior diagnosis and 
documentation of Gilbert’s syndrome in which case total bilirubin must be  
≤ 3 mg/dL 
• ALT > 2.[ADDRESS_39221] 
• AST > 2.[ADDRESS_39222] 
b. Renal:  
• Persistently positive (2 out of 3 consecutive tests ≥ 1+) for protein on urine 
dipstick.  In the event of a positive test eligibility may be confirmed by a 
quantitative total urine protein measurement of <  500 mg/24 hrs 
• Persistently positive (2 out of 3 consecutive tests ≥  trace positive) for blood on 
urine dipstick.  In the event of a positive test eligibility may be confirmed with 
urine microscopy showing ≤ 5 red blood cells per high power field 
• Estimated creatinine clearance calculated according to the f ormula of Cockcroft 
and Gault < 50 mL/min (MDRD or CKD-EPI [INVESTIGATOR_37629]- Gault for estimation of GFR in patients with low body weight after 
discussion with Sponsor Medical Monitor) 
c. Cardiac Troponin I >  ULN at Screening  
d. LDL- C > 130 mg/dL at Screening  
e. Any other laboratory abnormalities which, in the opi[INVESTIGATOR_37555], would make the patient unsuitable for inclusion 
6. Uncontrolled hypertension (BP > 160/100 mm Hg) 
7. History of bleeding diathesis o r coagulopathy or clinically- significant abnormality in 
coagulation parameters at Screening  
8. History of heart failure with NYHA greater than Class II  
9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day [ADDRESS_39223] for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
11. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ  of the cervix tha t has been successfully treated  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
39  12. Treatment with another investigational drug, biological agent, or device within 1-month 
of screening, or 5 half-lives of investigational agent, whichever is longer 
13. Unwilling to comply with lifestyle requirements ( Section 6.3) 
14. Use of any of the following: 
a. Statins, omega -3 fatty acids (prescription and OTC), or fibrates unless on a stable 
dose for at least 3 months prior to screening and dose and regimen expected to remain 
constant during the treatment period.  P atients taking OTC omega -3 fatty acids should 
make every effort to remain on the same brand throughout the study 
b. Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening 
c. Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening unless 
approved by [CONTACT_37755] 
d. Atypi[INVESTIGATOR_16703] (e.g., olanzapi[INVESTIGATOR_37448]) unless on a stable 
dose for at least [ADDRESS_39224] 4 weeks prior to 
screening and dose and regimen expected to remain constant during the treatment period 
f. Glybera gene therapy within 2 years prior to screening 
g. Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]) unless on 
a stable dose for at least [ADDRESS_39225] 4 weeks prior to screening (Occasional or 
intermittent use of over -the- counter medications will be allowed at Investigator’s 
discretion) 
15. Blood donation of 50 to 499 mL within 30 days of screening or of > 499 mL within 
60 days of screenin g 
16. Known hypersensitivity to any of the excipi[INVESTIGATOR_37449] (ISIS 304801 or 
placebo)  
17. Have any other conditions, which, in the opi[INVESTIGATOR_37548], or could interfere wit h the patient participating 
in or completing the study 
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
40  6. STUDY PROCEDURES 
6.1 Study Schedule 
All required study procedures are outlined in Appendices A , B, C, and D . 
6.1.1 Qualification (Groups 1 and 2) Please refer to Section 4.1  and Appendix A. 
6.1.2 Screening and Qualification (Group 3) Before any study-specific procedures or evaluations are initiated, patients must sign and date the 
informed consent form.  An 8-week period, incl uding a diet stabiliza tion period of at least 
6 weeks (screening and diet stabilization period may be reduced, per Sponsor approval, if the 
patient is following a diet for optimal control of  TGs and disease management prior to screening) 
is given to perform the screening evaluations.  The qualification assessments will be performed at Week -[ADDRESS_39226] patient’s Week [ADDRESS_39227]. 
During the treatment period, patients  will report to the study center fo r clinic visits a minimum of 
5 times during Weeks 1-52 (see Schedule of Pro cedures in Appendix A).  Study Drug will be 
administered once weekly ( Section 8.1 ).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs, 
concomitant medication/procedure information, lipi d panel, volanesorsen plasma concentrations, 
immunogenicity (IM) testing, live r/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the sc hedule of procedures in Appendix A.  Adverse 
events at the injection site should be collected  as adverse events.  Dietary counseling will be 
reinforced at intervals thr oughout the treatment and follow- up period and all patients will 
complete a daily food diary for one week prior to their quarterly visi t.  All blood and urine 
samples should be collected prior to volanesorsen administration.  Blood sampling at Weeks 2.5, 4, 6, 8, 10, 12, 15, 17, 19, 21, 23, 25, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, and [ADDRESS_39228] be fasted prior to drawing all bl ood samples and samples drawn locally should also 
be sent to the central laboratory  for analysis whenever possible.  Every effort should be made to 
ensure the previous week’s dose is given 7 days  prior to a scheduled clinic visit.  Dosing 
instructions and training will be provi ded to the patient where applicable. 
All reasonable attempts should be made to ensure  compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a vi sit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
ISIS 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
41  6.1.4 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on Study Day [ADDRESS_39229]-dose blood draw after dosing on Day 1.  The detailed PK sampling schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for si tes and patients, and consent may be withdrawn 
for the subgroup-specific procedures (e.g., mu ltiple blood draws for PK) without being 
withdrawn from the study.  If a patient withdraw s consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessm ents and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_39230]-treatment evaluation period.  This period c onsists of 4 Study Center visits on Weeks 54, 56, 
and 58 (which may be conducted by a home health care nurse), and Week [ADDRESS_39231] of these analytes is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed  locally.  In the event that both the central and 
local sample are unreportable (e.g., due to hemoly zed or clumped blood samples) another sample 
must be repeated within 1-week  and determined not to have met a stoppi[INVESTIGATOR_37607].  
If there is no reportable platelet  count within [ADDRESS_39232] the patient to hold dosing until a ne w platelet count is obtained and reviewed. 
All platelet count results will be promptly review ed by [CONTACT_37900][INVESTIGATOR_37639] 75,000/mm
3. 
Any case of a platel et count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs 
Physical exams and vital signs wi ll be performed as indicated in the Schedule of Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate, respi[INVESTIGATOR_37557].  Blood pressure and pulse rate w ill be recorded after the patient has been in a 
sitting position for at least 5 minutes.  Semi-supi[INVESTIGATOR_37613] 304801-CS7 CONFIDENTIAL Amendment 5
Protocol  6 July 2016
 
42  always be measured on the same arm (preferentially on the left arm).  Height will be measured at 
the Day 1 visit. 
[IP_ADDRESS] Eruptive Xanthoma 
At each visit, patients will be asked whether th ey have had any epi[INVESTIGATOR_37640] a nd the number/duration of the events wi ll be recorded.  Physical exams 
should also include skin examina tion for presence/resolution of er uptive xanthomas.  If a patient 
experiences an epi[INVESTIGATOR_37641], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis 
If possible, lipemia retinalis will be assessed by [CONTACT_37980] (for ISIS 304801-CS16 ro llover patients) and repeated at Week 52.  
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment 
assignment. 
6.2.[ADDRESS_39233] 
5 minutes.  ECGs will be performed in tripli cate at Week 13, Week 26, Week 38, Week 52, and 
Week 65. 
6.2.5 MRI 
MRI of the liver and spleen w ill be conducted at Week 52 for a ll patients for whom MRI is not 
contraindicated, e.g., patien ts having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767] . 
6.2.6 Quality of Life Assessments 
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week 13, Week 26, Week 52, and Week 65. 
6.2.[ADDRESS_39234]-treatment follow-up period. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
43  6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows: 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post treatment follow -up periods. 
6.2.[ADDRESS_39235] refrain from sperm/egg donation and 
either be abstinent* or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_39236]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as an y female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
44  effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal liga tion), hormonal contraception, 
intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligatio n), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
*Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the pati ent.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception  
6.3.[ADDRESS_39237] 10 hours and preferably not more than 12 hours before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39238] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39239] (ISIS 304801) characteristics are listed in  Table 1. 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
45  Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for Weeks 1-52.  Patients  entering this ISIS 304801-CS7 study on 
a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or ISIS 304801-CS16), will receive a reduced dose or 
dose frequency of volanesor sen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_39240] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
46  8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study.  
8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_39241] measurement p rior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may also be initiated as noted in Section 8.7.  If any of the stoppi[INVESTIGATOR_37466] 
(refer to Sections 8.6.1 to 8.6.3) a re met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluated fully as outlined below and in consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up in accordance with 
Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Pre marketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in  Section 8.[ADDRESS_39242] measurement that is >  [ADDRESS_39243]  (or the greater of [ADDRESS_39244] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmato ry measurements should also be performed if ALT or AST levels increase 
to [ADDRESS_39245]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39246] (or 
the greater of [ADDRESS_39247] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_39248] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39249]  (or the greater of [ADDRESS_39250] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_39251] . 
8.5.2 Safety Monitoring for Platelet Count Results  
Actions to be taken in the event of reduced platelet count are shown in Table 2 in Section 8.6.3. 
Additional lab tests will be determined by [CONTACT_37901] .  
Any case of a platelet count < 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
ISIS [ADDRESS_39252] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_39253] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monit ored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and man agement of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37609]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] 
≤ 70 mg/dL (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
49  ≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV  glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglyc emia will be qualified as a SAE only if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could 
occur if blood sugar correction is not performed.  
If pati ents suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it 
is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_39254] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within 1- week of the initial test).  
HbA1c is mo nitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit,  the patient should 
check it again on the following [ADDRESS_39255] the Investigator and an unscheduled central laboratory FPG measurement and HbA1 c should be performed. 
The threshold values are defined as: 
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
50  In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_39256]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e- CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to diet and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37981] . 
8.[ADDRESS_39257] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_37642], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
ISIS [ADDRESS_39258] >  [ADDRESS_39259] >  [ADDRESS_39260] , which is confirmed and persists for ≥ [ADDRESS_39261] >  [ADDRESS_39262] (or the greater of [ADDRESS_39263] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_39264]  or INR  > 1.[ADDRESS_39265] >  [ADDRESS_39266] (or the greater of [ADDRESS_39267] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e. , onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_39268] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. S erum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measure ment of > 1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 2 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non- major bleeding ( defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any platelet count less than 25,000/mm3, or a platelet count less than 75,000/mm3 
that occurs while the patient is on dosing at 300 mg every 2 weeks or 150 mg every week then 
dosing of a patient with volanesorsen will be stopped permanently.  Platelet count will be 
monitored daily until 2 successive values show improvement then monitored every 2-3 days until 
platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is le ss than 
25,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks  for 1 -4 cycles ; Prednis(ol)one 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
52  0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:  may require continuation with oral steroids after methylprednisolone). 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered 
to> 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg 
every 2 weeks or a reduced dose of 150 mg per week (refer to Section 8.7) .  The suitability of the 
patient for continued dosing will be determined by [CONTACT_37904]’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of 
recovery of platelet count upon holding of dos ing. 
If after the first dosing rechallenge the platelet count again falls below 75,000/mm
3, then dosing 
of the patient with Study Drug will be s topped permanently. 
Following a rechallenge platelet count should be tested every week until count is stable. 
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450].  
If there is no reportable platelet count within [ADDRESS_39269] the patient to hold dosing until a new platelet count is obtained and reviewed. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
53  Table 2 Actions in Patients with Low Platelet Count  
Platelet C ount on Rx  Drug Dose Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every 1-week  until stable*  
75K-100K/mm3 Permanently reduce dose frequency to 
300 mg every 2  weeks  or reduce dose to 
150 mg weekly  Closer observation  
Monitor every  1-week  
50K-75K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/ mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37905] 2-3 days until 2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/N SAIDS/ 
anticoagulant medication  
25K-50K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37930] 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet count < 50K/mm
3 if possible  
< 25K/mm3 Permanently discontinue Study Drug Closer observation:  
Monitor daily until 2 successive 
values show improvement then monitor every 2-3 days until 
platelet count stable  
Steroids recommended* * 
Consider need for hospi[INVESTIGATOR_37590]/NSAIDS/anticoagulant 
medication while platelet  count 
< 50K/mm
3 if possible  
* At least 3 consecutive values measured weekly  that are stable as determined by [CONTACT_37906] > 100,000/mm3 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 w eeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note :  may require continuation with oral steroids after methyl prednisolone)  
 
8.[ADDRESS_39270] be made in accordance with Section 8.6.3 and 
Table 2  (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
ISIS [ADDRESS_39271] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent d iscontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39272] 6 weeks after 
discontinuing Study Drug.  Following this period, if the platelet count is stable (at least 
3 consecutive values that are stable as determined by [CONTACT_1034] M edical Monitor and 
> 100,000/mm
3), the next platelet count should be taken within at least [ADDRESS_39273] 12  weeks after discontinuing Study Drug .  Patients  should also be 
strongly encouraged to attend applicable landmark visits at Week s 12, 13, 25, 26, and 50, 52 
(calculated based on the time elapsed since Day 1) to collect  fasting lipid panels  and conduct 
safety assessments in accordance with the Schedule of P rocedures in Appendix A .  Any patient 
who discontinues treatment after  Week 44 should also be strongly encouraged to attend a final 
follow-up visit ( Week 65 visit assessments) approximately [ADDRESS_39274] dose of 
Study Drug , in addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_39275] 6 weeks after discontinuing Study Drug.  Following this period, if the 
platelet count is stable (a t least 3 consecutive values that are stable as determined by [CONTACT_37859] > 100,000/mm3), the next platelet count should be taken within at least 
[ADDRESS_39276] 1 2 weeks after discontinuing Study Drug.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
55  Patients  should also be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A ) 
prior to leaving the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39277] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the d iscretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from s tudy, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to com plete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_39278] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
56  Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallow ed Concomitant Therapy  
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be star ted or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investig ator or designee prior to initiating any new 
medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical the rapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_39279] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
E6.  Country- specific regulatory requirements will be followed in accordance with loc al country 
regulations and guidelines. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
57  Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter . 
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 3 Expected Event for the Protocol Defined Population by [CONTACT_37931] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events  including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37932] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
58  A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event that  in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life -threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death , are not life-threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes list ed in this definition .  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug  dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not re corded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_39280] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
ISIS [ADDRESS_39281] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_39282] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen, e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
60  • Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted  
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on  the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of  death should be entered as the SAE resolution date) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
61  9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudi cated.  
9.[ADDRESS_39283] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_37586] 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
62  9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_39284] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is rep orted on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
63  10. STATI STICAL CONSIDERATIONS 
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and 
Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are 
defined as the average of Week 50 (Day 344) and Week  52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including  
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints 
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an open- label study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
64  10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39285] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_39286] 1 evaluable PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient  in Groups 1 and 2:  
Group 1 (ISIS 304801- CS6) or Group 2 ( ISIS 304801-CS16) index study baseline and the 
baseline in this open-label study, which is defined as the average of Day [ADDRESS_39287] measurement prior to Day 1 (e.g ., qualification assessments or assessments from 
final visit of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline for safety will be the last non- missing assessment prior to the first dose of Study Drug . 
10.[ADDRESS_39288] patient’s Week [ADDRESS_39289] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be  used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoints will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be assessed in the PK Set as applicable.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
65  10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_37942].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudic ated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_37948].  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, 
Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a 
range of  fasting plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37947]-HDL-C, apoB, HDL-C, apoA-1, VLDL-C, and LDL-C, total cholesterol, and fasting total 
apoC- III. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
66  The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification for Group 1 and 2 patients by [CONTACT_37949]  304801- CS6 and ISIS 304801-CS16 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open -label study from 
the intensive PK sub group, following a single-dose (i.e., single-dose PK) or multiple doses (i.e., 
steady -state PK), depending on their earlier treatment in the index studies (Group 1 and 2 
patients) .  On Week 1  Day 1 of the open- label study, patients who received placebo in the index 
study (and all patients in Group 3) will receive the first treatment of volanesorsen (single -dose 
PK), while  patients who received volanesorsen in the index studies had been on volanesorsen 
treatment for 12 months (ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data 
collected from these patients reflect steady -state PK .  The maximum observed drug 
concentration (C max) and the time taken to reach C max (Tmax) will be obtained directly from the 
concentration -time data .  Area under the plasma concentration -time curve from time zero to 
24 hours ( AUC 0-24hr) will be calculated using the linear trapezoidal rule.  Apparent systemic 
(plasma) clearance after SC administration (CL 0-24hr /F0-24hr) will be calculated from  
CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean residence time (MRT) from time zero to 
24 hours after the SC administration  will be calculated from the equation,  
MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the  moment plasma 
concentration -time curve from time zero to [ADDRESS_39290]. 
Plasma PK parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_2030] p rior treatment in Study ISIS 304801- CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be  reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with  Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
67  listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 (Groups 1 and 2) 
and study day.  Subject ADA status (positive/negative or not evaluable) for all evaluable 
patients, along with the study day associated with the first positive IM status emerged (T first, i.e., 
onset of ADA development), the last positive IM status observed (T last), the duration of ADA 
response (number of days between T first and T last) if appropriate , the last ADA sample collection 
day, and subject - peak titer if applicable, will be listed by [CONTACT_37950] 304801-CS6 and ISIS 304801-CS16 (Groups 1 and 2) and study day.  Subjects with 
positive anti-volanesorsen antibody status may be further classified (when applicable) as being 
either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable, 
will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., % change in  fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whether to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed informed consent form should be retained in the Study Master File and in any other locations required by  [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_39291] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated  
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
68  11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_39292] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC /IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_39293] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulato ry authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
ISIS [ADDRESS_39294].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
  
ISIS [ADDRESS_39295], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensur e that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s C linical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, 
ICH GCP, and appl icable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any appare nt discrepancies .  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Ce nter for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the S tudy Center  notifications, and agrees with the content. 
12.[ADDRESS_39296] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
71  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processi ng of chylomicrons . Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED,  Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial  
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet ], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress  in antisense oligonucleotide therapeutics . Ann Rev Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of  Biological Chemistry 2009; [ADDRESS_39297] 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia  Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia . N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharma cokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
72  Ito Y, Azrolan N, O'C onnell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37643] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism o f very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleoti des containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable pl asma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos R D, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schu lman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC). Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isola ted acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
73   
  
 
  
 
14. APPENDICES  
   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
74   
  
 
  
 
Appendix A  Schedule of Procedures 
 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
75  Appendix A  Schedule of Procedures 
Study Period  Screen/  
Run Ina Quala Treatment Period  Post Treatment 
Follow -up 
Study Week  -8 to -2 -2 to -
1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent  X X                           
Outpatient Visit  X X X Xj Xj Xj Xj Xj Xj Xj X Xj Xj Xj Xj X Xj Xj Xj X Xj Xj Xj Xj X Xj Xj X 
Inclusion/Exclusion Criteria  X X                           
Vital Signs + body weight  
(+ height on Day 1 only)  X X X   X  X   X     X    X     X   X 
Physical Examination  X  X        X     X    X     X   X 
12- lead ECG (triplicate)  X          X     X    X     X   X 
MRI (liver/spleen)  X                       Xk    
Echocardiography X              Xk         Xk    Blood Draw (Fasting)c Chemistry Panel  X X X   X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialb X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel  X X X   X  X  X X    X X    X    X X   X 
Coagulation (aPTT, PT, INR)  X PG      X   X     X    X     X    
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]    X        X     X         X   X 
Sedimentation Rate    X        X     X         X   X 
Complement (C5a, Bb)    X        X     X         X   X 
Plasma PK - Volanesorsen    Xl X  X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies    X   X  X   X     X    X     X   X 
FSH (women only, if applicable)  X                            
Serum Pregnancy Testd X X    X  X   X  X   X  X  X  X   X  X X 
Archived Serum & Plasma 
Samplese   X     X   X     X         X   X 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
77  Appendix A  Schedule of Procedures  Continued  
Study Period  Screen/ 
Run Ina Quala Treatment Period Post 
Treatment 
Follow -up 
Study Week  -8 to -2 -2 to -
1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day  -56 to -
15 -14 to 
-7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 372 
& 
386 400 449 
Visit Window+/- Days  0 0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Urinalysisc X X Xm   X  X   Xm  X
m   Xm  X
m  X
m  Xm   Xm  X
m X
m 
Fundus Photographyf X                       Xk    
Genetic testing for FCS 
diagnosis (if not available in 
medical history)g X                           
Weekly Study Drug:  SC 
Injection   X  X X X X X X X X X X X X X X X X X X X X X    
Symptom Diary (weekly) X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)    X       
 X     X         X   X 
Food/Drink Diary (quarterly)h   X        X     X         X   X 
Diet/Alcohol Counselingi X X X   X  X   X     X    X     X  X X 
Adverse Events X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication X X X  X X X X X X X X X X X X X X X X X X X X X X X X 
a Screening and Qualification (Group 3) procedures performed (Please refer to Sections 3.4, 4.1, and 6.1.2) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g. , due to hemolyzed or clumped blood samples) another sample must be repeated 
within 1- week  and determined not to have met a stoppi[INVESTIGATOR_10450].  If there is no reportable platelet count within [ADDRESS_39298] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count r esults will be 
promptly reviewed by [CONTACT_37909][INVESTIGATOR_37604] 75,000/ mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
ISIS [ADDRESS_39299] 10 hours  and preferably not more than 12 hours .  During treatment period urine and blood 
samples will be collected prior to Study Drug  administration .  Does not  apply to 24-hour PK blood draw  
d Females of childbearing pot ential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies  of  
volanesorsen  
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug ( Group 2 [ISIS 304801-CS16 rollover patients ] and 
Group 3)  and repeated at Week 52 (Please refer to Section [IP_ADDRESS] ) 
g Genetic testing can be conducted for study qualification (Group 2 [ISIS 304801-CS16 rollover patients ] and Group 3) ; genetic testing will on ly be conducted if 
allowed in the geographic region and only after the patient has given specific written informed consent for genetic testing  
h In addition to diary, patients will be contact[CONTACT_37787]  
i To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
j Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
k A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
l Full or abbreviated PK profile (see Appendix C ) 
m Expanded urinalysis (see Appendix B ) 
 
ISIS [ADDRESS_39300] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_39301]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_39302]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_39303] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
84  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 5  
Protocol   6 July 2016  
 
85  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 Adverse Event Mild Moderate Severe 
Urine 
Prote inuria 
Adults 1 + prote inuria; 2+ prote inuria; Urinary prote in g/24 hrs; urinary protein < 1.0 g/24 hrs urinary protein 1.0 - 3.4 g/24 hrs; 
Children -Urine PIC (Protein /Creat inine) Urine P/C >1.9 ratio 0.5 - 1.9 
Gross hema turia; transfusion, 
Asymp tomatic; clinical or diagnostic IV medications or 
Symp tomat ic; urina ry cathe ter or hospi[INVESTIGATOR_37591] ; Hematur ia observat ions only; interven tion not bladder irrigation indicated elective endoscop ic, radiologic indicated or operat ive intervention 
indicated 
tGrading for this paramete r is derived from the Toxicity Grad ing Scale for Healthy Adult and Adol escent Volun teers Enrolled in 
Preventi ve V accine Clinical Trials, Sept 2007 
*Grading for this parameter is derived from the Division of AIDS (DAIDS) Table for Grad ing the Seve rity of Adult and Pediatric 
Adverse Events Version 2.0, Nov 2014 
tModifi ed for consistency with the ADA and Endocrine Society Guidelines (Seaqu ist ER, Anderson J, Childs B, et al. 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Associa tion and The Endocrine Society. 
Diabetes Care 2013 ;36: 1384 -95) 
 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_39304] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_39305] 
Cambridge, MA [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 4  –[ADDRESS_39306] No:  2015-003755-21 
 
 
 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
2  
ISIS 304801-CS7 
 
The APPROACH Open Label Extension Study  
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 4  – 6 June 2016  
 
Protocol History: 
Original Protocol:   [ADDRESS_39307] 2015 
Protocol Amendment 1: 2 February 2016 
Protocol Amendment 2: 22 April 2016 
Protocol Amendment 3: 9 May 2016  
Sponsor:  
Ionis Pharmaceuticals, Inc. 
[ADDRESS_39308] Carlsbad, CA  [ZIP_CODE] 
__________________________________ 
 M.D., M.B
.A. 
 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_39309] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_39310] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:   [CONTACT_37829].D.  
[ADDRESS_39311] 
Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator:  Akcea Therapeutics  
[ADDRESS_39312] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_39313] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Amendment:  Amendment 4 
Date:    [ADDRESS_39314] read and understand the attached clinical protocol , entitled “An 
Open -Label Extension  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_39315] the study 
as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_39316] ................................................................................27  
4. PATIENT ENROLLMENT ...............................................................................................27  
4.1 Qualification  ..................................................................................................................27  
4.2 Enroll ment  .....................................................................................................................27  
5. PATIENT ELIGIBILITY  ..................................................................................................27  
5.1 Inclusion Criteria  ...........................................................................................................27  
5.2 Exclusion Criteria  ..........................................................................................................28  
6. STUDY PROCEDURES  ....................................................................................................29  
6.1 Study Schedule ..............................................................................................................29  
6.1.1  Qualification  ...........................................................................................................29  
6.1.2  Treatment Period  ....................................................................................................29  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_39317]- Treatment Period  ............................................................................................30  
6.2 Additional Study Assessments  .......................................................................................30  
6.2.1  Laboratory Assessments  .........................................................................................30  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
6  6.2.2  Physical Exams and Vital Signs  .............................................................................30  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................30  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_39318]- Treatment Follow -up Period .43  
8.9 Withdrawal of Patients from the Study  ..........................................................................43  
8.10  Concomitant Therapy and P rocedures  ...........................................................................44  
8.10.1  Concomitant Therapy .............................................................................................44  
8.10.2  Concomitant Procedures .........................................................................................45  
8.11  Treatment Compliance  ...................................................................................................45  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................45  
9.1 Sponsor Review of Safety Information .........................................................................45  
9.2 Regulatory Requirements  ..............................................................................................45  
9.3 Definitions  .....................................................................................................................46  
9.3.1  Advers e Event  ........................................................................................................46  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................46  
9.3.3  Serious Adverse Event (SAE) ................................................................................46  
9.4 Monitoring and Recording Adverse Events  ...................................................................47  
9.4.1  Serious Adverse Events ..........................................................................................47  
9.4.2  Non-Serious Adverse Events ..................................................................................47  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................48  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................48  
[IP_ADDRESS]  Severity  ............................................................................................................48  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................48  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................49  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................49  
9.4.4  Adjudication Committees  .......................................................................................49  
9.5 Procedures for Handling Special Situations ..................................................................50  
9.5.1  Abnormalities of Laboratory Tests .........................................................................50  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............50  
9.5.3  Dosing Errors .........................................................................................................50  
9.5.4  Contraception and Pregnancy .................................................................................51  
10. STATISTICAL CONSIDERATIONS  ..............................................................................51  
10.1  Study Endpoints  .............................................................................................................51  
10.1.1  Efficacy Endpoints .................................................................................................51  
10.1.2  Safety Endpoints .....................................................................................................52  
10.2  Sample Size  ....................................................................................................................52  
10.3  Populations .....................................................................................................................52  
10.4  Definition of Baseline ....................................................................................................53  
10.5  Interim Analysis  .............................................................................................................53  
10.6  Planned Methods of Analysis ........................................................................................53  
10.6.1  Demographic and Baseline Characteristics  ............................................................53  
10.6.2  Safety Analysis  .......................................................................................................53  
10.6.3  Efficacy Analysis  ...................................................................................................54  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
8  10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................54  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................54  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................55  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_39319] of the Study .........................................................................................56  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_39320] of Laboratory Analytes  .............................................................................67  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................69  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnor malities ......71  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ................................................................ 33  
Table 2  Actions in Patients With Low Platelet Count  ............................................................... 42  
Table 3  Expected Event for the Protocol Defined Population by [CONTACT_37935]  ................................................................................................. 46  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 20  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of volanesorsen is shown ................................... 22  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  .............. 24  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patient s with Familial Chylomicronemia 
Syndrome (FCS) 
Amendment Number:  4 
Amendment Date:  6 June 2016 
 
The purpose of this protocol amendment is to implement the following modification s to Protocol 
ISIS 304801-CS7 Amendment 3 dated 9 May 2016: 
1. To add hematology blood draws so that platelet counts are measured every [ADDRESS_39321] dose of 
Study Drug. 
2. To update the platelet safety monitoring rules (shown in Table 2).   
3. To add language to indicate that if th ere is no reportable platelet count within [ADDRESS_39322] the patient to hold dosing until a new 
platelet count is obtained and reviewed .  
4. To add language to indicate that all platelet count results will be promptly reviewed by 
[CONTACT_37909][INVESTIGATOR_37644] 75,000/ mm3. 
5. To change the platelet dose pause/ stoppi[INVESTIGATOR_37645] 50,000/mm3 to 75,000/mm3 and to 
add that when platelet count returns to ≥ 100,000/mm3 dosing may be continued but at a 
reduced dose frequency of 300 mg every 2 weeks or a reduced dose of 150 mg per week and only if approved by [CONTACT_37755]. 
6. To add language to indicate that in the event of any platelet count less than 25,000/mm
3, 
or a platelet count less than 50,000/mm3 that occurs while the patien t is on dosing at 
300 mg every 2 weeks or 150 mg per week, then dosing of a patient with volanesorsen 
will be stopped permanently.  Platelet count will be monitored daily until 2 successive values show improvement then monitored every 2-3 days until platel et count is stable . 
7. To add language to indicate that administration of steroids is recommended for patients 
whose platelet count is less than 25,000/mm
3 and to provide treatment guidelines for the 
administration of steroids.   
8. To add a Table summarizing ac tions to be taken in the event of a low platelet count. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
10  9. To add language to indicate that patients will receive a suitable dose or dose frequency of 
volanesorsen, when they enter  this CS7 study, based on safety/ tolerability or non-
safety/tolerability dosing  rules.  
Minor administrative changes or corrections (not included in the list of changes) have been made throughout the protocol in order to improve the overall clarity of the protocol but these changes 
do not impact the study design. 
The following table provides a summary list of changes to the protocol: 
Protocol Section  Description of Change  Rationale  
Section 6.1.[ADDRESS_39323] the patient to hold dosing until a new 
platelet count is obtained and reviewed.  To increase platelet count 
monitoring and provide adde d 
patient safety regarding ISIS 304801 
dose exposure  
Section 6.2.1 
Laboratory 
Assessments  
Appendix A 
Schedule of  
Procedures  All platelet count results will be promptly reviewed by [CONTACT_37909][INVESTIGATOR_37572] 75,000/mm3.   To in crease 
platelet count 
monitoring for 
safety purposes  
Section 8.6.3 
Stoppi[INVESTIGATOR_37646]/ stoppi[INVESTIGATOR_37647] 50,000/mm3 to 75,000/mm3 and 
when platelet count returns to ≥  100,000/mm3 dosing may be continued 
but at a reduced dose frequency of 300 mg every 2 weeks or a reduced 
dose of 150 mg per week and only if approved by [CONTACT_37956].  To increase 
platelet count 
monitoring and provide adde d 
patient safety 
regarding 
ISIS 304801 
dose exposure  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
11  Protocol Section  Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37648] 25,000/mm3, or a platelet 
count less than 50,000/mm3 that occurs while the patient is on dosing at 
300 mg every 2 week s or 150 mg per week, then dosing of a patient with 
volanesorsen will be stopped permanently. Platelet count will be 
monitored daily until 2 successive values show improvement then 
monitored every 2-3 days until p latelet count is stable.  To increase 
platelet count 
monitoring for safety purposes  
Section 8.6.3 
Stoppi[INVESTIGATOR_37649] 25,000/mm3.  Recovery in platelet count may be 
accelerated by [CONTACT_37711].  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010 ) 
recommend Dexamethasone 40 mg daily for 4 days every 2-4 weeks  for 
1-4 cycles; Prednis(ol)one 0.5- 2 mg/kg/d for 2-4 weeks then taper; or 
Methylprednisolone 30 mg/kg/day for 7 days ( note : may require 
continuation with oral steroids after methyl prednisolone).  To provide added patient safety 
regarding platelet 
count reductions 
and treatment 
recommendations  
Section 8.6.3 
Stoppi[INVESTIGATOR_37650] 2  Actions in Patients with Low Platelet Count  
Platelet 
Count on 
Rx Drug Dose Monitoring  
Normal 
range, 
> 140K/mm3 No action  Monitor every 
2 weeks  
100K -
140K/mm3 No action  Closer observation  
Monitor every one 
week  
75K-
100K/mm3 Reduce dose frequency to 
300mg every 2 weeks or 
reduce dose to 150 mg weekly  Closer observation  
Monitor every one week  
50K-
75K/mm3 Dose pause  
When platelet count returns to 
> 100K/mm3 restart dosing at 
dose frequency of 300 mg 
every 2 weeks or 150 mg 
weekly only if approved by 
[CONTACT_37905] 2-3 days until 2 
successive values 
show improvement  
Consider 
discontinuation of 
antiplatelet 
agents/NSAIDS/antic
oagulant medication  
25K-
50K/mm3 If occurs while on dose of 
300 mg every 2 weeks or 
150 mg every week then 
permanently discontinue Study Drug, otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at 
dose frequency of 300 mg 
every 2 weeks or 150 mg 
weekly only if approved by 
[CONTACT_37930] 2 successive values 
show improvement then monitor every 
2-3 days until platelet 
count stable  
Discontinue 
antiplatelet agents/NSAIDS/antic
oagulant medication 
while platelet count 
< 50K/mm
3 if possible  
 To provide added 
patient safety 
regarding platelet 
count reductions, ISIS 304801 dose exposure, and 
treatment 
recommendations  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
12  Protocol Section  Description of Change  Rationale  
Section 8.6.3 
Stoppi[INVESTIGATOR_37651] 2  Actions in Patients with Low Platelet Count  Continued  
< 25K/mm3 Permanently discontinue Study 
Drug  Closer observation:  
Monitor daily until 2 successive values 
show improvement 
then monitor every 
2-3 days until platelet 
count stable.  
Stero ids 
recommended*  
Consider need for hospi[INVESTIGATOR_37652]/NSAIDS/anticoagulant medication 
while platelet count 
< 50K/mm
3 if possible  
* Recovery in platelet count may be accelerated by [CONTACT_37982].  Treatment guidelines for immune 
thrombocytopenia ( Provan et al. 2010) recommend Dexamethasone 
40 mg daily for 4 days every 2-4 w eeks for 1-4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note : may require continuation with oral 
steroids after methylprednisolone)   
Section 8.1 Volanesorsen Administration  Patients entering this ISIS 304801-CS7 study on a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or –CS16), will receive a reduced 
dose or dose frequency of volanesorsen for continued safety or tolerability 
as outlined in Sections 8.5 and 8.6.  Patients entering this CS7 study 
having dose or dose frequency reduced in the CS16 index study after 
13 weeks of treatment, as outlined in CS16 Amendment 4 Section 8.7, 
can receive the 300 mg once weekly dose of volanesorsen. To allow patients 
to receive a suitable dose or 
dose frequency of vol anesorsen, 
based on safety/  
tolerability or non-safety/  
tolerability dosing 
rules   
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
13  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)  
Study  Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study  Objective s To evaluate the safety and efficacy of extended dosing with volanesorsen  
(volanesorsen sodium 300 mg ) in patients with FCS  
Study Design  This is a multi -center, open-label extension study  of ISIS 304801-CS6  and 
ISIS 304801-CS16 .  All patients will receive volanesorsen [ADDRESS_39324] -treatment evaluation period.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and  any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Satisfactory completion of ISIS 304801-CS6  or ISIS 304801- CS16  
(index studies)  with an acceptable safety profile, per  Sponsor  and 
Investigator judge ment .  Patients who are enrolled in ISIS 304801-CS16 
must also meet the following criteria in order to enter  into the Extension 
Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by [CONTACT_37685] 1 of the 
following:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the 
ISIS 304801-CS16 study  
4. Able and willing to participate in a 65-week study  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent *, or if engaged in 
sexual relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39325] dose of Study Drug administration  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
14  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_39326] dose of Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria:  
1. Have any new  condition or worsening of existing condition which in 
the opi[INVESTIGATOR_37601], or could interfere with the patient participating in or 
completing the study  
2. Unwilling to comply with lifestyle require ments for the duration of the 
study ( Section 6.3 ) 
Treatment Group Volanesorsen 300 mg once per week  
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
Rationale for Dose and Schedule Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6 - and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies which included a subset of patients with FCS .  This is an 
extension to the ISIS 304801- CS6 and ISIS 304801-CS16  index studies.  
Only the subset of patients  from ISIS 304801 -CS16 with FCS  diagnosis  may 
enter  the Extension Study.  (Please refer to inclusion criteria #3, above)  
Study Visit Schedule and Procedures  The study for an individual patient will generally consist of the following 
periods:  
• A qualification period of up to 2 weeks (unless approved by [CONTACT_429]) .  Please refer to Section 4.1 and Appendix A .  A 52 -week 
treatment period during which volanesorsen will be administered as 
a once weekly SC injection  
• A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_39327] . 
Collection and measurement of vital signs, clinical laboratory parameters (including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39328] -treatment 
evaluation period.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
15  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37798] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planne d Analyses  Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinali s 
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an extension study to the double-blind placebo controlled ISIS 304801-CS6  and ISIS 304801-CS16  
index studies . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
16  STUDY DESIGN AND TREATMENT SCHEMA  
 
QUALIFICATION  
PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
enco uraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks 53 to 65 
Safety, efficacy, PK and PD assessments  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
17  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39329]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39330] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OLE  Open Label Extension  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39331]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
19  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of extended dosing with 
volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis .  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37605] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancr eatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al.  2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
20  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37653] 
(Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulati on of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1  = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
21  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apoC -III an d TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma TG have also been recently described (Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BM I] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken t ogether, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC- III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity o f other lipases also involved in the metabolism and breakdown 
of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediate d reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide the potential 
to manage triglyc eride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
22  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
23  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monke ys (Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral an d pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay. 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, s pecies -dependent 
proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39332] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
24  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen  Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
adminis tered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70%, respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG -lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an open 
label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39333] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_39334]- treatment period and was not associated with platelet -related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February  29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of 
major bleeding or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the 
monitoring and stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered 
following suspension of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39335] Level ( NOAEL ) 
was defined by [CONTACT_37845] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of s afety for the  Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
26  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label extension  to the Phase 3 study of volanesorsen in patients with F CS 
(ISIS  304801- CS6 or ISIS 304801-CS16).  Up to approximately [ADDRESS_39336] of the following periods: 
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer to 
Section 4.1 and Appendix A . 
• A 52-week  treatment period during which volanesorsen  will be administered as a once 
weekly SC injection  
• A [ADDRESS_39337]- treatment evaluation period 
Please refer to the Schedule of Procedures in Appendix A. 
3.4.1 Qualification  
A period of up to 2 weeks  is given to complete  qualification  assessments outlined in the 
Schedule of Procedures (Appendix A). 
3.4.2 Treatment  
The treatment peri od is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule or Procedures (Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_39338] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open label study are performed .  During t he 
qualification period, the eligibility of the patient to continue in the extension study will be 
determined .  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may be 
used for qualification.  A period of up to 2 weeks after completio n of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_39339] been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_39340] give written infor med consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 (index studies) with an acceptable safety profile, per Sponsor and Investigator judgement.  Patients who are 
ISIS [ADDRESS_39341] also meet the following criteria in order to enter  into 
the Extension Study: 
a. History of chylomicronemia as evidenced by [CONTACT_37983] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37972] 1 of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of norm al 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-CS16 study. 
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH  levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39342] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Se ction 6.3.1) from the time of signing the informed consent form until [ADDRESS_39343] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception  
5.[ADDRESS_39344] any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the 
patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study 
(Section  6.3). 
ISIS [ADDRESS_39345] patient’s Week [ADDRESS_39346]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunoge nicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary coun seling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesorsen administration .  Blood sampling  at Week s 2.5, 
4, 6, 8, 10, 12, 15, 17, 19, 21, 23, 25, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, 50, 54, 56, a nd [ADDRESS_39347] be fasted prior to drawing all blood samples and samples drawn locally 
should also be sent to the central laboratory for analysis  whenever possible.  Every e ffort should 
be made to ensure the previous week’s dose is given 7 days prior to a scheduled clinic visit.  
Dosing instructions and training will be provided to the patient where applicable. 
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_39348]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in App endix C. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
30  Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_39349] of these analytes  is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed local ly.  In the event that both the central and 
local sample are unreportable (e.g., due to hemolyzed or clumped blood samples ) another sample 
must be repeated within 1-week and determined not to have met a stoppi[INVESTIGATOR_37607].  
If there i s no reportable platelet count within [ADDRESS_39350] the patient to hold dosing until a new platelet count is obtained and reviewed. All platelet count results will be promptly reviewed by [CONTACT_37984][INVESTIGATOR_37587] 75,000/mm
3. 
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially  on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events will be recorded.  Physical exams 
should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
31  [IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 rollover patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment 
assignment.  
6.2.[ADDRESS_39351] 
5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, and 
Week 65 . 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e .g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37703].  
6.2.6 Quality of Life Assessments  
All patients will c omplete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_39352]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to provide diet/alcohol counseling for visi ts that are conducted by a clinical service.  
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post 
treatment follow -up periods. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
32  6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
6.2.10 Lipoprotein Lipase Activity Sample Collection  
Lipoprotein lipase (LPL) activity will be measured in ISIS 304801-CS16 rollover patients if 
needed for study qualification.  In brief, fasted patients will be given a low intravenous dose of 
heparin.  A blood sample will be drawn prior to and at [ADDRESS_39353] refrain from sperm/egg donation and 
either be abstinent* or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_39354]’s last dose of study 
treatment.  
For the purposes of this Study , women of chil dbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patien ts must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
33  For female patien ts: 
• Using one or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
*Note : A female condom an d a male condom should not be used together as friction between the 
two can result in either product failing . 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic ab stinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception  
6.3.[ADDRESS_39355] 10 hours and preferably not more than 12 hours before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39356] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39357] (ISIS 304801) characteristics are listed in Table 1 . 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
34  7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
300 mg injection once weekly for Weeks 1-52.  Patients entering this ISIS 304801-CS7 study on a reduced dose or dose frequency of Study Drug (volanesorsen), for safety or tolerability reasons 
in their index study (ISIS 304801-CS6 or –CS16), will receive a reduced dose or dose frequency 
of volanesorsen for continued safety or tolerability as outlined in Sections 8.[ADDRESS_39358] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treat ment procedures for this study. 
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
ISIS [ADDRESS_39359] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index s tudies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request 
confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  Reduction in dose or dose frequency 
may also be initiated as noted in Section 8.7.  If any of the stoppi[INVESTIGATOR_37466] 
(refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be dose paused or permanently 
discontinued (as described in the stoppi[INVESTIGATOR_37467]) from further treatment with volanesorsen, and evaluat ed fully as outlined below and in consultation with the Sponsor 
Medical Monitor or appropriately qualified designee, and will be followed up in accordance with 
Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in  Section 8.[ADDRESS_39360] measurement that is > [ADDRESS_39361]  (or the greater of [ADDRESS_39362] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase to [ADDRESS_39363]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39364] (or 
the greater of [ADDRESS_39365] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
36  (INR) and total bi lirubin) retested at least once -weekly until AL T and AST levels become 
≤ 1.[ADDRESS_39366] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39367]  (or the greater of [ADDRESS_39368] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and  dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_39369] . 
8.5.2 Safety Monitoring for Platelet Count Results  
Actions to be taken in the event of reduced platelet count are shown in Table 2 in Section 8.6.3. 
Additional lab tests will be determined by [CONTACT_37901] .  
Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a m inor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_39370] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin do se for patients  who are already on treatment).  
8.5.[ADDRESS_39371] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate wil l ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37504] t. 
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient require s 
assistance of another person to obtain treatment for the event and has a plasma glucose level ≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptomati c hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place 
patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
38  If a patient pr esents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could 
occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example,  then obtain and record a blood glucose value as soon as possible 
thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_39372] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within [ADDRESS_39373]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_39374] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
The threshold values are defined as:  
• FPG > 270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_39375]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
39  • Compliance to diet and lifestyle is appropriate 
If any of the above can reasonab ly explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_39376] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_37654] a, and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be pr esumed confirmed : 
1. ALT or AST >  [ADDRESS_39377] >  [ADDRESS_39378] , which is confirmed and persists for ≥ [ADDRESS_39379] >  [ADDRESS_39380] (or the greater of [ADDRESS_39381] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_39382]  or INR  > 1.[ADDRESS_39383] >  [ADDRESS_39384] (or the greater of [ADDRESS_39385] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue , nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37965] [ADDRESS_39386] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to t he formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37985] h the Sponsor Medical 
Monitor or designee. 
8.6.3 Stoppi[INVESTIGATOR_37563] a low platelet count are summarized in Table 2 below. 
In the event of a platelet count less than 75,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564].  
In the event of any platelet count less than 25,000/mm3, or a platelet count less than 50,000/mm3 
that occurs while the patient is on dosing at 300 mg every 2 weeks or 150 mg every week then 
dosing of a patient with volanesorsen will be stopped permanently . Platelet count will be 
monitored daily until 2 successive values show improvement then monitor ed every 2 -3 days until 
platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is less than 25,000/mm
3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytope nia (Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks  for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days  
(note:  may requ ire continuation with oral steroids after methylprednisolone). 
In the event of a platelet count less than 75,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered to 
≥ 100,000/mm3.  If dosing is continued it should be at a reduced dose frequency of 300 mg every 
2 weeks or a reduced dose of 150 mg per week (refer to Section 8.7).  The suitability of the 
patient for continued dosing will be determined by [CONTACT_37879]’s platelet count, whether any bleeding events were experienced by [CONTACT_102], and the speed of 
recovery of platelet count upon holding of dosing. 
ISIS [ADDRESS_39387] dosing rechallenge the platelet count again falls below 75,000/mm3, then dosing 
of the patient must be held until the platelet count again returns to at least 100,000/mm3.  The 
suitability of the patient for continued dosing and the need for any further modification to 
treatment schedule or dose (refer to Section 8.7) will be re -examined by [CONTACT_37986] n with the Study Medical Monitor based on (at least) the factors mentioned above. 
If after the second rechallenge the platelet count falls below 75,000/mm3 and is subsequently 
confirmed (see Section 8.5), dosing with volanesorsen  will be stopped permanently.  The 
follow- up schedule for any events meeting this stoppi[INVESTIGATOR_37655]. 
Following a rechallenge platelet count should be tested every week until count is stable. 
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450].  If there is no reportable platelet count within [ADDRESS_39388] the patient to  hold dosing until a new platelet count is obtained and reviewed. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperi toneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non- Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
42  Table 2 Actions in Patients with Low Platelet Count  
Platelet C ount on Rx  Drug Dose Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every one week  
75K-100K/mm3 Reduce dose frequency to 300 mg every 
2 weeks  or reduce dose to 150 mg weekly  Closer observation  
Monitor every one week  
50K-75K/mm3 Dose pause  
When platelet count returns to >100K/mm3 
restart dosing at dose frequency of 300 mg 
every 2 weeks or 150 mg weekly only if 
approved by [CONTACT_37905] 2-3 days until 
2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/NSAIDS/  
anticoagulant medication  
25K-50K/mm3 If occurs while on dose of 300 mg every 
2 weeks or 150 mg every week then 
permanently discontinue Study Drug, 
otherwise dose pause.  
When platelet count returns to 
> 100K/mm3 restart dosing at dose 
frequency of 300 mg every 2 weeks or 
150 mg weekly only if approved by 
[CONTACT_37930] 2 successive 
values show improvement then monitor  every 2 -3 days until 
platelet count stable  
Discontinue antiplatelet agents/NSAIDS/anticoagulant medication while platelet count 
< 50K/mm
3 if possible  
< 25K/mm3 Permanently discontinue Study Drug Closer observation:  
Monitor daily until two successive 
values show improvement then monitor every 2-3 days until platelet count stable  
Steroids recommended*  
Consider need for hospi[INVESTIGATOR_37656]/NSAIDS/anticoagulant medication while platelet count 
< 50K/mm
3 if possible  
* R ecovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for 
immune thrombocytopenia ( Provan et al.  2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 w eeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days ( note:  may require continuation with oral steroids after methyl prednisolone)  
 
8.[ADDRESS_39389] be made in accordance with Section 8.6.3 and 
Table 2  (above).  
Other dose adjustments, including dose interruptions, and/or decreasing the dose or dose 
frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment 
schedule must be discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to [ADDRESS_39390] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39391] be recorded in the CRF and source 
documentation. 
8.8.1 Follow- up Visits for Early Termination from Treatment Period  
Any patient who discontinues early from the Treatment Period should be strongly encouraged to 
attend applicable landmark visits at Week s 12, 13, 25, 26, and 51, 52 (calculated based on the 
time elapsed since Day 1) to collect  fasting lipid panels  and conduct safety assessments in 
accordance with the schedule of procedures in Appendix A .  Any patient who discontinues 
treatment after  Week 44 should also be strongly encouraged to attend a final follow-up visit 
(Week 65 visit assessments) approximately [ADDRESS_39392] dose of Study Drug , in 
addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_39393]- Treatment Follow-up 
Period should be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A) prior 
to leaving the study. If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39394] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
44  • At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures a nd observations at the time of withdrawal 
(see Section 8.8 and Appendix A ). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of w ithdrawal  
(see Section 8.8 and Appendix A). 
8.[ADDRESS_39395] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current  medications,  must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [inclu ding OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement the rapy,  
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
45  Patients should consult with the Site Investigator or designee prior to initiating any new 
medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_39396] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE  according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still h as the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
46  Table 3 Expected Event for the Protocol Defined Population by [CONTACT_37889] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE ) 
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
47  • Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medi cal events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_39397] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center ’s first knowledge of th e event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_39398] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_39399] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
48  9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: 
[IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen e.g., 
confirmation by [CONTACT_37865]  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows:  
• Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
49  • Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the ev ent is a non-serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be ente red as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
ISIS [ADDRESS_39400] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be listed in preference to  abnormal l aboratory values as AEs .  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormali ties deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or  Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The pres cheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and  contact [CONTACT_10557] 
[ADDRESS_39401] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are  
defined as the average of Week 51 (Day 351) and Week 52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
52  • Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ- 5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints  
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an extension study to the double-blind, 
placebo -controlled ISIS 304801- CS6 and ISIS 304801-CS16 studies .  Approximately 70 patients 
may be eligible to enroll into this study.  
10.3 Populations 
Full Analysis Set (FAS) :  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39402] efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_39403] 1 evaluable PK sample collected , analyzed , and reported. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
53  10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient:  ISIS 304801-CS6 or 
ISIS 304801-CS16 index study baseline and the baseline in this open label study, which is 
defined as the average of Day [ADDRESS_39404] measurement prior to Day 1 
(e.g., qualification assessments or assessments from final visit of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies if used for qualification) . 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline for safety will be the last non- missing assessment prior to the first dose of Study Drug . 
10.[ADDRESS_39405] patient’s Week [ADDRESS_39406] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoints will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be assessed in the PK Set as applicable.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_37942].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
54  All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summar ized by [CONTACT_37948].  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, 
Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a 
range of fasting plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37947]-HDL -C, apoB, HDL-C, apoA-1, VLDL-C, and LDL-C, total cholesterol, and fasting total 
apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and tot al amount of drug received will be examined, as 
appropriate. Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas an d lipemia retinalis  will be summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification by [CONTACT_37950] 304801- CS6 and ISIS 304801-CS16 and IM status.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
55  For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open label extension 
(OLE ) study from the intensive PK sub group, following a single dose (i.e., single-dose PK) or 
multiple doses (i.e., steady -state PK), depending on their earlier treatment in the index studies.  
On Week [ADDRESS_39407] treatment of volanesorsen (single -dose PK), while patients who received 
volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16) , thus the PK data collected from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C max) and the time 
taken to reach C max (Tmax) will be obtained directly from the concentration -time data .  Area under 
the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24hr) will be calculated 
using the linear trapezoidal rule.  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24hr /F0-24hr) will be calculated from CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean 
residence time (MRT) from time zero to 24 hours after the SC administration will be calculated 
from the equation, MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the 
moment plasma concentration -time curve from time zero to [ADDRESS_39408]. 
Plasma PK  parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_37732] 304801 -CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK  analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 and study day.  
Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day ass ociated  with the first positive IM status emerged (T
first, i.e., onset of ADA 
development), the last positive IM status observed (T last), the duration of ADA response (number 
of days between T first and T last) if appropriate , the last ADA sample collection day, and subject - 
peak titer if applicable, will be listed by [CONTACT_37732] 304801 -CS6 and 
ISIS 304801-CS16  study day .  Subjects with positive anti-volanesorsen antibody status may be 
further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, 
if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized  as the total number and percent of evaluated subjects with antibody negative, 
positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable,  
will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
56  Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., % chang e in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_39409] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated 
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must al so be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the  IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also noti fy the IEC/IRB  of serious adve rse events 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
57  occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_39410] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., sign ed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_39411] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_39412].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
58  Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copie s 
of pre -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final stu dy 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written a greement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_39413], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensur e that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s C linical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and appl icable regulatory requirements.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
59  To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37657] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_39414] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
60  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclea se resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphos phatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertrigly ceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a cli nically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev. Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label tr ial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified anti sense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -depen dent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
61  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice . Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12 -week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486]. Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C -III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268:  [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic f atty liver disease. N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.   
Provan D, Stasi R, Newland AC , et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010;  115: 168-186. 
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization  
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin L ipi[INVESTIGATOR_37487]  2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13-[ADDRESS_39415] Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_39416] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk  
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40  
&  
42 Wk 
44 Wk 
46  
&  
48 Month 12  Wk54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52  
or ET  
Study Day  -14 to -
7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
&  
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Informed Consent  X                           
Outpatient Visit  X X Xk Xk Xk Xk Xk Xk Xk X Xk Xk Xk Xk X Xk Xk Xk X Xk Xk Xk Xk X Xk Xk X 
Inclusion/Exclusion Criteria  X                           
Vital Signs + body weight  
(+ height on Day 1 only)  X X   X  X   X     X    X     X   X 
Physical Examination   X        X     X    X     X   X 
12- lead ECG (triplicate)           X     X    X     X   X 
MRI (liver/spleen)                         Xl    
Echocardiography               Xl         Xl    Blood Draw (Fasting)c Chemistry Panel  X X   X  X   X  X   X  X  X  X   X  X X 
CBC with Differentialb X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel  X X   X  X  X X    X X    X    X X   X 
Coagulation (aPTT, PT, INR) PG      X   X     X    X     X    
hsCRP, HbA1c, FPG, and 
de-lipi[INVESTIGATOR_37489]   X        X     X         X   X 
Sedimentation Rate   X        X     X         X   X 
Complement (C5a, Bb)   X        X     X         X   X 
Plasma PK - Volanesorsen   Xm X  X  X   X     X    X     X   X 
Anti-Volanesorsen Antibodies   X   X  X   X     X    X     X   X 
FSH (women only, if applicable)                             
Serum Pregnancy Testd X    X  X   X  X   X  X  X  X   X  X X 
Archived Serum & Plasma 
Samplese  X     X   X     X         X   X 
 
ISIS [ADDRESS_39417] 
Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
2.5 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Month 3  Wk 
15 
& 
17 Wk 
19 Wk 
21 
& 
23 Month 6  Wk 
28 
& 
30 Wk 
32 Wk 
34 
& 
36 Wk 
38 Wk 
40 
& 
42 Wk 
44 Wk 
46 
& 
48 Month 12  Wk 
54 
& 
56 Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
50 Wk 52 
or ET  
Study Day  -14 to -7 1 2 11 22 36 50 64 78 85 99 
& 
113 127 141 
& 
155 169 176 190 
& 
204 218 232 
& 
246 260 274 
& 
288 302 316 
& 
330 344 358 372 
& 
386 400 449 
Visit Window+/ - Days  0 0 0 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 
Urinalysisc X Xn   X  X   Xn  Xn   Xn  Xn  Xn  Xn   Xn  Xn Xn 
Fundus Photographyf X                       Xl    
Genetic testing for FCS 
diagnosis (if not available in 
medical history)g X                           
Postheparin Lipoprotein 
Lipase activityh X                           
Weekly Study Drug:  SC 
Injection   X  X X X X X X X X X X X X X X X X X X X X X    
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X        X     X         X   X 
Food/Drink Diary (quarterly)i  X        X     X         X   X 
Diet/Alcohol Counselingj X X   X  X   X     X    X     X  X X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X X X X X 
a Qualification procedures performed (Please refer to Section 4.1) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g. , due to hemolyzed or clumped blood samples) another sample must be repeated 
within 1-week  and determined not to have met a stoppi[INVESTIGATOR_10450].  If there is no reportable platelet count within [ADDRESS_39418] the patient to hold dosing until a new platelet count is obtained and reviewed.  All platelet count results will be 
promptly reviewed by [CONTACT_37909][INVESTIGATOR_37611] e of decline is suggestive that 
the patient could be approaching the dose pause rule of 75,000/ mm3.  Any case of a platelet count < 50,000/mm3 should be reported in an expedited fashion 
to the Sponsor  
ISIS [ADDRESS_39419] 10 hours  and preferably not more than 12 hours .  During treatment period urine and blood 
samples will be collected prior to Study Drug  administration .  Does not  apply to 24-hour PK blood draw  
d Females of childbearing pot ential only  
e Serum and plasma samp les will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of  
volanesorsen  
f If possible, fundus photography should be completed prior to administration of the first dose of Study Drug (ISIS 304801-CS16 rollover patients) and repeated at Week 52 (Please refer to Section [IP_ADDRESS]) 
g Genetic testing can be conducted for study qualification (ISIS 304801-CS16 rollover patients); genetic testing will only be conducted if allowed in the geographic region and only after the patient has given specific written informed consent for genetic tes ting 
h Post-heparin lipoprotein lipase activity  can be conducted for study qualification (ISIS 304801 -CS16 rollover patients; please refer to Section 6.2.10) 
i In addition to diary, patients will be contact[CONTACT_37987] r current eating and drinking habits  
j To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
k Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
l A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
m Full or abbreviated PK profile (see Appendix C ) 
n Expanded urinalysis (see Appendix B ) 
 
ISIS [ADDRESS_39420] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stor ed samples to better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells 
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_39421]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_39422]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_39423] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
73  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 4  
Protocol   6 June 2016  
 
74  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 Adverse Event Mild Moderate Severe 
Urine 
Prote inuria 
Adults 1 + prote inuria; 2+ prote inuria; Urinary prote in g/24 hrs; urinary protein < 1.0 g/24 hrs urinary protein 1.0 - 3.4 g/24 hrs; 
Children -Urine PIC (Protein /Creat inine) Urine P/C >1.9 ratio 0.5 - 1.9 
Gross hema turia; transfusion, 
Asymp tomatic; clinical or diagnostic IV medications or 
Symp tomat ic; urina ry cathe ter or hospi[INVESTIGATOR_37591] ; Hematur ia observat ions only; interven tion not bladder irrigation indicated elective endoscop ic, radiologic indicated or operat ive intervention 
indicated 
tGrading for this paramete r is derived from the Toxicity Grad ing Scale for Healthy Adult and Adol escent Volun teers Enrolled in 
Preventi ve V accine Clinical Trials, Sept 2007 
*Grading for this parameter is derived from the Division of AIDS (DAIDS) Table for Grad ing the Seve rity of Adult and Pediatric 
Adverse Events Version 2.0, Nov 2014 
tModifi ed for consistency with the ADA and Endocrine Society Guidelines (Seaqu ist ER, Anderson J, Childs B, et al. 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Associa tion and The Endocrine Society. 
Diabetes Care 2013 ;36: 1384 -95) 
 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_39424] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_39425] 
Cambridge, MA [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 3  –[ADDRESS_39426] No:  2015-003755-21 
 
 
 

ISIS 304804-CS7 CONFIDENTIAL Amendment 3
Protocol  9 May 2016
 
2   
 
ISIS 304801-CS7 
 
The APPROACH Open La bel Extension Study 
Volanesorsen (ISIS 304801)  
An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients wi th Familial Chylomicronemia 
Syndrome (FCS) 
 
Protocol Amendment 3 – 9 May 2016 
  
Protocol History: 
Original Protocol:  [ADDRESS_39427] 2015 
Protocol Amendment 1: 2 February 2016 
Protocol Amendment 2: 22 April 2016 
  
 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_39428] Carlsbad, CA  [ZIP_CODE] 
______________________ 
M.D., M.B.A. 
 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_39429] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_39430] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:  [CONTACT_37829].D.  
[ADDRESS_39431] 
Carlsbad, CA [ZIP_CODE] Phone:  
Collabo rator:  Akcea Therapeutics  
[ADDRESS_39432] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_39433] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Amendment:  Amendment 3 
Date:    [ADDRESS_39434] read and understand the attached clinical protocol , entitled “An 
Open -Label Extension  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_39435] the study 
as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good C linical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuti cals, Inc .   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_39436] ................................................................................25  
4. PATIENT ENROLLMENT ...............................................................................................25  
4.1 Qualification  ..................................................................................................................25  
4.2 Enrollment .....................................................................................................................25  
5. PATIENT ELI GIBILITY  ..................................................................................................25  
5.1 Inclusion Criteria  ...........................................................................................................25  
5.2 Exclusion Criteria  ..........................................................................................................26  
6. STUDY PROCEDURES  ....................................................................................................27  
6.1 Study Schedule ..............................................................................................................27  
6.1.1  Qual ification  ...........................................................................................................27  
6.1.2  Treatment Period  ....................................................................................................27  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_39437]- Treatment Period  ............................................................................................28  
6.2 Additional Study Assessments  .......................................................................................28  
6.2.1  Laboratory Assessments  .........................................................................................28  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
6  6.2.2  Physical Exams and Vital Signs  .............................................................................28  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................28  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_39438]- Treatment Follow -up Period .40  
8.9 Withdrawal of Patients from the Study  ..........................................................................40  
8.10  Concomitant Therapy and Procedures ...........................................................................41  
8.10.1  Concomitant Therapy .............................................................................................41  
8.10.2  Concomitant Procedures .........................................................................................41  
8.11  Treatment Compliance ...................................................................................................42  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................42  
9.1 Sponsor Review of Safety Information .........................................................................42  
9.2 Regulatory Requirements  ..............................................................................................42  
9.3 Definitions  .....................................................................................................................43  
9.3.1  Adverse Event  ........................................................................................................43  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................43  
9.3.3  Serious Adverse Event (SAE) ................................................................................43  
9.4 Monitoring and Recording Adverse Events ...................................................................44  
9.4.1  Serious Adverse Events ..........................................................................................44  
9.4.2  Non-Serious Adverse Events ..................................................................................44  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................44  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................44  
[IP_ADDRESS]  Severity  ............................................................................................................45  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................45  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................45  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................46  
9.4.4  Adjudication Committees  .......................................................................................46  
9.5 Procedures for Handling Special Situations ..................................................................46  
9.5.1  Abnormalities of Laboratory Tests .........................................................................46  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Tre atments  ............47  
9.5.3  Dosing Errors .........................................................................................................47  
9.5.4  Contraception and Pregnancy .................................................................................47  
10. STATISTICAL CONSIDERATIONS  ..............................................................................48  
10.1  Study Endpoints  .............................................................................................................48  
10.1.1  Efficacy Endpoints .................................................................................................48  
10.1.2  Safety Endpoints  .....................................................................................................49  
10.2  Sample Size  ....................................................................................................................49  
10.3  Populations .....................................................................................................................49  
10.4  Definition of Baseline ....................................................................................................49  
10.5  Interim Analysis  .............................................................................................................50  
10.6  Planned Methods of Analysis ........................................................................................50  
10.6.1  Demographic and Baseline Characteristics  ............................................................50  
10.6.2  Safety Analysis  .......................................................................................................50  
10.6.3  Efficacy Analysis  ...................................................................................................51  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
8  10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................51  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................51  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................52  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_39439] of the Study .........................................................................................53  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_39440] of Laboratory Analytes  .............................................................................64  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................66  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......68  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ........................................................ 32  
Table 2  Expected Event for the Protocol Defined Population by [CONTACT_37895]  .................................................................................. 42  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 18  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer).  The sequence of volanesorsen is shown ................................... 20  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with  Volanesorsen  .............. 22  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patient s with Familial Chylomicronemia 
Syndrome (FCS) 
Amendment Number:  3 
Amendment Date:  9 May 2016 
 
The purpose of this protocol amendment is to implement the following modification s to Protocol 
ISIS 304801-CS7 Amendment 2 dated 22 April 2016: 
1. To add language that any case of a platelet count ≤ 50,000/mm3 should be reported in an 
expedited fashion to the Sponsor. 
2. To add language regarding the frequency of obtaining platelet counts after a Study Drug 
dose pause and subsequent rechallenge.  
3. To add language that an y unreportable platelet count result must be rechecked and 
determined not to have met a stoppi[INVESTIGATOR_10450]. 
Minor administrative changes or corrections (not included in the list of changes) have b een made 
throughout the protocol in order to improve the overall clarity of the protocol but these changes do not impact the study design. 
The following table provides a summary list of changes to the protocol: 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
10  Protocol Section  Description of Change  Rationale  
Section 6.2.1  
Laboratory Assessments  
Section 8.5.2  
Safety Monitoring for 
Platelet Count Results  
Appendix A Schedule  
of Procedures  Any case of a platelet count ≤ 50,000/mm3 should 
be reported in an expedited fashion to the Sponsor  To ensure that Sponsor is 
aware in a timely fashion of 
platelet counts performed in 
local lab that have met the 
rule for dose pause  
Section 8.6.[ADDRESS_39441] met a stoppi[INVESTIGATOR_37658] 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
11  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study  Objective s To evaluate the safety and efficacy of extended dosing with volanesorsen  
(volanesorsen sodium 300 mg ) in patients with FCS  
Study Design  This is a multi -center, open-label extension study  of ISIS 304801-CS6  and 
ISIS 304801-CS16 .  All patients will receive volanesorsen [ADDRESS_39442] -treatment evaluation period.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed 
and dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Satisfactory completion of ISIS 304801-CS6  or ISIS 304801 -CS16  
(index studies)  with an acceptable safety profile, per  Sponsor  and 
Investigator judge ment .  Patients who are enrolled in ISIS 304801-CS16 
must also meet the following criteria in order to enter  into the Extension 
Study:  
a. History of chylomicronemia as evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement 
≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37685] 1 of the 
following:  
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or L MF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the 
ISIS 304801-CS16 study  
4. Able and willing to participate in a 65-week study  
5. Satisfy 1 of the following:  
a. Females:  Non- pregnant and n on-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females ≤ 55 years, 12 months of sp ontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent *, or if engaged in 
sexual relations of child- bearing potential, patient is using an 
acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39443] 
dose of Study Drug administration  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
12  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_39444] dose of  Study Drug administration  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declar ation of abstinence for the duration of a trial and 
withdrawal are not acceptable methods of contraception  
Exclusion Criteria:  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37601], or could interfere with the patient participating in or 
completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the 
study ( Section 6.3 ) 
Treatment Group Volanesorsen 300 mg once per week  
Study Drug Administration Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
Rationale for Dose and Schedule Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies ( ISIS 304801 -CS6 - and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies which included a subset of patients with FCS .  This is an 
extension to the ISIS 304801- CS6 and ISIS 304801-CS16  index studies.  
Only the subset of patients  from ISIS 304801-CS16 with FCS  diagnosis  may 
enter  the Extension Stu dy.  (Please refer to inclusion criteria #3, above)  
Study Visit Schedule and Procedures  The study for an individual patient will generally consist of the following 
periods:  
• A qualification period of up to 2 weeks (unless approved by [CONTACT_429]) .  Please refer to Section 4.1 and Appendix A .  A 52 -week 
treatment period during which volanesorsen will be administered as 
a once weekly SC injection  
• A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will r emain blinded to 
lipid data through the last patient’s Week [ADDRESS_39445] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39446] -treatment 
evaluation period.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
13  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37798] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planned Analyses  Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry, hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF-36)  
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an extension study to the double-blind placebo controlled ISIS 304801-CS6  and ISIS 304801-CS1 6 
index studies . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
14  STUDY DESIGN AND TREATMENT SCHEMA  
 
QUALIFICATION  
PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
enco uraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks 53 to 65 
Safety, efficacy, PK and PD assessments  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
15  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39447]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39448] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OLE  Open Label Extension  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39449]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
17  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of extended dosing with 
volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xantho mas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity .  LPL norm ally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: 
apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
18  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons 
(Beigneu x et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] 
(Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC-III also inhi bits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the r emodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarde d clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepati c lipase, IDL = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
19  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly low er levels of 
apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasm a TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), a nd the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -medi ated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen  may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
20  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradatio n of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to  the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability  and affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
21  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volanesorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertrig lyceridemic monkeys  (Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral an d pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay. 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, s pecies -dependent 
proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39450] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
22  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen  Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
adminis tered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70%, respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG -lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an open 
label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39451] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_39452]- treatment period and was not associated with platelet -related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February 29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of major bleeding 
or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the monitoring and 
stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered following suspension 
of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39453] Level ( NOAEL ) 
was defined by [CONTACT_37845] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of s afety for the  Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
24  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label extension  to the Phase 3 study of volanesorsen in patients with F CS 
(ISIS  304801- CS6 or ISIS 304801-CS16).  Up to approximately [ADDRESS_39454] of the following periods: 
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer to 
Section 4.1 and Appendix A . 
• A 52-week  treatment period during which volanesorsen  will be administered as a once 
weekly SC injection  
• A [ADDRESS_39455]- treatment evaluation period 
Please refer to the Schedule of Procedures in Appendix A. 
3.4.1 Qualification  
A period of up to 2 weeks  is given to complete  qualification  assessments outlined in the 
Schedule of Procedures (Appendix A). 
3.4.2 Treatment  
The treatment peri od is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule or Procedures (Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_39456] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open label study are performed .  During t he 
qualification period, the eligibility of the patient to continue in the extension study will be 
determined .  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may be 
used for qualification.  A period of up to 2 weeks after completio n of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801-CS16 index studies .  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_39457] been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_39458] give written infor med consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 (index studies) with an acceptable safety profile, per Sponsor and Investigator judgement.  Patients who are 
ISIS [ADDRESS_39459] also meet the following criteria in order to enter  into 
the Extension Study: 
a. History of chylomicronemia as evidenced by [CONTACT_37983] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37972] 1 of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of norm al 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-CS16 study. 
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH  levels in the postmenopausal range for the laboratory 
involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39460] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Se ction 6.3.1) from the time of signing the informed consent form until [ADDRESS_39461] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception  
5.[ADDRESS_39462] any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the 
patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study 
(Section  6.3). 
ISIS [ADDRESS_39463] patient’s Week [ADDRESS_39464]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunoge nicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary coun seling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesorsen administration .  Blood sampling  at Week s 4, 8, 
12, 16, 19, 22, 25, 29, 32, 35, 41, 44, 47, 51, and [ADDRESS_39465] be sent to the central laboratory for 
analysis .  Every effort should be made to ensure the previous week’s dose is given 7 days prior 
to a scheduled clinic visit.  Dosing instructions and training will be provided to the patient where 
applicable.  
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection .  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_39466]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
28  Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_39467] of these analytes  is 
contained in Appendix B . 
Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional 
sample should be collected in parallel and analyzed locally.  In the event that both the central and local sample are unreportabl e (e.g., due to hemolyzed or clumped blood samples ) another sample 
must be repeated within 1-week and determined not to have met a stoppi[INVESTIGATOR_37607]. 
Any case of a platelet count ≤ 50,000/mm
3 should be reported in an expedited fashion to the 
Sponsor. 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events will be recorded.  Physical exams 
should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 rollover patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37702], blinded to the patient’s treatment 
assignment.  
ISIS [ADDRESS_39468] 
5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, and 
Week 65 . 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_39469]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to provide diet/alcohol counseling for visi ts that are conducted by a clinical service.  
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post 
treatment follow -up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
30  6.2.10 Lipoprotein Lipase Activity Sample Collection  
Lipoprotein lipase (LPL) activity will be measured in ISIS 304801-CS16 rollover patients if 
needed for study qualification.  In brief, fasted patients will be given a low intravenous dose of 
heparin.  A blood sample will be drawn prior to and at [ADDRESS_39470] refrain from sperm/egg donation and 
either be abstinent* or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_39471]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age o r, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hyster ectomy  
For the purposes of the study, effective contraception is defined as follows: For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using one or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
31  contraception/device, or any 2 barrier methods (a combination of male or female 
condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
*Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception  
6.3.[ADDRESS_39472] 10 hours and preferably not more than 12 hours before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39473] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast- enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39474] (ISIS 304801) characteristics are listed in Table 1. 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
32  Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of  Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.[ADDRESS_39475] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
33  8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for  Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_39476] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the fi nal visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37659] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_37660], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  If any of the stoppi[INVESTIGATOR_37661] (refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be permanently discontinued 
from further treatment with volanesorsen, evaluated fully as outlined below and in consultation 
with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up 
in accordance with Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S.  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to 
guidance in Section 8.[ADDRESS_39477] measurement that is > [ADDRESS_39478]  (or the greater of [ADDRESS_39479] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurement s should also be performed if ALT or AST levels increase 
to [ADDRESS_39480]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39481] (or 
the greater of [ADDRESS_39482] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
34  (INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_39483] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39484]  (or the greater of [ADDRESS_39485] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets  
3. Obtain  a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered i f a 
patient ’s ALT and/or AST levels reach [ADDRESS_39486] . 
8.5.2 Safety Monitoring for Platelet Count Results  
In the event of any significant fall in platelet count, or if the absolute platelet count is 
75,000/mm
3 or less, then the patient’s platelet counts should be monitored more frequently.  The 
frequency of monitoring and additional lab tests will be determined by [CONTACT_37916].  
Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the 
Sponsor (See also Stoppi[INVESTIGATOR_37468] 8.6.3).  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_39487] to notify the Investigator if a patient has 
a low-density lipoprotein-cholesterol (LDL-C ) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL-C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to in itiate/adjust treatment 
to lower LDL-C according to country-specific guidelin es (e.g., initiate statin therapy or increase 
the statin dose for patients who are already on treatment). 
8.5.[ADDRESS_39488] 
practice guidelines and bring their gl ucometer or glucometer log printout to every clinic visit.  In 
addition, patients who are not on insulin but use a glucometer should also bring their glucometer 
and/or glucometer log print out to every clinic visit. 
• The Investigator or delegate will review the gl ucometer reading or printout at every clinic 
visit to evaluate if fasting pre-breakfast self-monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below. 
All diabetic patients will note any changes in their insulin dose and /or oral antidiabetic therapy, 
as well as any hypoglycemic ep isode they may experience. 
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral an tidiabetic therapy, and if they  experienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37562]. 
o Documented symptomatic hypoglycemic ep isodes should be captured as adverse 
events in the adverse event CRF. Document ed symptomatic hypoglycemia is defined 
as typi[INVESTIGATOR_37472] ≤ 70 mg/dL ( ≤ 3.9 mmol/L). 
o Any changes in insulin dose or  oral antidiabetic therapy should be captured into the 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia 
A documented severe hypoglycemic event is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL ( ≤ 3.9 mmol/L).  The rescue treatment of  hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia  includes all epi[INVESTIGATOR_37473]-tre atment and which were thus thought to place 
patients at risk for injury to themselves or othe rs.  Note that “requires assistance” means that the 
patient could not help himself or herself.  So meone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE only if it fulfills SAE criteria. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
36  If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakne ss.  Coma could 
occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
8.5.[ADDRESS_39489] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within [ADDRESS_39490]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_39491] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
The threshold values are defined as:  
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% an d HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_39492]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
37  • Compliance to diet and lifestyle is appropriate 
If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following:  
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Di etician or other qualified nutrition 
professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  If none from the above- mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_39493] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_39494] >  [ADDRESS_39495] , which is confirmed and persists for ≥ [ADDRESS_39496] >  [ADDRESS_39497] (or the greater of [ADDRESS_39498] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_39499]  or INR  > 1.[ADDRESS_39500] >  [ADDRESS_39501] (or the greater of [ADDRESS_39502] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37965] [ADDRESS_39503] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according  to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37988] n with  the Sponsor Medical 
Monitor or designee. 
8.6.3 Stoppi[INVESTIGATOR_37662] a platelet count less than 50,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564]. 
In the event of a platelet count less than 50,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the pla telet count has recovered to 
≥ 100,000/mm3.  The suitability of the patient for continued dosing and the need for any 
modification to treatment schedule (refer to Section 8.7) will be determined by [CONTACT_37989]’s platelet count, whether any bleeding events were experienced by 
[CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If after the first dos ing rechallenge the platelet count again falls below 50,000/mm3, then dosing 
of the patient must be held until the platelet count again returns to at least 100,000/mm3.  The 
suitability of the patient for continued dosing and the need for any further modif ication to 
treatment schedule or dose (refer to Section 8.7) will be re -examined by [CONTACT_37990] (at least) the factors mentioned above. 
If after the second rechallenge the platelet count falls be low 50,000/mm3 and is subsequently 
confirmed (see Section 8.5), dosing with volanesorsen  will be stopped permanently.  The 
follow- up schedule for any events meeting this stoppi[INVESTIGATOR_37655]. Following a rechallenge platelet count should be tested every week until count is stable. 
Any unrepor table platelet count result must be rechecked and determined not to have met a 
stoppi[INVESTIGATOR_10450]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
39  Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndr ome, and/or  
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non- Major Bleeding Events (Schulman et al . 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleed ing, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
8.7 Adjustment of Dose Frequency  
Dose adjustments, including dose interruptions, and/or decreasing the dose frequency will be allow ed for safety and tolerability.  Any proposed adjust ment to treatment schedule must be 
discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to 2  adjustments in the treatment schedule may be allowed for patients that are unable to tolerate 
the once weekly dose (for example if platelet counts fall below 50,000/mm
3 as described in 
Section  8.6.3).  If the patient remains stable after adjustment, they may be cautiously returned to 
the original once weekly regimen after consultation with the Study Medical Monitor.  
Patients may be do se paused in response to AE s after consultatio n with Study Medical Monitor. 
8.[ADDRESS_39504] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
40  • The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39505] be recorded in the CRF and source 
documentation. 
8.8.1 Follow- up Visits for Early Termination from Treatment Period  
Any patient who discontinues early from the Treatment Period should be strongly encouraged to 
attend applicable landmark visits at Week s 12, 13, 25, 26, and 51, 52 (calculated based on the 
time elapsed since Day 1) to collect  fasting lipid panels  and conduct safety assessments in 
accordance with the schedule of procedures in Appendix A .  Any patient who discontinues 
treatment after  Week 44 should also be strongly encouraged to attend a final follow-up visit 
(Week 65 visit assessments) approximately [ADDRESS_39506] dose of Study Drug , in 
addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_39507]- Treatment Follow-up 
Period should be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A) prior 
to leaving the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39508] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Signific ant protocol deviation 
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who w ithdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
41  encouraged to complete the ET study procedures and observations at the time of withdra wal 
(see Section 8.8 and Appendix A ). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_39509] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37663].  
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in  the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_37991]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or di etary supplements with potential lipid -altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure  
Plasma apheresis is not allowed during the study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
42  8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and re turn/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_39510] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable re gulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesor sen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 2 Expected Event for the Protocol Defined Population by [CONTACT_37931] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
43  aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the ev ent will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that, had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE 
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
44  medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_39511] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_39512] the patient ’s last protocol- specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Event s 
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week 65 visit.  
The Investigator will monitor each  patient  closely and recor d all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen e.g., 
confirmation by [CONTACT_37720] 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
45  • Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adve rse Ev ent 
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
46  [IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then  the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be ente red as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter.  
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_39513] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37992] 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
47  Medical Monitor.  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_39514] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
48  Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are  
defined as the average of Week 51 (Day 351) and Week 52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ- 5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
49  10.1.2 Safety Endpoints  
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an extension study to the double-blind, 
placebo -controlled ISIS 304801- CS6 and ISIS 304801-CS16 studies .  Approximately 70 patients 
may be eligible to enroll into this study.  
10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39515] 
efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_39516] 1 evaluable PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient:  ISIS 304801-CS6 or 
ISIS 304801-CS16 index study baseline and the baseline in this open label study, which is 
defined as the average of Day [ADDRESS_39517] measure ment prior to Day 1 
(e.g., qualification assessments or assessments from final visit of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
ISIS [ADDRESS_39518] patient’s Week [ADDRESS_39519] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoints will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be asses sed in the PK Set as applicable.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_37942].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AE s will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
51  Laboratory tests to ensure patient safety inclu ding chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
These safety variables will also be presented as change and percent chan ge from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_37948].  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, 
Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a 
range of fasting plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 w ill also be 
summarized by [CONTACT_37947]-HDL -C, apoB, HDL-C, apoA-1, VLDL-C, and LDL-C, total cholesterol, and fasting total 
apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, qual ity of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification by [CONTACT_37950] 304801- CS6 and ISIS 304801-CS16 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open label extension 
(OLE ) study from the intensive PK sub group, following a single dose (i.e., single-dose PK) or 
multiple dose s (i.e., steady -state PK), depending on their earlier treatment in the index studies.  
On Week [ADDRESS_39520] treatment of volanesorsen (single -dose PK), while patients who received 
volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data collected from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C max) and the time 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
52  taken to reach C max (Tmax) will be obtained directly from the concentration -time data .  Area under 
the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24hr) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24hr /F0-24hr) will be calculated from CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean 
residence time (MRT) from time zero to 24 hours after the SC administration will be calculated 
from the equation, MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the 
moment plasma concentration -time curve from time zero to [ADDRESS_39521]. 
Plasma PK  parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_37993] 304801- CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK  analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be rep orted separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Stu dy Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 and study day.  
Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the 
study day associated  with the first positive IM status emerged (T first, i.e., onset of ADA 
development), the last positive IM status observed (T last), the duration of ADA response (number 
of days between T first and T last) if appropriate, the last ADA sample collection day,  and subject - 
peak titer if applicable, will be listed by [CONTACT_37732] 304801 -CS6 and 
ISIS 304801-CS16  study day .  Subjects with positive anti-volanesorsen antibody status may be 
further classified ( when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, 
if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable, 
will be summarized as median, quartiles (25 % and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and  included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
53  11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study. 
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by t he patient  and by [CONTACT_37994] (not necessarily an Investigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569] , and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_39522] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October  2002 the applicable regulations and guidelines of curre nt Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
ISIS [ADDRESS_39523] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentialit y of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_39524] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_39525].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and of fice charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
55  Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IE C/IRB  and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence 
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the I nvestigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_39526], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
ISIS [ADDRESS_39527] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials an d will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
57  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification an d definitions by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, et al. Apo lipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism  of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, Universit y of Washington, Seattle; 1999- 2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleo tide therapeutics . Ann Rev. Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term s afety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther  2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
58  Ito Y, Azrolan N, O'Connell A, et al. Hyper triglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486]. Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ , Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very -low-density lip oprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.  
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566-575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in  clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic li pase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
  
ISIS [ADDRESS_39528] 
Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3   
Wk 
16 Wk 
19 Wk 
22 Month 6  
Wk 
29 Wk 
32 Wk 
35 Wk 
38 Wk 
41 Wk 
44 Wk 
47 Month 12  
Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52  
or ET 
Study Day  -14 to -7 1 2 22 50 78 85 106 127 148 169 176 197 218 239 260 281 302 323 351 358 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 3 3 3 2 2 3 3 3 3 3 3 3 2 2 7 7 
Informed Consent  X                       
Outpatient Visit  X X Xk Xk Xk Xk X Xk Xk Xk Xk X Xk Xk Xk X Xk Xk Xk Xk X Xk X 
Inclusion/Exclusion Criteria  X                       
Vital Signs + body weight  
(+ height on Day 1 only)  X X  X X  X     X    X     X  X 
Physical Examination   X     X     X    X     X  X 
12- lead ECG (triplicate)        X     X    X     X  X 
MRI (liver/spleen)                      Xl   
Echocardiography            Xl         Xl   Blood Draw (Fasting)c Chemistry Panel  X X  X X  X  X   X  X  X  X   X X X 
CBC with Differentialb X X  X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel  X X  X X X X    X X    X    X X  X 
Coagulation (aPTT, PT, INR)  PG    X  X     X    X     X   
hsCRP, HbA1c, FPG, and de -lipi[INVESTIGATOR_37491]   X     X     X         X  X 
Sedimentation Rate   X     X     X         X  X 
Complement (C5a, Bb)   X     X     X         X  X 
Plasma PK - Volanesorsen   Xm X X X  X     X    X     X  X 
Anti-Volanesorsen Antibodies   X  X X  X     X    X     X  X 
FSH (women only, if applicable)                         
Serum Pregnancy Testd X   X X  X  X   X  X  X  X   X X X 
Archived Serum & Plasma Samplese  X   X  X     X         X  X 
 
ISIS [ADDRESS_39529] 
Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3  
Wk 
16 Wk 
19 Wk 
22 Month 6  
Wk 
29 Wk 
32 Wk 
35 Wk 
38 Wk 
41 Wk 
44 Wk 
47 Month 12  
Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52 
or ET  
Study Day  -14 to -7 1 2 22 50 78 85 106 127 148 169 176 197 218 239 260 281 302 323 351 358 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 3 3 3 2 2 3 3 3 3 3 3 3 2 2 7 7 
Urinalysisc X Xn  X X  Xn  Xn   Xn  Xn  Xn  Xn   Xn Xn Xn 
Fundus Photographyf X                    Xl   
Genetic testing for FCS diagnosis (if not 
available in medical history)g X                       
Postheparin Lipoprotein Lipase activityh X                       
Weekly Study Drug:  SC Injection  X  X X X X X X X X X X X X X X X X X X   
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X     X     X         X  X 
Food/Drink Diary (quarterly)i  X     X     X         X  X 
Diet/Alcohol Counselingj X X  X X  X     X    X     X X X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X  X X X X X X X X X X X X X X X X X X X X 
a Qualification procedures performed (Please refer to Section 4.1) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are unreportable (e.g. , due to hemolyzed or clumped blood samples) another sample must be repeated 
within 1-week  and determined not to have met a stoppi[INVESTIGATOR_10450].  Any case of a platelet count ≤ 50,000/mm3 should be reported in 
an expedited fashion to the Sponsor  
c Blood samples to be collected after an overnight fast of at least 10 hours  and preferably not more than 12 hours .  During treatment period urine and blood 
samples will be collected prior to Study Drug  administration .  Does not  apply to 24-hour PK blood draw  
d Females of childbearing pot ential only  
e Serum and plasma samples will  be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or su bseq uent clinical studies of  
volanesorsen  
ISIS [ADDRESS_39530] dose of Study Drug (ISIS 304801-CS16 rollover patients) and repeated 
at Week 52 (Please refer to Section [IP_ADDRESS]) 
g Genetic testing can be conducted for study qualification (ISIS 304801-CS16 rollover patients); genetic testing will only be conducted if allowed in the 
geographic region and only after the patient has  given specific written informed consent for genetic testing  
h Post-heparin lipoprotein lipase activity  can be conducted for study qualification (ISIS 304801-CS16 rollover patients; please refer to Section 6.2.10) 
i In addition to diary, patients will be contact[CONTACT_37787]  
j To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
k Assessments and procedures to be conducted by [CONTACT_5640] a home healthcare nurse, or the Study Center as arranged by [CONTACT_37747]  
l A ± 7-day window is allowed for MRI , echocardiography procedures and fundus photography  
m Full or abbreviat ed PK profile (see Appendix C ) 
n Expanded urinalysis (see Appendix B ) 
 
ISIS [ADDRESS_39531] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other Assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_39532]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days  0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
 PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days  [ADDRESS_39533]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24- hour PK profile beginning on 
Study  Day 1.  Participation is optional  
 
  
ISIS [ADDRESS_39534] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
70  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 3  
Protocol   9 May  2016  
 
71  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 

 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_39535] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_39536] 
Cambridge, MA [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 2  –[ADDRESS_39537] No:  2015-003755-21 
 
 
 

ISIS 304801-CS7 
Protocol CONFIDENTIAL 
ISIS 304801-CS7 
The APPROACH Open Label Extension Study 
Volanesorsen (ISIS 304801) Amendment2 
22 April 2016 
An Open-Label Extension Study ofVolanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Amendment 2-22 April 2016 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_39538] 2015 
2 February 2016 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_39539] No:   2015-003755-21 
Clinical Phase:   3 
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_39540]  
Carlsbad, CA [ZIP_CODE] 
Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:   [CONTACT_37829].D.  
[ADDRESS_39541] 
Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator:  Akcea Therapeutics  
[ADDRESS_39542] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_39543] of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Amendment:  Amendment 2 
Date:    [ADDRESS_39544] read and understand the attached clinical protocol , entitled “An 
Open -Label Extension  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_39545] the 
study as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_39546] ................................................................................26  
4. PATIENT ENROLLMENT ...............................................................................................26  
4.1 Qualification  ..................................................................................................................26  
4.2 Enroll ment  .....................................................................................................................26  
5. PATIENT ELIGIBILITY  ..................................................................................................26  
5.1 Inclusion Criteria  ...........................................................................................................26  
5.2 Exclusion Criteria  ..........................................................................................................27  
6. STUDY PROCEDURES  ....................................................................................................28  
6.1 Study Schedule ..............................................................................................................28  
6.1.1  Qualification  ...........................................................................................................28  
6.1.2  Treatment Period  ....................................................................................................28  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_39547]- Treatment Period  ............................................................................................29  
6.2 Additional Study Assessments  .......................................................................................29  
6.2.1  Laboratory Assessments  .........................................................................................29  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
6  6.2.2  Physical Exams and Vital Signs  .............................................................................29  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................29  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_39548]- Treatment Follow -up Period .41  
8.9 Withdrawal of Patients from the Study  ..........................................................................41  
8.10  Concomitant Therapy and P rocedures  ...........................................................................41  
8.10.1  Concomitant Therapy .............................................................................................41  
8.10.2  Concomitant Procedures .........................................................................................42  
8.11  Treatment Compliance  ...................................................................................................42  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................42  
9.1 Sponsor Review of Safety Information .........................................................................42  
9.2 Regulatory Requirements  ..............................................................................................42  
9.3 Definitions  .....................................................................................................................43  
9.3.1  Advers e Event  ........................................................................................................43  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................44  
9.3.3  Serious Adverse Event (SAE) ................................................................................44  
9.4 Monitoring and Recording Adverse Events  ...................................................................44  
9.4.1  Serious Adverse Events ..........................................................................................44  
9.4.2  Non-Serious Adverse Events ..................................................................................45  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................45  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................45  
[IP_ADDRESS]  Severity  ............................................................................................................46  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................46  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................46  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................46  
9.4.4  Adjudication Committees  .......................................................................................47  
9.5 Procedures for Handling Special Situations ..................................................................47  
9.5.1  Abnormalities of Laboratory Tests .........................................................................47  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............47  
9.5.3  Dosing Errors .........................................................................................................48  
9.5.4  Contraception and Pregnancy .................................................................................48  
10. STATISTICAL CONSIDERATIONS  ..............................................................................49  
10.1  Study Endpoints  .............................................................................................................49  
10.1.1  Efficacy Endpoints .................................................................................................49  
10.1.2  Safety Endpoints .....................................................................................................49  
10.2  Sample Size  ....................................................................................................................50  
10.3  Populations .....................................................................................................................50  
10.4  Definition of Baseline ....................................................................................................50  
10.5  Interim Analysis  .............................................................................................................50  
10.6  Planned Methods of Analysis ........................................................................................50  
10.6.1  Demographic and Baseline Characteristics  ............................................................51  
10.6.2  Safety Analysis  .......................................................................................................51  
10.6.3  Efficacy Analysis  ...................................................................................................51  
ISIS 304801-CS7 CONFIDENTIAL Amendment 2
Protocol  22 April 2016
 
8  10.6.4 Pharmacokinetic and Imm unogenicity Analysis ....................................................52  
[IP_ADDRESS] Pharmacokinetic Analysis ................................................................................52  
[IP_ADDRESS] Immunogenicity Analysis ................................................................................53  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS .................................................[ADDRESS_39549] of the Study .........................................................................................54  
11.3 Independent Ethics Committee/ Institutional Review Board .........................................[ADDRESS_39550] of Laboratory Analytes .............................................................................64  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................66  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities ......68  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ........................................................ 32  
Table 2  Expected Event for the Protocol Defined Population by [CONTACT_37895] .................................................................................. 43  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC-III Regulates Lipoprotein Metabolism by [CONTACT_37675] .............. 19  
Figure 2  Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE-Gapmer).  The sequence of volanesorsen is shown ................................... 21  
Figure 3  Fasting Triglycerides in Patients with  FCS Treated with Volanesorsen .............. 23  
  
ISIS 304801-CS7 CONFIDENTIAL Amendment 2
Protocol  22 April 2016
 
9  PROTOCOL AMENDMENT 
 
Protocol Number: ISIS 304801-CS7 
Protocol Title: An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 
Amendment Number:  2 
Amendment Date: 22 April 2016 
 
The purpose of this protocol amendment is to imp lement the following modifications to Protocol 
ISIS 304801-CS7 Amendment 1 dated 02 February 2016: 
1. To modify the clinical experi ence safety language to reflect updated blinded safety data 
from ongoing studies. 
2. To indicate that the DSMB is independent. 
3. To revise the contraceptive requirements to stat e that abstinence is only acceptable as true 
abstinence, i.e., when it is in line with the preferred and usual lifes tyle of the patient. 
4. To add lipoprotein lipase activity as a qualification assessmen t for ISIS 304801-CS16 
rollover patients. 
5. To add genetic testing as  a qualification assessment for ISIS 304801-CS16 rollover 
patients. 
6. To increase the frequency of the pregnancy testing. 
7. To add hematology blood draws at Weeks 12, 16, 22, 25, 29, 35, 41, 47, and 51 to more frequently assess platelet counts. 
8. To allow blood sampling at Weeks 4, 8, 12, 16, 19, 22, 25, 29, 32, 35, 41, 44, 47, 51, and 58 to be conducted by a home healthcare nurse. 
9. To allow blood sampling at the 24-hour PK blood draw to be conducted by a home 
healthcare nurse. 
10. To add language that each time a hematol ogy lab is drawn and sent to the central 
laboratory for analysis, an additional sample should be collected in parallel and analyzed 
locally, to reduce the occurrence of  unreportable hematology results. 
11. To provide guidance that the length of fasting should preferably not be more than 
12 hours. 
ISIS 304801-CS7 CONFIDENTIAL Amendment 2
Protocol 22 April 2016
10  12.To update platelet monitoring rule language to allow for more frequent monitoring as
determined by [CONTACT_37995].
13.To add language to the safety monitoring for insulin, oral antidi abetic medication and
glucose that all patients, incl uding those not on insulin, who use a glucometer should also
bring their glucometer and/ or glucometer log printout  to every clinic visit.
14.To clarify guidance on determining relatedness of a S[LOCATION_003]R.
Minor administrative changes or corrections (not in cluded in the list of ch anges) have been made 
throughout the protocol in order to  improve the overall clarity of the protocol but these changes 
do not impact the study design. 
The following table provides a summary list of changes to the protocol: 
Protocol Section Description of Change Rationale 
Section 2.3.[ADDRESS_39551] on the renal (serum 
creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase (ALT), as partate aminotran
sferase 
(AST), bilirubin). 
 In Phase [ADDRESS_39552]-treatment period an d was not associated with 
platelet-related adverse events.  In the blinded 
ongoing cli nical trials of ISIS 304801, 2 patients of 
142 dosed (as of February 29, 2016) had 
a 
decrease in platelet count to less 
than 50,000/mm3 
in the absence of major bleeding or clinically-
relevant non-major bleeding and had 
Study Drug 
paused as per the monitoring and stoppi[INVESTIGATOR_37516] (Section 8.6.3).  Platelet counts 
recovered 
following suspension of dosing. To modify the clinical 
experience safety language to reflect updated blinded 
safety data from ongoing 
studies 
Section 3.[ADDRESS_39553] (DSMB) To clarify that the DSMB is independent  
Protocol Synopsis Study Population 
Section 5.1 Inclusion 
Criteria 
Section 6.3.1 
Contraception 
Requirements  Abstinence is only acceptable as true abstinence, 
i.e., when this is in line with the preferred and usual
lifestyle of the patient.  Periodic abstinence (e.g.,
calendar, ovulation, symptothermal, post-ovulation
methods), declaration of abstinence for the duration
of a trial and withdrawal are not acceptable methods
of contraceptionPer the MHRA’s guidance to 
state that only true 
abstinence would be 
acceptable, and that periodic 
abstinence is not an 
acceptable method of 
contraception 
Section 6.2.10 Lipoprotein 
Lipase Activity Sample Collection 
Appendix A Schedule  
of Procedures Lipoprotein lipase (LPL) activity will be measured in 
ISIS 304801-CS16 rollover pat ients 
if needed for 
study qualification.  In brief, fasted patie nts will be 
given a low i ntravenous 
dose of heparin.  A blood 
sample will be drawn prior to and at [ADDRESS_39554] heparin lipoprotein lipase activit y can be 
conducted for study qualification (ISIS 304801-CS16 
rollover patients; please refer to Section 6.2.10) Lipoprotein lipase activity 
added as a qualification assessment for 
ISIS 304801-CS16 rollover patients 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol  22 April 2016  
11  Protocol Section  Description of Change  Rationale  
Appendix A Schedule  
of Procedures  Genetic testing can be conducted for study 
qualification (ISIS 304801-CS16 rollover patients); 
genetic testing will only be conducted if allowed in 
the geographic region and only after the patient has 
given specific written informed consent for genetic testing  Genetic testing added as a 
qualification assessment for 
ISIS 304801-CS16 rollover 
patients  
Appendix A Schedule  
of Procedures  Pregnancy testing was added at Weeks 4, 19, 32, 
44, an d 58 To reduce the time period 
between pregnancy tests  
Appendix A Schedule  
of Procedures  Hematology blood draws were added at Weeks 12, 16, 22, 25, 29, 35, 41, 47, and 51  To implement more frequent evaluation of platelet counts to assess platelet 
fluctuations during the course of the study and to increase monitoring of 
platelet counts in patients for 
safety purposes  
Section 6.1.2 Treatment  
Period 
Appendix A Schedule  
of Procedures  Blood sampling at Weeks 4, 8, 12, 16, 19, 22, 25, 
29, 32, 35, 41, 44, 47, 51, and 58  may be 
conducted by a home healthcare nurse  To decrease study burden 
on the patient by [CONTACT_37996] a visit to 
the clinic or study  center for 
blood draws  
Section 6.1.3 
Pharmacokinetic (PK) 
Subgroup  
Appendix A Schedule  
of Procedures  Patients in this subgroup will have an additional visit 
to the clinic, or by a home healthcare nurse, on 
Day [ADDRESS_39555] -dose blood draw 
after dosing on Day 1  To decrease study burden 
on the patient by [CONTACT_37996] a visit to the clinic or study  center for 
the 24- hour PK blood draw  
Appendix A Schedule  
of Procedures  Each time a hematology lab is drawn and sent to the 
central laboratory for analysis an additional sample 
should be collected in parallel and analyzed locally.  
In the event that both the central and local sample 
are uninterpretable (e.g. , due to hemolyzed or 
clumped blood samples) another sample must be 
repeated within 1 -week.  To reduce the occurrence of unreportable hematology 
results (e.g., hemolyzed or 
clumped blood samples)  
Section 6.3.2 Treatment  
Period 
Appendix A Schedule  
of Procedures  Wording was added to note that fasting should 
preferably not be more than 12 hours  To provide guidance on the length of fasting  
Section 8.5.2  
Safety Monitoring for 
Platelet Count Results  Addition to platelet monitoring rules that more frequent testing may also be required  To allow more frequent monitoring of platelets when 
appropriate  
Section 8.5.6  
Safety Monitoring for Insulin, Oral Antidiabetic  
Medication and Gl ucose  In addition, patients who are not on insulin (e.g. , 
patients with type 2 diabetes), but use a glucometer should also bring their glucometer and/or 
glucometer log printout to every clinic visit.  To implement that all patients, including those not 
on insulin, who use a 
glucometer should also bring their glucometer and/or glucometer log printout to 
every clinic visit  
Section 9.2 Regulatory  
Requirements  In addition to the Investigator’s assessment of 
relatedness, the Sponsor  or designee will evaluate 
the available information and perform an 
independent assessment of relatedness .  While the 
Sponsor may upgrade an Investigator ’s decision it is 
not permissible to downgrade the I nvestigator’s 
opi[INVESTIGATOR_37664] d efinition of a S[LOCATION_003]R.  To clarify guidance on determining relatedness of a S[LOCATION_003]R 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol  22 April 2016  
12  PROTOCOL SYNOPSIS  
Protocol Title An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome 
Study  Objective s To evaluate the safety and efficacy of extended dosing with volanesorsen  
(volanesorsen sodium 300 mg ) in patients with FCS  
Study Design  This is a multi -center, open-label extension study  of ISIS 304801-CS6  and 
ISIS 304801-CS16 .  All patients will receive volanesorsen [ADDRESS_39556] -treatment evaluation period.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria:  
1. Must give written informed consent to participate in the study (signed
and dated) and any authorizations required by [CONTACT_2371]
2. Age ≥ 18 years at time of informed consent
3. Satisfactory completion of ISIS 304801-CS6  or ISIS 304801- CS16
(index studies)  with an acceptable safety profile, per  Sponsor  and
Investigator judge ment .  Patients who are enrolled in ISIS 304801-CS16
must also meet the following criteria in order to enter  into the Extension
Study:
a.History of chylomicronemia as evidenced by [CONTACT_37997] (a creamy top layer after ultracentrifugation of a
fasting blood sample) or documentation of fasting TG measurement
≥ 880 mg/dL (10 mmol/L)
b.A diagnosis of Familial Chylomicronemia Syndrome (Type 1
Hyperlipoproteinemia) by [CONTACT_37685] 1 of the
following:
•Confirmed homozygote, compound heterozygote or double
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoC -II, GPI[INVESTIGATOR_37445]1, or LMF1)
•Post heparin plasma LPL activity of ≤ 20% of normal
c.Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the
ISIS 304801-CS16 study
4. Able and willing to participate in a 65-week study
5. Satisfy 1 of the following:
a.Females:  Non- pregnant and non-lactating; surgically sterile (e.g.,
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral
oophorectomy), post -menopausal (defi ned as 12 months of
spontaneous amenorrhea in females > 55 years of age or, in
females ≤ 55 years, 12 months of spontaneous amenorrhea without
an alternative medical cause and FSH levels in the postmenopausal
range for the laboratory involved), abstinent *, or if engaged in
sexual relations of child- bearing potential, patient is using an
acceptable contraceptive method (refer to Section 6.3.1) from time
of signing the informed consent form until 13 weeks after the lastdose of Study Drug administration
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
13  PROTOCOL SYNOPSIS Continued  
Study Population Continued  Inclusion Criteria:  Continued  
b. Males:  Surgically sterile, abstinent * or if engaged in sexual 
relations with a female of child -bearing potential, patient is utilizing 
an acceptable contraceptive method (refer to Section 6.3.1) from 
the time of signing the informed consent form until [ADDRESS_39557] dose of Study Drug administration 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
Exclusion Criteria:  
1. Have any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37601], or could interfere with the patient participating in or 
completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the 
study ( Section 6.3 ) 
Treatment Group Volanesorsen 300 mg once per week  
Study Drug Administration Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
Rationale for Dose and Schedule Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6 - and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies which included a subset of patients with FCS .  This is an 
extension to the ISIS 304801- CS6 and ISIS 304801-CS16  index studies.  
Only the subset of patients  from ISIS 304801 -CS16 with FCS  diagnosis  may 
enter  the Extension Stu dy.  (Please refer to inclusion criteria #3, above)  
Study Visit Schedule and Procedures  The study for an individual patient will generally consist of the following 
periods:  
• A qualification period of up to 2 weeks (unless approved by [CONTACT_429]) .  Please refer to Section 4.1 and Appendix A .  A 52 -week 
treatment period during which volanesorsen will be administered as 
a once weekly SC injection  
• A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will r emain blinded to 
lipid data through the last patient’s Week [ADDRESS_39558] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms 
and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow -up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39559] -treatment 
evaluation period.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
14  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen will be assessed by 
[CONTACT_37798] (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters.  
Planned Analyses  Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis 
and MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints:  
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid 
measurements including total cholesterol, non- high-density 
lipoprotein-cholesterol (non-HDL -C), apolipoprotein B [apoB], high-
density lipoprotein- cholesterol (HDL -C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adj udicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations  Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients, more frequent assessment of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detailed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an extension study to the double-blind placebo controlled ISIS 304801-CS6  and ISIS 304801-CS1 6 
index studies . 
Sponsor  Ionis Pharmaceuticals, Inc . 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
15  STUDY DESIGN AND TREATMENT SCHEMA  
 
QUALIFICATION  
PERIOD  
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
enco uraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
Weeks 1 to 52 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
Weeks 53 to 65 
Safety, efficacy, PK and PD assessments  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
16  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39560]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39561] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OLE  Open Label Extension  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39562]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
18  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of extended dosing with 
volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inh erited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 
15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanth omas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, 1 hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37552], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are tho ught to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL acti vity.  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a numb er of key genes, and loss -of-function mutations in one of these genes, or 
the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
19  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL- mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] (Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC- III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hyd rolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1 = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
20  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype 
analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC- III protein, a fav orable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC- III polymorphisms associated with higher plasma TG have also been recently described 
(Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC-III and TG levels, and decreased ability to clear postprandial plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the l imit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide  the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ unt ranslated region  of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
21  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity , it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
22  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volan esorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  Gen eral toxicity studies with volanesorsen for up to 39 weeks of 
treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardio vascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  huma n  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39563] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotox ic (in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
23  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen  from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG- lowering therap y, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an open 
label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39564] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine 
aminotransferase [ ALT ], aspartate aminotransferase [ AST ], bilirubin).  In Phase [ADDRESS_39565]- treatment  period and was not associated with platelet- related adverse events  (AEs).  
In the blinded ongoing clinical trials of ISIS 304801, 2 patients of 142 dosed (as of February 29, 2016) had a decrease in platelet count to less than 50,000/mm
3 in the absence of major bleeding 
or clinically -relevant  non- major bleeding and had S tudy Drug paused as per the monitoring and 
stoppi[INVESTIGATOR_37498] ( Section 8.6.3).  Platelet counts recovered following suspension 
of dosing. 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39566] Level ( NOAEL ) 
was defined by [CONTACT_37921] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well-tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen wa s studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
25  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label extension  to the Phase 3 study of volanesorsen in patients with F CS 
(ISIS  304801- CS6 or ISIS 304801-CS16).  Up to approximately [ADDRESS_39567] of the following periods: 
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer to 
Section 4.1 and Appendix A . 
• A 52-week  treatment period during which volanesorsen  will be administered as a once 
weekly SC injection  
• A [ADDRESS_39568]- treatment evaluati on period 
Please refer to the Schedule of Procedures in Appendix A. 
3.4.1 Qualification  
A period of up to 2 weeks  is given to complete  qualification  assessments outlined in the 
Schedule of Procedures (Appendix A). 
3.4.2 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule or Procedures (Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_39569] (DSMB) will review (as needed)  safety, 
tolerability and efficacy data collected on volanesorsen during this stu dy.  Based on its ongoing 
assessment of the safety and tolerability of volanesorsen, the DSMB will provide 
recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  
Details on the safety assessments, frequency of review and meeting schedules are outlined in the 
DSMB Charter and /or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form,  and all other patient  information . 
Patient s or their legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open label study are performed .  During the 
qualification period, the eligibility of the patient to continue in the extension study will be 
determined .  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may be 
used for qualification.  A period of up to 2 weeks after completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801- CS16 index s tudies.  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_39570] been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_39571] give written informed consent to participate in the study (signed and dated) and any 
authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-CS16 (index studies) with 
an acceptable safety profile, per Sponsor and Investigator judgement.  Patients who are 
ISIS [ADDRESS_39572] also meet the fol lowing criteria in order to enter  into 
the Extension Study: 
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation 
of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) by [CONTACT_37685] 1 of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1 -causing genes (such as LPL, apoC -II, 
GPI[INVESTIGATOR_37445]1, or LMF1) 
• Post heparin plasma LPL activity of ≤ 20% of normal 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-CS16 study. 
4. Able and willing to participate in a 65 -week study  
5. Satisfy 1 of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH levels in the postmenopausal range for the laboratory involved), abstinent*, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39573] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent* or if engaged in sexual relations with a female of 
child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_39574] dose of Study Drug administration. 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a 
trial and withdrawal are not acceptable methods of contraception  
5.[ADDRESS_39575] any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37524], or could interfere with the 
patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section  6.3). 
ISIS [ADDRESS_39576] patient’s Week [ADDRESS_39577]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
5 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunoge nicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Dietary counseling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesorsen a dministration .  Blood sampling  at Week s 4, 8, 
12, 16, 19, 22, 25, 29, 32, 35, 41, 44, 47, 51, and [ADDRESS_39578] be sent to the central laboratory for 
analysis .  Every effort should be made to ensure the previous week’s dose is given 7 days prior 
to a scheduled clinic visit.  Dosing instructions and training will be provided to the patient where 
applicable.  
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an  extended PK collection .  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_39579]-dose blood draw after dosing on Day 1.  The detailed PK sampling 
schedules are outlined in Appendix C. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
29  Participation in the PK subgroup is optional for sites and  patients,  and consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A . 
6.1.[ADDRESS_39580]- treatment evaluation period .  This period consists of 2 Study Center visits on Weeks 58 and 
65 as outlined in the Schedule of Procedures in Appendix A. 
6.2 Additional Study  Assessments 
6.2.1 Laboratory Assessments  
Laboratory analyte samples will be collected throughout the study. 
A lis t of these analytes  is contained in Appendix B . 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate, respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (pr eferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis will be assessed by [CONTACT_37849] (for ISIS 304801-CS16 rollover patients) and repeated at Week 52.   
Images will be evaluated by [CONTACT_37998], blinded to the patient’s treatment 
assignment.  
6.2.[ADDRESS_39581] 
5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26, Week 3 8, Week 52, and 
Week 65 . 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week 1, 
Week  13, Week  26, Week 52, and Week 65. 
6.2.[ADDRESS_39582]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_37704].  Qualified study personnel will telephone the patient to provide diet/alcohol couns eling for visits that are conducted by a clinical service.  
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, 
telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintain ing their diet will be conducted randomly during the treatment and post 
treatment follow -up periods. 
6.2.9 Family  History  
Family history of hypertriglyceridemia and pancreatitis  will be collected for each patient.  
6.2.10 Lipoprotein Lipase Activity Sample Collection  
Lipoprotein lipase (LPL) activity will be measured in ISIS 304801-CS16 rollover patients if needed for study qualification.  In brief, fasted patients will be given a low intravenous dose of 
heparin.  A blood sample will be drawn prior to and at [ADDRESS_39583] refrain from sperm/egg donation and 
either be abstinent* or, if engaged in sexual relations of child-bearing potential, practice effective 
contraception from the time of signing the informed consent form until at least [ADDRESS_39584]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgic al sterilization (e.g., bilateral tubal ligation), hormonal contraception, 
intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using one or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
*Note : A female condom and a male condom should not be used together as friction between the 
two can result in either product failing . 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
32  * Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the pati ent.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not 
acceptable methods of contraception  
6.3.[ADDRESS_39585] 10 hours and preferably not more than 12 hours 
before visits requiring fasted blood sampling. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39586] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered  to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39587] (ISIS 304801) characteristics are listed in Table 1. 
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
ISIS [ADDRESS_39588] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for  Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_39589] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the fi nal visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37659] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_37660], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest 
must be available prior to administering the next  dose of volanesorsen. 
ISIS [ADDRESS_39590] 
confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  If any of the stoppi[INVESTIGATOR_37661] (refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be permanently discontinued 
from further treatment with volanesorsen, evaluated fully as outlined below and in consultation 
with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up 
in accordance with Section 8.8 of the protocol. 
8.5.1 Safety Monitoring for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury
: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S.  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in Section 8.[ADDRESS_39591] measurement that is > [ADDRESS_39592]  (or the greater of [ADDRESS_39593] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurement s should also be performed if ALT or AST levels increase 
to [ADDRESS_39594]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39595] (or 
the greater of [ADDRESS_39596] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_39597] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39598]  (or the greater of [ADDRESS_39599] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain  a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
35  Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered i f a 
patient ’s ALT and/or AST levels reach [ADDRESS_39600] . 
8.5.2 Safety Monitoring for Platelet Count Results  
In the event of any significant fall in platelet count, or if the absolute platelet count is 
75,000/mm3 or less, then the patient’s platelet counts should be monitored more frequently.  The 
frequency of monitoring and additional lab tests will be determined by [CONTACT_37878].  
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically -
relevant , non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a m inor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_39601] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, L DL-C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or increase 
the statin  dose for patients who are already on treatment).  
8.5.[ADDRESS_39602] 
practice guidelines and bring their glucometer or glucometer log printout to every clinic visit.   In 
addition, patients who are not on insulin (e.g., patients with type 2 diabetes), but use a glucometer should also bring their glucometer and/or glucometer log printout to every clinic 
visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
36  All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or delegate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37505]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] ≤ 70 mg/dL  (≤ 3.9 mmol/L. 
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as 1 in which the patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level ≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at risk for injury to themselves or others.  Note that “requires assistance” mean s that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from patient to patient.  However, there are 
certain classical signs and symptoms, of which patients should be aware as a clue that their blood glucose may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating, and weakness.  Coma could 
occur if blood sugar correction is not performed.  
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, th en obtain and record a blood glucose value as soon as possible 
thereafter.  The time and nature of treatment should be noted, and especially if any blood glucose 
result was before or after treatment.  It would be helpful for the patient to note if a contributory 
factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day 
of the event.  
ISIS [ADDRESS_39603] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within [ADDRESS_39604]).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value exceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_39605] the Investigator and an unscheduled 
central laboratory FPG measurement and HbA1c should be performed. 
The threshold values are defined as:  
• FPG > 270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condition (i.e., after at least [ADDRESS_39606]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonab ly explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  (AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
38  8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable.  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_39607] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_39608] >  [ADDRESS_39609] , which is confirmed and persists for ≥ [ADDRESS_39610] >  [ADDRESS_39611] (or the greater of [ADDRESS_39612] if the baseline 
value was > ULN) , which is confirmed and total bilirub in > [ADDRESS_39613]  or INR  > 1.[ADDRESS_39614] >  [ADDRESS_39615] (or the greater of [ADDRESS_39616] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37854]  
8.6.[ADDRESS_39617] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
3 criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and Gault ≤ 40 m L/min that is confirmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37855]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
39  8.6.3 Stoppi[INVESTIGATOR_37662] a platelet count less than 50,000/mm3 that is associated with  major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up sch edule for any events meeting  
this stoppi[INVESTIGATOR_37564]. 
In the event of a platelet count less than 50,000/mm3, and in the absence of major bleeding or 
clinically -relevant  non-major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered to 
≥ 100,000/mm3.  The suitability of the patient for continued dosing and the need for any 
modification to treatment schedule (refer to Section 8.7) will be determined by [CONTACT_37999]’s platelet count, whether any bleeding events were experienced by 
[CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If after the first dosing re -challenge the platelet count again falls below 50,000/mm3, then dosing 
of the patient must be held until the platelet count again returns to at least 100,000/mm3.  The 
suitability of the patient for continued dosing and the need for any further modification to 
treatment schedule or dose (refer to Section 8.7) will be re -examined by [CONTACT_37990] (at least) the factors mentioned above. 
If after the second re- challenge the platelet count falls below 50,000/mm3 and is subsequently 
confirmed (see Section 8.5), dosing with volanesorsen  will be stopped permanently.  The 
follow- up schedule for any events meeting this stoppi[INVESTIGATOR_37655]. 
Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events ( Schulman et al . 2005):  
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related)  
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
40  5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis 
6. Bleeding after venipuncture for > 5 minutes 
8.7 Adjustment of Dose Frequency  
Dose adjustments, including dose interruptions, and/or decreasing the dose frequency will be 
allow ed for safety and tolerability.  Any proposed adjustment to treatment schedule must be 
discussed with, and approved by, the Study Medical Monitor prior to initiation .  Up to 
2  adjustments in the treatment schedule may be allowed for patients that are unable to tolerate 
the once weekly dose (for example if platelet counts fall below 50,000/mm3 as described in 
Section  8.6.3).  If the patient remains stable after adjustment, they may be cautiously returned to 
the original once weekly regimen after consultation with the Study Medical Monitor.  
Patients may be dose paused in response to AE s after consultatio n with Study Medical Moni tor. 
8.[ADDRESS_39618] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patient experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39619] be recorded in the CRF  and source 
documentation. 
8.8.1 Follow- up Visits for Early Termination from Treatment Period  
Any patient who discontinues early from the Treatment Period should be strongly encouraged to 
attend applicable landmark visits at Week s 12, 13, 25, 26, and 51, 52 (calculated based on the 
time elapsed since Day 1) to collect  fasting lipid panels  and conduct safety assessments in 
accordance with the schedule of procedures in Appendix A .  Any patient who discontinues 
treatment after  Week 44 should also be strongly encouraged to attend a final follow-up visit 
(Week 65 visit assessments) approximately [ADDRESS_39620] dose of Study Drug , in 
addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_39621]- Treatment Follow-up 
Period should be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A ) prior 
to leaving the study. 
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39622] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from s tudy, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
8.[ADDRESS_39623] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37665]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing 
informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
42  recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega- 3 fatty acids should make every effort t o remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] ( e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents during the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas  measurement, bacterial cultures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diar y that will be reviewed periodically by [CONTACT_37860].  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.[ADDRESS_39624] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
43  E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guideline s. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Independent DSMB  will be notified of any SAE 
as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While  the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator ’s opi[INVESTIGATOR_37567] a 
S[LOCATION_003]R.  
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 2 Expected Event for the Protocol Defined Population by [CONTACT_37889] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, 
pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
great er severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event.  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
44  9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about  causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening:  that is,  poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm  requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording Adverse Events  
Any pre -existin g conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should al ways group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_39625] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relati onship to volanesorsen) should be reported to the Sponsor  or designee 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
45  within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_39626] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_39627] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen e.g., 
confirmation by [CONTACT_38000]- challenge test  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship  is 
unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
46  [IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (re fer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by 1 of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by 1 of the following: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
47  • Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on  the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of  death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_39628] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_37866].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
48  • The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief descriptio n 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_39629] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy t est will be performed .  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known  (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
49  Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are  
defined as the average of Week 51 (Day 351) and Week 52 (Day 358) fasting assessments. 
10.1.1 Efficacy End points 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints  
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
50  10.2 Sample Size  
No sample size calculations were performed as this is an extension study to the double-blind, 
placebo -controlled ISIS 304801- CS6 and ISIS 304801- CS16 studies .  Approximately 70 patients 
may be eligible to enroll into this study.  
10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39630] efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least 1 dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least [ADDRESS_39631] 1 evaluable PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient:  ISIS 304801-CS6 or 
ISIS 304801-CS16 index study baseline and the baseline in this open label study, which is 
defined as the average of Day [ADDRESS_39632] measurement prior to Day 1 
(e.g., qualif ication assessments or assessments from final visit of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in the ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline for safety will be the last non- missing assessment prior to the first dose of Study Drug . 
10.[ADDRESS_39633] patient’s Week [ADDRESS_39634] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
51  will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoints will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be assessed  in the PK Set as applicable.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_38001].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
These safety variables will also be presented as change and percent change fr om baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_37948].  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Mon th 3, 
Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a 
range of fasting plasma TG thresholds for determination of responder status. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
52  Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37947]-HDL -C, apoB, HDL-C, apoA-1, VLDL-C, and LDL-C, total cholesterol, and fasting total 
apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of l ife assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification by [CONTACT_37950] 304801- CS6 and ISIS 304801-CS16 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open label extension 
(OLE ) study fro m the intensive PK sub group, following a single dose (i.e., single-dose PK) or 
multiple dose s (i.e., steady -state PK), depending on their earlier treatment in the index studies.  
On Week [ADDRESS_39635] treatment of volanesorsen (single -dose PK), while patients who received 
volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16), thus the PK data colle cted from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C max) and the time 
taken to reach C max (Tmax) will be obtained directly from the concentration -time data .  Area under 
the plasma concentration -time curve from time zero to 24 hours ( AUC 0-24hr) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24hr /F0-24hr) will be calculated from CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean 
residence time (MR T) from time zero to 24 hours after the SC administration will be calculated 
from the equation, MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the 
moment plasma concentration -time curve from time zero to [ADDRESS_39636]. 
Plasma PK  parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_38002] S tudy ISIS 304801- CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK  analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separatel y. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
53  [IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volane sorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 and study day.  
Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day associated  with the first positive IM status emerged (T
first, i.e., onset of ADA 
development), the last positive IM status observed (T last), the duration of ADA response (number 
of days between T first and T last) if appropriate , the last ADA sample collection day, and subject - 
peak titer if applicable, will be listed by [CONTACT_37732] 304801 -CS6 and 
ISIS 304801-CS16  study day .  Subjects with positive anti-volanesorsen antibody status may be 
further classified (when applicable) as being either ‘persistent’, ‘transient’, or ‘not determinable’, 
if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable, 
will be summarized as median, quartiles (25% and 75%), and range . 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy (e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and reported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whether to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by  [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
ISIS [ADDRESS_39637] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated 
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_39638] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC /IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
ISIS [ADDRESS_39639] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulato ry authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_39640].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the  Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
56  No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_39641], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensur e that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s C linical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and appl icable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any appare nt discrepancies .  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Ce nter for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the S tudy Center  notifications, and agrees with the content. 
12.[ADDRESS_39642] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
57  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein  genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylo microns . Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li  X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle,  WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev. Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; [ADDRESS_39643] 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmaco kinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of  apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 2  
Protocol   22 April 2016  
 
58  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin pla sma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very- low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotide s containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable pl asma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.  
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemo stasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase  (LPL) and 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the i ntrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
  
ISIS [ADDRESS_39644] 
Treatment 
Follow-up
Study Week -2 to -1Wk 
1 Wk
4 Wk
8 Month 3 
Wk 
16 Wk 
19 Wk 
22 Month 6 
Wk 
29 Wk
32 Wk 
35 Wk
38 Wk 
41 Wk
44 Wk 
47 Month 12 
Wk
58 Wk
65 Wk
12 Wk
13 Wk
25 Wk 
26 Wk 
51 Wk 52
or ET 
Study Day -14 to -7 1 2 22 50 78 85 106 127 148 169 176 197 218 239 260 281 302 323 351 358 400 449 
Visit Window+/- Days 0 0 0 2 2 2 2 3 3 3 2 2 3 3 3 3 3 3 3 2 2 7 7 
Informed Consent X                       
Outpatient Visit X X Xk XkXkXk X Xk Xk Xk Xk X Xk Xk Xk X Xk Xk Xk Xk X Xk X 
Inclusion/Exclusion Criteria X                       
Vital Signs + body weight  
(+ height on Day 1 only) X X  X X  X     X    X     X  X 
Physical Examination  X     X     X    X     X  X 
12- lead ECG (triplicate)       X     X    X     X  X 
MRI (liver/spleen)                     Xl   
Echocardiography            Xl         Xl   Blood Draw (Fasting)c Chemistry Panel X X  X X  X  X   X  X  X  X   X X X 
CBC with Differentialb X X  X X X X X X X X X X X X X X X X X X X X 
Serum Lipid Panel X X  X X X X    X X    X    X X  X 
Coagulation (aPTT, PT, INR)     X  X     X    X     X   
hsCRP, HbA1c, FPG, and de-lipi[INVESTIGATOR_37491]  X     X     X         X  X 
Sedimentation Rate  X     X     X         X  X 
Complement (C5a, Bb)  X     X     X         X  X 
Plasma PK - Volanesorsen  Xm X X X  X     X    X     X  X 
Anti-Volanesorsen Antibodies  X  X X  X     X    X     X  X 
FSH (women only, if applicable)                        
Serum Pregnancy Testd X   X X  X  X   X  X  X  X   X X X 
Archived Serum & Plasma Samplese  X   X  X     X         X  X 
ISIS 304801-CS7 CONFIDENTIAL Amendment [ADDRESS_39645] 
Treatment 
Follow-up
Study Week -2 to -1Wk 
1 Wk
4 Wk
8 Month 3 
Wk 
16 Wk 
19 Wk 
22 Month 6 
Wk 
29 Wk 
32 Wk 
35 Wk 
38 Wk 
41 Wk 
44 Wk 
47 Month 12 
Wk
58 Wk
65 Wk
12 Wk
13 Wk
25 Wk 
26 Wk 
51 Wk 52 
or ET 
Study Day -14 to -7 1 2 22 50 78 85 106 127 148 169 176 197 218 239 260 281 302 323 351 358 400 449
Visit Window+/- Days 0 0 0 2 2 2 2 3 3 3 2 2 3 3 3 3 3 3 3 2 2 7 7 
Urinalysisc X Xn  X X  Xn  Xn   Xn  Xn  Xn  Xn   Xn Xn Xn 
Fundus Photographyf X                    Xl   
Genetic testing for FCS diagnosis (if not 
available in medical history)g X                       
Postheparin Lipoprotein Lipase activityh X                       
Weekly Study Drug:  SC Injection  X  X X X X X X X X X X X X X X X X X X   
Symptom Diary (weekly) X X  X X X X X X X X X X X X X X X X X X X X 
Quality of Life Assessment(s)  X     X     X         X  X 
Food/Drink Diary (quarterly)i  X     X     X         X  X 
Diet/Alcohol Counselingj X X  X X  X     X    X     X X X 
Adverse Events X X  X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication X X  X X X X X X X X X X X X X X X X X X X X 
a Qualification procedures performed (Please refer to Section 4.1) 
b Each time a hematology lab is drawn and sent to the central laboratory for analysis an additional sample should be collected in parallel and analyzed locally. 
In the event that both the central and local sample are uninterp retable (e.g., due to hemolyzed or clumped blood samples) anoth er sample must be repeated 
within 1-week 
c Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours.  During tre atment period urine and blood 
samples will be collected prior to Study Drug administr ation.  Does not apply to 24-hour PK blood draw 
d Females of childbearing potential only 
e Serum and plasma samples will be collected and stored for follo w-up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of ki dney function, measurement of anti bodies, etc.) in this or subs equent clinical studies of  
volanesorsen 
f If possible, fundus photography should be completed prior to  administration of the first dose of Study Drug (ISIS 304801-CS16  rollover patients) and repeated 
at Week 52 (Please refer to Section [IP_ADDRESS] ) 
ISIS 304801-CS7 CONFIDENTIAL Amendment 2
Protocol 22 April 2016
 
63  Appendix A Schedule of Procedures Continued 
Legend Text Continued  
g Genetic testing can be conducted for study qualification (ISIS 304801-CS16 rollover pat ients); genetic testing will only be c onducted if allowed in the 
geographic region and only after the patient has given specific written informed consent for genetic testing 
h Post-heparin lipoprotein lipase activity can be conducted for study qualification (ISIS 304801- CS16 rollover patients; please  refer to Section 6.2.10 ) 
i In addition to diary, patients will be contact[CONTACT_37969] s during the study to review their current eating and drinking habits 
j To reinforce compliance to the diet and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be pe rformed by [CONTACT_37828] 
k Assessments and procedures to be conducted by [CONTACT_5640] a home he althcare nurse, or the Study Cent er as arranged by [CONTACT_37970] 
l A ± 7-day window is allowed for MRI, echocardiography procedures and fundus photography 
m Full or abbreviated PK profile (see Appendix C ) 
n Expanded urinalysis (see Appendix B) 
 
ISIS 304804-CS7 CONFIDENTIAL Amendment [ADDRESS_39646] of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better character ize the profile of volanes orsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel 
• Sodium 
• Potassium 
• Chloride 
• Bicarbonate 
• Total protein 
• Albumin 
• Calcium 
• Magnesium 
• Phosphorus 
• Glucose 
• BUN 
• Creatinine 
• Uric Acid 
• Total bilirubin 
• Direct (conjugated) 
bilirubin 
• Indirect (unconjugated) 
bilirubin 
• ALT 
• AST 
• Alkaline phosphatase Coagulation 
• aPTT (sec) 
• PT (sec) 
• INR 
 
Lipid Panel 
• Total Cholesterol 
• LDL-C 
• HDL-C 
• Triglycerides 
• Non-HDL-C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC-III 
 Hematology 
• Red blood cells 
• Hemoglobin 
• Hematocrit 
• MCV, MCH, MCHC 
• Platelets 
• White blood cells 
• WBC Differential (% 
and absolute) 
• Neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes 
• Monocytes 
 
Pharmacokinetics1  
& Immunogenicity 
• Volanesorsen levels in 
plasma 
• Anti-volanesorsen antibodies in plasma 
 
Other assessments 
• hsCRP 
• Sedimentation Rate 
• C5a, Bb 
• De-lipi[INVESTIGATOR_37490] 
• HbA1c, FPG Urinalysis 
• Color 
• Appearance 
• Specific gravity 
• pH 
• Protein 
• Blood 
• Ketones 
• Urobilinogen 
• Glucose 
• Bilirubin 
• Leukocyte esterase 
• Nitrate 
• Microscopic 
examination2 
 
Additional Measures for 
Expanded Urinalysis 
• Total protein (quantitative) 
• Microalbumin 
• β2-microglobulin 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabo lite assessments, IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents 
[ADDRESS_39647]-treatment follow-up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup) 
Week Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day D1 D22 D50 D85 D176 D260 D358 D449 
Visit Window 
+/- Days 0 2 2 2 2 3 2 7 
Time Point Pre-dose Pre-dose Pre-dose Pr e-dose Pre-dose Pre-dose Pre-dose Anytime 
 PK Sampling Schedule (PK Subgroup only*) 
Week Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day D1 D2 D22 D50 D85 D176 D260 D358 D449 
Visit Window 
+/- Days [ADDRESS_39648]-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Anytime 
* Patients at selected sites will be asked to participate in the extended 24-hour PK profile beginning on 
Study Day 1.  Partic ipation is optional. 
 
  
ISIS 304804-CS7 CONFIDENTIAL Amendment [ADDRESS_39649] abnormalities are 
based upon the Common Terminology Criteria for Adv erse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804-CS7 CONFIDENTIAL Amendment 2
Protocol  22 April 2016
 
70  Appendix D Grading Scale for Adverse Events  Relating to Laboratory Abnormalities 
Continued 
 
 
  

ISIS 304804-CS7 CONFIDENTIAL Amendment 2
Protocol  22 April 2016
 
71  Appendix D Grading Scale for Adverse Events  Relating to Laboratory Abnormalities 
Continued 
 
  

  
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_39650] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_39651] 
Cambridge, MA [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH Open Label Extension Study  
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Supplement 1 - [LOCATION_006] – [ADDRESS_39652] No:  2015-003755-21 
 
 
 
 

ISIS 304801-CS7 CONFIDENTIAL 
ISIS 304801-CS7 Protocol Supplement I -[LOCATION_006] 
15 A ril2016 
The APPROACH Open Label Extension Study 
Volanesorsen (ISIS 304801) 
An Open-Label Extension Study ofVolanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS) 
Protocol Supplement 1 -[LOCATION_006] -15 April2016 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
[ADDRESS_39653] 
Carlsbad, CA 920
M.D., M.B.A. 
2 

ISIS 304801 -CS7 CONFIDENTIAL  Protocol  Supplement 1 - [LOCATION_006] 
  15 April 2016  
 
3  Protocol Supplement Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Supplement : 1 - [LOCATION_006]  
Date:    [ADDRESS_39654] read and understand the attached clinical protocol supplement 
for the protocol entitled “An Open -Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)”, dated  
[ADDRESS_39655] the study as described herein.  
I agree to comply with the International Conference on Harmonization Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 304801 -CS7 CONFIDENTIAL  Protocol  Supplement 1 - [LOCATION_006] 
  15 April 2016  
 
4  PROTOCOL SUPPLEMENT - [LOCATION_006] 
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Supplement : 1 - [LOCATION_006]  
Date:    15 April 2016 
 
The purpose of this supplement (to the global study protocol) is to  fulfill MHRA req uirements.  
The following changes will be made to the protocol: 
1. To indicate that the DSMB is independent. 
2. To revise the contraceptive requirements to state that abstinence is only acceptable as 
true abstinence, i.e., when it is in line with the preferred and usual lifestyle of the 
patient.  
3. To increase the frequency of the pregnancy testing.  
4. To clarify guidance on determining relatedness of a S[LOCATION_003]R.  
The following table provides a summary list of the modifications to the protocol. 
  
ISIS [ADDRESS_39656]  Was:  
The Data and Safety Monitoring Board (DSMB) will review (as 
needed) safety, tolerability and efficacy data collected on 
volanesorsen during this study.  Based on its ongoing assessment of the safety and tolerability of volanesorsen, the DSMB will provide recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_37666].  Details on the safety 
assessments, frequency of review and meeting s chedules are 
outlined in the DSMB Charter and/or the statistical analysis plan 
(SAP). 
 
Is: 
An independent  Data and Safety Monitoring Board (DSMB) will be 
assembled to review safety, tolerability and efficacy (as needed) 
data collected on ISIS 304801 during  this study.  Based on its 
ongoing assessment of the safety and tolerability of ISIS 304801, 
the DSMB will provide recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  Details on 
the safety assessments, frequency of r eview, meeting schedules 
and controlled access to unblinded data are outlined in the DSMB 
Charter and/or the statistical analysis plan (SAP).  To clarify that the 
DSMB is independent  
Section 5.1 Inclusion Criteria  
 
Section 6.3.1 
Contraception Requirements  New:  
* Abstinence is only acceptable as true abstinence, i.e., when this is 
in line with the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence for the duration of a trial and 
withdrawal are not acceptable methods of contraception  Per the MHRA’s 
guidance to state that only true abstinence 
would be acceptable, and that periodic abstinence is not an 
acceptable method of 
contraception  
Appendix A 
Sched ule of 
Procedures  Pregnancy testing added at Weeks 4, 19, 32, 44, and 58 
(See Appendix A  below ) To reduce the time 
period between 
pregnancy tests  
Section 9.2 
Regulatory 
Requirements  Was:  
The Sponsor or designee will evaluate the available information 
and decide if there is a reasonable possibility that volanesorsen 
caused the AE and, therefore, meets the definition of a S[LOCATION_003]R.  
 
Is: 
In addition to the Investigator’s assessment of relatedness, the 
Sponsor or designee will evaluate the available information a nd 
perform an independent assessment of relatedness.  While the Sponsor may upgrade an investigator’s decision it is not permissible to downgrade the investigator’s opi[INVESTIGATOR_37479] a 
S[LOCATION_003]R. To clarify guidance on 
determining 
relatedness of a 
S[LOCATION_003]R 
ISIS [ADDRESS_39657] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3   Wk 
19 Month 6  Wk 
32 Wk 
38 Wk 
44 Month 12  Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52  
or ET  
Study Day  -14 to -7 1 2 22 50 78 85 127 169 176 218 260 302 351 358 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 3 2 2 3 3 3 2 2 7 7 
Informed Consent  X                 
Outpatient Visit  X X X X X Xh X Xh Xh X Xh X Xh Xh X Xh X 
Inclusion/Exclusion Criteria  X                 
Vital Signs + body weight  (+ height on 
Day 1 only ) X X  X X  X   X  X   X  X 
Physical Examination   X     X   X  X   X  X 
12- lead ECG  (triplicate)        X   X  X   X  X 
MRI (liver/spleen)                Xi   
Echocardiography           Xi     Xi   
Fundus Photographyb X              Xi   Blood Draw  (Fasting)c Chemistry Pane l X X  X X  X Xh  X Xh X Xh  X Xh X 
CBC with Differential  X X  X X  X Xh  X Xh X Xh  X Xh X 
Serum Lipid Panel X X  X X Xh X  Xh X  X  Xh X  X 
Coagulation  (aPTT, PT, INR)      X  X   X  X   X   
hsCRP, HbA1c, FPG, and de -
lipi[INVESTIGATOR_37489]   X     X   X     X  X 
Sedimentation Rate   X     X   X     X  X 
Complement (C5a, Bb)   X     X   X     X  X 
Plasma  PK - Volanesorsen   Xk X X X  X   X  X   X  X 
Anti-Volanesorsen  Antibodies   X  X X  X   X  X   X  X 
FSH (women only, if applicable)                   
Serum Pregnancy Testd X   X X  X X  X X X X  X X X 
Archived Serum & Plasma 
Samplese  X   X  X   X     X  X 
ISIS [ADDRESS_39658] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3  Wk 
19 Month 6  Wk 
32 Wk 
38 Wk 
44 Month 12  Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52 
or ET  
Study Day  -14 to -7 1 2 22 50 78 85 127 169 176 218 260 302 351 358 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 3 2 2 3 3 3 2 2 7 7 
Urinalysisc X Xj  X X  Xj Xj,h  Xj Xj,h Xj Xj,h  Xj Xj,h Xj 
Weekly Study Drug:   SC Injection   X  X X X X X X X X X X X X   
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X     X   X     X  X 
Food/Drink Diary (quarterly)f  X     X   X     X  X 
Diet/Alcohol Counselingg X X  X X  X   X  X   X X X 
Adverse Events X X  X X  X   X  X   X  X 
Concomitant Medication  X X  X X  X   X  X   X  X 
a Qualification procedures performed (Please refer to Section 4.1)  
b If possible, prior to administration of the first dose of Study Drug and repeated at Week 52 (Please refer to Section [IP_ADDRESS])  
c Blood samples to be collected after an overnight fast of at least 10 hours.  During treatment period urine and blood samples will be collected prior to Study 
Drug administration.  Does not apply to 24-hour PK blood draw  
d Females of childbearing potential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine level s, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical stud ies of  
volanesorsen  
f In addition to diary, patients will be contact[CONTACT_37787]  
g To reinforce compliance to the diet and alcohol restrictions.  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37743]  
h To be collected by [CONTACT_5640] a clinical service, or Study Center as arranged by [CONTACT_37747].  Approval for study procedures to be conducted by a 
clinical service on other outpatient visit days will require prior approval by [CONTACT_1034].  
i A ± 7 day window is allowed for MRI, echocardiography procedures and fundus photography  
j Expanded urinalysis (see Appendix B)  
k Full or abbreviated PK profile (see Appendix C)  
 
  
Sponsor:  
Ionis Pharmaceuticals, Inc.  
[ADDRESS_39659] 
Carlsbad, CA  [ZIP_CODE] Collaborator: 
Akcea Therapeutics  
[ADDRESS_39660] 
Cambridge, MA [ZIP_CODE] 
 
 
ISIS 304801-CS7 
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Protocol Amendment 1  –[ADDRESS_39661] No:  2015-003755-21 
 
 
 

ISIS 304801-CS7
ProtocolCONFIDENTIAL Amendment I
2Februaw 2016
rsrs 304801-cs7
The APPROACH Open Label Bxtension Study
Volanesorsen (ISIS 304801)
An Open-Label Bxtension Study of Volanesorsen Administered
Subcutaneously to Patients with Familial Chylomicronemia
Syndrome (FCS)
Protocol Amendment 1 - 2 February 2016
Protocol History:
Original Protocol: [ADDRESS_39662] 2015
Sponsor:
Ionis Pharmaceuticals, Inc.
2855 Gazelle Co
Carlsbad, CA
 M.D., M.B.A
2

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
3   
Ionis Protocol Number:  ISIS [ADDRESS_39663] No:   2015-003755-21 
Clinical Phase:  3  
 
The APPROACH  Open Label Extension Study 
Volanesorsen (ISIS 304801)  
An Open- Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia 
Syndrome (FCS)  
 
Trial Sponsor:  Ionis Pharmaceuticals,  Inc. 
[ADDRESS_39664] 
Carlsbad, CA [ZIP_CODE] Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:   [CONTACT_37829].D.  
[ADDRESS_39665] 
Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator:  Akcea Therapeutics  
[ADDRESS_39666] Cambridge, MA [ZIP_CODE] 
Date:  [ADDRESS_39667] of the clinical investigation 
without the prior written c onsent of Ionis Pharmaceuticals, Inc. 

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Amendment:  Amendment 1 
Date:    [ADDRESS_39668] read and understand the attached clinical protocol , entitled “An 
Open -Label Extension  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_39669] the 
study as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the con fidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
  
ISIS [ADDRESS_39670] ................................................................................26  
4. PATIENT ENROLLMENT ...............................................................................................26  
4.1 Qualification  ..................................................................................................................26  
4.2 Enrollment .....................................................................................................................26  
5. PATIENT ELIGIBILITY  ..................................................................................................26  
5.1 Inclusion Criteria  ...........................................................................................................26  
5.2 Exclusion Criteria  ..........................................................................................................27  
6. STU DY PROCEDURES  ....................................................................................................27  
6.1 Study Schedule ..............................................................................................................27  
6.1.1  Qualification  ...........................................................................................................28  
6.1.2  Treatment Period  ....................................................................................................28  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_39671]- Treatment Period  ............................................................................................29  
6.2 Additional Study Assessments  .......................................................................................29  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
6  6.2.1  Laboratory Assessments  .........................................................................................29  
6.2.2  Physical Exams and Vital Signs  .............................................................................29  
[IP_ADDRESS]  Eruptive Xanthoma ..........................................................................................29  
[IP_ADDRESS]  Lipemia Retinalis  .............................................................................................[ADDRESS_39672]- Treatment Follow -up Period .40  
8.9 Withdrawal of Patients from the Study  ..........................................................................40  
8.10  Concomitant Therapy and P rocedures  ...........................................................................41  
8.10.1  Concomitant Therapy .............................................................................................41  
8.10.2  Concomitant Procedures .........................................................................................41  
8.11  Treatment Compliance  ...................................................................................................41  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................42  
9.1 Sponsor Review of Safety Information .........................................................................42  
9.2 Regulatory Requirements  ..............................................................................................42  
9.3 Definitions  .....................................................................................................................43  
9.3.1  Advers e Event  ........................................................................................................43  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................43  
9.3.3  Serious Adverse Event (SAE) ................................................................................43  
9.4 Monitoring and Recording Adverse Events  ...................................................................44  
9.4.1  Serious Adverse Events ..........................................................................................44  
9.4.2  Non-Serious Adverse Events ..................................................................................44  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................44  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................44  
[IP_ADDRESS]  Severity  ............................................................................................................45  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................45  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................45  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................45  
9.4.4  Adjudication Committees  .......................................................................................46  
9.5 Procedures for Handling Special Situations ..................................................................46  
9.5.1  Abnormalities of Laboratory Tests .........................................................................46  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............47  
9.5.3  Dosing Errors .........................................................................................................47  
9.5.4  Contraception and Pregnancy .................................................................................47  
10. STATISTICAL CONSIDERATIONS  ..............................................................................48  
10.1  Study Endpoints  .............................................................................................................48  
10.1.1  Efficacy Endpoints .................................................................................................48  
10.1.2  Safety Endpoints .....................................................................................................48  
10.2  Sample Size  ....................................................................................................................49  
10.3  Populations .....................................................................................................................49  
10.4  Definition of Baseline ....................................................................................................49  
10.5  Interim Analysis  .............................................................................................................50  
10.6  Planned Methods of Analysis ........................................................................................50  
10.6.1  Demographic and Baseline Characteristics  ............................................................50  
10.6.2  Safety Analysis  .......................................................................................................50  
10.6.3  Efficacy Analysis  ...................................................................................................51  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
8  10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................51  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................51  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................52  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_39673] of the Study .........................................................................................53  
11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_39674] of Laboratory Analytes  .............................................................................63  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................65  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnor malities ......67  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ........................................................ 32  
Table 2  Expected Event for the Protocol Defined Population by [CONTACT_37895]  .................................................................................. 42  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 19  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer).  The sequence of volanesorsen is shown ................................... 21  
Figure 3  Fasting Triglycerides in Patients with FCS Treated with Volanesorsen  .............. 23  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patient s with Familial Chylomicronemia 
Syndrome (FCS) 
Amendment Number:  1 
Amendment Date:  [ADDRESS_39675] 2015: 
1. To update the approximate anticipated number of patients that may enroll into the study 
(now approximately 70 patients) so that the number of patients is reflective of the 
estimated number of qualified patients from the ISIS 304801-CS6 and ISIS 304801-CS16 
index studies . 
2. To define the specific patient  population from ISIS 304801-CS16 who will be  allowed  to 
enter the Open Label  Extension Study. 
3. Clarification of when final assessment s from the ISIS 304801-CS6 and ISIS 304801-
CS16 index studies  may be used for enrollment into ISIS 304801- CS7. 
4. Clarification of how food and alcohol will be monitored during the study. 
5. An addition to the platelet monitoring rule  language to allow for more frequent 
monitoring has been included. 
6. To provide guidance to Investigators w ith enrolled FCS patients who also have T2DM.  
Specific glucose monitoring rules are provided for patients on insulin and oral antidiabetic medications.  The definition of documented severe hypoglycemia is included and safety monitoring rules have been defined.  Also, specific monitoring rules are 
incorporated into the protocol for hyperglycemic events. 
Minor administrative changes or corrections (not included in the list of changes below) have 
been made throughout the protocol in order to improve the overall clarity of the protocol but 
these changes d o not impact the study design. 
The following table  provides a summary list of changes to the protocol: 
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol  2 February  2016  
10  Protocol Section  Description of Change  Rationale  
Synopsis  
Section 3: 
Experimental Plan  
Section 10.2: Sample Size  Up to approximately 50 patients dosed has been 
changed to up to approximately 70 patients 
dosed. Reflective of the updated patient numbers in the ISIS 304801-CS6  
study  and the addition of ISIS 304801-
CS16 patients - with a diagnosis of 
FCS who will be allowed to enter the 
Extension Study after successful 
completion of ISIS  304801-CS16 . 
Synopsis  
Study Population: Inclusion Criteria #3  
Section 5.1: Inclusion Criteria #3  3.Satisfactory completion of ISIS 304801-
CS6 or ISIS 304801-CS16 (index studies)with an acceptable safety profile, per
Sponsor and Investigator  judgement.
Patients who are enrolled in ISIS 304801-CS16 must also meet the following criteria
in order to enter  into the Extension Study:
a.History of chylomicronemia as
evidenced by [CONTACT_37997] (a creamy top layerafter ultracentrifugation of a fastingblood sample) or documentation of
fasting TG measurement ≥ 880 mg/dL
(10 mmol/L)
b.A diagnosis of Familial
Chylomicronemia Syndrome (Type 1Hyperlipoproteinemia) by[CONTACT_38003] (1)  of the
following:
•Confirmed homozygote,compound heterozygote or doubleheterozygote for known loss -of-
function mutations in Type 1-
causing genes (such as LPL,
apoCII, GPI[INVESTIGATOR_37445]1, or LMF1)
•Post heparin plasma LPL activity
of ≤ 20% of normal
c.Fasting TG ≥ 750 mg/dL (8.4 mmol/L)
at Screening for the ISIS 304801-CS16studyInclusion of the specific  criteria that 
must be met in order for patients who 
successfully complete ISIS 304801-CS16 to enter into the Open Label 
Extension Study . 
Section 4.1: 
Qualification  Eligibility requirements provided for enrol lment 
into the extension study.  Clarification of when final assessments from the ISIS 304801-CS6 or 
ISIS 304801-CS16 study  may be used 
for qualification.  
Section 6.1.[ADDRESS_39676] get prior approval from the Sponsor  for study procedures to be 
conducted by a clinical service  on 
days  not listed above 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
11   
Protocol Section  Description of Change  Rationale  
Section [IP_ADDRESS] 
Eruptive Xanthoma  
Section [IP_ADDRESS] 
Lipemia Retinalis  
Section 10.1.1 Efficacy Endpoints  Inquiries into the number and duration of 
Eruptive Xanthoma by [CONTACT_38004]. Fundus photography will be 
performed prior to Day 1 Study  Drug  
administration and at Week 52  Eruptive Xanthoma and Lipemia 
Retinalis included as efficacy 
endpoints  to obtain additional clinical 
endpoint data .  
Section 6.2.8: 
Diet Monitoring  Explanation of how food /alcohol will be 
monitored throughout the course of the study . Clarification of how and when 
food/alcohol will be monitored by [CONTACT_4677] , dietician or qualified study 
personnel. 
Section 8.5.2: 
Safety  Monitoring 
Rules for Platelet 
Count Results  Addition to platelet monitoring rules that more frequent testing may be required.  More frequent monitoring of platelets 
may be warranted if a patient is 
experiencing a significant decline in 
platelet count . 
Section 8.5.6  
Section 8.5.7  
Section 8.5.8  
Glucose Monitoring 
in T2DM  Addition of monitoring rules for patients with 
T2DM.  Monitoring rules established for patients 
on insulin and oral antidiabetic medications.  Also included are monitoring rules for 
document ed hypoglycemia and hyperglycemia. Added sections to enhance safety 
monitoring for 52-week study in 
diabetic patients with FCS . 
Appendix A  
Footnote “j” A ±7 day window is allowed for MRI and 
echocardiography  Window expanded from 2 days to 7 days for scheduling flexibility  and 
patient convenience.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
12  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of extended dosing with volanesorsen  
(volanesorsen sodium 300 mg ) in patients with FCS  
Study Design  This is a multi -center, open-label extension study  of ISIS 304801-CS6  and 
ISIS 304801-CS16 .  All patients will receive volanesorsen [ADDRESS_39677] -treatment evaluation period.  
Number of  Patient s Up to approximately 70 patients dosed  
Study Population  Inclusion Criteria : 
1. Must give written informed consent to participate in the study (signed and 
dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Satisfactory completion of ISIS 304801-CS6  or ISIS 304801- CS16  (index 
studies)  with an acceptable safety profile, per  Sponsor  and Investigator 
judge ment .  Patients who are enrolled in ISIS 304801-CS16 must also 
meet the following criteria in order to enter  into the Extension Study:  
a. History of chylomicronemia as  evidenced by [CONTACT_37830] (a creamy top layer after ultracentrifugation of a 
fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 
Hyperlipoproteinemia) by  [CONTACT_38003] (1) of the 
following: 
• C onfirmed homozygote, compound heterozygote or double 
heterozygote for known loss -of-function mutations in Type 1-
causing genes (such as LPL, apoCII, GPI[INVESTIGATOR_37445]1, or LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal  
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the 
ISIS 304801-CS16 study  
4. Able and willing to participate in a 65-week study  
5. Satisfy one (1) of the following:  
a. Females:  Non- pregnant and non-lactating; surgically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females  ≤ 55 years, 12 months of spontaneous amenorrhea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time of signing 
the informed consent form until [ADDRESS_39678] dose of 
Study Drug administration  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
13  PROTOCOL SYNOPSIS Continued  
Study Population  Continued  Inclusion Criteria : Continued  
b. Males:   Surgically sterile, abstinent or if engaged in sexual relations 
with a female of child-bearing potential, patient is utilizing an 
acceptable contraceptive method (refer to Section 6.3.1) from the 
time of signing the informed consent form until [ADDRESS_39679] dose of Study Drug administration  
Exclusion Criteria : 
• Have any new condition or worsening of existing condition which in 
the opi[INVESTIGATOR_37580], or could interfere with the patient participating in or completing the study  
Unwilling to comply with lifestyle requirements for the duration of the study 
(Section 6.3) 
Treatment Group  Volanesorsen 300 mg once per week   
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
Rationale for Dose and Sche dule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index studies (ISIS 304801-CS6 - and 
ISIS 304801-CS16 ) based on the pharmacodynamic and safety analysis of 
the Phase 2 studies which included a subset  of patients with FCS .  This is an 
extension to the ISIS 304801- CS6 and ISIS 304801-CS16  index studies.  
Only the subset of patients  from ISIS 304801 -CS16 with FCS  diagnosis  may 
enter  the Extension Study.  (Please refer to  inclusion criteria #3, above)  
Study Visit Schedule and 
Procedures  The study for an individual patient will generally consist of the following 
periods:  
• A qualification period of up to 2 weeks (unless approved by [CONTACT_429]) .  Please refer to Section 4.1 and Appendix A .  A 52 -week 
treatment period during which volanesorsen will be administered as 
a once weekly SC injection  
• A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week [ADDRESS_39680] . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, 
volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms and 
quality of life assessments will be performed according to the schedule of procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow-up period and a daily food /drink  diary will 
be completed  for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39681] -treatment 
evaluation period.  
  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
14  PROTOCOL SYNOPSIS Continued  
Safety and Tolerability 
Evaluations  Overall safety and tolerability of volanesorsen  will be assessed by 
[CONTACT_37840]  (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events,  and changes in laboratory and 
other safety parameters . 
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis and 
MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
Efficacy Endpoints: 
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the 
treatment period  
• Percent change and change from baseline in other fasting lipid measurements including total cholesterol, non-high-density 
lipoprotein-cholesterol ( non-HDL -C), apolipoprotein B [ apoB ], high -
density lipoprotein- cholesterol ( HDL-C), apolipoprotein A -1 [apoA -1], 
very-low -density lipoprotein- cholesterol ( VLDL -C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C -III 
(apoC -III) 
• Quality of Life questionnaires (EQ -5D, SF -36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows : trough levels  (pre- dose)  throughout treatment and 
post-treatment levels during the post -treatment follow -up period .  In a subset 
of patients,  more frequent assessment of  plasma concentrations of  
volanesorsen will b e performed to determine volanesorsen pharmacokinetic 
parameters .  Plasma sample collection time points are detail ed in Appendix A  
and Appendix C . 
Statistical Considerations  No sample size calculations were performed as this is an extension study to the double-blind placebo controlled ISIS 304801-CS6  and ISIS 304801-CS16  
index studies . 
Sponsor  Ionis Pharmaceuticals,  Inc. 
Collaborator  Akcea Therapeutics  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
15  STUDY DESIGN AND TREATMENT SCHEMA  
 
QUALIFICATION  
PERIOD 
 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET)  
 
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
enco uraged to visit 
clinic for 
post-treatment 
assessments  
TREATMENT PERIOD  
 
Weeks 1 to 52 
 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points  
POST -TREATMENT EVALUATION 
PERIOD 
 
Weeks 53 to 65 
 
2 clinic visits for safety, efficacy, PK and 
PD assessments 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
16  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39682]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39683] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not clinically -significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OLE  Open Label Extension  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39684]  upper limit of normal  
VLDL  Very -Low-Density Lipoprotein  
VLDL -C Very -Low-Density Lipoprotein -Cholesterol  
VLDL -TG Lipoprotein -Triglyceride  
WMA  World Medical Association  
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
18  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of extended dosing with 
volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive (Brunzell 1999-2011; Tremblay et al. 2011).  Physical examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from pat ients appears lactescent, interfering with 
determination of other laboratory parameters (Tremblay et al. 2011). 
Patients with fasting triglyceride levels >  10 mmol/L probably have a co mponent of 
chylomicronemia .  Clinical diagnosis would include evidence o f clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagn osis of FCS may be made more 
specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreat ic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been completely 
elucidated, one (1) hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37667], with the subsequent release of free fatty acids through the hydrolysis of chylomicron- associated TGs .  High concentrations of free fatty acids are thought to 
damage pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al.  
2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extremely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicr ons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS ( Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently identified in FCS patients, and known to directly influence LPL activity include: 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
19  apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
(APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons (Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figure 1 ).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] (Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL ( Brown et al.  
2010).  In addition, increased apoC -III content adversely affects apoE -mediated hepatic uptake 
of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels are associated 
with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in the 
accumulation of lipoprotein- triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1  = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
20  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish 
that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype 
analy sis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma TG have also been recently described (Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI]  = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC- III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976), and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake o f 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action, volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
21  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base position 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity , it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
Figure 2 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
 
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H 1 
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
22  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volan esorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  Gen eral toxicity studies with volanesorsen for up to 39 weeks of 
treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardio vascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  huma n  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39685] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotox ic (in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if any, drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precli nical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
23  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from 50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering ther apy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, 3 patients with FCS were treated with 300 mg/wk volanesorsen  in an open 
label fashion .  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
3 patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39686] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine aminotransferase [ALT ], aspartate aminotransferase [ AST ], bilirubin) despi[INVESTIGATOR_37668] [ADDRESS_39687]- treatment 
period and was not associated with platelet- related adverse events  (AEs). 
The most frequently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, 
tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39688] Level ( NOAEL ) 
was defined by [CONTACT_37921] .  No nonclinical findings were consi dered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well -tolerated  at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administratio n 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A pooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between t he different doses tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was studied at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
25  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label extension  to the Phase 3 study of volanesorsen in patients with F CS 
(ISIS  304801- CS6 or ISIS 304801-CS16).  Up to approximately [ADDRESS_39689] of the following periods: 
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034]).  Please refer to 
Section 4 .1 and Appendix A . 
• A 52-week  treatment period during which volanesorsen  will be administered as a once 
weekly SC injection  
• A [ADDRESS_39690]- treatment evaluation period  
Please refer to the Schedule of Procedures in Appendix A . 
3.4.1 Qualification  
A period of up to 2 weeks  is given to complete  qualification  assessments outlined in the 
Schedule of Procedures (Appendix A). 
3.4.2 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals th roughout the 52-week treatment period  as detailed in the 
Schedule or Procedures (Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_39691] (DSMB) will review (as needed)  safety, tolerability and 
efficacy data collected on volanesorsen during this study .  Based on its ongoing assessment of 
the safety and tolerability of volanesorsen, the DSMB will provide recommendations to the 
Sponsor for modifying, stoppi[INVESTIGATOR_10483].  Details on the safety assessments, frequency of review and meeting schedules are outlined in the DSMB Charter 
and/or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Patient s or the ir legally acceptable representatives must sign the consent form  before any  study-
specific procedures or evaluations  related to this open label study are performed .  During the 
qualification period, the eligibility of the patient to continue in the extension study will be 
determined .  Final assessments from the ISIS 304801-CS6 or ISIS 304801-CS16 studies may be 
used for qualification.  A period of up to 2 weeks after completion of the ISIS 304801-CS6 or ISIS 304801-CS16 index studies (unless approved by [CONTACT_16049]) is given to complete 
qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the ISIS 304801-CS6 or ISIS 304801- CS16 index studies .  The patient 
identification number will be used to identify the patient  throughout the extension trial and must 
be used on all stud y documentation related to that patient .  The patient  identification number 
must remain constant throughout the extension trial. 
4.[ADDRESS_39692] been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to enrollment. 
Eligible patients will be enrolled using an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_39693] give written informed consent to participate in the study (signed and dated) and any authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Satisfactory completion of I SIS 304801-CS6 or ISIS 304801-CS16 (index studies) with 
an acceptable safety profile, per Sponsor and Investigator judgement.  Patients who are 
ISIS [ADDRESS_39694] also meet the following criteria in order to enter  into 
the Extension Study: 
a. History of chylomicronemia as evidenced by [CONTACT_37684] (a 
creamy top layer after ultracentrifugation of a fasting blood sample) or documentation of fasting TG measurement ≥ 880 mg/dL (10 mmol/L)  
b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) 
by [CONTACT_38003] (1) of the following: 
• Confirmed homozygote, compound heterozygote or double heterozygote for 
known loss-of-function mutations in Type 1- causing genes (such as LPL, apoCII, 
GPI[INVESTIGATOR_37445]1, or LMF1)  
• Post heparin plasma LPL activity of ≤ 20% of normal 
c. Fasting TG ≥ 750 mg/dL (8.4 mmol/L) at Screening for the ISIS 304801-CS16 
study.  
4. Able and willing to participate in a 65 -week study  
5. Satisfy one (1) of the following: 
a. Females:  Non -pregnant and non-l actating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH levels in the postmenopausal range for the laboratory involved), abstinent, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39695] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_39696] any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37601], or could interfere with the patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section  6.3). 
6. STUDY PROCEDURES  
6.[ADDRESS_39697] patient’s Week [ADDRESS_39698]. 
During the treatment period , patients will report to the study center for clinic visits a minimum of  
10 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekl y (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunogenicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A.  Adverse events at the injection site should be collected as adverse events .  Die tary counseling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine samples should be collected  prior to volanesor sen administration .  Blood sampling  for lipid 
panels at Week s 12, 25, and [ADDRESS_39699] be sent to the central laboratory for analysis .  
Every effort should be made to ensure the previous week’s dose is given 7 da ys prior to a 
scheduled clinic visit.  Dosing instructions and training will be provided to the patient where 
applicable.  
All reasonable attempts should be made to ensure compliance with the visit schedule as outlined 
in Appendix A.  However, in the event that a visit does not occur or is delayed, all subsequent 
visits should be calculated based on the time elapsed since Day 1 rather than from the date of the 
previous visit. 
6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an e xtended PK collection .  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_39700]-dose blood 
draw after dosing on Day 1.  The detailed PK sampling schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for sites and patients, and  consent may be with drawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup a ssessments and procedures 
as outlined in Appendix A. 
ISIS [ADDRESS_39701] of these analytes  is contained in Appendix B . 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be performed as indicated in the Schedule o f Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially on the left arm) .  Height will be measured at  
the Day 1  visit. 
[IP_ADDRESS] Eruptive Xanthoma  
At each visit, patients will be asked whether they have had any epi[INVESTIGATOR_37500]/duration of the events will be recorded.  Physical exams should also include skin examination for presence/resolution of eruptive xanthomas.  If a patient experiences an epi[INVESTIGATOR_37462], photos of the area should be 
taken, if possible. 
[IP_ADDRESS] Lipemia Retinalis  
If possible, lipemia retinalis  will be assessed by [CONTACT_38005] 52.  Images will be evaluated by [CONTACT_10943], blinded to the patient’s treatment assignment. 6.2.[ADDRESS_39702] 5 minutes .  ECGs will be performed in triplicate at Week 13, Week 26 , Week 3 8, Week 52, and 
Week 65 . 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
30  MRIs will be conducted using standardized procedures and settings.  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week [ADDRESS_39703]- treatment follow-up period. 
6.2.8 Diet Monitoring  
The diets of patients enrolled in the study will be monitored as follows : 
1. All patients will be required to maintain a 7 -day food diary prior to Week 1, Week 13, 
Week  26, Week 52, and Week 65. 
2. Patients will receive diet/alcohol counseling by [CONTACT_38006].  Qualified study personnel will telephone the patient 
to provide diet/alcohol counseling for visits that are conducted by a clinical service. 
3. In addition to the 7-day food diary and the diet /alcohol counseling during clinic visits, telephone calls from a dietitian or qualified study personnel to assess as to how each 
patient is maintaining their diet will be conducted randomly during the treatment and post 
treatment follow -up periods.  
6.2.[ADDRESS_39704] refrain from sperm/egg donation and 
practice effective contraception from the time of signing the informed consent form until at least 
[ADDRESS_39705]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet one (1) of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH level s in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
31  For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patients must also encourage their female partner to use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrau terine contraception/device, or barrier methods (female condom*, diaphragm, 
sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ensure that the fetus is not 
exposed to the Study Drug . 
For female patien ts: 
• Using one ( 1) or more of the following acceptable methods of contraception:  surgical 
sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
*Note : A female condom and a male condom should not be used together as friction between 
the two can result in either product failing. 
6.3.[ADDRESS_39706] 10 hours before visits requiring fasted blood 
samplin g. 
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39707] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39708] (ISIS 304801) characteristics are listed in  Table 1. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
32  Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Volanesorsen  Administration  
For each individual patient, volanesorsen will be administered subcutaneously as a single 1.5 mL 
injection once weekly for Weeks 1-52. 
Patients should receive one ( 1) dose per week, with weeks always defined relative to Study 
Day 1.  For exa mple if a patient receives the  first dose on a Monday, subsequent doses should be 
given on Mondays, if possible.  If a patient misses an injection, or if dosing on the usual day is 
not possible, the patient can reschedule the injection provided that  [ADDRESS_39709] 2  days apart. 
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_38007].  
8.2 Other Protocol -Required Drugs  
There are no other protocol- required drugs  (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
33  8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 
8.5 Safety Monitoring Rules 
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_39710] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  the final visits of ISIS 304801-CS6 and ISIS 304801-CS16 index studies if 
used for qualification). In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specime ns.  All new specimen collections should 
take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest must be av ailable prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values tha t reach a stoppi[INVESTIGATOR_10447]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  If any of the stoppi[INVESTIGATOR_10449] (refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be permanently discontinued 
from further treatment with volanesorsen, evaluated fully as outlined below and in consultation 
with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up 
in accordance with Section 8.8 of the protocol. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human  
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to guidance in Section 8.[ADDRESS_39711] measurement that is > [ADDRESS_39712]  (or the greater of [ADDRESS_39713] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase to [ADDRESS_39714]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
34  Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39715] (or 
the greater of [ADDRESS_39716] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), internat ional normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_39717] or 1.2 x baseline value if the baseline value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39718]  (or the greater of [ADDRESS_39719] if the baseline value was 
> ULN ), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serolo gy for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI  scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_39720] . 
8.5.2 Safety Monitoring Rules fo r Platelet Count Results  
If a patient’s platelet count falls by 30% or greater from baseline and  the absolute platelet count 
is 75,000/mm3 or less, then the patient’s platelet counts should be monitored more frequently.  In 
the event of any significant fall in platelet count, the frequency of monitoring and additional lab 
tests will be determined by [CONTACT_38008]. 
8.5.3 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically 
relevant, non-major bleeding events (which are defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a m inor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet count should be performed. 
8.5.[ADDRESS_39721] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on 2 consecutive visits.  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate statin therapy or in crease 
the statin dose for patients who are already on treatment).  
8.5.[ADDRESS_39722] practice 
guidelines and bring their glucometer or glucometer log printout to every clinic visit.  
• The Investigator or delegate will review the glucometer  reading or printout at every clinic 
visit to evaluate if fasting  pre-breakfast self -monitored plasma glucose values exceed 
threshold values as per the Safety Monitoring Rules for Hyperglycemia below.  
All diabetic patients  will note any changes in their insulin dose and /or oral antidiabetic  therapy, 
as well as any hypoglycemic  epi[INVESTIGATOR_37469].  
• The Investigator or dele gate will ask patients at every clinic visit if they made changes in 
their insulin dose or oral antidiabetic therapy, and if they expe rienced a hypoglycemic 
epi[INVESTIGATOR_1865]. 
o Patients will be instructed on the monitoring and management of hypoglycemic 
epi[INVESTIGATOR_37562].  
o Documented symptomatic hypoglycemic epi[INVESTIGATOR_37609]. Documented symptomatic hypoglycemia is defined as typi[INVESTIGATOR_37472] 
≤ 70 mg/dL (≤ 3.9 mmol/L.  
o Any changes in insulin dose or oral antidiabetic therapy should be captured into t he 
Concomitant Medication CRF. 
8.5.7 Safety Monitoring Rule for Documented Severe Hypoglycemia  
A documented severe hypoglycemic event is defined as one (1) in which t he patient requires 
assistance of another person to obtain treatment for the event and has a plasma glucose level 
≤ 70 mg/dL (≤ 3.9 mmol/L).  The rescue treatment of hypoglycemia may include IV glucose or 
buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place patients at risk for injury to themselves or others.  Note that “requires assistance” means that the 
patient could not help himself or herself.  Someone being kind that assists spontaneously the 
patient when not necessary does not qualify as “requires assistance.” 
Severe hypoglycemia will be qualified as a SAE on ly if it fulfills SAE criteria.  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
36  If a patient presents with symptoms of hypoglycemia, the Investigator will need to take 
immediate action to confirm the patient’s glucose level and  treat the patient accordingly.  
The experience of hypoglycemia may vary greatly from pati ent to patient.  However, there are certain 
classical signs and symptoms, of which patients should be aware as a clue that their blood glucose 
may be low.  Common symptoms include headache, heart pounding, confusion, disorientation, numbness or tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or 
nervousness, lightheadedness or dizziness, sweating, and weakness.  Many of these symptoms are 
listed in the diary provided to patients.  These diaries will be used only to assist the Investigator in assessing the event.  Appropriate source documentation should capture the necessary information on 
the event with the aid of the diaries.  Patients must be given adequate instructions on the use of the diaries. 
If patients suspect they might be having a hypoglycemia reaction, they should check their blood 
glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so.  If there is doubt about safety they should treat the event first, using some sugar, milk, 
or juice for example, then obtain and record a blood glucose value as soon as possible thereafter.  
The time and nature of treatment should be noted, and especially if any blood glucose result was before or after treatment.  It would be helpful for the patient to note if a contributory factor (e.g., missed or reduced meals, unaccustomed physical activity) occurred earlier in the day of the event.  
8.5.[ADDRESS_39723] dose titration and/or addition of any other anti- hyperglycemic agent(s) will not be 
allowed during the course of the study, unless specific threshold values are met at Week 13 or 
later and confirmed on subsequent testing (ideally within one (1) week  of the initial test).  
HbA1c is monitored every 3 months throughout the study.  In addition, patients on insulin should 
self-monitor their plasma glucose (SMPG) routinely on a glucometer as per practice guidelines.  
If a fasting  pre-breakfast SMPG value ex ceeds the specific glycemic limit, the patient should 
check it again on the following [ADDRESS_39724] the Investigator and an unscheduled 
central l aboratory FPG measurement and HbA1c should be performed. 
The threshold values are defined as:  
• FPG >  270 mg/dL (15.0 mmol/L) 
• HbA1c  > 9% (for patients with baseline HbA1c < 8% and HbA1c increase of more than 
1% from baseline (for patients with baseline HbA1c ≥ 8 and < 9%) 
In case of confirmed FPG/HbA1c above the threshold value, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: 
• Plasma glucose was actually measured in the fasting condi tion (i.e., after at least [ADDRESS_39725]) 
• Absence of intercurrent disease which may jeopardize glycemic control.  In case of an 
emergency (e.g., surgery, infection), the Investigator can take appropriate measur es for 
glycemic control  
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
37  • Compliance to treatmen t is appropriate 
• Compliance to diet and lifestyle is appropriate 
If any of the above can reasonably explain the insufficient glycemic control, the Investigator 
should consider the following: 
• Investigation and treatment of intercurrent disease (to be reported in adverse event  
(AE)/concomitant medication parts of the e -CRF)  
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to die t and lifestyle 
recommendations 
A FPG/HbA1c follow-up assessment should be arranged after appropriate action has been taken.  
If none from the above-mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c under the threshold values, additional medication may be introduced at the Investigator’s discretion and according to local guidelines after discussion with the Sponsor 
Medical Monitor. 
8.5.9 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with S tudy Drug should be suspended 
temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_39726] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_10453], and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be presumed confirmed : 
1. ALT or AST >  [ADDRESS_39727] >  [ADDRESS_39728] , which is confirmed and persists for ≥ [ADDRESS_39729] >  [ADDRESS_39730] (or the greater of [ADDRESS_39731] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_39732]  or INR  > 1.[ADDRESS_39733] >  [ADDRESS_39734] (or the greater of [ADDRESS_39735] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness,  fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37965] [ADDRESS_39736] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
three criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24-hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 m L/min that is con firmed by a 24 -hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_37855]. 
8.6.3 Stoppi[INVESTIGATOR_37669] a platelet count less than 50,000/mm3 that is associated with  major bleeding or 
clinically relevant non -major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564]. 
In the event of a platelet count less than 50,000/mm3, and in the absence of major bleeding or 
clinically relevant non -major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the platelet count has recovered to 
≥ 100,000/mm3.  The suitability of th e patient for continued dosing and the need for any 
modification to treatment schedule (refer to Section 8.7) will be determined by [CONTACT_37999]’s platelet count, whether any bleeding events were experienced by 
[CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If after the first dosing re -challenge the platelet count again falls below 50,000/mm3, then dosing 
of the patient must be held until the platelet count again returns to at least 100,000/mm3.  The 
suitability of the patient for continued dosing and the need for any further modification to 
treatment schedule or dose (refer to Section 8.7) will be re-examined by [CONTACT_37990] (at least) the factors mentioned above. 
If after the second re- challenge the platelet count falls below 50,000/mm3 and is subsequently 
confirmed (see Section 8.5), dosing with volanesorsen  will be stopped permanently.  The 
follow- up schedule for any events meeting this stoppi[INVESTIGATOR_37655]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
39  Definition of Major Bleeding Events ( Schulma n et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically Relevant, Non -Major Bleeding Events ( Schulman et al . 2005):  
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm
2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemes is 
6. Bleeding after venipuncture for > 5 minutes 
8.7 Adjustment of Dose Frequency  
Dose adjustments, including dose interruptions, and/or decreasing the dose frequency will be allow ed for safety and tolerability.  Any proposed adjustment to treatment schedule must be 
discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to 2  adjustments in the treatment schedule may be allowed for patients that are unable to tolerate 
the once weekly dose (for example if platelet counts fall below  50,000/mm
3 as described in 
Section  8.6.3).  If the patient remains stable after adjustment, they may be cautiously returned to 
the original once weekly regimen after consultation with the Study Medical Monitor.  
Patients may be dose paused in response to AE s after consultatio n with Study Medical Monitor. 
8.[ADDRESS_39737] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Secti on 9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalities that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39738] be recorded in the CRF and source 
documentation. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
40  8.8.1 Follow- up Visits for Early Termination from Treatment Period  
Any patient who discontinues early from the Treatment Period should be strongly encouraged to 
attend  applicable landmark visits at Week s 12, 13, 25, 26, and 51, 52 (calculated based on the 
time elapsed since Day 1) to collect  fasting lipid panels  and conduct safety assessments in 
accordance with the schedule of procedures in Appendix A .  Any patient who discontinues 
treatment after  Week 44 should also be strongly encouraged to attend a final follow-up visit 
(Week 65 visit assessments) approximately [ADDRESS_39739] dose of Study Drug , in 
addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimum, and 
ideally within [ADDRESS_39740]- Treatment Follow-up 
Period should be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A ) prior 
to leaving the study.  
If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39741] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons  
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination stud y procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
ISIS [ADDRESS_39742] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing informed consent and completion of the post- treatment follow -up period.  All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543]. 
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin,  fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), -glucagon-like peptide-1 ( GLP -1) agonists, Glybera, 
or systemic corticosteroids may be started  or adjusted  after  baseline qualification .  Doses of 
existing  oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, 
anticoagulants, or drugs or dietary supplements with potential lipid-altering effects should not be 
adjusted .  Study patients are prohibited from receiving other experimental agents dur ing the 
study.  This includes marketed agents at experimental dosages that are being tested for the 
treatment of hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non- prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cult ures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37815] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that will be reviewed periodic ally by [CONTACT_37860].  
ISIS [ADDRESS_39743] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adver se reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
E6.  Country- specific regulatory requirements will be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IR B)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Data and Safety Monitoring Board ( DSMB ) will 
be notified of any SAE as specified in the DSMB  charter.  
The Sponsor or designee  will evaluate the available information and decide if there is a 
reasonable possibility that volanesorsen caused the AE and, therefore, meets the definition of a 
S[LOCATION_003]R . 
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still has the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 2 Expected Event for the Protocol Defined Population by [CONTACT_37931] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, pancreatitis relapsing  0.2-0.35  events  per patient -year   
 
Fatal pancreatitis associated events will be considered as unexpected  and are reportable.  The  
Sponsor and DSMB  will monitor  non- fatal pancreatitis associated SAEs  using the incidence rate 
of the event compared to the rate expected in a non -volanesorsen exposed population.  If the 
aggregate analysis indicates that an event is occurring significantly more frequently  or at a 
greater severity  than expected , then the event will be reported. 
SAEs not specified in the table will be evaluated on case by [CONTACT_37862] a reasonable possibility that the drug caused the event .  If the event is considered by [CONTACT_37863] a S[LOCATION_003]R  the event will be reported. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
43  9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant  
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criter ia: 
• Results in death  
• Is life threatening:  that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37670] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate 
medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm  requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
44  9.4 Monitoring and Recording Adverse Events  
Any pre -existin g conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should al ways group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_39744] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_39745] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is u nlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_39746] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious) 
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by [CONTACT_31806] (1) of the following: 
• Related:   There is clear evidence that the event is related to the use of volanesorsen e.g., 
confirmation by [CONTACT_38000]- challenge test  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration   
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
45  • Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped together with Not 
Related)  
• Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying m edical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is eas ily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Volanesorsen  
Action taken with volanesorsen due to the event is characterized by [CONTACT_31806] (1) of the following: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by [CONTACT_31806] (1) of the 
following: 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
46  • AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
If the event is a SAE then the event’s outcome is characterized by [CONTACT_31806] (1) of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely  from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent w ith a major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be  adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudication Charter.  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_39747] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_38009] e parameter 
returns to its baseline value or until agreement is reached between the Investigator and Sponsor Medical Monitor.  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_10555].  Similarly, l aboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
47  The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 D osing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the event accidental or intentional. 
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_39748] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
48  Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesors en.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known  (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center  and 
Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
avera ge of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are  
defined as the average of Week 51 (Day 351) and Week 52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period  
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 ( apoA -1), VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
• Other symptoms: eruptive xanthoma, lipemia retinalis  
10.1.2 Safety Endpoints  
• Adverse events  including adjudicated events of pancreatitis and MACE 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
49  • Vital signs and weight 
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulation, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
10.2 Sample Size  
No sample size calculations were performed as this is an extension study to the double-blind, 
placebo -controlled ISIS 304801- CS6 and ISIS 304801-CS16 studies .  Approximately 70 patients 
may be eligible to enroll into this study.  
10.3 Populations 
Full Analy sis Set (FAS) :  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population as delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39749] efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least one (1) dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least one (1) dose of volanesorsen, and 
have at least one (1) evaluable PK sample collected , analyzed , and reported. 
10.4 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , 2 baselines are defined for each patient:  ISIS 304801-CS6 or 
ISIS 304801-CS16 index study baseline and the baseline in this open label study, which is 
defined as the average of Day [ADDRESS_39750] measurement prior to Day 1 
(e.g., qualification assessments or assessments from final visit of the ISIS 304801-CS6 or 
ISIS 304801-CS16 index studies if used for qualification). 
For other measurements , baseline for patients on active treatment in the ISIS 304801-CS6 or 
ISIS 304801-CS16 index study will be the ISIS 304801-CS6 or ISIS 304801-CS16 index study 
baseline.  For patients on placebo in t he ISIS 304801-CS6 or ISIS 304801-CS16 index study, 
baseline for safety will be the last non- missing assessment prior to the first dose of Study Drug . 
ISIS [ADDRESS_39751] patient’s Week [ADDRESS_39752] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categoric al 
variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
All efficacy  endpoints will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be assessed in the PK Set as applicable.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_37942].  All patients enrolled will be included in a summary of patient disposition . 
10.6.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_37943]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index studies.  Narratives of treatment- emergent  
deaths, serious and significant AE s, including early withdrawals due to AE s, will also be 
provided. All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug, all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_37944], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_37945]. 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_37946]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
51  These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echoc ardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_37944]. 
10.6.3 Efficacy Analysis  
Percent change and change from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_1570] o f the index studies.  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, 
Month 6, and Month 12 will be summarized .  Response analysis will also be conducted using a 
range of fasting plasma TG thresholds for determination of responder status. 
Percent change and change from baseline to Month 3, Month 6, and Month 12 will also be 
summarized by [CONTACT_37947]-HDL -C, apoB, HDL-C, apoA-1, VLDL-C, and LDL-C, total cholesterol, and fasting total 
apoC- III. 
The incremental effects of volanesorsen on lipid measures  will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, quality of life assessments , and comparison of other symptoms including eruptive 
xanthomas and lipemia retinalis  will be  summarized by [CONTACT_37948]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all patients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification by [CONTACT_37950] 304801- CS6 and ISIS 304801 CS16 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open label extension 
(OLE ) study from the intensive PK sub group, following a single dose (i.e., single -dose PK) or 
multiple dose s (i.e., steady -state PK), depending on their earlier treatment in the index studies.  
On Week [ADDRESS_39753] treatment of volanesors en (single -dose PK), while patients who received 
volanesorsen in the index studies had been on volanesorsen treatment for 12 months 
(ISIS  304801- CS6) or 6 months (ISIS 304801-CS16) , thus the PK data collected from these 
patients reflect steady -state PK .  The maximum observed drug concentration (C max) and the time 
taken to reach C max (Tmax) will be obtained directly from the concentration -time data .  Area under 
the plasma concentration -time curve from time zero to 24  hours ( AUC 0-24hr) will be calculated 
using the linear trapezoidal rule .  Apparent systemic (plasma) clearance after SC administration 
(CL 0-24hr /F0-24hr) will be calculated from CL 0-24hr /F0-24hr = Actual Dose/AUC 0-24hr.  Mean 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
52  residence time (MRT) from time zero to [ADDRESS_39754] ration  will be calculated 
from the equation, MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where AUMC 0-24hr is the area under the 
moment plasma concentration -time curve from time zero to [ADDRESS_39755]. 
Plasma PK  parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_37732] 304801 -CS6 and ISIS 304801-CS16 and IM 
status .  Additional details regarding the PK  analysis will be described in the SAP.  
Population PK, PK/PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with Study Drug  (volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37871] 304801- CS6 or ISIS 304801-CS16 and study day.  
Subject ADA status (positive/negative or not evaluable) for all evaluable patients, along with the study day ass ociated  with the first positive IM status emerged (T
first, i.e., onset of ADA 
development), the last positive IM status observed (T last), the duration of ADA response (number 
of days between T first and T last) if appropriate , the last ADA sample collection day, and subject - 
peak titer if applicable, will be listed by [CONTACT_37732] 304801 -CS6 and 
ISIS 304801-CS16  study day .  Subjects with positive anti-volanesorsen antibody status may be 
further classified (when applicable) as being ei ther ‘persistent’, ‘transient’, or ‘not determinable’, 
if deemed appropriate.  
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by [CONTACT_37732] 304801- CS6 and 
ISIS 304801-CS16.  Furthermore, onset, duration, and t iter of the ADA response, if applicable, 
will be summarized as median, quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase 2 and 3 studies and re ported separately . 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by [CONTACT_1034]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
53  Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Inve stigator) .  The original signed 
informed consent form should be retained in the Study Master File and in any other locations 
required by [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_39756] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated 
October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must al so be received b y the Sponsor before recruitment of patients into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the  IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also noti fy the IEC/IRB  of serious adve rse events 
occurring at the Study Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_39757] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., sign ed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
54  In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_39758] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
12.[ADDRESS_39759].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) application 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence .  In this study, CRFs 
may not be used as source documents. 
The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_37671] 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
55  • Study fi les containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor 
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volane sorsen  Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_39760], inspecting the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study-related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensur e that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by [CONTACT_10576]’s C linical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, 
ICH GCP, and appl icable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any appare nt discrepancies .  In addition, the data will be reviewed 
for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Ce nter for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
ISIS [ADDRESS_39761] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage f or clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
57  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757] . Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processi ng of chylomicrons . Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED,  Le N -A, Li X, et al. Apolipoprotein C -III displacement of apolipoprotein E from VLDAL: Effect of 
particle size. J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial  
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet ], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress  in antisense oligonucleotide therapeutics . Ann Rev. Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, Ben -Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; [ADDRESS_39762] 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficiency: An open -label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhib ition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation i n 
mice . J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS 304801 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
58  Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in 
transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salomon H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486] . Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression . J Biol Chem 1999; 274: 1715- 1722.  
Mendivil CO, Zheng C, Furtado J, et al. Metabo lism of very -low-density lipoprotein and low -density lipoprotein 
containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 2010; 30: 
239-245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour S, Hariri A, et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plas ma lipid profile 
and apparent cardioprotection . Science 2008; 322: 1702- 1705.  
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLDL -TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, et al. Identification of mutations in the lipoprotein lipase (LPL) an d 
apolipoprotein C -II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . Clinica 
Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyceridaemia. J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lip idol 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_39763] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3   Wk 
19 Month 6  Wk 
32 Wk 
38 Wk 
44 Month 12  Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52  
or ET 
Study Day  -14 to -7 1 2 22 50 78 85 127 169 176 218 260 302 351 358 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 3 2 2 3 3 3 2 2 7 7 
Informed Consent  X                 
Outpatient Visit  X X X X X Xh X Xh Xh X Xh X Xh Xh X Xh X 
Inclusion/Exclusion Criteria  X                 
Vital Signs + body weight  (+ height on 
Day 1 only ) X X  X X  X   X  X   X  X 
Physical Examination   X     X   X  X   X  X 
12- lead ECG  (triplicate)        X   X  X   X  X 
MRI (liver/spleen)                Xi   
Echocardiography           Xi     Xi   
Fundus Photographyb X              Xi   Blood Draw  (Fasting)c Chemistry Pane l X X  X X  X Xh  X Xh X Xh  X Xh X 
CBC with Differential  X X  X X  X Xh  X Xh X Xh  X Xh X 
Serum Lipid Panel X X  X X Xh X  Xh X  X  Xh X  X 
Coagulation  (aPTT, PT, INR)      X  X   X  X   X   
hsCRP, HbA1c, FPG , and  de-
lipi[INVESTIGATOR_37489]   X     X   X     X  X 
Sedimentation Rate   X     X   X     X  X 
Complement (C5a, Bb)   X     X   X     X  X 
Plasma  PK - Volanesorsen   Xk X X X  X   X  X   X  X 
Anti-Volanesorsen  Antibodies   X  X X  X   X  X   X  X 
FSH (women only, if applicable)                   
Serum Pregnancy Testd X    X  X   X  X   X  X 
Archived Serum & Plasma 
Samplese  X   X  X   X     X  X 
ISIS [ADDRESS_39764] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3  Wk 
19 Month 6  Wk 
32 Wk 
38 Wk 
44 Month 12  Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52 
or ET 
Study Day  -14 to -7 1 2 22 50 78 85 127 169 176 218 260 302 351 358 400 449 
Visit Window+/- Days  0 0 0 2 2 2 2 3 2 2 3 3 3 2 2 7 7 
Urinalysisc X Xj  X X  Xj Xj,h  Xj Xj,h Xj Xj,h  Xj Xj,h Xj 
Weekly Study Drug:   SC Injection   X  X X X X X X X X X X X X   
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X 
Quality of Life Assessment(s)   X     X   X     X  X 
Food/Drink Diary (quarterly)f  X     X   X     X  X 
Diet/Alcohol Counselingg X X  X X  X   X  X   X X X 
Adverse Events X X  X X  X   X  X   X  X 
Concomitant Medication  X X  X X  X   X  X   X  X 
a Qualification procedures performed (Please refer to Section 4.1) 
b If possible, prior to administration of the first dose of Study Drug and repeated at Week 52  (Please refer to Section [IP_ADDRESS] ) 
c Blood samples to be  collected after an overnight fast of at least 10 hours .  During treatment period urine and blood samples will be collected prior to Study 
Drug  administration .  Does not  apply to 24-hour PK blood draw  
d Females of childbearing pot ential only  
e Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc. ) in this or subsequent clinical studies of  
volanesorsen  
f In addition to diary, patients will be contact[CONTACT_37787]  
g To reinforce compliance to the diet  and alcohol restrictions .  Random diet/alcohol assessments (phone visits) will also be performed by [CONTACT_37828]  
h To be collected by [CONTACT_5640] a clinical service, or Study Center as arranged by [CONTACT_37747].  Approval for study procedures to be conducte d by a 
clinical service on other outpatient visit days will require prior approval by [CONTACT_1034].  
i A ± 7 day window is allowed for MRI , echocardiography procedures and fundus photography 
j Expanded urinalysis (see Appendix B ) 
k Full or abbreviated PK profile (see Appendix C ) 
ISIS [ADDRESS_39765] of Laboratory Analytes 
Based on emerging  data from this or future studies, additional tests not listed below may be 
performed on stored samples t o better characterize the profile of volanesorsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Lipid Panel  
• Total Cholesterol  
• LDL-C 
• HDL -C 
• Triglycerides  
• Non-HDL -C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC -III 
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1  
& Immunogenicity  
• Volanesorsen levels in 
plasma  
• Anti-volanesorsen 
antibodies  in plasma  
 
Other assessments  
• hsCRP  
• Sedimentation Rate  
• C5a, Bb  
• De-lipi[INVESTIGATOR_37490]  
• HbA1c , FPG  Urinalysis  
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood 
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte esterase  
• Nitrate  
• Microscopic examination
2 
 
Additional  Measures for 
Expanded Uri nalysis  
• Total protein 
(quantitative)  
• Microalbumin  
• β2-microglobulin  
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments,  IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents  
[ADDRESS_39766]- treatment follow -up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup)  
Week  Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D22 D50 D85 D176  D260  D358  D449  
Visit Window  
+/- Days 0 2 2 2 2 3 2 7 
Time Point  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Anytime  
 
PK Sampling Schedule (PK Subgroup only*)  
Week  Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day  D1 D2 D22 D50 D85 D176  D260  D358  D449  
Visit Window 
+/- Days [ADDRESS_39767]-dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Pre-
dose  Anytime  
* Patients  at selected sites will be asked to participate in the extended 24-hour PK profile beginning on 
Study  Day 1.  Participation is optional.  
 
  
ISIS [ADDRESS_39768] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
69  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  

ISIS 304804 -CS7 CONFIDENTIAL  Amendment 1  
Protocol   2 February  2016  
 
70  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
 

 
 
Sponsor:  
Isis Pharmaceuticals, Inc. 
[ADDRESS_39769] Carlsbad, CA  [ZIP_CODE] Collaborator:
Akcea Therapeutics
[ADDRESS_39770]
Cambridge, MA [ZIP_CODE]
 
 
ISIS 304801-CS7 
 
The APPROACH Open La bel Extension Study 
Volanesorsen (ISIS 304801)  
An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients wi th Familial Chylomicronemia 
Syndrome (FCS) 
 
Original Protocol – [ADDRESS_39771] No:  2015-003755-[ADDRESS_39772] 2015
rsrs 304801-cs7
The APPROACH Open Label Extension Study
Volanesorsen (ISIS 304801)
An Open-Label Extension Study of Volanesorsen Administered
Subcutaneously to Patients with Familial Chylomicronemia
Syndrome (FCS)
Original Protocol - [ADDRESS_39773] 2015
Sponsor:
Isis Pharmaceuticals, Inc
[ADDRESS_39774]
Carlsbad, CA [ZIP_CODE]
M.D., M.B.A.
2

ISIS 304801-CS7 CONFIDENTIAL Original
Protocol  28 Augus t2015
 
3   
Isis Protocol Number:  ISIS 304801-CS7 
Original Protocol 
EudraCT No:  2015-003755-21 
Clinical Phase:  3 
 
The APPROACH Open La bel Extension Study 
Volanesorsen (ISIS 304801)  
An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients wi th Familial Chylomicronemia 
Syndrome (FCS) 
 
Trial Sponsor: Isis Pharmaceuticals, Inc. 
[ADDRESS_39775] Carlsbad, CA [ZIP_CODE] 
Phone: + 01 [PHONE_207] 
Fax:  
Key Sponsor Contact:  [CONTACT_37829].D. 
[ADDRESS_39776] Carlsbad, CA [ZIP_CODE] Phone:  
Collaborator: Akcea Therapeutics 
[ADDRESS_39777] Cambridge, MA [ZIP_CODE] 
Date: [ADDRESS_39778]  2015  
 
4  Protocol Signature [CONTACT_38020]:  ISIS 304801- CS7 
Protocol Title:  An Open-Label Extension Study of Volanesorsen  Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome 
(FCS)  
Date:    [ADDRESS_39779] read and understand the attached clinical protocol , entitled “An 
Open -Label Extension  Study of Volanesorsen  Administered Subcutaneously to Patients with 
Familial Chylomicronemia Syndrome (FCS) ”, dated  [ADDRESS_39780] the 
study as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Isis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date ( DD Month YYYY) 
 
 
ISIS [ADDRESS_39781] ................................................................................22  
4. PATIENT ENROLLMENT ...............................................................................................23  
4.1 Qualification  ..................................................................................................................23  
4.2 Enrollment .....................................................................................................................23  
5. PATIENT ELI GIBILITY  ..................................................................................................23  
5.1 Inclusion Criteria  ...........................................................................................................23  
5.2 Exclusion Criteria  ..........................................................................................................24  
6. STU DY PROCEDURES  ....................................................................................................24  
6.1 Study Schedule ..............................................................................................................24  
6.1.1  Qualification  ...........................................................................................................24  
6.1.2  Treatment Period  ....................................................................................................24  
6.1.3  Pharmacokinetic (PK) Subgroup ............................................................................[ADDRESS_39782]  2015  
 
7  9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................36  
9.1 Sponsor Review of Safety Information .........................................................................36  
9.2 Regulatory Requirements  ..............................................................................................36  
9.3 Definitions  .....................................................................................................................37  
9.3.1  Adverse Event  ........................................................................................................37  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................37  
9.3.3  Serious Adverse Event (SAE) ................................................................................37  
9.4 Monitoring and Recording Adverse Events ...................................................................38  
9.4.1  Serious Adve rse Events  ..........................................................................................38  
9.4.2  Non-Serious Adverse Events ..................................................................................38  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................38  
[IP_ADDRESS]  Relationship  to the Study Drug ........................................................................38  
[IP_ADDRESS]  Severity  ............................................................................................................39  
[IP_ADDRESS]  Action Taken with Volanesorsen .....................................................................39  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................39  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................39  
9.4.4  Adjudication Committees  .......................................................................................40  
9.5 Procedures for Handling Special Situations ..................................................................40  
9.5.1  Abnormalities of Laboratory Tests .........................................................................40  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............40  
9.5.3  Dosing Errors .........................................................................................................41  
9.5.4  Contraception and Pregnancy .................................................................................41  
10. STATISTICAL CONSIDERATIONS  ..............................................................................42  
10.1  Study Endpoints  .............................................................................................................42  
10.1.1  Efficacy Endpoints .................................................................................................42  
10.1.2  Safety Endpoints  .....................................................................................................42  
10.2  Sample Size  ....................................................................................................................43  
10.3  Populations .....................................................................................................................43  
10.3  Definition of Baseline  ....................................................................................................43  
10.4  Interim Analysis  .............................................................................................................43  
10.5  Planned Methods of Analysis ........................................................................................43  
10.5.1  Demographic and Baseline Characteristics  ............................................................44  
10.5.2  Safety Analysis  .......................................................................................................44  
10.5.3  Efficacy Analysis  ...................................................................................................44  
10.5.4  Pharmacokinetic and Immunogenicity Analysis ....................................................45  
[IP_ADDRESS]  Pharmacokinetic Analysis  ................................................................................45  
[IP_ADDRESS]  Immunogenicity Analysis  ................................................................................45  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................[ADDRESS_39783]  2015  
 
8  11.3  Independent Ethics Committee/Institutional Review Board  .........................................[ADDRESS_39784] of Laboratory Analytes  .............................................................................56  
Appendix C  Pharmacokinetic Sampling Schedule ...............................................................58  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......60  
 
 
TABLE OF TABLES 
Page 
Table 1  Volanesorsen (ISIS 304801) Characteristics ........................................................ 28  
Table 2  Expected Event for the Protocol Defined Population by [CONTACT_37895]  .................................................................................. 36  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37675]  .............. 16  
Figure 2  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides 
(MOE -Gapmer).  The sequence of volanesorsen is shown ................................... [ADDRESS_39785]  2015  
 
9  PROTOCOL SYNOPSIS  
Protocol Title  An Open-Label Extension Study of Volanesorsen Administered 
Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)  
Study Phase  3 
Indication  Familial Chylomicronemia Syndrome  
Study Objective s To evaluate the safety and efficacy of extended dosing with volanesorsen  
(volanesorsen sodium 300 mg ) in patients with FCS  
Study Design  This is a multi -center, open-label extension study  of ISIS 304801-CS6 .  All 
patients will receive volanesorsen [ADDRESS_39786]-treatment evaluation period.  
Number of  Patients Up to approximately 50 patients  dosed  
Study Population  Inclusion Criteria : 
1. Must give written informed consent to participate in the study (signed and 
dated) and any authorizations required by [CONTACT_2371]  
2. Age ≥ 18 years at time of informed consent  
3. Satisfactory completion of ISIS 304801-CS6 (index study) with an 
acceptable safety profile, per  Sponsor  and Investigator judgment  
4. Able and willing to participate in a 65-week study  
5. Satisfy one of the following:  
a. Females:  Non- pregnant and non-lactating; sur gically sterile (e.g., 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy), post -menopausal (defined as 12 months of 
spontaneous amenorrhea in females > 55 years of age or, in 
females ≤ 55 years, 12 months of spontaneous amenorr hea without 
an alternative medical cause and FSH levels in the postmenopausal 
range for the laboratory involved), abstinent, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time of signing 
the informed consent form until [ADDRESS_39787] dose of 
Study Drug administration  
b. Males:  Surgically sterile, abstinent or if engaged in sexual relations 
with a female of child-bearing potential, patient is utilizing an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_39788] dose of Study Drug administration  
Exclusion Criteria : 
1. Have any new condition or worsening of existing condition which  in the 
opi[INVESTIGATOR_37601], or could interfere with the patient participating in or 
completing the study  
2. Unwilling to comply with lifestyle requirements for the duration of the study ( Section 6.3 ) 
Treatment Group  Volanesorsen 300 mg once per week   
Study Drug Administration  Volanesorsen will be administered as subcutaneous ( SC) injections.  
ISIS [ADDRESS_39789]  2015  
 
10  PROTOCOL SYNOPSIS  Continued  
Dose Adjustments  Dose adjustments, including dose interruptions and/or decreasing the dose 
frequency will be allowed for safety or tolerability after consultation with the 
Sponsor Medical Monitor.  
Rationale for Dose and Schedule 
Selection  The dose of 300 mg once weekly was chosen  for the double- blinded 
placebo- controlled Phase 3 index study (ISIS 304801-CS6 ) based on the 
pharmacodynamic and safety analysis of the Phase [ADDRESS_39790] of the following 
periods:  
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034])  
• A 52-week treatment period during which volanesorsen will be 
administered as a once weekly SC injection  
• A 13-week post -treatment evaluation period  
The patients, Investigators, study staff, and the Sponsor will remain blinded to 
lipid data through the last patient’s Week 13 visit of the extension study or 
until results from  the database lock for the index study (ISIS 30 4801-CS6) 
becomes available, whichever comes first . 
Collection and measurement of vital signs, clinical laboratory parameters 
(including hematology, serum chemistry, and urinalysis), adverse events  
(AE), concomitant medication/procedure information, lipid panel, 
volanesorsen plasma concentrations, immunogenicity (IM) testing, 
liver/spleen magnetic resonance imaging ( MRI), ECGs, echocardiograms and 
quality of life assessments will be performed according to the schedule of 
procedures in Appendix A .  Dietary counseling will be repeated at intervals 
throughout the treatment and follow-up period and a daily food /drink  diary will 
be completed for the week prior to each quarterly visit by [CONTACT_6904] .  
Following the Week  [ADDRESS_39791] -treatment 
evaluation period.  
Safety and Tolerability Evaluations  Overall safety and tolerability of volanesorsen  will be assessed by 
[CONTACT_37840]  (including independently adjudicated events of  acute pancreatitis and 
MACE), withdrawals due to adverse events, and changes in laboratory and 
other safety parameters . 
Planned Analyses Safety Endpoints : 
• Adverse events including adjudicated events of acute pancreatitis and 
MACE  
• Vital signs and weight  
• Physical examination s 
• Clinical  laboratory test s (serum chemistry,  hematology, coagulation, 
urinalysis ) 
• Echocardiography  
• Electrocardiograms (ECGs)  
• Use of concomitant medications  
• MRIs  
  
ISIS 304801-CS7 CONFIDENTIAL Original
Protocol  28 Augus t2015
 
11  PROTOCOL SYNOPSIS Continued 
Planned Analyses Continued Efficacy Endpoints: 
• Percent change and absolute change from baseline in fasting TG 
• Frequency and severity of patient reported abdominal pain during the 
treatment period 
• Percent change and change from baseline in other fasting lipid 
measurements including total c holesterol, non-high-density 
lipoprotein-cholesterol (non-HDL-C), apolipoprotein B [apoB], high-
density lipoprotein-cholesterol (HDL-C), apolipoprotein A-1 [apoA-1], 
very-low-density lipoprotein-cholesterol (VLDL-C), and LDL-C 
• Percent change from baseline in fasting total apolipoprotein C-III 
(apoC-III) 
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate 
Pharmacokinetic Evaluations Plasma samples will be taken from all patients for the measurement of 
volanesorsen as follows: trough levels (pre-dose) throughout treatment and 
post-treatment levels during the post-treat ment follow-up period.  In a subset 
of patients, more frequent assessment  of plasma concentrations of 
volanesorsen will be performed to determine volanesorsen pharmacokinetic 
parameters.  Plasma sample collection time points are detailed in Appendix A 
and Appendix C . 
Statistical Considerations No sample size calculations were perf ormed as this is an extension study to 
the double-blind placebo cont rolled ISIS 304801-CS6 study. 
Sponsor Isis Pharmaceuticals, Inc. 
Collaborator Akcea Therapeutics 
ISIS 304801-CS7 CONFIDENTIAL Original
Protocol  28 Augus t2015
 
12  STUDY DESIGN AND TREATMENT SCHEMA 
 QUALIFICATION 
PERIOD 
 
Weeks -2 to -1 
EARLY 
TERMINATION 
(ET) 
 
Follow Week 52 
Schedule of 
Procedures at ET; 
Patient strongly 
encouraged to visit 
clinic for 
post-treatment 
assessments  TREATMENT PERIOD 
 
Weeks 1 to 52 
 
Once Weekly 300 mg SC injection of 
volanesorsen.  Routine safety assessments.  
PK and PD/efficacy assessments at 
specified time points 
POST-TREATMENT  EVALUATION 
PERIOD 
 
Weeks [ADDRESS_39792]  2015  
 
13  STUDY GLOSSARY 
Abbreviation/Acronym  Definition  
ADA  anti-drug antibody  
AE adverse Event  
ALP  alkaline Phosphatase  
ALT  alanine Aminotransferase  
ANA  antinuclear Antibody  
apoA -[ADDRESS_39793]  
IXRS  Interactive Voice/Web -Response System  
LDL  Low-Density Lipoprotein  
LDL -C Low-Density Lipoprotein -Cholesterol  
LMF1  Lipase Maturation Factor [ADDRESS_39794] Lipoprotein Lipase  
MACE  Major Acute Cardiovascular Event  
MOE  2′-O-(2-methoxyethyl)  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid 
NCS  not c linically significant  
NOAEL  No-Observed -Adverse -Effect Level  
non-HDL -C Non-High -Density Lipoprotein -Cholesterol  
OLE  Open Label Extension  
OTC  over the counter  
PFS prefilled syringe  
PD pharmacodynamic  
PK pharmacokinetic  
PPS per protocol set 
PT prothrombin time 
SAE  serious  adverse event 
SAP Statistical Analysis Plan  
SC subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2DM  type [ADDRESS_39795]  2015  
 
15  1. OBJECTIVES  
The objective of the study is to evaluate the safety and efficacy of extended dosing with 
volanesorsen in patients with familial chylomicronemia syndrome.  
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Familial Chylomicronemia Syndrome (FCS) is an inherited disease characterized by [CONTACT_37756] , and  risk or history of pancreatitis.  It is a rare 
autosomal recessive disease that can be diagnosed ei ther in childhood or adulthood. 
Fasting plasma triglyceride (TG) levels in FCS patients are typi[INVESTIGATOR_897] 10 -fold to 100-fold above 
normal (1,500 to 15,000 mg/dL), despi[INVESTIGATOR_37452] (20 g or approximately 15-20% of daily calorie intake) ( Brunzell 1999-2011).  Patients with FCS often present in 
infancy or childhood with frequent and severe abdominal pain, repetitive colicky pain, repeated epi[INVESTIGATOR_37520], and failure to thrive ( Brunzell 1999-2011; 
Tremblay et al. 2011).  Physical  examination frequently reveals eruptive xanthomas, lipemia 
retinalis and hepatosplenomegaly, and plasma from patients appears lactescent, interfering with 
determination of other laboratory parameters ( Tremblay et al. 2011).  
Patients with fasting triglycer ide levels > 10 mmol/l probably have a component of 
chylomicronemia .  Clinical diagnosis would include evidence of clinical features of 
chylomicronemia syndrome and secondary causes such as uncontrolled type 1 or type 2 diabetes 
mellitus  (T2DM), hypothyroidism, poor diet, alcohol use, nephrotic syndrome or use of 
associated medications should be ruled out.  The diagnosis of FCS may be made more specifically by [CONTACT_37688][INVESTIGATOR_37550] (LPL) 
enzyme activity in post heparin plasma ( Brunzell 1999-2011).  
Patients with FCS carry a heavy burden of medical complications, the most serious, as described 
above, being an extreme risk of recurrent and potentially fatal pancreatitis .  Due to the recurrent 
epi[INVESTIGATOR_37551], these patients may also develop chronic pancreatitis and signs of exocrine or endocrine pancreatic insufficiency, including diabetes mellitus ( Gaudet et al. 2013).  
While the pathophysiology underlying chylomicron- related pancreatitis has not been  completely 
elucidated, one hypothesis is that large chylomicrons lodged in pancreatic capi[INVESTIGATOR_37672], with the subsequent release of free fatty acids through the hydrolysis of chylomicron -associated TGs .  High concentrations of free fatty acids are thought to damage 
pancreatic cells leading to emergent pancreatitis ( Yang et al. 2009; Berglund et al. 2012).  
The etiology of extreme hypertriglyceridemia in FCS is considered to be ineffective triglyceride clearance, due to an extr emely low level of LPL activity .  LPL normally functions to hydrolyze 
triglycerides  (TG) in chylomicrons along the luminal surface of capi[INVESTIGATOR_11037], mainly in heart, 
skeletal muscle, and adipose tissue, promoting triglyceride clearance from the circulation .  LPL 
is regulated by a number of key genes, and loss-of-function mutations in one of these genes, or the LPL gene itself, results in FCS  (Surendran et al. 2012).  In addition to loss of function 
mutations, null mutations, and nonsense mutations in the LPL gene, other genes currently 
identified in FCS patients, and known to directly influence LPL activity include: apolipoprotein C- II (APOC2) a cofactor for LPL (Schuster et al. 2011); apolipoprotein A- V 
ISIS [ADDRESS_39796]  2015  
 
16  (APOA5)  an enhancer of LPL activity ( Schaap et al. 2004); lipase maturation F actor 1 (LMF1), a 
transmembrane protein involved in LPL maturation ( Doolittle et al. 2009); 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPI[INVESTIGATOR_37445]1), a capi[INVESTIGATOR_37553] a platform for LPL-mediated processing of chylomicrons 
(Beigneux et al. 2007).  
2.2 T herapeutic Rationale 
Apolipoprotein C- III (ApoC- III), a key regulator of plasma triglyceride levels, is a 79 amino acid 
glycoprotein synthesized principally in the liver ( Ooi et al. 2008; Figu re 1).  ApoC- III is a major 
regulator of lipoprotein metabolism and plays a pi[INVESTIGATOR_37496] 
(Chan  et al. 2008).  It is a component of triglyceride-rich lipoproteins (TRLs) and a potent 
inhibitor of LPL ( Lemieux et al. 2003).  At  higher concentrations apoC- III also inhibits hepatic 
lipase activity ( Kinnunen and Ehnolm 1976), an enzyme which plays an important role in the 
conversion of dense very-low-density lipoprotein ( VLDL ) to intermediate density lipoprotein 
(IDL) and to LDL ( Mendivil et al. 2010), as well as in the remodeling of HDL  
(Brown et al. 2010).  In addition, increased apoC- III content adversely affects apoE -mediated 
hepatic uptake of TG -rich remnants ( Mann et al. 1997).  Thus, elevated plasma apoC- III levels 
are associated with impaired hydrolysis and retarded clearance of TG -rich particles, resulting in 
the accumulation of lipoprotein -triglyceride ( VLDL -TG) and chylomicrons in plasma and the 
development of hypertriglyceridemia ( Ito et al. 1990).  
 
Figure 1 ApoC- III Regulates Lipoprotein Metabolism by [CONTACT_37757]. 2008; ABCA1  = ATP -binding cassette A1, apo  = apolipoprotein, CE  = cholesterol ester, 
CETP  = cholesterol ester transfer protein, FC  = free cholesterol, HDL  = high- density lipoprotein, 
HL = hepatic lipase, IDL  = intermediate -density lipoprotein, LCAT  = lecithin cholesterol acyltransferase, 
LDL = low-density lipoprotein, LDLr  = LDL receptor, LPL  = lipoprotein lipase, LSR  = lipolysis -stimulated 
receptor, SR -B1 = scavenger receptor B -1, TG  = triglyceride, VLDL  = very low -density lipoprotein.  

ISIS [ADDRESS_39797]  2015  
 
17  Mechanistically, FCS is primarily a consequence of ineffective clearance of TRL .  ApoC- III is a 
prominent component of TRL (e.g., VLDL and chylomicrons).  In addition to its role in 
inhibiting LPL, apoC- III inhibits TRL remnant (TG -depleted remnant lipoprotein) uptake by 
[CONTACT_37842]. 
Human genetic data have demonstrated positive phenotypic associations with loss (e.g., null or 
nonsense mutations) and negative effects with gain of function mutations ( Atzmon et al. 2006; 
Pollin et al. 2008; Petersen et al. 2010).  A novel nonsense mutation in the apoC- III gene was 
identified in the heritability and phenotype intervention (HAPI) heart study in Old Order Amish 
that results in lower plasma apoC -III and TG levels and lower LDL- C, increased HDL -C and 
reduced atherosclerosis ( Pollin  et al. 2008).  In another study involving a group of 
214 Ashkenazi Jews of advanced age (had passed or nearly reached 100 years of age), genotype analysis revealed a polymorphism in the apoC- III gene (APOC3 -641CC genotype) with a clear 
pattern of age-dependent frequency that was associated with significantly lower levels of apoC-III protein, a favorable lipoprotein profile and increased longevity ( Atzmon  et al. 2006).  In 
contrast to the Amish and Ashkenazi apoC-III polymorphisms associated with lower plasma TG, apoC-III polymorphisms associated with higher plasma TG have also been recently described (Petersen  et al. 2010).  In a cohort of lean (mean body mass index [BMI] = 24.7 ± 3.6 kg/m
2) 
Asian Indians, carriers of apoC- III variant alleles (C -482T, T-455C, or both) were noted to have 
significantly higher plasma apoC -III and TG levels, and decreased ability to clear postprandial 
plasma TG from the circulation .  Taken together, the available data strongly support the 
development of a therapy that reduces plasma apoC -III levels in order to reduce the very high 
circulating triglyceride and chylomicron levels that are accompanied by [CONTACT_37899].  
Given the profound reductions in TG s observed with volanesorsen treatment in FCS patients 
who have no detectable LPL activity (See Section 2.3.4), and the mechanistic data available to 
date on apoC-III function, potential mechanisms that explain how apoC-III inhibition results in 
triglyceride reduction in FCS patients include:  (1) enhancing the very small residual amounts of 
LPL activity that these patients may have, below the limit of detection of the assay in many cases 
(2) potentially enhanced activity of other lipases also involved in the metabolism and breakdown of TGs, such as hepatic lipase or endothelial lipase  (Kinnunen and Ehnolm 1976),  and 
(3) apoC- III interact ion with Apolipoprotein E ( apoE), an important factor in liver reuptake of 
lipid particles by [CONTACT_37691]- mediated uptake of lipid particles in the liver  
(Breyer et al. 1999), and therefore, reducing apoC- III might enhance apoE -mediated uptake of 
lipid particles .  Volanesorsen -mediated reduction of apoC-III could be contributing to one or all 
of these mechanisms resulting in the observed potent and sustained reductions in TG. 
Through a novel apoC- III lowering mechanism of action , volanesorsen may provide the potential 
to manage triglyceride levels in FCS patients.  
2.3 Volanesorsen  
2.3.1 Mechanism of Action  
Volanesorsen  is a second -generation antisense oligonucleotide (ASO) drug targeted to human 
apoC-III.  It is complementary to a region within the 3ʹ untranslated region of the ap oC-III 
messenger ribonucleic acid ( mRNA) and binds to the mRNA by [CONTACT_37800].  
ISIS [ADDRESS_39798]  2015  
 
18  The hybridization (binding) of volanesorsen to the cognate mRNA , results  in the RNase 
H1-mediated degradation of the ap oC-III mRNA, thus preventing production of the ap oC-III 
protein.  Maximal a ntisense- mediated reduction of target mRNA levels is typi[INVESTIGATOR_37458] 
90% of control levels in sensitive tissues (Crooke and Ben nett 1996; Zhang et al. 2010).  
Furthermore, reduction in target mRNA levels using this approach correlates directly  with a 
subsequent reduction in target protein levels. 
2.3.2 Chemistry  
Chemically, volanesorsen is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_37693].  The nucleotide sequence of  volanesorsen 
(Figure 2 ) is complementary to a 20-nucleotide stretch within  the 3 ʹ untranslated region of the 
apoC-III mRNA transcript at base positio n 489-508.  Structurally, the oligonucleotide has 
3 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 nucleotides at the 3′ end, are 
composed of 2ʹ- O-(2-methoxyethyl)  (MOE)-modified ribonucleotides.  These MOE -modified 
nucleotides confer (1) increased affinity to the target mRNA ( Altmann  et al. 1996;  
McKay  et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_37759])  (Geary et al. 2003), and (3) amelioration of some of the high dose 
toxicities thereby [CONTACT_37920] (DNA) ( Henry et al. 2000).  
The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and volanesorsen 
employs  this chimeric structure to enable use of the RNase H 1-mechanism for antisense activity .  
This is because while the 2 ʹ-MOE modification confers increased stability and  affinity, it does 
not support RNase H 1 catalysis of RNA hybridized to 2ʹ- MOE -modified nucleotides  
(McKay  et al. 1999).  This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H 1 enzymes ( Inoue et al. 1987; 
Monia et al. 1993).  By [CONTACT_37761] 2 ʹ-MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2ʹ- MOE chemistry 
are preserved while also retaining RNase H 1 recognition. 
 
 
Figure 2 Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer) .  The sequence of volanesorsen  is shown  
2ʹ-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H  
 Sensitive)  
A  G  C   
T 
T  
C  T   
T 
G   
T 
C   
C 
A 
G   
C 
T 
T   
T 
A 
T 
Phosphorothioate  
Backbon e 
ISIS [ADDRESS_39799]  2015  
 
19  2.3.3 Preclinical Experience  
Inhibition of apoC- III using volanesorsen  has been shown to potently reduce hepatic apoC- III 
mRNA as well as plasma apoC -III protein and TG in a dose- and time -dependent fashion in 
several species, including human apoC-III transgenic mice, and other rodent and monkey 
models.  Treatment with volan esorsen  also resulted in reduced VLDL and chylomicron TG and 
reduced postprandial TG in hypertriglyceridemic monkeys ( Graham et al. 2013). 
The pharmacokinetics (PK) and toxicity of volanesorsen have been assessed in mice, rats, and 
cynomolgus monkeys.  General toxicity studies with volanesorsen for up to 39 weeks of treatment followed by [CONTACT_8622] a 20- week recovery period are complete.  The preclinical toxicology 
program for volanesorsen consists of single dose safety pharmacology studies in the monkey 
(cardiovascular) and mouse (neurobehavioral and pulmonary assessment studies), in vitro  and 
in vivo  genetic toxicity assessment, repeat dose fertility and/or developmental reproductive 
toxicology studies in the mouse and rabbit and evaluation in the in vitro  human  
Ether -á-go-go-related gene (hERG)  assay . 
Volanesorsen  treatment -related findings in mice and monkeys were generally consistent with 
those expected for the 2′- MOE -class of ASOs .  Treatment -related findings included effects 
consistent with drug accumulation in tissues in rodents and monkeys, species-dependent proinflammatory response in rodents and monkeys and complement activation and reductions in platelet counts in the monkey.  In the mouse and monkey general toxicity studies, reduction of hepatic apoC -III mRNA (>  75%) was not associated with any findings that could be considered 
related to the pharmacologic inhibition of apoC-III for up to [ADDRESS_39800] effects in safety pharmacology studies ( in vitro  and in vivo ) 
and was non-genotoxic ( in vitro  and in vivo ).  Volanesorsen  had no effects on fertility or 
embryo/fetal development in the mouse or rabbit reproductive toxicity studies.  In these studies, volanesorsen was detected in placental tissue but not in fetal tissue indicating that little, if a ny, 
drug was able to cross the placenta to reach the fetus .  Reduction of apoC- III mRNA (64% in 
males and 47% in females) also did not affect fertility or cause untoward effects on emb ryo/fetal 
development in mice. 
Detailed information concerning the precl inical studies conducted with volanesorsen can be 
found in the volanesorsen Investigator’s Brochure. 
ISIS [ADDRESS_39801]  2015  
 
20  2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with volanesorsen can be found 
in the volanesorsen Investigator’s Brochure .  A summary is included below.  
Volanesorsen  has been evaluated in one Phase 1 study and two Phase 2 studies, all double 
blinded and placebo controlled.  The total exposures comprise 99 patients and healthy volunteers 
administered volanesorsen from  50 to 400 mg subcutaneously up to 3 months (compared to 
37 administered placebo). 
All clinical trials of volanesorsen  have shown large and clinically meaningful reductions in 
fasting plasma apoC -III and TG (~ 80% and 70% , respectively,  mean reduction from baseline 
with 300 mg dose) with a very high degree of consistency of response between the different 
patient groups.  This includes healthy volunteers, patients with moderate to severe 
hypertriglyceridemia not on background TG-lowering therapy, patients with moderate to severe 
hypertriglyceridemia on a background stable fibrate therapy  (Gaudet et al. 2015) , patients with 
FCS, and patients with T2DM. 
In a Phase 2 study, three patients with FCS were treated with 300 mg/wk volanesorsen  in an 
open label fashion.  These patients had a mean baseline fasting TG level of 1,844  mg/dL and all 
three patients achieved TG levels below or close to 500 mg/dL during the dosing period out to 
Day 92 (Figure 3).  Two (2) of the FCS patients had an absolute reduction in fasting TG in 
excess of 1,500 mg/dL  (Gaudet  et al. 2014). 
 
Figure [ADDRESS_39802] on the renal (serum creatinine, proteinuria) or hepatic systems (alanine aminotransferase [ALT ], aspartate aminotransferase [ AST ], bilirubin) despi[INVESTIGATOR_37668] [ADDRESS_39803]- treatment 
period and was not associated with platelet- related adverse events  (AEs). 
The most freq uently observed AE s with volanesorsen  were local reactions at the injection site .  
Local cutaneous reactions at the injection site defined as those events presenting as either pain, tenderness,  erythema,  pruritus or swelling occurring on the day of injection and persisting for at 
least 2 days were  infrequent (~15% of injections), were almost always mild, resolved 
spontaneously, were non-progressive, and were not associated with systemic sequelae.  
2.[ADDRESS_39804] Level ( NOAEL ) 
was defined by [CONTACT_38010] .  No nonclinical findings were considered to be related to the 
pharmacologic inhibition of apoC- III. 
The safety data to date suggest that volanesorsen  has been well tolerated at dose levels up to 
300 mg  in patients with high triglycerides (including type 2 diabetes patients and administration 
in combination with fibrates and statins) with the most common AEs being local to the injection 
site and predominantly mild .  A p ooled analysis of safety for the Phase 2  studies did not 
demonstrate any clear difference in safety or tolerability between the different doses  tested 
(100 mg, 200 mg, and 300 mg per week for 13 weeks). 
Analysis of the cohorts in which volanesorsen was stu died at different doses demonstrates 
dose-dependent pharmacology with respect to pharmac odynamic (PD) effect on the target, 
apoC- III, with a clear difference in the TG -lowering effect between the diff erent doses in the 
100 mg to 300 mg dose range as compared to placebo. 
In addition to the nonclini cal and clinical experience of volanesorsen , the dose and schedule of 
administration  is supported by [CONTACT_37697] 
2′-MOE -modified ASOs that have been safely administered intravenously and subcutaneously in 
multiple clinical studies at doses up to 1000 mg and for treatment durations that exceed 
24 months ( Santos et al. 2015). 
ISIS [ADDRESS_39805]  2015  
 
22  3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is an open- label extension  to the Phase 3 study of volanesorsen in patients with F CS 
(ISIS  304801-CS6).  Up to a pproximately [ADDRESS_39806] of the following periods: 
• A qualification period of up to 2 weeks (unless approved by [CONTACT_1034])  
• A 52-week  treatment period during which volanesorsen  will be administered as a once 
weekly SC injection  
• A [ADDRESS_39807]- treatment evaluation period  
Please refer to the Schedule of Procedures in Appendix A . 
3.4.1 Qualification  
A period of up to 2 weeks  is given to complete  qualification  assessments outlined in the 
Schedule of Procedures (Appendix A). 
3.4.2 Treatment  
The treatment period is 52 weeks .  Eligible patients  will report to the Study Center  for 
assessments at specified  intervals throughout the 52-week treatment period  as detailed in the 
Schedule or Procedures (Appendix A).  During the treatment period, volanesorsen  is 
administered by  [CONTACT_37847].  
3.4.[ADDRESS_39808] (DSMB) will review (as  needed)  safety, tolerability and 
efficacy data collected on volanesorsen during this study .  Based on its ongoing assessment of 
ISIS [ADDRESS_39809]  2015  
 
23  the safety and tolerability of volanesorsen, the DSMB will provide recommendations to the 
Sponsor for modifying, stoppi[INVESTIGATOR_10483].  Details on the safety assessments, frequency of review and meeting schedules are outlined in the DSMB Charter 
and/or the statistical analysis plan ( SAP). 
4. PATIENT  ENROL LMENT  
4.1 Qualification  
Before patient s may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient  information . 
Final assessments from the index study may be used for qualification as long as they were 
conducted within [ADDRESS_39810] sign the consent form before any  study- specific procedures or evaluations  
related to this open label study are performed .  During the qualification period, the eligibility of 
the patient  to continue in the extension study will be determined .  A period  of up to 2 weeks after 
completion of the index study (unless approved by [CONTACT_1034]) is given to complete qualification .  Qualified patients will retain the unique patient  identification number  that was 
assigned to them during the index study.  The patient identification number will be used to 
identify the patient  throughout the ex tension trial and must be used on all study documentation 
related to that patient .  The patient  identification number must remain constant throughout the 
extension trial. 
4.[ADDRESS_39811] been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to enrollment. 
Eligible patients will be enrolled u sing an Interactive Voice/Web -Response System (IXRS).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria 
within [ADDRESS_39812] give written informed consent to participate in the study (signed and dated) and any authorizations required by [CONTACT_2371] 
2. Age ≥ 18 years at time of informed consent 
3. Satisfactory completion of ISIS 304801- CS6 (index study)  with an acceptable safety 
profile, per Sponsor and Investigator judgment 
4. Able and willing to participate in a [ADDRESS_39813]  2015  
 
24  5. Satisfy one of the following: 
a. Females:  Non -pregnant and non- lactating; surgically sterile (e.g., tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy), post- menopausal 
(defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in 
females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH levels in the postmenopausal range for the laboratory involved), abstinent, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from time 
of signing the informed consent form until [ADDRESS_39814] dos e of Study Drug 
administration.  
b. Males:  Surgically sterile, abstinent or if engaged in sexual relations with a female of child -bearing potential, patient is utilizing an acceptable contraceptive method (refer 
to Section 6.3.1) from the time of signing the informed consent form until [ADDRESS_39815] any new condition or worsening of existing condition which in the opi[INVESTIGATOR_37601], or could interfere with the patient participating in or completing the study.  
2. Unwilling to comply with lifestyle requirements for the duration of the study (Section  6.3). 
6. STUDY PROCEDURES  
6.[ADDRESS_39816] patient’s Week [ADDRESS_39817].  
During the treatment period , patients will report to the study center for clinic visits a minimum of  
10 times during Weeks 1-52 (see Schedule of Procedures in Appendix A).  Study Drug will be 
administered once weekly  (Section 8.1).  Collection and measurement of vital signs, clinical 
laboratory parameters (including hematology, serum chemistry, and urinalysis), AEs , 
ISIS [ADDRESS_39818]  2015  
 
25  concomitant medication/procedure information, lipid panel, volanesorsen p lasma concentrations,  
immunogenicity  (IM)  testing , liver/spleen MRI, ECGs, echocardiograms and quality of life 
assessments will be performed according to the schedule of procedures in Appendix A .  Adverse 
events at the injection site should be collected as adverse events .  Dietary counseling will be 
reinforc ed at intervals throughout the treatment and follow-up period and all patients will 
complete a daily food diary for one week prior to their quarterly visit.  All blood and urine 
samples should be collected  prior to volanesorsen administration .  Blood sampling  for lipid 
panels at Week s 12, [ADDRESS_39819] be sent to the central laboratory for analysis .  Every ef fort should be made to ensure 
the previous week’s dose is given [ADDRESS_39820] ± 2 days .  All reasonab le attempts should be made to 
ensure compliance with the visit schedule as outlined in Appendix A.  However, in the event that 
a visit does not occur or is delayed, all subsequent visits should be calculated based on the time 
elapsed since Day 1 rather than from the date of the previous visit. 
6.1.3 Pharmacokinetic (PK) Subgroup 
A subgroup of patients will participate in an extended PK collection.  Patients in this subgroup 
will have more frequent PK sampling over a 24-hour period following the first dose on 
Study Day [ADDRESS_39821]-dose blood 
draw  after dosing on Day 1.  The detailed PK sampling schedules are outlined in Appendix C . 
Participation in the PK subgroup is optional for sites and patients, and  consent may be withdrawn 
for the subgroup- specific procedures (e.g. , multiple blood draws for PK) without being 
withdrawn from the study .  If a patient withdraws consent from the subgroup procedures, he/she 
should remain on study and continue to follow all the non-subgroup assessments and procedures 
as outlined in Appendix A. 
6.1.[ADDRESS_39822] of these analytes  is contained in Appendix B . 
6.2.2 Physical Exams and Vital Signs  
Physical exams and vital signs will be pe rformed as indicated in the Schedule of Procedures 
(Appendix A).  Vital signs should include weight, blood pressure, pulse rate , respi[INVESTIGATOR_37557].  Blood pressure and pulse rate will be recorded after the patient has been in a 
ISIS [ADDRESS_39823] 5 minutes .  Semi -supi[INVESTIGATOR_37558] (preferentially on the left arm) .  Height will be measured at  
the Day [ADDRESS_39824] 5 minutes .  ECGs will be performed in triplicate at W eek 13, Week 26, Week 3 8, Week 52, and 
Week 65 . 
6.2.5 MRI 
MRI of the liver and spleen will be conducted at Week 52 for all patients for whom MRI is not 
contraindicated, e.g., patients having metal implants. 
MRIs will be conducted using standardized procedures and settings .  MRIs will be read by [CONTACT_37767].  
6.2.6 Quality of Life Assessments  
All patients will complete Quality of Life Questionnaires (EQ-5D and SF-36) at Week [ADDRESS_39825] refrain from sperm/egg donation and 
practice effective contraception from the time of signing the informed consent form until at least 
[ADDRESS_39826]’s last dose of study 
treatment.  
For the purposes of this Study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet one of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternat ive 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows:  
For male patien ts: 
• Effective male contraception includes a vasectomy with negative semen analysis at follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository.  Male patien ts must also encourage their female partner to  use 
effective contraception from the time of signing the informed consent until 3 months after 
the patien t’s last dose of study treatment.  Effective contraceptive for the female partner 
includes: surgical sterilization (e.g., bilateral tubal ligation), h ormonal contraception, 
intrauterine contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male 
patien ts with partners that are pregnant must use condoms to ens ure that the fetus i s not 
exposed to the study drug. 
For female patien ts: 
• Using 1 or more of the following acceptable methods of contraception:  surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female condom* with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository . 
*Note : A female condom and a male condom should not be used together as friction between 
the two can result in either product failing. 
6.3.[ADDRESS_39827] 10 hours before visits requiring fasted blood 
sampling.  
All patients will be encouraged to follow a diet comprising ≤ [ADDRESS_39828] will explain that the patient is in a clinical trial 
and that serum lipase and/or amylase measures should be done in order to adjudicate the event, 
based on Atlanta Classification ( Banks et al. 2013 ).  If serum or amylase activity is less than 
3 x upper limit of normal ( ULN ), imaging, preferably contrast-enhanced computed tomography, 
should be considered to confirm the diagnosis of acute pancreatitis per the Atlanta Criteria . 
7. STUDY DRUG  
7.[ADDRESS_39829] (ISIS 304801) characteristics are listed in Table 1.  
Volanesorsen  (ISIS 304801) is contained in glass prefilled syringes (PFS) .  Volanesorsen  and its 
storage and preparation instructions will be provided by [CONTACT_16015].  Volanesorsen  
must be stored securely at 2° to 8° C and be protected from light. 
Table 1 Volanesorsen  (ISIS  304801) Characteristics  
Strength  200 mg/mL  
Volume/Formulation  1.5 mL solution per PFS  
Dose  300 mg once weekly  
Route of Administration  SC 
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged volanesorsen  labeled  (ISIS 304801) in 
accordance with specific country regulatory requirements.  
7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of 
volanesorsen provided by [CONTACT_1034].  The S tudy C enter  must return all unused volanesorsen to 
the Sponsor or designee.  All used syringes must be disposed of as per the site’s hazardous waste 
destruction policy. 
8. T REATMENT OF PATIENTS 
8.[ADDRESS_39830] 
2 days apart.  
Every effort should be made to ensure the previous week’s dose is given 7 days prior to a 
scheduled clinic visit.  
Please refer to the Study Drug Manual provided by [CONTACT_37850]. 
8.2 Other Protocol -Required Drugs  
There are no other protocol-required d rugs (Section  6.2.5). 
8.3 Other Protocol -Required Treatment Procedures  
There are no other protocol required treatment procedures for this study. 
8.4 Treatment Precautions  
There are no specific treatment precautions required for this study. 8.5 Safety Monitoring Rules  
Please refer also to the ‘Guidance for Investigator’ section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of Day [ADDRESS_39831] measurement prior to Day 1  (e.g., qualification assessments or 
assessments from  final visit of the index study if used for qualification). 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical observations. 
Confirmation Guidance:  At any time during the study (Treatment or Post-Tr eatment P eriods), 
the initial clinical laboratory results meeting the safety monitoring or stoppi[INVESTIGATOR_37560] (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should take place as soon as possible (ideally within 3 days of the initial collection) .  For stoppi[INVESTIGATOR_004], 
if the initial laboratory result is observed during the Treatment Period, the results from the retest must be available prior to administering the next  dose of volanesorsen. 
In addition to the safety monitoring parameters listed below, the Sponsor may request confirma tion of additional lab values. 
Re-dosing Guidance:  Patients  with initial laboratory test values that reach a stoppi[INVESTIGATOR_37561]-dosed until the re- test results are available.  In general, patien ts who do not meet the 
stoppi[INVESTIGATOR_10448].  However, the Investigator and the Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patien t is appropriate .  If any of the  stoppi[INVESTIGATOR_10449] (refer to Sections 8.6.1 to 8.6.3) are met, the patien t will be permanently discontinued 
from further treatment with volanesorsen, evaluated fully as outlined below and in consultation 
with the Sponsor Medical Monitor or appropriately qualified designee, and will be followed up 
in accordance with Section 8.[ADDRESS_39832]  2015  
 
30  8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug- Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline please refer to 
guidance in Section 8.[ADDRESS_39833] meas urement that is >  [ADDRESS_39834]  (or the greater of [ADDRESS_39835] if the baseline value was > ULN)  at any time during the study ( Treatment or 
Post- Treatment Period ), the initial measurement(s) should be confirmed as described above.  
Additional confirmatory measurements should also be performed if ALT or AST levels increase to [ADDRESS_39836]. 
Frequency of Repeat Measurements :  Patien ts with confirmed ALT or AST levels > [ADDRESS_39837] (or 
the greater of [ADDRESS_39838] if the baseline value was > ULN)  should have their 
liver chemistry tests (ALT, AST, alkaline phosphatase ( ALP ), international normalized ratio 
(INR) and total bi lirubin) retested at least once -weekly until ALT and AST levels become 
≤ 1.[ADDRESS_39839] or 1.2 x baseline value if the baseline  value was > ULN . 
Further Investigation into Liver Chemistry Elevations:  For patien ts with confirmed ALT or AST 
levels > [ADDRESS_39840]  (or the greater of [ADDRESS_39841] if the baseline value was 
> ULN ), the following evaluations should be perform ed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if a 
patient ’s ALT and/or AST levels reach [ADDRESS_39842] . 
8.5.2 Safety Monitoring Rules for Platelet Count Results  
If a patient’s platelet count falls by 30% or greater from baseline and  the absolute platelet count 
is 75,000/mm3 or less, then the patient’s platelet counts should be monitored more frequently.  
The frequency of monitoring and additional lab tests will be determined by [CONTACT_37771]. 
8.5.3 Safety Monitorin g for Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically 
relevant, non-major bleeding events (which are defined in Section 8.6.3), for example excess 
ISIS [ADDRESS_39843] notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT ), prothrombin time ( PT), INR  and 
platelet c ount should be performed. 
8.5.[ADDRESS_39844] to notify the Investigator if a patient has 
a low-density lipoprotein- cholesterol ( LDL-C) > 160 mg/dL (> 130 mg/dL for patients with 
T2DM) on two cons ecutive visits .  If this occurs, LDL- C values for this patient will be unblinded 
for the remainder of the study and the Investigator will be encouraged to initiate/adjust treatment 
to lower LDL-C according to country- specific guidelines (e.g., initiate sta tin therapy or increase 
the statin dose for patients who are already on treatment).  
8.5.6 Acute Pancreatitis  
If a patient has an epi[INVESTIGATOR_37507], dosing with study drug should be suspended temporarily until the patient is clinically stable .  The suitability of the patient for continued 
dosing and the need for any modification to treatment schedule (refer to Section 8.7) will be 
determined by [CONTACT_37902] . 
8.[ADDRESS_39845] measurement prior to Day 1.  
8.6.1 Stoppi[INVESTIGATOR_37654] a, and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient  
with volanesorsen will be stopped permanently; values that are not confirmed due to failure to 
retest or missing lab values will be pr esumed confirmed : 
1. ALT or AST >  [ADDRESS_39846] >  [ADDRESS_39847] , which is confirmed and persists for ≥ [ADDRESS_39848] >  [ADDRESS_39849] (or the greater of [ADDRESS_39850] if the baseline 
value was > ULN) , which is confirmed and total bilirubin >  [ADDRESS_39851]  or INR  > 1.[ADDRESS_39852] >  [ADDRESS_39853] (or the greater of [ADDRESS_39854] if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (>  ULN ) felt by [CONTACT_37965] [ADDRESS_39855] Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for any of the 
three criteria below, dosing of a patient with volanesorsen may be stopped temporarily:  
1. Serum creatinine increase that fulfill all of the following  criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine values and  > ULN  
2. Proteinuria, dipstick 2 + (confirmed by [CONTACT_37709] a 
quantitative total urine protein measurement of >  1.0 g/24 hour) 
3. Estimated creatinine clearance calculated according to the formula of Cockcroft and 
Gault ≤ 40 mL/min that is confirmed by a 24 hour urine collection 
The possible dosing re- initiation or follow -up schedule for any events meeting either of these 
criteria will be determined by [CONTACT_38011]. 
8.6.3 Stoppi[INVESTIGATOR_37669] a platelet count less than 50,000/mm3that is associated with  major bleeding or 
clinically relevant non -major bleeding (defined below; Schulman et al. 2005), dosing of a patien t 
with volanesorsen will be stopped permanently.  The follow-up schedule for any events meeting 
this stoppi[INVESTIGATOR_37564]. 
In the event of a platelet count less than 50,000/mm3, and in the absence of major bleeding or 
clinically relevant non -major bleeding (defined below; Schulman et al. 2005), dosing of a patient 
with volanesorsen should be suspended temporarily until the pla telet count has recovered to 
≥ 100,000/mm3.  The suitability of the patient for continued dosing and the need for any 
modification to treatment schedule (refer to Section 8.7) will be determined by [CONTACT_37989]’s platelet count, whether any bleeding events were experienced by 
[CONTACT_102], and the speed of recovery of platelet count upon holding of dosing. 
If after the first dos ing re -challenge the platelet count again falls below 50,000/mm3, then dosing 
of the patient must be held until the platelet count again returns to at least 100,000/mm3.  The 
suitability of the patient for continued dosing and the need for any further modi fication to 
treatment schedule or dose (refer to Section 8.7) will be re -examined by [CONTACT_37990] (at least) the factors mentioned above. 
If after the second re- challenge the platelet count falls below 50,000/mm3 and is subsequently 
confirmed (see Section 8.5), dosing with volanesorsen  will be stopped permanently.  The 
follow- up schedule for any events meeting this stoppi[INVESTIGATOR_37655]. 
ISIS [ADDRESS_39856]  2015  
 
33  Definition of Major Bleeding Events ( Schulman et al . 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of two or more units of whole or red cells 
Definition of Clinically Relevant, Non -Major Ble eding Events ( Schulman et al . 2005):  
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm
2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting >  24 hours if associated with an 
intervention) 
5. Spontaneous recta l bleeding; epi[INVESTIGATOR_37476], gingival bleeding, hemoptysis, hematemesis  
6. Bleeding after venipuncture for > 5 minutes 
8.7 Adjustment of Dose Frequency  
Dose adjustments, including dose interruptions, and/or decreasing the dose frequency will be allow ed for safety an d tolerability .  Any proposed adjustment to treatment schedule must be 
discussed with, and approved by, the Study Medical Monitor prior to initiation.  Up to two adjustments in the treatment schedule may be allowed for patients that are unable to tolerate the 
once weekly dose (for example if platelet counts fall below 50,000/mm
3 as described in 
Section  8.6.3).  If the patient remains stable after adjustment, they may be cautiously returned to 
the original once weekly regimen after consultation with the Study Medical Monitor. 
Patients may be dose paused in response to AE s after consultatio n with Study Medical Monitor. 
8.[ADDRESS_39857] permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent  
• The patien t experiences an AE that necessitates permanent discontinuation of study 
treatment  
• The patien t develops laboratory test abnormalitie s that meet any of  the stoppi[INVESTIGATOR_37565]  8.[ADDRESS_39858]  2015  
 
34  8.8.1 Follow- up Visits for Early Termination from Treatment Period  
Any patient who discontinues early from the Treatment Period should be strongly encouraged to 
attend applicable landmark visits at Week s 12, 13, 25, 26, and 51, 52 (calculated based on the 
time elapsed since Day 1) to collect  fasting lipid panels  and conduct safety assessments  in 
accordance with the schedule of procedures in Appendix A .  Any patient who discontinues 
treatment after  Week 44 should also be strongly encouraged to attend a final follow-up visit 
(Week 65 visit assessments) approximately [ADDRESS_39859] dose of Study Drug, in 
addition to the applicable landmark visits. 
If the patient declines or is unable to participate in the above, an  early termination (ET) visit 
(Week 52 visit assessments) should be performed at the time of withdrawal, at a minimu m, and 
ideally within [ADDRESS_39860]- Treatment Follow-up 
Period should be encouraged to undergo a final  follow-up visit ( Week 65, see Appendix A ) prior 
to leaving the study. If a patient withdraws due to an AE at any time during the study, the Investigator should arrange 
for the patient to have appropriate follow-up until the AE has resolved or stabilized. 
8.[ADDRESS_39861] be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from Study, must 
be recorded in the CRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal (see Section 8.8 and Appendix A). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at the time of withdrawal 
(see Section 8.8 and Appendix A). 
ISIS [ADDRESS_39862] be recorded on the patient ’s 
CRF .  AEs related to administration of these therapi[INVESTIGATOR_37566]. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non -protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between signing 
informed consent and completion of the post- treatment follow -up period.  All concomita nt 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a patient , including changes in the patient’s current medications, must be 
recorded in the patient’s source documents and CRF.  Patients taking over the counter ( OTC ) 
omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
Allowed Concomitant Therapy 
Any medications deemed necessary by [CONTACT_10543].  
Disallowed Concomitant Therapy 
No lipid lowering therapi[INVESTIGATOR_014] (e.g., fibrates, niacin, fish oil or other products containing omega-3 
fatty acids  [including OTC preparations]), glucacon -like peptide-1 ( GLP -1) agonists, Glybera, or 
systemic  corticosteroids may be started  or adjusted after  baseline qualification .  Doses of existing 
oral anti -diabetic medication, oral contraceptives, hormone replacement therapy, anticoagulants, 
or drugs or dietary supplements with potential lipid- altering effe cts should not be adjusted.  
Study patients are prohibited from receiving other experimental agents during the study.  This includes marketed agents at experimental dosages that are being tested for the treatment of 
hypertriglyceridemia.  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and Week 65 visit. 
Disallowed Concomitant Procedure 
Plasma apheresis is not allowed during the study. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by [CONTACT_37714] .  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
volanesorsen.  Patient s that are self -administering volanesorsen at home must record treatment in 
a dosing diary that wi ll be reviewed periodically by [CONTACT_37860].  
ISIS [ADDRESS_39863] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of 
serious adverse events (SAEs) including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH 
E6.  Country- specific regulatory requirements w ill be followed in accordance with local country 
regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations.  The Data and Safety Monitoring Board ( DSMB ) will 
be notified of any SAE as specified in the DSMB  charter.  
The Sponsor or designee  will evaluate the available information and decide if there is a 
reasonable possibility that volanesorsen caused the AE and, therefore, meets the definition of a 
S[LOCATION_003]R . 
The following table identifies the SAEs  that the Sponsor or designee will not report on an 
individual basis in an expedited manner because they are anticipated to occur in the study 
population independent of volanesorsen exposure.  The I nvestigator still h as the responsibility to 
report all SAEs to the Sponsor as described in Sections 9.4.1 to [IP_ADDRESS]. 
Table 2 Expected Event for the Protocol Defined Population by [CONTACT_37931] D efined 
Population (Gaudet et al. 2010 and 2013) 
Pancreatitis associated events including the PTs of 
hereditary pancreatitis, pancreatitis, pancreatitis 
acute, pancreatitis chronic, pancreatitis necrotizing, pancreatitis relapsing  0.2-0.[ADDRESS_39864]  2015  
 
37  9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically significant 
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event cau sed by [CONTACT_37719] . 
A suspected adverse reaction  is any adverse event for which there is  a reasonable possibility that 
volanesorsen drug caused the adverse event .  A suspected adverse reaction implies a lesser 
degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening: that is, poses an immediate risk of death a t the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE  or suspected adverse reaction that , had it occurred in a more severe form, might 
have caused death . 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether  the 
patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_10462], based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse. 
ISIS [ADDRESS_39865]  2015  
 
38  9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of th e 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying  diagnosis  if possible. 
9.4.[ADDRESS_39866] of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to volanesorsen) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event .  The collection of SAEs will 
begin after the patient  signs the informed consent form and stop at the end of the patient ’s 
follow-up period which is defined as the Week [ADDRESS_39867] the patient ’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864].  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the 
follow-up requirement. 
9.4.2 Non-Serious Adverse Events  
The reco rding of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow- up period, which is defined as the Week [ADDRESS_39868] all observed or volunteered AEs on 
the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]: [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to volanesorsen is characterized by [CONTACT_080]:  
• Related:   There is clear evidence that the event is related to the use of volanesorsen e.g., 
confirmation by [CONTACT_38000]- challenge test  
• Possible:   The event cannot be explained by [CONTACT_102] ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and volanesorsen administration  
• Unlikely/Remote:  An event for which an alternative explanation is mor e likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to volanesorsen administration and/or exposure suggests that a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be grouped toge ther with Not 
Related)  
ISIS [ADDRESS_39869]  2015  
 
39  • Not Related:   The event can be readily explained by [CONTACT_102] ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes 
no relationship exists between the event and volanesorsen  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is easily tolerated by [CONTACT_37721] ’s usual 
daily activities  
• Moderate:   The event causes the patient  more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient ’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Vo lanesorsen  
Action taken with volanesorsen due to the event is characterized by [CONTACT_080]: 
• None:  No changes were made to volanesorsen administration and dose 
• Permanently Discontinued:   Volanesorsen  was discontinued and not restarted 
• Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
• Reduced schedule:   Dosing frequency was reduced 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
[IP_ADDRESS] Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by [CONTACT_38012]: 
• AE Persists:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious  (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the corresponding SAE) 
• Change in Severity  (if applicable):  AE severity changed  
ISIS [ADDRESS_39870]  2015  
 
40  If the event is a SAE then the event’s outcome is characteri zed by [CONTACT_080]: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non- serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE)  
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.4.4 Adjudication Committees  
All SAEs that occur during the study that are consistent with a  major acute cardiovascular event  
(MACE) will be adjudicated by a blinded, independent committee as outlined in the MACE 
Adjudication Charter. 
All AEs and SAEs that occur during the study that are consistent with an event of acute 
pancreatitis will be adjudicated by a blinded, independent committee according to the Atlanta 
classification of acute pancreatitis ( Banks et al. 2013) and as outlined in the Pancreatitis 
Adjudi cation Charter .  In addition, data for prior epi[INVESTIGATOR_37568]’s medical chart and these events w ill also 
be adjudicated.  
9.[ADDRESS_39871] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with sy mptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically significant abnormalities will be monitored by [CONTACT_38013].  Laboratory abnormalities deemed not clinically significant (NCS) by [CONTACT_10555].  Similarly, laboratory abnormalities reported as AEs 
by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports .  The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
ISIS [ADDRESS_39872]  2015  
 
41  • The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study  
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_37615] ’s consent to participate in the study and the timin g of the 
procedure or treatment  
• The prescheduled or electi ve procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Volanesorsen dosing errors should be documented as Protocol Deviations.  A brief description should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of volanesorsen that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_39873] learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and 
reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patien t’s 
responsibility. 
Female patien ts:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patient  with a confirmed pregnancy will be immediately 
withdrawn from treatment with volanesorsen.  However, the patient  will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patient  in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known  (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and 
ISIS [ADDRESS_39874]  2015  
 
42  Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks 
after birth.  
Male patient s:  The progress of the pregnancy in a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the p regnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by [CONTACT_37867]. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
For fasting lipid measurements, the values at Month 3 analysis time point are defined as the 
average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments, the values of Month 6 
analysis time point is at the end of Month 6 are defined as the average of Week 25 (Day 169) and Week 26 (Day 176) fasting assessments, and the values at the Month 12 analysis time point are  
defined as the average of Week 51 (Day 351) and Week 52 (Day 358) fasting assessments. 
10.1.1 Efficacy Endpoints 
• Percent change and absolute change from baseline in fasting TG  
• Frequency and severity of patient reported abdominal pain during the treatment period 
• Percent change and change from baseline in other fasting lipid measurements including 
total cholesterol, non-HDL -C, apoB, HDL-C, apolipoprotein A-1 [apoA-1] , VLDL -C, 
and LDL -C 
• Percent change from baseline in fasting  total apolipoprotein C- III  
• Quality of Life questionnaires (EQ-5D, SF-36) 
• Adjudicated acute pancreatitis event rate  
10.1.2 Safety Endpoints  
• Adverse events  including adjudicated events of pancreatitis and MACE 
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology,  coagulati on, urinalysis) 
• Echocardiography 
• Electrocardiogram s (ECGs)  
• Use of concomitant medications  
• MRIs  
ISIS [ADDRESS_39875]  2015  
 
43  10.2 Sample Size  
No sample size calculations were performed as this is an extension study to the double-blind, 
placebo -controlled ISIS 304801- CS6 study.  Approximately 50 patients may be eligible to enroll 
into this study.  
10.3 Populations 
Full Analysis Set (FAS):  All patients who are enrolled  and have a baseline TG assessment .  The 
FAS represents the practically -feasible intent- to-treat (ITT) population a s delineated in ICH 
Guideline E9. 
Per Protocol Set (PPS) :  Subset of the FAS who received [ADDRESS_39876] efficacy and PD assessments .  The detailed criteria will be specified and finalized prior to the 
final database lock . 
Safety Set :  All patients who are enrolled  and receive at least one dose of volanesorsen. 
PK Population:  All patients who are enrolled, recei ve at least one dose of volanesorsen, and 
have at least one evaluable PK sample collected , analyzed , and reported. 
10.3 Definition of Baseline  
Definitions of baseline are given below for the purposes of the final analysis. 
For fasting lipid measurements , two baselines are defined for each patient: index study baseline 
and the baseline in this open label study, which is defined as the average of Day [ADDRESS_39877] measurement prior to Day 1  (e.g., qualification assessments or 
assessmen ts from final visit of the index study if used for qualification) . 
For other measurements , baseline for patients on active treatment in the index study will be the 
index study baseline.  For patients on placebo in the index study, baseline for safety will be the 
last non-missing assessment prior to the first dose of Study Drug. 
10.[ADDRESS_39878] error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data by [CONTACT_1570] .  Where appropriate, p- values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with 5% Type I error 
rates unless otherwise stated.  
ISIS [ADDRESS_39879]  2015  
 
44  All efficacy  endpoints will be assessed in the F AS and PPS.  All safety assessments will be 
performed on the Safety Set .  PK endpoints will be asses sed in the PK Set as applicable.  
10.5.1 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_1570] .  The patient disposition will be summarized  by [CONTACT_38014].  All patients enrolled will be included in a summary of patient disposition . 
10.5.2 Safety Analysis  
Treatment duration and amount of S tudy Drug received will be  summarized by [CONTACT_38015]. 
Patient incidence rates of AEs will be tabulated by [CONTACT_11189], MedDRA 
preferred  term , and treatment group of the index study.  Narratives of treatment emergent  deaths, 
serious and significant AE s, including early withdrawals due to AE s, will also be provided. 
All treatment emergent AEs, all treatment emergent AEs potentially related to Study Drug, all 
treatment emergent serious AEs, and all treatment emergent serious AEs potentially related to 
Study Drug will be summarized.  
Injection Site Reactions (I SRs) will be summarized by [CONTACT_38016], 
MedDRA preferred term and severity . 
Independently adjudicated events of MACE and pancreatitis will be summarized by [CONTACT_38017]. 
Laboratory tests to ensure patient safety including chemis try panel, complete blood count (CBC) 
with differential, coagulation panel, IM, complement etc., will be summarized by [CONTACT_38018].  These safety variables will also be presented as change and 
percent change from baseline over time after study drug admin istration, as appropriate. 
Vital sign s, weight, ECG measures , echocardiography assessments, and MRI assessments  will be 
tabulated by [CONTACT_38016]. 
10.5.3 Efficacy Analysis  
Percent change and ch ange  from baseline to Month 3, Month 6, and Month 12 in fasting TG  will 
be summarized by [CONTACT_38017].  Response rate of patients with fasting 
plasma TG < 750 mg/dL or achieving fasting TG ≥ 40% reduction from baseline at Month 3, Month 6, and Month [ADDRESS_39880]  2015  
 
45  The incremental effects of volanesorsen on lipid meas ures will be explored  and the association 
between changes in lipid parameters and total amount of drug received will be examined, as 
appropriate. 
Frequency and severity of patient reported abdominal pain, adjudicated  acute pancreatitis event 
rate, and qual ity of life assessments will be summarized by [CONTACT_38017]. 
Additional details of the analyses to be conducted will be provided in the SAP.  
10.5.4 Pharmacokinetic and Immunogenicity Analysis  
[IP_ADDRESS] Pharmacokinetic Analysis 
For all p atients, pre-dose and post- treatment volanesorsen plasma concentrations will be 
summarized using descriptive statistics, with stratification by [CONTACT_37950] 304801-CS6 and IM status.  
For patients in the PK subgroup only, non- compartmental PK analysis of volanesorsen will be 
carried out on each individual patient data set using data collected  in the open label extension 
(OLE ) study from the intensive PK sub group, following a single dose (i.e., single -dose PK) or 
multiple dose s (i.e., steady -state PK), depending on their earlier treatment in the index study.  On 
Week [ADDRESS_39881] treatment of volanesorsen  (single -dose PK), while patients who received volanesorsen in 
the index study had been on volanesorsen treatment for twelve months, thus the PK data 
collected from these patients reflect steady -state PK .  The maximum observed drug 
concentration (C max) and  the time taken to reach C max (Tmax) will be obtained directly from the 
concentration -time data .  Area under the plasma concentration -time curve from time zero to 
24 hours ( AUC 0-24hr) will be calculated using the linear trapezoidal rule.  Apparent systemic  
(plasma) clearance after SC administration (CL/ F0-24hr) will be calculated from CL/F 0-24hr = 
Actual Dose/AUC 0-24hr.  Mean residence time (MRT) from time zero to 24 hours after the SC 
administration  will be calculated from the equation, MRT 0-24hr = AUMC 0-24hr /AUC 0-24hr, where 
AUMC 0-24hr is the area under the moment plasma concentration -time curve from time zero to 
24 hours after the SC administration .  Other PK parameters, as appropriate, may be determined 
or calculated at the discretion of the PK scientis t. 
Plasma PK  parameters will be summarized using descriptive statistics , with and without 
stratification by [CONTACT_37732] 304801 -CS6 and IM status .  Additional details 
regarding the PK  analysis will be described in the SAP. 
Population PK, PK /PD, and covariate analysis may be performed if deemed appropriate, and 
results will be reported separately.  
[IP_ADDRESS] Immunogenicity Analysis  
Immunogenicity (IM) results (screen positive/negative, confirmed positive/negative or not 
evaluable, and when applicable, titer of anti- volanesorsen  antibodies) before, during, and after 
treatment with study drug ( volanesorsen ) (i.e., sample [anti-drug antibody] ADA status) will be 
listed by [CONTACT_37732] 304801-CS6 and study day.  Subje ct ADA status 
(positive/negative or not evaluable) for all evaluable patients, along with the study day associated  
ISIS [ADDRESS_39882] positive IM status emerged (T first, i.e., onset of ADA development), the last positive 
IM status observed (T last), the duration of ADA response (number of days between T first and T last) 
if appropriate , the last ADA sample collection day,  and subject maximum titer if applicable, will 
be listed by [CONTACT_37732] 304801 -CS6 and study day.  Subjects with 
positive anti -volanesorsen antibody status may be further classified (when applicable) as being 
either ‘persistent’, ‘transient’, or ‘not determinable’, if deemed appropriate. 
Additionally, the sample and subject IM incidence (number) and incidence rate (percent) will be 
summarized as the total number and percent of evaluated subjects with antibody negative, positive, and unknown status by [CONTACT_37732] 304801- CS6.  Furthermore, 
onset, duration, and t iter of the ADA response, if applicable, wi ll be summarized as median, 
quartiles (25% and 75%), and range. 
Additional details regarding the IM data analysis will be described in the SAP. 
Potential relationships between immunogenicity results (e.g., IM status) and selected efficacy 
(e.g., % change in fasting TG from baseline at 3 -, 6-, and 12-month endpoints), safety, and PK  
(e.g., C
trough) measures will be evaluated using graphical analysis and statistical analysis .  These 
analyses will be either conducted and included in the study report, or data pooled and analyzed 
from all available Phase II and III studies  and reported separately  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population , based on an English version provided by [CONTACT_1034]. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific qualification 
procedures or any Study Drug  are administered .  The patient  must be given sufficient time to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_37873] (not necessarily an Investigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by [CONTACT_10569], and a copy of the signed consent form should be provided to the 
patient . 
11.[ADDRESS_39883] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated 
October  2002 the applicable regulations and guidelines of current Good Clinic al Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
ISIS [ADDRESS_39884]  2015  
 
47  11.3 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informe d consent  form, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of patient s into the study and shipment of volanesorsen .  A copy of 
the written approval of any other items/materials that must be approved by [CONTACT_37874]/IRB must also be received b y the Sponsor before recruitment of patien ts into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IRB  of serious adve rse events 
occurring at the Study Center and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study .  Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor. 
11.[ADDRESS_39885] ensure that the patient ’s confidentiality is maintained .  On the case report 
forms  (CRF)  or other documents submitted t o the Sponsor , patient s should be identified by 
[CONTACT_37735] a patient  study number only.  Documents that are not for submission to the 
Sponsor ( e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review th e patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_39886] be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IEC/IRB mu st be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patient s or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the Sponsor . 
ISIS [ADDRESS_39887].  The Investigator/Sponsor should notify the IEC/IRB in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) ap plication 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s CRF  data 
are obtained .  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence.  In this study, CRFs 
may not be used as source documents. The Investigator and S tudy Center staffs are  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section  8 of the ICH Guidelines (E6) , suitable for inspection at any time by [CONTACT_37875]/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed CRF s, informed consents, and supporting copi[INVESTIGATOR_33775] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB and the 
Sponsor  
• If volanesorsen supplies are maintained at the Study Center, proof of receipt, 
volanesorsen Accountability Record, Return of volanesorsen  for Destruction, final study 
volanesorsen reconciliation, and all volanesorsen- related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor or  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.[ADDRESS_39888], inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that patient  
confidentiality is respected.  
ISIS [ADDRESS_39889]  2015  
 
49  The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; 
and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient  medical records and other study- related r ecords needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by [CONTACT_10576]’s Clinical Quality Assurance Department .  Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of 
study-related records will occur to evaluate the trial conduct and compliance with the protocol, 
ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed on 
patient  data received by [CONTACT_1034].  During this review, patient  data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clini cal data 
management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator [INVESTIGATOR_37484] .  These signatures 
will indicate that the principal Investigator [INVESTIGATOR_37485] , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.[ADDRESS_39890] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated a nd/or compensated for any 
study- related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
 
ISIS [ADDRESS_39891]  2015  
 
50  13. REFERENCES  
Altmann KH, Fabbrot D, Dean NM, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Atzmon G, Rincon M, Schechter CB, et al . Lipoprotein genotype and conserve pathway for exceptional longevity in 
humans . PLoS Biol 2006; 4: e113.  
Banks P, Bollen T, Dervenis  C, et al; and  Acute Pancreatitis Classification Working Group . Classification of acute 
pancreatitis – 2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut 2013; 62:  
102-111. 
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol -anchored high -density lipoprotein -binding 
protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 Apr; 5(4): 279-2 91. 
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hy pertriglyceridemia: An endocrine 
society clinical practice guideline. J Clin Endocrinol Metab  2012; 97: 2969- 2989.  
Breyer ED, Le N -A, Li X, Martinson D, Brown WV . Apolipoprotein C -III displacement of apolipoprotein E from 
VLDAL: Effect of particle size . J Lipid Re s 1999; 40: 1875- 1882.  
Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial 
lipase on the metabolism of both high -density lipoproteins and apolipoprotein B -containing lipoproteins . Circ Res 
2010; 107: 357- 364. 
Brunzell JD . Familial lipoprotein lipase deficiency . In Pagon RA, Adam MP, Bird TD, et al.  editors . GeneReviews 
[Internet], Seattle, WA, University of Washington, Seattle; 1999 -2011.  
Chan DC, Chen MM, Ooi MM, Watts GF . An ABC of apolipoprotein C -III: a clinically useful new cardiovascular 
risk factor? Int J Clin Pract 2008; 62 (5): 799- 809. 
Crooke ST and Bennett CF . Progress in antisense oligonucleotide therapeutics . Ann Rev. Pharmacol Toxicol 1996; 
36: 107- 129. 
Doolittle MH, Neher SB, B en-Zeev O, et al. Lipase maturation factor 1 (LMF1): Membrane topology and 
interaction with lipase proteins in the endoplasmic reticulum . J of Biological Chemistry 2009; 1- 19. 
Gaudet D, de Wal J, Tremblay K, et al . Review of the clinical development of alipogene tiparvovec gene therapy for 
lipoprotein lipase deficiency . Atherosclerosis Suppl 2010; 11:  55-56. 
Gaudet D, Méthot  T, Déry S, et al. Efficacy and long -term safety of alipogene tiparvovec (AAV1 -LPLS447X) gene 
therapy for lipoprotein lipase deficie ncy: An open- label trial. Gene Therapy 2013 ; 20: 361 -369. 
Gaudet D, Brisson, D Tremblay K, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome . N Engl J 
Med 371; 23  Dec, 2014; 2200 -2206. 
Gaudet D, Alexander V, Baker BF, et al . Antisense Inhibition of Apolipoprotein C -III in Patients with 
Hypertriglyceridemia N Engl J Med 2015; 373(5):  438-447. 
Geary RS, Yu RZ, Watanabe T, et al . Pharmacokinetics of a tumor necrosis factor -alpha phosphorothiate 2′ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Lee RG, Bell TA , et al . Antisense oligonucleotide inhibition of apolipoprotein C -III reduces plasma 
triglycerides in rodents, nonhuman primates, and humans . Circ Res 2013 May 24; 112(11): 1479- 1490. 
Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF . Chemically modified oligonucleotides exhibit 
decreased immune stimulation in mice. J Pharmacol Exp Ther 2000; 292: 468- 479. 
Inoue H, Hayase Y, Iwai S, Ohtsuka E . Sequence -dependent hydrolysis of RNA using modified oligonucleotide 
splints and RNase H . Federation of European Biochemical Societies 1987; 215: 327- 330. 
ISIS [ADDRESS_39892]  2015  
 
51  Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL . Hypertriglyceridemia as a result of human apo CIII  gene 
expression in transgenic mice. Science 1990 Aug 17; 249: 790- 793. 
Kinnunen PK and Ehnolm C . Effect of serum and C -apoproteins from very low density lipoproteins on human 
postheparin plasma hepatic lipase. FEBS Lett  1976; 65: 354 –357. 
Lemieux I, Salom on H, Després JP . Contribution of apo CIII reduction to the greater effect of 12- week micronized 
fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipi[INVESTIGATOR_37486]. Ann Med 2003; 
35: 442- 448. 
Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C- III isoforms on the binding of 
triglyceride -rich lipoproteins to the lipolysis -stimulated receptor . J Biol Chem 1997; 272: [ZIP_CODE]- [ZIP_CODE].  
McKay RA, Miraglia LJ, Cummins LL, Owens SR, Samor H, Dean NM. Characterization of a potent and specific 
class of antisense oligonucleotide inhibitor of human protein kinase C -alpha expression . J Biol Chem 1999; 274: 
1715- 1722.  
Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM . Metabolism of very -low-density lipoprotein a nd low -density 
lipoprotein containing apolipoprotein C -III and not other small apolipoproteins . Arterioscler Thromb Vasc Biol 
2010; 30: 239- 245. 
Monia BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression . J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE].  
Ooi EMM, Barrett PHR, Chan DC, Watts GF . Apolipoprotein C -III: Understanding an emerging cardiovascular risk 
factor . Clin  Sci (Lond)  2008; 114: 611- 624. 
Petersen KF, Dufour  S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease . N Engl J 
Med 2010; 362: 1082- 1089.  
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardiopr otection . Science 2008; 322: 1702- 1705.  
Santos RD, Duell PB, East C, et al. Long -term efficacy and safety of mipomersen in patients with fa milial 
hypercholesterolaemia: 2-year interim results of an open -label extension . Eur  Heart J  2015 Mar; 36(9) : 566 -575. 
ePub 2013 Dec 23: doi: 10.1093/eurheartj/eht549.  
Schaap FG, Resen PCN, Voshol, et al . ApoAV reduces plasma triglycerides by [CONTACT_37737] -triglyceride (VLDL -TG) production and stimulating lipoprotein lipase -mediated VLD L-TG hydrolysis . 
J Biol Chem 2004; 279: [ZIP_CODE]- [ZIP_CODE].  
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical 
investigations of antihemostatic medical prod ucts in non -surgical patients . J Thromb Haemost 2005; 3(4):  692-694. 
Schuster KB, Wilfert W, Evans D, Thiery J, Teupser D . Identification of mutations in the lipoprotein lipase (LPL) 
and apolipoprotei n C-II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC) . 
Clinica Chimia Acta 2011; 412: 240- 244. 
Surendr an RP, Visser ME, Heemelaar S, et al . Mutations in LPL, APOC2, APOA5, GPI[INVESTIGATOR_37445]1 and LMF1 in patients 
with severe hypertriglyc eridaemia . J Internal Med 2012; 272: 185- 196. 
Tremblay K, Méthot J, Brisson D, Gaudet D . Etiology and risk of lactescent plasma and severe 
hypertriglyceridemia . J Clin Lipi[INVESTIGATOR_37487] 2011; 5: 37- 44. 
Yang F, Wang Y, Sternfeld L, et al . The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of 
isolated acinar cells and pancreatitis model in lipoprotein lipase -deficient mice . Acta Physiologica 2009; 195: 13- 28. 
Zhang H, Lowenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleed risk . Blood 2010; 116: 4684- 4692.  
ISIS [ADDRESS_39893] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3   Wk 
19 Month 6  Wk 
32 Wk 
38 Wk 
44 Month 12  Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52  
or ET 
Study Day  -14 to -7 1 2 22 50 78 85 127 169 176 218 260 302 351 358 400 449 
Visit W indow+/ - Days  0 0 0 2 2 2 2 3 2 2 3 3 3 2 2 7 7 
Informed Consent  X                 
Outpatient Visit  X X X X X Xg X  Xg X  X  Xg X  X 
Inclusion/Exclusion Criteria  X                 
Vital Signs + body weight  (+ height on 
Day 1 only ) X X  X X  X   X  X   X  X 
Physical Examination   X     X   X  X   X  X 
12- lead ECG  (triplicate)        X   X  X   X  X 
MRI (liver/spleen)                X   
Echocardiography           X     X   
Urinalysisb X Xe  X X  Xe Xe  Xe Xe Xe Xe  Xe Xe Xe Blood Draw  (Fasting)b Chemistry Pane l X X  X X  X Xg  X Xg X Xg  X Xg X 
CBC with Differential  X X  X X  X Xg  X Xg X Xg  X Xg X 
Serum Lipid Panel X X  X X Xg X  Xg X  X  Xg X  X 
Coagulation  (aPTT, PT, INR)      X  X   X  X   X   
hsCRP, HbA1c, FPG   X     X   X     X  X 
Sedimentation Rate   X     X   X     X  X 
Complement (C5a, Bb)   X     X   X     X  X 
Plasma  PK - Volanesorsen   Xh X X X  X   X  X   X  X 
Anti-Volanesorsen  Antibodies   X  X X  X   X  X   X  X 
FSH (women only, if applicable)                   
Serum Pregnancy Testc X    X  X   X  X   X  X 
Archived Serum & Plasma 
Samplesf  X   X  X   X     X  X 
ISIS [ADDRESS_39894] Treatment 
Follow -up 
Study Week  -2 to -1 Wk 
1 Wk 
4 Wk 
8 Month 3  
Wk 
19 Month 6  
Wk 
32 Wk 
38 Wk 
44 Month 12  
Wk 
58 Wk 
65 Wk 
12 Wk 
13 Wk 
25 Wk 
26 Wk 
51 Wk 52 
or ET 
Study Day  -14 to -7 1 2 22 50 78 85 127 169 176 218 260 302 351 358 400 449 
Visit Window+/ - Days  0 0 0 2 2 2 2 3 2 2 3 3 3 2 2 7 7 
Weekly Study Drug:  SC Injection  X  X X X X X X X X X X X X   
Symptom Diary (weekly)  X X  X X X X X X X X X X X X X X 
Food/Drink Diary ( quarterly )i  X     X   X     X  X 
Quality of Life Assessment(s)   X     X   X     X  X 
Diet/Alcohol Counselingd X X  X X  X   X  X   X X X 
Adverse Events X X  X X  X   X  X   X  X 
Concomitant Medication  X X  X X  X   X  X   X  X 
a Qualification procedures performed and the patient continue s the symptom diary .  Assessments from the Week [ADDRESS_39895] 10 hours .  During treatment period urine and blood samples will be collected prior to study 
drug administration.  Does not  apply to 24 hour PK blood draw  
c Females of childbearing pot ential only  
d To reinforce compliance to the diet  and alcohol restrictions  
e Expanded urinalysis (see Appendix B ) 
f Serum and plasma samples will be collected  and s tored for follow -up exploration of laboratory findings and/or adverse events (e.g., measurement of cytokine 
and/or chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of  
volanesorsen  
g To be collected by [CONTACT_5640] a clinical service, or Study Center as arranged by [CONTACT_37747]  
h F ull or abbreviated PK profile (see Appendix C ) 
i In addition to diary, patients will be contact[CONTACT_38019] 304804-CS7 CONFIDENTIAL Original
Protocol  [ADDRESS_39896] of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better character ize the profile of volanes orsen or other similar 
oligonucleotides. 
Clinical Chemistry Panel 
• Sodium 
• Potassium 
• Chloride 
• Bicarbonate 
• Total protein 
• Albumin 
• Calcium 
• Magnesium 
• Phosphorus 
• Glucose 
• BUN 
• Creatinine 
• Uric Acid 
• Total bilirubin 
• Direct (conjugated) 
bilirubin 
• Indirect (unconjugated) 
bilirubin 
• ALT 
• AST 
• Alkaline phosphatase Coagulation 
• aPTT (sec) 
• PT (sec) 
• INR 
 
Lipid Panel 
• Total Cholesterol 
• LDL-C 
• HDL-C 
• Triglycerides 
• Non-HDL-C 
• VLDL-C 
• apoA-1 
• apoB 
• apoC-III 
 Hematology 
• Red blood cells 
• Hemoglobin 
• Hematocrit 
• MCV, MCH, MCHC 
• Platelets 
• White blood cells 
• WBC Differential (% 
and absolute) 
• Neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes 
• Monocytes 
 
Pharmacokinetics1  
& Immunogenicity 
• Volanesorsen levels in 
plasma 
• Anti-volanesorsen antibodies in plasma 
 
Other assessments 
• hsCRP 
• Sedimentation Rate 
• C5a, Bb 
• De-lipi[INVESTIGATOR_37490] 
• HbA1c, FPG Urinalysis 
• Color 
• Appearance 
• Specific gravity 
• pH 
• Protein 
• Blood 
• Ketones 
• Urobilinogen 
• Glucose 
• Bilirubin 
• Leukocyte esterase 
• Nitrate 
• Microscopic 
examination2 
 
Additional Measures for 
Expanded Urinalysis 
• Total protein (quantitative) 
• Microalbumin 
• β2-microglobulin 
 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabo lite assessments, IM testing (or possibly for purposes of IM assay 
development and/or validation), or to assess other actions of volanesorsen with plasma constituents 
[ADDRESS_39897]-treatment follow-up period 
as noted in the tables below. 
PK Sampling Schedule (All Patients except PK Subgroup) 
Week Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day D1 D22 D50 D85 D176 D260 D358 D449 
Visit Window 
+/- Days 0 2 2 2 2 3 2 7 
Time Point Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Anytime 
 
PK Sampling Schedule (PK Subgroup only*) 
Week Wk 
1 Wk 
1 Wk 
4 Wk 
8 Wk 
13 Wk 
26 Wk 
38 Wk 
52 Wk 
65 
Study Day D1 D2 D22 D50 D85 D176 D260 D358 D449 
Visit Window 
+/- Days [ADDRESS_39898]-dose Pre-
dose Pre-
dose Pre-
dose Pre-
dose Pre-
dose Pre-
dose Anytime 
* Patients at selected sites will be asked to participate in the extended 24-hour PK profile beginning on 
Study Day 1.  Partic ipation is optional. 
 
  
ISIS 304801-CS7 CONFIDENTIAL Original
Protocol  [ADDRESS_39899] abnormalities are 
based upon the Common Terminology Criteria for Adv erse Events (CTCAE) Version 4.03, 
June 2010 
 
  

ISIS 304801-CS7 CONFIDENTIAL Original
Protocol  28 Augus t2015
 
62  Appendix D Grading Scale for Adverse Events  Relating to Laboratory Abnormalities 
Continued 
 
 
  

ISIS 304801-CS7 CONFIDENTIAL Original
Protocol  28 Augus t2015
 
63  Appendix D Grading Scale for Adverse Events  Relating to Laboratory Abnormalities 
Continued 
 
  
